EP	0600858	B1	2000-05-17	de	TITLE	1	KONDOM FÃœR ORAL-GENITALEN GEBRAUCH
EP	0600858	B1	2000-05-17	en	TITLE	1	CONDOM FOR ORAL-GENITAL USE
EP	0600858	B1	2000-05-17	fr	TITLE	1	PRESERVATIF A USAGE ORO-GENITAL
EP	0600858	B1	2000-05-17	en	DESCR	1	<heading id="h0001"><u><b>Background of the Invention</b></u></heading><p id="p0001" num="0001">In recent years, the appearance of the HIV virus and the impending Acquired Immune Deficiency Syndrome epidemic have created an atmosphere of fear, caution and prudence in which sexually active adults must consider protecting themselves from infection by HIV virus as well as other venereal diseases. It is generally accepted as fact that the condom provides the best protection from venereal disease and HIV virus, aside from complete sexual abstinence. Unfortunately, such a positive barrier device is, at present, the only sure or certain way to prevent transmission of all STD's, many of which cause great personal suffering and, in the cases of AIDS and syphilis, death.</p><p id="p0002" num="0002">Condoms are generally designed to be applied to the male member, although recent adaptations have been introduced which permit their use by women in the form a liner for the vaginal canal. Such a condom is disclosed in US-A-4805604. However, a significant form of sexual activity, namely oral-genital sexual contact, has not been well served by the forms of condoms known in the prior art. Although many individuals do not openly discuss or acknowledge participating in such practices, many surveys have shown that oral-genital sex is highly desired and engaged in frequently. Commercially available condoms are not designed to facilitate or accommodate oral-genital sex. Moreover, the oral cavity, together with the lips and surrounding skin, provides many opportunities for disease transmission. Brushing and flossing of teeth, biting the cheek or tongue accidentally, or STD lesions in the mouth and throat areas all create breaks in the skin and mucosa that provide direct vectors to the blood. The present invention is directed toward a condom-like prophylactic that protects the oral cavity during oral sexual activity, so that disease transmission is blocked. It also protects the genitals, thus avoiding transmission in either direction. This is a unique solution to a very serious problem.</p><p id="p0003" num="0003">The typical male condom device may be used to prevent skin-to-skin contact during fellatio, but it suffers from the same drawback for this use as for other uses; i.e., it<!-- EPO <DP n="2"> --> requires male arousal prior to use, so that the condom may be applied to the male member. If arousal can be achieved only through sensual contact, then the safety desired by the user of the condom may have been abrogated. Moreover, the typical male condom is required to engage the penis in a tight, compressive grip to prevent accidental removal during vaginal sex; this tight fit is undesirable for fellatio and uncomfortable for the fellatee. Examples of such condoms are disclosed in US-A-4872464 and US-A-4888007. These documents disclose a male condom with a shield surrounding the open end of the condom, said shield extending away from the open mouth of the condom.</p><p id="p0004" num="0004">Furthermore, the condoms known in the prior art are not designed to protect against skin-to-skin contact during cunnilingus. Devices have been invented to protect a person's tongue from contact with unpalatable medicine, as well as other devices such as impervious sheets and garments, but none of these inventions permit the practice of cunnilingus while eliminating the risk of disease transmission through direct contact. This is a major failing of the prior art, especially since many individuals participate in cunnilingus without protection, and such practices can be a major vector of disease transmission. Only one device has been proposed in the prior art that allows the performance of cunnilingus. That is the device disclosed in CA-A-1274352. That device comprises a facial mask which has a stretchable portion over the mouth to allow the extension of a wearers tongue. This device is, however, inelegant and unsatisfactory in use.</p><p id="p0005" num="0005">From a commercial standpoint, surveys have shown that nearly 50% of condoms purchased are sold to women, although it is clear that condoms as known in the prior art are predominantly worn by the male. Therefore there is an implication that many women are concerned about contraception and disease prevention, and desirous of taking steps toward prevention of both. Many persons of both sexes may wish to participate in oral sex but hesitate. These "aesthetically fastidious" individuals may now safely and pleasurably benefit themselves and their sex partners, using the present invention. Studies show that only 50% of women achieve orgasm via penile/vaginal sex. One-half require oral or digital manipulation to achieve climax. Indeed, at present a woman who desires to achieve a climax via cunnilingus must do so unprotected. Combined with the facts that many women desire to<!-- EPO <DP n="3"> --> participate in cunnilingus and fellatio, clearly there is an unfilled need and a large market for condoms which permit the safe practice of oral sex.</p><p id="p0006" num="0006">It should also be noted that condoms currently available on the market are not designed nor directed toward oral use. The lubricants typically provided in condom packages have odors and tastes that are at best inoffensive, and at worst are completely aversive.<!-- EPO <DP n="4"> --></p><p id="p0007" num="0007">The present invention generally comprises a condom-like prophylactic designed to permit the practice of oral sex while preventing the transmission of venereal and other contagious diseases through oral-genital contact. In one aspect of the invention, there is provided a condom adapted to be worn in the mouth of the person practising oral sex, as described in claim 1.</p><p id="p0008" num="0008">The condom includes a tubular member having one closed end and formed of thin, pliant, impervious material. Joined to the open end of the tubular member are a pair of flanges extending generally radially outwardly and spaced closely together.</p><p id="p0009" num="0009">The flanges may be curved out of a plane transverse to the axis of the tubular member to define a channel having the general configuration of the lips and mouth of the average person. The device is gripped by placing the lips within the channel, and closing the jaws slightly to compress and retain the open end of the device. A third flange may be provided, generally parallel to the other flanges, to define a further channel in which the teeth of the user may be engaged.</p><p id="p0010" num="0010">The tubular member may be formed to extend into the mouth of the wearer, for the purpose of performing fellatio. A penis may be inserted into the tubular member without making direct contact with the lips or mouth or tongue of the wearer. In an alternative form of the invention, the tubular member may extend outwardly from the flanges and the mouth, so that the tongue of the wearer may be extended into the tubular member to perform cunnilingus without making direct contact with the vulva.</p><p id="p0011" num="0011">The invention also includes an embodiment in which the condom is provided with a progressively expanding diameter from the base to the closed end. The expanded head provides far more comfort and sensation during fellatio.</p><p id="p0012" num="0012">In all of the embodiments described, the device may be packaged not only with a lubricating substance but also, or alternatively, with a substance that imparts a pleasant scent and taste to the device, adding further sensual pleasure to oral sexual activity. In addition, the pliant material that forms the condom-like prophylactic may be provided with surface texture and colour to enhance enjoyment during use.<!-- EPO <DP n="5"> --></p><heading id="h0002"><u>Brief Description of the Drawing</u></heading><p id="p0013" num="0013"><ul id="ul0001" list-style="none" compact="compact"><li>Figure 1 is a perspective view of one embodiment of the condom for oral-genital use of the present invention</li><li>Figure 2 is a fragmentary, partially broken away view of the tubular portion of the embodiment of the invention shown in Figure 1.</li><li>Figure 3 is a side elevation of the embodiment of the invention shown in Figures 1 and 2.</li><li>Figure 4 is an end elevation of the embodiment shown in Figures 1-3.</li><li>Figure 5 is a cross-sectional elevation taken along line 5-5 of Figure 4.</li><li>Figure 6 is a cross-sectional elevation similar to Figure 5, depicting a further development of the embodiment of Figures 1-5.</li><li>Figure 7 is a cross-sectional schematic side view of the average human dentition and oral structure.</li><li>Figure 8 is a cross-sectional view as in Figure 7, showing the use of the embodiment of the condom of the present invention for fellatio.<!-- EPO <DP n="6"> --></li><li>Figure 9 is a cross-sectional view as in Figure 7, showing the use of a further embodiment of the condom of the present invention for cunnilingus.</li><li>Figure 10 is an end view of the condom of the present invention, as in Figure 4, showing an alternative placement in the mouth.</li><li>Figure 11 is a perspective view of another embodiment of the invention, adapted for particular use in cunnilingus.</li><li>Figure 12 is an end view of the embodiment shown in Figure 11.</li><li>Figure 13 is a side elevation of the embodiment shown in Figures 11 and 12.</li><li>Figure 14 is a perspective view of another embodiment of the invention adapted for fellatio.</li><li>Figure 15 is a cross-sectional view as in Figure 7, showing the use of the embodiment of Figure 14 of the present invention for fellatio.</li><li>Figure 16 is a perspective view of another embodiment of the invention adapted for cunnilingus.</li><li>Figure 17 is a cross-sectional view as in Figure 7, showing the use of the embodiment of Figure 16 of the present invention for cunnilingus.</li></ul><!-- EPO <DP n="7"> --></p><heading id="h0003"><u>Description of the Preferred Embodiments</u></heading><p id="p0014" num="0014">The present invention generally comprises a condom designed to permit the practice of oral sex while preventing the transmission of venereal and other contagious diseases through oral-genital contact. With reference to Figures 1-5, one embodiment of the invention comprises a condom 31 which includes a tubular portion 32 having a rounded, dosed end 33 and an opposed open end 34. The length of the tubular portion from the closed end 33 to the opening 34 is generally a few inches, and may be shorter than a typical prior art male condom. The tubular member adjacent to the opening 34 is formed with an oval, ellipsoid cross-section, and the opening end 34 describes a smoothly curved arc, with the arc extending in the same direction as the major axis of the ellipsoidal cross-section, as can been observed by comparing Figures 3 and 4. The tubular portion 32 may be provided with an expanded diameter adjacent to the closed end 33 and extending toward the open end, as shown in Figure 2, to establish a non-constrictive fit with the male member.</p><p id="p0015" num="0015">A significant feature of the condom 31 is the provision of a pair of flanges 36 and 37 disposed adjacent to the open end 34. The flanges 36 and 37 are closely spaced apart, and are defined as toroidal surfaces that are generally parallel. Both flanges are ovoid or elliptical when viewed in an end elevation (Figure 4), and flange 36 is slightly smaller in major and minor axis dimensions. The flanges extend in outwardly flaring fashion toward the dosed end 33, and there is defined between the flanges 36 and 37 a channel 38. The flanges 36 and 37 are each provided with a thickened rim 39 and 41,<!-- EPO <DP n="8"> --> respectively, extending continuously about the distal edge portion of each flange to impart form-retaining characteristics to the flanges. The rims 39 and 41 maintain the open end of the condom and prevent collapse thereof, and maintain the parallel spacing and disposition of the flanges. In an alternative embodiment shown in Figure 6, the distal edges of the flanges 36 and 37 are provided with a pair of O-Rings 42 and 43, respectively, each incorporated into one of the distal edges of one of the flanges. The O-Rings serve the same purposes as the rims 39 and 41.</p><p id="p0016" num="0016">The condom 31 may be formed of a pliant, thin, elastic, impervious material such as latex rubber, vinyl, or any similar non-toxic, non-allergenic, non-irritative material by multiple dipping processes, molding processes, or the like. With reference to Figure 2, the majority of the tubular portion 32 is rather thin, on the order of 0.051-0.25 mm (0.002-0.010 inch), whereas the end portion 44 of the tubular member adjacent to the open end 34 is thicker. One satisfactory version has an end portion thickness of 0.76 mm (0.030 inch). The end portion 44, which flares slightly to join the flanges 36 and 37, is subject to the most stress and flexure of the assembly, and the thickness of this portion is increased proportionally.</p><p id="p0017" num="0017">The embodiments depicted in Figures 1-6 are designed to be used as shown in Figures 7 and 8. Figure 7 shows a schematic cross-sectional elevation of the jaw area of a human head, including the upper jaw and teeth 51, the lower jaw and teeth 52, and the tongue 53 in the mouth 54. The condom 31 is applied to the mouth 54, with the dosed end 33 and tubular portion 32 placed into the mouth. The condom 31 is oriented so that the<!-- EPO <DP n="9"> --> upper and lower lips are engaged in the channel 38, preferably at opposite ends of the major axis of the ellipsoid formed by the opening 34. (Physiological variations may determine that the condom 31 is more easily used when oriented with upper and lower lips aligned with at opposite ends of the minor axis.) The jaws are dosed slightly to squeeze the condom therebetween, deforming the ellipsoid into a more cylindrical shape, or further into a laterally extending ellipsoid, as shown in phantom line in Figure 10.</p><p id="p0018" num="0018">The flange 37 is disposed outside of the lips of the condom user, and the flange 36 is disposed between the lips and teeth, as shown in Figure 8. The open end 34 of the condom is directed outwardly to receive a penis for performing fellatio, and the length of the condom limits penetration of the penis to prevent triggering of the gag reflex. Furthermore, there is no interference with the nose of the condom user, so that the user may breathe freely. The condom permits fellatio while preventing skin-to-skin contact between the oral surfaces and the genital surfaces. After use, the condom 31 may be removed by grasping the outer flange 37 and pulling it from the mouth 54.</p><p id="p0019" num="0019">A further embodiment of the present invention, shown in Figures 11-13, comprises a condom designed to permit the practice of cunnilingus while preventing skin-to-skin contact between oral and genital surfaces. (Throughout the description of the preferred embodiments, common reference numerals applied to different Figures and embodiments refer to the same structures.) The condom 61 includes a tapered, convex tubular portion<!-- EPO <DP n="10"> --> 62 having a narrow, rounded dosed end 63 and an open end 64. Joined to the tubular portion 62 adjacent to the open end 64 are a pair of flanges 36 and 37, as described previously, with a channel 38 defined therebetween. The flanges 36 and 37 are substantially the same as described previously, in form and function. The tubular portion 62 is formed of a similar material as described above.</p><p id="p0020" num="0020">With regard to Figure 9, the condom 61 is employed by being applied to the mouth 54, with the closed end 63 and tubular portion 62 placed outside the mouth. The condom 61 is oriented so that the upper and lower lips are engaged in the channel 38 at opposite ends of the major axis of the ellipsoid formed by the opening 64. The jaws are dosed slightly to squeeze the condom therebetween, deforming the ellipsoid into a more cylindrical shape, or further into a laterally extending ellipsoid, as shown in phantom line in Figure 10. The flange 37 is disposed outside of the lips of the condom user, and the flange 36 is disposed between the lips and teeth, as shown in Figure 9. The tubular portion 62 extends outwardly, providing a sheath for the extended tongue 53 of the user. The condom 61 permits the user to perform cunnilingus while the tongue 53 , lips, and surrounding area of the user are protected from contact with the vulva of the recipient. After use, the condom is removed by manually grasping the outer flange 37 and disengaging the dentition and lips from the flanges and channel 38.<!-- EPO <DP n="11"> --></p><p id="p0021" num="0021">Another embodiment of the invention, depicted in Figure 14, is similar in many aspects to the embodiment of Figures 1 and 3, and common reference numerals are used to designate common features. This embodiment includes a tubular portion 32 having a rounded, dosed end 33 and an opposed open end 34. The length of the tubular portion from the closed end 33 to the opening 34 is generally a few inches, and may be shorter than a typical prior art male condom. The tubular member adjacent to the opening 34 is formed with an oval, ellipsoid cross-section, and the opening end 34 describes a smoothly curved arc, with the arc extending in the same direction as the major axis of the ellipsoidal cross-section. As described previously, a pair of flanges 36 and 37 are disposed adjacent to the open end 34. The flanges 36 and 37 are closely spaced apart, and are defined as toroidal surfaces that are generally parallel. The flanges extend in outwardly flaring fashion toward the closed end 33, and there is defined between the flanges 36 and 37 a channel 38.</p><p id="p0022" num="0022">The embodiment of Figure 14 further includes a third flange 101, extending parallel to the flanges 36 and 37 and spaced apart and adjacent to flange 36. The flanges 101 and 36 define therebetween a channel 102 extending about the condom parallel to the channel 38. As depicted in Figure 15, the channel 38 is engaged by the lips of the user, and the channel 102 is disposed to be engaged by the front teeth of the user, providing greater retention of the condom in the oral cavity with less effort by the lips. As noted with regard to Figures 1-3, the condom of Figures 14 and 15 eliminates skin-to-skin contact during fellatio.<!-- EPO <DP n="12"> --></p><p id="p0023" num="0023">A further embodiment of the invention, depicted in Figure 16, is similar in many aspects to the embodiment of Figures 11-13, and common reference numerals are used to designate common features. This embodiment includes a tapered tubular portion 62 having a narrow, rounded closed end 63 and an open end 64. Joined to the tubular portion 62 adjacent to the open end 64 are a pair of flanges 36 and 37, as described previously, with a channel 38 defined therebetween. The flanges 36 and 37 are substantially the same as described previously, in form and function. The tubular portion 62 is formed of a similar material as described above. Also provided is a third flange 104, extending parallel to the flanges 36 and 37 and disposed adjacent to and spaced apart from the flange 36. The flanges 36 and 104 define therebetween a channel 106 extending about the condom.</p><p id="p0024" num="0024">As shown in Figure 17, the condom of Figure 16 is adapted to be applied to the oral cavity, with the upper and lower lips disposed in the channel 38 and the upper and lower front teeth disposed in the channel 106. The portion 62 extends outwardly from the mouth, and provides a sheath within which the tongue may be extended for performing cunnilingus and similar sexual acts. The channel 106 permits greater retention of the condom in the mouth without significant effort by the lips of the user.</p><p id="p0025" num="0025">It may be appreciated that all embodiments of the present invention are directed toward facilitating the safe practice of oral sex. To further this goal, any of the embodiments may be packaged together with substances that impart a pleasing flavor and aroma to the condom, so that the use thereof will not be hindered by unpleasant taste or scent. In addition, coloring and<!-- EPO <DP n="13"> --> surface texture may be added to the condoms to enhance the pleasure of their use.</p>
EP	0600858	B1	2000-05-17	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A condom (31) suitable for oral-genital use, comprising an elongated tubular body (32) closed at one end (33) and open at the other end (34), said tubular body being of a flexible material impermeable to liquids; characterised in that the condom (31) is provided with first and second annular flanges (36, 37) positioned near the open end (34) of said tubular body (32) and spaced apart from each other; said annular flanges (36, 37) and tubular body being adapted to engage the lips of a user for oral-genital use and prevent skin-to-skin contact between the oral and genital surfaces.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A condom (31) according to claim 1, wherein said first and second flanges (36, 37) define therebetween an annular channel (38) adapted to receive the lips of the condom user to retain said condom (31) within the mouth.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A condom (31) according to claim 2, wherein said first and second flanges (36, 37) are disposed in generally parallel, spaced apart fashion, said flanges (36, 37) extending outwardly from said portion of said tubular portion (32) and flaring towards said distal, closed end (33).</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A condom (31) according to claim 2 or claim 3, wherein said flanges (36, 37) are of a pliant, form-retaining, impervious material, and said tubular portion (32) is of a pliant, thin, elastic, impervious material, said flanges (36, 37) being joined to said tubular portion (32) in continuous, sealing engagement.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A condom (31) according to any of claims 2 to 4, wherein said tubular portion (32) and said flanges (36, 37) extend about a common axis of symmetry, and said flanges (36, 37) define toroidal surfaces about said axis of symmetry.<!-- EPO <DP n="15"> --></claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A condom (31) according to claim 5, wherein said flanges (36, 37) define an ovoid shape in a plane intersecting said axis of symmetry and extending orthogonal thereto, said ovoid shape having major and minor axes, said annular channel including opposed portions intersected by said major axis which are adapted to be engaged by the lips and mouth of the condom user and compressed by partial closure of the jaws of the user to retain said condom (31) within the mouth.<!-- EPO <DP n="16"> --></claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A condom according to any of claims 1 to 6, wherein said first flange comprises a shield extending orthogonally in a plane generally orthogonal to said longitudinal axis of said tubular portion, said shield having an oval circumferential configuration.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A condom according to claim 7, wherein said tubular portion is dimensioned to receive a penis therein and said shield is disposed to mask the genital area surrounding the penis, and further including surface means applied to the proximal and distal surfaces of said shield to prevent adhesion to pubic hairs.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A condom according to claim 7 or claim 8, further including means for releasably securing said shield to said tubular portion, whereby said tubular portion may be removed from said shield and replaced after use.</claim-text></claim>
EP	0600858	B1	2000-05-17	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Kondom (31) fÃ¼r oral-genitalen Gebrauch bestehend aus einem lÃ¤nglichen, an einem Ende (33) geschlossenen und am anderen Ende (34) offenen SchlauchkÃ¶rper (32), wobei der SchlauchkÃ¶rper aus einem flÃ¼ssigkeitsdichten, flexiblen Material besteht, <b>dadurch gekennzeichnet</b>, dass das Kondom (31) erste und zweite ringfÃ¶rmige voneinander beabstandete Flansche (36, 37) nahe dem offenen Ende (34) des SchlauchkÃ¶rpers (32) aufweist, wobei die ringfÃ¶rmigen Flansche (36, 37) und der SchlauchkÃ¶rper zum Erfassen mit den Lippen des Benutzers beim oralgenitalen Gebrauch ausgebildet sind und der direkte gegenseitige Hautkontakt zwischen oralen und genitalen FlÃ¤chen verhindert wird.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Kondom (31) nach Anspruch 1, <b>dadurch gekennzeichnet</b>, dass die ersten und zweiten Flansche (36, 37) zwischen sich einen ringfÃ¶rmigen Kanal (38) zur Aufnahme der Lippen des Kondom-Benutzers bilden, um das Kondom (31) in der MundhÃ¶hle zu halten.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Kondom (31) nach Anspruch 2, <b>dadurch gekennzeichnet,</b> dass die ersten und zweiten Flansche (36, 37) im wesentlichen parallel beabstandet voneinander angeordnet sind, wobei die Flansche (36, 37) vom SchlauchkÃ¶rper (32) nach auÃŸen vorstehen und gegen das distale geschlossene Ende (33) hin konisch erweitert sind.<!-- EPO <DP n="18"> --></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Kondom (31) nach Anspruch 2 oder Anspruch 3, <b>dadurch gekennzeichnet</b>, dass die Flansche (36, 37) aus einem biegsamen, formbestÃ¤ndigen, undurchlÃ¤ssigen Material bestehen, und dass der SchlauchkÃ¶rper (32) aus einem biegsamen, dÃ¼nnen, elastischen undurchlÃ¤ssigen Material besteht, wobei die Flansche (36, 37) mit dem SchlauchkÃ¶rper (32) durchgehend und dichtend verbunden sind.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Kondom (31) nach einem der AnsprÃ¼che 2 bis 4, <b>dadurch gekennzeichnet</b>, dass der SchlauchkÃ¶rper (32) und die Flansche (36, 37) sich entlang einer gemeinsamen Symmetrieachse erstrecken und dass die Flansche (36, 37) RingflÃ¤chen um diese Symmetrieachse bilden.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Kondom (31) nach Anspruch 5, <b>dadurch gekennzeichnet</b>, dass die Flansche (36, 37) in einer die Symmetrieachse schneidenden Ebene eine ovale und zur Symmetrieachse senkrechte FlÃ¤che mit Haupt- und Nebenachsen bilden, wobei der ringfÃ¶rmige Kanal einander gegenÃ¼berliegende, von der Hauptachse geschnittene Abschnitte aufweist, die zur Aufnahme der Lippen und des Mundes des Kondombenutzers ausgebildet sind und durch leichtes SchlieÃŸen der Backen des Kiefers des Benutzers zusammengedrÃ¼ckt werden und so das Kondom (31) in der MundhÃ¶hle halten.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Kondom nach einem der AnsprÃ¼che 1 bis 6, <b>dadurch gekennzeichnet</b>, dass der erste Flansch einen Schirm umfasst, der sich senkrecht in einer zur LÃ¤ngsachse des Schlauchabschnitts im wesentlichen senkrechten Ebene erstreckt und an seinem Umfang oval ausgebildet ist.<!-- EPO <DP n="19"> --></claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Kondom nach Anspruch 7, <b>dadurch gekennzeichnet</b>, dass der Schlauchabschnitt zur Aufnahme eines Penis bemessen ist und der Schirm so angeordnet ist, dass er den genitalen Bereich um den Penis abdeckt und auÃŸerdem an den proximalen und distalen FlÃ¤chen anliegende FlÃ¤chen beinhaltet und ein Haften an den Schamhaaren verhindert.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Kondom nach Anspruch 7 oder Anspruch 8 auÃŸerdem mit Mitteln zum lÃ¶sbaren Befestigen des Schirms am Schlauchabschnitt, sodass der Schlauchabschnitt vom Schirm abnehmbar ist und nach Gebrauch ersetzt werden kann.</claim-text></claim>
EP	0600858	B1	2000-05-17	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>PrÃ©servatif (31) adaptÃ© Ã  une utilisation buccogÃ©nitale, comprenant un corps tubulaire allongÃ© (32) fermÃ© Ã  une extrÃ©mitÃ© (33) et ouvert Ã  l'autre extrÃ©mitÃ© (34), ce corps tubulaire Ã©tant constituÃ© dans un matÃ©riau flexible impermÃ©able aux liquides ; caractÃ©risÃ© en ce que le prÃ©servatif (31) est pourvu d'une premiÃ¨re et d'une deuxiÃ¨me brides annulaires (36, 37) placÃ©es prÃ¨s de l'extrÃ©mitÃ© ouverte (34) du corps tubulaire (32) et espacÃ©es l'une de l'autre ; ces brides annulaires (36, 37) et le corps tubulaire Ã©tant adaptÃ©s Ã  s'appliquer sur les lÃ¨vres d'un utilisateur, pour une utilisation buccogÃ©nitale, et Ã  empÃªcher le contact peau-Ã -peau entre les surfaces buccales et gÃ©nitales.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>PrÃ©servatif (31) selon la revendication 1, dans lequel les premiÃ¨re et deuxiÃ¨me brides (36, 37) dÃ©finissent, entre elles, un canal annulaire (38) susceptible de recevoir les lÃ¨vres de l'utilisateur du prÃ©servatif afin de retenir le prÃ©servatif (31) Ã  l'intÃ©rieur de la bouche.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>PrÃ©servatif (31) selon la revendication 2, dans lequel les premiÃ¨re et deuxiÃ¨me brides (36, 37) sont placÃ©es de faÃ§on globalement parallÃ¨le et espacÃ©e, ces brides (36, 37) s'Ã©tendant en direction de l'extÃ©rieur, Ã  partir de la partie tubulaire (32) et allant en s'Ã©vasant en direction de l'extrÃ©mitÃ© distale, fermÃ©e (33).</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>PrÃ©servatif (31) selon la revendication 2 ou la revendication 3, dans lequel les brides (36, 37) sont constituÃ©es dans un matÃ©riau flexible, conservant sa forme, impermÃ©able, et ladite partie tubulaire (32) est constituÃ©e en un matÃ©riau flexible, fin. Ã©lastic et impermÃ©able, les brides (36, 37) Ã©tant montÃ©es sur la partie tubulaire (32) selon un assemblage continu, Ã©tanche.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>PrÃ©servatif (31) selon l'une des revendications 2 Ã  4, dans lequel la partie tubulaire (32) et les brides (36, 37) s'Ã©tendent autour d'un axe commun de symÃ©trie, et les brides (36, 37) dÃ©finissent des surfaces toroÃ¯dales autour de cet axe de symÃ©trie.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>PrÃ©servatif (31) selon la revendication 5, dans lequel les brides (36, 37) dÃ©finissent une forme ovoÃ¯de dans un plan coupant l'axe de symÃ©trie et s'Ã©tendant perpendiculairement Ã  celui-ci, cette forme ovoÃ¯de ayant un grand axe et un second axe, le canal annulaire comprenant des parties opposÃ©es, coupÃ©es par le grand axe, sur lesquelles les lÃ¨vres et la bouche de l'utilisateur du prÃ©servatif sont susceptibles de s'appliquer, et<!-- EPO <DP n="21"> --> qui sont comprimÃ©es par la fermeture partielle des mÃ¢choires de l'utilisateur afin de retenir le prÃ©servatif (31) Ã  l'intÃ©rieur de la bouche.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>PrÃ©servatif (31) selon l'une quelconque des revendications 1 Ã  6, dans lequel la premiÃ¨re bride comprend une protection s'Ã©tendant perpendiculairement dans un plan globalement perpendiculaire Ã  l'axe longitudinal de la partie tubulaire, cette protection prÃ©sentant une configuration circonfÃ©rentielle ovale.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>PrÃ©servatif selon la revendication 7, dans lequel la partie tubulaire prÃ©sente des dimensions adaptÃ©es Ã  recevoir un pÃ©nis, dans lequel la protection est disposÃ©e de faÃ§on Ã  masquer la zone gÃ©nitale entourant le pÃ©nis et comprend, en outre, des dispositifs superficiels, appliquÃ©s sur les surfaces proximales et distales de la protection, afin d'empÃªcher l'adhÃ©sion sur les poils pubiens.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>PrÃ©servatif selon la revendication 7 ou la revendication 8, comprenant, en outre, des moyens permettant de fixer, de faÃ§on dÃ©tachable, la protection sur la partie tubulaire, la partie tubulaire pouvant Ãªtre dÃ©tachÃ©e de la protection et remplacÃ©e aprÃ¨s utilisation.</claim-text></claim>
EP	0600858	B1	2000-05-17	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0600858&ki=B1&pd=2000-05-17
EP	0600865	B1	2000-09-20	de	TITLE	1	XYLANASEPRODUKTION
EP	0600865	B1	2000-09-20	en	TITLE	1	XYLANASE PRODUCTION
EP	0600865	B1	2000-09-20	fr	TITLE	1	PRODUCTION DE XYLANASE
EP	0600865	B1	2000-09-20	en	DESCR	1	<p id="p0001" num="0001">This invention lies in the field of recombinant DNA technology. The invention is directed in particular at a recombinant DNA material comprising a nucleotide sequence encoding at least a ripening form of a Î²-1,4 endoxylanase of fungal origin having bread improving activity, said nucleotide sequence being selected from the group comprising the nucleotide sequence of Figure nr. 1 and equivalent nucleotide sequences such that<ul id="ul0001" list-style="dash" compact="compact"><li>the equivalent nucleotide sequence corresponds either to a nucleotide sequence encoding the amino acid sequence of Figure nr. 1 or to those parts of the amino acid sequence of Figure nr. 1 essential for an active ripening form of Î²-1,4 endoxylanase with bread improving activity, said ripening form being selected from the group comprising the mature, the pre, pro and prepro form and/or</li><li>the equivalent nucleotide sequence has a complementary strand capable of hybridizing under stringent hybridizing conditions to the nucleotide sequence of Figure nr. 1, said stringent hybridizing conditions being incubation in 6xSSC at 68Â°C with washing steps at the same temperature with 2x and 0,4xSSC respectively.</li></ul></p><p id="p0002" num="0002">A transformed cell comprising such recombinant DNA material also falls within the scope of the invention. As does such a transformed cell suitable for use in a process in which a cellulose and/or hemicellulose containing raw material is used in a functional manner known per se for the non transformed host cell, said cell becoming polyfunctional for said process upon expression of the recombinant DNA encoding the ripening form of Î²-1,4 endoxylanase and subsequently secreting at least a mature form of the Î²-1,4-endoxylanase having bread improving activity, thereby enabling degradation of xylan.</p><p id="p0003" num="0003">A Î²-1,4-endoxylanase having bread improving activity obtainable by expression of the recombinant DNA material according to the invention is also covered. A process for producing a ripening form of Î²-1,4-endoxylanase comprising an amino acid sequence according to figure 1, sequence id no 7 or 8 comprising culturing a cell according to the invention in a suitable nutrient medium and optionally isolating the resulting enzyme ripening form also forms an embodiment of the invention. Bakery products, flour compositions, bread improver compositions and dough compositions comprising the recombinant DNA material, the cell or the Î²-1,4-endoxylanase according to the invention are also claimed as part of the invention. The new products also lead to improved processes for preparing a bakery product, and for processing a cellulose containing material to prepare beer, paper, starch, gluten etc., or<!-- EPO <DP n="2"> --> to decompose cellulose- and/or hemicellulose containing waste and is directed at a cell having a certain function in a process, containing recombinant DNA encoding at least one enzyme. The invention is directed especially at a cell having a function in the field of food processing and also at cells with a function in processes in which a cellulose-containing raw material is used, such as processes for preparing beer, paper, starch, gluten etc, and processes for decomposing cellulose-containing waste such as agricultural waste, waste from paper mills etc.</p><p id="p0004" num="0004">In particular the invention is directed at cells having a function in the process of fermentation, more especially at cells with a function in the process of preparing bakery products.</p><p id="p0005" num="0005">The cell according to the invention is characterized in that the cell becomes polyfunctional for the process in which it has a function, upon expression of the recombinant DNA encoding at least one enzyme. In the case of a fermentation process for example, such as the preparation of bread, yeast is used as a cell with a particular function in said process. A yeast cell according to the invention does not only have its normal function, i.c. a function that a yeast lacking the recombinant DNA can also carry out, but also has another function in said process of bread preparation. An example of such an additional function is the expression and secretion of a bread improving enzyme.</p><p id="p0006" num="0006">The present invention is directed in particular at a cell with a function in the preparation of bakery products. Cells containing recombinant DNA encoding enzymes selected from the group of enzymes with amylolytic and/or hemicellulolytic and/or cellulolytic activity are suitable.</p><p id="p0007" num="0007">The invention is also directed at a process for the production of at least one enzyme by a polyfunctional cell as described above comprising culturing such a polyfunctional<!-- EPO <DP n="3"> --> cell in a suitable nutrient medium and optionally isolating the resulting enzyme form. In such a process, said enzyme is preferably selected from the group of enzymes with amylolytic and/or hemicellulolytic and/or cellulolytic activity. A suitable medium for carrying out the process according to the invention can consist of the medium in which the process for which the cell is polyfunctional is carried out. In the process of the preparation of a bakery product for example said medium can be the dough that is to be baked. Naturally the other usual media for culturing cells can also be used. The choice of media will depend on whether the enzyme is to be used in situ or has to be isolated. In some cases it will suffice to use the medium containing said enzyme and in other cases the enzyme will have to be isolated from the medium.</p><p id="p0008" num="0008">The invention is also directed at an enzyme encoded by the recombinant DNA in said polyfunctional cell, whereby said enzyme is obtainable from such a polyfunctional cell via the afore mentioned process for producing an enzyme. The invention is further directed at the use of such a polyfunctional cell or such an enzyme, for example in the processes described above, such as food processing and processes using a cellulose containing raw material, preferably in a process for the preparation of a bakery product.</p><p id="p0009" num="0009">Flour, yeast, water and salt are the basic ingredients of bread and other bakery products. For centuries materials having a positive effect on the manageability of the dough or the quality of the baked product have been added in the manufacture of bread and similar bakery products, for the sake of convenience further referred to as bread making. Said additives, referred to as "bread improvers", contain enzymes from malt or of microbial origin which play an important part in the different phases of bread making, namely, the preparation of the bread batter, fermentation, baking, and storage of the bread product.</p><p id="p0010" num="0010">One of the relevant characteristics of bread that is influenced by adding specific enzymes is the so-called bread volume. In order to obtain a high bread volume in practice compositions containing cellulolytic, hemicellulolytic and/or amylolytic enzymes are added. The commercially available compositions<!-- EPO <DP n="4"> --> of microbial origin, mostly originating from a fungus of one of the genera <u>Aspergillus</u> and <u>Trichoderma</u>, are substantially unpurified complex mixtures of different enzyme activities, whereby it is not exactly known which enzymes are present in the composition and which have a bread improving activity. This lack of knowledge impedes further bread improvement and especially impedes the control of the different dough processing and bread properties, such as the bread volume.</p><p id="p0011" num="0011">Further investigation into the process of preparation of bakery products resulted in the discovery that, in addition to Î±-amylase, at least a xylanase enzyme is also of importance for the bread volume. A xylanase is an enzyme that catalyzes the degradation of xylans occurring in the pentosan part of starch "tailings". The term "tailings" is directed at a fraction of, e.g., wheat starch consisting of water-insoluble hemicellulose (pentosans and arabinoxylans) and damaged starch. This fraction is formed as the intermediate or top layer of the starch pellet during centrifugation of a dough suspension obtained by washing dough to remove the gluten fraction.</p><p id="p0012" num="0012">Different xylanases have already been described in the literature, including xylanases of the bacterial species <u>Bacillus</u> <u>pumilus</u> (Panbangred et al., Mol. Gen. Genet. 192, 335-341, 1983, and Fukusaki et al., FEBS Lett. <u>171</u>, 197-201, 1984), <u>Bacillus</u> <u>subtilis</u> (Paice et al., Arch. Microbiol. <u>144</u>, 201-206, 1986), and <u>Bacillus</u> <u>circulans</u> (Yang et al., Nucl. Acids Res. <u>16</u>, 7187, 1988), of the yeast <u>Aureobasidium</u> (Leathers, Biotech. Lett. <u>10</u>, 775-780, 1988) and of the fungus <u>Aspergillus</u> <u>niger</u> (Fournier et al., Biotechnology and Bioengineering <u>27</u>, 539-546, 1985).</p><p id="p0013" num="0013">It is known from European patent application EP-A-0338452 that the properties of dough and the quality of bread can be improved by adding different enzyme compositions to the dough, including an enzyme composition having hemicellulose degrading or xylanase activity, the origin of which is not further specified. Such a hemicellulolytic enzyme composition is a relatively undefined enzyme mixture which may contain different hemicellulolytic enzymes having various<!-- EPO <DP n="5"> --> effects on the dough and bread properties. The presence of xylanases having bread improving activity to a smaller or greater extent is the coincidental result of the manner in which the enzyme composition that is intended as a bread improver has been obtained. A controlled further optimization of bread improvers, however, was not possible due to the lack of the required knowledge and of suitable recombinant DNA constructs encoding a xylanase having bread improving activity that could be used for a high production of such a xylanase.</p><p id="p0014" num="0014">For the purpose of this invention, "bread improving activity" is generally taken to mean a favourable effect on any property of the prepared bakery product (including bread) or of the dough from which the bakery or bread product is made, and is particularly taken to mean a favourable effect on the bread volume.</p><p id="p0015" num="0015">The investigation on which the invention is based has extended to the identification and cloning of a gene (<u>xylA</u>) encoding an enzyme, xylanase having bread improving activity, originating from a fungus of the species <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u>, as well as to the transformation of different species of host cells in such a manner that the gene is expressed or can be expressed in said host cells. The invention comprises recombinant DNA material as defined in the introduction originating from fungi and especially from fungal strains from the same genus and therefore the invention is not limited to the actually cloned gene.</p><p id="p0016" num="0016">The term "ripening form" refers to the different forms in which the enzyme may occur after expression of the associated gene. More in particular, it refers to both the naturally and the not naturally occurring prepro-, pre- and pro-forms and to the ultimate mature form of the enzyme resulting after cleavage of a "leader" peptide.</p><p id="p0017" num="0017">More in particular, the invention, relates to recombinant DNA material comprising DNA with a nucleotide sequence encoding<!-- EPO <DP n="6"> --> at least a ripening from of a xylanase of <u>Aspergillus</u> origin.</p><p id="p0018" num="0018">Preferably, this aspect of the invention is concerned with recombinant DNA material comprising DNA with a nucleotide sequence encoding a ripening form of a xylanase of <u>Aspergillus</u> <u>niger</u> origin, especially of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> origin.</p><p id="p0019" num="0019">A preferred embodiment of this aspect of the invention is recombinant DNA material comprising DNA with a nucleotide sequence encoding at least a ripening form of xylanase with an amino acid sequence as shown in Fig. 1, and more in particular recombinant DNA material comprising DNA with a nucleotide sequence encoding a ripening form of xylanase, as shown in Fig. 1. The invention is also directed at recombinant DNA material comprising DNA with a nucleotide sequence encoding at least a ripening form of xylanase with a nucleotide sequence that is equivalent to the nucleotide sequence of Fig. 1 with deletions, insertions or alterations in comparison to the nucleotide sequence of Fig. 1 such that the nucleotide sequence with deletions, insertions or alterations corresponds either to the amino acid sequence as shown in Fig. 1 or to those parts of the amino acid sequence of Fig. 1 essential for an active ripening form of xylanase such as mature xylanase or active pre(pro) xylanase or the nucleotide sequence with deletions, insertions or alterations has a complementary strand capable of hybridizing under hybridizing conditions to the nucleotide sequence of Fig. 1.</p><p id="p0020" num="0020">The the recombinant DNA according to the invention contains at least a sequence encoding the fungal, in particular the <u>Aspergillus</u> xylanase ripening form. In addition, the recombinant DNA may contain many other types of information, such as regulating sequences (especially a transcription promoter) and a vector part usually provided with one or more marker genes. These other types of information will often be connected with the selected host. Thus, for instance, the vector, the marker genes and the regulating sequences will be selected depending on the selected host.</p><p id="p0021" num="0021">The recombinant DNA encoding at least a ripening xylanase of fungal origin, however, may also contain other genes to be<!-- EPO <DP n="7"> --> expressed in the selected host. Such a gene nay advantageously encode at least one other enzyme, wherein said other enzyme has amylolytic and/or hemicellulolytic and/or cellulolytic activity.</p><p id="p0022" num="0022">Another aspect of the invention is a cell containing genetic material derived from recombinant DNA material according to the invention as defined above, and more in particular such a cell capable of expression of at least the xylanase ripening form encoded on said recombinant DNA material.A preference exists for such a cell that is also a polyfunctional cell according to the invention and more especially for such a polyfunctional cell capable of expressing the recombinant DNA material encoding a ripening form of xylanase of fungal origin under conditions present in raw material during preparation of a bakery product.</p><p id="p0023" num="0023">Both a polyfunctional cell containing recombinant DNA encoding at least one enzyme according to the invention, and a cell containing recombinant DNA material encoding a ripening form of xylanase of fungal origin according to the invention (as well as the combination thereof) may either be a cell which is itself the direct result of gene manipulation or be a cell originating in any manner from a cell that has been transformed by such gene manipulation. The invention further extends to both live cells and cells that are no longer alive.</p><p id="p0024" num="0024">In principle the invention knows no special limitations with respect to the nature of the cells, whereby those cells capable of expression of a xylanase ripening form of fungal origin are preferred. However the cells are preferably selected from the group consisting of bacterial cells, fungal cells, yeast cells, and plant cells.</p><p id="p0025" num="0025">Preferred examples of eminently suited host cells are<ul id="ul0002" list-style="none" compact="compact"><li>(a) fungal cells of one of the genera <u>Aspergillus</u> and <u>Trichoderma</u>, in particular fungal cells of one of the species <u>Aspergillus</u> <u>niger</u> var. <u>niger</u>, <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u>, <u>Aspergillus</u> <u>nidulans</u>, <u>Aspergillus</u> <u>oryzae</u>, <u>Trichoderma</u> <u>reisei</u> and <u>Trichoderma</u> <u>viride</u>;</li><li>(b) yeast cells of one of the genera <u>Saccharomyces</u>, <u>Kluyveromyces</u>, <u>Hansenula</u> and <u>Pichia</u>, in particular yeast<!-- EPO <DP n="8"> --> cells of one of the species <u>Saccharomyces</u> <u>cerevisiae</u>, <u>Saccharomyces</u> <u>carlbergensis</u>, <u>Kluyveromyces</u> <u>lactis</u>, <u>Kluyveromyces</u> <u>marxianus</u>, <u>Hansenula</u> <u>polymorpha</u> and <u>Pichia pastoris</u>;</li><li>(c) plant cells of a plant genus selected from the group consisting of wheat, barley, oats, maize, pea, potato and tobacco, such as plant cells of one of the species <u>Solanum</u> <u>tuberosum</u> and <u>Nicotania</u> <u>tabacum</u>; and</li><li>(d) bacterial cells of one of the bacterial genera <u>Bacillus</u>, <u>Lactobacillus</u> and <u>Streptococcus</u>, such as bacteria of the species <u>Bacillus</u> <u>subtilis</u>.</li></ul></p><p id="p0026" num="0026">Cells according to the invention as defined above (polyfunctional and/or simply containing recombinant DNA encoding a ripening form of xylanase of fungal origin) may be important as agents for multiplying the recombinant DNA or as agents for producing at least one enzyme encoded on said recombinant DNA, such as the ripening form of xylanase.</p><p id="p0027" num="0027">In the case of enzyme production it is possible to use the cell to produce enzyme and either isolate the enzyme from the culturing medium or use the medium containing the enzyme after removal of the cells as such, or in the case of the polyfunctional cells to use the cells themselves to produce the enzyme in situ in the process for which they are polyfunctional.</p><p id="p0028" num="0028">A direct use of the cells themselves is possible, e.g., if the host strain can be admitted without objection, in the production of foodstuffs as is the case for various fungal, yeast, plant, and bacterial species. In connection with bread making the yeast strains that are genetically manipulated in accordance with the present invention can for example be used directly.</p><p id="p0029" num="0029">Partly depending on the selected host the gene encoding xylanase will be used, either with or without introns occurring in said gene, either with its own transcription termination signals or originating from another gene, and either with its own leader sequence or with a signal sequence originating from another gene. For transformation of yeast, such as <u>Saccharomyces</u> <u>cerevisiae</u> (baker's yeast), it is preferable that the introns are removed and that the own<!-- EPO <DP n="9"> --> leader sequence is replaced by a signal sequence suitable for yeast, such as the signal sequence of the invertase gene, ensuring correct processing and secretion of the mature protein.</p><p id="p0030" num="0030">The removal of introns is necessary upon transformation of bacteria, such as <u>Bacillus</u> <u>subtilis</u>. In this case e.g. the Î±-amylase signal sequence can be used as signal sequence.</p><p id="p0031" num="0031">Suitable transformation methods and suitable expression vectors provided with, e.g., a suitable transcription promoter, suitable transcription termination signals, and suitable marker genes for selecting transformed cells are already known for many organisms, including different bacterial, yeast, fungal, and plant species. Reference may be made for yeast for example to Tajima et al., Yeast <u>1</u>, 67-77, 1985, which shows expression of a foreign gene under control of the <u>GAL7</u> promoter inducible by galactose in yeast, and for <u>Bacillus</u> <u>subtilis</u> for example to EP-A-0 157 441, describing a plasmid pMS48 containing the SPO2 promoter as an expression vector. For other possibilities in these and other organisms reference is made to the general literature.</p><p id="p0032" num="0032">In another aspect the present invention consists of a ripening form of a xylanase of a fungus, in particular of <u>Aspergillus</u> origin, obtained by expression of recombinant DNA material according to the invention, as defined above. Herein, special preference is given to a mature xylanase with an amino acid sequence as illustrated in figure 1, as well as to a pre(pro)-xylanase with an amino acid sequence as illustrated in figure 1 and to any amino acid sequence of an active equivalent form of xylanase comprising the amino acids of the sequence of figure 1 which are essential for xylanase activity. The invention is therefore directed at an amino acid structure leading to a tertiary enzyme structure with the same enzyme activity as the enzyme with the sequence of figure 1.</p><p id="p0033" num="0033">Yet another aspect of the invention consists of a process for producing a ripening form of a xylanase of a fungus, in particular of <u>Aspergillus</u> origin, comprising culturing a polyfunctional cell capable of expressing a xylanase ripening form and or a cell capable of expressing the recombinant DNA<!-- EPO <DP n="10"> --> material according to the invention encoding a ripening form of xylanase of fungal origin in a suitable nutrient medium, and optionally isolating the resulting xylanase ripening form. The tern "isolating the resulting xylanase ripening form" also comprises a partial purification in which an enzyme composition is recovered comprising the relevant xylanase.</p><p id="p0034" num="0034">Further aspects of the present invention are a bread improver composition comprising an enzyme selected from the group of enzymes with amylolytic and/or hemicellulolytic and/or cellulolytic activity such as a ripening form of xylanase, in particular a mature xylanase of a fungus, especially of <u>Aspergillus</u> origin, whereby said enzyme is obtainable from a polyfunctional cell according to the invention and/or from expression of recombinant DNA according to the invention encoding a ripening form of a xylanase of fungal origin and a bread improver composition comprising a polyfunctional cell according to the invention; a flour and dough composition comprising an enzyme selected from the group of enzymes with amylolytic and/or hemicellulolytic and/or cellulolytic activity such as a ripening form of xylanase, in particular a mature xylanase of a fungus, especially of <u>Aspergillus</u> origin, whereby said enzyme is obtainable from a polyfunctional cell according to the invention and/or from expression of recombinant DNA according to the invention encoding a ripening form of a xylanase of fungal origin; a flour and dough composition comprising a polyfunctional cell according to the invention; a bakery product obtained using such flour or dough compositions as described above; and a process for the preparation of a bakery product, using such flour or dough compositions especially in which a mature xylanase of a fungus, in particular of <u>Aspergillus</u> origin is included.</p><p id="p0035" num="0035">The invention, however, also extends to other uses of fungal xylanases, such as use within the scope of beer making, particularly the preparation of beers on the basis of wheat, in order to improve filterability, use in the paper-making industry to reduce water absorption by the paper material, use in the treatment of agricultural waste, etc.<!-- EPO <DP n="11"> --></p><p id="p0036" num="0036">The invention will now be elucidated by means of an extensive description of the identification, cloning and expression of a xylanase suitable as a bread improver. In the experimental work described in the examples the fungal strain <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> CBS 115.52 (ATCC 11358) is used as a source for the xylanase. According to investigations carried out by the inventors, said strain, after induction with wheat bran, is capable of producing a xylanase having bread improving properties, while the culture medium exhibits an Î±-amylase activity, a low glucanase activity and a low protease activity under these induction conditions. The amount of xylanase produced by the wild-type strain, however, is too low for use in a commercial process. For this reason the invention also provides gene manipulations enabling a biotechnological production of the xylanase on a commercial scale.</p><p id="p0037" num="0037">The conducted experimental work comprises the isolation of the gene encoding a xylanase enzyme (the <u>xylA</u> gene) from a gene library of chromosomal <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> DNA made in a Î» vector. For said isolation a probe was made with a composition derived from the N-terminal amino acid sequence of the purified mature protein as determined by the inventors. By means of this probe a number of Î» clones were isolated which possibly contained the gene. A DNA fragment from these positive A clones was subcloned. Subsequently, the DNA sequence of part of the cloned chromosomal DNA fragment was determined. By means of these results and those of mRNA analysis, the length of the <u>xylA</u> gene, the length of the mRNA, and the presence and position of an intron have been determined. It could be derived from the data that the <u>xylA</u> gene encodes a protein of 211 amino acids (a pre(pro)-form) in which the mature protein of 184 amino acids is preceded by a "leader" peptide of 27 residues.</p><p id="p0038" num="0038">Three expression vectors containing the xylanase gene including the <u>xylA</u> terminator have been constructed. In one of these vectors the <u>xylA</u> gene is preceded by its own expression signals. In the second vector the <u>xylA</u> expression signals (up to the ATG codon) have been replaced by the constitutive expression signals of the <u>Aspergillus</u> <u>nidulans</u><!-- EPO <DP n="12"> --> glyceraldehyde 3-phosphate dehydrogenase (<u>gpdA</u>) gene (see Punt et al., Gene <u>69</u>, 49-57, 1988), while in the third vector the <u>xylA</u> gene is preceded by the inducible expression signals of the <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> glucoamylase (<u>glaA</u>) gene. All the expression vectors contain the <u>Aspergillus</u> <u>nidulans</u> acetamidase (<u>amdS</u>) gene as selection marker as described by K. Wernars, "DNA mediated transformation of the filamentous fungus Aspergillus nidulans", thesis, Landbouw Hogeschool Wageningen 1986. By means of this selection marker transformants can be obtained in which the vector, and consequently also the <u>xylA</u> gene, is integrated into the genome in a large number of copies.</p><p id="p0039" num="0039">Multicopy transformants were obtained by transformation of the <u>Aspergillus</u> strains <u>A</u>. <u>niger</u> var. <u>awamori</u> and <u>A</u>. <u>niger</u> var. <u>niger</u> N402 with the above mentioned expression vectors. In shaking flask experiments the production of xylanase was measured after culturing the resulting transformants in different media. The results (maximum production levels) are listed in Table A given below, in which the xylanase activity is expressed in 10<sup>3</sup> units (U) per ml. A unit is defined as the amount of enzyme which, per 1 minute, releases an amount of reducing groups from xylan equivalent to 1 mg xylose.<!-- EPO <DP n="13"> --><tables id="tabl0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="157" he="198" img-content="table" img-format="tif"/></tables></p><p id="p0040" num="0040">After induction with xylan the <u>A</u>. <u>niger</u> var. <u>awamori</u> and <u>A</u>. <u>niger</u> var. <u>niger</u> N402 "<u>xylA</u>" multicopy transformants with <u>xylA</u> promoter produce much more xylanase than the wild type <u>A</u>. <u>niger</u> var. <u>awamori</u> and <u>A</u>. <u>niger</u> var. <u>niger</u> strains. From this and from data obtained in the molecular analysis of the gene it can be derived that the cloned gene encodes a<!-- EPO <DP n="14"> --> functional xylanase. Furthermore it is apparent from the afore mentioned that the multicopy transformants are capable of overproduction of the active enzyme. In baking tests this enzyme composition also has the desired properties.</p><p id="p0041" num="0041">Multicopy transformants of the host strains with the heterologous <u>gpdA</u> or <u>glaA</u> promoter are also capable of an increased production of active xylanase. In rich medium the "<u>gpdA</u>" transformants produce a clearly larger amount of xylanase than the wild type <u>A</u>. <u>niger</u> var. <u>awamori</u> strain. However, the production levels observed in the conducted tests are substantially lower than the level obtained in the tests with "<u>xylA</u>" multicopy transformants. After induction with starch the production levels of "<u>glaA</u>" multicopy transformants are comparable to those of "<u>xylA</u>" multicopy transformants in xylan medium.</p><p id="p0042" num="0042">In medium with wheat bran the best <u>A</u>. <u>niger</u> var. <u>awamori</u> "<u>xylA</u>" multicopy transformants produce much more xylanase than is the case in xylan medium. In this medium the best <u>A</u>. <u>niger</u> var. <u>niger</u> N402 "<u>xylA</u>" transformants reach a very high xylanase production level. The highest producing "<u>gpdA</u>" multicopy transformants of both <u>A</u>. <u>niger</u> var. <u>awamori</u> and of <u>A</u>. <u>niger</u> var. <u>niger</u> N402 in bran produce as much xylanase as in rich medium. In medium with wheat bran the production by <u>A</u>. <u>niger</u> var. <u>awamori</u> "<u>glaA</u>" transformants is lower than in starch. In this medium, however, <u>A</u>. <u>niger</u> var. <u>niger</u> N402 "<u>glaA</u>" transformants produce more than in starch.</p><p id="p0043" num="0043">The production reached by <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> N402 transformants is higher than that of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> transformants. The production level of the <u>A</u>. <u>niger</u> var. <u>awamori</u> transformants, however, can be further increased by using suitable <u>A</u>. <u>niger</u> var. <u>awamori</u> mutant strains, such as <u>A</u>. <u>niger</u> var. <u>awamori</u> #40, which produces clearly more xylanase than the wild type strain. The mutant <u>A</u>. <u>niger</u> var. <u>awamori</u> #40 has been obtained by mutagenesis of <u>A</u>. <u>niger</u> var. <u>awamori</u> spores and selection for xylanase production. In bran medium the "<u>xylA</u>" <u>A</u>. <u>niger</u> var. <u>awamori</u> #40 transformant produced 190 000 U xylanase, which is a considerable increase over the best producing <u>A</u>. <u>niger</u> var. <u>awamori</u> transformant.<!-- EPO <DP n="15"> --></p><p id="p0044" num="0044">Further experiments relate to the isolation and use of the thus produced xylanase as a bread improver (see example II) and expression experiments in a yeast strain and a bacterium (examples III and IV, respectively). While example V demonstrates the use of a polyfunctional yeast according to the invention in the preparation of bread, whereby said yeast produces xylanase during fermentation of lean bread dough.</p><heading id="h0001"><u>Discussion of the figures</u></heading><p id="p0045" num="0045"><ul id="ul0003" list-style="none" compact="compact"><li>Fig. 1 shows the DNA sequence of a part of a ca 2.1 kb <u>Pst</u>I-<u>Pst</u>I <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> fragment present in the plasmid pAW14B, which fragment contains a gene encoding a xylanase, indicated as the <u>xylA</u> gene. The translation start and the stop codon are doubly underlined. The 49 bp intron is underlined. The start of the mature protein is indicated. The amino acid acid sequence of the protein (both of the pre(pro)-form and of the mature protein) is also mentioned in Fig. 1, using the one-letter code.</li><li>Fig. 2 shows the restriction map of the genomic DNA region of <u>A.</u> <u>niger</u> var. <u>awamori</u>, comprising the <u>xylA</u> gene cloned in the phages Î»-1 and Î»-14. The used abbreviations stand for: S: <u>Sal</u>I; E: <u>Eco</u>RI; H: <u>Hind</u>III; P: <u>Pst</u>I; B: <u>Bam</u>HI; S#: <u>Sal</u>I site originating from the polylinker of Î»-EMBL3; D: <u>Sau</u>3A. The massive bar indicates a 1.2 kb <u>Pst</u>I*-<u>Bam</u>HI fragment hybridizing with Xyl06.</li><li>Fig. 3 shows the plasmid pAW14B obtained by an insertion of a 5.3 kb <u>A</u>. <u>niger</u> var. <u>awamori</u> <u>Sal</u>I fragment in pUC19.</li><li>Fig. 4 shows the plasmid pAW14S containing the <u>xylA</u> gene with its own promoter and <u>amdS</u> as a selection marker.</li><li>Fig. 5 shows the plasmid pAW14B-2 containing a translation fusion of the <u>xylA</u> gene with the <u>A</u>. <u>nidulans</u> <u>gpdA</u> promoter.</li><li>Fig. 6 shows the plasmid pAW14S-2 containing a translation fusion of the <u>xylA</u> gene with the <u>Aspergillus nidulans</u> <u>gpdA</u> promoter and <u>amdS</u> as a selection marker.</li><li>Fig. 7 shows the plasmid pAW14S-3 containing a translation fusion of the <u>xylA</u> gene with the <u>Aspergillus niger</u> <u>glaA</u> promoter and <u>amdS</u> as a selection marker.<!-- EPO <DP n="16"> --></li><li>Fig. 8 shows the nucleotide sequences of the DNA fragment BAK1 and of the synthetic oligonucleotides from which this fragment is built up.</li><li>Fig. 9 is a schematic representation of the construction of the plasmid pBAK1.</li><li>Fig. 10 shows the nucleotide sequences of the DNA fragment BAK2 and of the synthetic oligonucleotides from which this fragment is built up.</li><li>Fig. 11 is a schematic representation of the construction of the plasmid pBAK21.</li><li>Fig. 12 is a schematic representation of the construction of the plasmid pUR2901.</li><li>Fig. 13 is a schematic representation of the construction of the plasmid pUR2904.</li><li>Fig. 14 is a schematic representation of the construction of the plasmid pUR2921.</li><li>Fig. 15 shows the nucleotide sequences of the DNA fragment BAK4 and of the synthetic oligonucleotides from which this fragment is built up.</li><li>Fig. 16 is a schematic representation of the construction of the plasmid pUR2950.</li><li>Fig. 17 is a schematic representation of the construction of the plasmid pUR2951.</li><li>Fig. 18 shows the nucleotide sequence of the <u>in</u> <u>vitro</u> amplified <u>S</u>. <u>cerevisiae</u> <u>PGK</u> promoter. In the double stranded sequence the primers are shown bold, the ATG start codon is on a shaded background, and the restriction sites <u>Eco</u>RI, <u>Bgl</u>II, <u>Bsp</u>MI and <u>Hin</u>dIII are indicated.</li><li>Fig. 19 is a schematic representation of the construction of the plasmid pUR2918.</li><li>Fig. 20 shows the nucleotide sequences of the DNA fragment BAK5 and of the synthetic oligonucleotides from which this fragment is built up.</li><li>Fig. 21 is a schematic representation of the construction of the plasmid pUR2920.</li><li>Fig. 22 is a schematic representation of the construction of the plasmid pUR2922.</li><li>Fig. 23 is a schematic representation of the construction of the plasmid pUR2923.</li></ul><!-- EPO <DP n="17"> --></p><heading id="h0002"><u>EXAMPLE I</u></heading><heading id="h0003"><u>CLONING AND CHARACTERISATION OF THE XYLANASE GENE (xylA) OF ASPERGILLUS NIGER VAR. AWAMORI 1.1 Isolation of the Aspergillus_niger_var. awamori xylA gene</u></heading><p id="p0046" num="0046">In order to isolate the <u>xylA</u> gene from chromosomal DNA of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> different probes were synthesized consisting of mixtures of oligonucleotides (Table B). The composition of these mixtures was derived from the N-terminal amino acid sequence of purified xylanase protein.<tables id="tabl0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="157" he="161" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="18"> --><tables id="tabl0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="157" he="92" img-content="table" img-format="tif"/></tables></p><p id="p0047" num="0047">By means of Southern blot analysis it was established that in digests of chromosomal DNA - under stringent conditions - only one band hybridizes with the probes used. In the <u>Eco</u>RI, <u>Sal</u>I and <u>Bam</u>HI digest of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> DNA one band of respectively 4.4, 5.3 and 9.5 kb hybridizes with both Xyl01, Xyl04 and Xyl06. With Xyl05 no clear signal was found at 41Â°C. On the basis of this result a Î» gene library of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> DNA was hybridized at 65Â°C with the oligonucleotide mixture Xyl06 as a probe. Of the 65000 tested plaques (corresponding to 32 times the genome) three plaques (Î»-1, Î»-14 and Î»-63) hybridized with this probe. After hybridization of digests of Î»-1 and Î»-14 DNA with Xyl06 a hybridizing band of &gt;10 kb was found in the <u>Eco</u>RI digest of Î»-1. The size of the hybridizing band in the Î»-14 and the chromosomal <u>Eco</u>RI digest was 4.4. kb. In the <u>Sal</u>I digest of Î»-1 a 4.6 kb band hybridizes; in the <u>Sal</u>I digest of Î»-14 this is, like in chromosomal DNA, a 5.3 kb band. Also a 1.2 kb <u>Pst</u>I-<u>Bam</u>HI fragment (figure 2) hybridizes with Xyl06. On the basis of restriction patterns with different enzymes and cross-hybridization of Î»-1 and Î»-14 digests with the 5.3 kb <u>Sal</u>I fragment of Î»-14 it was confirmed that these Î»'s contained overlapping fragments of the genome of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u>. Also homologous hybridization of total induced RNA with respectively Î»-1,<!-- EPO <DP n="19"> --> Î»-14 and the 5.3 kb <u>Sal</u>I fragment of Î»l-14 confirmed the presence of <u>xyl</u> A sequences on these Î»'s. Hybridization was found with a xylan-induced mRNA of ca. 1 kb. The size thereof corresponds to that of the mRNA molecule hybridizing with Xyl06.</p><heading id="h0004"><u>1.2 Subcloning of the A.niger var. awamori xyl A gene</u></heading><p id="p0048" num="0048">The <u>Sal</u>I fragments hybridizing with Xyl06 of respectively Î»-1 (4.6 Kb) and Î»-14 (5.3 Kb) were cloned in two orientations in the <u>Sal</u>I site of pUC19, which resulted in plasmid pAW1 (A and B) and plasmid pAW14 respectively (A and B, see Fig. 3). The 1.2 Kb <u>Pst</u>I-<u>Bam</u>HI fragment hybridizing with Xyl06 and the adjacent 1.0 kb <u>Bam</u>HI-<u>Pst</u>I fragment from respectively pAW14A and pAW1A were subcloned into M13mp18 and M13mp19 cleaved with <u>Bam</u>HI and <u>Pst</u>I, resulting in the m18/m19 AW vectors of Table C. <tables id="tabl0004" num="0004"><table frame="all"><title>Table C</title><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm"/><colspec colnum="2" colname="col2" colwidth="78.75mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col2" align="left">Single-stranded subclones of Î»-1 and Î»-14 fragments</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">fragment</entry><entry namest="col2" nameend="col2" align="left">resulting vectors</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">pAW 1A BamHI-<u>Pst</u>I* (1.2 kb)</entry><entry namest="col2" nameend="col2" align="left">m18AW 1A-1 / m19AW 1A-1</entry></row><row><entry namest="col1" nameend="col1" align="left">pAW14A BamHI-<u>Pst</u>I* (1.2 kb)</entry><entry namest="col2" nameend="col2" align="left">m18AW14A-1 / m19AW14A-1</entry></row><row><entry namest="col1" nameend="col1" align="left">pAW 1A <u>Pst</u>I-BamHI (1.0 kb)</entry><entry namest="col2" nameend="col2" align="left">m18AW 1A-2 / m19AW 1A-2</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">pAW14A <u>Pst</u>I-BamHI (1.0 Kb)</entry><entry namest="col2" nameend="col2" align="left">m18AW14A-2 / m19AW14A-2</entry></row></tbody></tgroup></table></tables></p><heading id="h0005"><u>1.3 Determination of the transcription direction of the xylA gene</u></heading><p id="p0049" num="0049">The transcription direction of the <u>xylA</u> gene was established by means of spot blot hybridization of ss-DNA of respectively m18AW14A-1 and m19AW14A-1 with Xyl06. It was found that ss-DNA of m19AW14A-1 (5' *<u>Pst</u>I-<u>Bam</u>HI 3') hybridizes with this probe. Because the sequence of Xyl06 is<!-- EPO <DP n="20"> --> equal to that of the non-coding strand, m19AW14A-1 contains the coding strand. On the basis thereof the transcription direction shown in Fig. 2 was determined. This direction is confirmed by the results of a primer extension experiment.</p><heading id="h0006"><u>1.4 Identification of the xylA gene</u></heading><p id="p0050" num="0050">The DNA sequence of a part of the promoter region was determined by sequence analysis of pAW14 with Xyl06 as a primer (5' part of the gene). In this region a primer Xyl11 with the sequence 5'- GCA TAT GAT TAA GCT GC-3' was selected, with which the DNA sequence of complementary strand of m18AW14A-1 and m18AW1A-1 was determined. The results showed that these vectors contained a DNA sequence which was substantially equal to that of Xyl06, while the amino acid sequence derived from the base pair sequence was identical to the N-terminal amino acid sequence of the mature xylanase protein. Thus the cloning of at least the 5' end of the <u>xylA</u> gene was proved. The presence of the whole <u>xylA</u> gene in the vectors pAW14 and pAW1 seemed plausible on the basis of the position of the 5' end of the gene on the <u>Sal</u>I fragments (Fig. 2) and the size of the <u>xylA</u> mRNA (ca. 1 kb).<!-- EPO <DP n="21"> --></p><heading id="h0007"><u>1.5 Sequence analysis</u></heading><p id="p0051" num="0051">The base sequence of the <u>xylA</u> gene was established in two directions in both the m13AW14 and the m13AW1 subclones by means of the Sanger dideoxy procedure (Sanger et al., Proc. Natl. Acad. Sci. USA 74, 5463-5467, 1977). The sequence around the <u>Bam</u>HI site located downstream of the <u>Pst</u>I* site (Fig. 2) was established by sequence analysis of double-stranded pAW14 and pAW1 DNA. Compressions are cleared up by using dITP instead of dGTP. In the independent clones Î»-1 and Î»-14 an identical <u>xylA</u> sequence is established. The complete (coding) sequence of the pre(pro) xylanase gene is shown in Fig. 1. The mature xylanase protein is preceded by a leader peptide of 27 amino acids. Between the alanine residues at the positions 16 and 17 a cleaving site is probably present for the signal peptidase. From the length of the leader peptide it can be derived that a second processing site is present in the protein. The cleaving of the band between Arg (27) and Ser (28) possibly takes place by a KEX2-like protease.</p><heading id="h0008"><u>1.6 Localization of the intron</u></heading><p id="p0052" num="0052">In the <u>xylA</u> gene an intron of 49 or 76 bp (231-279 or 231-306, see Fig. 1) was predicted on the basis of the presence of sequences corresponding to "donor" and "acceptor" sites of introns in <u>Aspergilli</u>. Definite proof of the absence of a 76 bp intron was obtained by isolation of a xylanase peptide with the sequence Tyr-Ser-Ala-Ser-Gly... This peptide can only be localized in the protein from position 302 (see Fig. 1).</p><heading id="h0009"><u>1.7 Determination of the 3' end of the xylA gene</u></heading><p id="p0053" num="0053">The position of the stop codon of the <u>xylA</u> gene (position 683 in Fig. 1) was derived from DNA sequence data. This stop codon was confined, since the amino acid sequence of a peptide is identical to the C-terminal amino acid sequence derived from DNA sequence data (position 641-682 in Fig. 1).</p><heading id="h0010"><u>1.8 Evaluation of DNA and protein data</u></heading><!-- EPO <DP n="22"> --><p id="p0054" num="0054">On the basis of the above data the gene encoding a xylanase of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> is cloned on a 5.3 kb <u>Sal</u>I fragment. The DNA sequence of the gene, the position of the intron and the length of the mRNA were established. The established N-terminal amino acid sequence of the mature protein was fully confirmed by the DNA sequence. On the basis of the above data it can be concluded that the <u>xylA</u> gene encodes a protein of 211 amino acids and that the first 27 amino acids are post-translationally removed. The amino acid sequence derived from the DNA sequence of the <u>xylA</u> gene demonstrates a high degree of homology with the amino acid sequence of <u>Bacillus</u> <u>pumilus</u> (201 amino acids) and <u>Bacillus circulans</u> (213 amino acids including signal) xylanases.</p><heading id="h0011"><u>2 Expression vectors</u></heading><p id="p0055" num="0055">Three expression vectors were constructed containing the genomic <u>xylA</u> gene from the translation start including the <u>xylA</u> terminator. These vectors were derived from pAW14B (Fig. 3).</p><heading id="h0012"><u>2.1 Vector pAW14S with Aspergillus niger var.awamori xylA promoter</u></heading><p id="p0056" num="0056">The vector pAW14S (Fig. 4) comprises a 5.3 kb chromosomal DNA fragment of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> on which the <u>xylA</u> gene is located with its own expression signals. Further a 5.3 kb fragment of <u>Aspergillus</u> <u>nidulans</u> on which the acetamidase (<u>amdS</u>) gene is located is present on this plasmid. In pAW14S the <u>amdS</u> and the <u>xylA</u> gene have the same transcription direction.</p><heading id="h0013"><u>2.2 Vector pAW14S-2 with Aspergillus nidulans gpdA promoter</u></heading><p id="p0057" num="0057">The plasmid pAW14S-2 (Fig. 6) differs from pAW14S in that the <u>Aspergillus niger</u> var. <u>awamori</u> fragment located upstream of the ATG codon of the <u>xylA</u> gene is replaced by the constitutive expression signals (up to the ATG triplet) of the <u>Aspergillus</u> <u>nidulans</u> glyceraldehyde-3-phosphate dehydrogenase (<u>gpdA</u>) gene. In the plasmid the <u>amdS</u> and the <u>xylA</u> gene have the same orientation. The right connection between The <u>gpdA</u> promoter and the ATG codon of the <u>xylA</u> gene<!-- EPO <DP n="23"> --> was obtained by means of a synthetic DNA fragment. During the construction the plasmid pAW14B-2 in which the <u>amdS</u> selection marker is absent was also obtained (Fig. 5).</p><heading id="h0014"><u>2.3 Vector pAW14S-3 with Aspergillus niger var. niger glaA promoter</u></heading><p id="p0058" num="0058">The vector pAW14S-3 (Fig. 7) comprises the inducible expression signals of the <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> glucoamylase (<u>glaA</u>) gene up to the ATG codon followed by <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> sequences, starting at the ATG triplet of the <u>xylA</u> gene. In addition, this plasmid also comprises the <u>Aspergillus</u> <u>nidulans</u> <u>amdS</u> gene as a selection marker. The <u>amdS</u> gene and the <u>xylA</u> gene have the same orientation.</p><p id="p0059" num="0059">By means of the <u>amdS</u> selection marker transformants with the three above mentioned plasmids can be obtained in which the vector, and consequently also the (optionally hybrid) <u>xylA</u> gene, has been integrated into the genome in a large number of copies, in order to increase the production of the xylanase protein.</p><heading id="h0015"><u>3 Transformation of Aspergillus</u></heading><p id="p0060" num="0060">The transformation frequency of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> varied from 0.03 to 0.23 (AW) transformants per Âµg vector DNA. In total, this resulted in five AW14S (<u>xylA</u> promoter), forty AW14S-2 (<u>gpdA</u> promoter) and eight AW14S-3 (<u>glaA</u> promoter) transformants. In the continued investigation different transformants prove to have a deviating growth behaviour. One of them, AW14S #1, yielded properly sporulating (AW14S #1A) and poorly sporulating (AW14S #1B) colonies.</p><p id="p0061" num="0061">Transformation of <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> N402 proceeded more efficiently than that of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u>. With pAW14S, pAW14S-2 and pAW14S-3 0.3, 0.3 and 1 (AB) transformants were found respectively per mg DNA. Twenty pAB14S (<u>xylA</u> promoter), thirty pAB14S-2 (<u>gpdA</u> promoter) and sixteen pAB14S-3 (<u>glaA</u> promoter) transformants were streaked.<!-- EPO <DP n="24"> --></p><p id="p0062" num="0062">Co-transformation of <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> <u>pyrG</u> AB4.1 with pAW14S and the <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> <u>pyrG</u> gene in pAB4.1 resulted in 0.2 transformants per Âµg pAW14S DNA when both markers were selected. Upon the first selection for <u>amdS</u> 2 transformants per Âµg DNA were found, while the frequency in the first selection for <u>pyrG</u> was ca. 20 Âµg pAW14S DNA. It appeared that ca. 30% of the co-transformants (AB4.1-14S) possessed both markers. Six of them were analyzed further.</p><heading id="h0016"><u>4 Analysis of multicopy transformants</u></heading><heading id="h0017"><u>4.1 Analysis of A. niger var. awamori "xylA" transformants (AW14S) after culturing in medium with xylan as an inducer</u></heading><p id="p0063" num="0063">After culturing AW14S transformants with xylan as an inducer the xylanase production level obtained in the medium after 10 days was significantly higher than with the wild-type <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> strain. Upon storage of the media at 4Â°C the enzyme is completely stable. The production levels in xylan medium are listed in the following Table D. <tables id="tabl0005" num="0005"><table frame="all"><title>Table D</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" align="center">Xylanase production levels (in 10<sup>3</sup> U/ml) of AW14S transformants after various culturing periods in xylan medium at 25Â°C</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">No.</entry><entry namest="col2" nameend="col2" align="center">3 days</entry><entry namest="col3" nameend="col3" align="center">10 days</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">1A</entry><entry namest="col2" nameend="col2" align="right">28</entry><entry namest="col3" nameend="col3" align="right">58</entry></row><row><entry namest="col1" nameend="col1" align="left">2</entry><entry namest="col2" nameend="col2" align="right">21</entry><entry namest="col3" nameend="col3" align="right">56</entry></row><row><entry namest="col1" nameend="col1" align="left">3</entry><entry namest="col2" nameend="col2" align="right">20</entry><entry namest="col3" nameend="col3" align="right">31</entry></row><row><entry namest="col1" nameend="col1" align="left">4</entry><entry namest="col2" nameend="col2" align="right">25</entry><entry namest="col3" nameend="col3" align="right">58</entry></row><row><entry namest="col1" nameend="col1" align="left">5</entry><entry namest="col2" nameend="col2" align="right">8</entry><entry namest="col3" nameend="col3" align="right">22</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">wt</entry><entry namest="col2" nameend="col2" align="right">5</entry><entry namest="col3" nameend="col3" align="right">13</entry></row></tbody></tgroup></table></tables></p><heading id="h0018"><u>4.2 Analysis of Aspergillus niger var. niger N402 "xylA" (co)transformants (AB4.1-14S) after culturing in medium with xylan as an inducer</u></heading><!-- EPO <DP n="25"> --><p id="p0064" num="0064">The xylanase activity was determined in xylan medium of the host strain <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> <u>pyrG</u> AB4.1 and of seven AB14S-1 Pyr+ co-transformants after 48 and 72 hours of culturing respectively (see Table E). <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> AB4.1 produces little xylanase (ca. 5 000 U). For four out of seven co-transformants a high xylanase activity of ca. 30 000 U was found. The other co-transformants produced somewhat less xylanase. <tables id="tabl0006" num="0006"><table frame="all"><title>Table E</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" align="center">Xylanase production levels (in 10<sup>3</sup> U/ml) of AB4.1-14S and AB14S transformants after different culturing periods in xylan medium at 25Â°C</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">AB4.1-14S</entry><entry namest="col2" nameend="col2" align="center">48 hours</entry><entry namest="col3" nameend="col3" align="center">72 hours</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">#1</entry><entry namest="col2" nameend="col2" align="right">36</entry><entry namest="col3" nameend="col3" align="right">36</entry></row><row><entry namest="col1" nameend="col1" align="left">#6</entry><entry namest="col2" nameend="col2" align="right">31</entry><entry namest="col3" nameend="col3" align="right">20</entry></row><row><entry namest="col1" nameend="col1" align="left">#12</entry><entry namest="col2" nameend="col2" align="right">29</entry><entry namest="col3" nameend="col3" align="right">23</entry></row><row><entry namest="col1" nameend="col1" align="left">#23</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">6</entry></row><row><entry namest="col1" nameend="col1" align="left">#42</entry><entry namest="col2" nameend="col2" align="right">15</entry><entry namest="col3" nameend="col3" align="right">10</entry></row><row><entry namest="col1" nameend="col1" align="left">#44</entry><entry namest="col2" nameend="col2" align="right">21</entry><entry namest="col3" nameend="col3" align="right">30</entry></row><row><entry namest="col1" nameend="col1" align="left">#45 pyrG</entry><entry namest="col2" nameend="col2" align="right">22</entry><entry namest="col3" nameend="col3" align="right">18</entry></row><row><entry namest="col1" nameend="col1" align="left">AW.wt</entry><entry namest="col2" nameend="col2" align="right">3</entry><entry namest="col3" nameend="col3" align="right">7</entry></row><row><entry namest="col1" nameend="col1" align="left">N402</entry><entry namest="col2" nameend="col2" align="right">3</entry><entry namest="col3" nameend="col3" align="right">5</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">AB4.1</entry><entry namest="col2" nameend="col2" align="right">4</entry><entry namest="col3" nameend="col3" align="right">5</entry></row></tbody></tgroup></table></tables></p><heading id="h0019"><u>4.3 Characterisation of overproduced xylanase enzyme</u></heading><p id="p0065" num="0065">It can be derived from the highly increased xylanase activity in the medium of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> and <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> N402 multicopy "<u>xylA</u>" transformants that the cloned gene encodes xylanase from <u>Aspergillus niger</u> var. <u>awamori</u> and that the transformants are capable of overproduction of active xylanase. The presence of the desired product was shown by protein-chemical analysis of the medium of AW14S #1A. One dominant protein was present in the medium. The isoelectric point (pI) and the N-terminal amino acid sequence of this main component were equal to those of purified xylanase from wild-type <u>Aspergillus</u> <u>niger</u> var.<!-- EPO <DP n="26"> --> <u>awamori</u>. The pI value found corresponded to the value calculated for the mature protein of 184 amino acids for which the composition has been derived from the DNA sequence. In baking tests the produced xylanase also proved to possess the desired properties.</p><heading id="h0020"><u>4.4 Analysis of A. niger var. awamori (AW14S-2) and A. niger var. niger (AB14S-2) "gpdA" transformants after culturing in rich medium</u></heading><p id="p0066" num="0066">Six AW14S-2 transformants were cultured in rich medium (Table F). After two to three days a xylanase activity varying from 15 000 to 20 000 U was found in the medium of three transformants, while the other three produced less than half said activity. The wild-type strain produces no xylanase in rich medium. In addition, ten AB14S-2 transformants were tested. Three of them produced ca. 11 000 U xylanase after 40 hours, which level was maintained for at least up to 72 hours. The other five produced less xylanase enzyme, while the activity in the medium of #21B fell from 9 000 to 0 U within 24 hours.</p><p id="p0067" num="0067">It was shown that the production maximum of the best producing AW14S-2 and AB14S-2 transformants is in general reproducible. However, the maximum is not reached when the mycelium grows in large globules, while a higher maximum was found (19 000 instead of 11 000 U) in one culture of AB14S-2 #5 in duplicate. The production levels are listed in Table F.</p><p id="p0068" num="0068">The results show that it is possible to produce active xylanase by means of a translation fusion of the <u>gpdA</u> promoter and the <u>xylA</u> gene. However, the production by means of both AW14S-2 and AB14S-2 transformants regulated by the <u>gpdA</u> promoter in rich medium is lower than the xylanase production of "<u>xylA</u>" transformants in medium with xylan.<!-- EPO <DP n="27"> --> <tables id="tabl0007" num="0007"><table frame="all"><title>Table F</title><tgroup cols="6" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm"/><colspec colnum="2" colname="col2" colwidth="26.25mm"/><colspec colnum="3" colname="col3" colwidth="26.25mm"/><colspec colnum="4" colname="col4" colwidth="26.25mm"/><colspec colnum="5" colname="col5" colwidth="26.25mm"/><colspec colnum="6" colname="col6" colwidth="26.25mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col6" align="center">Xylanase production levels (in 10<sup>3</sup> U/ml) of AW14S-2 and AB14S-2 transformants after various culturing periods in rich medium at 25Â°C</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">AW14S-2</entry><entry namest="col2" nameend="col2" align="center">24 hours</entry><entry namest="col3" nameend="col3" align="center">48 hours</entry><entry namest="col4" nameend="col4" align="center">72 hours</entry><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">#1</entry><entry namest="col2" nameend="col2" align="right">&lt;1</entry><entry namest="col3" nameend="col3" align="right">3</entry><entry namest="col4" nameend="col4" align="right">&gt;3</entry><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#4</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">2</entry><entry namest="col4" nameend="col4" align="right">2</entry><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#10</entry><entry namest="col2" nameend="col2" align="right">11</entry><entry namest="col3" nameend="col3" align="right">15</entry><entry namest="col4" nameend="col4" align="right">13</entry><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#22 â–³ *</entry><entry namest="col2" nameend="col2" align="right">4</entry><entry namest="col3" nameend="col3" align="right">20</entry><entry namest="col4" nameend="col4" align="right">20</entry><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#36</entry><entry namest="col2" nameend="col2" align="right">3</entry><entry namest="col3" nameend="col3" align="right">7</entry><entry namest="col4" nameend="col4" align="right">7</entry><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">#39 *</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">16</entry><entry namest="col4" nameend="col4" align="right">12</entry><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/></row></tbody></tgroup><tgroup cols="6" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm"/><colspec colnum="2" colname="col2" colwidth="26.25mm"/><colspec colnum="3" colname="col3" colwidth="26.25mm"/><colspec colnum="4" colname="col4" colwidth="26.25mm"/><colspec colnum="5" colname="col5" colwidth="26.25mm"/><colspec colnum="6" colname="col6" colwidth="26.25mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">AB14S-2</entry><entry namest="col2" nameend="col2" align="center">24 hours</entry><entry namest="col3" nameend="col3" align="center">40 hours</entry><entry namest="col4" nameend="col4" align="center">48 hours</entry><entry namest="col5" nameend="col5" align="center">66 hours</entry><entry namest="col6" nameend="col6" align="center">72 hours</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">#2</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="right">4</entry><entry namest="col4" nameend="col4" align="right">4</entry><entry namest="col5" nameend="col5" align="right">9</entry><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#5 â–³</entry><entry namest="col2" nameend="col2" align="right">3</entry><entry namest="col3" nameend="col3" align="right">11</entry><entry namest="col4" nameend="col4" align="right">11</entry><entry namest="col5" nameend="col5" align="right">11</entry><entry namest="col6" nameend="col6" align="right">12</entry></row><row><entry namest="col1" nameend="col1" align="left">double</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="right">15</entry><entry namest="col4" nameend="col4" align="right">16</entry><entry namest="col5" nameend="col5" align="right">19</entry><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#7 â–³</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">5</entry><entry namest="col4" nameend="col4" align="right">5</entry><entry namest="col5" nameend="col5" align="right">5</entry><entry namest="col6" nameend="col6" align="right">4</entry></row><row><entry namest="col1" nameend="col1" align="left">#8</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="right">4</entry><entry namest="col4" nameend="col4" align="right">3</entry><entry namest="col5" nameend="col5" align="right">4</entry><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#11</entry><entry namest="col2" nameend="col2" align="right">&lt;1</entry><entry namest="col3" nameend="col3" align="right">&lt;1</entry><entry namest="col4" nameend="col4" align="right">1</entry><entry namest="col5" nameend="col5" align="right">1</entry><entry namest="col6" nameend="col6" align="right">0</entry></row><row><entry namest="col1" nameend="col1" align="left">#14</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="right">2</entry><entry namest="col4" nameend="col4" align="right">2</entry><entry namest="col5" nameend="col5" align="right">3</entry><entry namest="col6" nameend="col6"/></row><row><entry namest="col1" nameend="col1" align="left">#16 â–³</entry><entry namest="col2" nameend="col2" align="right">3</entry><entry namest="col3" nameend="col3" align="right">10</entry><entry namest="col4" nameend="col4" align="right">10</entry><entry namest="col5" nameend="col5" align="right">11</entry><entry namest="col6" nameend="col6" align="right">10</entry></row><row><entry namest="col1" nameend="col1" align="left">#17 â–³</entry><entry namest="col2" nameend="col2" align="right">3</entry><entry namest="col3" nameend="col3" align="right">10</entry><entry namest="col4" nameend="col4" align="right">11</entry><entry namest="col5" nameend="col5" align="right">10</entry><entry namest="col6" nameend="col6" align="right">10</entry></row><row><entry namest="col1" nameend="col1" align="left">#18</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">5</entry><entry namest="col4" nameend="col4" align="right">8</entry><entry namest="col5" nameend="col5" align="right">10</entry><entry namest="col6" nameend="col6" align="right">8</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">#21B</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="right">4</entry><entry namest="col4" nameend="col4" align="right">8</entry><entry namest="col5" nameend="col5" align="right">9</entry><entry namest="col6" nameend="col6" align="right">0 0</entry></row></tbody></tgroup><tgroup cols="6" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm"/><colspec colnum="2" colname="col2" colwidth="26.25mm"/><colspec colnum="3" colname="col3" colwidth="26.25mm"/><colspec colnum="4" colname="col4" colwidth="26.25mm"/><colspec colnum="5" colname="col5" colwidth="26.25mm"/><colspec colnum="6" colname="col6" colwidth="26.25mm"/><tbody valign="top"><row><entry namest="col1" nameend="col6" align="justify">â–³ maxima, found when repeating the culture; a culture of AB14S-2 #5 in duplicate gave a higher maximum. In rich medium <u>A</u>. <u>niger</u> var. <u>awamori</u> and transformant AW14S #4 produce no xylanase.</entry></row></tbody></tgroup></table></tables></p><heading id="h0021"><u>4.5 Analysis of Aspergillus niger var.awamori (AW14S-3 and Aspergillus niger var. niger (AB14S-3) "glaA" transformants after culturing in medium with starch as an inducer</u></heading><p id="p0069" num="0069">Some AW14S-3 transformants and the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> wild-type strain were cultured in starch medium<!-- EPO <DP n="28"> --> (Table G). A xylanase activity of 67 000 U/ml was found in the medium of one transformant after 90 hours of culturing , while two other transformants produced up to 36 000 U/ml. The production maximum of six analyzed AB14S-3 transformants lies one day earlier than of AW14S-3 transformants. An activity of 51 000 U/ml was found in the medium of one transformant two others produced about 43 000 U/ml, after 63 hours of culturing. The results show that the translation fusion between the <u>glaA</u> promoter and the <u>xylA</u> gene is effected in the right manner. Both AW14S-3 and AB14S-3 transformants produce substantially as much xylanase enzyme in starch medium, regulated by the <u>glaA</u> promoter, as "<u>xylA</u>" transformants in medium with xylan. <tables id="tabl0008" num="0008"><table frame="all"><title>Table G</title><tgroup cols="4" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm"/><colspec colnum="2" colname="col2" colwidth="39.37mm"/><colspec colnum="3" colname="col3" colwidth="39.37mm"/><colspec colnum="4" colname="col4" colwidth="39.37mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col4" align="center">Xylanase production levels (in 10<sup>3</sup> U/ml) of "<u>glaA</u>" transformants AW14S-3 and AB14S-3 after different culturing periods (hours) in starch medium at 25Â°C</entry></row><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" rowsep="0" align="center">40 hour</entry><entry namest="col3" nameend="col3" rowsep="0" align="center">63 hour</entry><entry namest="col4" nameend="col4" rowsep="0" align="center">90 hour</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">AW14S-3</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">#1</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="right">37</entry><entry namest="col4" nameend="col4" align="right">37</entry></row><row><entry namest="col1" nameend="col1" align="left">#2</entry><entry namest="col2" nameend="col2" align="right">4</entry><entry namest="col3" nameend="col3" align="right">14</entry><entry namest="col4" nameend="col4" align="right">15</entry></row><row><entry namest="col1" nameend="col1" align="left">#4</entry><entry namest="col2" nameend="col2" align="right">8</entry><entry namest="col3" nameend="col3" align="right">31</entry><entry namest="col4" nameend="col4" align="right">36</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">#7</entry><entry namest="col2" nameend="col2" align="right">16</entry><entry namest="col3" nameend="col3" align="right">49</entry><entry namest="col4" nameend="col4" align="right">67</entry></row></tbody></tgroup><tgroup cols="4" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm"/><colspec colnum="2" colname="col2" colwidth="39.37mm"/><colspec colnum="3" colname="col3" colwidth="39.37mm"/><colspec colnum="4" colname="col4" colwidth="39.37mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">AB14S-3</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">#4</entry><entry namest="col2" nameend="col2" align="right">23</entry><entry namest="col3" nameend="col3" align="right">51</entry><entry namest="col4" nameend="col4" align="right">29</entry></row><row><entry namest="col1" nameend="col1" align="left">#5</entry><entry namest="col2" nameend="col2" align="right">19</entry><entry namest="col3" nameend="col3" align="right">37</entry><entry namest="col4" nameend="col4" align="right">21</entry></row><row><entry namest="col1" nameend="col1" align="left">#7</entry><entry namest="col2" nameend="col2" align="right">23</entry><entry namest="col3" nameend="col3" align="right">44</entry><entry namest="col4" nameend="col4" align="right">18</entry></row><row><entry namest="col1" nameend="col1" align="left">#8</entry><entry namest="col2" nameend="col2" align="right">17</entry><entry namest="col3" nameend="col3" align="right">28</entry><entry namest="col4" nameend="col4" align="right">32</entry></row><row><entry namest="col1" nameend="col1" align="left">#14</entry><entry namest="col2" nameend="col2" align="right">21</entry><entry namest="col3" nameend="col3" align="right">43</entry><entry namest="col4" nameend="col4" align="right">19</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">#16</entry><entry namest="col2" nameend="col2" align="right">6</entry><entry namest="col3" nameend="col3" align="right">21</entry><entry namest="col4" nameend="col4" align="right">10</entry></row></tbody></tgroup></table></tables></p><heading id="h0022"><u>4.6 Analysis of "xylA" transformants after culturing in medium with wheat bran</u></heading><p id="p0070" num="0070">It is apparent from the results (Tables H and I) that the production level observed for AW14S #4 when culturing in medium with wheat bran is higher than that in xylan medium. A<!-- EPO <DP n="29"> --> high production level was obtained with AB4.1-14S (#1 and #44) and AB14S (#5 and #14) transformants. The xylanase activity obtained with said transformants was determined as being as high as 140 000 U/ml. This means a considerable increase with respect to the production in xylan medium (30 000 U/ml). It further appears that the production level of these <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> transformants is also maintained upon prolonging the culturing period, as was found earlier with <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> "<u>xylA</u>" transformants in xylan medium.</p><heading id="h0023"><u>4.7 Analysis of "gpdA" transformants after culturing in medium with wheat bran</u></heading><p id="p0071" num="0071">AW14S-2 #22 and #39 produced up to 28 000 U/ml xylanase. The AB14S-2 #5 and #17 transformants produced relatively little xylanase (activity up to 15 000 U/ml) with wheat bran, as was also found in rich medium. The production levels are listed in Tables H and I.</p><heading id="h0024"><u>4.8 Analysis of "glaA" transformants after culturing in medium with wheat bran</u></heading><p id="p0072" num="0072">The tested AW14S-3 (#1 and #7) transformants produced up to 25 000 and 45 000 U/ml xylanase respectively in medium with wheat bran, which for both is ca. 60-65% of the values found in starch (Table I). With AB14S-3 (#4 and #14) transformants, however, a higher production was determined with wheat bran than in starch. The production levels determined are 1.5 times higher than in starch. A production of 72 000 U/ml was obtained with AB14S-3. A value of 66 000 U/ml was found with AB14S-3 #14 (Table I).<!-- EPO <DP n="30"> --> <tables id="tabl0009" num="0009"><table frame="all"><title>Table H</title><tgroup cols="7" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col7" align="center">Xylanase production levels (in 10<sup>3</sup> U/ml) of some AW and AB "<u>xylA</u>" and "<u>gpdA</u>" transformants after various culturing periods in medium containing bran at 25Â°C</entry></row><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="center">40 hours</entry><entry namest="col4" nameend="col4" align="center">63 hours</entry><entry namest="col5" nameend="col5" align="center">4 days</entry><entry namest="col6" nameend="col6" align="center">7 days</entry><entry namest="col7" nameend="col7" align="center">12 days</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Aw wt</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">1</entry><entry namest="col5" nameend="col5" align="right">2</entry><entry namest="col6" nameend="col6" align="right">16</entry><entry namest="col7" nameend="col7" align="right">17</entry></row><row><entry namest="col1" nameend="col1" align="left">AW14S</entry><entry namest="col2" nameend="col2" align="left">#4</entry><entry namest="col3" nameend="col3" align="right">8</entry><entry namest="col4" nameend="col4" align="right">20</entry><entry namest="col5" nameend="col5" align="right">27</entry><entry namest="col6" nameend="col6" align="right">61</entry><entry namest="col7" nameend="col7" align="right">80</entry></row><row><entry namest="col1" nameend="col1" align="left">AB14S</entry><entry namest="col2" nameend="col2" align="left">#14</entry><entry namest="col3" nameend="col3" align="right">6</entry><entry namest="col4" nameend="col4" align="right">74</entry><entry namest="col5" nameend="col5" align="right">114</entry><entry namest="col6" nameend="col6" align="right">126</entry><entry namest="col7" nameend="col7" align="right">122</entry></row><row><entry namest="col1" nameend="col1" align="left">AB4.1-14S</entry><entry namest="col2" nameend="col2" align="left">#1</entry><entry namest="col3" nameend="col3" align="right">17</entry><entry namest="col4" nameend="col4" align="right">87</entry><entry namest="col5" nameend="col5" align="right">123</entry><entry namest="col6" nameend="col6" align="right">135</entry><entry namest="col7" nameend="col7" align="right">145</entry></row><row><entry namest="col1" nameend="col1" align="left">AW14S-2</entry><entry namest="col2" nameend="col2" align="left">#22</entry><entry namest="col3" nameend="col3" align="right">17</entry><entry namest="col4" nameend="col4" align="right">22</entry><entry namest="col5" nameend="col5" align="right">22</entry><entry namest="col6" nameend="col6" align="right">34</entry><entry namest="col7" nameend="col7" align="right">33</entry></row><row><entry namest="col1" nameend="col1" align="left">AW14S-2</entry><entry namest="col2" nameend="col2" align="left">#39</entry><entry namest="col3" nameend="col3" align="right">18</entry><entry namest="col4" nameend="col4" align="right">22</entry><entry namest="col5" nameend="col5" align="right">21</entry><entry namest="col6" nameend="col6" align="right">24</entry><entry namest="col7" nameend="col7" align="right">20</entry></row><row><entry namest="col1" nameend="col1" align="left">AB14S-2</entry><entry namest="col2" nameend="col2" align="left">#5</entry><entry namest="col3" nameend="col3" align="right">13</entry><entry namest="col4" nameend="col4" align="right">15</entry><entry namest="col5" nameend="col5" align="right">11</entry><entry namest="col6" nameend="col6" align="right">8</entry><entry namest="col7" nameend="col7" align="right">8</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">AB14S-2</entry><entry namest="col2" nameend="col2" align="left">#17</entry><entry namest="col3" nameend="col3" align="right">9</entry><entry namest="col4" nameend="col4" align="right">13</entry><entry namest="col5" nameend="col5" align="right">11</entry><entry namest="col6" nameend="col6" align="right">7</entry><entry namest="col7" nameend="col7" align="right">7</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="31"> --> <tables id="tabl0010" num="0010"><table frame="all"><title>Table I</title><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col7" align="center">Xylanase production levels (in 10<sup>3</sup> U/ml) of AW and AB transformants after various culturing periods in wheat bran medium at 25Â°C</entry></row><row><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="center">2 days</entry><entry namest="col3" nameend="col3" align="center">3 days</entry><entry namest="col4" nameend="col4" align="center">4 days</entry><entry namest="col5" nameend="col5" align="center">7 days</entry><entry namest="col6" nameend="col6" align="center">9 days</entry><entry namest="col7" nameend="col7" align="center">14 days</entry></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">Aw wt</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">2</entry><entry namest="col5" nameend="col5" align="right">8</entry><entry namest="col6" nameend="col6" align="right">10</entry><entry namest="col7" nameend="col7" align="right">11</entry></row><row><entry namest="col1" nameend="col1" align="left">N402 wt</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">4</entry><entry namest="col5" nameend="col5" align="right">2</entry><entry namest="col6" nameend="col6" align="right">1</entry><entry namest="col7" nameend="col7"/></row></tbody></tgroup><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center">AW14S</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/><entry namest="col7" nameend="col7"/></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">#1A</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">18</entry><entry namest="col5" nameend="col5" align="right">39</entry><entry namest="col6" nameend="col6" align="right">51</entry><entry namest="col7" nameend="col7"/></row><row><entry namest="col1" nameend="col1" align="left">#4</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">34</entry><entry namest="col5" nameend="col5" align="right">67</entry><entry namest="col6" nameend="col6" align="right">76</entry><entry namest="col7" nameend="col7" align="right">76</entry></row></tbody></tgroup><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center">AB14S</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/><entry namest="col7" nameend="col7"/></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">#5</entry><entry namest="col2" nameend="col2" align="right">45</entry><entry namest="col3" nameend="col3" align="right">80</entry><entry namest="col4" nameend="col4" align="right">100</entry><entry namest="col5" nameend="col5" align="right">111</entry><entry namest="col6" nameend="col6" align="right">109</entry><entry namest="col7" nameend="col7" align="right">118</entry></row><row><entry namest="col1" nameend="col1" align="left">#14</entry><entry namest="col2" nameend="col2" align="right">45</entry><entry namest="col3" nameend="col3" align="right">77</entry><entry namest="col4" nameend="col4" align="right">79</entry><entry namest="col5" nameend="col5" align="right">100</entry><entry namest="col6" nameend="col6" align="right">92</entry><entry namest="col7" nameend="col7"/></row></tbody></tgroup><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center">AB4.1-14S</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/><entry namest="col7" nameend="col7"/></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">#1</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="right">95</entry><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5" align="right">90</entry><entry namest="col6" nameend="col6" align="right">73</entry><entry namest="col7" nameend="col7"/></row><row><entry namest="col1" nameend="col1" align="left">#44</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">121</entry><entry namest="col5" nameend="col5" align="right">144</entry><entry namest="col6" nameend="col6" align="right">148</entry><entry namest="col7" nameend="col7" align="right">145</entry></row></tbody></tgroup><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center">AW14S-2</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/><entry namest="col7" nameend="col7"/></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">#22</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">22</entry><entry namest="col5" nameend="col5" align="right">29</entry><entry namest="col6" nameend="col6" align="right">29</entry><entry namest="col7" nameend="col7"/></row><row><entry namest="col1" nameend="col1" align="left">#39</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">17</entry><entry namest="col5" nameend="col5" align="right">26</entry><entry namest="col6" nameend="col6" align="right">28</entry><entry namest="col7" nameend="col7"/></row></tbody></tgroup><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center">AB14S-2</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/><entry namest="col7" nameend="col7"/></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">#5</entry><entry namest="col2" nameend="col2" align="right">15</entry><entry namest="col3" nameend="col3" align="right">14</entry><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5" align="right">12</entry><entry namest="col6" nameend="col6" align="right">-</entry><entry namest="col7" nameend="col7"/></row><row><entry namest="col1" nameend="col1" align="left">#17</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">11</entry><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5" align="right">9</entry><entry namest="col6" nameend="col6" align="right">-</entry><entry namest="col7" nameend="col7"/></row></tbody></tgroup><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center">AW14S-3</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/><entry namest="col7" nameend="col7"/></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">#1</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">18</entry><entry namest="col5" nameend="col5" align="right">26</entry><entry namest="col6" nameend="col6" align="right">25</entry><entry namest="col7" nameend="col7"/></row><row><entry namest="col1" nameend="col1" align="left">#7</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4" align="right">37</entry><entry namest="col5" nameend="col5" align="right">45</entry><entry namest="col6" nameend="col6" align="right">45</entry><entry namest="col7" nameend="col7" align="right">41</entry></row></tbody></tgroup><tgroup cols="7" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="22.50mm"/><colspec colnum="2" colname="col2" colwidth="22.50mm"/><colspec colnum="3" colname="col3" colwidth="22.50mm"/><colspec colnum="4" colname="col4" colwidth="22.50mm"/><colspec colnum="5" colname="col5" colwidth="22.50mm"/><colspec colnum="6" colname="col6" colwidth="22.50mm"/><colspec colnum="7" colname="col7" colwidth="22.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center">AB14S-3</entry><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3"/><entry namest="col4" nameend="col4"/><entry namest="col5" nameend="col5"/><entry namest="col6" nameend="col6"/><entry namest="col7" nameend="col7"/></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">#4</entry><entry namest="col2" nameend="col2" align="right">72</entry><entry namest="col3" nameend="col3" align="right">54</entry><entry namest="col4" nameend="col4" align="right">44</entry><entry namest="col5" nameend="col5" align="right">23</entry><entry namest="col6" nameend="col6" align="right">17</entry><entry namest="col7" nameend="col7"/></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">#14</entry><entry namest="col2" nameend="col2" align="right">64</entry><entry namest="col3" nameend="col3" align="right">66</entry><entry namest="col4" nameend="col4" align="right">69</entry><entry namest="col5" nameend="col5" align="right">55</entry><entry namest="col6" nameend="col6" align="right">55</entry><entry namest="col7" nameend="col7" align="right">55</entry></row></tbody></tgroup></table></tables></p><heading id="h0025"><u>4.9 Evaluation of the results</u></heading><p id="p0073" num="0073">The results as summarized in Table A show that multicopy transformants of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> (AW14S) and <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> (AB14S) are capable of overproduction of active xylanase after induction of their own <u>xylA</u> promoter with respectively xylan and wheat bran as<!-- EPO <DP n="32"> --> an inducer. Expression of xylanase by multicopy transformants of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> and <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> N402 with the <u>xylA</u> gene under control of the <u>gpdA</u> promoter (respectively AW14S-2 and AB14S-2) and the <u>glaA</u> promoter (respectively AW14S-3 and AB14S-3) indicates that xylanase can be produced in a wide range of substrates. Variability in the productivities between the different transformants may be the result of differences in copy number and/or of differences in the site of integration into the genome. Of course, the testing conditions may also have a significant effect on the xylanase production. For optimization of the production, however, preference will be given to strains showing a relatively high productivity.</p><heading id="h0026"><u>5 Materials and methods</u></heading><heading id="h0027"><u>5.1 Strains and plasmids</u></heading><p id="p0074" num="0074">In the experiments the following strains and plasmids were used:<ul id="ul0004" list-style="dash" compact="compact"><li><u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> strain CBS 115.52, ATCC11358;</li><li><u>Aspergillus</u> <u>niger</u> var. <u>niger</u> strain N402, a cspA1 (short conidiophores) mutant of <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> ATCC9029, CBS 120.49;</li><li><u>Aspergillus</u> <u>niger</u> var. <u>niger</u> AB4.1, a <u>pyrG</u> mutant of <u>Aspergillus niger</u> var. <u>niger</u> N402, described by Van Hartingsveldt et al., Mol.Gen.Genet. 206, 71-75, 1987;</li><li><u>Escherichia</u> <u>coli</u> strain JM109 (for plasmid isolation, see Yanisch-Perron et al., Gene 33, 103-119, 1985);</li><li><u>Escherichia</u> <u>coli</u> strain NM539 (for construction and amplification of the lambda-gene library);</li><li>plasmid pGW325, containing the <u>amdS</u> gene of <u>Aspergillus nidulans</u> see K. Wernars, "DNA-mediated transformation of the filamentous fungus Aspergillus nidulans", Thesis, Agricultural University of Wageningen, 1986;</li><li>plasmid pAB4.1, containing the <u>pyrG</u> gene of <u>Aspergillus niger</u> var. <u>niger</u> N402, see Van Hartingsveldt et al., Mol. Gen.Genet. 206,71-75, 1987;<!-- EPO <DP n="33"> --></li><li>plasmid pAN52-1, described by Punt et al., Gene 56, 117-124, 1987; and plasmid pAN52-6, described by P.J. Punt, J. Biotechn., in press;</li><li>vector Î»-EMBL3 (for construction of an <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> gene library), obtainable from Promega Biotec.</li></ul></p><p id="p0075" num="0075">An <u>Escherichia</u> <u>coli</u> JM109 strain containing the plasmid pAW14B was deposited with the Centraalbureau voor Schimmelcultures (CBS) of Baarn, The Netherlands, under number CBS 237.90, on May 31, 1990.</p><heading id="h0028"><u>5.2 Aspergillus transformation</u></heading><p id="p0076" num="0076">Aspergillus <u>niger</u> var. <u>awamori</u> protoplasts were made from mycelium by means of Novozym 234 (NOVO). The yield of protoplasts was 1-5 x 107/g mycelium and the viability was 3-8%. Per transformation 3-8 x 105 viable protoplasts were incubated with 5, 10 or 20 mg, plasmid DNA that had twice undergone CsCl purification. Transformed protoplasts were plated on osmotically stabilized selection plates (acetamide as a nitrogen source) and incubated at 25Â°C. After 6-10 days colonies were visible. Transformation of <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> N402 and <u>A.</u> <u>niger</u> var. <u>niger</u> AB4.1 respectively was in principle carried out as described above. In the case of <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> <u>pyrG</u> AB4.1, however, uridine was added to the medium. In the co-transformation of <u>A.</u> <u>niger</u> var. <u>niger</u> AB4.1, pAW14S and pAB4.1 DNA were mixed in a weight ratio of 4 : 1; transformants were selected on acetamide plates with uridine (<u>amdS</u> selection), without uridine (<u>amdS</u> and <u>pyrG</u> selection) and on minimal medium plates with nitrate (<u>pyrG</u> selection) respectively. After 4-5 days colonies became visible. (Co-)transformants were streaked twice onto acetamide plates. In order to obtain large amounts of spores, spores from the second streak were streaked through onto plates with rich medium and incubated for 5-6 days at 25-28Â°C. The resulting spores were stored as a suspension (108-109 spores/ml) or adsorbed to silica gel so that the spores can be stored for a long time.</p><heading id="h0029"><u>5.3 Construction of A.niger var. awamori gene library</u></heading><!-- EPO <DP n="34"> --><p id="p0077" num="0077">Chromosomal DNA was isolated from mycelium of <u>Aspergillus niger</u> var. <u>awamori</u>. The high molecular DNA was partially cleaved with <u>Sau</u>3AI, followed by isolation of fragments of 13-17 kb after electrophoresis on a 0.4% agarose gel. Of these fragments 0.4 mg were ligated with 1.2 mg Î»-EMBL3 DNA which was cleaved with <u>Bam</u>HI and <u>Eco</u>RI. The ligation mixture was provided with phage coats by means of an <u>in</u> <u>vitro</u> packaging system (Amersham). By transduction to <u>E.</u> <u>coli</u> NM539 a gene library of ca. 154 000 plagues was obtained. These represented ca. 75 x the genome of <u>A.</u> <u>niger</u> var. <u>awamori</u>. 65 000 Plaques were transferred to nitrocellulose filters (in duplicate).</p><heading id="h0030"><u>5.4 Hybridisation experiments</u></heading><p id="p0078" num="0078">Southern blot analysis: hybridisation of digests of chromosomal <u>A.</u> <u>niger</u> var. <u>awamori</u> DNA with radioactively labelled oligonucleotide mixtures Xyl04 and Xyl06 (47 mers) was carried out in 6 x SSC at respectively 68Â°C, 62Â°C and 56Â°C; for Xyl01 and Xyl05 (23 mers) a hybridization temperature of 41Â°C was used. The selected hybridization temperature was at least 5Â°C below the calculated melting temperature. Blots were washed at the hybridization temperature with 5 x and 3 x SSC respectively. Hybridization was carried out at 68Â°C in 6 x SSC, while the last washing steps were carried out at the same temperature with 2x and 0.4xSSC respectively.</p><p id="p0079" num="0079">Northern blot analysis: total, non-induced RNA of <u>A.</u> <u>niger</u> var. <u>awamori</u> was isolated from mycelium of rich medium cultures (after 3 days of culturing at 25Â°C). Induced RNA originated from cultures in which 1% xylan or 4% wheat bran was used as an inducer. Mycelium was collected from the last-mentioned cultures after different culturing periods. After 3 and 6 days respectively mycelium was isolated from medium with wheat bran. Mycelium of xylan medium was collected after 6 and 11 days of culturing respectively. Hybridization conditions were equal to those in the Southern blot analysis.</p><heading id="h0031"><u>5.5 Culturing conditions</u></heading><!-- EPO <DP n="35"> --><p id="p0080" num="0080">Media: xylan medium contains 1% xylan, 0.67% yeast extract with amino acids (Difco) and 0.1% cas. amino acids. Medium with wheat bran consists of 4 g wheat bran in 50 ml mains water, to which 50 ml of a salt solution (pH 5.0) is added up to a final concentration of 0.5% (NH4)2SO4, 0.15% KH2PO4, 0.025% MgSO4 AND 0.025% KCl. Rich medium for expression tests is minimal medium (0.05% MgSO4, 0.6% NaNO3, 0.05% KCl, 0.15% KH2PO4 and trace elements), with 1% glucose, 0.2% trypticase (BBL), 0.5% yeast extract, 0.1% cas. amino acids and vitamin. Starch medium contains 5% starch and 0.1% glucose in minimal medium. Media were sterilized for 30 min. at 120Â°C. Medium (100 ml in a 500 ml flask) was inoculated with 2 x 105 spores/ml, followed by culturing in an air incubator (300 rpm) at 25Â°C for different periods. Cultures with wheat bran as an inducer (Table I) were inoculated with 4 x 105 spores/ml.</p><heading id="h0032"><u>5.6 Determination of xylanase activity in medium of Aspergillus cultures</u></heading><p id="p0081" num="0081">The xylanase activity was established by determining the formation of reducing sugars. Procedure: a (diluted) medium sample was added to 125 Âµl 2% xylan (Sigma) in 0.5 M Na acetate pH 5.0 at 40Â°C, followed by incubation of the reaction mixture for 30 min. at 40Â°C. The reaction was immediately stopped with 0.5 ml 2-hydroxy-3,5-dinitro-benzoic acid (DNS) reagent, followed by supplementing the volume with water up to 1 ml. The reaction mixture was heated for 5 min. at 100Â°C and cooled to room temperature. The OD was determined at 534 nm against a blank. The xylanase activity determination of one sample was carried out at least twice. 0.5 M Na acetate pH 5.0 was used for diluting the media .</p><heading id="h0033"><u>5.7 Selection of transformants</u></heading><p id="p0082" num="0082">In the analysis of the many transformants the host strains and ca. 6 transformants from one series were cultured in rich or selective medium, followed by determination of the xylanase production level. Two transformants from each series, with the highest xylanase production, were analyzed again in the same medium. In addition, the production level<!-- EPO <DP n="36"> --> of these transformants was determined in medium with wheat bran.</p><heading id="h0034"><u>5.8 Construction of expression vectors</u></heading><p id="p0083" num="0083">pAW14S (with the <u>Aspergillus</u> <u>niger</u> var. <u>niger</u> <u>xylA</u> promoter): the expression vector pAW14S (Fig. 4) was constructed by insertion of a 5.0 kb <u>Eco</u>RI fragment of plasmid pGW325, on which the <u>Aspergillus</u> <u>nidulans</u> <u>amdS</u> gene is located, into the <u>Eco</u>RI site of the polylinker of pAW14B (Fig. 3). In pAW14S the <u>amdS</u> and <u>xylA</u> gene have the same transcription direction.</p><p id="p0084" num="0084">pAW14S-2 (with the <u>A.</u> <u>nidulans</u> <u>gpdA</u> promoter): the linear 1.8 kb <u>Stu</u>I-<u>Nco</u>I fragment of pAN52-1, on which the <u>A.</u> <u>nidulans gpdA</u> promoter (up to the ATG triplet) is located, was ligated with the 7.2 kb <u>Nco</u>I*-<u>Sma</u>I fragment of pAW14B, obtained by partial digestion with <u>Nco</u>I and complete digestion with <u>Sma</u>I. Transformation of <u>E.</u> <u>coli</u> JM109 resulted in isolation of plasmid pAW14B-1 (9.0 kb1). The 7.2 kb <u>Nru</u>I*-<u>Nco</u>I* fragment of pAW14B-1, obtained by partial digestion with <u>Nco</u>I and complete digestion with <u>Nru</u>I, was ligated with a synthetic fragment (79 bp, nucleotides Nos. 1-78 of the coding strand and nucleotides Nos. 4-78 of the template strand), consisting of <u>xylA</u> sequences from the ATG triplet, resulting in pAW14B-2 (Fig. 5). The 5.0 kb <u>Eco</u>RI fragment of pGW325 (<u>Aspergillus</u> <u>nidulans</u> <u>amdS</u> gene) was introduced into the unique <u>Eco</u>RI site of pAW14B-2, resulting in pAW14S-2 (Fig. 6). The <u>amdS</u> and the <u>xylA</u> gene have the same orientation in this plasmid. The connection of the <u>gpdA</u> promoter to the ATG codon of the <u>xylA</u> gene as well as the sequence of the synthetic fragment was verified by means of DNA sequence analysis.</p><p id="p0085" num="0085">pAW14S-3 (with the <u>A.</u> <u>niger</u> var. <u>niger</u> N402 <u>glaA</u> promoter): pAN52-6 was partially cleaved with <u>Xmn</u>I (3 sites). The linear 7.5 kb fragment, on which the <u>A.</u> <u>niger</u> var. <u>niger</u> N402 <u>glaA</u> promoter is located, was isolated. After cleaving this fragment with <u>Bss</u>HII a 7.35 kb <u>Bss</u>HII-<u>Xmn</u>I fragment was ligated with a synthetic DNA fragment (ca. 150 bp) containing the 3' end of the <u>glaA</u> promoter up to the ATG triplet, followed by the <u>xylA</u> gene from the ATG triplet to the <u>Nru</u>I site<!-- EPO <DP n="37"> --> located in the gene with a <u>Bss</u>HII terminus behind that. The plasmid pAN52-6.URL that was thus obtained was cleaved with <u>Nco</u>I and with <u>Nru</u>I, after filling in the <u>Nco</u>I site. The DNA sequence of the synthetic fragment in pAN52-6.URL was checked. The <u>glaA</u> promoter was placed before the <u>xylA</u> gene by ligation of the 2.5 kb "filled <u>Nco</u>I"-<u>Nru</u>I fragment from pAN52-6.URL with the ca. 10 kb <u>Nru</u>I fragment of pAW14S. Insertion of this fragment in the right orientation resulted in pAW14S-3 (Fig. 7).</p><heading id="h0035"><u>EXAMPLE II</u></heading><heading id="h0036"><u>BAKING TESTS</u></heading><p id="p0086" num="0086">The bread improving activity of the xylanase, obtained after isolation from fermentation broth, was tested by measuring the volume increase of Belgian bread rolls baked after addition of increasing amounts of enzyme and dough. The xylanase was isolated as follows.</p><p id="p0087" num="0087"><u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> transformant AW14S.1A was cultured for 7 days on medium with 4% wheat bran in a fermentor having an operating volume of 8 liter. The xylanase production was ca. 85 000 U/ml. The fungal cells were removed by a filtration over a cloth. Ammonium sulphate was then added to 6 litres of filtrate, with stirring, up to 50% by weight. The precipitate was centrifuged in a Sorvall GSA rotor at 10 000g for 20 minutes. The pellet was suspended in 500 ml aqua dest. and then centrifuged again at 10 000g. The supernatant was then concentrated by ultrafiltration by means of an Amicon PM10 ultrafiltration membrane up to a volume of 60 ml. In order to remove the ammonium sulphate the ultrafiltration was repeated twice after dilution with aqua dest. to 300 and 600 ml respectively. The finally obtained material that was present in a volume of 50 ml was then freeze dried. The yield was 4.8 g with a specific activity of 60 000 U/mg (56% overall). For use in baking tests the xylanase was mixed with starch to a concentration of 240 U/mg.</p><p id="p0088" num="0088">600 ml Water, 20 g salt, 20 g sugar (sucrose), 50 g yeast (Koningsgist from Gist Brocades) and 0, 50, 100 or 200 mg/kg xylanase (240 U/mg) were added to 1000 g wheat flour Banket<!-- EPO <DP n="38"> --> Extra (from Wessanen). The dough species were kneaded in an Eberhardt kneader for ten minutes at a dough temperature of 24Â°C. After 20 minutes of fermentation at 28Â°C the dough was beaten, divided into small dough portions of ca. 50 g and once again fermented in a raising cabinet for 60 minutes at 35Â°C to 38Â°C. The dough portions were then baked at 230Â°C for 20 minutes. The specific volumes (in ml/g) were determined by dividing the volume (in ml), determined by means of the seed displacement method, by the weight (in g).</p><p id="p0089" num="0089">For an average of 10 bread rolls the following results were found: <tables id="tabl0011" num="0011"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm"/><colspec colnum="2" colname="col2" colwidth="31.50mm"/><colspec colnum="3" colname="col3" colwidth="31.50mm"/><colspec colnum="4" colname="col4" colwidth="31.50mm"/><colspec colnum="5" colname="col5" colwidth="31.50mm"/><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">enzyme level</entry><entry namest="col2" nameend="col2" align="char" char=".">0</entry><entry namest="col3" nameend="col3" align="char" char=".">50 ppm</entry><entry namest="col4" nameend="col4" align="char" char=".">100 ppm</entry><entry namest="col5" nameend="col5" align="char" char=".">200 ppm</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">specific volume</entry><entry namest="col2" nameend="col2" align="char" char=".">6.8</entry><entry namest="col3" nameend="col3" align="char" char=".">7.9</entry><entry namest="col4" nameend="col4" align="char" char=".">8.7</entry><entry namest="col5" nameend="col5" align="char" char=".">8.9</entry></row></tbody></tgroup></table></tables></p><p id="p0090" num="0090">The same trends can be established if, moreover, other bread improving ingredients such as vitamin C, fat, emulsifiers and Î±-amylase are added. Other properties such as dough processing and crumb structure are also positively affected by adding the xylanase enzyme.</p><heading id="h0037"><u>EXAMPLE III</u></heading><heading id="h0038"><u>PRODUCTION OF ASPERGILLUS NIGER VAR. AWAMORI XYLANASE BY SACCHAROMYCES CEREVISIAE</u></heading><p id="p0091" num="0091">As an example of the heterologous production of <u>Aspergillus niger</u> var. <u>awamori</u> xylanase by microorganisms, expression vectors were constructed for the expression of the xylanase in <u>Saccharomyces</u> <u>cerevisiae</u> regulated by the inducible <u>GAL7</u> promoter (Nogi and Fukasawa, 1983). The GAL7 promoter effects production of enzyme under inducing conditions: growth on medium with galactose as the only carbon source (Hopper and Rowe, 1978). The use of this promoter for induced production of heterologous proteins has already been described (Tajima et al., 1985). The fungal gene encoding xylanase was first rendered suitable for expression in <u>Saccharomyces</u> <u>cerevisiae</u> by removing the intron (non-coding sequence) by means of a synthetic DNA fragment. The same technique has been used to provide a correct connection of the xylanase gene to the <u>Saccharomyces cerevisiae</u> <u>GAL7</u> promoter. Optionally, a <u>Saccharomyces<!-- EPO <DP n="39"> --> cerevisiae</u> signal sequence, the invertase signal sequence, was also introduced to realize the secretion of the fungal enzyme xylanase by the yeast <u>Saccharomyces</u> <u>cerevisiae</u>. Autonomously replicating vectors as well as (multicopy) integrating vectors have been used in the production of the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase by the yeast <u>Saccharomyces cerevisiae</u>. All cloning procedures were carried out in <u>E.</u> <u>coli</u> strain JM109 (Yanisch-Perron et al., 1985) and all methods and techniques according to Maniatis et al. (1982).</p><heading id="h0039"><u>Construction of vector pUR2901</u></heading><p id="p0092" num="0092">The first intermediate construction was directed at the correct removal of the intron from the xylanase gene, i.e. without changing or disturbing the coding sequence. The synthetic DNA oligonucleotides shown in Fig. B (BAK 02, 03, 04, 05, 06, 07, 08, 09, 10, 23 and 24) were annealed and ligated together resulting in the fragment BAK1. The fragment BAK1 measures 205 bp and comprises the <u>Sac</u>I - <u>Kpn</u>I xylanase fragment (bp 185-bp 427) from which the intron has been removed. The synthetic DNA oligonucleotides have been designed in such a manner that upon removal of the intron a correct connection to the fragments has been made so that the open reading frame (encoding xylanase) is not disturbed. In order to simplify the continued construction the <u>Sac</u>I site was changed to an <u>Xho</u>I site. On the 5' side the fragment was provided with an <u>Eco</u>RI site. The ligation mixture was digested with the restriction enzymes <u>Kpn</u>I and <u>Eco</u>RI and the correct 205 bp fragment was isolated by means of agarose gel electrophoresis for the separation of the fragment and gel elution for the isolation of the fragment from the agarose gel. The <u>Kpn</u>I-<u>Eco</u>RI BAK1 fragment was cloned into the <u>Kpn</u>I and the <u>Eco</u>RI site of vector pTZ19R (obtained from Pharmacia) resulting in pBAK1 (see Fig. 9). The inserted fragment in the constructed plasmid pBAK1 was checked by means of sequence analysis.</p><p id="p0093" num="0093">The continued constructions were directed at the realization of a correct connection of the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase gene to the <u>Saccharomyces</u> <u>cerevisiae GAL7</u> promoter. For this purpose the synthetic DNA oligonucleotides shown in Fig. 10 (BAK13, 14, 15, 18, 19, 20,<!-- EPO <DP n="40"> --> 21, 25, 26, 27 and 28) were annealed and ligated resulting in fragment BAK2. Fragment BAK2 measures 202 bp and comprises the synthetic transition from the <u>Sac</u>I site of the <u>GAL7</u> promoter via the invertase signal sequence to the mature xylanase gene up to the <u>Sac</u>I (bp 185) site. In order to simplify the continued construction the <u>Sac</u>I site was changed to an <u>Xho</u>I site, in a manner identical to the one used in the construction of pBAK1. An additional <u>Eco</u>RI site was provided on the 5' side of the fragment. The ligation mixture was digested with <u>Eco</u>RI and <u>Xho</u>I and the correct 202 bp BAK2 fragment was isolated. Plasmid pBAK1 was digested with <u>Eco</u>RI and <u>Xho</u>I and the BAK2 fragment with the same termini was cloned in the vector fragments, resulting in plasmid pBAK21 (see Fig. 11). The inserted BAK2 fragment was checked by means of sequence analysis. In plasmid pBAK21 the connection of fragments BAK1 and BAK2 to the <u>Xho</u>I site was effected in such a manner that the open reading frame encoding xylanase was correctly restored. Plasmid pBAK21 therefore contains the <u>Saccharomyces</u> <u>cerevisiae</u> <u>GAL7</u> promoter transition from the <u>Sac</u>I site, the <u>Saccharomyces</u> <u>cerevisiae</u> invertase signal sequence (including an ATG start codon) and the <u>Aspergillus niger</u> var. <u>awamori</u> xylanase (encoding mature xylanase) from which the fungal intron (non-coding sequence) has been correctly removed up to the <u>Kpn</u>I site (the 5' part of the xylanase gene).</p><p id="p0094" num="0094">Plasmid pAW14B was digested with <u>Kpn</u>I and <u>Bam</u>HI and the 327 bp <u>Kpn</u>I - <u>Bam</u>HI fragment, containing the 3' part of the xylanase gene, was isolated. Plasmid pBAK21 was also digested with <u>Kpn</u>I and <u>Bam</u>HI and the vector fragment was isolated. The isolated 327 bp fragment and the vector fragment were ligated together resulting in plasmid pUR2901 (see Fig.12). Plasmid pUR2901 was checked by means of restriction enzyme analysis. Plasmid pUR2901 contains the <u>S.</u> <u>cerevisiae</u> <u>GAL7</u> promoter fusion site at the <u>Sac</u>I site, the <u>S.</u> <u>cerevisiae</u> invertase signal sequence (including an ATG start codon), and the complete <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase gene (encoding mature xylanase) from which the fungal intron (non-coding sequence) has correctly been removed.<!-- EPO <DP n="41"> --></p><heading id="h0040"><u>Construction of the S. cerevisiae expression vector pUR2904</u></heading><p id="p0095" num="0095">The construction of expression vector pUR2904 started from plasmid pUR2740. Plasmid pUR2740 is a derivative of pUR2730 (Overbeeke 1987) used for the production of Î±-galactosidase in <u>S.</u> <u>cerevisiae</u>. Plasmid pUR2740 is not essentially different from pUR2730, some superfluous sequences in the non-functional part of the vector have been removed. Plasmid pUR2740 is an <u>E.</u> <u>coli</u>/<u>S.</u> <u>cerevisiae</u> shuttle vector. Use was made of the 2 Âµm origin of replication, and the <u>S.</u> <u>cerevisiae LEU2d</u> gene served as a selection gene for the replication in <u>S.</u> <u>cerevisiae</u>. Plasmid pUR2740 was digested with <u>Sac</u>I and <u>Hind</u>III, and the vector fragment was isolated. As a result of this digestion, the Î±-galactosidase gene was removed. Plasmid pUR2901 was also digested with <u>Sac</u>I and <u>Hind</u>III, and the 730 bp fragment comprising the <u>S.</u> <u>cerevisiae GAL7</u> promoter fusion site at the <u>Sac</u>I site, the <u>S.</u> <u>cerevisiae</u> invertase signal sequence (including an ATG start codon), and the complete <u>A.</u> <u>niger</u> var. <u>awamori</u> xylanase gene (encoding mature xylanase) was isolated. The pUR2740 vector fragment and the 730 bp fragment of pUR2901 were ligated together, resulting in pUR2904 (see Fig. 13). Plasmid pUR2904 was checked by means of restriction enzyme analysis. Plasmid pUR2904 is the expression vector for the production of the <u>Aspergillus</u> <u>niger</u> var.<u>awamori</u> xylanase by the yeast <u>Saccharomyces cerevisiae</u> Plasmid pUR2904 is an <u>E.</u> <u>coli</u>/<u>S.</u> <u>cerevisiae</u> shuttle vector. It contains the DNA sequence encoding xylanase with the invertase signal sequence fused to it; the invertase signal sequence will provide the secretion of the xylanase. The DNA sequence in pUR2904 encodes exactly the same xylanase as the wild-type <u>A.</u> <u>niger</u> var. <u>awamori</u> strain. During secretion the resulting fusion protein will, in principle, undergo processing by the <u>Saccharomyces</u> <u>cerevisiae</u> signal peptidase resulting in secreted mature xylanase enzyme. The expression of the xylanase is regulated by the <u>Saccharomyces</u> <u>cerevisiae</u> galactose inducible <u>GAL7</u> promoter.</p><heading id="h0041"><u>Analysis of the production of A. niger var. awamori xylanase by S. cerevisiae</u></heading><!-- EPO <DP n="42"> --><p id="p0096" num="0096">Yeast cells of the <u>Saccharomyces</u> strain SU10 (Î±, <u>leu2</u>, <u>ura3</u>, <u>his3</u>, <u>cir+</u>; deposited with the Centraalbureau voor Schimmelcultures, P.O. Box 273, 3740 AG Baarn, The Netherlands, under number CBS 323.87) were transformed with plasmid pUR2904 via the spheroplast method (Beggs, 1978). The resulting <u>leu+</u> transformed yeast cells were analyzed for the presence of xylanase. The yeast cells were twice grown overnight on MM medium (0.67% Yeast Nitrogen Base w/o amino acids, 2% glucose) supplemented with uracil and histidine. Subsequently, the yeast cells were transferred to a ten times larger volume of YPG medium (1% Yeast Extract, 2% Bacto peptone, 5% galactose) and grown until the yeast cells had reached the stationary phase. The yeast cells were cultured under agitation at 30Â°C. The yeast cells were separated from the medium by centrifugation. The medium was analyzed for the presence of the xylanase with the enzyme assay as described in Example I. The expression level of xylanase was about 10000 units in 1 ml medium. By means of isoelectric focussing (see Example I) it was demonstrated that the xylanase produced by <u>Saccharomyces</u> <u>cerevisiae</u> is identical to the xylanase produced by wild-type <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u>. The functionality of the xylanase, produced and secreted by <u>Saccharomyces</u> <u>cerevisiae</u> was shown in baking tests carried out as described in Example II. The results described above show that the yeast <u>Saccharomyces</u> <u>cerevisiae</u> is capable of efficiently producing and secreting <u>Aspergillus niger</u> var. <u>awamori</u> xylanase.</p><heading id="h0042"><u>Construction of the S. cerevisiae expression vector pUR2921 (multi-copy integration)</u></heading><p id="p0097" num="0097">The expression of the xylanase gene of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> in <u>Saccharomyces</u> <u>cerevisiae</u> was also studied by an integrative vector system. For this purpose the high-copy integration system was used (Lopes, 1989).</p><p id="p0098" num="0098">The construction of expression vector pUR2921 started from plasmid pUR2778. Plasmid pUR2778 is a multi-integrative plasmid integrating in the ribosomal DNA locus of <u>S</u>. <u>cerevisiae</u>. It was used for stable multi-copy integration of the Î±-galactosidase expression cassette in <u>S</u>. <u>cerevisiae</u>. It<!-- EPO <DP n="43"> --> also contains vector sequences for replication and selection in <u>E</u>. <u>coli</u> and the <u>S</u>. <u>cerevisiae</u> <u>LEU2d</u> gene as a selection gene for yeast. Plasmid pUR2778 is a derivative of pMIRY2 (Lopes, 1989), from which the <u>Sma</u>I - <u>Bgl</u>II fragment containing the <u>Spirodella</u> <u>oligorhiza</u> DNA has been removed, and the <u>Bam</u>HI - <u>Hin</u>dIII fragment containing a part of the rDNA sequences has been replaced by the <u>Bgl</u>II - <u>Hin</u>dIII fragment of pUR2730 (Overbeeke, 1987) containing the Î±-galactosidase expression cassette. Plasmid pUR2778 was digested with <u>Sac</u>I and <u>Hin</u>dIII, and the vector fragment was isolated from agarose gel. As a result of this digestion the Î±-galactosidase coding sequence including the invertase signal sequence was removed. This vector fragment was ligated with the 730 bp <u>Sac</u>I - <u>Hin</u>dIII fragment from pUR2901, which was also used for the construction of pUR2904, resulting in plasmid pUR2921 (see Fig. 14). The 730 bp <u>Sac</u>I - <u>Hin</u>dIII fragment of pUR2901 comprises the <u>S</u>. <u>cerevisiae</u> <u>GAL7</u> promoter fusion site at the <u>Sac</u>I site, the <u>S</u>. <u>cerevisiae</u> invertase signal sequence (including ATG start codon), and the complete <u>A</u>. <u>niger</u> var. <u>awamori</u> xylanase gene (encoding mature xylanase) from which the fungal intron (non-coding sequence) has correctly been removed. Plasmid pUR2921 was checked by means of restriction enzyme analysis. Plasmid pUR2921 is an expression vector for the production of the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase by the yeast <u>Saccharomyces</u> <u>cerevisiae</u>. Plasmid pUR2921 contains sequences of the ribosomal DNA locus of the <u>S</u>. <u>cerevisiae</u> chromosomal DNA. As it does not contain any yeast replication origins the vector will integrate at the ribosomal DNA locus upon transformation to <u>S</u>. <u>cerevisiae</u>. When the pUR2921 plasmid is transformed to a <u>S</u>. <u>cerevisiae leu2</u> strain, under selective conditions multiple copies of the vector will integrate, due to the low expression of the <u>LEU2</u> marker gene of the pUR2921 plasmid. As a result of this process, the xylanase expression cassette will be present in multiple copies in the yeast chromosome. As the xylanase expression cassette is exactly the same as in the pUR2904 plasmid, this <u>S</u>. <u>cerevisiae</u> strain will secrete the mature xylanase enzyme in the same way as the <u>S</u>. <u>cerevisiae</u> strain with the pUR2904 plasmid.<!-- EPO <DP n="44"> --></p><heading id="h0043"><u>Analysis of the production of A. niger var. awamori xylanase by S. cerevisiae</u></heading><p id="p0099" num="0099">Yeast cells of the <u>Saccharomyces</u> strain SU50 (YT6-2-1, a, <u>leu</u>2, <u>his</u>4, <u>can</u>1, cirÂ°; Erhart and Hollenberg, 1981) were transformed by the spheroplast method with plasmid pUR2921, linearized with <u>Hpa</u>I. The resulting <u>leu</u>+ transformed yeast cells were analyzed for xylanase production as described for the SU10 yeast cells transformed with the pUR2904 plasmid. For these yeast cells the MM medium was only supplemented with histidine. The expression level was about 60,000 units secreted in 1 ml medium.</p><heading id="h0044"><u>References</u></heading><p id="p0100" num="0100"><ul id="ul0005" list-style="none" compact="compact"><li>Beggs, J.D. (1978), Nature 275: 104-109.</li><li>Erhart, Hollenberg (1981), Curr. Genet. 3:83-89.</li><li>Hopper, J.E. and Rowe, L.B. (1978), J. Biol. Chem. 253:7566-7569.</li><li>Lopes, T.S., Klootwijk, J., Veenstra, A.E., van der Aar, P.C., van Heerikhuizen, H., RauÃ©, H.A. and Planta, R.J. (1989), Gene 79:199-206.</li><li>Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982), Molecular Cloning. A laboratory manual, Cold Spring Harbor Laboratory.</li><li>Nogi, Y. and Fukasawa, T. (1983), Nucleic Acids Res. 11:8555-8568.</li><li>Overbeeke, N., Fellinger, A.J. and Hughes, S.G. (1987), PCT International. WO 87/07641.</li><li>Tajima, M., Nogi, Y. and Fukasawa, T. (1985), Yeast 1:67-77.</li><li>Yanisch-Perron, C., Viera, J. and Messing, J. (1985) Gene 33:103-119.</li></ul></p><heading id="h0045"><u>EXAMPLE IV</u></heading><heading id="h0046"><u>PRODUCTION OF ASPERGILLUS NIGER VAR. AWAMORI XYLANASE BY BACILLUS SUBTILIS</u></heading><p id="p0101" num="0101">As an example of the heterologous production of <u>Aspergillus niger</u> var. <u>awamori</u> xylanase by a prokaryotic microorganism, expression vectors were constructed for the production of xylanase by <u>Bacillus</u> <u>subtilis</u>. Various vector systems,<!-- EPO <DP n="45"> --> promoters and signal sequences are known for the production of heterologous proteins. For this example the SPO2 promoter and Î±-amylase signal sequence were used for the expression of the xylanase enzyme. This approach has been successful for the expression of the plant Î±-galactosidase in <u>B</u>. <u>subtilis</u> (Overbeeke et al, 1990).</p><p id="p0102" num="0102">For the construction of a vector for the expression of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase by <u>Bacillus</u> <u>subtilis</u>, plasmids constructed for the expression of xylanase in <u>Saccharomyces cerevisiae</u> (see example III), in which the intron (non-coding sequence) of the xylanase gene was correctly removed, were used as a starting point. Removal of the intron is essential, because a prokaryotic microorganism such as <u>Bacillus</u> <u>subtilis</u> is not capable, unlike the eukaryote <u>Aspergillus niger</u> var. <u>awamori</u>, of removing introns by a process called splicing.</p><heading id="h0047"><u>Construction of vector pUR2950</u></heading><p id="p0103" num="0103">The synthetic DNA oligonucleotides shown in Fig. 15 (BAK 15, 18, 26, 27, 41 and 42) were annealed and ligated together resulting in fragment BAK4. Fragment BAK4 measures 107 bp and comprises the DNA sequence encoding mature xylanase up to the <u>Sac</u>I site (bp 185 in Fig. 1). In order to simplify the continued construction, the <u>Sac</u>I site was changed to a <u>Xho</u>I site without changing the derived amino acid sequence. Moreover, in order to obtain a correct connection of the mature xylanase to the Î±-amylase signal sequence in the continued construction, the first codon of the mature xylanase encoding alanine was changed. The codon GCT was changed to GCC, also encoding alanine. Thus a <u>Sac</u>II site was created on the 5' side of the BAK4 fragment. Continuous with this <u>Sac</u>II site the BAK4 fragment was provided with an <u>Eco</u>RI site. The ligation mixture was digested with <u>Eco</u>RI and <u>Xho</u>I and the 107 bp <u>Eco</u>RI - <u>Xho</u>I fragment was isolated from agarose gel. Plasmid pUR2901 (see example III) was digested with <u>Eco</u>RI and <u>Xho</u>I and the BAK4 fragment was cloned in the vector fragment with the same restriction enzyme termini, resulting in pUR2950 (see Fig. 16). The inserted fragment BAK4 in pUR2950 was checked by means of sequence analysis. In plasmid pUR2950<!-- EPO <DP n="46"> --> the connection of fragment BAK4 and BAK1 by means of the <u>Xho</u>I site was carried out in such a manner that the open reading frame encoding the 5' part of xylanase was correctly restored. Moreover, as described in Example III, the intron of the xylanase gene was correctly removed. Accordingly, plasmid pUR2950 contains the DNA sequence from the first alanine codon of mature xylanase, in which a <u>Sac</u>II site has been made at that location, and the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase gene encoding mature xylanase from which the fungal intron (non-coding sequence) has been correctly removed.</p><heading id="h0048"><u>Construction of B. subtilis expression vector pUR2951</u></heading><p id="p0104" num="0104">Plasmid pUR2601 (Overbeeke, 1990) was used as a base for the construction in which the mature <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase gene present in pUR2950 has been fused to the Î±-amylase signal sequence for secretion of the enzyme to be produced, while this fusion gene is regulated by the SPO2 promoter. Plasmid pUR2601 was digested with <u>Sac</u>II and <u>Hin</u>dIII and the vector fragment with the SPO2 promoter and the Î±-amylase signal sequence was isolated. The <u>Sac</u>II - <u>Hin</u>dIII fragment of pUR2950 with the mature xylanase gene was isolated and ligated to the pUR2601 vector fragment, resulting in plasmid pUR2951 (Fig. 17). In plasmid pUR2951 the Î±-amylase signal sequence has been fused in exactly the correct manner to the mature xylanase gene. The ligation mixture was transformed to the <u>Bacillus</u> <u>subtilis</u> strain DB104 (Kawamuri and Doi, 1984) using the protoplast/PEG method (Chang and Cohen, 1979) with kanamycin for selection. The plasmid pUR2951 was checked with restriction enzyme analysis.</p><heading id="h0049"><u>Analysis of the production of A. niger var. awamori xylanase by B. subtilis</u></heading><p id="p0105" num="0105">Because the DB104 strain has some residual protease activity, fermentation of DB104 with pUR2951 under controlled conditions is necessary to avoid proteolysis of the secreted enzyme. The approach described by Overbeeke et al. (1990) for the production of plant Î±-galactosidase by <u>B</u>. <u>subtilis</u>, can be used as starting point for the production of <u>Aspergillus</u><!-- EPO <DP n="47"> --> conditions is necessary to avoid proteolysis of the secreted enzyme. The approach described by Overbeeke et al. (1990) for the production of plant Î±-galactosidase by <u>B</u>. <u>subtilis</u>, can be used as starting point for the production of <u>Aspergillus niger</u> var. <u>awamori</u> xylanase by <u>Bacillus</u> <u>subtilis</u>. In this fermentation special attention is paid to the glucose and ammonium levels during fermentation.</p><heading id="h0050"><u>References</u>.</heading><p id="p0106" num="0106"><ul id="ul0006" list-style="none" compact="compact"><li>Chang, S., and Cohen, S.N. (1979), Mol. Gen. Genet. 182:77-81.</li><li>Kawamura, F., and Doi, R.H (1984), J. Bacteriol. 160:442-444.</li><li>Overbeeke, N., Termorshuizen, G.H.M., Giuseppin, M.L.F., Underwood, D.R., and Verrips, C.T. (1990), Appl. Environ. Microbiol. 56:1429-1434.</li></ul></p><heading id="h0051"><u>EXAMPLE V</u></heading><heading id="h0052"><u>PRODUCTION OF ASPERGILLUS NIGER VAR. AWAMORI XYLANASE BY SACCHAROMYCES CEREVISIAE DURING FERMENTATION OF LEAN BREAD DOUGH</u></heading><p id="p0107" num="0107">As an example of the direct use of cells which produce the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase in foodstuffs, a <u>Saccharomyces</u> <u>cerevisiae</u> strain which produces the xylanase during fermentation of lean bread dough has been constructed. For this purpose the <u>S</u>. <u>cerevisiae</u> strain must secrete the xylanase under conditions present during the fermentation of wheat dough. In lean wheat dough no sugar is added and therefore the main carbon sources for the fermenting bakers yeast are glucose and maltose. The xylanase gene should therefore be regulated by a promoter which is not affected by glucose repression. Promoters of the genes of the glycolytic pathway (<u>GAPDH</u>, <u>PGK</u>, <u>ADH1</u>, <u>PYK</u>, etc.) of yeast are extremely useful for this purpose. Just by way of example the promoter of the phosphoglycerate kinase (<u>PGK</u>) gene of <u>Saccharomyces cerevisiae</u> was used. This promoter is used for the expression by <u>S</u>. <u>cerevisiae</u> of numerous heterologous proteins, for example the production of human interferon-alpha (Tuite et al., 1982).<!-- EPO <DP n="48"> --></p><p id="p0108" num="0108">The preferred way to achieve the expression of an enzyme during bread making is to use an integrative vector (single-copy or multi-copy integration), although autonomously replicating vectors can also be used.</p><p id="p0109" num="0109">The <u>GAL7</u> promoter from the pUR2921 plasmid, used for the expression of the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase in <u>Saccharomyces</u> <u>cerevisiae</u> (see example III), was replaced by the <u>PGK</u> promoter. <u>S</u>. <u>cerevisiae</u> strains transformed with this new vector, and which secretes the xylanase enzyme in culture media containing glucose, could be used in bread making. Addition of this yeast to dough before mixing results in secretion of the xylanase enzyme during bread making, and thus exhibits the positive effect of this bread improving enzyme, resulting in an increased specific volume of the bread.</p><heading id="h0053"><u>Construction of plasmid pUR2918</u></heading><p id="p0110" num="0110">For the fusion of the <u>Saccharomyces</u> <u>cerevisiae</u> <u>PGK</u> promoter sequences to the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase gene several approaches were possible. Among others the creation of a suitable restriction endonuclease site at the end of the promoter by means of site directed mutagenesis that could yield a DNA molecule which, for example, could be fused to the <u>Sac</u>I site between the <u>GAL7</u> promoter and invertase signal sequence of pUR2904, the plasmid used for the expression of the mature xylanase by <u>Saccharomyces cerevisiae</u>. Another way of creating suitable restriction sites at the end of a DNA molecule is by way of an <u>in</u> <u>vitro</u> amplification technique of DNA known as Polymerase Chain Reaction. This PCR technique was used to generate a DNA molecule containing all important sequences of the <u>Saccharomyces cerevisiae</u> phosphoglycerate kinase promoter up to the ATG startcodon, with an <u>Eco</u>RI and a <u>Bgl</u>II site at its 5' end and a <u>Bsp</u>MI recognition sequence and a <u>Hin</u>dIII site (see Fig. 18) 3' to the ATG start codon. The primers used for the amplification were PGP01: 5'-GGA ATT CAG ATC TTG AAT TGA TGT TAC CCT CAT AAA GCA CGT G-3' and PGP02: 5'-CCC AAG CTT ACC TGC TGC GCA TTG TTT TAT ATT TGT TGT AAA AAG TAG ATA ATT ACT TCC-3'. Template DNA was pUR2801, a yeast expression vector<!-- EPO <DP n="49"> --> with the complete <u>Saccharomyces</u> <u>cerevisiae</u> <u>PGK</u> promoter. The reaction mixture (total volume 100 Âµl) was composed as follows: Approx. 1 ng pUR2801 cleaved with <u>Sal</u>I, 100 pmoles of PGP01 and 100 pmoles of PGP02, 1 U Amplitaq polymerase (Perkin Elmer), 0.2 mmol/l of each dNTP: dATP, dCTP, dGTP and dTTP, 1.5 mmol/l MgCl<sub>2</sub>, 50 mmol/l KCl, 10 mmol/l TrisÂ·HCl pH 8.3 (at 25Â°C), 0.001 % (w/v) gelatine. After 2 minutes of incubation at 95Â°C, 25 cycles of the following temperature steps were carried out: 1 min at 95Â°C, 1:45 min at 52Â°C, 2 min at 72Â°C. After these cycles the reaction mixture was maintained at 72Â°C for 5 min before cooling to 4Â°C. All temperature cycles were performed in a Perkin Elmer DNA Thermal Cycler. 60 Âµl was precipitated from the reaction mixture with ethanol and subsequently the band of approximately 600 bp was isolated from agarose gel. The isolated DNA was then cleaved with <u>Eco</u>RI and <u>Hin</u>dIII and isolated again from agarose gel. This DNA fragment starts with an <u>Eco</u>RI sticky end followed by a <u>Bgl</u>II site and the sequence from position - 568 relative to the ATG codon up to the ATG codon of the <u>Saccharomyces cerevisiae</u> phosphoglycerate kinase promoter. The ATG codon is followed by a <u>Bsp</u>MI site and a <u>Hin</u>dIII sticky end. The multi-purpose cloning plasmid pTZ19R (obtained from Pharmacia) was cleaved with <u>Eco</u>RI and <u>Hin</u>dIII and ligated with the <u>PGK</u> promoter fragment, yielding pUR2918 (see Fig. 19). The plasmid was checked by means of sequence analysis.</p><heading id="h0054"><u>Construction of plasmid pUR2920</u></heading><p id="p0111" num="0111">For the fusion of the <u>PGK</u> promoter of pUR2918 to the xylanase gene the synthetic DNA oligonucleotides shown in Fig. 20 (BAK14, 15, 18, 19, 20, 21, 51, 52 and 53) were annealed and ligated together resulting in the fragment BAK5. The oligonucleotides BAK51 and BAK53 were not phosphorylated to prevent self-ligation of the resulting fragment, and the fragment was subsequently isolated from agarose gel. The fragment BAK5 measures 169 bp and comprises the invertase signal sequence and the mature xylanase gene up to the <u>Xho</u>I site for a correct fusion to fragment BAK1 (see example III). It differs from the earlier mentioned fragment BAK2 (example III) at both ends. At the 5' end it contains a sticky end<!-- EPO <DP n="50"> --> just before the second codon of the invertase signal sequence to obtain an exact fusion to the <u>PGK</u> promoter sequence in pUR2918. At the 3' side of the <u>Xho</u>I site it contains an additional <u>Hin</u>dIII sticky end. The plasmid pUR2918 is cut with <u>Bsp</u>MI and <u>Hin</u>dIII and ligated to fragment BAK5 resulting in plasmid pUR2920 (see Fig. 21). The inserted fragment BAK5 was checked by means of sequence analysis. Plasmid pUR2920 contains the <u>Saccharomyces</u> <u>cerevisiae</u> phosphoglycerate kinase (<u>PGK</u>) promoter, from nucleotide -568 relative to the ATG start codon, up to the ATG start codon, the <u>Saccharomyces cerevisiae</u> invertase signal sequence correctly fused to this ATG codon, and the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> xylanase gene up to the <u>Sac</u>I site. In order to simplify the continued construction the <u>Sac</u>I site was changed to a <u>Xho</u>I site as described in example III.</p><heading id="h0055"><u>Construction of plasmid pUR2922 and pUR2923</u></heading><p id="p0112" num="0112">The 2 micron based episomal expression vector pUR2904 (see example III) was used to construct a plasmid vector for the expression of the xylanase gene regulated by the <u>PGK</u> promoter in <u>S</u>. <u>cerevisiae</u>. Plasmid pUR2920 was cleaved with <u>Bgl</u>II and <u>Xho</u>I and the 735 bp fragment containing the <u>PGK</u> promoter, the invertase signal sequence and the xylanase gene up to the <u>Xho</u>I site was isolated from agarose gel. Plasmid pUR2904 was also cleaved with <u>Bgl</u>II and <u>Xho</u>I and the large vector fragment was isolated. As a result of this digestion, the <u>GAL7</u> promoter and invertase signal sequence were removed. This pUR2904 vector was ligated with the <u>Bgl</u>II - <u>Xho</u>I fragment of pUR2920, yielding pUR2922 (see Fig. 22). Plasmid pUR2922 differs from the <u>Saccharomyces</u> <u>cerevisiae</u> expression vector pUR2904 (example III) as it contains the <u>Saccharomyces cerevisiae</u> phosphoglycerate kinase promoter before the invertase signal sequence instead of the <u>GAL7</u> promoter.</p><p id="p0113" num="0113">For the construction of a multi-copy integration vector with the <u>PGK</u>-xylanase expression cassette, plasmid pUR2792 served as starting point. Plasmid pUR2792 is a derivative of pMIRY2 (Lopes, 1989). It contains a <u>Bgl</u>II - <u>Hin</u>dIII polylinker instead of the <u>Bgl</u>II - <u>Hin</u>dIII part containing the <u>S</u>. <u>oligorhiza</u> DNA, and the part between the <u>Bal</u>I site in the<!-- EPO <DP n="51"> --> pAT153 sequence and the <u>Hin</u>dIII site in the rDNA sequence has been deleted. Plasmid pUR2792 was cleaved with <u>Bgl</u>II and <u>Hin</u>dIII and the vector band was isolated from agarose gel. The <u>Bgl</u>II - <u>Hin</u>dIII fragment containing the <u>PGK</u> controlled xylanase expression cassette was isolated from plasmid pUR2922 and ligated to pUR2792 vector that had been cleaved with <u>Bgl</u>II - <u>Hin</u>dIII. The resulting plasmid pUR2923 (see Fig. 23) is a <u>Saccharomyces</u> <u>cerevisiae</u> multi-copy integration plasmid which contains the <u>Saccharomyces</u> <u>cerevisiae</u> phosphoglycerate kinase promoter up to the ATG start codon, the <u>Saccharomyces</u> <u>cerevisiae</u> invertase signal sequence fused to this promoter and the <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> mature xylanase gene fused in frame to the invertase signal sequence. The intron (non-coding sequence) has been correctly removed from the xylanase gene.</p><p id="p0114" num="0114">Yeast cells of the <u>Saccharomyces</u> <u>cerevisiae</u> strain SU50 were transformed by the spheroplast method with plasmid pUR2923, linearized with <u>Hpa</u>I (see example III). The resulting <u>leu</u>+ transformed yeast cells were analyzed for xylanase production as described for the SU50 yeast cells with the pUR2921 plasmid, with one alteration, the use of YPD medium (1% Yeast Extract, 2% Bacto peptone, 2% glucose) instead of YPG at the final culturing stage. The expression level was about 10,000 units secreted in 1 ml medium.</p><heading id="h0056"><u>Production of xylanase by pUR2923 containing yeast in dough</u></heading><p id="p0115" num="0115"><u>Saccharomyces</u> <u>cerevisiae</u> SU50 cells containing the pUR2923 plasmid multi-copy integrated in the yeast chromosome were used in a baking test as described below. The increase in bread volume by the addition of xylanase is caused by an enzymatic alteration of the starch tailings, through which the dough is capable of taking more advantage of the gassing activity of the yeast in the dough. A yeast with a high gassing power is therefore required to obtain the full benefit of the addition of the xylanase enzyme. As the SU50 strain is a laboratory strain, it does not possess good gassing properties. For a baking experiment with the xylanase producing SU50 yeast strain, supplementation with a good gassing yeast strain is thus necessary.<!-- EPO <DP n="52"> --></p><p id="p0116" num="0116">The baking test described below was based on the 10 grams micro-loaf test (Shogren and Finney, 1984). The formulation of the dough was 10 g wheat flour (Columbus: MENEBA, The Netherlands); 0.15 g NaCl; 5.9 ml water; 0.2 g pressed yeast (Koningsgist; Gist-Brocades, The Netherlands). Supplementations to this formulation (xylanase producing and non-producing yeast, xylanase enzyme) were dissolved in water just before mixing of the dough. Mixing took place for 5 minutes in a 10-gram mixograph from National Manufacturing Co. Lincoln, NE. After mixing, the dough was fermented for 80 min. at 30Â°C with two punches, one punch at 40 min. and one at 80 min. Sheeting rolls used for the punching were spaced 2.0 mm. After fermentation the dough was moulded and proofed for 70 min at 30Â°C before baking. Baking took place for 12 min at 240Â°C. After weighing, the volume of the loaves was measured by means of dwarf rapeseed displacement.</p><p id="p0117" num="0117">Supplementations to the dough were: <u>Saccharomyces cerevisiae</u> SU50 with pUR2923 (xylanase producing yeast), <u>Saccharomyces cerevisise</u> SU50 (parent strain) and purified xylanase enzyme. The SU50 yeast strains used, were first grown on selective media: YNB w.o. amino acids (Difco) and 20 g/l glucose, supplemented with 60 mg/l leucine (SU50 parent only) and 20 mg/l histidine. These cultures were grown for 40 hours at 30Â°C and then 5 ml was used to inoculate 45 ml of YPD (see above), and grown for 16 hours at 30Â°C. Yeast cells were collected by centrifugation, washed once with fresh YPD, and centrifugated again. Various amounts of the (wet) pellet were resuspended in 5.9 ml of water just before mixing the dough. When applied, the amount of purified xylanase added was 5 Âµl of a 40 U/Âµl solution (200 U). The effect of the various supplementations on the specific volume (S.V) of the bread is shown in the table below:<!-- EPO <DP n="53"> --> <tables id="tabl0012" num="0012"><table frame="all"><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm"/><colspec colnum="2" colname="col2" colwidth="78.75mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Supplementation</entry><entry namest="col2" nameend="col2" align="center">S.V. (ml/g)</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">none</entry><entry namest="col2" nameend="col2" align="char" char=".">3.31</entry></row><row><entry namest="col1" nameend="col1" align="left">none</entry><entry namest="col2" nameend="col2" align="char" char=".">3.40</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">5 mg SU50</entry><entry namest="col2" nameend="col2" align="char" char=".">3.40</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">15 mg SU50</entry><entry namest="col2" nameend="col2" align="char" char=".">3.39</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">50 mg SU50</entry><entry namest="col2" nameend="col2" align="char" char=".">3.66</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">5 mg SU50; 200 U xylanase</entry><entry namest="col2" nameend="col2" align="char" char=".">3.78</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">15 mg SU50; 200 U xylanase</entry><entry namest="col2" nameend="col2" align="char" char=".">3.97</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">50 mg SU50; 200 U xylanase</entry><entry namest="col2" nameend="col2" align="char" char=".">4.01</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">5 mg SU50:pUR2923</entry><entry namest="col2" nameend="col2" align="char" char=".">3.88</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">15 mg SU50:pUR2923</entry><entry namest="col2" nameend="col2" align="char" char=".">4.03</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="char" char=".">50 mg SU50:pUR2923</entry><entry namest="col2" nameend="col2" align="char" char=".">4.31</entry></row></tbody></tgroup></table></tables></p><p id="p0118" num="0118">From the results shown in this table it is clear that the yeast strain producing the xylanase (SU50:pUR2923) has a positive effect on the specific volume of the bread, comparable to that of the addition of purified xylanase enzyme. The parent strain, when added in equivalent amounts, does not exhibit this effect. Of course this effect is accomplished by blending of a bakers yeast with good gassing power characteristics, and an engineered laboratory yeast. The same positive effect, however, can be obtained when a bakers yeast with good gassing power is engineered in a comparable way to produce the fungal xylanase. Furthermore, these yeast strains can be engineered to produce other enzymes with bread improving capabilities (Î±-amylases, hemicellulases etc.)</p><heading id="h0057">References</heading><p id="p0119" num="0119"><ul id="ul0007" list-style="none" compact="compact"><li>Lopes, T.S., Klootwijk, J., Veenstra, A.E., van der Aar, P.C., van Heerikhuizen, H., RauÃ©, H.A. and Planta, R.J. (1989), Gene 79:199-206.</li><li>Shogren, M.D. and Finney, K.F. (1984), Cereal Chem. 61:418-423.<!-- EPO <DP n="54"> --></li><li>Tuite, M.F., Dobson, M.J., Roberts, N.A., King, R.M., Burke, D.C., Kingsman, S.M. and Kingsman, A.J. (1982), EMBO Journal 1:603-608.</li></ul></p>
EP	0600865	B1	2000-09-20	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A recombinant DNA material comprising a nucleotide sequence encoding at least a ripening form of a Î²-1,4 endoxylanase of fungal origin having bread improving activity, said nucleotide sequence being selected from the group comprising the nucleotide sequence of Figure nr. 1 and equivalent nucleotide sequences such that<claim-text>- the equivalent nucleotide sequence corresponds either to a nucleotide sequence encoding the amino acid sequence of Figure nr 1 or to those parts of the amino acid sequence of Figure nr. 1 essential for an active ripening form of Î²-1,4 endoxylanase with bread improving activity, said ripening form being selected from the group comprising the mature, the pre, pro and prepro form and/or</claim-text><claim-text>- the equivalent nucleotide sequence has a complementary strand capable of hybridizing under stringent hybridizing conditions to the nucleotide sequence of figure nr. 1, said stringent hybridizing conditions being incubation in 6xSSC at 68Â°C with washing steps at the same temperature with 2x and 0,4xSSC respectively.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A recombinant DNA material according to claim 1, comprising DNA with a nucleotide sequence encoding at least a ripening form of a Î²-1,4 endoxylanase of <u>Aspergillus</u> origin.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A recombinant DNA material according to claim 1 or 2, comprising DNA with a nucleotide sequence encoding at least a ripening form of a Î²-1,4endoxylanase of <u>Aspergillus</u> <u>niger</u> origin.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A recombinant DNA material according to any of the preceding claims, comprising DNA with a nucleotide sequence encoding at least a ripening form of a Î²-1,4 - endoxylanase of <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u> origin.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A recombinant DNA material according to any of the preceding claims, comprising a nucleotide sequence encoding at least a ripening form of Î²-1,4 endoxylanase with an amino acid sequence selected from Figure nr. 1.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A recombinant DNA material according to any of the preceding claims comprising DNA with a nucleotide sequence encoding at least the mature form of Î²-1,4 endoxylanase.<!-- EPO <DP n="56"> --></claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A recombinant DNA material according to any of the preceding claims, further encoding at least one other enzyme, wherein said other enzyme has amylolytic and/or hemicellulolytic and/or cellulolytic activity.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A transformed cell comprising recombinant DNA material according to any of claims 1-7, said cell being capable of expressing at least the ripening form of Î²-1,4 endoxylanase encoded on the recombinant DNA material and said cell being capable of secreting at least the mature form of Î²-1,4 endoxylanase encoded by the recombinant DNA material.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A transformed cell according to claim 8 suitable for use in a process in which a cellulose and/or hemicellulose containing raw material is used in a functional manner known per se for the non transformed host cell, said cell becoming polyfunctional for said process upon expression of the recombinant DNA encoding the ripening form of Î²-1,4 endoxylanase and subsequently secreting at least a mature form of the Î²-1,4-endoxylanase having broad improving activity, thereby enabling degradation of xylan.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A cell according to claim 9, wherein the process for which said non-transformed cell is functional and the transformed cell is polyfunctional lies in the field of food processing and production.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A transformed cell according to claim 9 or 10, wherein the process for which said cell is polyfunctional is directed at fermentation and said cell is a yeast cell.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A transformed cell according to any of claims 9-11, said cell being a yeast cell wherein the process for which said cell is polyfunctional is directed at the preparation of bakery products.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A transformed cell according to any of claims 8-12, wherein said cell is selected from the group consisting of a bacterial cell, a fungal cell, a yeast cell and a plant cell.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A cell according to any of claims 8-13, wherein the cell is a fungal cell selected from the genera <u>Aspergillus</u> and <u>Trichoderma</u>.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A cell according to any of claims 8-14, wherein the cell is a fungal cell selected from the species <u>Aspergillus</u> <u>niger</u> var. <u>awamori</u>, <u>Aspergillus</u> <u>niger</u> var. <u>niger</u>, <u>Aspergillus</u> <u>nidulans</u> and <u>Aspergillus</u> <u>oryzae</u>.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>A cell according to any of claims 8-13, wherein the cell is a bacterial cell selected from the genera <u>Bacillus</u>, <u>Lactobacillus</u> and <u>Streptococcus</u>.<!-- EPO <DP n="57"> --></claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>A cell according to any of claims 8-13, wherein the cell is selected from yeast cells of the genera <u>Saccharomyces</u>, <u>Kluyveromyces</u>, <u>Hansenula</u> and <u>Pichia</u>.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>A cell according to claim 17, wherein the cell is selected from the yeast cells of species <u>Saccharomyces</u> <u>cerevisiae</u>, <u>Saccharomyces</u> <u>carlsbergensis</u>, <u>Kluyveromyces lactis</u>, <u>Kluyveromyces</u> <u>marxianus</u>, <u>Hansenula</u> <u>polymorpha</u> and <u>Pichia</u> <u>pastoris</u>.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>A Î²-1,4 endoxylanase having bread improving activity obtainable by expression of recombinant DNA material according to any of claims 1-7, preferably in isolated form.</claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>A process for producing a ripening form of a Î²-1,4 endoxylanase, said ripening form comprising an amino acid sequence selected from Figure nr. 1 comprising:<claim-text>- culturing a cell according to any of claims 8-18 in a suitable nutrient medium, and</claim-text><claim-text>- optionally isolating the resulting enzyme ripening form.</claim-text></claim-text></claim><claim id="c-en-01-0021" num="0021"><claim-text>A process for producing a ripening form of a Î²-1,4 endoxylanase, said ripening form comprising an amino acid sequence selected from Sequence id. no. 7 and 8 comprising:<claim-text>- culturing a cell according to any of claims 9-18 in a suitable nutrient medium, and</claim-text><claim-text>- optionally isolating the resulting enzyme ripening form.</claim-text></claim-text></claim><claim id="c-en-01-0022" num="0022"><claim-text>A bread improver composition comprising a ripening form of Î²-1,4 endoxylanase encoded by a DNA sequence according to any of claims 1-7 as bread improving component.</claim-text></claim><claim id="c-en-01-0023" num="0023"><claim-text>A bread improver composition according to claim 22 comprising a mature form of the Î²-1,4 endoxylanase.</claim-text></claim><claim id="c-en-01-0024" num="0024"><claim-text>A bread improver composition according to claim 22 or 23, wherein said Î²-1,4 endoxylanase is of <u>Aspergillus</u> origin.</claim-text></claim><claim id="c-en-01-0025" num="0025"><claim-text>A bread improver composition comprising a cell according to any of claims 8-12, 17 and 18.</claim-text></claim><claim id="c-en-01-0026" num="0026"><claim-text>A flour composition comprising a ripening form of Î²-1,4 endoxylanase encoded by a DNA sequence according to any of claims 1-7 as bread improving component.</claim-text></claim><claim id="c-en-01-0027" num="0027"><claim-text>A flour composition according to claim 26 wherein the ripening form is the mature form of the Î²-1,4 endoxylanase.</claim-text></claim><claim id="c-en-01-0028" num="0028"><claim-text>A flour composition according to claim 26 or 27, wherein said Î²-1,4 endoxylanase is of <u>Aspergillus</u> origin.<!-- EPO <DP n="58"> --></claim-text></claim><claim id="c-en-01-0029" num="0029"><claim-text>A flour composition comprising a cell according to any of claims 8-12, 17 and 18.</claim-text></claim><claim id="c-en-01-0030" num="0030"><claim-text>A dough composition comprising a ripening form of Î²-1,4 endoxylanase encoded by a DNA sequence according to any of claims 1-7 as bread improving component.</claim-text></claim><claim id="c-en-01-0031" num="0031"><claim-text>A dough composition according to claim 30 wherein the ripening form is the mature form of the Î²-1,4 endoxylanase.</claim-text></claim><claim id="c-en-01-0032" num="0032"><claim-text>A dough composition according to claim 30 or 31, wherein the Î²-1,4 - endoxylanase is of <u>Aspergillus</u> origin.</claim-text></claim><claim id="c-en-01-0033" num="0033"><claim-text>A dough composition comprising a cell according to any of claims 8-12, 17 and 18.</claim-text></claim><claim id="c-en-01-0034" num="0034"><claim-text>A bakery product obtained by using a flour composition according to any of claims 26-29 or a dough composition according to any of claims 30-33.</claim-text></claim><claim id="c-en-01-0035" num="0035"><claim-text>A process for preparing a bakery product by baking a flour composition which comprises using the flour or dough composition according to any of claims 26-29 or 30-33 respectively.</claim-text></claim><claim id="c-en-01-0036" num="0036"><claim-text>The method of processing a cellulose-containing raw material to prepare beer, paper, starch, gluten etc, or to decompose cellulose- and/or hemicellulose-containing waste which comprises contacting said material with a ripening form of the Î²-1,4-endoxylanase according to claim 19 or a cell according to any of claims 9-18.</claim-text></claim><claim id="c-en-01-0037" num="0037"><claim-text>The method of claim 36, wherein the ripening form of Î²-1,4 endoxylanase which is used is a mature form.</claim-text></claim><claim id="c-en-01-0038" num="0038"><claim-text>The method of claim 36 or 37, wherein the ripening form of Î²-1,4 endoxylanase which is used is of <u>Aspergillus</u> origin.</claim-text></claim><claim id="c-en-01-0039" num="0039"><claim-text>The method of any of claims 36-38 wherein the cellulose containing material is agricultural waste which is contacted with the Î²-1,4-endoxylanase.</claim-text></claim><claim id="c-en-01-0040" num="0040"><claim-text>The method of any of claims 36-39 wherein the cellulose containing material is waste from paper mills.</claim-text></claim><claim id="c-en-01-0041" num="0041"><claim-text>The method of any of claims 36-40 which comprises contacting said material with a cell according to any of claims 9-18 such that it secretes a ripening form of the Î²-1,4 endoxylanase in situ.</claim-text></claim>
EP	0600865	B1	2000-09-20	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Ein rekombinantes DNA-Material, umfassend eine Nucleotidsequenz, die wenigstens eine reifende Form einer Î²-1,4-Endoxylanase fungalen Ursprungs mit brotverbessernder Wirkung kodiert, wobei die Nucleotidsequenz ausgewÃ¤hlt ist aus der Gruppe, welche die Nucleotidsequenz von Figur Nr. 1 und Ã¤quivalente Nucleotidsequenzen umfaÃŸt, so daÃŸ<claim-text>- die Ã¤quivalente Nucleotidsequenz entweder einer Nucleotidsequenz, welche die AminosÃ¤uresequenz von Figur Nr. 1 kodiert, oder denjenigen Teilen der AminosÃ¤uresequenz von Figur Nr. 1, die fÃ¼r eine aktive reifende Form von Î²-1,4-Endoxylanase mit brotverbessernder Wirkung essentiell sind, entspricht, wobei die reifende Form ausgewÃ¤hlt ist aus der Gruppe, welche die reite, die PrÃ¤-, die Pro- und die PrÃ¤pro-Form umfaÃŸt, und/oder</claim-text><claim-text>- die Ã¤quivalente Nucleotidsequenz einen KomplementÃ¤rstrang besitzt, der in der Lage ist, unter stringenten Hybridisierungsbedingungen mit der Nucleotidsequenz von Figur Nr. 1 zu hybridisieren, wobei die stringenten Hybridisierungsbedingungen die Inkubation in 6xSSC bei 68Â°C mit Waschschritten bei derselben Temperatur mit 2x- bzw. 0,4xSSC sind.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Ein rekombinantes DNA-Material gemÃ¤ÃŸ Anspruch 1, umfassend DNA mit einer Nucleotidsequenz, die wenigstens eine reifende Form einer Î²-1,4-Endoxylanase mit <u>Aspergillus</u>-Ursprung kodiert.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Ein rekombinantes DNA-Material gemÃ¤ÃŸ Anspruch 1 oder 2, umfassend DNA mit einer Nucleotidsequenz, die wenigstens eine reifende Form einer Î²-1,4-Endoxylanase mit <u>Aspergillus</u>-<u>niger</u>-Ursprung kodiert.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Ein rekombinantes DNA-Material gemÃ¤ÃŸ irgendeinem der vorhergehenden AnsprÃ¼che, umfassend DNA mit einer Nucleotidsequenz, die wenigstens eine reifende Form einer Î²-1,4-Endoxylanase mit <u>Aspergillus</u>-<u>niger</u>-Var. -<u>awamori</u>-Ursprung kodiert.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Ein rekombinantes DNA-Material gemÃ¤ÃŸ irgendeinem der vorhergehenden AnsprÃ¼che, umfassend eine Nucleotidsequenz, die wenigstens eine reifende Form von Î²-1,4-Endoxylanase mit einer aus Figur Nr. 1 ausgewÃ¤hlten AminosÃ¤uresequenz kodiert.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Ein rekombinantes DNA-Material gemÃ¤ÃŸ irgendeinem der vorhergehenden AnsprÃ¼che, umfassend DNA mit einer Nucleotidsequenz, die wenigstens die reife Form von Î²-1,4-Endoxylanase kodiert.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Ein rekombinantes DNA-Material gemÃ¤ÃŸ irgendeinem der vorhergehenden<!-- EPO <DP n="60"> --> AnsprÃ¼che, das ferner wenigstens ein anderes Enzym kodiert, wobei das andere Enzym amylolytische und/oder hemicellulolytische und/oder cellulolytische AktivitÃ¤t besitzt.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Eine transformierte Zelle, die rekombinantes DNA-Material gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 1-7 enthÃ¤lt, wobei die Zelle in der Lage ist, wenigstens die von dem rekombinanten DNA-Material kodierte reifende Form von Î²-1,4-Endoxylanase zu exprimieren, und die Zelle in der Lage ist, wenigstens die von dem rekombinanten DNA-Material kodierte reife Form von Î²-1,4-Endoxylanase auszuscheiden.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Eine transformierte Zelle gemÃ¤ÃŸ Anspruch 8, die bei einem Verfahren geeignet ist, bei dem ein cellulose- und/oder hemicellulosehaltiges Rohmaterial in einer funktionellen Weise, die an sich fÃ¼r die nichttransformierte Wirtszelle bekannt ist, verwendet wird, wobei die Zelle bei der Expression der rekombinanten DNA, welche die reifende Form von Î²-1,4-Endoxylanase kodiert, fÃ¼r das Verfahren polyfunktionell wird und anschlieÃŸend wenigstens eine reife Form der Î²-1,4-Endoxylanase mit brotverbessernder Wirkung ausscheidet, wodurch die Zersetzung von Xylan mÃ¶glich wird.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Eine Zelle gemÃ¤ÃŸ Anspruch 9, wobei das Verfahren, fÃ¼r das die nichttransformierte Zelle funktionell und die transformierte Zelle polyfunktionell ist, auf dem Gebiet der Nahrungsmittelverarbeitung und -produktion liegt.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Eine transformierte Zelle gemÃ¤ÃŸ Anspruch 9 oder 10, wobei das Verfahren, fÃ¼r das die Zelle polyfunktionell ist, auf die Fermentation bezogen ist und die Zelle eine Hefezelle ist.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Eine transformierte Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 9-11, wobei die Zelle eine Hefezelle ist und das Verfahren, fÃ¼r das die Zelle polyfunktionell ist, auf die Herstellung von Backwaren bezogen ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Eine transformierte Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-12, wobei die Zelle ausgewÃ¤hlt ist aus der Gruppe, bestehend aus einer Bakterienzelle, einer Pilzzelle, einer Hefezelle und einer Pflanzentelle.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Eine Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-13, wobei die Zelle eine Pilzzelle ist, ausgewÃ¤hlt aus den Gattungen <u>Aspergillus</u> und <u>Trichoderma</u>.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Eine Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-14, wobei die Zelle eine Pilzzelle ist, ausgewÃ¤hlt aus den Arten <u>Aspergillus</u> <u>niger</u> Var. <u>awamori</u>, <u>Aspergillus</u> <u>niger</u> Var. <u>niger</u>, <u>Aspergillus</u> <u>nidulans</u> und <u>Aspergillus oryzae</u>.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Eine Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-13, wobei die Zelle eine Bakterienzelle ist, ausgewÃ¤hlt aus den Gattungen <u>Bacillus</u>, <u>Lactobacillus</u><!-- EPO <DP n="61"> --> und <u>Streptococcus</u>.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Eine Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-13, wobei die Zelle ausgewÃ¤hlt ist aus Hefezellen den Gattungen <u>Saccharomyces</u>, <u>Kluyveromyces</u>, <u>Hansenula</u> und <u>Pichia</u>.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Eine Zelle gemÃ¤ÃŸ Anspruch 17, wobei die Zelle ausgewÃ¤hlt ist aus den Hefezellen der Arten <u>Saccharomyces</u> <u>cerevisiae</u>, <u>Saccharomyces</u> <u>carlsbergensis</u>, <u>Kluyveromyces</u> <u>lactis</u>, <u>Kluyveromyces</u> <u>marxianus</u>, <u>Hansenula</u> <u>polymorpha</u> und <u>Pichia</u> <u>pastoris</u>.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Eine Î²-1,4-Endoxylanase mit brotverbessernder Wirkung, die durch Expression von rekombinantem DNA-Material gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 1-7 vorzugsweise in isolierter Form erhalten werden kann.</claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>Ein Verfahren zur Herstellung einer reifenden Form einer Î²-1,4-Endoxylanase, wobei die reifende Form eine AminosÃ¤uresequenz enthÃ¤lt, die aus Figur Nr. 1 ausgewÃ¤hlt ist, umfassend:<claim-text>- Kultivieren einer Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-18 in einem geeigneten NÃ¤hrmedium und</claim-text><claim-text>- gegebenenfalls Isolieren der resultierenden reifenden Enzymform.</claim-text></claim-text></claim><claim id="c-de-01-0021" num="0021"><claim-text>Ein Verfahren zur Herstellung einer reitenden Form einer Î²-1,4-Endoxylanase, wobei die reitende Form eine AminosÃ¤uresequenz enthÃ¤lt, die aus Sequenz-Ident.-Nr. 7 und 8 ausgewÃ¤hlt ist, umfassend;<claim-text>- Kultivieren einer Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 9-18 in einem geeigneten NÃ¤hrmedium und</claim-text><claim-text>- gegebenenfalls Isolieren der resultierenden reifenden Enzymform.</claim-text></claim-text></claim><claim id="c-de-01-0022" num="0022"><claim-text>Eine Brotverbesserungszusammensetzung, die eine reifende Form einer durch eine DNA-Sequenz gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 1-7 kodierten Î²-1,4-Endoxylanase als brotverbessernde Komponente enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0023" num="0023"><claim-text>Eine Brotverbesserungszusammensetzung gemÃ¤ÃŸ Anspruch 22, die eine reife Form der Î²-1,4-Endoxylanase enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0024" num="0024"><claim-text>Eine Brotverbesserungszusammensetzung gemÃ¤ÃŸ Anspruch 22 oder 23, bei der die Î²-1,4-Endoxylanase von <u>Aspergillus</u> abstammt.</claim-text></claim><claim id="c-de-01-0025" num="0025"><claim-text>Eine Brotverbesserungszusammensetzung, die eine Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-12, 17 und 18 enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0026" num="0026"><claim-text>Eine Mehlzusammensetzung, die eine reifende Form einer durch eine DNA-Sequenz gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 1-7 kodierten Î²-1,4-Endoxylanase als brotverbessernde Komponente enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0027" num="0027"><claim-text>Eine Mehlzusammensetzung gemÃ¤ÃŸ Anspruch 26, worin die reifende Form die reite Form der Î²-1,4-Endoxylanase ist.</claim-text></claim><claim id="c-de-01-0028" num="0028"><claim-text>Eine Mehlzusammensetzung gemÃ¤ÃŸ Anspruch 26 oder 27, bei der die Î²-1,4-Endoxylanase von <u>Aspergillus</u> Ursprung ist.</claim-text></claim><claim id="c-de-01-0029" num="0029"><claim-text>Eine Mehlzusammensetzung, die eine Zelle gemÃ¤ÃŸ irgendeinem der<!-- EPO <DP n="62"> --> AnsprÃ¼che 8-12, 17 und 18 enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0030" num="0030"><claim-text>Eine Teigzusammensetzung, die eine reifende Form einer durch eine DNA-Sequenz gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 1-7 kodierten Î²-1,4-Endoxylanase als brotverbessernde Komponente enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0031" num="0031"><claim-text>Eine Teigzusammensetzung gemÃ¤ÃŸ Anspruch 30, worin die reifende Form die reife Form der Î²-1,4-Endoxylanase ist.</claim-text></claim><claim id="c-de-01-0032" num="0032"><claim-text>Eine Teigzusammensetzung gemÃ¤ÃŸ Anspruch 30 oder 31, bei der die Î²-1,4-Endoxylanase von <u>Aspergillus</u> Ursprung ist.</claim-text></claim><claim id="c-de-01-0033" num="0033"><claim-text>Eine Teigzusammensetzung, die eine Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 8-12, 17 und 18 enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0034" num="0034"><claim-text>Ein Backprodukt, das durch Verwendung einer Mehlzusammensetzung gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 26-29 oder einer Teigzusammensetzung gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 30-33 erhalten wird.</claim-text></claim><claim id="c-de-01-0035" num="0035"><claim-text>Ein Verfahren zur Herstellung eines Backprodukts durch Backen einer Mehlzusammensetzung, umfassend die Verwendung der Mehl- oder Teigzusammensetzung gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 26-29 bzw. 30-33.</claim-text></claim><claim id="c-de-01-0036" num="0036"><claim-text>Das Verfahren zur Verarbeitung eines cellulosehaltigen Rohmaterials, um Bier, Papier, StÃ¤rke, Gluten usw. herzustellen oder um cellulose- und/oder hemicellulosehaltigen Abfall zu zersetzen, umfassend das Inkontaktbringen des Materials mit einer reifenden Form der Î²-1,4-Endoxylanase gemÃ¤ÃŸ Anspruch 19 oder einer Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 9-18.</claim-text></claim><claim id="c-de-01-0037" num="0037"><claim-text>Das Verfahren nach Anspruch 36, bei dem die reitende Form von Î²-1,4-Endoxylanase, die verwendet wird, eine reife Form ist.</claim-text></claim><claim id="c-de-01-0038" num="0038"><claim-text>Das Verfahren nach Anspruch 36 oder 37, bei dem die reifende Form von Î²-1,4-Endoxylanase, die verwendet wird, von <u>Aspergillus</u> Ursprung ist.</claim-text></claim><claim id="c-de-01-0039" num="0039"><claim-text>Das Verfahren nach irgendeinem der AnsprÃ¼che 36-36, bei dem das cellulosehaltige Material landwirtschaftlicher Abfall ist, der mit der Î²-1,4-Endoxylanase in Kontakt gebracht wird.</claim-text></claim><claim id="c-de-01-0040" num="0040"><claim-text>Das Verfahren nach irgendeinem der AnsprÃ¼che 36-39, bei dem das cellulosehaltige Material Abfall aus Papierfabriken ist.</claim-text></claim><claim id="c-de-01-0041" num="0041"><claim-text>Das Verfahren nach irgendeinem der AnsprÃ¼che 36-40, welches das Inkontaktbringen des Materials mit einer Zelle gemÃ¤ÃŸ irgendeinem der AnsprÃ¼che 9-18 umfaÃŸt, so daÃŸ sie eine reifende Form der Î²-1,4-Endoxylanase in situ ausscheidet.</claim-text></claim>
EP	0600865	B1	2000-09-20	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Fragment d'ADN recombinant comprenant une sÃ©quence de nuclÃ©otides codant pour au moins une forme maturante d'une Î²-1,4-endoxylanase d'origine fongique ayant une activitÃ© amÃ©liorant le panification, ladite sÃ©quence de nuclÃ©otides Ã©tant choisie dans le groupe comprenant la sÃ©quence de nuclÃ©otides de la figure 1 et les sÃ©quences de nuclÃ©otides Ã©quivalentes telles que<claim-text>- la sÃ©quence de nuclÃ©otides Ã©quivalente corresponde soit Ã  une sÃ©quence de nuclÃ©otides codant pour la sÃ©quence d'acides aminÃ©s illustrÃ©e sur la figure 1, soit pour les parties de la sÃ©quence d'acides aminÃ©s illustrÃ©e sur la figure 1 qui sont essentielles pour donner une forme maturante active de la Î²-1,4-endoxylanase ayant une activitÃ© amÃ©liorant la panification, ladite forme maturante Ã©tant choisie dans le groupe comprenant les formes mature, prÃ©-, pro- et prÃ©pro-, et/ou</claim-text><claim-text>- la sÃ©quence de nuclÃ©otides Ã©quivalente prÃ©sente un brin complÃ©mentaire capable de s'hybrider dans des conditions d'hybridation strictes avec la sÃ©quence de nuclÃ©otides de la figure 1, lesdites conditions d'hybridation strictes Ã©tant une incubation dans 6xSSC Ã  68Â°C et des Ã©tapes de lavage Ã  la mÃªme tempÃ©rature avec 2 x et 0,4xSSC, respectivement.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Fragment d'ADN recombinant selon la revendication 1, comprenant un fragment d'ADN dont la sÃ©quence de nuclÃ©otides code pour au moins une forme maturante d'une Î²-1,4-endoxylanase provenant de <i>Aspergillus</i>.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Fragment d'ADN recombinant selon la revendication 1 ou 2, comprenant un fragment d'ADN dont la sÃ©quence de nuclÃ©otides code pour au moins une forme maturante d'une Î²-1,4-endoxylanase provenant de <i>Aspergillus niger.</i></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Fragment d'ADN recombinant selon l'une quelconque des revendications prÃ©cÃ©dentes, comprenant un fragment d'ADN dont la sÃ©quence de nuclÃ©otides code pour au moins une forme maturante d'une Î²-1,4-endoxylanase provenant de <i>Aspergillus niger</i> var. <i>awamori</i>.<!-- EPO <DP n="64"> --></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Fragment d'ADN recombinant selon l'une quelconque des revendications prÃ©cÃ©dentes, comprenant une sÃ©quence de nuclÃ©otides codant pour au moins une forme maturante d'une Î²-1,4-endoxylanase ayant une sÃ©quence d'acides aminÃ©s choisie parmi les sÃ©quences illustrÃ©es sur la figure 1.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Fragment d'ADN recombinant selon l'une quelconque des revendications prÃ©cÃ©dentes, comprenant l'ADN dont la sÃ©quence de nuclÃ©otides code pour au moins une forme mature de la Î²-1,4-endoxylanase.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Fragment d'ADN recombinant selon l'une quelconque des revendications prÃ©cÃ©dentes, qui code pour au moins une autre enzyme, dans lequel ladite autre enzyme possÃ¨de une activitÃ© amylolytique et/ou hÃ©micellulolytique et/ou cellulolytique.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Cellule transformÃ©e comprenant un fragment d'ADN recombinant selon l'une quelconque des revendications 1 Ã  7, ladite cellule Ã©tant apte Ã  exprimer au moins la forme maturante de la Î²-1,4-endoxylanase codÃ©e par le fragment d'ADN recombinant et ladite cellule Ã©tant apte Ã  sÃ©crÃ©ter au moins la forme mature de la Î²-1,4-endoxylanase codÃ©e par le fragment d'ADN recombinant.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Cellule transformÃ©e selon la revendication 8 adaptÃ©e pour Ãªtre utilisÃ©e dans un procÃ©dÃ© dans lequel la cellule hÃ´te non transformÃ©e est utilisÃ©e d'une maniÃ¨re fonctionnelle connue <i>per</i> se avec une matiÃ¨re premiÃ¨re contenant de la cellulose et/ou de l'hÃ©micellulose, ladite cellule transformÃ©e devenant polyfonctionnelle dans ledit procÃ©dÃ© lors de l'expression de l'ADN recombinant codant pour la forme maturante de la Î²-1,4-endoxylanase et secrÃ©tant ensuite au moins une forme mature de la Î²-1,4-endoxylanase ayant une activitÃ© amÃ©liorant la panification, permettant ainsi la dÃ©gradation du xylane.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Cellule selon la revendication 9, dans laquelle le procÃ©dÃ© dans lequel ladite cellule non transformÃ©e est fonctionnelle et ladite cellule transformÃ©e est polyfonctionnelle appartient au domaine de la production et de la transformation agro-alimentaires.<!-- EPO <DP n="65"> --></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Cellule transformÃ©e selon la revendication 9 ou 10, ledit procÃ©dÃ© dans lequel ladite cellule est polyfonctionnelle Ã©tant destinÃ© Ã  la fermentation et ladite cellule Ã©tant une cellule de levure.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Cellule transformÃ©e selon l'une quelconque des revendications 9 Ã  11, ladite cellule Ã©tant une cellule de levure et ledit procÃ©dÃ© dans lequel ladite cellule est polyfonctionnelle Ã©tant destinÃ© Ã  la prÃ©paration de produits de boulangerie.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Cellule transformÃ©e selon l'une quelconque des revendications 8 Ã  12, ladite cellule Ã©tant choisie dans le groupe consistant en une cellule bactÃ©rienne, une cellule de champignon, une cellule de levure et une cellule vÃ©gÃ©tale.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Cellule selon l'une quelconque des revendications 8 Ã  13, ladite cellule Ã©tant une cellule de champignon choisie parmi les genres <i>Aspergillus</i> et <i>Trichoderma</i>.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Cellule selon l'une quelconque des revendications 8 Ã  14, ladite cellule Ã©tant une cellule de champignon choisie parmi les espÃ¨ces <i>Aspergillus niger</i> var. <i>awamori</i>, <i>Aspergillus niger</i> var. <i>niger</i>, <i>Aspergillus nidulans</i> et <i>Aspergillus oryzae</i>.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Cellule selon l'une quelconque des revendications 8 Ã  13, ladite cellule Ã©tant une cellule bactÃ©rienne choisie parmi les genres <i>Bacillus</i>, <i>Lactobacillus</i> et <i>Streptococcus</i>.</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>Cellule selon l'une quelconque des revendications 8 Ã  13, ladite cellule Ã©tant choisie parmi les cellules de levure des genres <i>Saccharomyces</i>, <i>Kluyveromyces</i>, <i>Hansenula</i> et <i>Pichia</i>.</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>Cellule selon la revendication 17, ladite cellule Ã©tant choisie parmi les cellules de levure des espÃ¨ces <i>Saccharomyces cerevisiae</i>, <i>Saccharomyces carlsbergensis</i>, <i>Kluyveromyces lactis</i>, <i>Kluyveromyces marxianus</i>, <i>Hansenula polymorpha</i> et <i>Pichia pastoris</i>.<!-- EPO <DP n="66"> --></claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>Î²-1,4-endoxylanase ayant une activitÃ© amÃ©liorant la panification pouvant Ãªtre obtenue par l'expression d'un fragment d'ADN recombinant selon l'une quelconque des revendications 1 Ã  7, de prÃ©fÃ©rence sous forme purifiÃ©e.</claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>ProcÃ©dÃ© de production d'une forme maturante d'une Î²-1,4-endoxylanase, ladite forme maturante comprenant une sÃ©quence d'acides aminÃ©s choisie parmi les sÃ©quences illustrÃ©es sur la figure 1 comprenant :<claim-text>- la mise en culture d'une cellule selon l'une quelconque des revendications 8 Ã  18 dans un milieu nutritif appropriÃ©, et</claim-text><claim-text>- facultativement, la purification de la forme maturante de l'enzyme ainsi obtenue.</claim-text></claim-text></claim><claim id="c-fr-01-0021" num="0021"><claim-text>ProcÃ©dÃ© de production d'une forme maturante d'une Î²-1,4-endoxylanase, ladite forme maturante comprenant une sÃ©quence d'acides aminÃ©s choisie parmi les sÃ©quences identifiÃ©es sous les rÃ©fÃ©rences 7 et 8 comprenant :<claim-text>- la mise en culture d'une cellule selon l'une quelconque des revendications 9 Ã  18 dans un milieu nutritif appropriÃ©, et</claim-text><claim-text>- facultativement, la purification de la forme maturante de l'enzyme ainsi obtenue.</claim-text></claim-text></claim><claim id="c-fr-01-0022" num="0022"><claim-text>Composition amÃ©liorant la panification comprenant une forme maturante de la Î²-1,4-endoxylanase codÃ©e par une sÃ©quence d'ADN selon l'une quelconque des revendications 1 Ã  7 en tant que constituant amÃ©liorant la panification.</claim-text></claim><claim id="c-fr-01-0023" num="0023"><claim-text>Composition amÃ©liorant la panification selon la revendication 22 comprenant une forme mature de la Î²-1,4-endoxylanase.</claim-text></claim><claim id="c-fr-01-0024" num="0024"><claim-text>Composition amÃ©liorant la panification selon la revendication 22 ou 23, dans laquelle ladite Î²-1,4-endoxylanase provient d'Aspergillus.</claim-text></claim><claim id="c-fr-01-0025" num="0025"><claim-text>Composition amÃ©liorant la panification comprenant une cellule selon l'une quelconque des revendications 8 Ã  12, 17 et 18.</claim-text></claim><claim id="c-fr-01-0026" num="0026"><claim-text>Composition de farine comprenant une forme maturante de la Î²-1,4-endoxylanase codÃ©e par une sÃ©quence d'ADN selon l'une quelconque des revendications 1 Ã  7 en tant que constituant amÃ©liorant la panification.<!-- EPO <DP n="67"> --></claim-text></claim><claim id="c-fr-01-0027" num="0027"><claim-text>Composition de farine selon la revendication 26 dans laquelle la forme maturante est la forme mature de la Î²-1,4-endoxylanase.</claim-text></claim><claim id="c-fr-01-0028" num="0028"><claim-text>Composition de farine selon la revendication 26 ou 27 dans laquelle ladite Î²-1,4-endoxylanase provient d'<i>Aspergillus</i>.</claim-text></claim><claim id="c-fr-01-0029" num="0029"><claim-text>Composition de farine comprenant une cellule selon l'une quelconque des revendications 8 Ã  12, 17 et 18.</claim-text></claim><claim id="c-fr-01-0030" num="0030"><claim-text>Composition de pÃ¢te Ã  pain comprenant une forme maturante de la Î²-1,4-endoxylanase codÃ©e par une sÃ©quence d'ADN selon l'une quelconque des revendications 1 Ã  7 en tant que constituant amÃ©liorant la panification.</claim-text></claim><claim id="c-fr-01-0031" num="0031"><claim-text>Composition de pÃ¢te Ã  pain selon la revendication 30 dans laquelle la forme maturante est la forme mature de la Î²-1,4-endoxylanase.</claim-text></claim><claim id="c-fr-01-0032" num="0032"><claim-text>Composition de pÃ¢te Ã  pain selon la revendication 30 ou 31 dans laquelle la Î²-1,4-endoxylanase provient d'<i>Aspergillus</i>.</claim-text></claim><claim id="c-fr-01-0033" num="0033"><claim-text>Composition de pÃ¢te Ã  pain comprenant une cellule selon l'une quelconque des revendications 8 Ã  12, 17 et 18.</claim-text></claim><claim id="c-fr-01-0034" num="0034"><claim-text>Produit de boulangerie obtenu en utilisant une composition de farine selon l'une quelconque des revendications 26 Ã  29 ou une composition de pÃ¢te Ã  pain selon l'une quelconque des revendications 30 Ã  33.</claim-text></claim><claim id="c-fr-01-0035" num="0035"><claim-text>ProcÃ©dÃ© de prÃ©paration d'un produit de boulangerie par cuisson d'une composition de farine qui comprend l'utilisation de la composition de farine ou de la composition de pÃ¢te Ã  pain selon l'une quelconque des revendications 26 Ã  29 ou 30 Ã  33, respectivement.<!-- EPO <DP n="68"> --></claim-text></claim><claim id="c-fr-01-0036" num="0036"><claim-text>ProcÃ©dÃ© de traitement d'une matiÃ¨re premiÃ¨re contenant de la cellulose afin de prÃ©parer de la biÃ¨re, du papier, de l'amidon, du gluten, etc., ou pour dÃ©composer des rebuts contenant de la cellulose et/ou de l'hÃ©micellulose, ledit procÃ©dÃ© comprenant la mise en contact de ladite matiÃ¨re avec une forme maturante de la Î²-1,4-endoxylanase selon la revendication 19 ou une cellule selon l'une quelconque des revendications 9 Ã  18.</claim-text></claim><claim id="c-fr-01-0037" num="0037"><claim-text>ProcÃ©dÃ© selon la revendication 36 dans lequel la forme maturante de la Î²-1,4-endoxylanase qui est utilisÃ©e est la forme mature.</claim-text></claim><claim id="c-fr-01-0038" num="0038"><claim-text>ProcÃ©dÃ© selon la revendication 36 ou 37 dans lequel la forme maturante de la Î²-1,4-endoxylanase qui est utilisÃ©e provient d'<i>Aspergillus</i>.</claim-text></claim><claim id="c-fr-01-0039" num="0039"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 36 Ã  38 dans lequel la matiÃ¨re contenant de la cellulose est un rebut agricole qui est mis en contact avec la Î²-1,4-endoxylanase.</claim-text></claim><claim id="c-fr-01-0040" num="0040"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 36 Ã  39 dans lequel la matiÃ¨re contenant de la cellulose est un rebut de moulin Ã  papier.</claim-text></claim><claim id="c-fr-01-0041" num="0041"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 36 Ã  40 qui comprend la mise en contact de ladite matiÃ¨re avec une cellule selon l'une quelconque des revendications 9 Ã  18 de maniÃ¨re Ã  ce qu'elle secrÃ¨te une forme maturante de la Î²-1,4-endoxylanase <i>in situ</i>.</claim-text></claim>
EP	0600865	B1	2000-09-20	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0600865&ki=B1&pd=2000-09-20
EP	0668908	B1	2000-05-03	de	TITLE	1	DNS-SEQUENZEN VON EINER NEMATODE, VERWENDBARE FÃœR DIAGNOSE VON INFEKTIONEN
EP	0668908	B1	2000-05-03	en	TITLE	1	SPECIFIC DNA SEQUENCES OF A NEMATODE WHICH CAN BE USED FOR THE DIAGNOSIS OF INFECTION WITH THE NEMATODE
EP	0668908	B1	2000-05-03	fr	TITLE	1	SEQUENCES D'ADN SPECIFIQUES D'UN NEMATODE APTES A SERVIR A DIAGNOSTIQUER UNE INFECTION PAR CE NEMATODE
EP	0668908	B1	2000-05-03	en	DESCR	1	<p id="p0001" num="0001">The present invention relates to a method for the diagnosis of a worm infection of nematodes in general and at kits for carrying out said diagnosis, in particular at the diagnosis of <u>Haemonchus contortus</u>.</p><p id="p0002" num="0002">Furthermore, the invention is also directed at use of specific DNA sequences of a tubulin gene of <u>Haemonchus contortus</u> and parts thereof, at insertions of the sequences in vectors and microorganisms and the use thereof, inter alia for the diagnosis of infection with said nematode.</p><p id="p0003" num="0003">Parasitic helminths (worms) cause serious infectious diseases in humans and animals. In the case of livestock, infections arise at all ages and in virtually every farm.</p><p id="p0004" num="0004">The use of anthelmintics is widespread in veterinary medicine. In the Netherlands 35 million guilders were spent on anthelmintics in 1987. In 1985 worldwide spending on anthelmintics was US$ 540 million. The total costs of parasitic worm infections in cattle (anthelmintics, loss of production, etc.) are estimated to be 100 to 200 million guilders per year in the Netherlands (thesis by H.W. Ploeger 1988, Agricultural University of Wageningen).</p><p id="p0005" num="0005">Little is known about the molecular biology of the mechanism of action of the various control agents. Three groups of broad spectrum anthelmintics are known, each of which have their own mechanism of action. These are<ul id="ul0001" list-style="none" compact="compact"><li>i) benzimidazoles, which probably act via binding to tubulin and consequently inhibit transport within the cell and cell division (Lacey, E., 1988, The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles, Int. J. Parasitol. <u>18</u>, 885-936).</li><li>ii) levamisole and morantel, ganglion stimulants which lead to paralysis of the parasite, and</li><li>iii) avermectins, which intensify the inhibitory effect of gamma-aminobutyric acid (GABA). In nematodes GABA is the most important neurotransmitter for inhibitory signals from interneurons to motor neurons (Barragry, T., 1984a, Anthelmintics - A review, N.Z. Vet. J. <u>32</u>, 161-164; Barragry, T., 1984b, Anthelmintics- review Part II, N.Z. Vet. J. <u>32</u>, 191-199).</li></ul><!-- EPO <DP n="2"> --></p><p id="p0006" num="0006">Of these three, the benzimidazoles are the most widely used.</p><p id="p0007" num="0007">Using molecular biological techniques, we have studied one of the most harmful gastrointestinal parasites in sheep: <u>Haemonchus contortus</u>. This occurs worldwide, causes haemonchosis and is responsible for losses of 50 million guilders per year in sheepfarming in the Netherlands.</p><p id="p0008" num="0008">With a view to effective control of this harmful organism, a sensitive and reliable method for the detection of this worm is indispensable. Parasitic worm infections in sheep are usually mixed infections and a method is therefore needed which is able to differentiate between <u>H. contortus</u> and the other parasitic worms present. The methods which are currently used for the diagnosis of <u>H. contortus</u> are:<ul id="ul0002" list-style="none" compact="compact"><li>1) the detection of the specific symptoms of the disease in sheep, and</li><li>2) differentiation of the larval culture from faeces of the sheep.</li></ul></p><p id="p0009" num="0009">A disadvantage of 1) lies in the fact that clinical diagnosis of an infection with parasitic intestinal worms is difficult to make because the symptoms of the disease cannot always be differentiated from those of other diseases or poor nutrition. In the case of <u>H. contortus</u> the external symptoms (inter alia anaemia and oedema) are only detectable when there is a severe degree of infection, whereas damage (loss in weight, wool loss, milk loss) is already caused by an infection without these external symptoms of disease.</p><p id="p0010" num="0010">A disadvantage of method (2) lies in the fact that the eggs of various nematodes in the faeces of infected animals appear to be very similar to one another, as a result of which in the case of eggs it is not possible to make a diagnosis of the worm species. For this purpose, a larval culture must first be carried out, which takes about one week. In practice, this method is little used (Janssens, P.G., Vercruysse, J. and Jansen, J., editors: Wormen en wormziekten bij mens en dier (Worms and worm diseases in humans and animals) (1989) Samsom Stafleu, Alphen aan de Rijn/Brussels).</p><p id="p0011" num="0011">A new, rapid and species-specific test is therefore needed to be able to diagnose infection with <u>H. contortus</u>. In the case of other nematodes there are a number of tests which are used, such as:<ul id="ul0003" list-style="none" compact="compact"><li>a) the polymerase chain reaction (PCR), and</li><li>b) the dot-blot assay.</li></ul></p><p id="p0012" num="0012">The dot-blot assay is very sensitive and rapidly yields<!-- EPO <DP n="3"> --> results, such as, for example, in the diagnosis of the human nematode <u>Brugia</u>, which causes filariasis (McReynolds, L.A., deSimone, S.M., Williams, S.A. (1986) Cloning and comparison of repeated DNA sequences from the human filarial parasite <u>Brugia pahangi</u>, Proc. Natl. Acad. Sci. USA <u>83</u>, 797-801). In this test, total DNA from the eggs is applied to a nylon membrane and hybridised with the specific DNA probe.</p><p id="p0013" num="0013">In the case of PCR, specific DNA sequences can be used as primer, by which means a fragment of the specific gene is amplified. This can be rendered visible by analysing the reaction mixture using an agarose gel, or by coupling a (fluorescent) label to the primer (De Bruijn, M.H.L., (1988) Diagnostic DNA amplification: no respite for the elusive parasite, Parasitol. Today, 4:293-295). To date, no <u>Haemmonchus contortus</u> DNA is known which is specific for the species and therefore these tests are not possible for the diagnosis of infection with <u>H. contortus</u>. Surprisingly, it has been found that DNA coding for tubulin is species-specific for <u>H. contortus</u>.</p><p id="p0014" num="0014">In Parasitology Today volume 6 no 4 April 1990 Roos M.H. et al describe determining whether populations of <u>Haemonchus</u> <u>contortus</u> are of the benzamidazole sensitive type or resistant genotype and suggest using Î± and Î² tubulin nucleic acid.</p><p id="p0015" num="0015">The present invention relates to use of a DNA sequence of a tubulin gene of <u>H. contortus</u> or a part thereof. The DNA sequence of the tubulin gene or a part thereof comprises the alpha-tubulin gene of <u>H. contortus</u> or a part thereof or the beta-tubulin gene of <u>H. contortus</u> or a part thereof.(In figure 1 the DNA and aminoacid sequence of the Î±-tubulin clone, determined as described further on in the example are given. The numbering of the aminoacids in the Î±-tubulin gene is from 395-425) (In figure 2 DNA and amino acid sequence of the Î²-tubulin clone determined as described further on in the example, are illustrated). The numbering of the DNA bases is given above the DNA sequence, that of the amino acids is given below said sequence. The clone contains the 3' half of the gene and the numbering of the amino acids in the Î²-tubulin gene is 223-448. The polyadenylation signal (bases 1538-1543) is underlined. The site of the oligonucleotide primers is illustrated with a dashed line above the DNA sequence: Î²-1, bases 1-19 according to the strand<!-- EPO <DP n="4"> --> illustrated here; Î²-2 bases 1311-1331 according to the complementary strand).</p><p id="p0016" num="0016">It was known from study of previously published DNA-sequences of Î²-tubulin genes of other organisms that Î²-tubulin genes are strongly conserved [(Cleveland, D.W. and Sullivan, K.F. (1985) Molecular Biology and genetics of tubulin. Ann. Rev. Biochem., 54; 331-365), (Little, M. and Seehaus, T. (1988) Comparative analysis of tubulin sequences. Comp. Biochem. Physiol., 90B; 655-670), (MacRae, T.H. and Langdon, C.M. (1989) Tubulin synthesis, structure and function: what are the relationships?<!-- EPO <DP n="5"> --> Biochem. Cell Biol., 67; 770-789)].</p><p id="p0017" num="0017">Furthermore, it was apparent from previously published DNA-sequences of a number of nematodes (also of Î²-tubulin, see Driscoll et al. The Journal of Biology, 1989, volume 109, pages 2993-3003) that the known nematode DNA sequences mostly resemble higher eucaryotic tubulin sequences. Various Î²-tubulin genes occur in most higher eucaryotes. From what is presently known there appears to be more difference between the different types (genes) of Î²-tubulin within one animal species than between the same type among different animal species. For example: the degree of conservation between tubulin type Î²-4 and Î²-5 of the human is 91,2 %, whereas conservation between type Î²-4 of the human and type Î²-4 of the chicken is 99,3 %.</p><p id="p0018" num="0018">Considering the state of the art as described above it is therefore surprising that DNA of Î²-tubulin is species specific for <u>H. contortus</u>.</p><p id="p0019" num="0019">Fragments of a DNA-sequence according to the invention can be used as oligonucleotide probes for specifically determining <u>H.</u> <u>contortus</u> especially in mixed infections. Preferably the PCR method is used for this. Probes comprising a part of the sequence according to the invention react specifically with, <u>H.</u> <u>contortus</u>, whereby a probe comprising a part of the Î²-tubulin sequence is especially suited for use in specifically determining <u>H.</u> <u>contortus</u> in this manner.</p><p id="p0020" num="0020">Upon studying the conservation of DNA of tubulin genes it was found that the location of the introns is generally conserved. Introns generally occur in the 5' half of the tubulin gene. In the article of Driscoll et al. already cited it was demonstrated that introns also occur in the 3' half of the 3 Î²-tubulin genes of the nematode <u>C.</u> <u>elegans</u>. These introns can be distinguished from the introns of the Î²-tubulin genes of other higher eucaryotes.</p><p id="p0021" num="0021">It has now been found that the DNA-sequence of the 3' half of the Î²-tubulin gene of <u>H.</u> <u>contortus</u> also contains introns. The 3' half of Î²-tubulin of <u>H.</u> <u>contortus</u> has been found to contain a lot more introns than the 3' half of Î²-tubulin of <u>C.</u> <u>elegans</u> and the introns also differ in length from the introns of <u>C.</u> <u>elegans</u>. The location and length of introns in the 3' half of the Î²-tubulin gene appears not to be conserved in nematodes.</p><p id="p0022" num="0022">Further research of Î²-tubulin genes of other nematodes further to the above mentioned discovery have revealed that there are other nematodes beside <u>H.</u> <u>contortus</u> and <u>C.</u> <u>elegans</u> which also contain non<!-- EPO <DP n="6"> --> conserved introns in the 3' half of their Î²-tubulin genes.</p><p id="p0023" num="0023">The subject invention is therefore in general directed at the use of a DNA sequence of a specific nematode as oligonucleotide probe, which probe comprises a part of the DNA sequence of the 3' half of a Î²-tubulin gene, for specifically determining the specific nematode. The subject invention is therefore not restricted to a method for specifically detecting <u>H.</u> <u>contortus</u> in which method a DNA sequence is used as oligonucleotide probe comprising a part of the 3' half of the Î²-tubulin gene of <u>H.</u> <u>contortus</u>. The detection of <u>H.</u> <u>contortus</u> in this manner serves as an example of a method for the diagnosis of an infection with a certain nematode according to the subject invention.</p><p id="p0024" num="0024">Another suitable example of a nematode which can specifically be detected using an oligonucleotide probe comprising a part of the DNA sequence of the 3' half of the Î²-tubulin gene is <u>Trichostrongylus colubriformis.</u></p><p id="p0025" num="0025">The presence of differences in the 3' half of Î²-tubulin genes of nematodes when compared with eachother made a species specific PCR possible. Parts of a DNA sequence comprising a Î²-tubulin gene can be used as oligonucleotide probes for specifically detecting a nematode with the aid of the PCR in mixed infections.</p><p id="p0026" num="0026">A particular embodiment of the method that has been described above comprises the use of parts of the Î²-tubulin gene as primers, which primers are conserved in various nematodes, whereby two sequences are selected as primers which are located in such a manner that the DNA sequence which is amplified from the total DNA of the nematode via PCR, the amplification product, has a species specific length per nematode. because the DNA sequence which is located between the primers is species specific. It is preferable to amplify DNA from the DNA sequence comprising a part of the 3' half of the Î²-tubulin gene, as the DNA sequence of the 3' half has been found to differ in intron length per nematode.</p><p id="p0027" num="0027">Two Î²-tubulin oligonucleotides, Î²-1 and Î²-2 were made on the basis of a DNA sequence of the Î²-tubulin gene of <u>H.</u> <u>contortus</u> as determined by the inventors and illustrated in figure 2, in order to be able to measure the difference in introns among various nematode species. The oligonucleotides namely contain DNA sequences coding for amino acid sequences supposed to be conserved in Î²-tubulin genes of all higher eucaryotes. Oligonucleotide Î²-1 comprises amino acids 1-7 of the Î²-tubulin gene of <u>H.</u> <u>contortus</u> and oligonucleotide Î²-2 comprises amino<!-- EPO <DP n="7"> --> acids 198-204. The DNA sequence of Î²-1 is: 5' ACGGATCTCAACCACCTTG 3' and the sequence of Î²-2 on the complementary strand is 5' CTGGTACTGCTGGTATTCGGA 3'.</p><p id="p0028" num="0028">The PCR carried out with these oligonucleotides always gave a positive reaction to the presence of <u>H.</u> <u>contortus</u> DNA also in mixed infections. With this PCR a DNA fragment of approximately 1300 bases was generated. This PCR always gave a positive result when <u>H.</u> <u>contortus</u> DNA was present and then the fragment of 1300 bases was found with the Î²-1 and Î²-2 primers. The PCR always gave a negative reaction when no fragment of 1300 bases was present and no <u>H.</u> <u>contortus</u> DNA was present.</p><p id="p0029" num="0029">The PCR with the Î²-1 and Î²-2 primers was also tested on DNA of other prevalent sheep parasites. A positive reaction was also found with <u>Trychostrongylus</u> <u>colubriformis</u> also in mixed infections, however the DNA fragment was smaller approximately 900 bases and clearly discernable from the <u>H.</u> <u>contortus</u> fragment.</p><p id="p0030" num="0030">The PCR with the Î²-1 and Î²-2 primers was also tested on DNA of <u>Ostertagia</u> <u>circumcincta</u>, <u>Nippostrongylus</u> <u>brasiliensis</u>, <u>Trichinella spiralis</u> and <u>Trichinella</u> <u>native</u>. No reaction was found not even with so called degenerate primers, which take into account the degenaracy of the genetic code. These were, primers Î²-7 (albino acids 1-6) with DNA sequence: 5' (CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3' and Î²-8 (amino acids 199-205) on the complementary strand with DNA sequence: 5' TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3' (figure 2). The PCR with the Î²-7 and Î²-8 primers was positive with DNA of <u>H.</u> <u>contortus</u> and <u>T. colubriformis</u> giving the DNA fragments that were described previously.</p><p id="p0031" num="0031">As the used primers correspond to a DNA sequence coding for a very conserved region of the Î²-tubulin molecule it appears probable that the Î²-tubulin gene(s) of the nematode species leading to a negative result with these primers using PCR contain an intron in the sequence of the primers. This could prevent the primer from binding and could prevent any reaction taking place. A change in the amino acid sequence in the region of the primers could also be a possible explanation for the above mentioned result but does not seem probable considering the conservation of the amino acid sequence in this region.</p><p id="p0032" num="0032">By selecting the primers in a different region of the 3' half of the Î²-tubulin gene a species specific PCR can also be obtained for the nematodes giving a negative result with the primers Î²-1, Î²-2, Î²-7 and Î²-8.</p><p id="p0033" num="0033">The subject invention is therefore also directed at a method<!-- EPO <DP n="8"> --> for the diagnosis of a worm infection, with which method the total DNA from the eggs from the nematode is amplified preferably via PCR, which method is characterized in the use of two parts of the coding sequence of the Î²-tubulin gene which are conserved in various nematodes as primers, which primers are located in the DNA sequence of the Î²-tubulin gene in such a manner that the amplification product has a species specific length per nematode.</p><p id="p0034" num="0034">The beta-tubulin probes comprising the complete 2,2 kb Î²-tubulin clone of <u>H.</u> <u>contortus</u> (pEMBLaB, deposited at the CBS in Baarn under Nr. CBS 335.90) or the 1,3 kb Î²-1/Î²-2 PCR fragment always show a positive reaction to the presence of <u>H. contortus</u>, even in the case of a mixed infection. The beta-tubulin probes of <u>H. contortus</u> were also tested on the DNA of other frequently occurring sheep parasites and this reaction was found to be much less pronounced than with its own species. Yet specific bands were obtained with these large probes which indicates conservation. The weaker reaction could be caused by introns in conserved regions or small species specific DNA sequences within these large probes. The species which were tested are, inter alia: <u>Cooperia circumcincta</u>, <u>Nematodirus battus</u>, <u>Nippostrongylus brasiliensis</u>, <u>Ostertagia circumcincta</u>, <u>Trichostrongylus colubriformis</u>, <u>Trichostrongylus vitrinus</u>, <u>Trichinella spiralis</u> and <u>Trichinella native</u>.</p><p id="p0035" num="0035">By selecting a specific sequence from a DNA sequence according to the invention of for example, at least 10 nucleotides from a <u>H. contortus</u> specific intron or the DNA sequence coding for amino acids 332-335, which under specific conditions reacts solely with <u>H.</u> <u>contortus</u>, it is possible to establish a test by means of which it is possible, in the case of a mixed infection with nematodes, to diagnose infection with <u>H. contortus</u> from the DNA of the eggs.</p><p id="p0036" num="0036">Examples of tests which can be used are those which are used in the case of other nematodes:<ul id="ul0004" list-style="none" compact="compact"><li>a) the polymerase chain reaction (PCR), and</li><li>b) the dot-blot assay.</li></ul></p><p id="p0037" num="0037">The present invention also relates to a method for the diagnosis of a worm infection, in which method the total DNA from the eggs from the nematode is applied to a nylon membrane and hybridised with a DNA probe, which method is characterised in that a diagnosis of infection with <u>Haemonchus contortus</u> is made, using a sequence which corresponds to a specific part of a tubulin gene of <u>H. contortus</u> as oligonucleotide probe. A preferred method is a method in which specific<!-- EPO <DP n="9"> --> DNA fragments from the DNA of the eggs are amplified, for example by means of PCR, and are rendered visible. The diagnosis of an infection with <u>H. contortus</u> can be made because the amplification of specific fragments is successful when <u>H. contortus</u> DNA is present in the egg sample and sequences are used, such as a primer which corresponds to at least a conserved part of a tubulin gene of <u>H. contortus</u>, whereby said sequences are localised in the DNA sequence of the Î²-tubulin gene in such a manner that the amplification product has a species specific length.</p><p id="p0038" num="0038">The invention is also directed at a kit for carrying out the diagnosis of a worm infection which kit comprises at least a species specific part of the 3' half of the Î²-tubulin gene of the nematode to be detected as oligonucleotide probe and is also provided with other means and materials which are apparent to an expert.</p><p id="p0039" num="0039">The invention is further directed at a kit for carrying out a method for the diagnosis of infection with <u>H.</u> <u>contortus</u>, which kit comprises at least a part of the DNA sequence according to the invention and is also provided with other means and materials apparent to an expert. Such a kit shall preferably comprise a part of the 3' half of the Î²-tubulin gene of <u>H.</u> <u>contortus</u>.</p><p id="p0040" num="0040">The invention is further directed at a kit for carrying a method for the diagnosis of infection with <u>H</u>. <u>contortus</u>, which kit comprises at least primers comprising coding DNA sequences of the Î²-tubulin gene which are conserved in various nematodes, which primers are located in such a manner in the DNA sequence of the Î²-tubulin gene of <u>H. contortus</u> that the amplification product has a species specific length. Such a kit shall preferably comprise primers giving a part of the 3' half of the Î²-tubulin gene of <u>H.</u> <u>contortus</u> as amplification product. Such a kit will comprise for example the Î²-1 and Î²-2 primers and/or the Î²-7 and Î²-8 primers. Furthermore such a kit is also provided with the means and materials apparent for an expert.</p><p id="p0041" num="0041">The sequences according to the invention can also be used if they are incorporated in a vector, an expression vector being preferred. The invention relates to vectors of this type and also to recombinant microorganisms which comprise a DNA sequence according to the invention.</p><p id="p0042" num="0042">The invention also relates to a peptide which comprises at least one fragment of the amino acid sequence which is coded by a DNA sequence according to the invention.<!-- EPO <DP n="10"> --></p><heading id="h0001"><u>EXAMPLE</u></heading><heading id="h0002"><u>Construction of the gene libraries of H. contortus and analysis of the tubulin clones</u></heading><p id="p0043" num="0043">Genomic DNA was made from L3 larvae using the method of Coulson et al. (Coulson, A., Sulston, J., Brenner, S. and Karn, J. (1986) Toward a physical map of the genome of the nematode <u>Caenorhabditis elegans</u>, Proc. Natl. Acad. Sci. USA <u>83</u>, 7821-7825). The size of the DNA fragments to be cloned was 20 kb. In order to obtain arbitrary fragments of this size a partial digestion was carried out with a restriction enzyme that cuts frequently in genomic DNA. To this end, the concentration of the enzyme was chosen as described in Maniatis et al. (Maniatis, T., Fritsch, T. and Sambrook, J. (1982) Molecular cloning. A laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., USA). These fragments were isolated and ligated in the DNA of the bacteriophage arms of EMBL3 using the method of Frischauf et al. (Frischauf, A.M., Lehrach, H., Poustka, A., Murray, N. (1983) Lambda replacement vectors carrying polylinker sequences, J. Mol. Biol. <u>170</u>, 827-841). This DNA construct was then packaged in bacteriophage protein envelope and used to infect the bacterial strain Le 392. The infected bacteria were plated out with non-infected bacteria and after incubation at 37Â°C a plaque was visible at the location where infected bacteria were present (Frischauf, A.M., Lehrach, H., Poustka, A. and Murray, N. (1983) Lambda replacement vectors carrying polylinker sequences, J. Mol. Biol. <u>170</u>, 827-841). The plaques were then screened according to the method of Maniatis et al. (Maniatis, T., Fritsch, T. and Sambrook, J. (1982) Molecular cloning. A laboratory manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., USA). The tubulin probes used to isolate the alpha-tubulin DNA-containing clones were chicken alpha-tubulin [as described in Valenzuela et al. (Valenzuela, P., Quiroga, M., Zaldivar, J., Rutter, W.J., Kirshner, M.W. and Cleveland, D.W. (1981) Nucleotide and corresponding amino acid sequences encoded by alpha and beta tubulin mRNAs. Nature <u>289</u>, 650-655)] and <u>Drosophila hydei</u> alpha-tubulin [a gift from Dr. R. Brand of the Catholic University of Nijmegen (Michiels, F., Falkenburg. D., Muller, A.M., Hinz, U., Otto, U., Bellmann, R., Glazer, K.H., Brand, R.,<!-- EPO <DP n="11"> --> Bialojan, S. and Renkawitz-Pohl, R. (1987) Testis-specific beta2 tubulins are identical in <u>Drosophila melanogaster</u> and <u>D. hydei</u> but differ from the ubiquitous beta1 tubulin)].</p><p id="p0044" num="0044">The beta-tubulin probes used to isolate the beta-tubulin DNA-containing clones were a beta-tubulin clone of <u>Caenorhabditis elegans</u>, Ben-1 [which is described in Driscoll et al. (Driscoll, M., Dean, E., Reilly, E., Bergholz, E. and Chalfie, M. (1989) Genetic and molecular analysis of a <u>Caenorhabditis elegans</u> beta tubulin that conveys benzimidazole sensitivity, J. Cell Biol. <u>109</u>, 2993-3003)] and a beta-tubulin clone of <u>Drosophila hydei</u> pTB5 [a gift from Dr. R. Brand of the Catholic University of Nijmegen (Michiels. F., Falkenburg, D., Muller, A.M., Hinz, U., Otto, U., Bellmann, R., Glazer, K.H., Brand, R., Bialojan, S. and Renkawitz-Pohl, R. (1987) Testis-specific beta2 tubulins are identical in <u>Drosophila melanogaster</u> and <u>D. hydei</u> but differ from the ubiquitous beta1 tubulin)].</p><p id="p0045" num="0045">Of the clones obtained in this way, the clone pEMBL8cA (deposited with the CBS in Baarn under No. CBS 335.90), for alpha-tubulin, and the clone pEMBL7aB (deposited with the CBS in Baarn under No. CBS 334.90), for beta-tubulin, were further characterised. Subclones thereof, which contain DNA fragments coding for protein, were constructed in the vectors Bluescript and M13. The DNA of these subclones was sequenced using the dideoxy method of Sanger et al. (Sanger, F., Nicklen, S. and Coulson, A.R. (1977) DNA sequencing with chain terminating inhibitors, Proc. Natl. Acad. Sci. USA <u>74</u>, 5463-5467), as modified in the T7 sequencing kit from Pharmacia and the M13 sequencing kit from Amersham. Standard primers, which are supplied with the kits, were used. The analysis and comparison of the sequences thus obtained was carried out using the Microgenie (Beckman) and PC/Gene (Genofit, Geneva) computer programs. The sequences determined for these clones are shown in Figures 1 and 2 respectively.</p><heading id="h0003"><u>The PCR specific for H. contortus and T. colubriformis.</u></heading><p id="p0046" num="0046">The oligonucleotides Î²-1 and Î²-2 as described above were made in order to carry out a species specific PCR for DNA of <u>H.</u> <u>contortus</u> and <u>T.</u> <u>colubriformis</u>. The Î²-7 and Î²-8 primers were made in order to obtain a species specific PCR for the species <u>O.</u> <u>circumcincta</u>, <u>T.</u> <u>spiralis</u> and <u>T. nativa.</u> The PCR method was used according to Ehrlich et al. (Saiki, R.K., (1989) in: PCR technology, principles and applications for DNA amplification, Erlich, H.A. (ed.), Stockton Press, New York, London, pp. 7-16). The reaction conditions used in the present invention, which were<!-- EPO <DP n="12"> --> used to amplify the DNA, are: PCR with Î²-1 and Î²-2 primers with a magnesium concentration of 1,5 mM an annealing temperature of 61Â°C for 30 seconds, elongation at 72Â°C for 2 minutes and denaturing at 95Â°C for 30 seconds. This method amplifies the beta-tubulin of <u>H. contortus</u> and <u>T. colubriformis</u> from the genomic DNA, which can be rendered visible by electrophoresis in an agarose gel, whereby DNA of <u>H.</u> <u>contortus</u> gives a visible band of 1,3 kb and DNA of <u>T.</u> <u>colubriformis</u> gives a visible band of 0,9 kb. This method does not work with <u>Ostertagia</u>, <u>N,</u> <u>brasiliensis</u>, <u>T. spiralis</u> and <u>T.</u> <u>nativa</u>, which makes it clear that this PCR method with the abovementioned primers is specific for <u>Haemonchus contortus</u> and <u>Trichostrongylus</u> <u>colubriformis</u>.</p><p id="p0047" num="0047">The PCR conditions with the Î²-7 and Î²-8 primers were: 5 cycli as follows. An annealing temperature of 37Â°C for 1 minute, a slow rise in 5 minutes from 37Â°C to the elongation temperature of 72Â°C, 2 minutes at 72Â°C, 1 minute at 95Â°C. Subsequently 20 cycli of 1 minute at 55Â°C, 2 minutes at 72Â°C and 1 minute at 95Â°C. The magnesium concentration was 1,5 mM. This PCR visualized a positive reaction with <u>H.</u> <u>contortus</u> DNA and was negative with <u>O.</u> <u>circumcincta</u>, <u>T.</u> <u>spiralis</u> and <u>T.</u> <u>nativa.</u></p>
EP	0668908	B1	2000-05-03	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A method for differentiated diagnosis of nematode infection with a specific type of nematode useful in the case of mixed nematode infections said method comprising use of a DNA sequence, said DNA sequence being the Î²-tubulin gene or a part of said gene of said nematode as oligonucleotide probe and/or primer, said part comprising at least 10, preferably at least 18 nucleotides.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A method according to claim 1 wherein the specific nematode is <u>Haemonchus</u> <u>contortus</u> and the Î²-tubulin gene is the Î²-tubulin gene of <u>Haemonchus</u> <u>contortus</u>.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A method according to claim 1 or 2 wherein the probe and/or primer comprises a part of the 3' half of the Î²-tubulin gene.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A method according to any of claims 1-3 wherein the probe and/or primer is species specific.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A method according to claim 4, wherein the probe and/or primer is at least 10 nucleotides from a <u>H. contortus</u> specific intron.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A method according to any of claims 1-4 wherein the probe is derived from the DNA sequence encoding amino acids 332-335 of <u>H. contortus</u> Î²-tubulin.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A method according to any of claims 1-6 wherein the total nematode DNA is applied to a nylon membrane and hybridised with the probe.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A method according to any of claims 1-3 wherein a primer is selected that is conserved in various nematode types, whereby the primer is located such that the DNA that is amplified from the total DNA of the nematode has a species specific length per nematode.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A method according to claim 8 wherein the primer is a coding sequence for a conserved amino acid sequence.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A method acording to claim 9 wherein two primers are<!-- EPO <DP n="14"> --> selected that are conserved in various nematodes, which primers are located in the Î²-tubulin sequence such that the amplification product has species specific length per nematode.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A method according to any of claims 1-3 or 8-10, wherein any amplification product of the nematode DNA comprises a part of the 3' half of the Î²-tubulin gene.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A method according to any of claims 1-3 or 8-11, characterised in that Î²-1 and Î²-2 are used as primers, whereby Î²-1 has the sequence 5' ACGGATCTCAACCACCTTG 3' and Î²-2 has the sequence 5' CTGGTACTGCTGGTATTCGGA 3' on the complementary strand, or primers Î²-7 and Î²-8 are used whereby Î²-7 comprises the amino acids 1-6 of Î²-tubulin of <u>H. contortus</u> with DNA sequence: 5' (CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3' and Î²-8 comprises the amino acids 199-205 of Î²-tubulin of <u>H.</u> <u>contortus</u> with DNA sequence. 5' TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3' on the complementary strand.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A method according to any of the preceding claims wherein <u>H. contortus</u> infection can be differentiated from infection with the various nematodes <u>Cooperia</u> <u>circumcincta.</u>, <u>Ostertagia</u> <u>circumcincta</u>, <u>Nematodirus</u> <u>battus</u>, <u>Nippostrongylus</u> <u>brasiliensis</u>, <u>Trichinella</u> <u>spiralis</u>, <u>Trichinella</u> <u>nativa</u>, <u>Trichostrongylus</u> <u>vitrinus</u> and <u>Trichostrongylus colubriformis</u>.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A method according to any of claims 1-3 and 8-13, characterised in that a diagnosis of infection is carried out which is specific for <u>H.</u> <u>contortus</u> when the amplification product has a length of 1,3 kb.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A method according to any of claims 1-3, 8-14, characterised in that a diagnosis of infection is carried out which is specific for <u>Trichostrongylus</u> <u>colubriformis</u> when the amplification product has a length of 0,9 kb.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>Kit for carrying out a differentiated diagnosis of infection with <u>Haemonchus</u> <u>contortus</u> according to any of the preceding claims, which kit comprises at least a primer comprising DNA coding sequence, said DNA coding sequence being the 3' half of the Î²-tubulin<!-- EPO <DP n="15"> --> gene comprised in the nematode <u>Haemonchus</u> <u>contortus</u> in the plasmid deposited under accession number CBS 334.90 at the Centraal Bureau Schimmelcultures in Baarn The Netherlands, said primer having a length of at least 10 nucleotides preferably of at least 18, said primer being a sequence conserved in various nematodes and located in the DNA sequence of <u>Haemonchus</u> <u>contortus</u> such that the amplification product thereof has a species specific length.</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>Kit according to claim 16 which kit comprises the primers with nucleic acid sequences Î²-1 and Î²-2 and/or the primers Î²-7 and Î²-8 wherein<claim-text>Î²-1 =5'ACGGATCTCAACCACCTTG 3'</claim-text><claim-text>Î²-2 =5'CTGGTACTGCTGGTATTCGGA 3'</claim-text><claim-text>Î²-7 =5'(CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3'</claim-text><claim-text>Î²-8 =5'TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3'.</claim-text></claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>Kit for carrying out a differentiated diagnosis of infection with <u>Haemonchus</u> <u>contortus</u> according to any of claims 1-15 which kit comprises<br/>at least a probe and/or primer species specific for <u>Haemonchus</u> <u>contortus</u> said probe or primer being derived from a DNA coding sequence, said DNA coding sequence being the 3' half of the Î²-tubulin gene of <u>Haemonchus contortus</u> comprised in the plasmid deposited under accession number CBS 334.90 at the Centraal Bureau Schimmelcultures in Baarn The Netherlands.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>Kit according to claim 18 which kit comprises the primers with nucleic acid sequences Î²-1 and Î²-2 and/or the primers Î²-7 and Î²-8 wherein<claim-text>Î²-1 =5'ACGGATCTCAACCACCTTG 3'</claim-text><claim-text>Î²-2 =5'CTGGTACTGCTGGTATTCGGA 3'</claim-text><claim-text>Î²-7 =5'(CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3'</claim-text><claim-text>Î²-8 =5'TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3'.</claim-text></claim-text></claim>
EP	0668908	B1	2000-05-03	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zur differenzierten Diagnose einer NematodenInfektion mit einem speziellen Nematoden-Typ, das im Fall von gemischten Nematoden-Infektionen anwendbar ist, wobei bei dem Verfahren eine DNA-Sequenz, die das Î²-Tubulin-Gen oder ein Teil dieses Gens dieser Nematode ist, als Oligonukleotid-Sonde und/oder Primer verwendet wird, und der Teil mindestens 10, vorzugsweise mindestens 18 Nukleotide, umfaÃŸt.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren nach Anspruch 1, bei dem die spezielle Nematode Haemonchus contortus und das Î²-Tubulin-Gen das Î²-Tubulin-Gen von Haemonchus contortus ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren nach Anspruch 1 oder 2, bei dem die Sonde und/oder der Primer einen Teil der 3'-HÃ¤lfte des Î²-Tubulin-Gens umfaÃŸt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-3, bei dem die Sonde und/oder der Primer artenspezifisch ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verfahren nach Anspruch 4, bei dem es sich bei der Sonde und/oder dem Primer um mindestens 10 Nukleotide eines fÃ¼r H. contortus spezifischen Introns handelt.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-4, bei dem die Sonde von der DNA-Sequenz stammt, welche die AminosÃ¤uren 332-335 des Î²-Tubulins von H. contortus kodiert.<!-- EPO <DP n="17"> --></claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-6, bei dem die gesamte Nematoden-DNA auf eine Nylon-Membran aufgebracht und mit der Sonde hybridisiert wird.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-3, bei dem ein Primer ausgewÃ¤hlt wird, der in verschiedenen Nematoden-Typen konserviert ist, wobei der Primer so lokalisiert ist, daÃŸ die von der Gesamt-DNA der Nematode amplifizierte DNA fÃ¼r jede Nematode eine artspezifische LÃ¤nge hat.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verfahren nach Anspruch 8, bei dem der Primer eine kodierende Sequenz fÃ¼r eine konservierte AminosÃ¤uresequenz ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verfahren nach Anspruch 9, bei dem zwei Primer ausgewÃ¤hlt werden, die in verschiedenen Nematoden konserviert sind, wobei die Primer in der Î²-Tubulin-Sequenz so lokalisiert sind, daÃŸ das Amplifikationsprodukt jeder Nematode eine artenspezifische LÃ¤nge hat.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-3 oder 8-10, bei dem jedes Amplifikationsprodukt der Nematoden-DNA einen Teil der 3'-HÃ¤lfte des Î²-Tubulin-Gens umfaÃŸt.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-3 oder 8-11, dadurch gekennzeichnet, daÃŸ Î²-1 und Î²-2 als Primer verwendet werden, wobei Î²-1 die Sequenz 5' ACGGATCTCAACCACCTTG 3' und Î²-2 die Sequenz 5' CTGGTACTGCTGGTATTCGGA 3' auf dem komplementÃ¤ren Strang hat, oder die Primer Î²-7 und Î²-8 verwendet werden, wobei Î²-7 die AminosÃ¤uren 1-6 des Î²-Tubulins von H. contortus mit der DNA-Sequenz<claim-text>5' (CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3'</claim-text><!-- EPO <DP n="18"> --> und Î²-8 die AminosÃ¤uren 199-205 des Î²-Tubulins von H. contortus mit der DNA-Sequenz<claim-text>5' TC(CT)TGGTA(TC)TG(CT)(TG)(GA)TA(CT)TC 3'</claim-text> auf dem komplementÃ¤ren Strang umfaÃŸt.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, mit dem die Infektion mit H. contortus von Infektionen mit den unterschiedlichen Nematoden Cooperia circumcincta, Ostertagia circumcincta, Nematodirus battus, Nippostrongylus brasiliensis, Trichinella spiralis, Trichinella nativa, Trichostrongylus vitrinuns und Trichostrongylus colubriformis differenziert werden kann.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-3 und 8-13, dadurch gekennzeichnet, daÃŸ eine fÃ¼r H. contortus spezifische Diagnose der Infektion durchgefÃ¼hrt wird, wenn das Amplifikationsprodukt eine LÃ¤nge von 1,3 kb hat.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Verfahren nach einem der AnsprÃ¼che 1-3, 8-14, dadurch gekennzeichnet, daÃŸ eine fÃ¼r Trichostrongylus colubriformis spezifische Diagnose der Infektion durchgefÃ¼hrt wird, wenn das Amplifikationsprodukt eine LÃ¤nge von 0,9 kb hat.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Kit zur DurchfÃ¼hrung einer differenzierten Diagnose einer Infektion mit Haemonchus contortus nach einem der vorhergehenden AnsprÃ¼che, wobei der Kit mindestens einen Primer enthÃ¤lt, der eine kodierende DNA-Sequenz umfaÃŸt, welche die 3'-HÃ¤lfte des Î²-Tubulin-Gens der Nematode Haemonchus contortus ist, das in dem unter der Zugangsnummer CBS 334.90 beim Centraal Bureau Schimmelcultures in Baarn, Niederlande, hinterlegten Plasmid enthalten ist, und wobei der Primer eine LÃ¤nge von mindestens 10 Nukleotiden, vorzugsweise mindestens<!-- EPO <DP n="19"> --> 18, hat und wobei der Primer eine in verschiedenen Nematoden konservierte Sequenz ist und in der DNA-Sequenz von Haemonchus contortus so lokalisiert ist, daÃŸ deren Amplifikationsprodukt eine artenspezifische LÃ¤nge hat.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Kit nach Anspruch 16, wobei der Kit die Primer mit den NukleinsÃ¤uresequenzen Î²-1 und Î²-2 und/oder die Primer Î²-7 und<claim-text>Î²-8 enthÃ¤lt, wobei</claim-text><claim-text>Î²-1 = 5'ACGGATCTCAACCACCTTG 3'</claim-text><claim-text>Î²-2 = 5'CTGGTACTGCTGGTATTCGGA 3'</claim-text><claim-text>Î²-7 = 5'(CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3'</claim-text><claim-text>Î²-8 = 5'TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3' ist.</claim-text></claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Kit zur DurchfÃ¼hrung einer differenzierten Diagnose einer Infektion mit Haemonchus contortus nach einem der AnsprÃ¼che 1-15, wobei der Kit mindestens eine Sonde und/oder einen Primer enthÃ¤lt, die/der fÃ¼r Haemonchus contortus artenspezifisch ist, und wobei die Sonde oder der Primer von einer kodierenden DNA-Sequenz stammt, welche die 3'-HÃ¤lfte des Î²-Tubulin-Gens von Haemonchus contortus ist, das in dem unter der Zugangsnummer CBS 334.90 beim Centraal Bureau Schimmelcultures in Baarn, Niederlande, hinterlegten Plasmid enthalten ist.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Kit nach Anspruch 18, wobei der Kit die Primer mit den NukleinsÃ¤uresequenzen Î²-1 und Î²-2 und/oder die Primer Î²-7 und Î²-8 enthÃ¤lt, wobei<claim-text>Î²-1 = 5'ACGGATCTCAACCACCTTG 3'</claim-text><claim-text>Î²-2 = 5'CTGGTACTGCTGGTATTCGGA 3'</claim-text><claim-text>Î²-7 = 5'(CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3'</claim-text><claim-text>Î²-8 = 5'TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3' ist.</claim-text></claim-text></claim>
EP	0668908	B1	2000-05-03	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>MÃ©thode pour le diagnostic diffÃ©renciÃ© d'une infection Ã  nÃ©matode par un type spÃ©cifique de nÃ©matode, utile dans le cas d'infections mixtes par des nÃ©matodes, ladite mÃ©thode comprenant l'utilisation d'une sÃ©quence d'ADN, ladite sÃ©quence d'ADN Ã©tant le gÃ¨ne de la Î²-tubuline, ou une partie dudit gÃ¨ne dudit nÃ©matode, en tant que sonde et/ou amorce oligonuclÃ©otidique, ladite partie comprenant au moins 10, de prÃ©fÃ©rence au moins 18 nuclÃ©otides.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>MÃ©thode selon la revendication 1, dans laquelle le nÃ©matode spÃ©cifique est <u>Haemonchus</u> <u>contortus</u> et le gÃ¨ne de la Î²-tubuline est le gÃ¨ne de la Î²-tubuline d'<u>Haemonchus contortus</u>.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>MÃ©thode selon la revendication 1 ou la revendication 2, dans laquelle la sonde et/ou l'amorce comprennent une partie de la moitiÃ© 3' du gÃ¨ne de la Î²-tubuline.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  3, dans laquelle la sonde et/ou l'amorce sont spÃ©cifiques de l'espÃ¨ce.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>MÃ©thode selon la revendication 4, dans laquelle la sonde et/ou l'amorce sont constituÃ©es d'au moins 10 nuclÃ©otides d'un intron spÃ©cifique de <u>H. contortus</u>.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  4, dans laquelle la sonde est dÃ©rivÃ©e de la sÃ©quence d'ADN codant les acides aminÃ©s 332-335 de la Î²-tubuline de <u>H. contortus</u>.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  6, dans laquelle l'ADN total de nÃ©matode est appliquÃ© Ã  une membrane de nylon et hybridÃ© avec la sonde.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  3, dans laquelle on choisit une amorce qui est conservÃ©e chez divers types de nÃ©matodes, l'amorce Ã©tant ainsi situÃ©e de telle sorte que l'ADN qui est amplifiÃ© Ã  partir de l'ADN total du nÃ©matode ait une longueur spÃ©cifique de l'espÃ¨ce pour chaque nÃ©matode.<!-- EPO <DP n="21"> --></claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>MÃ©thode selon la revendication 8, dans laquelle l'amorce est une sÃ©quence codante pour une sÃ©quence d'acides aminÃ©s conservÃ©e.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>MÃ©thode selon la revendication 9, dans laquelle on choisit deux amorces qui sont conservÃ©es chez divers nÃ©matodes, ces amorces Ã©tant situÃ©es dans la sÃ©quence de la Î²-tubuline, de telle sorte que le produit d'amplification ait une longueur spÃ©cifique de l'espÃ¨ce pour chaque nÃ©matode.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  3 ou 8 Ã  10, dans laquelle tous les produits d'amplification de l'ADN de nÃ©matode comprennent une partie de la moitiÃ© 3' du gÃ¨ne de la Î²-tubuline.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  3 ou 8 Ã  11, caractÃ©risÃ©e en ce que l'on utilise comme amorce Î²-1 et Î²-2, Î²-1 ayant ainsi la sÃ©quence<br/>5' ACGGATCTCAACCACCTTG 3' et Î²-2 ayant ainsi la sÃ©quence<br/>5' CTGGTACTGCTGGTATTCGGA 3' sur le brin complÃ©mentaire, ou bien on utilise les amorces Î²-7 et Î²-8, Î²-7 comprenant ainsi les acides aminÃ©s 1-6 de la Î²-tubuline de <u>H. contortus</u> avec la sÃ©quence d'ADN :<claim-text>5' (CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T 3' et Î²-8 comprenant ainsi les acides aminÃ©s 199-205 de la Î²-tubuline de <u>H. contortus</u> avec la sÃ©quence d'ADN</claim-text><claim-text>5' TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3' sur le brin complÃ©mentaire.</claim-text></claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>MÃ©thode selon l'une quelconque des revendications prÃ©cÃ©dentes, dans laquelle une infection par <u>H. contortus</u> peut Ãªtre diffÃ©renciÃ©e d'une infection par les divers nÃ©matodes <u>Cooperia</u> <u>circumcincta</u>, <u>Ostertagia</u> <u>circumcincta</u>, <u>Nematodirus</u> <u>battus</u>, <u>Nippostrongylus</u> <u>brasiliensis</u>, <u>Trichinella</u> <u>spiralis</u>, <u>Trichinella</u> <u>nativa</u>, <u>Trichostrongylus vitrinus</u> et <u>Trichostrongylus</u> <u>colubriformis</u>.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  3 et 8 Ã  13, caractÃ©risÃ©e en ce que l'on effectue un diagnostic d'infection qui est spÃ©cifique de <u>H. contortus</u><!-- EPO <DP n="22"> --> lorsque le produit d'amplification a une longueur de 1,3 kb.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>MÃ©thode selon l'une quelconque des revendications 1 Ã  3 et 8 Ã  14, caractÃ©risÃ©e en ce que l'on effectue un diagnostic d'infection qui est spÃ©cifique de <u>Trichostrongylus</u> <u>colubriformis</u> lorsque le produit d'amplification a une longueur de 0,9 kb.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Kit pour effectuer un diagnostic diffÃ©renciÃ© d'une infection par <u>Haemonchus</u> <u>contortus</u> selon l'une quelconque des revendications prÃ©cÃ©dentes, ce kit comprenant au moins une amorce comprenant une sÃ©quence codante d'ADN, ladite sÃ©quence codante d'ADN Ã©tant la moitiÃ© 3' du gÃ¨ne de la Î²-tubuline comprise dans le nÃ©matode <u>Haemonchus</u> <u>contortus</u> dans le plasmide dÃ©posÃ© sous le numÃ©ro d'accÃ¨s CBS 334.90 au Centraal Bureau Schimmelcultures Ã  Baarn, Pays-Bas, ladite amorce ayant une longueur d'au moins 10 nuclÃ©otides, de prÃ©fÃ©rence d'au moins 18, ladite amorce Ã©tant une sÃ©quence conservÃ©e chez divers nÃ©matodes et situÃ©e dans la sÃ©quence d'ADN d'<u>Haemonchus</u> <u>contortus</u>, et telle que son produit d'amplification a une longueur spÃ©cifique de l'espÃ¨ce.</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>Kit selon le revendication 16, ce kit comprenant les amorces ayant les sÃ©quences d'acides nuclÃ©iques Î²-1 et Î²-2 et/ou les amorces Î²-7 et Î²-8, dans lequel<claim-text>Î²-1 = 5' ACGGATCTCAACCACCTTG 3'</claim-text><claim-text>Î²-2 = 5' CTGGTACTGCTGGTATTCGGA 3'</claim-text><claim-text>Î²-7 = 5'(CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T3'</claim-text><claim-text>Î²-8 = 5' TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3'.</claim-text></claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>Kit pour effectuer un diagnostic diffÃ©renciÃ© d'infection par <u>Haemonchus</u> <u>contortus</u> selon l'une quelconque des revendications 1-15, ce kit comprenant au moins une sonde et/ou une amorce spÃ©cifique de l'espÃ¨ce pour <u>Haemonchus</u> <u>contortus</u>, ladite sonde ou amorce Ã©tant dÃ©rivÃ©e d'une sÃ©quence codante d'ADN, ladite sÃ©quence codante d'ADN Ã©tant la moitiÃ© 3' du gÃ¨ne de la Î²-tubuline d'<u>Haemonchus</u> <u>contortus</u> comprise dans le plasmide dÃ©posÃ©<!-- EPO <DP n="23"> --> sous le numÃ©ro d'accÃ¨s CBS 334.90 au Centraal Bureau Schimmelcultures Ã  Baarn, Pays-Bas.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>Kit selon la revendication 18, ce kit comprenant les amorces ayant les sÃ©quences d'acides nuclÃ©iques Î²-1 et Î²-2 et/ou les amorces Î²-7 et Î²-8, dans lequel<claim-text>Î²-1 = 5' ACGGATCTCAACCACCTTG 3'</claim-text><claim-text>Î²-2 = 5' CTGGTACTGCTGGTATTCGGA 3'</claim-text><claim-text>Î²-7 = 5' CTA)G(GC)(GTAC)GA(CT)(CT)T(GCAT)AA(CT)CA(CT)(CT)T3'</claim-text><claim-text>Î²-8 = 5' TC(CT)TGGTA(TC)TG(CT)TG(GA)TA(CT)TC 3'.</claim-text></claim-text></claim>
EP	0668908	B1	2000-05-03	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0668908&ki=B1&pd=2000-05-03
EP	0600877	B1	2000-01-26	de	TITLE	1	AUSWAHL VON EFFIZIENT ZIEL-RNS SPALTENDEN RIBOZYMEN
EP	0600877	B1	2000-01-26	en	TITLE	1	SELECTION OF RIBOZYMES THAT EFFICIENTLY CLEAVE TARGET RNA
EP	0600877	B1	2000-01-26	fr	TITLE	1	SELECTION DE RIBOZYMES ASSURANT UN CLIVAGE EFFICACE D'ARN CIBLE
EP	0600877	B1	2000-01-26	en	DESCR	1	<heading id="h0001"><u>Field of the Invention</u></heading><p id="p0001" num="0001">This invention relates to the screening of ribozymes to determine which are most efficient at cleaving a target ribonucleic acid. The invention also relates to the generation of a variety of mutant ribozymes for screening.</p><heading id="h0002"><u>Background of the Invention</u></heading><p id="p0002" num="0002">Certain naturally occurring RNA molecules undergo self-catalyzed cleavage (Kruger et al.., 1982). The best studied examples occur in plants that are infected with viroids (Hutchins et al., 1986), virusoids (Forster &amp; Symons, 1987a), or satellite viruses (Prody et al., 1986). The genomic RNAs of these infectious agents are reproduced by a rolling circle mechanism that yields multimeric replication intermediates that undergo self-cleavage to produce monomeric genomes. The ability to self-cleave is imparted by distal consensus sequences that interact to form a highly structured RNA configuration (in the form of a "hammerhead") prior to cleavage (Forster &amp; Symons, 1987a, Forster &amp; Symons, 1987b). Although self-cleavage is entirely intramolecular, a careful analysis of the sequences and structures involved led Uhlenbeck to the realization that a synthetic RNA could be constructed that would<!-- EPO <DP n="2"> --> interact with a second RNA (the "substrate" strand) to form the hammerhead configuration, resulting in the cleavage of the substrate at a specific site (Uhlenbeck, 1987). He demonstrated that these synthetic RNAs act enzymatically.</p><p id="p0003" num="0003">Uhlenbeck's experiments raised the prospect that RNA enzymes ("ribozymes") could be constructed that would cleave a preselected sequence in any RNA. However, in his scheme some of the consensus sequences which were required to form the active hammerhead configuration were supplied by the substrate strand, severely limiting the number of natural RNAs that could serve as substrates. Haseloff and Gerlach markedly improved Uhlenbeck's design by including all the required consensus sequences in the ribozyme (Haseloff &amp; Gerlach, 1988). Their ribozyme works by first hybridizing to a particular site in the substrate RNA and then catalyzing the cleavage of the substrate at that site. They disclose that sites containing the trinucleotide GUC, and perhaps GUU or GUA, are cleaved, provided that the structures present in the substrate RNA do not prevent the binding of the ribozyme to the site. Figure 1A shows a typical Haseloff-Gerlach ribozyme hybridized to a substrate strand. The arrow indicates the site in the substrate where cleavage will occur. This site is immediately adjacent to the GUC sequence.</p><p id="p0004" num="0004">Haseloff-Gerlach ribozymes possess two different functional regions. The first functional region is a "catalytic domain" in the middle of the ribozyme (Figure 1B), which contains the consensus sequences that confer the ability to cleave the substrate. The catalytic domain in example shown is 22 nucleotides-long. This region<!-- EPO <DP n="3"> --> is common to Haseloff-Gerlach ribozymes. The second functional region consists of sequences on both sides of the catalytic domain. These sequences are chosen to be complementary to the sequences surrounding the cleavage site in the substrate (Figure 1C). They confer upon the ribozyme the ability to interact specifically with a preselected cleavage site. Because the combined length of these complementary sequences is typically between 12 and 16 nucleotides, the Haseloff-Gerlach ribozymes are highly specific.</p><p id="p0005" num="0005">Experiments that tested the activity of Haseloff-Gerlach ribozymes in vivo have been disappointing. The expression of targeted gene products was not eliminated, but only reduced (Cameron &amp; Jennings, 1989), and extremely high levels of ribozyme were required to destroy the intended substrate RNA (Cotten et al., 1989). Furthermore, our own in vitro studies showed that the optimal conditions for ribozyme activity (60 degrees Celsius in the presence of 40 mM magnesium chloride) are quite different from the conditions present in most eukaryotic cells. Naturally occuring hammerhead configurations are optimal only for cleavage within the same RNA (cleavage in cis). Moreover, in plant cells (where hammerheads normally function), cleavage might be aided by accessory proteins. The Haseloff-Gerlach ribozymes, on the other hand, are designed to cleave another RNA (cleavage in trans), without the benefit of cellular proteins. Furthermore, the Haseloff-Gerlach ribozymes might be particularly sensitive to cellular nucleases. It is thus not surprising that artificial ribozymes function less than optimally in vivo. The utility of therapeutic ribozymes will depend on their ability to function efficiently in a complex<!-- EPO <DP n="4"> --> cellular milieu (Sarver et al., 1990). Thus, it is clear from our own work and from the work of other laboratories that the efficiency of ribozymes as currently designed, either Haseloff-Gerlach or other, is too low for them to serve as commercially effective therapeutic agents. A purpose of the invention described herein is to design and screen ribozymes that will efficiently cleave target RNA.</p><p id="p0006" num="0006">By utilizing cells whose survival in the presence of an agent depends on the activity of an expressed ribozyme, we have invented a method for selecting mutant ribozymes that function efficiently under physiological conditions. Our method for screening ribozymes comprises culturing cells whose survival is dependent upon cleavage of RNA by a ribozyme of RNA, which cleavage causes the cells to survive, and selecting those cells which survive.</p><p id="p0007" num="0007">Ribozymes which are obtained by the screening method herein can be used to selectively destroy RNA, such as that encoding human immunodeficiency virus (HIV) proteins, in vivo.</p><p id="p0008" num="0008">Also described herein is a method for generating a variety of oligonucleotides for screening by employing mixtures of nucleotide precursors in a DNA synthesizer.<!-- EPO <DP n="5"> --></p><p id="p0009" num="0009">According to one aspect of the invention, there is provided a method for screening ribozymes for effectiveness in cleaving RNA comprising:<ul id="ul0001" list-style="none" compact="compact"><li>(a) creating a plurality of vectors encoding ribozymes having differing sequences, which ribozymes are to be screened for effectiveness in cleaving RNA containing a target RNA sequence;</li><li>(b) providing cells that possess an RNA containing the target RNA sequence and that, when the RNA is cleaved by one of the ribozymes in sufficient quantity, survive in a preselected culture medium;</li><li>(c) providing the cells with the vectors;</li><li>(d) culturing the cells in the preselected culture medium under conditions wherein the ribozymes are expressed; and</li><li>(e) selecting cells which survive.</li></ul></p><p id="p0010" num="0010">By way of example only, the present invention will now be described in greater detail with reference to the accompanying drawings.<ul id="ul0002" list-style="none"><li>Figure 1. Ribozyme structure. (A).<br/>Haseloff-Gerlach ribozyme bound to its substrate. The 36-nucleotide-long RNA shown on the top is the<!-- EPO <DP n="6"> --> ribozyme. The RNA on the bottom is the substrate strand. When the ribozyme is hybridized to the substrate and incubated with magnesium ions, it will catalyze the cleavage of the substrate at the site indicated by the arrow. (B). Catalytic domain of a Haseloff-Gerlach ribozyme. Invariant sequences (contained within the boxed region) are required for the cleavage of the substrate strand. (C). Complementary sequences of a Haseloff-Gerlach ribozyme. These variable sequences (shown as boxed regions) are chosen to be complementary to a preselected sequence in the substrate strand.</li><li>Figure 2. Predicted secondary structure of the ermC leader sequence. Two potential ribosome binding sites are present (shown as boxed sequences). Each is associated with an AUG initiation codon. The UAA codon that terminates the first open reading frame is shown in bold letters. The second open reading frame, which encodes the methylase responsible for resistance to the MLS antibiotics, cannot be translated because its AUG initiation codon is in a double-stranded region, where it is not accessible to ribosomes.</li><li>Figure 3. Structural reorganization of the ermC leader. (A). Reorganization by erythromycin induction. The panel on the left shows a schematic representation of the secondary structures formed by the ermC leader. The two ribosome binding sites are indicated by heavy lines. The methylase gene cannot be translated because its ribosome binding site is sequestered within the structure formed by regions c and d. The panel on the right shows a ribosome (to which erythromycin is bound) stalled in region a,<!-- EPO <DP n="7"> --> resulting in the release of region b. Since the alternative structure that could be formed by regions b and c is more stable than the structure formed by regions c and d, a structural reorganization occurs that releases region d, freeing the ribosome binding site for the synthesis of methylase. (B). Reorganization by ribozyme cleavage. The panel on the left shows a schematic representation of the ermC leader with a ribozyme bound to the hairpin loop of the structure formed by regions a and b. Cleavage of this hairpin loop by the ribozyme truncates the leader sequence and results in the release of region b. Since the alternative structure that could be formed by regions b and c is more stable than the structure formed by regions c and d, a structural reorganization occurs that releases region d, freeing the ribosome binding site for the synthesis of methylase.</li><li>Figure 4. Predicted secondary structure of the truncated ermC leader sequence. The ribosome binding site for the synthesis of methylase (shown as a boxed sequence) is in a single-stranded conformation that is accessible to ribosomes.</li><li>Figure 5. Specific cleavage of an RNA by a ribozyme. An equimolar mixture of MDV-1 RNA and recombinant RNA was mixed with a 10-fold molar excess of a ribozyme designed to cleave the MDV-1 RNA. The recombinant RNA was a modified MDV-1 RNA that contained an additional sequence inserted within the ribozyme binding site. This mixture was incubated at 50 degrees Celsius in the presence of 20 mM magnesium chloride and 50 mM Tris-HCl (pH 8). Samples were taken at 10 minute intervals and were analyzed by electrophoresis<!-- EPO <DP n="8"> --> through an 8% polyacrylamide gel containing 7 M urea. The amount of ribozyme and the amount of recombinant RNA remained the same throughout the course of the reaction. The disappearance of MDV-1 RNA was accompanied by the appearance of MDV-1 RNA fragments of the expected size.</li><li>Figure 6. Cleavage of HIV-1 RNA in vitro. (A). Target RNA was incubated with ribozymes at 50 degrees Celsius, then analyzed by electrophoresis and visualized by hybridization with a probe for the HIV-1 integrase gene. Lane 1: no ribozyme, 60 mm. Lane 2: ribozyme alpha, 30 min. Lane 3: ribozyme alpha, 60 mm. Lane 4: ribozyme beta (synthesized in vitro), 30 min. Lane 5: ribozyme beta (synthesized in vitro), 60 min. Lane 6: ribozyme beta (synthesized in vivo), 30 min. Lane 7: ribozyme beta (synthesized in vivo), 60 min. Lane 8: mutant ribozyme beta with a deleted catalytic domain (synthesized in vivo), 60 min. Lanes 9, 10, and 11: repeat of reactions analyzed in lanes 2, 4, and 6, respectively, except that incubation was at 37 degrees Celsius. (B). Analysis of the incubation products by hybridization with a probe for the E. coli trpE gene.</li><li>Figure 7. Cleavage of HIV-1 RNA in vivo. Four different E. coli strains were induced to synthesize a transcript containing a HIV-1 target sequence and to simultaneously synthesize a second transcript, to see whether the second transcript could catalyze the cleavage of the target. At different times after induction, the RNA in the cells was isolated and analyzed by northern blotting to see whether the HIV-1 target was present, and if so, to see whether it was intact.<!-- EPO <DP n="9"> --> The strains used and the time of induction are identified above each lane of the gel. The results demonstrate that if an intact ribozyme is present within the second transcript, then the HIV-1 RNA is completely destroyed.</li><li>Figure 8. Transcript containing a Haseloff-Gerlach ribozyme bound to a modified ermC leader. The 5' end of the transcript contains a secondary structure formed from the "palindromic" elements of the E. coli lac operator. The 3' end of the transcript contains a secondary structure that is characteristic of a rho-independent transcription terminator. The ribozyme is designed to catalyze the cleavage of the ermC leader (shown in bold letters) at the site indicated by the arrow.</li></ul></p><heading id="h0003"><u>Detailed Description of the Invention</u></heading><p id="p0011" num="0011">Using the method herein ribozymes are screened by culturing cells whose survival is dependent upon cleavage of RNA by a ribozyme within the cell. Cleavage by the ribozyme allows the cells to survive. The surviving cells are selected and contain the most effective ribozymes. The ribozymes obtained are more effective than those of the prior art. They are to be used, for example, to prevent viral replication in cells by cleaving the RNA required for the formation of the virus' constituent proteins.</p><p id="p0012" num="0012">This screening method can be utilized where the ribozyme to be screened cleaves any type of RNA which, when cleaved, permits the cell to survive. In one embodiment, the RNA is messenger RNA coding for a polypeptide, which when expressed causes the cells to survive in the media used to culture the cells. The cleavage by the ribozyme<!-- EPO <DP n="10"> --> can, for example, allow translation of the polypeptide by altering the secondary structure of the messenger RNA. The alteration in secondary structure may free a ribosomal binding site which allows translation to thereafter take place.</p><p id="p0013" num="0013">In a most preferred embodiment the method is used for screening mutant ribozymes of the Haseloff-Gerlach type. In this embodiment cells are cultured whose survival is dependent upon cleavage by the ribozymes at a sequence inserted in a hairpin loop of the ermC leader in ermC messenger RNA. The cleavage causes a change in structure of the ermC messenger RNA and frees a ribosome binding site to allow synthesis of methylase, thereby permitting the cell to survive in media containing an MLS antibiotic. Cells which survive are selected.</p><p id="p0014" num="0014">The screening method can also include the formation of a library of ribozyme clones by creating a large number of vectors encoding ribozymes having different sequences which are to be screened, and transforming cells with the vectors. A strategy for constructing a library of mutant ribozymes which are likely to be effective is described herein.</p><p id="p0015" num="0015">As stated above, the catalytic domain of a more effective ribozyme to be obtained by using the screening technique disclosed herein can be related to the sequence in the Haseloff-Gerlach design. The number of possible sequences to test becomes enormous when multiple nucleotide substitutions are envisioned. An extensive library of ribozymes can be synthesized, however, each possessing a different sequence in its catalytic domain, but all possessing the same complementary sequences in their flanking segments. The method for creating this library is<!-- EPO <DP n="11"> --> made possible because artificial ribozymes can be transcribed from synthetic DNA templates. During the synthesis of the template DNA for the ribozyme, nucleotide substitutions can be introduced at random at a relatively low frequency, into those positions in the sequence that specify the catalytic domain of the ribozyme. The RNAs transcribed from these DNA templates consist of a diverse collection of mutant ribozymes.</p><p id="p0016" num="0016">In order to identify the most efficient ribozymes in this mixture, a cell, for example a bacterial cell or a eukaryotic cell such as yeast, can be transformed and made to express the ribozyme. The survival of the cell is made dependent upon effective cleavage by the ribozyme of RNA in the cell. For example, DNA templates of ribozymes to be screened can be cloned into plasmids and introduced into a specially modified strain of Bacillus subtilis. These bacteria can be grown under conditions in which their survival in the presence of an antibiotic will depend on the efficient functioning of the ribozyme encoded in the plasmid. By examining plasmids from the few cells that are able to survive, mutant ribozymes can be identified that function efficiently under physiological conditions. Plasmids from these selected clones are isolated and their nucleotide sequences are determined in order to identify those nucleotide substitutions that are present in the most efficient ribozymes.</p><p id="p0017" num="0017">The ribozyme sequences selected from a first round of mutagenesis can then be used as the "wild-type" in a second round of mutagenesis and selection. In other words, a second set of ribozymes can be made for screening based on the<!-- EPO <DP n="12"> --> sequence of a ribozyme or ribozymes found to be effective in the first round of screening. By repeating this process a number of times, natural evolution is mimicked, and the ribozyme sequence can be gradually refined until it is optimally suited for cleavage in trans.</p><p id="p0018" num="0018">If desired, the ribozymes obtained by the screening technique can be further tested for their ability to cleave target RNA, for example, HIV-1 mRNA, and their ability to block expression of the target RNA in human cells, such as human lymphocytes.</p><p id="p0019" num="0019">In a preferred embodiment, the efficiency of different mutant ribozymes can be tested by seeing whether a cell in which each ribozyme is expressed can grow in the presence of one of the macrolide-lincosamide-streptogramin B (MLS) group of antibiotics, preferably tylosin. Survival of each clone depends on the ability of its expressed ribozyme to efficiently cleave the highly structured leader sequence of ermC messenger RNA. The ermC gene, which is constitutively transcribed (Shivakumar et al., 1980), encodes a methylase (Shivakumar &amp; Dubnau, 1981) whose activity confers resistance to the MLS antibiotics (Weisblum et al., 1979). However, the ermC methylase usually cannot be produced in sufficient quantity to confer resistance to the antibiotic because the AUG codon required for the initiation of methylase synthesis is sequestered in a secondary structure formed by the leader sequence of the ermC mRNA (Gryczan et al., 1980). Under natural conditions, resistance occurs in the presence of subinhibitory concentrations of another macrolide antibiotic, erythromycin, which initiates a sequence of events that leads to a structural reorganization of the ermC leader sequence that exposes the AUG<!-- EPO <DP n="13"> --> initiation codon, resulting in the synthesis of the methylase (Gryczan et al., 1980).</p><p id="p0020" num="0020">Instead of growing bacteria in the presence of erythromycin, however, bacteria can be induced to synthesize ribozymes that are designed to cleave the ermC leader. Cleavage leads to a structural reorganization of the mRNA that is similar to the reorganization that occurs when erythromycin is present at low concentration. Preferably, ribozyme synthesis is under the control of an inducer, and the concentration of the inducer can be adjusted so that only a few molecules of ribozyme are synthesized. Only those clones expressing the most efficient mutant ribozymes grow in the presence of the MLS antibiotic.</p><p id="p0021" num="0021">The ermC gene can be expressed in various bacteria. B. subtilis can be used as the host cell, but appropriate modifications will be apparent to one skilled in the art to adapt the methodology described herein to other bacteria.</p><p id="p0022" num="0022">Similarly, the method of the invention may be applied in host cells containing messenger RNAs other than ermC wherein the messenger RNA rearranges, upon cleavage by a ribozyme, to allow expression of a polypeptide which allows the cell to survive. It has been shown that cleavage of RNA results in structural rearrangements (Kramer &amp; Mills, 1981), and neighboring intrastrand complements that are predicted by a computer program to form stable secondary structures (Zuker and Stiegler, 1981) almost always form these structures (Jaeger et al., 1989). Thus, one skilled in the art can determine other messenger RNAs which can be cleaved in order to allow cell survival. The messenger RNA may encode, for example, a polypeptide which endows the cell with resistance to a different antibiotic, or which<!-- EPO <DP n="14"> --> allows the cell to utilize a particular nutrient in order to survive. For example, expression of the messenger RNA coding for chloramphenicol resistance is regulated in a manner similar to that of ermC messenger RNA. Using the method described herein, bacteria which expressed only the most efficient ribozymes would survive in chloramphenicol-containing media because of resistance due to efficient cleavage of target messenger RNA.</p><p id="p0023" num="0023">An alternative target messenger RNA is one encoding a toxic peptide. Toxic peptides are well known in the art and include antibacterial peptides as well as peptides which are toxic to yeast or other eukaryotic cells. Messenger RNA encoding the toxic peptide can be placed under the control of an inducible regulator. When the ribozymes to be screened and the messenger RNA encoding the toxic peptide are expressed, under appropriate concentrations of inducer, then only cells containing the most effective ribozymes will survive.</p><p id="p0024" num="0024">The screening method may also be applied where the ribozyme to be screened cleaves RNA which is not messenger RNA, but which is otherwise responsible for the survival of the cell. For example, the copy number of a plasmid encoding antibiotic resistance can be controlled by RNA expressed in a cell, possibly expressed by a second plasmid. Cleavage of the RNA by a ribozyme leads to increased copy number and therefore increased antibiotic resistance. In one known system RNA species I is specified by a first plasmid and controls the copy number of a second plasmid which encodes antibiotic resistance (Tomizawa and Itoh, 1981). Ribozymes can be screened for efficient cleavage of RNA I, which<!-- EPO <DP n="15"> --> cleavage increases the copy number of the plasmid encoding antibiotic resistance and allows the cell to survive in antibiotic containing media.</p><p id="p0025" num="0025">The structure and function of the ermC translational attenuator used in the preferred embodiment are now described.</p><p id="p0026" num="0026">Bacteria containing the ermC gene can resist all members of the macrolide-lincosamide-streptogramin B (MLS) group of antibiotics (including tylosin) when they are grown in the presence of erythromycin (Weisblum et al., 1971). The MLS antibiotics inhibit protein synthesis by binding to the 50S ribosomal subunit. The methylase specified by the ermC gene modifies a particular adenosine residue in 23S ribosomal RNA (Lai et al., 1973), preventing the binding of MLS antibiotics to the ribosome (Shivakumar et al., 1980). Figure 2 shows the leader sequence of the ermC transcript folded into the secondary structures that a computer program (Zuker and Stiegler, 1981; Zuker, 1989) predicts are most stable. There are two ribosome binding sites (Shine &amp; Dalgarno, 1974) in the sequence. The first ribosome binding site is in front of an open reading frame encoding a 19 amino acid leader peptide. Its AUG initiation codon is in a single-stranded conformation. The second ribosome binding site is in front of an open reading frame encoding the 244 amino acid ermC methylase, but its AUG initiation codon is sequestered in a double-stranded region of the leader. Nuclease digestion experiments and ribosome protection studies confirm that only the first binding site is available to ribosomes (Narayanan &amp; Dubnau, 1985).</p><p id="p0027" num="0027">The function of this translational attenuator has been extensively studied by Dubnau and his<!-- EPO <DP n="16"> --> colleagues (Dubnau, 1984), and is summarized below. In the absence of an MLS antibiotic, ribosomes bind to the first ribosome binding site and sweep through the leader, synthesizing many copies of the leader peptide. The methylase gene, on the other hand, is not translated because its initiation codon is not accessible to ribosomes. The rapid passage of ribosomes along the first open reading frame has no appreciable effect on the availability of the AUG codon at the beginning of the methylase gene. In the presence of most MLS antibiotics, the synthesis of proteins is halted after only one or two amino acids have been incorporated (Mao &amp; Robishaw, 1971). Consequently, ribosomes that initiate synthesis of the leader peptide halt almost immediately after synthesis begins. In the presence of erythromycin, on the other hand, longer peptides are synthesized before translation is halted (Mao &amp; Robishaw, 1972). Ribosomes that are bound to erythromycin and initiate the synthesis of the leader do not come to a halt until about nine amino acids have been incorporated (Mayford &amp; Weisblum, 1989a, Mayford &amp; Weisblum, 1989b). Figure 3A illustrates how the resulting presence of a stalled ribosome in the leader sequence disrupts the secondary structure of the leader, resulting in a structural reorganization that places the AUG initiation codon for the methylase in a single-stranded conformation (Mayford &amp; Weisblum, 1989b). At any given instant some ribosomes are not bound to an MLS antibiotic (Dubnau, 1984). Ribosomes that are not bound to the antibiotic are then able to synthesize the methylase, which goes on to modify ribosomal RNA, enabling the bacterium to survive in the presence of any MLS antibiotic.<!-- EPO <DP n="17"> --></p><p id="p0028" num="0028">Ribozymes can cleave the ermC leader sequence. The resulting truncated ermC mRNA undergoes the same structural reorganization that occurs when a ribosome bound to erythromycin stalls while synthesizing the leader peptide. The cleavage fragments are forced apart as tylosin-free ribosomes sweep through the leader sequence. After dissociation of the fragments, the truncated ermC mRNA undergoes a structural reorganization that exposes the AUG initiation codon, permitting the synthesis of methylase by tylosin-free ribosomes. Figure 3B illustrates this, and Figure 4 shows the predicted secondary structure (Zuker, 1989; Zuker and Stiegler, 1981) of the truncated leader after reorganization occurs.</p><p id="p0029" num="0029">In a preferred embodiment for screening ribozymes, B. subtilis clones containing the ermC gene are grown on agar plates in the presence of tylosin, but in the absence of erythromycin. Normally, they all fail to form colonies. However, each clone is transformed to express a different mutant ribozyme that is designed to cleave the ermC leader. If the mutant ribozyme in a given clone functions efficiently in vivo, then a sufficient number of ermC transcripts are cleaved (and undergo the structural reorganization that allows the methylase to be synthesized) for the cells to resist the tylosin. The number of ribozyme molecules synthesized per cell is under the control of an inducer and is preferably kept at a very low level. Therefore only those clones possessing an extremely efficient mutant ribozyme survive. An examination of the sequences encoding the catalytic domain of the ribozymes in the selected clones identifies the advantageous mutations.<!-- EPO <DP n="18"> --></p><p id="p0030" num="0030">There are a number of alternate experimental routes that can be taken to select an efficient ribozyme. For example, a natural target sequence can be substituted for part of the ermC leader sequence. In other words, if the cleavage site of interest is contained in an HIV-1 target, then an HIV-1 sequence which includes the cleavage site can be substituted for the part of the ermC leader sequence which is to be cleaved. This substitution could be made, for example, in the hairpin loop of the ermC leader in place of nucleotides 70 through 82, as shown in Figure 2. A mutant ribozyme can therefore be selected which will possess a catalytic domain that is already "fine-tuned" for the cleavage of the natural target sequence.</p><p id="p0031" num="0031">The selection method disclosed herein can be applied to ribozymes other than the Haseloff-Gerlach type. Recently, for example, another short ribozyme sequence has been identified (Hampel &amp; Tritz, 1989) that forms a unique "hairpin" catalytic domain (Hampel et al., 1990) and is active under physiological conditions. As improved types of ribozymes become available they can be screened using this method to determine the particular sequences which are most catalytic.</p><p id="p0032" num="0032">Furthermore, although Haseloff-Gerlach ribozymes are described herein which have a catalytic sequence of 22 nucleotides, ribozymes which are variations on this conventional Haseloff-Gerlach design can be screened as well. For example, while nucleotide substitutions in the 22 nucleotide domain may be screened, insertions, additions, and deletions which change the number of nucleotides of the ribozyme can also be screened for effectiveness. It is anticipated that these ribozymes may have different structures<!-- EPO <DP n="19"> --> than that shown in Figure 1. Similarly, although 12-16 nucleotides are typically incorporated in the Haseloff-Gerlach design which are complementary to the target strand, ribozymes can be constructed for screening which have fewer or more of the complementary nucleotides than this number. A sufficient number of nucleotides, however, should be incorporated to make the ribozyme highly specific for the target.</p><p id="p0033" num="0033">The screening method can be used to determine ribozyme sequences most effective at cleaving any desired target sequence. In choosing the complementary sequences of the ribozyme, however, it should be kept in mind that not all potential target sites of the ribozymes to be screened are equally susceptible to attack. There are several considerations in choosing a target sequence. Of primary importance in designing a ribozyme to cleave viral RNA is the conservation of the chosen sequence among different isolates of the virus. For example, in HIV-NL43 genomic RNA, GUC occurs 46 times. Among characterized isolates of HIV-1 (listed in the Human Retroviruses and AIDS database), GUC is conserved at only 35 of these 46 positions; and flanking sequences (eight nucleotides in length) are conserved at only 18 of the sites. When the comparison is extended to African HIV-1 isolates, only seven sites fulfill the requirements. Another important consideration in selecting a target viral RNA is that it be located in a gene whose function or product is essential to the reproduction or infectivity of the virus. For example, the tat gene would be a good target because its gene product is a positive regulator of viral expression. The target should also occur in a region of RNA that is physically accessible to the ribozyme. In vitro studies have<!-- EPO <DP n="20"> --> shown that the structure of the substrate RNA can be a major determinant of catalytic efficiency for Haseloff-Gerlach ribozymes (Fedor &amp; Uhlenbeck, 1990). A computer program (Zuker, 1989; Zuker and Steigler, 1981) aids in predicting which secondary structures are most likely to occur.</p><p id="p0034" num="0034">While GUC is the best characterized cleavage site of the Haseloff-Gerlach ribozymes, GUU and GUA may, however, also serve as cleavage sites. Any cleavage site of a ribozyme to be tested, however, can be used in the target sequence, either that which the Haseloff-Gerlach ribozymes cleave, or sites which other ribozymes cleave. The site may either occur naturally in the sequence, or the target sequence may be adapted to contain the target site. In the ermC example described herein a GUC site is inserted in the target sequence. Where a natural sequence of, for a example, a virus, is spliced into the ermC gene, or other gene used, the viral sequence will normally already contain the cleavage site.</p><p id="p0035" num="0035">Following isolation of the effective ribozyme according to the method of the invention, follow up tests can, of course, be performed to see whether ribozyme-containing sequences that are complementary to a chosen target can cleave the target RNA in vitro. A further follow up test can be performed to determine the suitability of the target site by constructing a ribozyme to cleave it, and then observing the biological consequences of expression of the ribozyme in human cells challenged with the agent being treated. For example, once an effective ribozyme has been found according to our screening method which cleaves HIV-1 RNA, human lymphocytes can be transfected with a vector from which is expressed the ribozyme and can then be challenged with HIV-1 virus. An<!-- EPO <DP n="21"> --> assay of HIV-1 infectivity can measure the effectiveness of the ribozyme in preventing HIV infection of the human cells. Such tests, while not involved with the practice of the invention, may neverthless be useful follow-ups.</p><p id="p0036" num="0036">Following are examples which illustrate the invention. These examples should not be construed to limit the coverage of the claims which follow.</p><heading id="h0004">EXAMPLE 1</heading><p id="p0037" num="0037">In this example we demonstrated the ability of Haseloff-Gerlach ribozymes, which were not screened according to the method of the invention, to cleave MDV-1 mRNA and HIV-1 integrase RNA.</p><p id="p0038" num="0038">We constructed and tested a ribozyme that was designed to cleave MDV-1 RNA, which is a well-characterized template for Q-beta replicase (Kacian et al., 1972, Mills et al., 1973). The time-course of cleavage of MDV-1 RNA in vitro by this ribozyme is shown in Figure 5. The incubation mixture included (as an internal control) a related recombinant RNA (Miele et al., 1983) which could not be cleaved because its ribozyme binding site was interrupted by the presence of an inserted heterologous sequence. Although the ribozyme cleaved its intended target (and did not cleave the control), the results demonstrated the relative inefficiency of the Haseloff-Gerlach design.</p><p id="p0039" num="0039">We prepared two Haseloff-Gerlach ribozymes, each designed to cleave the integrase gene of HIV-1 RNA at a position corresponding to the GUC at nucleotides 4669-4671 of the hybrid HIV-1 clone, HIV-NL43 (Adachi et al., 1986). The first ribozyme ("ribozyme alpha") was transcribed from a synthetic, single-stranded DNA template by<!-- EPO <DP n="22"> --> incubation in vitro with bacteriophage T7 RNA polymerase (Milligan et al., 1987). Its sequence is shown below. Capital letters indicate the nucleotides that are complementary to the HIV-1 target sequence:<br/>5'-g-CUACUACUCCUU-cugaugaguccgugaggacgaa-ACUUUGGGGA-3'</p><p id="p0040" num="0040">The second ribozyme ("ribozyme beta") was transcribed from a recombinant plasmid, both in vitro (Melton et al., 1984) and in vivo. This plasmid contained the sequence encoding the ribozyme, embedded between a promoter for T7 RNA polymerase and a T7 transcription terminator. The plasmid was introduced into E. coli cells that contained a chromosomal copy of the T7 RNA polymerase gene from which T7 RNA polymerase could be inducibly expressed. The presence of the terminator in the plasmid ensures that the transcripts are homogeneous. Moreover, the presence of the terminator sequence at the 3' end of the transcripts provides protection from cellular exonucleases. The sequence of the second ribozyme is shown below:<br/>5'-g-CUACUACUCCUU-cugaugaguccgugaggacgaa-ACUUUGGGGCA--cauaaccccuuggggccucuaaacgggucuugagggguuuuuug-3'</p><p id="p0041" num="0041">Both ribozymes were studied in vitro. Figure 6 shows a single experiment that illustrates the results. Each of the 11 reaction tubes contained "target RNA", which was total cellular RNA isolated from E. coli cells that express a trpE-HIV-1-integrase fusion protein. After incubation with a ribozyme, the RNA from each reaction was electrophoretically separated, transferred to a<!-- EPO <DP n="23"> --> membrane, and hybridized with a radioactive probe for the HIV-1 integrase gene. The results showed that both ribozyme alpha and ribozyme beta cleave the target RNA into fragments of the expected size. It did not matter whether ribozyme beta was obtained by transcription in vitro or by the isolation of total cellular RNA from a bacterium in which its synthesis was induced. The results also demonstrated that ribozymes are able to function in the presence of unrelated cellular RNAs, and that the presence of a terminator sequence at the 3' end of the ribozyme does not prevent it from functioning. No cleavage occurred when ribozymes were omitted; and no cleavage occurred when a mutant ribozyme (lacking a catalytic domain) was present. The ribozymes were active in vitro at 50 degrees Celsius but were inactive at 37 degrees Celsius. However, experiments below demonstrated the ability of ribozymes to function in vivo at 37 degrees Celsius.</p><p id="p0042" num="0042">To confirm that cleavage occurred in the integrase portion of the target transcript (rather than in the trpE portion), the membranes were rehybridized with a probe for the E. coli trpE gene. The results showed that cleavage occurred within the HIV-1 integrase gene.</p><p id="p0043" num="0043">We also conducted a series of experiments to demonstrate the ability of ribozymes to cleave HIV-1 RNA in vivo. We prepared E. coli cells that contained a chromosomal copy of the T7 RNA polymerase gene under lac control and that also contained a plasmid in which the transcription of the HIV-1 integrase gene is regulated by a promoter for T7 RNA polymerase (strain A). We then prepared three additional E. coli strains by the introduction of a second (compatible) plasmid<!-- EPO <DP n="24"> --> into strain A. The plasmids that were introduced into strain A contained an inserted gene under the control of a promoter for T7 RNA polymerase. In strain D, the inserted gene encoded ribozyme beta. In strain C, the inserted gene encoded a mutant ribozyme beta that lacked a catalytic domain. And in strain B, there was no inserted gene in the plasmid. The activity of the ribozymes transcribed from the inserted sequence in each strain was observed by transferring the bacteria to media containing an inducer of the lac operon. At various times after induction, growth was halted and the RNA in the cells was isolated, analyzed by electrophoresis, and visualized by hybridization with a radioactive probe for the HIV-1 integrase gene.</p><p id="p0044" num="0044">The results (shown in Figure 7) demonstrate that transcripts containing the HIV-1 target sequence are present after induction in cells that do not express a ribozyme (strains A and B). However, when ribozyme beta is expressed (strain D), the cleavage of the target RNA by the ribozyme apparently leads to the complete destruction of the cleaved transcripts by cellular endonucleases. A similar observation was made during the cleavage of HIV-1 RNA by ribozymes in cultured human cells (Sarver et al., 1990). The mutant ribozyme that lacked a catalytic domain (in strain C) apparently acted as a classic antisense RNA, modulating the expression of the target. Interestingly, ribozyme beta was active in vivo at 37 degrees Celsius, even though it was inactive in vitro at the same temperature. A ribozyme, therefore, apparently catalyzed the cleavage of an HIV-1 target at 37 degrees Celsius in vivo, leading to the complete destruction of the transcript.<!-- EPO <DP n="25"> --></p><heading id="h0005">EXAMPLE 2</heading><p id="p0045" num="0045">This example demonstrates the preparation of a B. subtilis clone containing a single copy of a modified ermC gene.</p><p id="p0046" num="0046">ErmC normally occurs on a plasmid, pE194, which was isolated from Staphylococcus aureus (Iordanescu, 1976), and which can be transferred to B. subtilis by transformation (Weisblum et al., 1979). pE194 is deposited at the ATCC under accession number 68359.</p><p id="p0047" num="0047">A modified pE194 can be used in which a single basepair substitution is introduced into the ermC gene, so that it contains a unique EcoRI restriction site. Although this substitution results in a guanosine at position 109 of the ermC leader, it has no effect on ermC function or induction by erythromycin. In a further modification, a 3-basepair segment cleavable by the ribozymes to be tested can be inserted into the ermC gene. For example, a GUC sequence can be inserted between nucleotides 75 and 76 of the ermC leader (see Figure 2). Since this insertion occurs in a hairpin loop and since it only adds a single in-phase codon to the leader sequence, it is unlikely to alter the function of the ermC gene. The insertion of a GUC sequence at this location allows the modified hairpin loop to serve as a substrate for cleavage by a Haseloff-Gerlach ribozyme. We know from our own work with a ribozyme that was designed to cleave MDV-1 RNA in a hairpin loop (see Figure 1) and from the work of others (Koizumi et al., 1988) that hairpin loops can serve as target sites for ribozymes.</p><p id="p0048" num="0048">Because a unique SstI restriction site occurs upstream of the ermC transcription initiation site (Narayanan &amp; Dubnau, 1985), the insertion of the<!-- EPO <DP n="26"> --> GUC, or other appropriate cleavage site, can be accomplished by replacing the SstI-EcoRI segment that encodes the beginning of the ermC leader with a synthetic DNA that is identical in all respects except that it contains the desired inserted basepairs.</p><p id="p0049" num="0049">In B. subtilis, pE194 is maintained at a copy number of approximately 10 at 37 degrees Celsius (Weisblum et al., 1979). It is desirable to reduce the amount of ermC mRNA that will be present in each cell to make it difficult for cells to survive unless they express an extremely efficient mutant ribozyme. Therefore, it is preferable to integrate a single copy of pE194, or other plasmid used which encodes ermC messenger RNA into the B. subtilis chromosome. An additional reason for integrating the particular plasmid pE194 into the chromosome is to prevent spontaneous loss of the plasmid, since the replication of pE194 is temperature-sensitive. The resulting clone can be tested to confirm that it is sensitive to tylosin in the absence of erythromycin, but resistant to tylosin in its presence. Integration of a single copy of pE194 containing the wild-type ermC gene can be accomplished by means known in the art (Hofemeister et al., 1983). In particular, the replication of pE194 is inhibited at elevated temperatures that do not interfere with the growth of B. subtilis. Selection for erythromycin-resistant organisms at elevated temperatures (circa 50 degrees Celsius) yields clones in which pE194 has been integrated into the B. subtilis chromosome, and the erythromycin resistant determinant is therefore replicated as part of the chromosome. Integration occurs at essentially random positions on the chromosome. pE194<!-- EPO <DP n="27"> --> containing a native ermC sequence, or pE194 containing an inserted cleavage site, may be integrated in a single copy into the chromosome in this manner.</p><p id="p0050" num="0050">These strains, carrying pE194 insertions, can also be used as recipients for transformation or transduction with plasmids carrying a DNA segment of interest, together with a region of homology to the integrated pE194 element. This permits integration into the chromosome, with replacement of the resident pE194 sequence by the sequence on the plasmid, which may be an altered version of pE194 containing the cleavage site of interest. In this way, the segment of interest can be readily integrated at a known site on the B. subtilis chromosome.</p><heading id="h0006">EXAMPLE 3</heading><p id="p0051" num="0051">This example demonstrates the preparation of a plasmid that can be induced to express a ribozyme to be screened for effectiveness. Use in the B. subtilis host is exemplified here but suitable plasmids may be made for expressing riboyzmes where other host cells are employed.</p><p id="p0052" num="0052">A recombinant plasmid, pLIQ-1, can be used in which transcription from a particular promoter is under the control of an E. coli lac operator, even though the plasmid is grown in B. subtilis (Yansura &amp; Henner, 1984). Construction of this plasmid is described in U.S. Patent 4,912,046, which is incorporated by reference into this application. This plasmid contains a hybrid promoter (called "spac"), that consists of a promoter from B. subtilis phage SPO-1 fused to an E. coli lac operator. The plasmid also contains an E. coli lac repressor gene under the control of<!-- EPO <DP n="28"> --> a promoter and ribosome binding site that allows expression of the repressor in B. subtilis. The spac promoter is immediately upstream from a sequence that contains unique restriction sites for HindIII and XbaI. Consequently, the transcription of a sequence inserted between the HindIII and XbaI sites can be modulated in B. subtilis by altering the concentration of isopropyl-B-D-thiogalactoside (IPTG), which is an inducer of the E. coli lac operon.</p><p id="p0053" num="0053">A sequence is inserted downstream from the spac promoter that consists of two sections. The first section encodes a Haseloff-Gerlach ribozyme designed to cleave the modified leader sequence of the ermC transcript at the site of the GUC insertion. The second section contains the sequence of a transcription terminator. One transcription terminator which can be used, and is used here, is the major rho-independent transcription terminator of the comG gene of B. subtilis (Albano et al., 1989), the sequence of which is contained in the second oligonucleotide shown below. Each section can be prepared on commercially available DNA synthesizers. The sequence of the first oligonucleotide (encoding the ribozyme) is<br/>5'-ggaa-GCTTATTT-ctgatgagtccgtgaggacgaa-ACTTTGTT-gtac-3'<br/>Capital letters identify the sequences that encode the portions of the ribozyme that hybridize to the ermC leader. The 22 nucleotide catalytic domain of the ribozyme is encoded by the region between the capitalized sequences. A HindIII recognition sequence (AAGCTT) is close to the 5' end of the<!-- EPO <DP n="29"> --> oligonucleotide. The sequence of the second oligonucleotide (containing the terminator) is<br/>5'-ggtctag-AAAAAAAAGGTACCCGCTCGCTCTGGTAC-aacaaagtttc-3'<br/>Capital letters identify the region that is the complement of the sequence that will occur at the 3' end of terminated transcripts. An XbaI recognition sequence (TCTAGA) is close to the 5' end of the oligonucleotide. The last 15 nucleotides at the 3' end of each oligonucleotide are complementary to each other. Therefore, the two oligonucleotides will hybridize to each other and can be extended by incubation with the Klenow fragment of E. coli DNA polymerase, generating a double-stranded DNA segment encoding both a ribozyme and a transcription terminator. This segment is digested with HindIII and XbaI to generate "sticky" ends, and then inserted in place of the short HindIII-XbaI segment downstream from the spac promoter in pLIQ-1. The resulting recombinant plasmid is used to transform B. subtilis cells containing the modified chromosomal ermC gene described above. pLIQ-1 also contains a chloramphenicol resistance gene (Yansura &amp; Henner, 1984), and transformants are selected by growth in the presence of chloramphenicol. Other resistance markers may, of course, be used.</p><p id="p0054" num="0054">When the selected clones are grown in the presence of IPTG, transcripts synthesized from the spac promoter consist of three sections: a 5' leader containing a copy of the E. coli lac operator, an ermC-specific Haseloff-Gerlach ribozyme, and a 3' tail containing the transcription terminator. Figure 8 shows this transcript bound to the modified ermC leader. The arrow indicates the site where cleavage will<!-- EPO <DP n="30"> --> occur. When deciding which terminator sequence to incorporate into the transcript, we used a computer program (Zuker, 1989; Zuker and Stiegler, 1981) to predict the secondary structures that are likely to form in the transcript. The program predicted that the comG terminator sequence is unlikely to interact with the sequence of the ribozyme. Furthermore, the program predicted that the sequences that must interact with the ermC leader for the ribozyme to function are likely to occur in a single-stranded conformation. Where ribozymes are designed to cleave targets contained in other sequences than the ermC leader, secondary structures may be similarly analyzed to select an appropriate terminator sequence, should a terminator sequence be included.</p><p id="p0055" num="0055">A northern blot procedure (Kornblum et al., 1988) can be used to confirm that the amount of ribozyme synthesized in transformed cells is dependent on the concentration of IPTG.</p><heading id="h0007">EXAMPLE 4</heading><p id="p0056" num="0056">This example describes the preparation of a plasmid library containing mutant ribozyme sequences to be screened according to the method of the invention.</p><p id="p0057" num="0057">The automated synthesis of DNA occurs in a stepwise fashion, beginning at the 3' end of the desired oligonucleotide. When a new nucleotide is added to a growing oligonucleotide chain, the automated synthesizer selects an appropriate nucleotide precursor solution from the four solutions (one solution for each possible nucleotide) that are available. At any step of the synthesis, the substitution of a mixture of all four nucleotides in place of a single<!-- EPO <DP n="31"> --> nucleotide will result in the incorporation of a mutant base at that location in some of the chains (Hutchison III et al., 1986). The proportion of oligonucleotides that will be mutant will depend on the relative amounts of "incorrect" nucleotide precursors present at each step. In this context, the terms "mutant nucleotides" and "incorrect nucleotides" refer to nucleotides which are different than those in the ribozyme whose sequence is being varied.</p><p id="p0058" num="0058">In one method for generating mutants, synthesis of the first oligonucleotide (encoding the ribozyme) proceeds until the first 12 nucleotides have been incorporated, forming a sequence which is complementary to the target sequence. At that point, all four of the precursor solutions are replaced with mixtures containing, for example, 85% of the "wild-type" nucleotide and 5% of each of the other three nucleotides. Synthesis of the oligonucleotide is then continued until the next 22 nucleotides (encoding the catalytic domain of the ribozyme) have been incorporated. Thus, in each of these 22 cycles of synthesis, 15% of the growing strands, at random, have incorporated one of the three "mutant" nucleotides. Synthesis is then halted, and the precursor mixtures are replaced with the original pure solutions. Synthesis is then continued until the remaining 12 nucleotides, which are complementary to the target sequence, have been incorporated. The product DNA therefore consists of a diverse collection of oligonucleotides encoding a variety of mutant ribozymes. These oligonucleotides are then hybridized to the second oligonucleotide, which encodes the transcription terminator, and extended and cloned into an appropriate plasmid, for<!-- EPO <DP n="32"> --> example pLIQ-1 as described above. We estimate that a single oligonucleotide preparation can be used to construct at least 1 microgram of recombinant plasmids.</p><p id="p0059" num="0059">Since transformation of B. subtilis requires plasmid oligomers (Contente &amp; Dubnau, 1979) and is therefore relatively inefficient, E. coli can be transformed with the recombinant plasmids, markedly increasing the number of transformants that can be obtained. Furthermore, if the DNA is transferred to the cells by electroporation, this should yield about a billion transformants per microgram of plasmid (Dower et al., 1988). The plasmids, markedly increasing the number of transformants that can be obtained. Furthermore, if the DNA is transferred to the cells by electroporation, this should yield about a billion transformants per microgram of plasmid (Dower et al., 1988). The main advantage of first introducing the plasmids into E. coli is that the proportion of oligomers in the plasmid population increases during bacterial growth (James et al., 1982). The transformed E. coli cells are grown on agar plates containing chloramphenicol, until they form nearly confluent bacterial lawns. The bacteria are then scraped off the plates and used to prepare plasmid DNA. The isolated plasmids are then transferred to B. subtilis by transformation. As a consequence of the preamplification in E. coli, approximately 10 million B. subtilis transformants should be obtained. Approximately 97% of these transformants encode a mutant ribozyme.</p><p id="p0060" num="0060">The number of different possible mutant sequences that are 22 nucleotides long, i.e. the length of the catalytic sequence which is to be varied, exceeds 17 trillion. If, for example, 10<!-- EPO <DP n="33"> --> million transformants are to be tested per experiment, a strategy should be employed to increase the chances of selecting a mutant ribozyme with enhanced activity. The number of different sequences n nucleotides long that contain exactly r mutations, S<sub>n,r,</sub> is given by the formula:<maths id="math0001" num=""><math display="block"><mrow><msub><mrow><mtext>S</mtext></mrow><mrow><mtext>n,r</mtext></mrow></msub><msub><mrow><mtext> = [C</mtext></mrow><mrow><mtext>n,r</mtext></mrow></msub><msup><mrow><mtext>] [3</mtext></mrow><mrow><mtext>r</mtext></mrow></msup><mtext>]</mtext></mrow></math><img id="ib0001" file="imgb0001.tif" wi="30" he="6" img-content="math" img-format="tif"/></maths> where C<sub>n,r</sub> is the number of combinations of n things taken r at a time. When n equals 22, as is the case for the catalytic domain of the ribozymes exemplified here, the first eight values of S<sub>n,r</sub> are given in the table below. From an examination of the table it is apparent that even with 10,000,000 transformants, only the different mutant strands that contain five or fewer nucleotide substitutions could be extensively explored. <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm"/><colspec colnum="2" colname="col2" colwidth="78.75mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">r</entry><entry namest="col2" nameend="col2" align="center">S<sub>2</sub>2,<sub>r</sub></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="right">0</entry><entry namest="col2" nameend="col2" align="right">1</entry></row><row><entry namest="col1" nameend="col1" align="right">1</entry><entry namest="col2" nameend="col2" align="right">66</entry></row><row><entry namest="col1" nameend="col1" align="right">2</entry><entry namest="col2" nameend="col2" align="right">2,079</entry></row><row><entry namest="col1" nameend="col1" align="right">3</entry><entry namest="col2" nameend="col2" align="right">41,580</entry></row><row><entry namest="col1" nameend="col1" align="right">4</entry><entry namest="col2" nameend="col2" align="right">592,515</entry></row><row><entry namest="col1" nameend="col1" align="right">5</entry><entry namest="col2" nameend="col2" align="right">6,399,162</entry></row><row><entry namest="col1" nameend="col1" align="right">6</entry><entry namest="col2" nameend="col2" align="right">54,392,876</entry></row><row><entry namest="col1" nameend="col1" align="right">7</entry><entry namest="col2" nameend="col2" align="right">372,979,712</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="right">8</entry><entry namest="col2" nameend="col2" align="right">2,098,011,008</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="34"> --></p><p id="p0061" num="0061">The number of transformants with sequences that are n nucleotides long and that contain exactly r mutations, N<sub>n,r,</sub> that are expected to appear in a population containing 10,000,000 transformants, is given by the formula:<maths id="math0002" num=""><math display="block"><mrow><msub><mrow><mtext>N</mtext></mrow><mrow><mtext>n,r</mtext></mrow></msub><msub><mrow><mtext> = 10,000,000 [C</mtext></mrow><mrow><mtext>n,r</mtext></mrow></msub><msup><mrow><mtext>] [(3p)</mtext></mrow><mrow><mtext>r</mtext></mrow></msup><msup><mrow><mtext>] [(1-3p)</mtext></mrow><mrow><mtext>(n-r)</mtext></mrow></msup><mtext>]</mtext></mrow></math><img id="ib0002" file="imgb0002.tif" wi="79" he="7" img-content="math" img-format="tif"/></maths> where p is the frequency at which a particular mutant nucleotide is substituted for the wild-type nucleotide at a given position in the sequence. When we described the synthesis of the collection of mutant oligonucleotides above, p was set at .05. When n equals 22, as is the case for the catalytic domain of ribozymes described in these examples, the first eight values of N<sub>n,r</sub> are given in the table on the next page. It is clear from an examination of the table that if the substitution frequency, p is altered by changing the proportions of the nucleotides in the precursor mixtures, the way in which the selection experiment explores changes in the 22 nucleotides will be varied. Lower values of p will result in a thorough exploration of the different sequences that have only a few nucleotide substitutions. However, lower values of p will also result in only a relatively few sequences possessing the multiple substitutions that might confer increased ribozyme activity. Higher values of p, on the other hand, sacrifice a thorough exploration of minor changes for a greater representation of relatively complex mutants.</p><p id="p0062" num="0062">Our preferred strategy recognizes that all the possibilities cannot be explored directly. Instead, a relatively moderate value of p (.05) is utilized to increase the probability of<!-- EPO <DP n="35"> --> identifying advantageous alterations involving only a few mutations. Once these mutations have been identified, the synthesis of a collection of mutant sequences can be repeated, but starting with one or more of the advantageous sequences identified in the first collection, and using more stringent selection conditions (e.g. lower concentrations of IPTG). This strategy thus mimics the evolution of genes in nature. The selection process can be repeated a number of times. With each cycle of mutation and selection, small changes should improve the efficiency of the ribozyme. In this manner, a ribozyme is selected that is much more suited to cleaving a substrate under physiological conditions than the starting ribozyme whose sequence is varied. The ribozyme obtained is also much more efficient at catalyzing cleavage in trans than the natural hammerhead that evolved to catalyze cleavage in cis. <tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="4" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm"/><colspec colnum="2" colname="col2" colwidth="39.37mm"/><colspec colnum="3" colname="col3" colwidth="39.37mm"/><colspec colnum="4" colname="col4" colwidth="39.37mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">r</entry><entry namest="col2" nameend="col2" align="center">p=.01</entry><entry namest="col3" nameend="col3" align="center">N<sub>n,r</sub> p=.05</entry><entry namest="col4" nameend="col4" align="center">p=.10</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="right">0</entry><entry namest="col2" nameend="col2" align="right">5,116,564</entry><entry namest="col3" nameend="col3" align="right">280,038</entry><entry namest="col4" nameend="col4" align="right">3,910</entry></row><row><entry namest="col1" nameend="col1" align="right">1</entry><entry namest="col2" nameend="col2" align="right">3,481,373</entry><entry namest="col3" nameend="col3" align="right">1,087,205</entry><entry namest="col4" nameend="col4" align="right">36,864</entry></row><row><entry namest="col1" nameend="col1" align="right">2</entry><entry namest="col2" nameend="col2" align="right">1,130,549</entry><entry namest="col3" nameend="col3" align="right">2,014,528</entry><entry namest="col4" nameend="col4" align="right">165,888</entry></row><row><entry namest="col1" nameend="col1" align="right">3</entry><entry namest="col2" nameend="col2" align="right">233,103</entry><entry namest="col3" nameend="col3" align="right">2,370,032</entry><entry namest="col4" nameend="col4" align="right">473,966</entry></row><row><entry namest="col1" nameend="col1" align="right">4</entry><entry namest="col2" nameend="col2" align="right">34,244</entry><entry namest="col3" nameend="col3" align="right">1,986,645</entry><entry namest="col4" nameend="col4" align="right">964,859</entry></row><row><entry namest="col1" nameend="col1" align="right">5</entry><entry namest="col2" nameend="col2" align="right">3,812</entry><entry namest="col3" nameend="col3" align="right">1,262,104</entry><entry namest="col4" nameend="col4" align="right">1,488,640</entry></row><row><entry namest="col1" nameend="col1" align="right">6</entry><entry namest="col2" nameend="col2" align="right">334</entry><entry namest="col3" nameend="col3" align="right">631,052</entry><entry namest="col4" nameend="col4" align="right">1,807,634</entry></row><row><entry namest="col1" nameend="col1" align="right">7</entry><entry namest="col2" nameend="col2" align="right">24</entry><entry namest="col3" nameend="col3" align="right">254,542</entry><entry namest="col4" nameend="col4" align="right">1,770,744</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="right">8</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">84,223</entry><entry namest="col4" nameend="col4" align="right">1,422,919</entry></row></tbody></tgroup></table></tables></p><p id="p0063" num="0063">We have described introducing mutations into all 22 nucleotides of the catalytic domain, even though the only conserved sequences (Forster &amp; Symons, 1987b) are those surrounding the hairpin<!-- EPO <DP n="36"> --> structure (see Figure 1B). We chose this route because the mechanism of catalysis is not understood, and the identity of the sequences that form this hairpin markedly influence the rate of cleavage (Heus et al., 1990). In another approach, however, a lesser number of nucleotides may be targeted for selection if it is believed those nucleotides are more influential in the ribozyme's catalytic action. For example, the ten unhybridized nucleotides shown in Fig. 1B "CUGAUGA ... GAA" can be varied, and the others in the 22 nucleotide catalytic sequence kept the same, based on a presumption that these nucleotides are more responsible for catalyzing the cleavage of the target RNA.</p><heading id="h0008">EXAMPLE 5</heading><p id="p0064" num="0064">In this example, transformants are selected which express the most efficient mutant ribozymes.</p><p id="p0065" num="0065">The library of transformed B. subtilis clones is grown on agar containing 10 micrograms/ml tylosin and varying concentrations of IPTG (between 0 and 1,000 micrograms/ml). No colonies should grow in the absence of IPTG because not enough ribozymes are synthesized for the cells to be able to grow in the presence of tylosin. In the presence of IPTG, many more ribozymes are synthesized in each cell. However, most of the clones are still unable to grow because the ribozymes they synthesize are not sufficiently active in vivo. The clones that do survive contain a mutant ribozyme that is considerably more active than the wild-type.</p><p id="p0066" num="0066">As noted above, the antibiotic resistance is caused by the disassociation of the RNA fragments<!-- EPO <DP n="37"> --> created when the ribozyme cleaves the ermC mRNA.</p><p id="p0067" num="0067">At lower IPTG concentrations, fewer molecules of ribozyme are transcribed. The IPTG concentration is determined at which only about 20 to 30 clones are able to survive. The clones that grow in this low IPTG concentration contain the most efficient ribozyme mutants. The fastest growing clones from this collection are isolated for further study. These clones are tested to confirm that they are sensitive to tylosin and that they are able to grow in tylosin if either IPTG or erythromycin is present. Active ribozyme mutants can be distinguished from constitutive mutants of ermC because the constitutive mutants are resistant to tylosin in the absence of inducer, while the ribozyme mutants are not.</p><p id="p0068" num="0068">Plasmid DNA from selected clones is isolated and the HindIII-XbaI fragment from each is sequenced to determine which nucleotide substitutions in the catalytic domain of the Haseloff-Gerlach ribozyme are responsible for increased activity in vivo.</p><heading id="h0009">REFERENCES</heading><p id="p0069" num="0069"><ul id="ul0003" list-style="none"><li>Adachi, A., Gendelman, H., Koenig, S., Folks, T., Willey, R., Rabson, A., &amp; Martin, M. (1986). Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59, 284-291.</li><li>Albano, M., Breitling, R., &amp; Dubnau, D. (1989). Nucleotide sequence and genetic organization of the Bacillus subtilis comG operon. J. Bacteriol. 171, 5386-5404.<!-- EPO <DP n="38"> --></li><li>Cameron, F., &amp; Jennings, D. (1989). Specific gene supression by engineered ribozymes in monkey cells. Proc. Natl. Acad. Sci. USA 86, 9139-9143.</li><li>Contente, S., &amp; Dubnau, D. (1979). Characterization of plasmid transformation in Bacillus subtilis: kinetic properties and the effect of DNA conformation. Mol. Gen. Genet. 167, 251-258.</li><li>Cotten, N., Schaffner, G., &amp; Birnstiel, M. L. (1989). Ribozyme, antisense RNA, and antisense DNA inhibition of U7 small nuclear ribonucleoprotein-mediated histone pre-mRNA processing in vitro. Mol. Cell. Biol. 9, 4479-4487.</li><li>Dower, W. J., Miller, J. F., &amp; Ragsdale, C. W. (1988). High efficiency transformation of E. coli by high voltage electroporation. Nucleic Acids Res. 16, 6127-6145.</li><li>Dubnau, D. (1984). Translational attenuation: the regulation of bacterial resistance to the macrolide-lincosamide-streptogramin B antibiotics. CRC Critical Rev. Biochem. 16, 103-132.</li><li>Fedor, M. J., &amp; Uhlenbeck, O. C. (1990). Substrate sequence effects on hammerhead RNA catalytic efficiency. Proc. Natl. Acad. Sci. USA 87, 1668-1672.</li><li>Forster, A. C., &amp; Symons, R. H. (1987a). Self-cleavage of plus and minus RNAs of a virusoid and a structural model for the active sites. Cell 49, 211-220.<!-- EPO <DP n="39"> --></li><li>Forster, A. C., &amp; Symons, R. H. (1987b). Self-cleavage of virusoid RNA is performed by the proposed 55-nucleotide active site. Cell 50, 9-16.</li><li>Gryczan, T. J., Grandi, G., Hahn, J., Grandi, R., &amp; Dubnau, D. (1980). Conformational alteration of mRNA structure and the posttranslational regulation of erythromycin-induced drug restance. Nucleic Acids Res. 8, 6081-6097.</li><li>Hampel, A., &amp; Tritz, R. (1989). RNA catalytic properties of the minimum (-)sTRSV sequence. Biochemistry 28, 4929-4933.</li><li>Hampel, A., Tritz, R., Hicks, M., &amp; Cruz, P. (1990). Hairpin catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Res. 18, 299-304.</li><li>Haseloff, J., &amp; Gerlach, W. L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585-591.</li><li>Heus, H. A., Uhlenbeck, O. C., &amp; Pardi, A. (1990). Sequence-dependent structural variations of hammerhead RNA enzymes. Nucleic Acids Res. 18, 1103-1108.</li><li>Hofemeister, J., Israeli-Reches, M., &amp; Dubnau, D. (1983). Integration of plasmid pE194 at multiple sites on the Bacillus subtilis chromosome. Mol. Gen. Genet. 189, 58-68.</li><li>Hutchins, C. J., Rathjen, P. D., Forster, A. C., &amp; Symons, R. H. (1986). Self-cleavage of plus and<!-- EPO <DP n="40"> --> minus RNA transcripts of avacado sunblotch viroid. Nucleic Acids Res. 14, 3627-3640.</li><li>Hutchison III, C. A., Nordeen, S. K., Vogt, K., &amp; Edgell, M. H. (1986). A complete library of point substitution mutations in the glucocorticoid response element of mouse mammary turmor virus. Proc. Natl. Acad. Sci. USA 83, 710-714.</li><li>Iordanescu, 5. (1976). Three distinct plasmids originating in the same Staphylococcus aureus strain. Arch. Roum. Pathol. Exp. Microbiol. 35, 111-118.</li><li>Jaeger, J. A., Turner, D. H., &amp; Zuker, M. (1989). Improved predictions of secondary structures for RNA. Proc. Natl. Acad. Sci. USA 86, 7706-7710.</li><li>James, A. A., Morrison, P. T., &amp; Kolodner, R. (1982). Genetic recombination of bacterial plasmid DNA. Analysis of the effect of recombination-deficient mutations on plasmid recombination. J. Mol. Biol. 160, 411-430.</li><li>Kacian, D. L., Mills, D. R., Kramer, F. R., &amp; Spiegelman, S. (1972). A replicating RNA molecule suitable for a detailed analysis of extracellular evolution and replication. Proc. Natl. Acad. Sci. USA 69, 3038-3042.</li><li>Koizumi, M., Iwai, S., &amp; Ohtsuka, E. (1988). Cleavage of specific sites of RNA by designed ribozymes. FEBS Lett. 239, 285-288.</li><li>Kornblum, J., Projan, S. J., Moghazeh, S. L., &amp; Novick, R. (1988). A rapid method to quantitate<!-- EPO <DP n="41"> --> non-labeled RNA species in bacterial cells. Gene 63, 75-85.</li><li>Kramer, F. R., &amp; Mills, D. R. (1981). Secondary structure formation during RNA synthesis. Nucleic Acids Res. 9, 5109-5124.</li><li>Kruger, K., Grabowski, P. J., Zaug, A. J., Sands, J., Gottschling, D. E., &amp; Cech, T. R. (1982). Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 31, 147-157.</li><li>Lai, C. J., Dahlberg, J. E., &amp; Weisblum, B. (1973). Structure of an inducibly methylatable nucleotide sequence in 23S ribosomal ribonucleic acid from erythromycin-resistant Staphylococcus aureus. Biochemistry 12, 457-460.</li><li>Mao, J. C. H., &amp; Robishaw, E. E. (1971). Effects of macrolides on peptide-bond formation and translocation. Biochemistry 10, 2054-2061.</li><li>Mao, J. C. H., &amp; Robishaw, E. E. (1972). Erythromycin, a peptidyltransferase effector. Biochemistry 11, 4864-4872.</li><li>Mayford, M., &amp; Weisblum, B. (1989a). ErmC leader peptide. Amino acid sequence critical for induction by translational attenuation. J. Mol. Biol. 206, 69-79.</li><li>Mayford, M., &amp; Weisblum, B. (1989b). Conformational alterations in the ermC transcript in vivo during induction. EMBO J. 8, 4307-4314.<!-- EPO <DP n="42"> --></li><li>Melton, D. A., Krieg, P. A., Rebagliati, M. R., Maniatis, T., Zinn, K., &amp; Green, M. R. (1984). Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res. 12, 7035-7056.</li><li>Miele, E. A., Mills, D. R., &amp; Kramer, F. R. (1983). Autocatalytic replication of a recombinant RNA. J. Mol. Biol. 171, 281-295.</li><li>Milligan, J. F., Groebe, D. R., Witherall, G. W., &amp; Uhlenbeck, O. C. (1987). Oligonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res. 15, 8783-8798.</li><li>Mills, D. R., Kramer, F. R., &amp; Spiegelman, S. (1973). Complete nucleotide sequence of a replicating RNA molecule. Science 180, 916-927.</li><li>Narayanan, C. S., &amp; Dubnau, D. (1985). Evidence for the translational attenuation model: ribosome-binding studies and structural analysis with an in vitro run-off transcript of ermC. Nucleic Acids Res. 13, 7307-7326.</li><li>Prody, G. A., Bakos, J. T., Buzayan, J. M., Schneider, I. R., &amp; Bruening, G. (1986). Autolytic processing of dimeric plant virus satellite RNA. Science 231, 1577-1580.</li><li>Sarver, N., Cantin, E. M., Chang, P. S., Zaia, J. A., Ladne, P. A., Stephens, D. A., &amp; Rossi, J. J. (1990). Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-1225.<!-- EPO <DP n="43"> --></li><li>Shine, J., &amp; Dalgarno, L. (1974). The 3'-terminal sequence of Escherichia coli 16S ribosomal RNA: complementarity to nonsense triplets and ribosome binding sites. Proc. Natl. Acad. Sci. USA 71, 1342-1346.</li><li>Shivakumar, A. G., Hahn, J., Grandi, G., Kozlov, Y., &amp; Dubnau, D. (1980). Posttranscriptional regulation of an erythromycin resistance protein specified by plasmid pE194. Proc. Natl. Acad. Sci. USA 77, 3903-3907.</li><li>Shivakumar, A. G., &amp; Dubnau, D. (1981). Characterization of a plasmid-specified ribosome methylase associated with macrolide resistance. Nucleic Acids Res. 9, 2549-2562.</li><li>Tomizawa, J., &amp; Itoh, T. (1981). Plasmid ColE1 incompatability determined by interaction of RNAI with primer transcript. Proc. Natl. Acad. Sci. USA 78, 6096-6100.</li><li>Uhlenbeck, O. C. (1987). A small catalytic oligoribonucleotide. Nature 328, 596-600.</li><li>Weisblum, B., Siddhikol, C., Lai, C. J., &amp; Demohn, V. (1971). Erythromycin-inducible resistance in Staphylococcus aureus: requirements for induction. J. Bacteriol. 106, 835-847.</li><li>Weisblum, B., Graham, M. Y., Gryczan, T., &amp; Dubnau, D. (1979). Plasmid copy number control: isolation and characterization of high-copy-number mutants of plasmid pE194. J. Bacteriol. 137, 635-643.<!-- EPO <DP n="44"> --></li><li>Yansura, D. G., &amp; Henner, D. J. (1984). Use of the Escherichia coli lac repressor and operator to control gene expression in Bacillus subtilis. Proc. Natl. Acad. Sci. USA 81, 439-443.</li><li>Zuker, M. (1989). On finding all suboptimal foldings of an RNA molecule. Science 244, 48-52.</li><li>Zuker, M. and Stiegler, P. (1981). Optimal computer folding of large RNA sequences using thermodynamics and auxillary information. Nucleic Acids Res. 9, 133-148.</li></ul></p>
EP	0600877	B1	2000-01-26	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A method for screening ribozymes for effectiveness in cleaving RNA comprising:<claim-text>(a) creating a plurality of vectors encoding ribozymes having differing sequences, which ribozymes are to be screened for effectiveness in cleaving RNA containing a target RNA sequence;</claim-text><claim-text>(b) providing cells that possess an RNA containing the target RNA sequence and that, when the RNA is cleaved by one of the ribozymes in sufficient quantity, survive in a preselected culture medium;</claim-text><claim-text>(c) providing the cells with the vectors;</claim-text><claim-text>(d) culturing the cells in the preselected culture medium under conditions wherein the ribozymes are expressed; and</claim-text><claim-text>(e) selecting cells which survive.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A method as claimed in claim 1 wherein the cells provided express a messenger RNA containing the target RNA sequence, when the messenger RNA is cleaved by one of the ribozymes it directs the expression of a polypeptide which can, in sufficient quantity cause the cells to survive in the preselected culture medium.<!-- EPO <DP n="46"> --></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A method as claimed in claim 2 for screening mutant ribozymes wherein<claim-text>(a) the plurality of vectors encode mutant ribozymes;</claim-text><claim-text>(b) the cell's survival is dependent upon the cleavage of a hairpin loop structure contained in the messenger RNA, by a ribozyme, which cleavage alters the secondary structure of the messenger RNA to free a ribosome binding site and allow translation of a sequence of the messenger RNA coding for a polypeptide which allows the cells to survive in the preselected culture medium and wherein the cells which survive are selected to determine the nucleotide sequence of the most effective mutant ribozymes.</claim-text></claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A method as claimed in claim 2 or claim 3, wherein the polypeptide causes antibiotic resistance.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A method as claimed in claim 4, wherein the messenger RNA is ermC messenger RNA encoding leader and methylase polypeptides.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A method as claimed in claim 5, wherein the cell contains a single copy of the ermC gene.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A method as claimed in any preceding claim wherein the vector is a plasmid.<!-- EPO <DP n="47"> --></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A method as claimed in any preceding claim wherein the cells are bacteria.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A method as claimed in claim 8, wherein the bacteria are <i>B. subtilis</i>.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A method as claimed in any of claims 2 to 9, wherein synthesis of the ribozyme is under the control of an operator and inducer is added in an amount which causes only some of the cells to survive due to a efficient cleavage of the messenger RNA by the ribozyme.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A method as claimed in any preceding claim wherein the ribozyme contains a transcription terminator.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A method as claimed in claim 11, wherein the transcription terminator is the major rho-dependent transcription terminator of the comG gene of <i>B. subtills</i>.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A method as claimed in any of claims 2 to 12, wherein bacterial cells are provided which express a messenger RNA which contains a cleavage site in a hairpin loop of ermC leader messenger RNA, cleavage of<!-- EPO <DP n="48"> --> this site by a ribozyme causes a change in structure of the ermC messenger RNA and frees a ribosome binding site to allow synthesis of methylase, which in sufficient quantity causes the cell to survive in preselected culture media containing macrolide-lincosamide-streptogramin B (MLS) antibiotic.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A method as claimed in any preceding claim, wherein the ribozymes are of the Haselhoff-Gerlach type.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A method as claimed in claim 13 or claim 14, wherein the sequence cleavable by the ribozyme is GUC, GUU or GUA.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>A method as claimed in claim 15, wherein the sequence cleavable by the ribozyme is GUC.</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>A method as claimed in any of claims 4 to 16, wherein the cells are cultured in media containing the MLS antibiotic tylosin.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>A method as claimed in claims 4 to 17, for screening Haselhoff-Gerlach ribozymes wherein the cleavage site is a non-native cleavage site located at about position 109 of the hairpin loop of the ermC<!-- EPO <DP n="49"> --> leader messenger RNA, wherein cleavage of this site by ribozymes inducibly expressed in the cells causes the cells to survive in preselected culture media containing tylosin.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>A method as claimed in claim 18, wherein the sequence in the ermC hairpin loop which contains the cleavable site is a target sequence which is not a natural ermC sequence.</claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>A method as claimed in claim 19, wherein the non-ermC sequence is an HIV-1 RNA sequence.</claim-text></claim><claim id="c-en-01-0021" num="0021"><claim-text>A method as claimed in claim 20, wherein the HIV-1 sequence is from the intergrase gene.</claim-text></claim><claim id="c-en-01-0022" num="0022"><claim-text>A method as claimed in any preceding claim, wherein the expression of the ribozyme is under the control of a lac operator.</claim-text></claim><claim id="c-en-01-0023" num="0023"><claim-text>A method as claimed in any preceding claim, wherein the ribozyme is expressed by a recombinant plasmid containing a spac promoter.</claim-text></claim><claim id="c-en-01-0024" num="0024"><claim-text>A method as claimed in any preceding claim, wherein the vectors contain DNA encoding ribozymes<!-- EPO <DP n="50"> --> which is manufactured on a DNA synthesiser which selects nucleotide precursors from four solutions to construct the oligonucleotides by stepwise addition, and wherein a mixture of nucleotides is employed in at least one of the four solutions in order to randomly incorporate nucleotides during stepwise addition, resulting in generation of a variety of oligonucleotides to be screened.</claim-text></claim><claim id="c-en-01-0025" num="0025"><claim-text>A method as claimed in claim 24, wherein mixtures of oligonucleotide precursors are employed in all four of the solutions.</claim-text></claim><claim id="c-en-01-0026" num="0026"><claim-text>A method as claimed in claim 25, wherein each of the four mixtures of oligonuleotide precursors comprises about 85% wild type precursor and about 5% each of the remaining three oligonucleotide precursors.</claim-text></claim>
EP	0600877	B1	2000-01-26	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zum Screenen von Ribozymen auf die Wirksamkeit zum Spalten von RNA, welches umfaÃŸt:<claim-text>(a) Herstellen mehrerer Vektoren, die fÃ¼r Ribozyme mit unterschiedlichen Sequenzen kodieren, wobei die Ribozyme auf ihre Wirksamkeit zum Spalten von RNA, die eine Ziel-RNA-Sequenz enthÃ¤lt, gescreent werden soll;</claim-text><claim-text>(b) Bereitstellen von Zellen, welche die Ziel-RNA-Sequenz enthaltende RNA enthalten und die, wenn die RNA durch eines der Ribozyme in ausreichender Menge gespalten wird, in einem vorher ausgewÃ¤hlten Kulturmedium Ã¼berleben;</claim-text><claim-text>(c) Ausstatten der Zellen mit den Vektoren;</claim-text><claim-text>(d) Kultivieren der Zellen in dem vorher ausgewÃ¤hlten Kulturmedium unter Bedingungen, bei denen die Ribozyme exprimiert werden; und</claim-text><claim-text>(e) Selektieren der Ãœberlebenden Zellen.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren nach Anspruch 1, wobei die bereitgestellten Zellen eine Messenger-RNA exprimieren, welche die Ziel-RNA-Sequenz enthÃ¤lt, und wenn die Messenger-RNA durch eines der Ribozyme gespalten wird, bewirkt sie die Expression eines Polypeptids, das in ausreichender Menge bewirken kann, daÃŸ die Zellen in dem vorher ausgewÃ¤hlten Kulturmedium Ã¼berleben.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren nach Anspruch 2 zum Screenen von Ribozymmutanten, wobei<claim-text>(a) die mehreren Vektoren Ribozymmutanten kodieren;</claim-text><claim-text>(b) das Ãœberleben der Zellen von der Spaltung einer Haarnadelstruktur, die in der Messenger-RNA enthalten ist, durch ein Ribozym abhÃ¤ngt, wobei die Spaltung die SekundÃ¤rstruktur der Messenger-RNA dahingehend Ã¤ndert, daÃŸ eine Ribosomen-Bindungsstelle freigelegt wird und die<!-- EPO <DP n="52"> --> Translation einer Sequenz der Messenger-RNA, die fÃ¼r ein Polypeptid kodiert, ermÃ¶glicht, was den Zellen in dem vorher ausgewÃ¤hlten Kulturmedium das Ãœberleben ermÃ¶glicht, und wobei die Zellen, die Ã¼berleben, ausgewÃ¤hlt werden, um die Nukleotidsequenz der wirksamsten Ribozymmutanten zu bestimmen.</claim-text></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verfahren nach Anspruch 2 oder 3, wobei das Polypeptid eine Antibiotikaresistenz bewirkt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verfahren nach Anspruch 4, wobei die Messenger-RNA eine ermC-Messenger-RNA ist, die fÃ¼r Leader- und Methylasepolypeptide kodiert.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verfahren nach Anspruch 5, wobei die Zelle eine einzelne Kopie des ermC-Gens enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, wobei der Vektor ein Plasmid ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, wobei die Zellen Bakterien sind.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verfahren nach Anspruch 8, wobei die Bakterien B. subtilis sind.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verfahren nach einem der AnsprÃ¼che 2 bis 9, wobei die Synthese des Ribozyms unter der Kontrolle eines Operators ist und ein Induktor in einer Menge zugegeben wird, die bewirkt, daÃŸ nur einige der Zellen aufgrund einer wirksamen Spaltung der Messenger-RNA durch das Ribozym Ã¼berleben.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, wobei das Ribozym einen Transkriptionsterminator enthÃ¤lt.<!-- EPO <DP n="53"> --></claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verfahren nach Anspruch 11, wobei der Transkriptionsterminator der hauptsÃ¤chliche rho-abhÃ¤ngige Transkriptionsterminator des comG-Gens von B. subtilis ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verfahren nach einem der AnsprÃ¼che 2 bis 12, wobei bakterielle Zellen bereitgestellt werden, die eine Messenger-RNA exprimieren, die eine Spaltungsstelle in einer Haarnadelschleife der ermC-Leader-Messenger-RNA enthÃ¤lt, die Spaltung dieser Stelle durch ein Ribozym eine VerÃ¤nderung in der Struktur der ermC-Messenger-RNA bewirkt und eine Ribosomenbindungsstelle freilegt, um die Synthese von Methylase zu ermÃ¶glichen, die in ausreichender Menge bewirkt, daÃŸ die Zelle in den vorher ausgewÃ¤hlten Kulturmedien Ã¼berlebt, welche die Macrolid-Lincosamid-Streptogramin-B-(MLS)-Antibiotika enthalten.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, wobei die Ribozyme vom Haselhoff-Gerlach-Typ sind.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Verfahren nach Anspruch 13 oder 14, wobei die durch das Ribozym spaltbare Sequenz GUC, GUU oder GUA ist.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Verfahren nach Anspruch 15, wobei die durch das Ribozym spaltbare Sequenz GUC ist.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Verfahren nach einem der AnsprÃ¼che 4 bis 16, wobei die Zellen in Medien kultiviert werden, die das MLS-Antibiotikum Tylosin enthalten.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Verfahren nach einem der AnsprÃ¼che 4 bis 17 zum Screenen von Haselhoff-Gerlach-Ribozymen, wobei die Spaltstelle eine nicht native Spaltstelle ist, die sich etwa an der Position 109 der Haarnadelschleife der ermC-Leader-Messenger-RNA befindet, wobei die Spaltung dieser Stelle durch Ribozyme, die in den Zellen induzierbar exprimiert werden,<!-- EPO <DP n="54"> --> bewirkt, daÃŸ die Zellen in vorher ausgewÃ¤hlten Kulturmedien, die Tylosin enthalten, Ã¼berleben.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Verfahren nach Anspruch 18, wobei die Sequenz in der ermC Haarnadelschleife, welche die spaltbare Stelle enthÃ¤lt, eine Zielsequenz ist, die nicht eine natÃ¼rliche ermC-Sequenz ist.</claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>Verfahren nach Anspruch 19, wobei die nicht-ermC-Sequenz eine HIV-1-RNA-Sequenz ist.</claim-text></claim><claim id="c-de-01-0021" num="0021"><claim-text>Verfahren nach Anspruch 20, wobei die HIV-1-Sequenz aus dem Integrase-Gen stammt.</claim-text></claim><claim id="c-de-01-0022" num="0022"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, wobei die Expression des Ribozyms unter der Kontrolle eines lac-Operators ist.</claim-text></claim><claim id="c-de-01-0023" num="0023"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, wobei das Ribozym durch ein rekombinantes Plasmid exprimiert wird, das einen spac-Promotor enthÃ¤lt.</claim-text></claim><claim id="c-de-01-0024" num="0024"><claim-text>Verfahren nach einem der vorhergehenden AnsprÃ¼che, wobei die Vektoren fÃ¼r Ribozyme kodierende DNA enthalten, die in einem DNA-SynthetisiergerÃ¤t hergestellt wird, das NukleotidvorlÃ¤ufer aus vier LÃ¶sungen auswÃ¤hlt, um die Oligonukleotide durch allmÃ¤hliche Zugabe zu konstruieren, und wobei ein Gemisch von Nukleotiden in mindestens einer der vier LÃ¶sungen eingesetzt wird, um Nukleotide wÃ¤hrend der allmÃ¤hlichen Zugabe statistisch einzubauen, wobei verschiedene zu screenende Oligonukleotide erzeugt werden.</claim-text></claim><claim id="c-de-01-0025" num="0025"><claim-text>Verfahren nach Anspruch 24, wobei die Gemische von Oligonukleotid-VorlÃ¤ufern in allen vier LÃ¶sungen verwendet werden.<!-- EPO <DP n="55"> --></claim-text></claim><claim id="c-de-01-0026" num="0026"><claim-text>Verfahren nach Anspruch 25, wobei jedes der vier Gemische von Oligonukleotid-VorlÃ¤ufern etwa 85 % Wildtyp-VorlÃ¤ufer und etwa 5 % jedes der verbleibenden drei Oligonukleotid-VorlÃ¤ufer umfaÃŸt.</claim-text></claim>
EP	0600877	B1	2000-01-26	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>ProcÃ©dÃ© pour cribler des ribozymes en ce qui concerne leur efficacitÃ© de coupure d'ARN, comprenant les Ã©tapes consistant Ã  :<claim-text>(a) crÃ©er une pluralitÃ© de vecteurs codant pour des ribozymes ayant diffÃ©rentes sÃ©quences, lesquelles ribozymes doivent Ãªtre criblÃ©es en ce qui concerne leur efficacitÃ© de coupure d'ARN contenant une sÃ©quence d'ARN cible ;</claim-text><claim-text>(b) se munir de cellules qui possÃ¨dent un ARN contenant la sÃ©quence d'ARN cible et qui, quand l'ARN est coupÃ© par l'une des ribozymes en quantitÃ© suffisante, survivent dans un milieu de culture prÃ©sÃ©lectionnÃ© ;</claim-text><claim-text>(c) pourvoir les cellules avec les vecteurs ;</claim-text><claim-text>(d) rÃ©aliser la culture des cellules dans le milieu de culture prÃ©sÃ©lectionnÃ© dans des conditions dans lesquelles les ribozymes sont exprimÃ©es ; et</claim-text><claim-text>(e) sÃ©lectionner les cellules qui survivent.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>ProcÃ©dÃ© selon la revendication 1, dans lequel les cellules mises en oeuvre expriment un ARN messager contenant la sÃ©quence d'ARN cible, et quand l'ARN messager est coupÃ© par l'un des ribozymes, il dirige l'expression d'un polypeptide qui peut, en quantitÃ© suffisante, faire en sorte que les cellules survivent dans le milieu de culture prÃ©sÃ©lectionnÃ©.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>ProcÃ©dÃ© selon la revendication 2 pour cribler des ribozymes mutantes, dans lequel :<claim-text>(a) la pluralitÃ© de vecteurs codent pour des ribozymes mutantes ;</claim-text><claim-text>(b) la survie des cellules dÃ©pend de la coupure d'une structure en boucle en Ã©pingle Ã  cheveux, contenue dans l'ARN messager, par une ribozyme, laquelle coupure altÃ¨re la structure secondaire de l'ARN messager pour libÃ©rer un site de fixation au ribosome et permettre la traduction d'une sÃ©quence de l'ARN<!-- EPO <DP n="57"> --> messager codant pour un polypeptide permettant aux cellules de survivre dans le milieu de culture prÃ©sÃ©lectionnÃ©,<br/>et dans lequel les cellules qui survivent sont sÃ©lectionnÃ©es pour dÃ©terminer la sÃ©quence de nuclÃ©otides des ribozymes mutantes les plus efficaces.</claim-text></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>ProcÃ©dÃ© selon la revendication 2 ou la revendication 3, dans lequel le polypeptide provoque une rÃ©sistance Ã  un antibiotique.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>ProcÃ©dÃ© selon la revendication 4, dans lequel l'ARN messager est un ARN messager de ermC codant pour des polypeptides leaders et mÃ©thylase.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>ProcÃ©dÃ© selon la revendication 5, dans lequel la cellule contient une copie unique du gÃ¨ne ermC.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel le vecteur est un plasmide.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel les cellules sont des bactÃ©ries.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>ProcÃ©dÃ© selon la revendication 8, dans lequel les bactÃ©ries sont <i>B. subtilis</i>.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 2 Ã  9, dans lequel la synthÃ¨se de la ribozyme est sous le contrÃ´le d'un opÃ©rateur et un inducteur est ajoutÃ© en une quantitÃ© qui fait que seules certaines des cellules survivent du fait d'une coupure efficace de l'ARN messager par la ribozyme.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel la ribozyme contient un terminateur de transcription.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>ProcÃ©dÃ© selon la revendication 11, dans lequel le terminateur de transcription est le terminateur de transcription dÃ©pendant de rho majeur du gÃ¨ne comG de <i>B</i>. <i>subtilis</i>.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 2 Ã  12, dans lequel sont prÃ©vues des cellules bactÃ©riennes<!-- EPO <DP n="58"> --> qui expriment un ARN messager qui contient un site de coupure dans une boucle en Ã©pingle Ã  cheveux de l'ARN messager leader de ermC, et la coupure de ce site par une ribozyme provoque un changement dans la structure de l'ARN messager de ermC et libÃ¨re un site de fixation au ribosome pour permettre la synthÃ¨se de mÃ©thylase qui, en quantitÃ© suffisante, fait que les cellules survivent dans un milieu de culture prÃ©sÃ©lectionnÃ© contenant un antibiotique macrolide/lincosamide/streptogramine B (MLS).</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel les ribozymes sont du type Haselhoff-Gerlach.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>ProcÃ©dÃ© selon la revendication 13 ou la revendication 14, dans lequel la sÃ©quence pouvant Ãªtre coupÃ©e par la ribozyme est GUC, GUU ou GUA.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>ProcÃ©dÃ© selon la revendication 15, dans lequel la sÃ©quence pouvant Ãªtre coupÃ©e par la ribozyme est GUC.</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 4 Ã  16, dans lequel les cellules sont cultivÃ©es dans un milieu contenant l'antibiotique MLS tylosine.</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>ProcÃ©dÃ© selon les revendications 4 Ã  17, pour cribler des ribozymes de Haselhoff-Gerlach dans lesquelles le site de coupure est un site de coupure non natif situÃ© aux environs de la position 109 de la boucle en Ã©pingle Ã  cheveux de l'ARN messager leader de ermC, oÃ¹ la coupure de ce site par des ribozymes exprimÃ©es de faÃ§on inductible dans les cellules fait que les cellules survivent dans un milieu de culture prÃ©sÃ©lectionnÃ© contenant de la tylosine.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>ProcÃ©dÃ© selon la revendication 18, dans lequel la sÃ©quence dans la boucle en Ã©pingle Ã  cheveux de ermC qui contient le site pouvant Ãªtre coupÃ© est une sÃ©quence cible qui n'est pas une sÃ©quence naturelle de ermC.</claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>ProcÃ©dÃ© selon la revendication 19, dans lequel la sÃ©quence non-ermC est une sÃ©quence d'ARN de VIH-1.</claim-text></claim><claim id="c-fr-01-0021" num="0021"><claim-text>ProcÃ©dÃ© selon la revendication 20, dans lequel la<!-- EPO <DP n="59"> --> sÃ©quence de VIH-1 provient du gÃªne intergrase.</claim-text></claim><claim id="c-fr-01-0022" num="0022"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel l'expression de la ribozyme est sous le contrÃ´le d'un opÃ©rateur lac.</claim-text></claim><claim id="c-fr-01-0023" num="0023"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel la ribozyme est exprimÃ©e par un plasmide recombinÃ© contenant un promoteur spac.</claim-text></claim><claim id="c-fr-01-0024" num="0024"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel les vecteurs contiennent un ADN codant pour des ribozymes qui est fabriquÃ© sur un synthÃ©tiseur d'ADN qui sÃ©lectionne des prÃ©curseurs de nuclÃ©otides Ã  partir de quatre solutions pour construire les oligonuclÃ©otides par addition pas Ã  pas, et dans lequel un mÃ©lange de nuclÃ©otides est employÃ© dans au moins l'une des quatre solutions afin d'incorporer de faÃ§on alÃ©atoire des nuclÃ©otides durant l'addition pas Ã  pas, ce qui conduit Ã  la gÃ©nÃ©ration de divers oligonuclÃ©otides devant Ãªtre criblÃ©s.</claim-text></claim><claim id="c-fr-01-0025" num="0025"><claim-text>ProcÃ©dÃ© selon la revendication 24, dans lequel des mÃ©langes de prÃ©curseurs d'oligonuclÃ©otides sont employÃ©s dans toutes les quatre solutions.</claim-text></claim><claim id="c-fr-01-0026" num="0026"><claim-text>ProcÃ©dÃ© selon la revendication 25, dans lequel chacun des quatre mÃ©langes de prÃ©curseurs d'oligonuclÃ©otides comprend environ 85 % de prÃ©curseur de type sauvage et environ 5 % de chacun des trois prÃ©curseurs d'oligonuclÃ©otides restants.</claim-text></claim>
EP	0600877	B1	2000-01-26	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0600877&ki=B1&pd=2000-01-26
EP	0611955	B1	2000-01-12	de	TITLE	1	Einrichtung zur Untersuchung der StrÃ¶mungsbewegung in zylindrischen Bauteilen
EP	0611955	B1	2000-01-12	en	TITLE	1	Device for the examination of flow motion inside cylindrical components
EP	0611955	B1	2000-01-12	fr	TITLE	1	Dispositif pour l'examen de l'Ã©coulement d'un fluide dans des piÃ¨ces cylindriques
EP	0611955	B1	2000-01-12	de	DESCR	1	<p id="p0001" num="0001">Die Erfindung bezieht sich auf eine Einrichtung entsprechend dem Oberbegriff des Anspruchs 1, zur Untersuchung der StrÃ¶mungsbewegung in zylindrischen Bauteilen, wie sie insbesondere bei Hubkolbenmotoren eingesetzt wird, um die beim EinstrÃ¶mvorgang in den Zylinder erzeugte Ladungsbewequng zu analysieren .</p><p id="p0002" num="0002">Die bekannten MeÃŸverfahren beziehen sich auf die Untersuchung von DrallstrÃ¶mungen, deren Drehachse parallel zur Zylinderachse liegt. Ãœblicherweise findet man diese DrallstrÃ¶mungen bei Hubkolbenmotoren mit einem EinlaÃŸventil pro Zylinder. Bei diesen Motorkonzepten wird aufgrund der vielfach tangentialen Kanalanordnung diese DrallstrÃ¶mung beim EinstrÃ¶men in den Zylinder wÃ¤hrend der Ansaugphase erzeugt.</p><p id="p0003" num="0003">Bei konventionellen Hubkolbenmotoren mit zwei EinlaÃŸventilen pro Zylinder, die parallel zur Kurbelwellenachse angeordnet sind, wird wegen der symmetrisch aufgebauten EinlaÃŸsysteme keine DrallstrÃ¶mung dieser Art erzeugt. Bei diesen Hubkolbenmotoren dominiert eine StrÃ¶mungsform, deren Drehachse quer zur Zylinderachse angeordnet ist. Die Wirkungsweise dieser StrÃ¶mungsbewequng auf die motorische Verbrennung unterscheidet sich grundlegend von der der DrallstrÃ¶mung.</p><p id="p0004" num="0004">Bei der DrallstrÃ¶mung bewirken die rotatorischen Geschwindigkeitskomponenten, die in idealisierter Vorstellung nach der Drallerhaltung wÃ¤hrend der Kompressionsphase konstant sind, eine Wirbelstabilisierung. Bei StrÃ¶mungsformen mit Drehachse senkrecht zur Zylinderachse erfolgt dagegen durch die Kolbenbewequng ein Zerfall des Hauptwirbels in immer kleinere Partialwirbel. Dieser ZerfallprozeÃŸ transformiert Rotationsenergie in zusÃ¤tzliche Turbulenz, wodurch bei diesen StrÃ¶mungsformen hohe Turbulenzenergie entsteht.<!-- EPO <DP n="2"> --></p><p id="p0005" num="0005">Die unterschiedlichen Ladungsbewegungsformen wirken sich aus auf die Verbrennung, indem sie die Flammengeschwindigkeit als Summe der Brenn- und Transportgeschwindigkei beeinflussen. Intensive StrÃ¶mungen mit Drehachse senkrecht zur Zylinderachse fÃ¼hren durch die starke ErhÃ¶hung der Turbulenz wÃ¤hrend der Kompressionsphase, die eine deutliche AuffÃ¤cherung der FlammenoberflÃ¤che zur Folge hat, zu einer Zunahme der turbulenten Brenngeschwindigkeit.</p><p id="p0006" num="0006">Die Turbulentproduktion ist bei DrallstrÃ¶mungen, also bei StrÃ¶mungen, deren Drehachse parallel zur Zylinderachse liegt, infolge des geringeren Wirbelzerfalls weniger stark ausgeprÃ¤gt. Die daraus resultierende niedrige turbulente Brenngeschwindigkeit wird hier allerdings durch eine stÃ¤rkere Transportbewegung unterstÃ¼tzt, die unmittelbar nach Einleiten der ZÃ¼ndung bei fremdgezÃ¼ndeten Hubkolbenmotoren zu einem schnellen Anwachsen des Flammkerns fÃ¼hrt.</p><p id="p0007" num="0007">Obwohl beide StrÃ¶mungsformen, also DrallstrÃ¶mungen mit Drehachse parallel zur Zylinderachse und Wirbel mit Drehachse senkrecht zur Zylinderachse, zu einer schnellen Verbrennung fÃ¼hren, sind die Wirkungsmechanismen vollkommen verschieden.</p><p id="p0008" num="0008">Der Erfindung liegt die Aufgabe zugrunde, eine Einrichtung zu schaffen, mit der WirbelstrÃ¶mungen, deren Drehachse senkrecht zur Zylinderachse angeordnet sind, in konstruktiv gÃ¼nstiger und meÃŸtechnisch sicherer Weise unmittelbar in einem zylindrischen Bauteil erfaÃŸt und analysiert werden kÃ¶nnen.</p><p id="p0009" num="0009">Diese Aufgabe wird gemÃ¤ÃŸ der Erfindung gelÃ¶st mit den im Kennzeichnungsteil des Anspruchs 1 angegebenen Mitteln.</p><p id="p0010" num="0010">GemÃ¤ÃŸ einer bevorzugten AusfÃ¼hrungsform ist vorgesehen, daÃŸ das zylindrische Bauteil in seiner axialen Richtung in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel bzw. hinter den MeÃŸflÃ¼geln verschlossen ist und das in den zylindrischen Bauteil eintretende StrÃ¶mungsmedium durch wenigstens eine Ã–ffnung in der Wandung des zylindrischen Bauteils austreten kann, deren<!-- EPO <DP n="3"> --> Mittelpunkt bzw. deren Mittelpunkte im wesentlichen mit der Drehachse des MeÃŸflÃ¼gels bzw. den Drehachsen der MeÃŸflÃ¼gel zusammenfÃ¤llt bzw. zusammenfallen.</p><p id="p0011" num="0011">GemÃ¤ÃŸ einer weiteren bevorzugten AusfÃ¼hrungsform ist vorgesehen, daÃŸ das in das zylindrische Bauteil eintretende StrÃ¶mungsmedium durch eine in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel bzw. hinter den MeÃŸflÃ¼geln angeordnete strÃ¶mungsdurchlÃ¤ssige Wandung ausstrÃ¶men kann.</p><p id="p0012" num="0012">Besondere meÃŸtechnische Vorteile sind erreichbar, wenn die Achse des MeÃŸflÃ¼gels bzw. der MeÃŸflÃ¼gel gegenÃ¼ber dem strÃ¶mungsfÃ¼hrenden System in axialer Richtung des zylindrischen Bauteils verschiebbar und um die Achse des zylinderischen Bauteils drehbar ist.</p><p id="p0013" num="0013">Das zylindrische Bauteil kann in zweckmÃ¤ÃŸiger Weise in seiner axialen Richtung in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel bzw. hinter den MeÃŸflÃ¼geln durch eine in der axialen Richtung des Bauteils verschiebbare, strÃ¶mungsundurchlÃ¤ssige Wandung abgeschlossen sein.</p><p id="p0014" num="0014">Auch kann es vorteilhaft sein, daÃŸ die in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel bzw. hinter den MeÃŸflÃ¼geln angeordnete strÃ¶mungsdurchlÃ¤ssige Wandung in axialer Richtung des zylindrischen Bauteils verschiebbar ist.<!-- EPO <DP n="4"> --></p><p id="p0015" num="0015">GemÃ¤ÃŸ einer weiteren bevorzugten AusfÃ¼hrungsform ist vorgesehen, daÃŸ der MeÃŸflÃ¼gel bzw. die MeÃŸflÃ¼gel die Form eines Kreisringes hat bzw. haben.</p><p id="p0016" num="0016">Auch kÃ¶nnen mehrere zur Messung von Parametern der StrÃ¶mungsbewegung geeignete Einrichtungen kombinatorisch zusammenwirkend angeordnet sein, und der Druck in dem zylindrischen Bauteil kann kleiner sein als in StrÃ¶mungsrichtung gesehen der Druck vor dem die StrÃ¶mungsbewegung erzeugenden strÃ¶mungsfÃ¼hrenden System.</p><p id="p0017" num="0017">Weitere meÃŸtechnische Vorteile kÃ¶nnen erreicht werden, wenn das zylindrische Bauteil stationÃ¤r oder instationÃ¤r durchstrÃ¶mt wird.</p><p id="p0018" num="0018">AusfÃ¼hrungsbeispiele der Erfindung werden nachfolgend anhand der Zeichnungen beschrieben.</p><p id="p0019" num="0019">Fig. 1 zeigt eine erste AusfÃ¼hrungsform zur Bestimmung der Bewegung des StrÃ¶mungsmediums senkrecht zur Achse des Zylinders einer Hubkolben-Brennkraftmaschine.</p><p id="p0020" num="0020">Fig. 2 zeigt eine zweite AusfÃ¼hrungsform.</p><p id="p0021" num="0021">Fig. 3 zeigt eine weitere AusfÃ¼hrungsform.</p><p id="p0022" num="0022">Die dargestellten Einrichtungen dienen der Simulation und der Untersuchung der StrÃ¶mungsbewegung in zylindrischen Bauteilen von Hubkolben-Brennkraftmaschinen, also vor allem in den Zylindern, in denen die Verbrennung des Brennstoff/Luft-Gemisches erfolgt. Es soll dabei die Ladungsbewegung senkrecht zur Zylinderachse 1 untersucht werden.</p><p id="p0023" num="0023">Diesem Zweck dient ein zylindrisches Bauteil 2, dessen Innendurchmesser dem Innendurchmesser eines Zylinders einer Brennkraftmaschine entspricht, deren Eigenschaften zu untersuchen sind. Am oberen Teil, also in StrÃ¶mungsrichtung vor dem zylindrischen Bauteil 2, sind<!-- EPO <DP n="5"> --> die strÃ¶mungsfÃ¼hrenden Teile des Hubkolbenmotors angeordnet, insbesondere EinlaÃŸkanÃ¤le 3 und Ventile 4, deren Hub entsprechend der Arbeitsweise des Hubkolbenmotors eingestellt wird. Als VerschluÃŸ des zylindrischen Bauteils 2 in axialer Richtung dient ein Kolben 5, der in radialer Richtung entsprechend den Betriebsbedingungen des zu untersuchenden Motors gegenÃ¼ber dem (nicht dargestellten) Zylinderkopf passend angeordnet ist. In axialer Richtung wird die Position des Kolbens 5 entsprechend der tatsÃ¤chlichen Zuordnung zum Ventilhub wÃ¤hrend der Ansaugphase eingestellt.</p><p id="p0024" num="0024">Etwa in gleichem Abstand zwischen dem Zylinderkopf und dem Kolben 5 befindet sich ein MeÃŸflÃ¼gel 7, der um seine Achse 6 drehbar ist. Die Achse 6 des MeÃŸflÃ¼gels 7 ist senkrecht zur Zylinderachse 1 angeordnet. Durch ein extern erzeugtes DruckgefÃ¤lle angetrieben strÃ¶mt Luft stationÃ¤r durch die EinlaÃŸkanÃ¤le 3 in das zylindrische Bauteil 2 ein, und sie kann aus dem zylindrischen Bauteil 2 Ã¼ber Ã–ffnungen 8 in der Wandung des zylindrischen Bauteils 2 abstrÃ¶men. Dadurch wird der MeÃŸflÃ¼gel 7, der vorzugsweise die Form eines Kreisrings hat, in Drehung versetzt. Die Luft verlÃ¤ÃŸt das zylindrische Bauteil 2 in Richtung der Achse 6 des MeÃŸflÃ¼gels 7 durch die Ã–ffnungen 8.</p><p id="p0025" num="0025">Die Achse bzw. Welle 6 des MeÃŸflÃ¼gels 7 ist mit einer Einrichtung 20 zur Auswertung der Drehfrequenz und/oder der Winkelstellung des MeÃŸflÃ¼gels 7 zur Bestimmung eines oder mehrerer Parameter der StrÃ¶mungsbewegung in dem zylindrischen Bauteil 2 verbunden.</p><p id="p0026" num="0026">Die in Fig. 2 dargestellte AusfÃ¼hrungsform unterscheidet sich von der AusfÃ¼hrungsform nach Fig. 1 dadurch, daÃŸ Kolben 9 strÃ¶mungsdurchlÃ¤ssig ist. Zu diesem Zweck kÃ¶nnen beispielsweise Bohrungen 10 in dem Boden des Kolbens 9 vorhanden sein. Hierdurch ergeben sich im Vergleich zu der AusfÃ¼hrungsform nach Fig. 1 andere AusstrÃ¶mverhÃ¤ltnisse aus dem zylindrischen Bauteil 2.</p><p id="p0027" num="0027">Bei beiden AusfÃ¼hrungsformen ist zur Untersuchung der StrÃ¶mungsbewegung in einem zylindrischen Rohr, die von in StrÃ¶mungsrichtung<!-- EPO <DP n="6"> --> gesehen vor dem zylindrischen Rohr befindlichen strÃ¶mungsfÃ¼hrenden Bauteilen, also im wesentlichen den Teilen 3 und 4, erzeugt wird, mindestens ein MeÃŸflÃ¼gel in diesem zylindrischen Rohr drehbar gelagert, dessen Drehachse die Achse des zylindrischen Rohres unter einem einstellbaren Winkel schneidet, und der von OÂ° verschieden ist.</p><p id="p0028" num="0028">Mit einem derartigen MeÃŸsystem kÃ¶nnen die strÃ¶mungstechnischen VorgÃ¤nge im Zylinder von Hubkolbenmotoren auf einfache Weise nachgebildet und fÃ¼r das Brennverfahren wichtige StrÃ¶mungscharakteristiken detailliert beobachtet werden.</p><p id="p0029" num="0029">Zur Bestimmung der WirbelstÃ¤rke in Bezug auf eine beliebig im zylindrischen Rohr orientierte Bezugsachse wird die FlÃ¼gelachse entsprechend ausgerichtet und die FlÃ¼geldrehzahl gemessen. Hierbei wird bei der AusfÃ¼hrungsform nach Fig. 1 durch die Ã–ffnungen 8 in der Zylinderwand, deren Mittelpunkte mit der Drehachse 6 des MeÃŸflÃ¼gels 7 im wesentlichen zusammenfallen, sichergestellt, daÃŸ der gesamte Massenstrom und damit auch der Drehimpulsanteil der strÃ¶mungsbewegung bezÃ¼glich der Wirbelachse durch den MeÃŸflÃ¼gel 7 erfaÃŸt wird.</p><p id="p0030" num="0030">Die MeÃŸflÃ¼gelgeometrie wird so gewÃ¤hlt, daÃŸ nur die zur Drehachse 6 tangentialen Geschwindigkeitsanteile die FlÃ¼geldrehzahl beeinflussen. Hierdurch wird sichergestellt, daÃŸ die gemessene Drehzahl proportional zum gesamten Drehimpuls der StrÃ¶mung bezogen auf die Drehachse des MeÃŸflÃ¼gels 7 ist und damit die Ãœbertragbarkeit auf die VerhÃ¤ltnisse im Motorbetrieb gewÃ¤hrleistet ist. Die FlÃ¼gelanordnung unmittelbar im Zylinderrohr ist von besonderer Bedeutung, da hierdurch die Wirbelkomponenten direkt gemessen werden und die Bestimmung des fÃ¼r eine energetische Betrachtung erforderlichen tatsÃ¤chlichen Geschwindigkeitsniveaus der WirbelstrÃ¶mung ermÃ¶glicht wird.</p><p id="p0031" num="0031">Die in Figur 3 dargestellte AusfÃ¼hrungsform unterscheidet sich von der AusfÃ¼hrungsform nach den Fig. 1 und 2 dadurch, daÃŸ anstelle des MeÃŸflÃ¼gels 7 mit Drehachse 6 mehrere MeÃŸflÃ¼gel 14, 15, 16 mit<!-- EPO <DP n="7"> --> den jeweiligen Drehachsen 11, 12, 13, die voneinander unabhÃ¤ngig drehbar gelagert sind und deren Drehzahl einzeln gemessen wird, vorhanden sind.</p><p id="p0032" num="0032">Durch den Einsatz mehrerer MeÃŸflÃ¼gel 14, 15, 16 kann das StrÃ¶mungsprofil der WirbelstrÃ¶mung untersucht werden. Die so gewonnenen Informationen Ã¼ber die StrÃ¶mungsstruktur kÃ¶nnen zur Interpretation der MischungsvorgÃ¤nge bei einstrÃ¶menden Kraftstoff-Luftgemischen genutzt werden.</p><p id="p0033" num="0033">Da je nach der geometrischen AusfÃ¼hrung des zu untersuchenden strÃ¶mungsfÃ¼hrenden Bauteils beim EinstrÃ¶men in das zylindrische Rohr der StrÃ¶mung mit Drehachse senkrecht zur Zylinderachse auch StrÃ¶mungskomponenten mit Drehachse parallel zur Zylinderachse Ã¼berlagert sein kÃ¶nnen, ist der Winkel zwischen der Drehachse des MeÃŸflÃ¼gels 7 und der Zylinderachse 1 einstellbar. ZusÃ¤tzlich ist der MeÃŸflÃ¼gel 7 hinsichtlich des Abstands zum strÃ¶mungsfÃ¼hrenden Bauteil in axialer Richtung des zylindrischen Rohres verschiebbar und die MeÃŸflÃ¼gelachse um die Zylinderachse drehbar. Die VariabilitÃ¤t der MeÃŸflÃ¼gelposition schafft die MÃ¶glichkeit, neben der IntensitÃ¤t eines beim EinstrÃ¶men in das Zylinderrohr erzeugten Wirbels auch dessen genaue Ausrichtung zu ermitteln, die durch die maximale FlÃ¼geldrehzahl gekennzeichnet ist. So kÃ¶nnen in vorteilhafter Weise komplexere StrÃ¶mungsformen, die nach EinfÃ¼hrung der Mehrventiltechnologie in verstÃ¤rktem MaÃŸe auftreten, untersucht werden.</p><p id="p0034" num="0034">Ein weiterer wichtiger Vorteil kann durch die BerÃ¼cksichtigung der geometrischen EinfluÃŸparameter durch Nachbilden der exakten Zylindergeometrie des Hubkolbenmotors einschlieÃŸlich der Ablenkung der StrÃ¶mung am Kolben erreicht werden. Hierzu wird das zylindrische Rohr 2 durch den Kolben 5 eines Hubkolbenmotors oder eine Nachbildung in axialer Richtung in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel 7 bzw. den MeÃŸflÃ¼geln 14, 15, 16 verschlossen. In Verbindung mit dem Austritt der StrÃ¶mung durch die Ã–ffnungen 8 der Zylinderwand, deren Mittelpunkt im wesentlichen mit der Drehachse 6 des MeÃŸflÃ¼gels 7<!-- EPO <DP n="8"> --> bzw. der Drehachsen 11, 12, 13 der MeÃŸflÃ¼gel 14, 15, 16 zusammenfÃ¤llt, bzw. zusammenfallen, werden im stationÃ¤ren MeÃŸbetrieb RÃ¼ckwirkungen auf die Ausbildung der WirbelstrÃ¶mung vermieden. Hierdurch wird die Ãœbertragbarkeit der MeÃŸergebnisse auf den Motorbetrieb sichergestellt.</p><p id="p0035" num="0035">Bei der AusfÃ¼hrungsform gemÃ¤ÃŸ Fig. 2 verschlieÃŸt der strÃ¶mungsdurchlÃ¤ssige Kolben 9, der in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel 7 bzw. hinter den MeÃŸflÃ¼geln angeordnet ist, das zylindrische Rohr 2 in axialer Richtung. Der Vorteil dieser AusfÃ¼hrungsform besteht darin, daÃŸ im stationÃ¤ren Betrieb des MeÃŸverfahrens der durch den durchlÃ¤ssigen Kolben 9 entweichende StrÃ¶mungsanteil im Motorbetrieb dem Anteil der in den Zylinder einstrÃ¶menden Masse entspricht, der das beim Ansaugvorgang durch den abwÃ¤rts bewegten Kolben hinzukommende Zylindervolumen fÃ¼llt.</p><p id="p0036" num="0036">In vorteilhafter Weise ermÃ¶glicht die axiale Verschiebung der Position des in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel 7 bzw. den MeÃŸflÃ¼geln angebrachten Verschlusses bzw. strÃ¶mungdurchlÃ¤ssigen Kolbens 9 die Untersuchung des Einflusses der Kolbenstellung auf die StrÃ¶mungsbewegung im Zylinder. Diese Vorgehensweise ist zur KlÃ¤rung der detaillierten VorgÃ¤nge wÃ¤hrend der Ansaugphase, bei der sich infolge der Kolbenbewegung die Geometrie des Zylinderraums stÃ¤ndig Ã¤ndert, von groÃŸer Bedeutung.</p><p id="p0037" num="0037">Um die fÃ¼r den EinstrÃ¶mvorgang in das zylindrische Bauteil 2 der MeÃŸeinrichtung erforderliche Druckdifferenz zu erzeugen, wird der Druck im zylindrischen Bauteil 2 geringer als der Umgebungsdruck eingestellt. Diese Druckdifferenz kann entweder durch Absenkung des Drucks im zylindrischen Bauteil 2 oder durch ErhÃ¶hung des Drucks vor dem zu untersuchenden strÃ¶mungsfÃ¼hrenden Bauteil erzeugt werden.</p><p id="p0038" num="0038">In vorteilhafter Weise kann die StrÃ¶mungsmessung bei stationÃ¤rer DurchstrÃ¶mung durchgefÃ¼hrt werden. Der konstruktive Aufbau der MeÃŸeinrichtung stellt hierbei die gute Ãœbertragbarkeit der ermittelten MeÃŸwerte auf den Motorbetrieb sicher.<!-- EPO <DP n="9"> --></p><p id="p0039" num="0039">In einer anderen vorteilhaften Betriebsweise kann die MeÃŸeinrichtung instationÃ¤r durchstrÃ¶mt werden, um dabei zusÃ¤tzlich gasdynamische Effekte zu erfassen.</p><p id="p0040" num="0040">Es kÃ¶nnen auch mehrere gleichartige Einrichtungen zur Untersuchung der StrÃ¶mungsbewegungen in zylindrischen Rohren kombiniert werden, so daÃŸ beispielsweise ein Vollmotorzylinderkopf als strÃ¶mungsfÃ¼hrendes Bauteil auf allen Zylindern gleichzeitig durchstrÃ¶mt wird.</p>
EP	0611955	B1	2000-01-12	de	CLAIM	1	<claim id="c-de-01-0001" num="0001"><claim-text>Einrichtung zur Untersuchung der StrÃ¶mungsbewegung eines StrÃ¶mungsmediums in einem zylindrischen Bauteil (2) einer Hubkolben-Brennkraftmaschine,wobei die StrÃ¶mungsbewegung von einem in StrÃ¶mungsrichtung gesehen vor dem zylindrischen Bauteil (2) befindlichen strÃ¶mungsfÃ¼hrenden System (3, 4) erzeugt wird, dadurch gekennzeichnet, daÃŸ in dem zylindrischen Bauteil (2) wenigstens ein MeÃŸflÃ¼gel (7) drehbar gelagert ist, der mit einer Welle (6) verbunden ist, deren Drehachse die Achse (1 ) des zylindrischen Bauteils (2) unter einem einstellbaren, von 0Â° verschiedenen Winkel schneidet, und daÃŸ die Welle (6) mit einer Einrichtung (20) zur Auswertung der Drehfrequenz des MeÃŸflÃ¼gels (7) zur Bestimmung eines oder mehrerer Parameter der StrÃ¶mungsbewegung verbunden ist.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Einrichtung nach Anspruch 1, dadurch gekennzeichnet, daÃŸ das zylindrische Bauteil (2) in seiner axialen Richtung in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel (7) bzw. hinter den MeÃŸflÃ¼geln (14, 15, 16) verschlossen ist und das in das zylindrische Bauteil (2) eintretende StrÃ¶mungsmedium durch wenigstens eine Ã–ffnung (8) in der Wandung des zylindrischen Bauteils (2) austreten kann, deren Mittelpunkt im wesentlichen mit der Drehachse (6) des MeÃŸflÃ¼gels (7) bzw. den Drehachsen (11, 12, 13) der MeÃŸflÃ¼gel (14, 15. 16) zusammenfÃ¤llt bzw. zusammenfallen.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Einrichtung nach Anspruch 1, dadurch gekennzeichnet, daÃŸ das in das zylindrische Bauteil (2) eintretende StrÃ¶mungsmedium durch eine in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel (7) bzw. hinter den MeÃŸflÃ¼geln (14, 15, 16) angeordnete strÃ¶mungsdurchlÃ¤ssige Wandung (9) ausstrÃ¶men kann.<!-- EPO <DP n="11"> --></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Einrichtung nach Anspruch 1, dadurch gekennzeichnet, daÃŸ die Achse (6) des MeÃŸflÃ¼gels (7) bzw. der MeÃŸflÃ¼gel (14, 15, 16) gegenÃ¼ber dem strÃ¶mungsfÃ¼hrenden System (3, 4) in axialer Richtung des zylindrischen Bauteils (2) verschiebbar und um die Achse (1 ) des zylindrischen Bauteils (2) drehbar ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Einrichtung nach Anspruch 2, dadurch gekennzeichnet, daÃŸ das zylindrische Bauteil (2) in seiner axialen Richtung in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel (7) bzw. hinter den MeÃŸflÃ¼geln (14, 15, 16) durch eine in der axialen Richtung des Bauteils (2) verschiebbare, strÃ¶mungsundurchlÃ¤ssige Wandung (5) abgeschlossen ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Einrichtung nach Anspruch 3, dadurch gekennzeichnet, daÃŸ die in StrÃ¶mungsrichtung gesehen hinter dem MeÃŸflÃ¼gel (7) bzw. hinter den MeÃŸflÃ¼geln (14, 15, 16) angeordnete strÃ¶mungsdurchlÃ¤ssige Wandung (9) in axialer Richtung des zylindrischen Bauteils (2) verschiebbar ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Einrichtung nach Anspruch 1, dadurch gekennzeichnet, daÃŸ der MeÃŸflÃ¼gel (7) bzw. die MeÃŸflÃ¼gel (14, 15) die Form eines Kreisringes hat bzw. haben.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verfahren zum Betrieb einer Einrichtung zur Untersuchung der StrÃ¶mungsbewegung in einem zylindrischen Bauteil entsprechend Anspruch 1, dadurch gekennzeichnet, daÃŸ das zylindrische Bauteil (2) stationÃ¤r durchstrÃ¶mt wird.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verfahren zum Betrieb einer Einrichtung zur Untersuchung der StrÃ¶mungsbewegung in einem zylindrischen Bauteil entsprechend Anspruch 1, dadurch gekennzeichnet, daÃŸ daÃŸ zylindrische Bauteil (2) instationÃ¤r durchstrÃ¶mt wird.</claim-text></claim>
EP	0611955	B1	2000-01-12	en	CLAIM	2	<claim id="c-en-01-0001" num="0001"><claim-text>An apparatus for investigating the flow motion of a flow medium within a cylindrical component (2) of a reciprocating internal combustion engine, wherein the flow motion is generated by a flow-guiding system (3, 4) located in front of the cylindrical component (2) when viewed in the direction of flow, characterised in that at least one hydrometric vane (7) is rotatably mounted in the cylindrical component (2), which vane is connected to a shaft (6), the axis of rotation of which intersects the axis (1) of the cylindrical component (2) at an adjustable angle which is other than 0Â°, and that the shaft (6) is connected to an apparatus (20) for evaluating the rotary frequency of the hydrometric vane (7) to determine one or more parameters of the flow motion.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>An apparatus according to Claim 1, characterised in that the cylindrical component (2) is closed in its axial direction, when viewed in the direction of flow, after the hydrometric vane (7) or after the hydrometric vanes (14, 15, 16), and the flow medium entering the cylindrical component (2) can emerge through at least one opening (8) in the walls of the cylindrical component (2), the centre point of which substantially coincides with the axis of rotation (6) of the hydrometric vane (7) or the axes of rotation (11, 12, 13) of the hydrometric vanes (14, 15, 16).</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>An apparatus according to Claim 1, characterised in that the flow medium entering the cylindrical component (2) can flow out through a flow-permeable wall (9) located after the hydrometric vane (7) or after the hydrometric vanes (14, 15, 16), when viewed in the direction of flow.<!-- EPO <DP n="13"> --></claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>An apparatus according to Claim 1, characterised in that the axis (6) of the hydrometric vane (7) or of the hydrometric vanes (14, 15, 16) is displaceable relative to the flow-guiding system (3, 4) in the axial direction of the cylindrical component (2) and is rotatable about the axis (1) of the cylindrical component (2).</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>An apparatus according to Claim 2, characterised in that the cylindrical component (2) is closed in its axial direction, when viewed in the direction of flow, after the hydrometric vane (7) or after the hydrometric vanes (14, 15, 16), by a wall (5) impermeable to the flow which is displaceable in the axial direction of the component (2).</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>An apparatus according to Claim 3, characterised in that the flow-permeable wall (9) which, when viewed in the direction of flow, is located after the hydrometric vane (7) or after the hydrometric vanes (14, 15, 16), is displaceable in the axial direction of the cylindrical component (2).</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>An apparatus according to Claim 1, characterised in that the hydrometric vane (7) or the hydrometric vanes (14, 15) is or are in the form of a circular ring.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A method for operating an apparatus for investigating the flow motion within a cylindrical component in accordance with Claim 1, characterised in that the flow passing through the cylindrical component (2) is a steady flow.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A method for operating an apparatus for investigating the flow motion within a cylindrical component in accordance with Claim 1, characterised in<!-- EPO <DP n="14"> --> that the flow passing through the cylindrical component (2) is a non-steady flow.</claim-text></claim>
EP	0611955	B1	2000-01-12	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Dispositif pour l'examen de l'Ã©coulement d'un fluide dans une piÃ¨ce cylindrique (2) d'un moteur alternatif Ã  combustion interne, l'Ã©coulement du fluide Ã©tant gÃ©nÃ©rÃ© par un systÃ¨me (3, 4) guidant l'Ã©coulement se trouvant devant la piÃ¨ce cylindrique (2), vu dans le sens de l'Ã©coulement, caractÃ©risÃ© en ce que, dans la piÃ¨ce cylindrique (2), il est prÃ©vu au moins un moulinet hydromÃ©trique (7) qui est montÃ© en rotation et qui est assemblÃ© avec un arbre (6) dont l'axe de rotation coupe l'axe (1) de la piÃ¨ce cylindrique (2) selon un angle rÃ©glable, diffÃ©rent de 0Â°, et en ce que l'arbre (6) est assemblÃ© avec un dispositif (20) d'analyse de la frÃ©quence de rotation du moulinet hydromÃ©trique (7) pour la dÃ©termination d'un ou de plusieurs paramÃ¨tres de l'Ã©coulement.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Dispositif selon la revendication 1, caractÃ©risÃ© en ce que la piÃ¨ce cylindrique (2) est fermÃ©e dans son sens axial, vu dans le sens de l'Ã©coulement, derriÃ¨re le moulinet hydromÃ©trique (7) respectivement derriÃ¨re les moulinets hydromÃ©triques (14, 15, 16) et en ce que le fluide pÃ©nÃ©trant dans la piÃ¨ce cylindrique (2) peut sortir par au moins une ouverture (8) dans la paroi de la piÃ¨ce cylindrique (2) dont le centre coÃ¯ncide en substance avec l'axe de rotation (6) du moulinet hydromÃ©trique (7) respectivement les axes de rotation (11, 12, 13) des moulinets hydromÃ©triques (14, 15, 16).</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Dispositif selon la revendication 1, caractÃ©risÃ© en ce que le fluide pÃ©nÃ©trant dans la piÃ¨ce cylindrique (2) peut s'Ã©couler Ã  travers une paroi (9) permÃ©able Ã  l'Ã©coulement et disposÃ©e, vu dans le sens de l'Ã©coulement, derriÃ¨re le<!-- EPO <DP n="16"> --> moulinet hydromÃ©trique (7) respectivement derriÃ¨re les moulinets hydromÃ©triques (14, 15, 16).</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Dispositif selon la revendication 1, caractÃ©risÃ© en ce que l'axe (6) du moulinet hydromÃ©trique (7) respectivement des moulinets hydromÃ©triques (14, 15, 16) est mobile dans le sens axial de la piÃ¨ce cylindrique (2) et pivote autour de l'axe (1) de la piÃ¨ce cylindrique (2).</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Dispositif selon la revendication 2, caractÃ©risÃ© en ce que la piÃ¨ce cylindrique (2) est fermÃ©e dans son sens axial, vu dans le sens de l'Ã©coulement, derriÃ¨re le moulinet hydromÃ©trique (7) respectivement derriÃ¨re les moulinets hydromÃ©triques (14, 15, 16), par une paroi (5) mobile dans le sens axial de la piÃ¨ce (2) et impermÃ©able Ã  l'Ã©coulement.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Dispositif selon la revendication 3, caractÃ©risÃ© en ce que la paroi (9) permÃ©able Ã  l'Ã©coulement et disposÃ©e, vu dans le sens d'Ã©coulement, derriÃ¨re le moulinet hydromÃ©trique (7) respectivement derriÃ¨re les moulinets hydromÃ©triques (14, 15, 16) est mobile dans le sens axial de la piÃ¨ce cylindrique (2).</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Dispositif selon la revendication 1, caractÃ©risÃ© en ce que le moulinet hydromÃ©trique (7) respectivement les moulinets hydromÃ©triques (14, 15) a (ou ont) la forme d'un anneau circulaire.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>ProcÃ©dÃ© d'utilisation d'un dispositif pour l'examen de l'Ã©coulement dans une piÃ¨ce cylindrique selon la revendication 1, caractÃ©risÃ© en ce que la piÃ¨ce cylindrique (2) est traversÃ©e de faÃ§on stationnaire.<!-- EPO <DP n="17"> --></claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>ProcÃ©dÃ© d'utilisation d'un dispositif pour l'examen de l'Ã©coulement dans une piÃ¨ce cylindrique selon la revendication 1, caractÃ©risÃ© en ce que la piÃ¨ce cylindrique (2) est traversÃ©e de faÃ§on non-stationnaire.</claim-text></claim>
EP	0611955	B1	2000-01-12	de	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0611955&ki=B1&pd=2000-01-12
EP	0603422	B1	2000-05-24	de	TITLE	1	Verschleissteil und Verfahren zu seiner Herstellung
EP	0603422	B1	2000-05-24	en	TITLE	1	Wear component and method of making same
EP	0603422	B1	2000-05-24	fr	TITLE	1	PiÃ¨ce d'usure et son procÃ©dÃ© de fabrication
EP	0603422	B1	2000-05-24	en	DESCR	1	<p id="p0001" num="0001">This invention relates to a wear component and a method of making same. Furthermore, the invention relates to a method for producing synthetic diamond for use as a wear surface, and a method of investigating synthetic diamond to be utilized as a wear surface.</p><p id="p0002" num="0002">The use of natural diamond in wear components, such as in cutting and grinding tools, is very old. In addition to extreme hardness, diamond's superlative thermal conductivity, thermal stability, and inertness are unsurpassed for wear applications. In recent times synthetic polycrystalline diamond films have been successfully produced, such as by chemical vapor deposition (CVD), and used commercially in wear applications. The synthetic diamond films can be deposited directly on the base of a wear component, for example as a thin film (generally defined as a film having a thickness of less than 20 Âµm), or produced separately, generally as a thick film, and mounted on the base of a wear component, such as by brazing.</p><p id="p0003" num="0003">Even exceedingly hard diamond surfaces have a limited wear life, and the wear life of synthetic diamond, which can vary considerably for different synthetic diamond material, is a key factor in the cost-effectiveness of a wear component. A number of factors are recognized as affecting the wear life of synthetic diamond. The presence of foreign matter, voids, and cracks are all usually deleterious to the wear resistance of diamond. In this context, foreign matter also includes carbon not possessing the diamond structure, such as graphite.<!-- EPO <DP n="2"> --></p><p id="p0004" num="0004">Document EP 0 379 220 A1 discloses a diamond coated sintered body characterized by having a diamond film formed by a gas phase synthesis method on the surface of a sintered body obtained from a mixture of tungsten carbide and at least one compound selected from the group consisting of carbide and nitride of silicon or boron and, if necessary, additionally at least one compound selected from the group consisting of carbide, oxide, nitride, carbonitride, carbonate, boride and organic compound of at least one element selected from the group consisting of metals and rare earth elements belonging to Groups Ia, IIa, IIIa, IVa, Va, IIIb and IVb of the Mendelejeff's periodic table.</p><p id="p0005" num="0005">However, wear resistance of the diamond film is not addressed.</p><p id="p0006" num="0006">Document EP 0 449 571 A1 discloses a polycrystalline diamond tool wherein polycrystalline diamond has non-uniform quality along the direction of thickness. The diamond near the rake surface is of better quality. The diamond near the fixation surface is of worse quality. The worse diamond near the fixation surface alleviates a strong stress or absorbs an external shock. Owing to the worse diamond near the fixation surface, the diamond tool excels in chip resistance or toughness. The better diamond near the rake surface heightens abrasion resistance, adhesion resistance and strength.</p><p id="p0007" num="0007">Document EP 0 319 926 A2 discloses a method for the preparation of a diamond-clad machining tool. The diamond-clad machining tool of the invention is prepared by the steps of (a) forming a film of diamond of 10 to 1000 Âµm thickness by the method of vapor-phase deposition on the surface of a temporary substrate of, e.g., silicon, (b) bonding the diamond film as borne by the temporary substrate to the surface of a base body of the tool by brazing and (c) removing the temporary substrate, e.g., by grinding to leave<!-- EPO <DP n="3"> --> the diamond film bonded to the base body of the tool by brazing. The method is advantageous in the versatility in respect of the material of substrate on which a diamond film is deposited from the vapor phase as well as in the firmness of bonding between the cladding layer and the base body of the tool in comparison with the conventional vapor-phase deposition method of diamond directly to the surface of the base body of a tool.</p><p id="p0008" num="0008">Improvement of the wear resistance of the diamond film is not discussed in this document.</p><p id="p0009" num="0009">It is therefore the object of the present invention to provide synthetic diamond having improved wear properties. A further object is to provide an improved method of making such diamond.</p><p id="p0010" num="0010">These objects are solved by the method of making a wear component according to independent claim 7, a wear component according to independent claim 1, the method for producing synthetic diamond for use as a wear surface according to independent claim 16. Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description, examples and the drawings.</p><p id="p0011" num="0011">Generally spoken, the invention provides improvements in wear components comprising synthetic diamond wear surfaces and a method of making such improved wear components. Particularly, the invention provides improved synthetic diamonds for use in wear components and methods of making such diamond.<!-- EPO <DP n="4"> --></p><p id="p0012" num="0012">Applicant has discovered that the wear properties of synthetic diamond are related to the equivalent strain in the diamond crystal structure in an unexpected way, and this discovery is utilized in the invention to produce diamond with superior wear characteristics, as well as to monitor and modify processes of diamond deposition to obtain improved wear surfaces and wear components. [As used herein, a wear surface is intended to mean a surface employed for tribological application; for example, without limitation, a cutting surface, a grinding surface, a bearing surface or a valve surface. A wear component is intended to mean a wear surface secured to a base element; for example, without limitation, a cutting component, a grinding component, a bearing component, or a valve component.] Surprisingly, a certain minimum equivalent strain in the crystal lattice (that is, a displacement of atom positions with respect to positions they would occupy in a perfect lattice) results in improvement of the wear characteristics of synthetic diamond, rather than a degrading of wear characteristics that might be expected from lattice imperfection. In most ceramic applications, less perfect crystals exhibit poorer wear resistance.</p><p id="p0013" num="0013">A relatively high thermal conductivity can contribute to improvement of the wear characteristics of synthetic diamond.<!-- EPO <DP n="5"> --> Applicant has demonstrated that the obtainment of diamond having substantial equivalent strain improves wear characteristics for synthetic diamond film of a given thermal conductivity. Measurements of equivalent strain can also be used in the monitoring and control of synthetic diamond film production and in selection of synthetic diamond for wear applications.</p><p id="p0014" num="0014">In accordance with a form of the invention, a method is set forth for making a wear component. A base surface is provided. A synthetic diamond film is produced, the film having a thickness of at least 20 Âµm and an equivalent strain of at least 0.08 percent. The synthetic diamond film is applied to the base surface. The film can be deposited directly on the base surface, for example by having the base surface be the target surface in a chemical vapor deposition system. More typically, for thick film synthetic diamond, the film can be separately produced and then mounted on the base surface, such as by brazing a piece of synthetic diamond film to a tungsten carbide base surface in a manner well known in the art.</p><p id="p0015" num="0015">It is preferable to form a diamond film wear surface having a thermal conductivity of at least about 9 W/cmÂ°K. For thermal conductivities less than about 9 W/cmÂ°K, the diamond film should be formed with an equivalent strain of at least about 0.10 percent to exhibit improved wear characteristics in accordance with the principles hereof.</p><p id="p0016" num="0016">In a further form of the invention, there is set forth a<!-- EPO <DP n="6"> --> method for producing synthetic diamond film for use as a wear surface. Synthetic diamond is formed by chemical vapor deposition using initial deposition parameters. The equivalent strain of the diamond film is monitored, for example by measuring equivalent strain of each sample produced or of a sample from a produced batch. The deposition parameters are then modified when the equivalent strain of the synthetic diamond is less than a predetermined minimum percentage. In an embodiment hereof, the minimum equivalent strain percentage is about 0.08 percent. In a form of the invention, the thermal conductivity of the diamond is also measured. In this embodiment, the referenced minimum equivalent strain percentage is about 0.08 percent when the thermal conductivity is greater than about 9 W/cmÂ°K, and the referenced minimum equivalent strain percentage is about 0.10 percent when the thermal conductivity is less than about 9 W/cmÂ°K. The deposition parameters to be modified include at least one parameter selected from the group consisting of the ratio of feedstock gases for chemical vapor deposition and the deposition temperature.</p><p id="p0017" num="0017">In accordance with a further form of the invention, a method is set forth for inspecting synthetic diamond to be utilized as a wear surface to select synthetic diamond that is expected to have superior wear properties. In accordance with this method, synthetic diamond having an equivalent strain of greater than a predetermined percentage is selected for use in certain wear<!-- EPO <DP n="7"> --> application(s), whereas the synthetic diamond that does not meet the predetermined criteria (as described above) can be used for applications where the superior wear properties are not required, such as in lower cost wear components.</p><p id="p0018" num="0018">Further features and advantages of the invention will become more readily apparent from the following detailed description when taken in conjunction with the accompanying drawings.<!-- EPO <DP n="8"> --><ul id="ul0001" list-style="none" compact="compact"><li>Fig. 1 is a schematic diagram of a plasma jet deposition system of a type which can be utilized in practicing an embodiment of the invention.</li><li>Fig. 2 is a top view of a wear component of a type typically utilized as an insert for a milling machine cutting tool.</li><li>Fig. 3 is a side view of the wear component of Fig. 2.</li><li>Fig. 4 is an operational flow diagram of a procedure in accordance with an embodiment of the invention for producing synthetic diamond having improved wear characteristics.</li><li>Fig. 5 is an operational flow diagram of a procedure of the invention for selecting synthetic diamond based on suitability for wear applications.</li></ul><!-- EPO <DP n="9"> --></p><p id="p0019" num="0019">Referring to Fig. 1, there is shown a diagram of a plasma jet deposition system 200 of a type which can be utilized in practicing an embodiment of the invention. Reference can also be made to U.S. Patent No.s 4,471,003 and 4,487,162. The system 200 is contained within a vacuum housing 211 and includes an arc-forming section 215 which comprises a cylindrical anode 291, a rod-like cathode 292, and an injector 295 mounted adjacent the cathode so as to permit injected fluid to pass over the cathode 292. In the illustrated system the input fluid may be a mixture of hydrogen and methane. The anode 291 and cathode 292 are energized by a source of electric potential (not shown), for example a DC potential. Cylindrical magnets, designated by reference numeral 217, are utilized to control the plasma generated at the arc forming section. The magnets maintain the plasma within a narrow column until the plasma reaches the deposition region 60. Cooling coils 234, in which liquid nitrogen can be circulated, are located within the magnets and surround the focused plasma.</p><p id="p0020" num="0020">In operation, a mixture of hydrogen and methane is fed to the injector 295, and a plasma is obtained in front of the arc forming section and accelerated and focused toward the deposition region. The temperature and pressure at the plasma formation region are typically in the approximate ranges 1500-2700 Â°C<!-- EPO <DP n="10"> --> and 133-931 mbar (100-700 torr), respectively, and in the deposition region are in the approximate ranges 800-1100Â°C and 13.3-266 mbar (10-200 torr), respectively. As is known in the art, synthetic polycrystalline diamond can be formed from the described plasma, as the carbon in the methane is selectively deposited as diamond, and the graphite which forms is dissipated by combination with the hydrogen facilitating gas.</p><p id="p0021" num="0021">The bottom portion 105A of the chamber has a base 106 that can mount a medium 62 on which the synthetic diamond is to be deposited. The base can include a temperature controller. The medium 62 may be, for example, the base of a tool, an insert for a tool, the base of a bearing surface, etc. Alternatively, the medium 62 can be a substrate, such as molybdenum or graphite, on which synthetic diamond can be deposited, removed, and applied to a base to form a wear surface, such as for a tool or bearing or other wear component.</p><p id="p0022" num="0022">Figs. 2 and 3 illustrate an example of a wear component 20 of a type typically utilized as an insert for a milling machine. A tungsten carbide element or body 24 is provided in a generally rectangular shape with a chamfered corner having a depression 26 that receives a piece of diamond 28 that serves as a cutter. As is known in the art, the diamond 28 can be synthetic polycrystalline diamond film. The diamond can be deposited directly on the element 24 or, more typically for diamond thick films, a piece of synthetic diamond film that is mounted, such as<!-- EPO <DP n="11"> --> by brazing, on the element 24.</p><p id="p0023" num="0023">In accordance with the improvement of a form of the present invention, the diamond wear surface comprises a polycrystalline synthetic diamond thick film (i.e. a film at least 20 Âµm thick) having an equivalent strain of at least 0.08 percent. For thick film synthetic diamond wear surfaces having a thermal conductivity greater than about 9 W/cmÂ°K the equivalent strain should be at least about 0.08 percent to obtain superior wear characteristics. When the thermal conductivity is less than about 9 W/cmÂ°K, an equivalent strain of at least about 0.10 percent is needed to provide the desired superior wear characteristics. The relationship between equivalent strain and wear properties is particularly significant at substantial thick film thicknesses, viz. greater than about 200 Âµm.</p><p id="p0024" num="0024">As is known in the art, certain operating parameters of the plasma jet deposition equipment, or of other chemical vapor deposition equipments, are generally adjustable, such as by varying the ratio of feedstock gasses [for example, the relative percentages of hydrogen and methane], varying the temperature, and/or varying the pressure of the plasma and/or the target (e.g. the medium 62 in Fig. 1). In accordance with an aspect of the present invention, operating conditions are adjusted to obtain the desired minimum equivalent strain percentage. Increasing the deposition temperature tends to increase equivalent strain.</p><p id="p0025" num="0025">In an embodiment hereof, equivalent strain is measured as<!-- EPO <DP n="12"> --> follows: X-ray diffraction measurements are made using Cu Ka radiation (45kV, 40mA on the tube) on a Philips PW1700 X-ray diffraction analyzer machine. The patterns are recorded for the diamond as grown (i.e. without crushing). The angle 2Î¸ is scanned in 0.04 degree steps, dwelling 1 second at each step. Data are corrected in a standard manner using the Philips program provided for the user of the machine. In particular, a correction using the Lorentz polarization factor is made and the Ka2 peaks are stripped assuming the Ka2/Ka1 ratio is 0.5. Instrument broadening is estimated using 5-10 Âµm diamond powder as a standard. Finally, the integral breadth d of the 331 reflection is measured and the equivalent strain e computed from it assuming all of the broadening is induced by strain, using the formula<maths id="math0001" num=""><math display="block"><mrow><mtext>d = (e/4)tanÎ¸</mtext></mrow></math><img id="ib0001" file="imgb0001.tif" wi="24" he="5" img-content="math" img-format="tif"/></maths> where Î¸ is the usual diffraction angle, that is, 70.2 degrees for the 331 reflection. [See H.P. Klug, L.A. Alexander "X-ray Diffraction Procedures for Polycrystalline and Amorphous Materials", p661, Wiley-Interscience, New York, 1974.] The technique of measurement of equivalent strain is not, of itself, an inventive feature hereof, and it will be understood that any suitable technique for determining equivalent strain can be used, consistent with the principles of the invention.</p><p id="p0026" num="0026">It is known that an increase in the thermal conductivity can be achieved in CVD diamond by varying the chemistry of the<!-- EPO <DP n="13"> --> depositing gas. For example, additions of oxygen and reductions in carbon content are both known methods of increasing thermal conductivity of CVD diamond. Thermal conductivity in an embodiment hereof is measured by a method described in Enguhard et al, Materials Science &amp; Engineering, Volume B5, pp. 127-134 (1990).</p><p id="p0027" num="0027">Fig. 4 is an operational flow diagram of a procedure in accordance with an embodiment of the invention for producing synthetic diamond having improved wear characteristics. The block 410 represents the initializing of deposition operating parameters, for example the operating parameters of the Fig. 1 arc jet plasma deposition equipment. These parameters may include, inter alia, the ratio of feedstock gases, the control of temperature, and the control of pressure. The block 420 represents the deposition of synthetic diamond, and the block 430 represents the measurement of the equivalent strain of the synthetic diamond. The thermal conductivity of the synthetic diamond can also be measured, as represented by the block 440. If the measured equivalent strain percentage is below a predetermined threshold (which, as noted above, may also take into account the thermal conductivity), a decision is made (represented by decision block 450) to modify the deposition parameters. For example, the deposition temperature can be raised, which tends to increase the equivalent strain of the resultant CVD diamond. Also, the percentage of methane in the<!-- EPO <DP n="14"> --> feedstock gases can be increased, if necessary, to increase the thermal conductivity of the resultant CVD diamond. When the equivalent strain is above the desired minimum, the process can be periodically monitored, as represented by re-entry to the block 420.</p><p id="p0028" num="0028">In accordance with a further aspect of the invention, and as represented by the operational flow diagram of Fig. 5, measurement of equivalent strain is utilized in selecting diamond samples (or selecting batches or production runs from which samples are taken) for suitability in wear applications. Diamond samples (or runs or batches) which do not meet equivalent strain criteria can be used in applications where some compromise in wear properties may be acceptable, such as in lower cost wear components. The block 510 represents the production of thick film polycrystalline diamond. The block 520 represents the performance of testing for equivalent strain on a sample of the produced polycrystalline synthetic diamond. Thermal conductivity can also be measured, as represented by block 530. If the measured equivalent strain percentage is above a predetermined threshold (which, as noted above, may also take into account the thermal conductivity), the diamond can be accepted for a particular wear surface application or, conversely, rejected for such application (decision block 540).<!-- EPO <DP n="15"> --></p><heading id="h0001"><u>EXAMPLES</u></heading><p id="p0029" num="0029">Equipment of the type shown in Fig. 1, but without cooling coils, was utilized to produce synthetic diamond samples that were subjected to a number of wear tests. The tests performed on the samples were as follows:</p><heading id="h0002"><u>Milling Test</u></heading><p id="p0030" num="0030">The diamond sample, at least 250 Âµm thick, is ground flat and parallel within 10 Âµm, and polished on one side. The sample is then mounted with the finest grains uppermost by brazing on a tungsten carbide insert as illustrated in Figs. 2 and 3. The insert is mounted as a single tooth in a vertical spindle mill running at 1500 m/min. with an infeed of .25 mm/rev. and 1 mm depth of cut for a single tooth. The workpiece diameter is 100 mm. Performance is determined by implementing 100 passes of the tool head over a continuous cast A390 aluminum alloy workpiece and measuring the wear on the insert using a toolmaker's microscope.</p><heading id="h0003"><u>Sandblast Test</u></heading><p id="p0031" num="0031">The side of the sample that was in contact with the substrate is blasted with 120 grit SiC flowing at a rate of about 3 g/min. Air pressure is about 552 kPa (80 psig) and the nozzle size is about 0.7 mm. Performance is determined by blasting for 25 minutes at<!-- EPO <DP n="16"> --> a standoff of 2 cm and measuring the depth of the pit so formed in Âµm.</p><heading id="h0004"><u>EXAMPLE 1</u></heading><p id="p0032" num="0032">Samples 1-1 and 1-2 were produced using the following conditions of the DC arc jet plasma deposition equipment <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="left">Sample 1-1</entry><entry namest="col3" nameend="col3" align="center">Sample 1-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Gas enthalpy</entry><entry namest="col2" nameend="col2" align="char" char=".">40.8 kJ/g</entry><entry namest="col3" nameend="col3" align="char" char=".">40.7 kJ/g</entry></row><row><entry namest="col1" nameend="col1" align="left">%CH<sub>4</sub> in H<sub>2</sub></entry><entry namest="col2" nameend="col2" align="char" char=".">0.16</entry><entry namest="col3" nameend="col3" align="char" char=".">0.16</entry></row><row><entry namest="col1" nameend="col1" align="left">Pressure</entry><entry namest="col2" nameend="col2" align="char" char=".">26.6 mbar (20 Torr)</entry><entry namest="col3" nameend="col3" align="char" char=".">26.6 mbar (20 Torr)</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Deposition temp.</entry><entry namest="col2" nameend="col2" align="char" char=".">1050Â°C</entry><entry namest="col3" nameend="col3" align="char" char=".">1050Â°C</entry></row></tbody></tgroup></table></tables></p><p id="p0033" num="0033">The samples were measured and tested to determine equivalent strain thermal conductivity, and milling wear, using the measurements and tests first described above. The results were as follows: <tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="left">Sample 1-1</entry><entry namest="col3" nameend="col3" align="left">Sample 1-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Eq. strain</entry><entry namest="col2" nameend="col2" align="char" char=".">.13</entry><entry namest="col3" nameend="col3" align="char" char=".">.08</entry></row><row><entry namest="col1" nameend="col1" align="left">Thermal cond.</entry><entry namest="col2" nameend="col2" align="char" char=".">5.8 W/cmÂ°K</entry><entry namest="col3" nameend="col3" align="char" char=".">5.3 W/cmÂ°K</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Milling wear</entry><entry namest="col2" nameend="col2" align="char" char=".">.0196 cm (.0077 in.)</entry><entry namest="col3" nameend="col3" align="char" char=".">.0307 cm (.0121 in.)</entry></row></tbody></tgroup></table></tables></p><p id="p0034" num="0034">It is seen from this example that two materials made under similar conditions can have substantially differences in equivalent strain. The material with higher equivalent strain exhibited much better performance in the milling test. Specifically, the sample 1-2 had about 57% more wear than the sample 1-1.<!-- EPO <DP n="17"> --></p><heading id="h0005"><u>EXAMPLE 2</u></heading><p id="p0035" num="0035">Samples 2-1 and 2-2 were produced using the following conditions of the DC arc jet plasma deposition equipment <tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="left">Sample 2-1</entry><entry namest="col3" nameend="col3" align="left">Sample 2-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Gas enthalpy</entry><entry namest="col2" nameend="col2" align="char" char=".">178 kJ/g</entry><entry namest="col3" nameend="col3" align="char" char=".">170 kJ/g</entry></row><row><entry namest="col1" nameend="col1" align="left">%CH<sub>4</sub> in H<sub>2</sub></entry><entry namest="col2" nameend="col2" align="char" char=".">0.2</entry><entry namest="col3" nameend="col3" align="char" char=".">0.35</entry></row><row><entry namest="col1" nameend="col1" align="left">Pressure</entry><entry namest="col2" nameend="col2" align="char" char=".">5.99 mbar (4.5 Torr)</entry><entry namest="col3" nameend="col3" align="char" char=".">3.86 mbar (2.9 Torr)</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Deposition temp.</entry><entry namest="col2" nameend="col2" align="char" char=".">900Â°C</entry><entry namest="col3" nameend="col3" align="char" char=".">1050Â°C</entry></row></tbody></tgroup></table></tables></p><p id="p0036" num="0036">The samples were measured and tested to determine equivalent strain, thermal conductivity and sandblast test performance, using the measurements and tests first described above. In this Example (only) thermal conductivity was measured using a method more suitable for smaller samples, and described in Frederikse et al., Applied Optics, V27, pp. 4672-4675 (1988). The results were as follows: <tables id="tabl0004" num="0004"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="center">Sample 2-1</entry><entry namest="col3" nameend="col3" align="left">Sample 2-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Eq. strain</entry><entry namest="col2" nameend="col2" align="char" char=".">&lt;0.03</entry><entry namest="col3" nameend="col3" align="char" char=".">.12</entry></row><row><entry namest="col1" nameend="col1" align="left">Thermal cond.</entry><entry namest="col2" nameend="col2" align="char" char=".">3.7 W/cmÂ°K</entry><entry namest="col3" nameend="col3" align="char" char=".">4.5 W/cmÂ°K</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Sandblast pit depth</entry><entry namest="col2" nameend="col2" align="char" char=".">85 Âµm</entry><entry namest="col3" nameend="col3" align="char" char=".">65 Âµm</entry></row></tbody></tgroup></table></tables></p><p id="p0037" num="0037">The samples 2-1, made at substantially lower deposition temperature than sample 2-2 or the samples of Example 1, exhibited much lower equivalent strain than the other samples. Again, the sample with lower equivalent strain (2-1) exhibited greater wear; viz., about 30% deeper pit depth than sample 2-2. The lower pressure in making sample 2-2 is believed to have<!-- EPO <DP n="18"> --> contributed to this sample having a higher thermal conductivity notwithstanding the lower percentage of methane used in making sample 2-1.</p><heading id="h0006"><u>EXAMPLE 3</u></heading><p id="p0038" num="0038">Samples 3-1 and 3-2 were produced using the following conditions of the DC arc jet plasma deposition equipment <tables id="tabl0005" num="0005"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="left">Sample 3-1</entry><entry namest="col3" nameend="col3" align="left">Sample 3-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Gas enthalpy</entry><entry namest="col2" nameend="col2" align="char" char=".">46 kJ/g</entry><entry namest="col3" nameend="col3" align="char" char=".">41 kJ/g</entry></row><row><entry namest="col1" nameend="col1" align="left">%CH<sub>4</sub> in H<sub>2</sub></entry><entry namest="col2" nameend="col2" align="char" char=".">0.07</entry><entry namest="col3" nameend="col3" align="char" char=".">0.17</entry></row><row><entry namest="col1" nameend="col1" align="left">Pressure</entry><entry namest="col2" nameend="col2" align="char" char=".">26.6 mbar (20 Torr)</entry><entry namest="col3" nameend="col3" align="char" char=".">13.3 mbar (10 Torr)</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Deposition temp.</entry><entry namest="col2" nameend="col2" align="char" char=".">1050Â°C</entry><entry namest="col3" nameend="col3" align="char" char=".">1050Â°C</entry></row></tbody></tgroup></table></tables></p><p id="p0039" num="0039">The samples were measured and tested to determine equivalent strain, thermal conductivity and milling wear, using the measurements and tests first described above. The results were as follows: <tables id="tabl0006" num="0006"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="left">Sample 3-1</entry><entry namest="col3" nameend="col3" align="left">Sample 3-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Eq. strain</entry><entry namest="col2" nameend="col2" align="char" char=".">.099</entry><entry namest="col3" nameend="col3" align="char" char=".">.093</entry></row><row><entry namest="col1" nameend="col1" align="left">Thermal cond.</entry><entry namest="col2" nameend="col2" align="char" char=".">11.0 W/cmÂ°K</entry><entry namest="col3" nameend="col3" align="char" char=".">7.0 W/cmÂ°K</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Milling wear</entry><entry namest="col2" nameend="col2" align="char" char=".">.0185 cm (.0073 in.)</entry><entry namest="col3" nameend="col3" align="char" char=".">.0251 cm (.0099 in.)</entry></row></tbody></tgroup></table></tables></p><p id="p0040" num="0040">In this example the samples differ mainly in thermal conductivity and, as expected, the material having substantially higher thermal conductivity performed considerably better in the milling wear test. Sample 3-2 had about 35% more wear than sample 3-1.<!-- EPO <DP n="19"> --></p><heading id="h0007"><u>EXAMPLE 4</u></heading><p id="p0041" num="0041">Samples 4-1 and 4-2 were produced using the following conditions of the DC arc jet plasma deposition equipment <tables id="tabl0007" num="0007"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="left">Sample 4-1</entry><entry namest="col3" nameend="col3" align="left">Sample 4-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Gas enthalpy</entry><entry namest="col2" nameend="col2" align="char" char=".">34 kJ/g</entry><entry namest="col3" nameend="col3" align="char" char=".">35 kJ/g</entry></row><row><entry namest="col1" nameend="col1" align="left">%CH<sub>4</sub> in H<sub>2</sub></entry><entry namest="col2" nameend="col2" align="char" char=".">0.081</entry><entry namest="col3" nameend="col3" align="char" char=".">.088</entry></row><row><entry namest="col1" nameend="col1" align="left">Pressure</entry><entry namest="col2" nameend="col2" align="char" char=".">13.3 mbar (10 Torr)</entry><entry namest="col3" nameend="col3" align="char" char=".">13.3 mbar (10 Torr)</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Deposition temp.</entry><entry namest="col2" nameend="col2" align="char" char=".">900Â°C</entry><entry namest="col3" nameend="col3" align="char" char=".">1050Â°C</entry></row></tbody></tgroup></table></tables></p><p id="p0042" num="0042">The samples were measured and tested to determine equivalent strain, thermal conductivity and milling wear using the measurements and tests first described above. The results were as follows: <tables id="tabl0008" num="0008"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="left">Sample 4-1</entry><entry namest="col3" nameend="col3" align="left">Sample 4-2</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Eq. strain</entry><entry namest="col2" nameend="col2" align="char" char=".">.042</entry><entry namest="col3" nameend="col3" align="char" char=".">.17</entry></row><row><entry namest="col1" nameend="col1" align="left">Thermal cond.</entry><entry namest="col2" nameend="col2" align="char" char=".">12 W/cmÂ°K</entry><entry namest="col3" nameend="col3" align="char" char=".">8.5 W/cmÂ°K</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Milling wear</entry><entry namest="col2" nameend="col2" align="char" char=".">.0287 cm (.0113 in.)</entry><entry namest="col3" nameend="col3" align="char" char=".">.0216 cm (.0085 in.)</entry></row></tbody></tgroup></table></tables></p><p id="p0043" num="0043">This example shows two materials with thermal conductivities greater than 8.5 W/cm K and differing equivalent strains. The sample with lower equivalent strain (4-1) exhibited about 33% more milling wear.</p><p id="p0044" num="0044">In summary, the invention, in its various aspects, has been based upon the surprising discovery that synthetic diamond films having at least a certain equivalent strain percentage have substantially better wear properties than seemingly more "perfect" synthetic diamond films having a lower equivalent<!-- EPO <DP n="20"> --> strain percentage.</p><p id="p0045" num="0045">The invention has been described with reference to particular preferred embodiments, but variations will occur to those skilled in the art. For example, it will be understood that other types of chemical vapor deposition, such as microwave plasma deposition or hot filament deposition, can be utilized to produce synthetic diamond film.</p>
EP	0603422	B1	2000-05-24	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A wear component (20), comprising:<claim-text>a base surface; and</claim-text><claim-text>a synthetic diamond film mounted on said base surface, said diamond film having a thickness of at least 200 Âµm and an equivalent strain of at least 0.08 percent, the synthetic diamond film having an equivalent strain of at least 0.08 percent being obtainable by the following steps:<claim-text>depositing synthetic diamond by chemical vapor deposition utilizing initial deposition parameters;</claim-text><claim-text>monitoring the equivalent strain of the synthetic diamond;</claim-text><claim-text>modifying at least one of said deposition parameters when the equivalent strain of the synthetic diamond is less than a predetermined percentage; and</claim-text><claim-text>depositing further synthetic diamond utilizing the modified deposition parameters.</claim-text></claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The wear component (20) as defined by claim 1, wherein said diamond film has a thermal conductivity of at least 9 W/cmÂ°K.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The wear component (20) as defined by claim 1, wherein said thermal conductivity of said synthetic diamond film is less than about 9 W/cmÂ°K and said equivalent strain is at least 0.10 percent.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The wear component (20) as defined by one of claims 1 to 3, wherein said synthetic diamond film comprises CVD diamond film.<!-- EPO <DP n="22"> --></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The wear component (20) as defined by one of claims 1 to 4, wherein said base surface (24) comprises tungsten carbide, and said synthetic diamond film is brazed to said base surface.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The wear component (20) as defined by one of claims 1 to 5, wherein said wear component (20) is a cutting component, and wherein said diamond film comprises a cutting surface applied on a base surface of a cutting tool.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A method of making a wear component, comprising the steps of:<claim-text>providing a base surface;</claim-text><claim-text>producing a synthetic diamond film having a thickness of at least 20 Âµm and an equivalent strain of at least 0.08 percent by<claim-text>depositing synthetic diamond by chemical vapor deposition utilizing initial deposition parameters;</claim-text><claim-text>monitoring the equivalent strain of the synthetic diamond;</claim-text><claim-text>modifying at least one of said deposition parameters when the equivalent strain of the synthetic diamond is less than a predetermined percentage; and</claim-text><claim-text>depositing further synthetic diamond utilizing the modified deposition parameters, and</claim-text></claim-text><claim-text>applying said diamond film to said base surface.</claim-text></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The method as defined by claim 7, wherein said diamond film has a thermal conductivity of at least 9 W/cmÂ°K.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The method as defined by claim 7, wherein said thermal conductivity of said synthetic diamond film is less than<!-- EPO <DP n="23"> --> 9 W/cmÂ°K and said equivalent strain is at least 0.10 percent.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The method as defined by claim 7, wherein said step of producing a synthetic diamond film comprises producing said film by plasma deposition.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The method as defined by one of claims 7 to 10, wherein said producing and applying steps comprise depositing said synthetic diamond directly on said base surface.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The method as defined by one of claims 7 to 11, wherein said synthetic diamond film has a thickness of at least 200 Âµm, and wherein said step of applying said film to said base surface comprises mounting said film on said base surface using a mounting medium.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The method as defined by claim 12, wherein said mounting medium comprises a braze, and wherein said mounting step comprises brazing said diamond film to said base surface.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The method as defined by one of claims 7 to 13, wherein said base surface comprises tungsten carbide.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The method as defined by one of claims 7 to 14, wherein said wear component is a cutting component, and wherein said diamond film comprises a cutting surface applied on a base surface of a cutting tool.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>A method for producing synthetic diamond for use as a wear surface, comprising the steps of:<claim-text>depositing synthetic diamond by chemical vapor deposition utilizing initial deposition parameters;</claim-text><claim-text>monitoring the equivalent strain of the synthetic diamond;</claim-text><claim-text>modifying at least one of said deposition parameters when the equivalent strain of the synthetic diamond is less than a predetermined percentage; and<!-- EPO <DP n="24"> --></claim-text><claim-text>depositing further synthetic diamond utilizing the modified deposition parameters.</claim-text></claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>The method as defined by claim 16, wherein said predetermined equivalent strain percentage is at least 0.08 percent.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>The method as defined by claim 16 or 17, further comprising monitoring the thermal conductivity of said synthetic diamond, and modifying said at least one deposition parameter when said thermal conductivity is less than a predetermined magnitude.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>The method as defined by one of claims 16 to 18, wherein said at least one deposition parameter is deposition temperature.</claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>The method as defined by one of claims 16 to 19, wherein said modifying step comprises increasing the deposition temperature.</claim-text></claim><claim id="c-en-01-0021" num="0021"><claim-text>The method as defined by one of claims 16 to 20, wherein said chemical vapor deposition utilizes methane and hydrogen feedstock gases, and wherein said deposition parameters comprise at least one parameter selected from the group consisting of the ratio of feedstock gases and the deposition temperature.</claim-text></claim><claim id="c-en-01-0022" num="0022"><claim-text>The method as defined by one of claims 16 to 21, further comprising applying said further synthetic diamond to a wear component base to form a wear component.</claim-text></claim>
EP	0603422	B1	2000-05-24	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>VerschleiÃŸkomponente (20), enthaltend:<claim-text>eine BasisflÃ¤che; und</claim-text><claim-text>einen auf der BasisflÃ¤che angebrachten synthetischen Diamantfilm, wobei der Diamantfilm eine Dicke von wenigstens 200 Âµm und eine Ã„quivalenzdeformierung von wenigstens 0,08 Prozent aufweist, wobei der eine Ã„quivalenzdeformierung von wenigstens 0,08 Prozent aufweisende synthetische Diamantfilm durch die folgenden Schritte erhÃ¤ltlich ist:<claim-text>Aufbringung von synthetischem Diamant durch chemische Dampfabscheidung unter Anwendung anfÃ¤nglicher Aufbringungsparameter;</claim-text><claim-text>Ãœberwachung der Ã„quivalenzdeformierung des synthetischen Diamants;</claim-text><claim-text>Modifizierung wenigstens einer der Aufbringungsparameter, wenn die Ã„quivalenzdeformierung des synthetischen Diamants unter einem vorbestimmten Prozentsatz liegt; und</claim-text><claim-text>Aufbringung von weiterem synthetischen Diamant unter Anwendung der modifizierten Aufbringungsparameter.</claim-text></claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>VerschleiÃŸkomponente (20) gemÃ¤ÃŸ Anspruch 1, bei der der Diamantfilm eine WÃ¤rmeleitfÃ¤higkeit von wenigstens 9 W/cmÂ°K aufweist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>VerschleiÃŸkomponente (20) gemÃ¤ÃŸ Anspruch 1, bei der die WÃ¤rmeleitfÃ¤higkeit des synthetischen Diamantfilms weniger<!-- EPO <DP n="26"> --> als etwa 9 W/cmÂ°K und die Ã„quivalenzdeformierung wenigstens 0,10 Prozent betrÃ¤gt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>VerschleiÃŸkomponente (20) gemÃ¤ÃŸ einem der AnsprÃ¼che 1 bis 3, bei dem der synthetische Diamantfilm einen CVD-Diamantfilm umfaÃŸt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>VerschleiÃŸkomponente (20) gemÃ¤ÃŸ einem der AnsprÃ¼che 1 bis 4, bei dem die BasisflÃ¤che (24) Wolframcarbid aufweist und der synthetische Diamantfilm auf die BasisflÃ¤che gelÃ¶tet ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>VerschleiÃŸkomponente (20) gemÃ¤ÃŸ einem der AnsprÃ¼che 1 bis 5, bei dem die VerschleiÃŸkomponente (20) eine Schneidkomponente ist und der Diamantfilm eine SchneidflÃ¤che aufweist, die auf einer BasisflÃ¤che eines Schneidwerkzeugs angebracht ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verfahren zur Herstellung einer VerschleiÃŸkomponente, umfassend die Schritte:<claim-text>Bereitstellung einer BasisflÃ¤che;</claim-text><claim-text>Herstellung eines synthetischen Diamantfilms mit einer Dicke von wenigstens 20 Âµm und einer Ã„quivalenzdeformierung von wenigstens 0,08 Prozent durch<claim-text>Aufbringung von synthetischem Diamant durch chemische Dampfabscheidung unter Anwendung anfÃ¤nglicher Aufbringungsparameter;</claim-text><claim-text>Ãœberwachung der Ã„quivalenzdeformierung des synthetischen Diamants;</claim-text><claim-text>Modifizierung wenigstens einer der Aufbringungsparameter, wenn die<!-- EPO <DP n="27"> --> Ã„quivalenzdeformierung des synthetischen Diamants unter einem vorbestimmten Prozentsatz liegt; und</claim-text><claim-text>Aufbringung von weiterem synthetischen Diamant unter Anwendung der modifizierten Aufbringungsparameter,</claim-text></claim-text><claim-text>Anbringung des Diamantfilms auf der BasisflÃ¤che.</claim-text></claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 7, bei dem der Diamantfilm eine WÃ¤rmeleitfÃ¤higkeit von wenigstens 9 W/cmÂ°K aufweist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 7, bei dem die WÃ¤rmeleitfÃ¤higkeit des synthetischen Diamantfilms weniger als 9 W/cmÂ°K und die Ã„quivalenzdeformierung wenigstens 0,10 Prozent betrÃ¤gt.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 7, bei dem der Schritt der Herstellung eines synthetischen Diamantfilms die Herstellung des Films mittels Plasmaabscheidung umfaÃŸt.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 7 bis 10, bei dem die Herstellungs- und Aufbringungsschritte die Aufbringung des synthetischen Diamants direkt auf der BasisflÃ¤che umfaÃŸt.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 7 bis 11, bei dem der synthetische Diamantfilm eine Dicke von wenigstens 200 Âµm aufweist und der Schritt der Anbringung des Films auf der BasisflÃ¤che die Befestigung des Films auf der BasisflÃ¤che unter Verwendung eines Befestigungsmediums umfaÃŸt.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 12, bei dem das Befestigungsmedium ein LÃ¶tmittel ist und der Befestigungsschritt das LÃ¶ten des Diamantfilms auf die BasisflÃ¤che umfaÃŸt.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 7 bis 13, bei dem die BasisflÃ¤che Wolframcarbid umfaÃŸt.<!-- EPO <DP n="28"> --></claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 7 bis 14, bei dem die VerschleiÃŸkomponente eine Schneidkomponente ist und der Diamantfilm eine auf der BasisflÃ¤che eines Schneidwerkzeugs angebrachte SchneidflÃ¤che aufweist.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Verfahren zur Herstellung von synthetischem Diamant zur Verwendung als eine VerschleiÃŸflÃ¤che, umfassend die Schritte:<claim-text>Aufbringung von synthetischem Diamant durch chemische Dampfabscheidung unter Anwendung anfÃ¤nglicher Aufbringungsparameter;</claim-text><claim-text>Ãœberwachung der Ã„quivalenzdeformierung des synthetischen Diamants;</claim-text><claim-text>Modifizierung wenigstens einer der Aufbringungsparameter, wenn die Ã„quivalenzdeformierung des synthetischen Diamants unter einem vorbestimmten Prozentsatz liegt; und</claim-text><claim-text>Aufbringung von weiterem synthetischen Diamant unter Anwendung der modifizierten Aufbringungsparameter.</claim-text></claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 16, bei dem der bestimmte Ã„quivalenzdeformierungsprozentsatz wenigstens 0,08 Prozent betrÃ¤gt.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 16 oder 17, das des weiteren die Ãœberwachung der WÃ¤rmeleitfÃ¤higkeit des synthetischen Diamants umfaÃŸt sowie die Modifizierung des wenigstens einen Aufbringungsparameters, wenn die WÃ¤rmeleitfÃ¤higkeit weniger als die vorbestimmte GrÃ¶ÃŸe betrÃ¤gt.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 16 bis 18, bei dem der wenigstens eine Aufbringungsparameter die Aufbringungstemperatur ist.<!-- EPO <DP n="29"> --></claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 16 bis 19, bei dem der Modifizierungsschritt die ErhÃ¶hung der Aufbringungstemperatur umfaÃŸt.</claim-text></claim><claim id="c-de-01-0021" num="0021"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 16 bis 20, bei dem bei der chemischen Dampfabscheidung Methan- und Wasserstoffeduktgase eingesetzt werden und die Aufbringungsparameter wenigstens einen Parameter, ausgewÃ¤hlt aus der Gruppe bestehend aus dem VerhÃ¤ltnis der Eduktgase und der Aufbringungstemperatur, umfassen.</claim-text></claim><claim id="c-de-01-0022" num="0022"><claim-text>Verfahren gemÃ¤ÃŸ einem der AnsprÃ¼che 16 bis 21, das des weiteren die Aufbringung des weiteren synthetischen Diamants auf einer VerschleiÃŸkomponentenbasis zur Bildung einer VerschleiÃŸkomponente aufweist.</claim-text></claim>
EP	0603422	B1	2000-05-24	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>PiÃ¨ce d'usure (20), comprenant :<claim-text>une surface de base ; et</claim-text><claim-text>un film de diamant synthÃ©tique montÃ© sur ladite surface de base, ledit film de diamant ayant une Ã©paisseur d'au moins 200 Âµm et une dÃ©formation Ã©quivalente d'au moins 0,08 %, le film de diamant synthÃ©tique ayant une dÃ©formation Ã©quivalente d'au moins 0,08 % pouvant Ãªtre obtenu par les Ã©tapes suivantes :<claim-text>- le dÃ©pÃ´t du diamant synthÃ©tique par dÃ©pÃ´t chimique en phase vapeur en utilisant des paramÃ¨tres initiaux de dÃ©pÃ´t ;</claim-text><claim-text>- le contrÃ´le de la dÃ©formation Ã©quivalente du diamant synthÃ©tique ;</claim-text><claim-text>- la modification de l'un au moins desdits paramÃ¨tres de dÃ©pÃ´t lorsque la dÃ©formation Ã©quivalente du diamant synthÃ©tique est infÃ©rieure Ã  un pourcentage prÃ©dÃ©terminÃ©e ; et</claim-text><claim-text>- le dÃ©pÃ´t de davantage de diamant synthÃ©tique en utilisant les paramÃ¨tres de dÃ©pÃ´t modifiÃ©s.</claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>PiÃ¨ce d'usure (20) selon la revendication 1, dans laquelle ledit film de diamant Ã  une conductivitÃ© thermique d'au moins 9 W/cmÂ°K.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>PiÃ¨ce d'usure (20) selon la revendication 1, dans laquelle ladite conductivitÃ© thermique dudit film de diamant synthÃ©tique est infÃ©rieure Ã  environ 9 W/cmÂ°K et ladite dÃ©formation Ã©quivalente est d'au moins 0,10 %.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>PiÃ¨ce d'usure (20) selon l'une des revendications 1 Ã  3, dans laquelle ledit film de diamant synthÃ©tique est constituÃ© d'un film en diamant obtenu par dÃ©pÃ´t chimique en phase vapeur.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>PiÃ¨ce d'usure (20) selon l'une des revendications 1 Ã  4, dans laquelle ladite surface de base (24) est formÃ©e de carbure de tungstÃ¨ne et ledit film de diamant synthÃ©tique est brasÃ© sur ladite surface de base.<!-- EPO <DP n="31"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>PiÃ¨ce d'usure (20) selon l'une des revendications 1 Ã  5, dans laquelle ladite piÃ¨ce d'usure (20) est une piÃ¨ce de coupe, et dans laquelle ledit film de diamant rÃ©alise une surface de coupe appliquÃ©e sur une surface de base d'un outil de coupe.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>ProcÃ©dÃ© de fabrication d'une piÃ¨ce d'usure, comprenant les Ã©tapes suivantes :<claim-text>la fourniture d'une surface de base ;</claim-text><claim-text>la production d'un film de diamant synthÃ©tique ayant une Ã©paisseur d'au moins 20 Âµm et une dÃ©formation Ã©quivalente d'au moins 0,08 % par<claim-text>- dÃ©pÃ´t du diamant synthÃ©tique par dÃ©pÃ´t chimique en phase vapeur en utilisant des paramÃ¨tres de dÃ©pÃ´t initiaux ;</claim-text><claim-text>- contrÃ´le de la dÃ©formation Ã©quivalente du diamant synthÃ©tique ;</claim-text><claim-text>- modification de l'un au moins desdits paramÃ¨tres de dÃ©pÃ´t lorsque la dÃ©formation Ã©quivalente du diamant synthÃ©tique est infÃ©rieure Ã  un pourcentage prÃ©dÃ©terminÃ© ; et</claim-text><claim-text>- dÃ©pÃ´t de davantage de diamant synthÃ©tique en utilisant les paramÃ¨tres de dÃ©pÃ´t modifiÃ©s, et</claim-text></claim-text><claim-text>l'application dudit film de diamant sur ladite surface de base.</claim-text></claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>ProcÃ©dÃ© selon la revendication 7, dans lequel ledit film de diamant a une conductivitÃ© thermique d'au moins 9 W/cmÂ°K.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>ProcÃ©dÃ© selon la revendication 7, dans lequel ladite conductivitÃ© thermique dudit film de diamant synthÃ©tique est infÃ©rieure Ã  9 W/cmÂ°K et ladite dÃ©formation Ã©quivalente est d'au moins 0,10 %.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>ProcÃ©dÃ© selon la revendication 7, dans lequel ladite Ã©tape de production du film de diamant synthÃ©tique comprend la production dudit film par dÃ©pÃ´t de plasma.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>ProcÃ©dÃ© selon l'une des revendications 7 Ã  10, dans lequel lesdites Ã©tapes de production et d'application<!-- EPO <DP n="32"> --> comprennent le dÃ©pÃ´t dudit diamant synthÃ©tique directement sur ladite surface de base.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>ProcÃ©dÃ© selon l'une des revendications 7 Ã  11, dans lequel ledit film de diamant synthÃ©tique a une Ã©paisseur d'au moins 200 Âµm et dans lequel ladite Ã©tape d'application dudit film sur ladite surface de base comprend le montage dudit film sur ladite surface de base en utilisant un milieu de montage.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>ProcÃ©dÃ© selon la revendication 12, dans lequel ledit milieu de montage est constituÃ© d'une brasure et dans lequel ladite Ã©tape de montage consiste en le brasage dudit film de diamant sur ladite surface de base.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>ProcÃ©dÃ© selon l'une des revendications 7 Ã  13, dans lequel ladite surface de base est formÃ©e de carbure de tungstÃ¨ne.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>ProcÃ©dÃ© selon l'une des revendications 7 Ã  14, dans lequel ladite piÃ¨ce d'usure est une piÃ¨ce de coupe et dans lequel ledit film de diamant rÃ©alise une surface de coupe appliquÃ©e sur une surface de base d'un outil de coupe.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>ProcÃ©dÃ© de production de diamant synthÃ©tique destinÃ© Ã  Ãªtre utilisÃ© comme surface d'usure, comprenant les Ã©tapes suivantes :<claim-text>le dÃ©pÃ´t de diamant synthÃ©tique par dÃ©pÃ´t chimique en phase vapeur en utilisant des paramÃ¨tres de dÃ©pÃ´t initiaux ;</claim-text><claim-text>le contrÃ´le de la dÃ©formation Ã©quivalente dudit diamant synthÃ©tique ;</claim-text><claim-text>la modification de l'un au moins desdits paramÃ¨tres de dÃ©pÃ´t lorsque la dÃ©formation Ã©quivalente dudit diamant synthÃ©tique est infÃ©rieure Ã  un pourcentage prÃ©dÃ©terminÃ© ; et</claim-text><claim-text>le dÃ©pÃ´t de davantage de diamant synthÃ©tique en utilisant les paramÃ¨tres de dÃ©pÃ´t modifiÃ©s.</claim-text></claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>ProcÃ©dÃ© selon la revendication 16, dans lequel ledit pourcentage de dÃ©formation Ã©quivalente prÃ©dÃ©terminÃ© est d'au 0,08 %.<!-- EPO <DP n="33"> --></claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>ProcÃ©dÃ© selon la revendication 16 ou 17, comprenant en outre le contrÃ´le de la conductivitÃ© thermique dudit diamant synthÃ©tique et la modification dudit au moins un paramÃ¨tre de dÃ©pÃ´t lorsque ladite conductivitÃ© thermique est infÃ©rieure Ã  une amplitude prÃ©dÃ©terminÃ©e.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>ProcÃ©dÃ© selon l'une des revendications 16 Ã  18, dans lequel ledit au moins un paramÃ¨tre de dÃ©pÃ´t est la tempÃ©rature de dÃ©pÃ´t.</claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>ProcÃ©dÃ© selon l'une des revendications 16 Ã  19, dans lequel ladite Ã©tape de modification comprend l'augmentation de la tempÃ©rature de dÃ©pÃ´t.</claim-text></claim><claim id="c-fr-01-0021" num="0021"><claim-text>ProcÃ©dÃ© selon l'une des revendications 16 Ã  20, dans lequel ledit dÃ©pÃ´t chimique en phase vapeur utilise du mÃ©thane et de l'hydrogÃ¨ne comme gaz d'alimentation, et dans lequel lesdits paramÃ¨tres de dÃ©pÃ´t comprennent au moins un paramÃ¨tre choisi dans le groupe consistant en le rapport entre les gaz d'alimentation et la tempÃ©rature de dÃ©pÃ´t.</claim-text></claim><claim id="c-fr-01-0022" num="0022"><claim-text>ProcÃ©dÃ© selon l'une des revendications 16 Ã  21, comprenant en outre l'application dudit diamant synthÃ©tique supplÃ©mentaire Ã  une base de piÃ¨ce d'usure pour former une piÃ¨ce d'usure.</claim-text></claim>
EP	0603422	B1	2000-05-24	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0603422&ki=B1&pd=2000-05-24
EP	0604687	B1	2000-04-19	de	TITLE	1	Verfahren zum Ableiten der Merkmale von Zeichen in einem Zeichenerkennungssystem
EP	0604687	B1	2000-04-19	en	TITLE	1	Method for deriving character features in a character recognition system
EP	0604687	B1	2000-04-19	fr	TITLE	1	MÃ©thode pour dÃ©river des caractÃ©ristiques de caractÃ¨res dans un systÃ¨me de reconnaissance de caractÃ¨res
EP	0604687	B1	2000-04-19	en	DESCR	1	<heading id="h0001">A. <u>Background of the invention</u></heading><heading id="h0002">1. Field of the invention</heading><p id="p0001" num="0001">The invention is in the field of pattern recognition. It relates to a system for recognising characters, such as digits and letters, both in handwritten and printed form, and more particularly to a method for deriving features of a character to be recognised in a character recognition system of this type.</p><heading id="h0003">2. Prior art</heading><p id="p0002" num="0002">Character recognition systems such as those indicated above usually comprise a number of process steps which are described below with reference to a block diagram shown in Fig. 1. Said process steps are:<ul id="ul0001" list-style="none" compact="compact"><li>(1) optical scanning of a character on the surface of a carrier; such scanning, for example with a video camera, results in a two-dimensional pixel pattern, for example 64 Ã— 64 pixels, to which a grey value encoded in 5 bits is appended;</li><li>(2) binary quantisation of the pixel pattern, by subjecting the grey values of all the pixels to a threshold operation, the result, which can be seen as a black/white pattern or a pattern of "zeros" and "ones", being stored in a memory;</li><li>(3) deriving, from said quantised pixel pattern, an image description of the character to be recognised;</li><li>(4) deriving, from the image description, a set of character features of the character to be recognised;</li><li>(5) checking the set of character features found against results obtained previously with the aid of learning processes on known characters;<!-- EPO <DP n="2"> --></li><li>(6) deciding, on the basis of the check, which known character the character to be recognised is recognised as.</li></ul></p><p id="p0003" num="0003">A recognition technique of this type is known, for example, from reference [1] (cf. under C.). In this technique the quantised pixel pattern is used to derive a contour description. As a contour of a digitised pattern of a feature to be recognised is followed, the coordinates of certain points are selected. Those points are selected whose inner product of the point vector corresponding to each point and a directional vector in a number of predefined directions has the highest value. A selected point is characterised as an "extreme point" if the difference between said inner product at that point and the inner product at the following selected point exceeds a previously established limit value. Said extreme points define a polygonal approximation of the contour of the pattern. Said polygon shows a pattern of convex and concave structures. Said pattern is used for comparison with similar patterns, which are characteristic of known characters and stored in a previously compiled "dictionary". The character to be recognised is read as that known character whose patterns show the best correspondence.</p><p id="p0004" num="0004">A limitation of the pattern features derived in said known recognition technique is its being based on a structural description of the patterns to be recognised. This, however, produces acceptable recognition results only if the patterns to be recognised have a clear structure. This means that said known technique can be sensibly applied only for the recognition of characters from clear handwriting or typing. Another limitation is the variability of the number of features on which the recognition is based, i.e. the number of convex and concave structures in the pattern. This makes it difficult to apply deciders in the recognition, which work with a fixed number of features, such as, for example, those which make use of standard "feed-forward" neural<!-- EPO <DP n="3"> --> networks.</p><p id="p0005" num="0005">Reference [2] discloses another character recognition system of the above mentioned type. The recognition technique, on which this system is based, derives character features from a number of so-called views of an image, either the complete image or parts thereof, of a binary quantised pixel pattern of a character to be recognised. In this so-called views method, a number of different features of the pixel pattern is derived for each view, from above, from below and from the side, and for each image or part image. For these features, such as jumps, slopes, endpoints and islands, feature values are determined for specific patterns found in the views. During the check phase, the feature values found are weighted using adjustable weighting factors for each class of characters to be recognised. Said weighting factors have been obtained previously from a learning process on known characters. The weighted feature values are used to determine a score for each class. The character to be recognised is recognised as that character which belongs to the class in which the highest score has been determined.</p><p id="p0006" num="0006">This known technique, using the views method for deriving character features, has been developed in the first instance for recognising digits. The character features which are derived in this process have been found to be too general for acceptable letter recognition. Moreover, because of the many different features for which a character to be recognised has to be checked, the method for deriving the features is rather complex. Because of the type of the features, which are in fact structural features, a recognition based on said features is furthermore sensitive to breaks in an image pattern of a character to be recognised, and this recognition method is therefore unsuitable for, for example, matrix writing, such as, in particular, letters printed by a matrix printer.<!-- EPO <DP n="4"> --></p><p id="p0007" num="0007">In digital picture processing it is also known to make use of distance functions. Methods based thereon are sometimes denoted as "distance transform" or "distance mapping". A known "distance mapping" method of this type is, for example, disclosed by reference [3]. This involves appending to each pixel, which may form part of a subset of pixels, in the object (or in the background) of the original binary image, the shortest distance to the nearest pixel in the background (or the object). Corresponding to each point there is thus a distance tag. Further processing is then carried out on the basis of this two-component description, in which processing, inter alia, skeleton structures of the character to be recognised being traced. A distance tag of this type is inadequate per se as a character feature for the purpose of, in particular, recognising handwritten characters.</p><heading id="h0004">B. <u>Summary of the invention</u></heading><p id="p0008" num="0008">The object of the invention is to provide a method for deriving character features in a character recognition system, and a character recognition system in which this method is applied, which method and system do not have the above mentioned drawbacks and limitations. According to the invention, a method for deriving character features in a character recognition system for recognising characters, such as letters and digits, which comprises a step of deriving for each point of a plurality of points in an image plane of image points including a pattern of a character to be recognised feature data indicative of the distance to a nearest boundary point of the pattern, and which is known from reference [3], is, to this end, characterised according to Claim 1. An underlying idea in this context is that generally for such a reference point R<sub>i</sub> a nearest boundary point corresponds to a unique point of the image description of the character to be recognised, including its surroundings. By then considering the surroundings of such a unique point corresponding to a reference point R<sub>i</sub>, it is possible to select, in addition to the distance data D(R<sub>i</sub>), yet one or more additional features which may characterise the outline of the image description of the character in the vicinity of such a reference point. It was found that a very strong feature for this purpose is the feature which provides an estimate of the direction H(R<sub>i</sub>), which, if the image description of the character contains a contour description, has a contour in a unique<!-- EPO <DP n="5"> --> contour point corresponding to the reference point R<sub>i</sub>. Indeed, in a preferred embodiment the method according to the invention is characterised according to Claim 2.</p><p id="p0009" num="0009">Compared with the views method described above, the method according to the invention bases the recognition on a number of features which have been obtained, as it were, from local views of a character pattern, as seen from each of the reference points.</p><p id="p0010" num="0010">Reference [5] discloses a method for deriving features for the purpose of gray-level image recognition, in which features are determined in so called feature cells of which the locations for matching purposes are described by means of polar coordinates relative to an origin, called reference cell. The derived features are much more complicated than the features derived by the method of the present invention.</p><p id="p0011" num="0011">According to the invention, a character recognition system of a type indicated in the precharacterising clause of Claim 7 and which is known from reference [1] or [2], is, to this end, characterised as in Claim 7.</p><heading id="h0005">C. <u>References</u></heading><p id="p0012" num="0012"><ul id="ul0002" list-style="none" compact="compact"><li>[1] United States Patent document number 4,566,124, entitled "Pattern reading system";</li><li>[2] United States Patent document number 3,999,161, entitled "Method and device for the recognition of characters preferably of figures";</li><li>[3] P.-E. Danielsson, "Euclidean distance mapping, Computer Graphics and Image Processing 14, 227-248 (1980);</li><li>[4] R. P. Lippmann, "An introduction to computing with neural nets", IEEE ASSP Magazine, April 1987, pp. 4-22;</li><li>[5] M. Sano, et al., "Gray-level image recognition based on multiple cell-features", Systems and Computers in Japan, 22(1991) No. 5, New York, US, pp. 81-93.</li></ul></p><heading id="h0006">D. <u>Brief description of the drawings</u></heading><p id="p0013" num="0013">The invention will be explained in more detail by means of a description of an illustrative embodiment, with reference to a drawing in<!-- EPO <DP n="6"> --> which:<dl id="dl0001" compact="compact"><dt>Fig. 1</dt><dd>shows a block diagram of process steps of a character recognition system;</dd><dt>Fig. 2</dt><dd>represents a black/white pixel image of a character to be recognised having an inner and an outer contour;</dd><dt>Fig. 3</dt><dd>illustrates a process of tracing a contour, Fig. 3a showing the situation for a single black pixel, and Fig. 3b showing the situation after a kth contour point has been found;</dd><dt>Fig. 4</dt><dd>represents the contour outline after filtering of the contours of the pixel image according to Fig. 2;</dd><dt>Fig. 5</dt><dd>shows, in the subsections Figs 5a, 5b and 5c, three different situations of the position of a reference point with regard to a contour chord;</dd><dt>Fig. 6</dt><dd>shows an overview as a block diagram of processor and memory means for the specific purpose of carrying out the process steps (3) and (4) from Fig. 1 according to the invention;</dd><dt>Fig. 7</dt><dd>shows a diagram of a decider for carrying out the process steps (5) and (6) according to Fig. 1, as applied in combination with the method according to the invention.</dd></dl></p><heading id="h0007">E. <u>Description of an illustrative embodiment</u></heading><p id="p0014" num="0014">The invention relates to a method for deriving character features for the purpose of a recognition system for recognising characters, such as, for example, printed or handwritten digits and letters. Starting from a description of a character to be recognised, the recognition proceeds on the basis of a number of features, derived within suitably determined boundary points, of the described character. The invention therefore relates, in the first instance, to process step (4) in the character recognition system described with<!-- EPO <DP n="7"> --> reference to Fig. 1. The invention can be applied both to a pixel description and to a contour description of a character to be recognised. This relates to process step (3). Since a contour approach is preferred, it will be described in detail hereinafter, while the pixel approach will only be hinted at. The process steps (1) and (2) are carried out according to known techniques by recording means which are known per se and are therefore not described in further detail here. In the further description of an illustrative embodiment it is assumed that these steps have taken place and that a black/white pixel pattern of a character to be recognised has been stored in a two-dimensional image memory and is accessible for further operations. Such a black/white pixel pattern in an image plane comprising LxM pixels has an elementary description, called the pixel description, by means of a function B(i,j), of pixel values for each pixel (i,j) in the image plane, where i=1,--,L, and j=1,--,M, which function is defined by B(i,j)=1 for each black pixel (i,j) and B(i,j)=0 for each white pixel (i,j) in the image plane.</p><p id="p0015" num="0015">It is further assumed that, if the character to be recognised is part of a row of simultaneously recorded characters, a segmentation operation has already been carried out on said row, according to techniques known per se, in order to separate the characters and make them suitable for separate treatment. The process steps (5) and (6) are also carried out by known techniques. Since, however, the checking and decision means required there-for must previously have been learnt, so that certain characters may be recognised on the basis of the character features derived according to the method according to the invention, such means will be briefly explained in more detail following a full description of the method.</p><p id="p0016" num="0016">In the field of image processing and pattern recognition, the so-called distance transform is known. This transform appends a number D(P) to each<!-- EPO <DP n="8"> --> point P in an image plane of a black-and-white pattern of image points, in the following way:<ul id="ul0003" list-style="dash" compact="compact"><li>if the point P is situated in a white area of the image plane, then D(P) is equal to the distance to the nearest black image point; and</li><li>if the point P is situated in a black area which, for example, represents a digit or a letter, then D(P) is equal to the distance to the nearest white image point, provided with a minus sign.</li></ul></p><p id="p0017" num="0017">This distance transform is often used in so-called skeleton algorithms for tracing skeleton structures, the character recognition then being carried out on the basis of the skeleton structures found. An image signal thus transformed is also sometimes used directly for the purpose of the recognition process. A distance tag is then used as a character feature. If a limited number of image points is included in the process, for example to speed up the arithmetic operation, the distance tag is insufficient for describing a character to be recognised. To achieve an acceptable recognition probability, very large numbers, if not all, of the image points are therefore included in the transform. Nevertheless, the recognition of, in particular, handwriting is insufficient. The object of the invention, however, is to achieve a considerably higher recognition probability by appending one or more additional character features to each distance tag obtained on the basis of a distance transform on a limited number N of points R<sub>i</sub>, which have been preselected in a suitable way (where i=1,2,--,N), and which are called reference points, in the image plane.</p><p id="p0018" num="0018">This is based on the idea that, if such a reference point R<sub>i</sub> has a distance tag D(R<sub>i</sub>) appended to it, in general a unique boundary point P<sub>i</sub> of a character to be recognised will correspond thereto, including its surroundings. Boundary points are to be understood as those image points which have both white and black image points in their direct surroundings. In the case of a contour<!-- EPO <DP n="9"> --> description, a boundary point is a point on the contour, a contour point. Unless stated otherwise, from now on, a contour description and contour points will be assumed. By then considering the surroundings of a unique contour point P<sub>i</sub> of this type and corresponding to a reference point R<sub>i</sub>, it is possible to append, to the distance tag D(R<sub>i</sub>), one or more additional features, which, seen from such a reference point R<sub>i</sub>, describe the outline of the nearest contour segment C(R<sub>i</sub>). It was found that a very strong feature therefor is the feature which provides an estimate of the direction H(R<sub>i</sub>) of the contour in the contour point P<sub>i</sub>. Other supplementary features to be named, also those which provide an estimate of the second and third derivative of the contour in the contour point P<sub>i</sub>. Said supplementary features, however, do not provide much of an additional contribution to increasing the recognition probability of a character. All these descriptions, on the basis of said additional features, of the said nearest contour segments C(R<sub>i</sub>) for all the N reference points R<sub>i</sub> together are found to enable very effective recognition if N is sufficiently large. From 70 to 120 reference points are preferably used for each character, which points may be distributed regularly or randomly over the image plane.</p><p id="p0019" num="0019">In an example given below, the method for determining the features D(R<sub>i</sub>) and H(R<sub>i</sub>) for a reference point R<sub>i</sub> in the image plane of a pattern to be recognised will be explained in more detail.</p><p id="p0020" num="0020">For this purpose, Fig. 2 shows a black-and-white pattern of a separate character in a rectangle of 12 fields by 16, each field corresponding to a pixel. For the sake of clarity, the number of pixels in this example has been kept small. Each field is uniquely identifiable by means of its centre coordinates (i,j), where i=1,--,12 and j=1,--,16. The black fields are hatched. Each field is black or white. Thus field (2,3) is white and field (4,3) is black. If a field (i,j) is black, then it has a pixel value B(i,j)=1; and, if it is white, then it has the<!-- EPO <DP n="10"> --> pixel value B(i,j)=0. Where a black field adjoins a white field, the boundary lines are drawn as bold lines. Said two-dimensional description is then converted, by means of a process which is called contour tracer, into a one-dimensional contour description of the pattern of the character to be recognised. Said contour tracer successively runs through all the 12 Ã— 16 fields of the pixel image wile looking for contour points. Each time a starting point is found, a contour is generated. In this process, the contours are given a number, and their relative position is established by remembering whether a starting point found is situated within a previously determined contour. The process of tracing a contour is now explained in more detail with reference to Fig. 3 with sections 3a and 3b. In this process, each pixel is regarded as a black or white small square of finite dimensions. The corners of such a square are called grid points. In Fig. 3a, a single black pixel having centre coordinates (i,j) is shown as a hatched small square, with numbered grid points 1 to 4 inclusive. A separate black pixel by itself already has a well-defined contour, which is formed by the boldly drawn periphery segments from 1 to 2, from 2 to 3, etc., which encloses the black area in a clockwise direction (according to the direction of the arrow). The x,y coordinates of said four contour grid points 1 to 4 inclusive are chosen as:<maths id="math0001" num=""><math display="block"><mrow><mtable><mtr><mtd><mrow><mtable><mtr><mtd><mrow><mtext>(x(1),y(1)) = (i-0.5,j+0.5)</mtext></mrow></mtd></mtr><mtr><mtd><mrow><mtext>(x(2),y(2)) = (i+0.5,j+0.5)</mtext></mrow></mtd></mtr><mtr><mtd><mrow><mtext>(x(3),y(3)) = (i+0.5,j-0.5)</mtext></mrow></mtd></mtr><mtr><mtd><mrow><mtext>(x(4),y(4)) = (i-0.5,j-0.5)</mtext></mrow></mtd></mtr></mtable></mrow></mtd></mtr></mtable></mrow></math><img id="ib0001" file="imgb0001.tif" wi="52" he="26" img-content="math" img-format="tif"/></maths></p><p id="p0021" num="0021">In Fig. 3b the situation is shown where, when tracing a contour C after the (k-2)th and the (k-1)th contour grid point, when coming from an arrival direction v, a grid point (x(k),y(k)) has been found as the kth contour point. The arrival direction <maths id="math0002" num=""><math display="inline"><mrow><mtext>v = (vx,vy)</mtext></mrow></math><img id="ib0002" file="imgb0002.tif" wi="21" he="5" img-content="math" img-format="tif" inline="yes"/></maths> has four possible values, which can be<!-- EPO <DP n="11"> --> expressed as follows: (1,0), (-1,0), (0,1) and (0,-1). In the example drawn it is (1,0). To the left and to the right of the continuation of the arrival direction v, past the kth contour point, two pixels L and R are shown as broken lines.</p><p id="p0022" num="0022">Three directions are possible, in which the following (k+1)th contour point may be found, shown in the figure as v<sub>1</sub>, v<sub>2</sub> and v<sub>3</sub>. The direction in which the following contour point is found depends on the pixel value B of each of the pixels L and R. The centre coordinates of the pixels L and R, given the arrival direction (vx, vy) and the coordinates of the kth contour grid points, are:<maths id="math0003" num=""><math display="block"><mrow><mtable><mtr><mtd><mrow><mtable><mtr><mtd><mrow><mtext>iL = x(k) + (vx-vy)/2 and jL = y(k) + (vx+vy)/2</mtext></mrow></mtd></mtr><mtr><mtd><mrow><mtext>iR = x(k) + (vx=vy)/2 and jR = y(k) + (vx-vy)/2</mtext></mrow></mtd></mtr></mtable></mrow></mtd></mtr></mtable></mrow></math><img id="ib0003" file="imgb0003.tif" wi="97" he="14" img-content="math" img-format="tif"/></maths></p><p id="p0023" num="0023">The (k+1)th contour grid point and associated arrival direction are determined by means of a contour tracing algorithm, which may have the following appearance:<ul id="ul0004" list-style="none" compact="compact"><li><u>if</u> B(iL,jL) = 1 <u>then begin</u> vx := -vy; vy := vx <u>end</u> <u>else</u></li><li><u>if</u> B(iR,jR) = 0 <u>then</u> <u>begin</u> vx:= vy; vy := -vx <u>end</u>;</li><li>x(k+1) :=x(k) + vx; y(k+1) := y(k) + vy; k := k+1;<br/>continue to next point;</li></ul></p><p id="p0024" num="0024">To find the contours of a pixel image such as that shown in Fig. 2, the image plane is scanned from left to right and from top to bottom. A first starting point for a contour is found if, during this scan, the first black pixel, in the example pixel (6,14), is found. The first two contour points selected in this case are those corresponding to contour grid points 1 and 2 in Fig. 3a, with v = (1,0) as arrival direction in the second contour grid point. The contour tracing algorithm is then started until a return is made to the first contour<!-- EPO <DP n="12"> --> grid point. For each new start of the contour tracing algorithm, a contour number CN is increased by one. During each execution of the contour tracing algorithm, the pixels which belong to the same contour are marked with the same contour number CN. This marking is remembered in a separate, second image memory. Prior to the commencement of scanning of the image plane, all the pixels in the second image memory have the same initial mark, for example zero. After completion of a contour, the pixel image is scanned further in the search for a starting point for a next contour. The next starting point is found if, during further scanning, a black pixel is found which has not yet been marked, or if an unmarked white pixel is found within a previously found contour. In such a case the tracing algorithm is again run through. During the run-through, all the contour grid points found are recorded, in the order found, in a contour table, including an associated contour account. Said account comprises, for each contour, the number CN of the contour, pointers nrept and nrlpt to the first and last contour grid point of the contour in question, respectively, and a code cdoc which indicates the number of the immediately surrounding contour. The periphery of the whole pixel image is considered, in this context, as a virtual contour having the number 0. The pixel image of Fig. 2 has a first contour C1, whose contour grid points are successively numbered 1, 2, 3, --, 61 and 62. It has a second contour C2, whose contour grid points are numbered 63, 64, --, 77 and 78, and which is entirely situated within the first contour C1. The associated contour table is shown in Table 1 with subsections 1a and 1b, the contour account being incorporated in subsection 1a, and Table 1b forming the list of contour grid points.</p><p id="p0025" num="0025">By way of example, assume a set RP of reference points RP(m,n), comprising a number of pixel centres:<!-- EPO <DP n="13"> --><maths id="math0004" num=""><math display="block"><mrow><mtext>RP = {RP(m,n) = (4m-2,5n-2)|m,n = 1,2,3}</mtext></mrow></math><img id="ib0004" file="imgb0004.tif" wi="79" he="5" img-content="math" img-format="tif"/></maths></p><p id="p0026" num="0026">One of said reference points, RP(3,2), has been drawn in Fig. 2. If, from such a point, the local shape of the closest contour segment, in this case of contour C1, is investigated, features are obtained of a rather angular and busy pattern. Therefore, prior to commencing the feature derivation proper, the contour description obtained by the above contour tracing algorithm is first supplied to what can be called a contour filtering process, which produces a contour with a quieter outline. This is carried out, again by way of example, with a simple linear filter which, running along the contour, always determines a weighted mean of the corresponding contour grid points. In this process, the filtering step is always carried out with an offset of one grid spacing. The result of this filtering is a new, equally long list of contour points, which are usually no longer grid points, and which form the corners of a polygon with a quiet outline. If the length of such a linear filter is chosen to be four grid units, each filtering step always involves five successive contour grid points from the contour table. A new contour table is compiled by appending, new coordinates to the coordinates of each kth contour grid point in the now old contour table by:<maths id="math0005" num=""><math display="block"><mrow><mtable><mtr><mtd><mrow><mtable><mtr><mtd><mrow><mtext>X(k) = x(k-2)/8 + x(k-1)/4 + x(k)/4 + x(k+1)/4 + x(k+2)/8</mtext></mrow></mtd></mtr><mtr><mtd><mrow><mtext>Y(k) = y(k-2)/8 + y(k-1)/4 + y(k)/4 + y(k+1)/4 + y(k+2)/8</mtext></mrow></mtd></mtr></mtable></mrow></mtd></mtr></mtable></mrow></math><img id="ib0005" file="imgb0005.tif" wi="115" he="14" img-content="math" img-format="tif"/></maths></p><p id="p0027" num="0027">When applied to the image pattern shown in Fig. 2 with the contour table according to Table 1b, this produces a new contour outline which is depicted in Fig. 4, and whose associated contour table is shown in Table 2 with the list of new coordinates of the contour points. The contour account in this case has remained unchanged.<!-- EPO <DP n="14"> --> It is the case that the contour description is more suitable for the derivation proper of local contour features D and H for each of the reference points of the set RP. In this process, each contour is regarded as being composed of chords. A chord, with the number k, is the straight connection line segment between two successive numbered contour points k-1 and k, including the contour point k as the end point, and excluding the contour point k-1 as the starting point. The list of contour points in the contour table thus becomes a list of end points of successive chords which constitute the contours specified in the contour account. It is then determined, for each reference point from the set RP, which of the chords of all the contours in the contour table the reference point Dmin(RQ) is at the shortest distance from as well as said shortest distance itself. This is achieved by running successively through the list of end points of the chords. Depending on the position of a reference point RQ with regard to a chord k, three different situations may arise. These are shown diagrammatically in Fig. 5 with subsections 5a, 5b and 5c. In the situation according to Fig. 5a, the most closely situated point is in fact the starting point of the chord k. The minimum distance Dmin(RQ) found so far has therefore already been determined in the case of a preceding chord. In the situations according to Figs 5b and 5c, respectively, a point P of the chord k and the end point of the chord k are the nearest points which are at a distance d from the reference point RQ. In both cases a test is then carried out to discover whether this distance d found is shorter than the minimum distance Dmin(RQ) previously recorded so far. If so, the distance d found is recorded as the new value for Dmin(RQ), together with the associated chord number.</p><p id="p0028" num="0028">The following formulae are used for calculating the distance: in the situation according to Fig. 5b:<maths id="math0006" num=""><math display="block"><mrow><msup><mrow><mtext>d</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><msup><mrow><mtext> = (ax * cy - ay * cx)</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><msup><mrow><mtext>/(cx</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><msup><mrow><mtext> +cy</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><mtext>)</mtext></mrow></math><img id="ib0006" file="imgb0006.tif" wi="69" he="6" img-content="math" img-format="tif"/></maths><!-- EPO <DP n="15"> --> and in the situation according to Fig. 5c:<maths id="math0007" num=""><math display="block"><mrow><msup><mrow><mtext>d</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><msup><mrow><mtext> = ax</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><msup><mrow><mtext> + ay</mtext></mrow><mrow><mtext>2</mtext></mrow></msup></mrow></math><img id="ib0007" file="imgb0007.tif" wi="29" he="6" img-content="math" img-format="tif"/></maths> in which:<maths id="math0008" num=""><math display="block"><mrow><mtable><mtr><mtd><mrow><mtable><mtr><mtd><mrow><mtext>ax = x(RQ) - X(k) and ay = y(RQ) - Y(k)</mtext></mrow></mtd></mtr><mtr><mtd><mrow><mtext>cx = X(k) - X(k-1) and cy = Y(k) - Y(k-1)</mtext></mrow></mtd></mtr></mtable></mrow></mtd></mtr></mtable></mrow></math><img id="ib0008" file="imgb0008.tif" wi="88" he="14" img-content="math" img-format="tif"/></maths></p><p id="p0029" num="0029">In fact, the minimum d<sup>2</sup> is first determined, and only if this has been found is its root calculated. At the same time, the process checks whether the reference point RQ in question is located to the left or the right of the contour of which the chord with the minimum distance Dmin(RQ) forms part. This is done by determining the inner product (ax * cy - ay * cx) of the vector (cy,cx) perpendicular to the chord, which is now interpreted as a vector (cx,cy), with the vector (ax,ay) defined by the end point of the chord and the reference point RQ. If the value of the inner product is positive, the reference point RQ is located to the right and, if negative, to the left of the contour. Since a contour is always chosen clockwise around black, it is then known whether the reference point RQ in question is situated in a "black" or in a "white" area of the filtered image pattern.</p><p id="p0030" num="0030">The desired features at the reference point RQ are now determined as follows:<ul id="ul0005" list-style="none"><li>(i)<dl id="dl0002" compact="compact"><dt>D (RQ) =</dt><dd>Dmin(RQ) if RQ is in a "white" area;</dd><dt>D (RQ) =</dt><dd>-Dmin(RQ) if RQ is in a "black" area;</dd></dl></li><li>(ii)<dl id="dl0003" compact="compact"><dt>H (RQ) =</dt><dd>direction of the nearest chord found, which is calculated as the direction of the vector [X(k) - X(k-1), Y(k) - Y(k-1)] in the situation according to Fig. 5b;</dd><dt>H(RQ) =</dt><dd>direction of the vector perpendicular to the connecting line between the end point of the nearest<!-- EPO <DP n="16"> --> chord and the reference point RQ, which is calculated as the direction of the vector Â±[Y(k) - Y(RQ), -X(k) + X(RQ)] in the situation according to Fig. 5c, the plus/minus sign applying according to whether the reference point RQ is situated in "black" or "white", respectively.</dd></dl></li></ul></p><p id="p0031" num="0031">The direction feature is preferably expressed as an angle, and it can be calculated, for example, by means of a <maths id="math0009" num=""><math display="inline"><mrow><msup><mrow><mtext>cos</mtext></mrow><mrow><mtext>-1</mtext></mrow></msup></mrow></math><img id="ib0009" file="imgb0009.tif" wi="8" he="5" img-content="math" img-format="tif" inline="yes"/></maths>, a <maths id="math0010" num=""><math display="inline"><mrow><msup><mrow><mtext>sin</mtext></mrow><mrow><mtext>-1</mtext></mrow></msup></mrow></math><img id="ib0010" file="imgb0010.tif" wi="7" he="5" img-content="math" img-format="tif" inline="yes"/></maths> or a <maths id="math0011" num=""><math display="inline"><mrow><msup><mrow><mtext>tan</mtext></mrow><mrow><mtext>-1</mtext></mrow></msup></mrow></math><img id="ib0011" file="imgb0011.tif" wi="8" he="5" img-content="math" img-format="tif" inline="yes"/></maths> function.</p><p id="p0032" num="0032">When applied to the filtered contour description as shown in Fig. 4, it is found for a reference point RP(3,2) that the chord having number 14 are at the shortest distance. Since the reference point is located in "white" the minimum distance is to be regarded as positive, and the direction feature <maths id="math0012" num=""><math display="inline"><mrow><mtext>H(RP(3,2)) = direction of the vector [X(14) - X(13), Y(14) - Y(13)]</mtext></mrow></math><img id="ib0012" file="imgb0012.tif" wi="126" he="5" img-content="math" img-format="tif" inline="yes"/></maths> .</p><p id="p0033" num="0033">As already mentioned previously, the method according to the invention can be carried out not only with a contour description of an image pattern. A description on a pixel basis, the pixel description B(i,j), is similarly directly suitable for determining the features D(RQ) and H(RQ). In the case of this description, it is, moreover, possible to make use of one of the many known algorithms for determining the distance transform. If pixel centres are again<ul id="ul0006" list-style="none" compact="compact"><li>chosen as reference points, a simple algorithm can proceed as follows: if a reference point RQ is located in "white', the pixel surroundings round the reference point RQ are scanned in steadily increasing "circles" until the nearest "black" pixel Z has been found. Then the features are chosen as follows:<maths id="math0013" num=""><math display="block"><mrow><msup><mrow><mtext>D(RQ) = {(i(Z) - i(RQ))</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><msup><mrow><mtext> + (j(z) - j(RQ))</mtext></mrow><mrow><mtext>2</mtext></mrow></msup><msup><mrow><mtext>}</mtext></mrow><mrow><mtext>Â½</mtext></mrow></msup></mrow></math><img id="ib0013" file="imgb0013.tif" wi="83" he="6" img-content="math" img-format="tif"/></maths> and<maths id="math0014" num=""><math display="block"><mrow><mtext>H(RQ) = direction of the vector [-j(Z) + j(RQ), i(Z) - i(RQ)]</mtext></mrow></math><img id="ib0014" file="imgb0014.tif" wi="113" he="5" img-content="math" img-format="tif"/></maths></li></ul><!-- EPO <DP n="17"> --></p><p id="p0034" num="0034">If RQ is situated in a "black" area, the nearest "white" pixel W is, of course, searched for, and the analogous expressions then apply for the features. The above mentioned selection for the directional feature H(RQ) is very simple, but rather coarse. Refinements can be obtained by including surrounding points of Z or W, whose pixel value correlates with Z or W.</p><p id="p0035" num="0035">The features obtained according to the manner described above, on the basis of either a pixel description or a contour description of a character to be recognised, form the elements of a vector, the feature vector V = {v<sub>n</sub>} with n=1,--,2N, the row of vector coefficients being chosen as<maths id="math0015" num=""><math display="block"><mrow><msub><mrow><mtext>{v</mtext></mrow><mrow><mtext>n</mtext></mrow></msub><msub><mrow><mtext>} = {D(R</mtext></mrow><mrow><mtext>1</mtext></mrow></msub><msub><mrow><mtext>), H(R</mtext></mrow><mrow><mtext>1</mtext></mrow></msub><msub><mrow><mtext>), D(R</mtext></mrow><mrow><mtext>2</mtext></mrow></msub><msub><mrow><mtext>), H(R</mtext></mrow><mrow><mtext>2</mtext></mrow></msub><msub><mrow><mtext>),--, D(R</mtext></mrow><mrow><mtext>N</mtext></mrow></msub><msub><mrow><mtext>), H(R</mtext></mrow><mrow><mtext>N</mtext></mrow></msub><mtext>)}.</mtext></mrow></math><img id="ib0015" file="imgb0015.tif" wi="104" he="6" img-content="math" img-format="tif"/></maths></p><p id="p0036" num="0036">Figure 6 shows, as a block diagram, an overview of processor means PM and of memory means MM, which are specific for carrying out the process steps (3) and (4) from Fig. 1 according to the method described above for deriving character features. Below a broken dashed line, the memory means are shown, indicated by M1, M2, M3 and M4, and above said dashed line are shown the processor means PM for carrying out three processes indicated by CD, CF and FD. The relationship is as follows. The process CD describes the contour of a character. It carries out the contour tracing algorithm on the image pattern of the character which, after process steps (1) and (2) from Fig. 1 have been carried out, is available in a first memory M1, the image memory; and it puts the contour description obtained into a second memory M2. Then the process CF carries out the contour filtering process on the contour description put into the second memory M2, and puts the filtered contour description thus obtained into a third memory M3. Stored in a fourth memory M4 is a list with coordinate data of the reference points R<sub>i</sub> of the set RP. The process FD carries out the feature derivation for all the reference<!-- EPO <DP n="18"> --> points from the list in the fourth memory M4 on the filtered contour description present in the third memory, and outputs the feature vector V thus found.</p><p id="p0037" num="0037">The feature vector V is subsequently presented to combined checking and decision means, designated decider 100, of which a diagram is shown in Fig. 7, for carrying out the process steps (5) and (6) of Fig. 1. The decider 100 comprises a feature checker 101 and a maximum selector 102. The feature checker has as many inputs I<sub>n</sub> as the feature vector V has coefficients, in the present example, therefore, 2N, for receiving all the coefficients v<sub>n</sub>, the derived feature values; and as many outputs u<sub>m</sub> as the total number M of characters to be recognised. Said number M is, for example, 34, if the set of characters to be recognised is formed by the digits 0, 1, --, 9 and the capital letters A, B, --, Z. For each feature vector V presented at the input of the feature checker 101, the latter determines a score vector <maths id="math0016" num=""><math display="inline"><mrow><msub><mrow><mtext>S = {s</mtext></mrow><mrow><mtext>m</mtext></mrow></msub><mtext>|m=1,--,M}</mtext></mrow></math><img id="ib0016" file="imgb0016.tif" wi="34" he="6" img-content="math" img-format="tif" inline="yes"/></maths> , each coefficient s<sub>m</sub> of which expresses the measure, according to which the presented feature vector V fits the mth character from the set of characters to be recognised. The coefficients of the score vector S are presented, via the outputs u<sub>m</sub>, to the maximimum selector 102. Said maximum selector 102 determines the largest of the coefficients s<sub>m</sub> and outputs a signal CH at its output 103, according to the character from the character set to be recognised, which corresponds to the determined largest coefficient. The feature checker is preferably a multi-larger neural network, e.g. composed of three layers of perceptrons, as disclosed, for example, by reference [4]. In FIG. 7, however, the feature checker 101 has been shown simply only as a single-layer neural network having a number M of perceptrons. Three steps are to be distinguished in the feature checker 101, viz.:<ul id="ul0007" list-style="dash" compact="compact"><li>a distribution step, denoted by the letter T;<!-- EPO <DP n="19"> --></li><li>a weighting step, denoted by the letter W; and</li><li>a summation step, denoted by the letter Î£.</li></ul></p><p id="p0038" num="0038">The feature values presented with the feature vector V to the feature checker 101 are, as derived, continuous values. In the distribution step T each presented value v<sub>n</sub> is, as it were, distributed by distribution units t<sub>n</sub>(n=1,--,2N) by presenting the same value in a multiple way, viz. in M directions, i.e. as many as there are perceptrons. During the weigthing step W each feature value v<sub>n</sub> in each direction m is weighted by means of a weighting factor W<sub>nm</sub> from a set of weighting factors {W<sub>nm</sub>}. This set of weighting factors in fact forms a dimensional array, the weighting factor matrix, where n=1,--,2N is the number of a presented feature value v<sub>n</sub>, and m=1,--,M is the number of a character to be recognised in the set of characters to be recognised. With the aid of the weighting factors, a score is then determined in the summation step Î£ by each one of a number M of summators Ïƒ<sub>m</sub>, which score forms the previously mentioned coefficient s<sub>m</sub> of the score vector S. For each summator Ïƒ<sub>m</sub>, this score is:<maths id="math0017" num=""><math display="block"><mrow><msub><mrow><mtext>s</mtext></mrow><mrow><mtext>m</mtext></mrow></msub><msub><mrow><mtext>=f(Î£w</mtext></mrow><mrow><mtext>nm</mtext></mrow></msub><msub><mrow><mtext>*v</mtext></mrow><mrow><mtext>n</mtext></mrow></msub><mtext>)</mtext></mrow></math><img id="ib0017" file="imgb0017.tif" wi="26" he="6" img-content="math" img-format="tif"/></maths> in which the summation is carried out over all n=1,--,2N and f represents a non-linear function such as a sigmoid. This is indicated in FIG. 7 by arrows from each distribution unit t<sub>n</sub> to each of the summators Ïƒ<sub>m</sub>. The arrows here are provided with their associated weighting factor from the weighting factor matrix.</p><p id="p0039" num="0039">The coefficients s<sub>m</sub> of the score vector S are presented to the maximum selector 102. The weighting factor matrix {w<sub>nm</sub>} is located in a memory accessible to the decider. The coefficients of this matrix have been predetermined according to a training algorithm which is known as the "back propagation containing algorithm" (see, for example, reference [4], particularly<!-- EPO <DP n="20"> --> Box 6.). In that case, character features were presented to the decider of known characters from a training set of known characters, which had been derived with the aid of the new method described above.</p><p id="p0040" num="0040">When applied to a large test set of practice material (approximately 200,000) of readily separable handwritten digits, a character recognition system, which worked with the new method for deriving the character features "distance" and "direction", was found to satisfactorily recognise 99.3% of the characters presented. If only the character feature "distance" was used, the maximum yield was found to be 98.6%.<!-- EPO <DP n="21"> --> <tables id="tabl0001" num="0001"><table frame="all"><title>Table 1a</title><tgroup cols="4" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm"/><colspec colnum="2" colname="col2" colwidth="39.37mm"/><colspec colnum="3" colname="col3" colwidth="39.37mm"/><colspec colnum="4" colname="col4" colwidth="39.37mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">CN</entry><entry namest="col2" nameend="col2" align="center">nrept</entry><entry namest="col3" nameend="col3" align="center">nrlpt</entry><entry namest="col4" nameend="col4" align="center">cdoc</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="right">1</entry><entry namest="col2" nameend="col2" align="center">1</entry><entry namest="col3" nameend="col3" align="right">62</entry><entry namest="col4" nameend="col4" align="right">0</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="right">2</entry><entry namest="col2" nameend="col2" align="center">63</entry><entry namest="col3" nameend="col3" align="right">78</entry><entry namest="col4" nameend="col4" align="right">1</entry></row></tbody></tgroup></table></tables> <tables id="tabl0002" num="0002"><table frame="all"><title>Table 1b</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">k</entry><entry namest="col2" nameend="col2" align="center">x</entry><entry namest="col3" nameend="col3" align="center">y</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="center">1</entry><entry namest="col2" nameend="col2" align="char" char=".">5.5</entry><entry namest="col3" nameend="col3" align="char" char=".">14.5</entry></row><row><entry namest="col1" nameend="col1" align="center">2</entry><entry namest="col2" nameend="col2" align="char" char=".">6.5</entry><entry namest="col3" nameend="col3" align="char" char=".">14.5</entry></row><row><entry namest="col1" nameend="col1" align="center">3</entry><entry namest="col2" nameend="col2" align="char" char=".">7.5</entry><entry namest="col3" nameend="col3" align="char" char=".">14.5</entry></row><row><entry namest="col1" nameend="col1" align="center">4</entry><entry namest="col2" nameend="col2" align="char" char=".">8.5</entry><entry namest="col3" nameend="col3" align="char" char=".">14.5</entry></row><row><entry namest="col1" nameend="col1" align="center">5</entry><entry namest="col2" nameend="col2" align="char" char=".">8.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row><row><entry namest="col1" nameend="col1" align="center">6</entry><entry namest="col2" nameend="col2" align="char" char=".">9.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row><row><entry namest="col1" nameend="col1" align="center">7</entry><entry namest="col2" nameend="col2" align="char" char=".">9.5</entry><entry namest="col3" nameend="col3" align="char" char=".">12.5</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">60</entry><entry namest="col2" nameend="col2" align="char" char=".">3.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row><row><entry namest="col1" nameend="col1" align="center">61</entry><entry namest="col2" nameend="col2" align="char" char=".">4.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">62</entry><entry namest="col2" nameend="col2" align="char" char=".">5.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row><row><entry namest="col1" nameend="col1" align="center">63</entry><entry namest="col2" nameend="col2" align="char" char=".">6.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row><row><entry namest="col1" nameend="col1" align="center">64</entry><entry namest="col2" nameend="col2" align="char" char=".">6.5</entry><entry namest="col3" nameend="col3" align="char" char=".">12.5</entry></row><row><entry namest="col1" nameend="col1" align="center">65</entry><entry namest="col2" nameend="col2" align="char" char=".">5.5</entry><entry namest="col3" nameend="col3" align="char" char=".">12.5</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">76</entry><entry namest="col2" nameend="col2" align="char" char=".">8.5</entry><entry namest="col3" nameend="col3" align="char" char=".">12.5</entry></row><row><entry namest="col1" nameend="col1" align="center">77</entry><entry namest="col2" nameend="col2" align="char" char=".">7.5</entry><entry namest="col3" nameend="col3" align="char" char=".">12.5</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">78</entry><entry namest="col2" nameend="col2" align="char" char=".">7.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="22"> --> <tables id="tabl0003" num="0003"><table frame="all"><title>Table 2</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">k</entry><entry namest="col2" nameend="col2" align="center">X</entry><entry namest="col3" nameend="col3" align="center">Y</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="center">1</entry><entry namest="col2" nameend="col2" align="char" char=".">5.875</entry><entry namest="col3" nameend="col3" align="char" char=".">14.125</entry></row><row><entry namest="col1" nameend="col1" align="center">2</entry><entry namest="col2" nameend="col2" align="char" char=".">6.625</entry><entry namest="col3" nameend="col3" align="char" char=".">14.375</entry></row><row><entry namest="col1" nameend="col1" align="center">3</entry><entry namest="col2" nameend="col2" align="char" char=".">7.375</entry><entry namest="col3" nameend="col3" align="char" char=".">14.375</entry></row><row><entry namest="col1" nameend="col1" align="center">4</entry><entry namest="col2" nameend="col2" align="char" char=".">8.125</entry><entry namest="col3" nameend="col3" align="char" char=".">14.125</entry></row><row><entry namest="col1" nameend="col1" align="center">5</entry><entry namest="col2" nameend="col2" align="char" char=".">8.750</entry><entry namest="col3" nameend="col3" align="char" char=".">13.75</entry></row><row><entry namest="col1" nameend="col1" align="center">6</entry><entry namest="col2" nameend="col2" align="char" char=".">9.125</entry><entry namest="col3" nameend="col3" align="char" char=".">13.125</entry></row><row><entry namest="col1" nameend="col1" align="center">7</entry><entry namest="col2" nameend="col2" align="char" char=".">9.5</entry><entry namest="col3" nameend="col3" align="char" char=".">12.5</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">60</entry><entry namest="col2" nameend="col2" align="char" char=".">3.875</entry><entry namest="col3" nameend="col3" align="char" char=".">13.125</entry></row><row><entry namest="col1" nameend="col1" align="center">61</entry><entry namest="col2" nameend="col2" align="char" char=".">4.5</entry><entry namest="col3" nameend="col3" align="char" char=".">13.5</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">62</entry><entry namest="col2" nameend="col2" align="char" char=".">5.125</entry><entry namest="col3" nameend="col3" align="char" char=".">13.875</entry></row><row><entry namest="col1" nameend="col1" align="center">63</entry><entry namest="col2" nameend="col2" align="char" char=".">6.75</entry><entry namest="col3" nameend="col3" align="char" char=".">13.0</entry></row><row><entry namest="col1" nameend="col1" align="center">64</entry><entry namest="col2" nameend="col2" align="char" char=".">6.125</entry><entry namest="col3" nameend="col3" align="char" char=".">12.875</entry></row><row><entry namest="col1" nameend="col1" align="center">65</entry><entry namest="col2" nameend="col2" align="char" char=".">5.5</entry><entry namest="col3" nameend="col3" align="char" char=".">12.5</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">.</entry><entry namest="col2" nameend="col2" align="char" char=".">.</entry><entry namest="col3" nameend="col3" align="char" char=".">.</entry></row><row><entry namest="col1" nameend="col1" align="center">76</entry><entry namest="col2" nameend="col2" align="char" char=".">8.125</entry><entry namest="col3" nameend="col3" align="char" char=".">12.125</entry></row><row><entry namest="col1" nameend="col1" align="center">77</entry><entry namest="col2" nameend="col2" align="char" char=".">7.75</entry><entry namest="col3" nameend="col3" align="char" char=".">12.75</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">78</entry><entry namest="col2" nameend="col2" align="char" char=".">7.25</entry><entry namest="col3" nameend="col3" align="char" char=".">13.0</entry></row></tbody></tgroup></table></tables></p>
EP	0604687	B1	2000-04-19	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A method for deriving character features in a character recognition system for recognising characters, such as letters and digits, the method comprising a step of deriving for each point of a plurality of points in an image plane of image points including a pattern of a character to be recognised feature data indicative of the distance to a nearest boundary point of the pattern,<br/>wherein the plurality of points includes a set (<maths id="math0018" num=""><math display="inline"><mrow><msub><mrow><mtext>R = {R</mtext></mrow><mrow><mtext>i</mtext></mrow></msub><mtext>/i-1,--,N}</mtext></mrow></math><img id="ib0018" file="imgb0018.tif" wi="31" he="6" img-content="math" img-format="tif" inline="yes"/></maths>) of preselected points (R<sub>i</sub>), called reference points, and the method includes a further step of deriving, for each reference point, further feature data (H(R<sub>i</sub>)) indicative of the direction of the boundary in its corresponding nearest boundary point.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The method according to Claim 1, characterised in that the boundary points are contour points on a filtered contour (C1, C2), the filtered contour being obtained by steps of contour tracing and filtering, preceeding said first deriving step.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The method according to Claim 1 or 2, characterised in that the method comprises a step of determining a feature vector (<maths id="math0019" num=""><math display="inline"><mrow><msub><mrow><mtext>V = {v</mtext></mrow><mrow><mtext>n</mtext></mrow></msub><mtext>}/n=1,--,2N</mtext></mrow></math><img id="ib0019" file="imgb0019.tif" wi="35" he="6" img-content="math" img-format="tif" inline="yes"/></maths>) from said feature data and said further feature data, the feature vector including the distance data (D(R<sub>i</sub>)) and the directional data (H(R<sub>i</sub>)) for each reference point (R<sub>i</sub>) as vector coefficients.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The method according to Claim 1, 2 or 3, characterised in that the number of reference points is greater than 70 and less than 120.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The method according to any of the Claims 1,--,4, characterised in that the set of reference points includes points randomly distributed in the image plane.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The method according to any of the Claims 1,--,4, characterised in that the set of reference points includes points regularly distributed in the image plane.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>Character recognition system for recognising characters such as letters and digits, which system comprises:<claim-text>- means for recording an image pattern of a character to be recognised on the surface of a carrier,</claim-text><claim-text>- feature derivation means for deriving feature data for a number of character features of the character to be recognised from said recorded image pattern,</claim-text><claim-text>- checking means (101) for checking the derived feature data against results obtained previously on a set of known characters, and<!-- EPO <DP n="24"> --> for outputting checking results,</claim-text><claim-text>- deciding means (102), for deciding, on the basis of the checking results, which known character the character to be recognised is recognised as,<br/>wherein the feature derivation means (FD) include deriving means for deriving, for each point of a set of preselected points, called reference points, in an image plane of said recorded image pattern, feature data indicative of the distance to a nearest boundary point of the pattern, and feature data indicative of the direction of the boundary in its corresponding nearest boundary point.</claim-text></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>Character recognition system according to Claim 7, characterised in that the system further comprises a contour tracer (CD, CF) for locating a contour of the character to be recognised and for determining a contour description of the contour found, the deriving means being arranged for determining, for each reference point (RQ), the distance (<maths id="math0020" num=""><math display="inline"><mrow><mtext>D(RQ) = d</mtext></mrow></math><img id="ib0020" file="imgb0020.tif" wi="21" he="5" img-content="math" img-format="tif" inline="yes"/></maths>) to a nearest contour segment (k), and the direction (H(RQ)), at least as an approximation, of the nearest contour segment.</claim-text></claim>
EP	0604687	B1	2000-04-19	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zur Ableitung von Zeichenmerkmalen in einem Zeichenerkennungssystem zum Erkennen von Zeichen, wie Buchstaben und Zahlen, mit einem Schritt, mit dem fÃ¼r jeden Punkt einer Vielzahl von Punkten in einer Bildebene von Bildpunkten, die ein Muster eines zu erkennenden Zeichens umfassen, Merkmalsdaten abgeleitet werden, die fÃ¼r den Abstand zum nÃ¤chsten Grenzpunkt des Musters kennzeichnend sind, , <b>dadurch gekennzeichnet</b>, dass die Vielzahl von Punkten einen Satz (<maths id="math0021" num=""><math display="inline"><mrow><msub><mrow><mtext>R ={R</mtext></mrow><mrow><mtext>i</mtext></mrow></msub><mtext> Â¦ i = 1, ..., N}</mtext></mrow></math><img id="ib0021" file="imgb0021.tif" wi="43" he="6" img-content="math" img-format="tif" inline="yes"/></maths>) von vorausgewÃ¤hlten Punkten (R<sub>i</sub>), sogenannte Referenzpunkte, beinhalten und dass das Verfahren einen weiteren Schritt umfasst, in dem fÃ¼r jeden Referenzpunkt weitere Merkmalsdaten (H(R<sub>i</sub>)) abgeleitet werden, die fÃ¼r die Richtung der Grenze zu dem unmittelbar benachbarten nÃ¤chsten Grenzpunkt kennzeichnend sind.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren nach Anspruch 1, dadurch gekennzeichnet, dass die Grenzpunkte Umrisspunkte eines gefilterten Umrisses (C1, C2) sind, wobei der gefilterte Umriss durch Schritte der Umrissverfolgung und des Filterns erhalten wird, die dem besagten ersten Ableitungsschritt vorausgehen.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren nach Anspruch 1 oder Anspruch 2, dadurch gekennzeichnet, dass das Verfahren den Schritt umfasst, einen Merkmalsvektor (<maths id="math0022" num=""><math display="inline"><mrow><msub><mrow><mtext>V = {v</mtext></mrow><mrow><mtext>n</mtext></mrow></msub><mtext>} Â¦ n = 1, ..., 2N</mtext></mrow></math><img id="ib0022" file="imgb0022.tif" wi="48" he="6" img-content="math" img-format="tif" inline="yes"/></maths>) aus den besagten Merkmalsdaten und den weiteren besagten Merkmalsdaten festzustellen, und wobei der Merkmalsvektor die Distanzdaten (D(R<sub>i</sub>)) und die Richtungsdaten (H(R<sub>i</sub>)) fÃ¼r jeden Referenzpunkt (R<sub>i</sub>) als Vektorkoeffizienten beinhaltet.<!-- EPO <DP n="26"> --></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verfahren nach einem der AnsprÃ¼che 1, 2 oder 3, dadurch gekennzeichnet, dass die Anzahl der Referenzpunkte grÃ¶sser als 70 und kleiner als 120 ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verfahren nach einem der AnsprÃ¼che 1, 2, 3 oder 4, dadurch gekennzeichnet, dass der Satz an Referenzpunkten in der Bildebene zufÃ¤llig verteilte Punkte umfasst.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verfahren nach einem der AnsprÃ¼che 1, 2, 3 oder 4, dadurch gekennzeichnet, dass der Satz an Referenzpunkten in der Bildebene regelmÃ¤ssig verteilte Punkte umfasst.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Zeichenerkennungssystem zum Erkennen von Zeichen wie Buchstaben und Zahlen, wobei das System umfasst:<claim-text>- Mittel zum Aufnehmen eines Bildmusters eines zu erkennenden Zeichens auf der OberflÃ¤che eines TrÃ¤gers,</claim-text><claim-text>- Merkmalsableitungsmittel zum Ableiten von Merkmalsdaten fÃ¼r eine Anzahl von Zeichenmerkmalen des zu erkennenden Zeichens aus dem besagten aufgenommenen Bildmuster,</claim-text><claim-text>- ÃœberprÃ¼fungsmittel (101) zum ÃœberprÃ¼fen der abgeleiteten Merkmalsdaten gegen zuvor erhaltene Ergebnisse auf einem Satz von bekannten Zeichen und zur Ausgabe Ã¼berprÃ¼fter Ergebnisse,</claim-text><claim-text>- Entscheidermittel (102) zum Entscheiden auf der Basis der Ã¼berprÃ¼ften Ergebnisse, als welches bekannte Zeichen das zu erkennende Zeichen erkannt wird,<br/><b>dadurch gekennzeichnet</b>, dass die Merkmalsableitungsmittel (FD) Ableitungsmittel umfassen, um fÃ¼r jeden Punkt eines Satzes von vorab gewÃ¤hlten Punkten, sogenannten Referenzpunkten, in einer Bildebene des besagten aufgenommenen Bildmusters Merkmalsdaten, die fÃ¼r den Abstand zu einem nÃ¤chsten Grenzpunkt des Musters kennzeichnend sind, und Merkmalsdaten abzuleiten, die fÃ¼r die Richtung der Grenze zu seinem nÃ¤chsten Grenzpunkt kennzeichnend sind.</claim-text><!-- EPO <DP n="27"> --></claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Zeichenerkennungssystem nach Anspruch 7, dadurch gekennzeichnet, dass das System weiterhin einen Umrissverfolger (CD, CF) beinhaltet, um einen Umriss eines zu erkennenden Zeichens aufzufinden und um eine Umrissbeschreibung des aufgefundenen Umrisses festzustellen, wobei die Ableitungsmittel so angeordnet sind, um fÃ¼r jeden Referenzpunkt (RQ) den Abstand (<maths id="math0023" num=""><math display="inline"><mrow><mtext>D(RQ) = d</mtext></mrow></math><img id="ib0023" file="imgb0023.tif" wi="21" he="5" img-content="math" img-format="tif" inline="yes"/></maths>) zu einem nÃ¤chsten Umrisssegment (k) und die Richtung (H(RQ)), zumindest als AnnÃ¤herung, des nÃ¤chsten Umrisssegmentes zu bestimmen.</claim-text></claim>
EP	0604687	B1	2000-04-19	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>ProcÃ©dÃ© pour dÃ©river des caractÃ©ristiques de caractÃ¨re dans un systÃ¨me de reconnaissance de caractÃ¨res, tels que des lettres et des chiffres, le procÃ©dÃ© comprenant une Ã©tape de dÃ©rivation, pour chaque point d'une pluralitÃ© de points dans un plan d'image de points d'image incluant un motif d'un caractÃ¨re Ã  reconnaÃ®tre, de donnÃ©es de caractÃ©ristique indicatives de la distance jusqu'Ã  un point de frontiÃ¨re le plus proche du motif, dans lequel les points de la pluralitÃ© de points incluent un jeu (<maths id="math0024" num=""><math display="inline"><mrow><msub><mrow><mtext>R = {R</mtext></mrow><mrow><mtext>i</mtext></mrow></msub><mtext>/i=1. ..., N}</mtext></mrow></math><img id="ib0024" file="imgb0024.tif" wi="37" he="6" img-content="math" img-format="tif" inline="yes"/></maths>) de points prÃ©sÃ©lectionnÃ©s (R<sub>i</sub>), appelÃ©s points de rÃ©fÃ©rence, et le procÃ©dÃ© inclut une Ã©tape supplÃ©mentaire de dÃ©rivation, pour chaque point de rÃ©fÃ©rence, de donnÃ©es de caractÃ©ristique supplÃ©mentaires (H(R<sub>i</sub>)) indicatives de la direction de la frontiÃ¨re dans son point de frontiÃ¨re le plus proche correspondant.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>ProcÃ©dÃ© selon la revendication 1, caractÃ©risÃ© en ce que les points de frontiÃ¨re sont des points de contour sur un contour filtrÃ© (C1, C2), le contour filtrÃ© Ã©tant obtenu au moyen des Ã©tapes de suivi et de filtrage de contour qui prÃ©cÃ¨dent ladite premiÃ¨re Ã©tape de dÃ©rivation.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>ProcÃ©dÃ© selon la revendication 1 ou 2, caractÃ©risÃ© en ce que le procÃ©dÃ© comprend une Ã©tape de dÃ©termination d'un vecteur de caractÃ©ristique (<maths id="math0025" num=""><math display="inline"><mrow><msub><mrow><mtext>V = {v</mtext></mrow><mrow><mtext>n</mtext></mrow></msub><mtext>}/n=1, ..., 2N</mtext></mrow></math><img id="ib0025" file="imgb0025.tif" wi="40" he="6" img-content="math" img-format="tif" inline="yes"/></maths>) Ã  partir desdites donnÃ©es de caractÃ©ristique et desdites donnÃ©es de caractÃ©ristique supplÃ©mentaires, le vecteur de caractÃ©ristique incluant les donnÃ©es de distance (D(R<sub>i</sub>)) et les donnÃ©es directionnelles (H(R<sub>i</sub>)) pour chaque point de rÃ©fÃ©rence (R<sub>i</sub>) en tant que coefficients vectoriels.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>ProcÃ©dÃ© selon la revendication 1, 2 ou 3, caractÃ©risÃ© en ce que le nombre de points de rÃ©fÃ©rence est supÃ©rieur Ã  70 et infÃ©rieur Ã  120.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 1 Ã  4, caractÃ©risÃ© en ce que le jeu de points de rÃ©fÃ©rence inclut des points distribuÃ©s de faÃ§on alÃ©atoire dans le plan d'image.<!-- EPO <DP n="29"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 1 Ã  4, caractÃ©risÃ© en ce que le jeu de points de rÃ©fÃ©rence inclut des points distribuÃ©s rÃ©guliÃ¨rement dans le plan d'image.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>SystÃ¨me de reconnaissance de caractÃ¨res pour reconnaÃ®tre des caractÃ¨res tels que des lettres et des chiffres, lequel systÃ¨me comprend :<claim-text>un moyen pour enregistrer un motif d'image d'un caractÃ¨re Ã  reconnaÃ®tre sur la surface d'un support ;</claim-text><claim-text>un moyen de dÃ©rivation de caractÃ©ristique pour dÃ©river des donnÃ©es de caractÃ©ristique pour un certain nombre de caractÃ©ristiques de caractÃ¨re du caractÃ¨re Ã  reconnaÃ®tre Ã  partir dudit motif d'image enregistrÃ© ;</claim-text><claim-text>un moyen de vÃ©rification (101) pour vÃ©rifier les donnÃ©es de caractÃ©ristique dÃ©rivÃ©es vis-Ã -vis de rÃ©sultats obtenus prÃ©alablement sur un jeu de caractÃ¨res connus et pour Ã©mettre en sortie des rÃ©sultats de vÃ©rification ;</claim-text><claim-text>un moyen de dÃ©cision (102) pour dÃ©cider, sur la base des rÃ©sultats de vÃ©rification, en tant que quel caractÃ¨re connu le caractÃ¨re Ã  reconnaÃ®tre est reconnu, dans lequel le moyen de dÃ©rivation de caractÃ©ristique (FD) inclut un moyen de dÃ©rivation pour dÃ©river, pour chaque point d'un jeu de points prÃ©sÃ©lectionnÃ©s, appelÃ©s points de rÃ©fÃ©rence, dans un plan d'image dudit motif d'image enregistrÃ©, des donnÃ©es de caractÃ©ristique indicatives de la distance jusqu'Ã  un point de frontiÃ¨re le plus proche du motif et des donnÃ©es de caractÃ©ristique indicatives de la direction de la frontiÃ¨re dans son point de frontiÃ¨re le plus proche correspondant.</claim-text></claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>SystÃ¨me de reconnaissance de caractÃ¨res selon la revendication 7, caractÃ©risÃ© en ce que le systÃ¨me comprend en outre un suiveur de contour (CD, CF) pour localiser un contour du caractÃ¨re Ã  reconnaÃ®tre et pour dÃ©terminer une description de contour du contour trouvÃ©, le moyen de dÃ©rivation Ã©tant agencÃ© pour dÃ©terminer, pour chaque point de rÃ©fÃ©rence (RQ), la distance (<maths id="math0026" num=""><math display="inline"><mrow><mtext>D(RQ) = d</mtext></mrow></math><img id="ib0026" file="imgb0026.tif" wi="21" he="5" img-content="math" img-format="tif" inline="yes"/></maths>) jusqu'Ã  un segment de contour le plus proche (k) et la direction (H(RQ)), au moins en tant qu'approximation, du segment de contour le plus proche.</claim-text></claim>
EP	0604687	B1	2000-04-19	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0604687&ki=B1&pd=2000-04-19
EP	0600143	B1	2000-01-19	de	TITLE	1	GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung
EP	0600143	B1	2000-01-19	en	TITLE	1	Electromagnetic radiation monitor
EP	0600143	B1	2000-01-19	fr	TITLE	1	Appareil pour surveiller une radiation Ã©lectromagnÃ©tique
EP	0600143	B1	2000-01-19	en	DESCR	1	<p id="p0001" num="0001">This invention relates to radiation monitors, and more specifically relates to an electromagnetic radiation monitor which may either be worn by persons who may be exposed to potentially harmful levels of electromagnetic energy or may be strategically positioned at a fixed location whereby persons will be alerted as to the presence of potentially harmful levels of electromagnetic radiation. Even more particularly, this invention relates to a personal or area (fixed position) electromagnetic radiation monitor which exhibits broadband frequency performance and polarization independence.</p><p id="p0002" num="0002">Attempts have been made to male an electromagnetic radiation monitor which may be worn by a person working in areas where potentially harmful electromagnetic radiation may be present or which may be strategically positioned at a fixed location to detect excess leakage of RF radiation and alert persons to the leakage. Early studies, such as those reported by Beischer in his article <u>Microwave Reflection, Diffraction and Transmission By Man</u>, Department of Naval Aerospace Medical Research Lab, Pensacola, Florida, June, 1973, have shown that scattering from a body may produce errors greater than 2dB. This scattering becomes more significant where broadband frequency performance and independence of polarization are desired monitor characteristics. To this date, no practical device having a broadband frequency response and being independent of polarization, to the knowledge of the inventor, has been successfully marketed.<!-- EPO <DP n="2"> --></p><p id="p0003" num="0003">It is also known from document GB-A-803792 an apparatus for radio frequency measuring comprising a transmitter and a receiver located in a chamber. The transmitter is placed at the focus of a curved reflecting wall, and walls with wave-absorbing layers are placed along the lateral walls of the chamber so as to ensure that only the direct wave from the transmitter and the reflected waves from the curved reflecting wall can reach the receiver. The apparatus also presents a backing made of a graduated lossy material.<!-- EPO <DP n="3"> --></p><p id="p0004" num="0004">It is also known from document GB-A-998779 a portable measuring instrument for detecting high frequency electromagnetic radiation. The device comprises circular housing having two two pairs of slot aerials of different lenghts so as to detect the presence of electromagnetic radiations over a wide frequency range.</p><p id="p0005" num="0005">A conducting surface may be placed behind the low frequency aerials to provide a capacitive shunt effect so as to reduce their response to high frequency components of radiation, and the device may be backed by material having an appreciable dielectric loss at the higher frequencies to reduce the response of the high frequency aerials at the lower frequencies, at which frequencies the lossy material will appear reactive.</p><p id="p0006" num="0006">It is an object of the present invention to provide an electromagnetic radiation monitor which may be worn by persons who may be exposed to potentially harmful levels of electromagnetic energy.<!-- EPO <DP n="4"> --></p><p id="p0007" num="0007">It is another object of the present invention to provide an electromagnetic radiation monitor which exhibits broadband frequency performance and substantial independence of polarization.</p><p id="p0008" num="0008">It is a further object of the present invention to provide an unobtrusive, pocket-size personal electromagnetic radiation monitor which accurately detects RF radiation and sends out a warning the moment it senses that the wearer moves into a danger zone.</p><p id="p0009" num="0009">It is yet another object of the present invention to provide an electromagnetic radiation monitor that includes an audible and visual alarm which will indicate a need to leave an area promptly.</p><p id="p0010" num="0010">It is still another object of the present invention to provide a personal electromagnetic radiation monitor which includes a dual battery system and a low battery warning when battery replacement is required.</p><p id="p0011" num="0011">It is yet a further object of the present invention to provide a personal electromagnetic radiation monitor which includes structure that allows sensitive electronic circuitry contained in the monitor to operate correctly while effectively "surrounded" by high level RF radiation, thereby producing minimal false alarms within or outside of the monitor's specified frequency range.</p><p id="p0012" num="0012">It is still a further object of the present invention to provide a personal electromagnetic radiation monitor whose performance is substantially unaffected due to scattering when worn by a person.</p><p id="p0013" num="0013">It is yet a further object of the present invention to provide an area (fixed position) electromagnetic radiation monitor by which an area near a source of high<!-- EPO <DP n="5"> --> power RF or microwave energy can be monitored.</p><p id="p0014" num="0014">It is still a further object of the present invention to provide an area (fixed position) electromagnetic radiation monitor which accurately detects RF or microwave energy within a broad frequency range independent of polarization and sends out a warning when irradiated by power exceeding a threshold amount.</p><p id="p0015" num="0015">It is yet still a further object of the present invention to provide an area (fixed position) electromagnetic radiation monitor which includes an audio and visual alarm and includes structure that allows sensitive electronic circuitry contained in the monitor to operate correctly while irradiated.<!-- EPO <DP n="6"> --></p><p id="p0016" num="0016">In accordance with the present invention as defined in Claim 1, a personal electromagnetic radiation monitor includes an electromagnetic radiation sensor, a backing of graduated lossy material and a conductive shield spaced apart from the sensor. The electromagnetic radiation sensor may include thin film resistive thermocouples. The radiation sensor is situated in proximity of the backing of graduated lossy material so that the backing is between the radiation sensor and one side of the conductive shield. The backing is progressively more conductive through its thickness from the front surface of the backing which faces the sensor to the back surface which faces the conductive shield. The radiation monitor also comprises an audible alarm transducer connected with the electromagnetic radiation sensor and an ear plug assembly in communication with the audible alarm transducer, the ear plug assembly being electrically non-conductive to prevent RF energy from being received by the assembly and radiated to the wearer's head.</p><p id="p0017" num="0017">In accordance with a preferred embodiment, the radiation sensor, backing of lossy material and conductive shield are all mounted in a housing of the monitor. On the inside of one of the housing sides is mounted an audible alarm transducer, which transducer is situated in alignment with an opening formed through the thickness of the housing side. A first hook and loop fastener patch is mounted on<!-- EPO <DP n="7"> --> the outside surface of the housing side and surrounding the opening.</p><p id="p0018" num="0018">Preferably, the monitor ear plug assembly has an elongated pneumatic tube having opposite ends, a pneumatic ear plug mounted on one end of the tube and a hollow housing defining an interior cavity mounted on the other end. The cavity housing has an opening formed through its thickness, and includes a second hook and loop fastener patch surrounding the opening. The second fastener patch is adapted to mate with the first fastener patch of the monitor housing to allow the cavity housing of the ear plug assembly to be mounted adjacent to the transducer. In this manner, the non-conductive ear plug assembly may be quickly and easily secured to the monitor housing so that the wearer of the monitor may use the ear plug assembly in high noise environments.</p><p id="p0019" num="0019">In accordance with another preferred embodiment, the monitor includes an alarm circuit and a dual battery system, and a low battery sensor. When a low battery voltage is detected on one battery, the audible alarm transducer will chirp at a predetermined interval. At an extremely low battery level, the audible alarm will emit a continuous tone. The second battery is used substantially independently of the first battery to illuminate a warning light in dangerous radiation environments. If the warning light circuit fails, the audible alarm circuit will continue to function.</p><p id="p0020" num="0020">In a further preferred embodiment, the sensitive electronic circuitry of the monitor is protected from high level RF radiation by including a second section of graduated lossy material situated in the housing and at least partially surrounding the batteries of the monitor. In this way, RF energy<!-- EPO <DP n="8"> --> entering the monitor will be absorbed by this second section before it is "picked up" by the battery leads between the circuitry and the battery.</p><p id="p0021" num="0021">In accordance with a further embodiment, an area electromagnetic radiation monitor is provided. The area electromagnetic radiation monitor includes a radiation sensor proximately situated to a backing of graduated lossy material, a sensor and an extruded, non-conductive housing structure which is affixed to a conductive shield and encases the radiation sensor and graduated lossy material.</p><p id="p0022" num="0022">In accordance with another preferred solution, the backing of graduated lossy material comprises a laminate formed from at least first, second and third layers of lossy material having different resistivities, wherein the first layer is more resistive than the second layer and wherein the second layer is more resistive than the third layer. The third layer being positioned closest to the conductive shield and the first layer being tapered so as to minimize field distortion.</p><p id="p0023" num="0023">These and other objects, features and advantages of the present invention will become apparent from the following detailed description of illustrative embodiments thereof, which is to be read in connection with the accompanying drawings, in which:<ul id="ul0001" list-style="dash" compact="compact"><li>Fig. 1 is a front perspective view of a personal electromagnetic radiation monitor formed in accordance with the present invention;</li><li>Fig. 2 is a rear perspective view of the radiation monitor of the present invention;</li><li>Fig. 3 is an exploded view, in perspective, of a portion of the monitor shown in Fig. 1;</li><li>Fig. 4 is a front view of a preferred form of a radiation sensor for use in the monitor of the present<!-- EPO <DP n="9"> --> invention;</li><li>Fig. 5 is a cross-sectional view of an ear plug assembly for use with the monitor of the present invention;</li><li>Fig. 6 is a graph illustrating the performance of the radiation monitor of the present invention over frequency in free space and when worn by a user;</li><li>Fig. 7 is a preferred form of an electronic circuit used in conjunction with the monitor of the present invention;</li><li>Fig. 8 is an elevated perspective view of an area electromagnetic radiation monitor formed in accordance with a second form of the present invention;</li><li>Fig. 9 is a cross-sectional view of the area electromagnetic radiation monitor shown in Figure 8.</li></ul></p><p id="p0024" num="0024">A first embodiment of the electromagnetic radiation monitor of the present invention is shown in Figs. 1 and 2 of the drawings, it will be seen that a personal electromagnetic radiation monitor constructed in accordance with one form of the present invention includes a two piece housing 2. Mounted on the inside surface of the front wall 4 of the two piece housing is an audible alarm transducer 6 (see Fig. 3), such as a piezo ceramic transducer, which, as will be explained, provides a warning of high level RF radiation or that the battery used in the monitor is at a low voltage. During an initial turn-on test, the audible alarm 6 preferably provides a one second burst. Above a preset threshold of the detected RF energy, the alarm provides a periodic nominal one second burns with the repetition rate increasing with the level of exposure. When the monitor battery is at a low voltage, the alarm 6 provides an audible chirp every forty seconds to a continuous warble (as the battery voltage drops). If the battery voltage is so low that the electromagnetic radiation sensor used in the monitor fails, the audible alarm provides a continuous tone.<!-- EPO <DP n="10"> --></p><p id="p0025" num="0025">The personal electromagnetic radiation monitor of the present invention further includes a visual display in the form of a light emitting diode (LED) 8. The LED 8 is mounted on the upper wall 10 of the mated housing. During an initial turn-on test, the circuitry included in the monitor will illuminate the LED 8. When a predetermined amount of RF energy is detected by the monitor, the electronic circuitry will cause the LED 8 to light and the audible alarm 6 to beep, indicating a need for the wearer of the monitor to leave the area promptly.</p><p id="p0026" num="0026">The monitor further includes an on/off switch 12 mounted on a side wall 14 of the mated housing, as well as a resilient clip 16 mounted on the back wall 18 of the housing to allow the monitor to be carried by the wearer on his belt or shirt pocket.</p><p id="p0027" num="0027">The radiation monitor of the present invention also includes an ear plug assembly 20 so that the monitor may be used in high noise environments. As shown in Figs 1 and 5 of the drawings, a Velcro (TM) hook and loop fastener patch 22 is mounted on the outside surface of the housing wall 4 on which the transducer 6 is mounted and situated to surround an opening 23 formed in the wall and aligned with the transducer. The ear plug assembly 20 includes an elongated hollow tube 24. A pneumatic ear piece or ear plug 26 is mounted on one end of the tube 24, and a hollow housing 28 defining an interior cavity 30 is mounted on the other end. The cavity housing 28 has an opening 32 formed through its thickness, and includes a second hook and loop fastener patch 34 surrounding the opening 32 which is adapted to mate with the first hook and loop fastener patch 22 of the monitor housing. This will allow the cavity housing 28 to be mounted adjacent to the transducer 6 so that the tone emitted by the transducer will be carried by air pressure through the tube to the pneumatic ear plug<!-- EPO <DP n="11"> --> 26.</p><p id="p0028" num="0028">One advantage of the ear plug assembly 20 of the present invention is that it is completely electrically non-conductive. Thus, the ear plug assembly will not pick up RF energy which might have otherwise affected the electronic circuitry of the monitor, as a conventional electrical transducer would, and further provides a safety feature in that the user of the monitor does not wear an electrically conductive device on his head, to prevent electrical shock and to prevent RF energy from being picked up by the ear plug assembly and being radiated to the wearer's head. The mating Velcro (TM) hook and loop fastener patches 34, 22 on the ear plug assembly and the monitor housing allow the ear plug assembly to be quickly and easily connected non-electrically to the radiation monitor.</p><p id="p0029" num="0029">Referring now to Fig. 3 of the drawings, it will be seen that a preferred form of the personal electromagnetic radiation monitor of the present invention includes a first housing half 36 on which is mounted the transducer 6, as mentioned previously, and a second housing half 38 which includes a battery compartment 40, and on which is mounted the on/off switch 12. Sandwiched between the housing halves is an electromagnetic radiation sensor 44, a backing of graduated lossy material 46, a conductive shield 48 which acts as a back or ground plane, and a printed circuit board 50 containing the electronic circuitry for the monitor.</p><p id="p0030" num="0030">The electromagnetic radiation sensor 44 preferably includes thin film resistive thermocouples. In one form of the present invention, the electromagnetic radiation sensor includes a pair of mutually orthogonally disposed antenna elements 52 residing coplanarly to each other, but more preferably includes four interconnected antenna elements 52, adjacent antenna elements being at right<!-- EPO <DP n="12"> --> angles to each other, all four antenna elements 52 residing in the same plane, as shown in Fig. 4. Each antenna element 52 extends along a respective longitudinal axis, and includes an array of the thin film resistive thermocouples 54 arranged along the axis, and a plurality of spaced apart conductive elements 56 of discrete length arranged transversely to the axis of the array. Each thermocouple 54 of each antenna element is disposed between adjacent conductive elements 56. The antenna arrangement used in the radiation monitor of the present invention is very similar to that disclosed in U.S. Patent No. 4.518.912.</p><p id="p0031" num="0031">The thin film elements function as both antenna and detector. Preferably, the hot and cold junctions of the thermocouples are separated by only a 0,5 millimetre, thereby eliminating offsets due to changes in ambient temperature, either spatial or temporal. The use of the thin film resistive thermocouples 54 in the particular arrangement described above provides broadband, true RMS detection of electromagnetic energy.</p><p id="p0032" num="0032">The electromagnetic radiation sensor 44 is mounted against a thin Mylar (TM), or more preferably, Kapton (TM) spacer sheet 58. The spacer 58 is preferably about 0,0127 centimetres in thickness, and is provided to prevent shorting of the sensor on the lossy material backing 46.</p><p id="p0033" num="0033">The lossy material backing 46 is graduated in resistivity. More specifically, the backing includes a front surface 60 facing the sensor 44 and an opposite back surface 62 facing the conductive shield 48. The backing is progressively more conductive through its thickness from the front surface 60 to the back surface 62. In one form of the invention, the backing may be a laminate or sandwich of two or more layers of lossy<!-- EPO <DP n="13"> --> material having different resistivities, as shown in Fig. 3. Alternatively, the backing may be formed from a lossy material which is continuously more conductive through its thickness from the front surface to the back surface.</p><p id="p0034" num="0034">When a backing of a laminate of two layers of lossy material is used, the first layer 64 closest to the sensor is preferably a 0,635 centimetres thick high resistivity material, and the second layer 66 closest to the conductive shield is preferably a 0,635 centimetres thick low resistivity material. The first layer 64 preferably has a resistivity of about 15kÎ© (kilo ohms) per cubic centimetre, and has a surface resistivity of approximately 20.000 ohms per square centimetre. The second layer 66 has a lower resistivity of approximately 600 ohms per cubic centimetre, and has a surface resistivity of approximately 2.000 ohms per square centimetre.</p><p id="p0035" num="0035">The higher resistivity surface of the lossy material backing is positioned to face the radiation sensor 44, while the lower resistance surface of the backing is positioned to face the conductive shield plate 48 such that the resistive material becomes progressively more conductive as the electric field penetrates deeper into the backing. Thus, the lossy material backing is terminated with the substantially totally reflective plate 48. The conductive shield plate 48 also provides some of the shielding for the electronic circuitry of the monitor.</p><p id="p0036" num="0036">The distributed resistance of the sensor 44, in combination with the sensor's being mounted on the lossy material backing 46 which gradually decreases in resistivity towards the conductive shield plate, provides broadband operation. The resistance of the sensor being large relative to the antenna reactance<!-- EPO <DP n="14"> --> maintains a constant sensitivity with frequency over the operating band.</p><p id="p0037" num="0037">Fig. 6 compares the variation in the threshold which will sound the monitor alarm over the operating frequency, which is preferably between 2 Gigahertz and 18 Gigahertz when the monitor is worn by a user and when it is standing in free space. It is evident from the graph shown in Fig. 6 that the broadband personal monitor of the present invention is made essentially independent of its operative environment. The scattering from the wearer's body has little affect on the performance of the monitor. As essentially flat frequency response with less than Â± 1,5 dB variation and an independence of field perturbation due to scattering from the subject's body results from the utilization in the monitor of the thin film resistive thermocouple elements 54 mounted adjacent the graduated lossy material backing 46 which itself is backed with the conductive shield plate 48. The difference in response from when the monitor is irradiated by electromagnetic energy on a person from when it is supported in free space on a low dielectric material is less than 0,5 dB.</p><p id="p0038" num="0038">The radiation sensor 44 is coupled to the electronic circuitry of the monitor by using a flexible transmission line 68 consisting of at least two leads of carbon impregnated TFE material. The two leads of this transmission line 68 carry the DC output from the sensor to the electronic circuitry. These leads have a resistance of approximately 3937 ohms per centimetre. The two DC leads are connected to one of the four antenna elements 52 and in particular to respective conductive elements 56 at the most outward end of the antenna element, as shown in Fig. 4 of the drawings.</p><p id="p0039" num="0039">Fig. 7 illustrates one form of an electronic circuit for use with the radiation monitor. Integrated circuit U1<!-- EPO <DP n="15"> --> acts as a quasi-regulated voltage source, and provides regulated -3 volts on circuit terminal E2 (-V) and unregulated, approximately 9 volts on circuit terminal E1 (+V). Battery B1, which is preferably a 12 volt miniature battery, is coupled across terminals E1 and E2. Diode CR1 acts as a zener diode in a starved condition and provides approximately 3 volts as a reference voltage for integrated circuit U1. Potentiometer R28 provides an adjustment of the regulated -3 volts.</p><p id="p0040" num="0040">Integrated circuit U4 acts as a comparator. It triggers on a positive going pulse from integrated circuit U3, as will be explained, and latches up through hysteresis (i.e., feedback resistor R7) to cause LED CR3 (which is the visual alarm LED 8) to remain illuminated. The output of circuit U4 is coupled to the base of driver transistor Q1, whose collector is coupled to LED CR3. LED CR3 is powered by an auxiliary 3 volt battery.</p><p id="p0041" num="0041">Separate 12 volt and 3 volt batteries are used in the monitor to provide a fail-safe measure. Since the LED draws the most current, that is, approximately 500 milliamps, if the LED fails due to a low battery, the rest of the circuit which is powered by the 12 volt battery continues to operate to provide a warning to the user that high RF energy is present. Since the exposure light (i.e., the LED) is powered from a separate battery, maximum life is provided for the battery which powers the audible alarm. The battery for the audible alarm is envisioned to last approximately 30 days in a "sleep" mode and 6 hours in a continuous alarm state. The exposure light will last approximately 100 hours in a continuous lighted state.</p><p id="p0042" num="0042">Integrated circuit U2 is an operational amplifier configured as a conditioning amplifier with a gain of approximately 1.000. Potentiometer R9 is provided as a<!-- EPO <DP n="16"> --> gain adjustment. The amplifier amplifies the signal from the radiation sensor which is coupled to circuit terminals E7 and E8, and amplifies that signal before providing it to integrated circuit U3.</p><p id="p0043" num="0043">Resistor R10, which is coupled to one leg of potentiometer R9, is a sensitor (i.e., a thermally sensitive resistor, or thermistor) and is provided to compensate for temperature variations so that conditioning amplifier U2 will provide more or less gain, as needed, as the temperature varies.</p><p id="p0044" num="0044">Integrated circuit U3 is a conventional circuit used in smoke detectors. Smoke detector circuit U3 provides a regulated voltage on its pin 1 which, in the case of the monitor circuit, is a 3 volt reference voltage to ground. Resistor R19 and R20 comprise a resistor network which provides a 1 volt alarm threshold on pin 2 of circuit U3. A standard piezo electric transducer 6 is coupled through terminals E4, E5 and E6 to pin numbers 8, 9 and 10 of circuit U3. A suitable transducer which may be used is Part No. PKM 11-6A0 manufactured by Murata-Erie Co.</p><p id="p0045" num="0045">The resistor circuit shown in dashed line A, in conjunction with potentiometer R26, provides an adjustment to correct the offset bias of conditioning amplifier U2.</p><p id="p0046" num="0046">The circuit of the radiation monitor of the present invention operates in the following manner. The radiation sensor 44 generates 1 millivolt per 1 milliwatt per square centimetre of RF energy which irradiates it. This signal is carried by the transmission line 68 described previously to the inputs of conditioning amplifier U2. U2 amplifies the 1 millivolt signal from the radiation sensor (that is, when the sensor is irradiated with 1 milliwatt per<!-- EPO <DP n="17"> --> square centimetre of energy) by 1.000 to provide an output signal which is approximately 1 volt. The 1 volt signal is provided to pin 3 of the smoke detector circuit U3. If the amplified signal from conditioning amplifier U2 is greater than the 1 volt threshold on pin 2 of circuit U3, the output of circuit U3 of pin 12 will provide a positive going pulse through diode CR2 to the non-inverting input (pin 3) of comparator U4.</p><p id="p0047" num="0047">In response to this pulse, the output of comparator U4, at pin 6, will go to a positive voltage and bias transistor Q1 on. Transistor Q1 will conduct current through LED CR3 to illuminate the LED of the radiation monitor. Hysteresis will keep comparator U4 latched until the circuit is reset.</p><p id="p0048" num="0048">Also, smoke detector circuit U3 sounds the piezo electric alarm 6 (Fig. 3) when the threshold is exceeded. Circuit U3 further monitors the battery voltage. When the battery voltage drops to approximately 7,5 volts, circuit U3 will cause the alarm to emit a chirp every 40 seconds. If the battery drops further in voltage, the chirps emitted by the alarm will become more frequent until a battery voltage is reached which causes the alarm to emit a continuous warble tone.</p><p id="p0049" num="0049">The monitor of the present invention further provides a self-test upon turn on. Capacitor C2, which is connected between the input (pin 3) of the conditioning amplifier U2 and the regulated 3 volt output of circuit U3 (at pin 1), is initially uncharged, thus providing a test voltage to be applied to the inputs (pins 3 and 2) of conditioning amplifier U2 through the resistor divider network comprised of resistors R16 and R17 and the input resistor R15. This test voltage is approximately 1 millivolt, which is comparable to the voltage which would be provided by the radiation sensor when the sensor is illuminated with RF energy of 1 milliwatt per<!-- EPO <DP n="18"> --> square centimetre. The test voltage is amplified by circuit U2, and smoke detector circuit U3 sounds the alarm and causes comparator U4 to go to a positive state on its output, thereby turning on transistor Q1 and illuminating LED CR3. Comparator U4 is not latched under these test conditions. This is because capacitor C8, which is coupled between the regulated -3 volts and the positive supply voltage input (pin 7) of comparator U4 and one side of resistor R8 whose other side is connected to the unregulated 9 volt supply, is initially uncharged. Capacitor C8 prevents the positive supply voltage from being supplied to pin 7 of comparator U4. Circuit U4 will note latch up through hysteresis feedback resistor R7 under these conditions until capacitor C8 has become charged. At that time however, capacitor C2 has become fully charged and effectively removes the test voltage from the inputs of conditioning amplifier U2. The output of amplifier U2 thereby falls below the 1 volt threshold, and the output signal from circuit U3 returns to a low level. This, in turn, causes the output signal of comparator U4 to return to a low logic level, thereby cutting off transistor Q1 and turning off warning LED CR3.</p><p id="p0050" num="0050">To ensure that the various capacitors and other components in the electronic circuitry of the monitor are fully discharged when the monitor is shut off, which thereby prevents false alarms as well as prevents comparator U4 from latching, a single pole, double throw switch is used as the on/off switch 12. The positive side of battery B1 is coupled to one pole (S1-1) (fig. 3) of the switch. The wiper terminal (S1-2) (Fig. 3) of the switch is coupled to the E1 terminal of the electronic circuit board. The E2 terminal is connected directly to the negative terminal of the battery and to the other pole (S1-3) (Fig. 3) of the switch. Accordingly, when the switch 12 is in the on position, wiper S1-2 contacts pole S1-1 to provide voltage from<!-- EPO <DP n="19"> --> battery B1 across terminals E1 and E2. When the switch is in the off position, wiper S1-2 contacts the opposite pole S1-3 and provides a short circuit across terminals E1 and E2. Because transistor Q1 remains cut off, when LED CR3 is not illuminated, negligible current is drawn from battery B2 when the monitor is off.</p><p id="p0051" num="0051">A parts list for the circuit shown in Fig. 7 is provided below. Aslo, the pin members shown in Fig. 7 for integrated circuits U1-U4 relate to the parts specified in the list although, of course, it is envisioned that components comparable to those listed below, connected differently from that shown in Fig. 7, may be suitable for use. <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm"/><colspec colnum="2" colname="col2" colwidth="78.75mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col2" align="center">PARTS LIST FOR CIRCUIT SHOWN IN FIG. 7</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Part Description</entry><entry namest="col2" nameend="col2" align="center">Reference Designation</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">TRANSISTOR 2N4124</entry><entry namest="col2" nameend="col2" align="left">Q1</entry></row><row><entry namest="col1" nameend="col1" align="left">WIRE, BUSS</entry><entry namest="col2" nameend="col2" align="left">W1-2</entry></row><row><entry namest="col1" nameend="col1" align="left">CAPACITOR 22 ÂµF</entry><entry namest="col2" nameend="col2" align="left">C7-8</entry></row><row><entry namest="col1" nameend="col1" align="left">CAPACITOR 0, 1 ÂµF</entry><entry namest="col2" nameend="col2" align="left">C2,C3,C6</entry></row><row><entry namest="col1" nameend="col1" align="left">CAPACITOR 0,01 ÂµF</entry><entry namest="col2" nameend="col2" align="left">C4,C5</entry></row><row><entry namest="col1" nameend="col1" align="left">CAPACITOR 0,001 ÂµF</entry><entry namest="col2" nameend="col2" align="left">C1</entry></row><row><entry namest="col1" nameend="col1" align="left">LIGHT EMITTING DIODE</entry><entry namest="col2" nameend="col2" align="left">CR3</entry></row><row><entry namest="col1" nameend="col1" align="left">DIODE</entry><entry namest="col2" nameend="col2" align="left">CR2</entry></row><row><entry namest="col1" nameend="col1" align="left">ZENER DIODE</entry><entry namest="col2" nameend="col2" align="left">CR1</entry></row><row><entry namest="col1" nameend="col1" align="left">IC CHIP - CA3169A</entry><entry namest="col2" nameend="col2" align="left">U3</entry></row><row><entry namest="col1" nameend="col1" align="left">IC CHIP - CA3078</entry><entry namest="col2" nameend="col2" align="left">U1,U4</entry></row><row><entry namest="col1" nameend="col1" align="left">IC CHIP - OP22EZ</entry><entry namest="col2" nameend="col2" align="left">U2</entry></row><row><entry namest="col1" nameend="col1" align="left">CAPACITOR 1 ÂµF</entry><entry namest="col2" nameend="col2" align="left">C9</entry></row><row><entry namest="col1" nameend="col1" align="left">POTENTIOMETER 1 MÎ©</entry><entry namest="col2" nameend="col2" align="left">R27,R28</entry></row><row><entry namest="col1" nameend="col1" align="left">POTENTIOMETER 10 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R26</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 2,4 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R32</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 360 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R9</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 62 Î©</entry><entry namest="col2" nameend="col2" align="left">R23</entry></row><row><entry namest="col1" nameend="col1" align="left">rESISTOR 3 MÎ©</entry><entry namest="col2" nameend="col2" align="left">R15,22</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 200 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R8,18</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 20 MÎ©</entry><entry namest="col2" nameend="col2" align="left">R17,31</entry></row><!-- EPO <DP n="20"> --><row><entry namest="col1" nameend="col1" align="left">RESISTOR 6,2 MÎ©</entry><entry namest="col2" nameend="col2" align="left">R16</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 510 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R13-14, R20</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 10 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R9,R11,R12</entry></row><row><entry namest="col1" nameend="col1" align="left">SENSITOR 680 Î©</entry><entry namest="col2" nameend="col2" align="left">R10</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 2 MÎ©</entry><entry namest="col2" nameend="col2" align="left">R7</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 3,3 MÎ©</entry><entry namest="col2" nameend="col2" align="left">R6</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 5,1 MÎ©</entry><entry namest="col2" nameend="col2" align="left">R21</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 820 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R2,R5</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTORS 1 MEG Î©</entry><entry namest="col2" nameend="col2" align="left">R1,3,4,19,29</entry></row><row><entry namest="col1" nameend="col1" align="left">RESISTOR 100 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R24</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">RESISTOR 51 kÎ©</entry><entry namest="col2" nameend="col2" align="left">R30</entry></row></tbody></tgroup></table></tables></p><p id="p0052" num="0052">Battery B1 is a 12 volt miniature battery and is received by a receptacle 70 mounted in a battery compartment 40 of the housing. Battery B2, in one form of the invention, is comprised of a pair of 1,5 volt button batteries connected in series and mounted in a separate receptacle 72 containing a spring 74 for biasing the batteries against contacts in the housing.</p><p id="p0053" num="0053">To further ensure that no RF energy affects the performance of the monitor, the battery compartment 40 which houses batteries B1 and B2 is provided with additional lossy material 76 so that the receptacles 70, 72 which receive batteries B1 and B2, respectively, are at least partially surrounded by the material. The material 76 is preferably progressively more conductive through its thickness from the back wall 18 of the housing to the conductive shield plate 48, as with the lossy material backing 46 described previously.</p><p id="p0054" num="0054">The radiation monitor of the present invention accurately detects RF radiation without being affected by body scattering caused by the wearer's body. Its compact size allows it to be worn on a belt using the clip 16 (Fig. 2) provided or in the wearer's pocket. Its broadband frequency performance and independence of polarization make the monitor perfectly adaptable for<!-- EPO <DP n="21"> --> use in a variety of RF environments. The audible alarm 6 provides a warning of RF exposure, and the LED 8 provides a visual indication as well. The LED latches so as to provide a record that the wearer was exposed to RF energy, in the event the wearer did not hear the audible alarm before he left the danger zone.</p><p id="p0055" num="0055">The personal electromagnetic radiation monitor of the present invention is further quite suitable for use in high ambient noise environments. The ear plug assembly 20 includes ear plugs which may be used in conjunction with ear phones, and is non-electrically conductive to prevent injury to the wearer and misreadings or damage to the electronic circuitry of the monitor. The Velcro (TM) hook and loop fastener patches used on the ear plug assembly and the housing of the monitor allows the user to quickly and easily connect the ear plug assembly to the transducer on the housing with no electrical connection required.</p><p id="p0056" num="0056">An alternative embodiment of the electromagnetic radiation monitor of the present invention, specifically an area (fixed position) electromagnetic radiation monitor 100, is shown in Figure 8. The monitor includes an electromagnetic radiation sensor 121 (shown in fig. 9), a conductive shield 101, a housing 102, a conductive electronic casing 103 mounted upon the conductive shield, and a backing of graduated lossy material in the form of a first layer 118, a second layer 119 and a third layer 120 (as shown in Fig. 9). The backing of graduated lossy material is interposed between the radiation sensor and the conductive shield. The backing is progressively more conductive through its thickness from the first layer 118 to the third layer 120.</p><p id="p0057" num="0057">The area (fixed position) electromagnetic radiation monitor 100 is designed to monitor a region near a source of high power radio frequency (RF) or microwave<!-- EPO <DP n="22"> --> energy. In the event that a break or component failure occurs, the monitor will generate an alarm if it detects RF power exceeding a predetermined threshold. The operating frequency range of the present invention is 0,5 Gigahertz to 40 Gigahertz.</p><p id="p0058" num="0058">The area electromagnetic radiation monitor is designed with a backing of graduated lossy material 118,119,120 which becomes progressively more conductive through its thickness with increasing distance from the radiation sensor 121. The backing consists of three layers. The first layer 118, closest to the radiation sensor, has a volume resistivity of approximately 15kÎ© per cubic centimetre and a surface resistance of approximately 20kÎ© per square centimetre. The second layer 119, which is contiguous with the first layer 118, and a third layer 120, which is contiguous with the second layer 119, have volume resistivities and surface resistances of approximately 600Î© per cubic centimetre, 150Î© per cubic centimetre, 2000Î© per square centimetre and 500Î© per square centimetre respectively. The third layer 120, which is the least resistive layer, is affixed to the conductive shield 101.</p><p id="p0059" num="0059">The housing 102 is a substantially rectangular one-piece extrusion having a top level portion 111, a first side 107, a second side 104, a third side 105 opposite the first side and a fourth side 106 opposite the second side. The four sides are disposed adjacent to and orthogonal to the edges of conductive shield 101. Contiguous with the second side 104 is a tapered surface 108 which extends up at an angle to meet top level portion 111. In a like manner, a tapered surface 109 and a tapered surface 110 are respectively contiguous with third and fourth sides 105 and 106, extending therefrom at an angle to meet top level portion 111. The optimal taper angle of surface 108, 109 and 110 is 45Â° so as to provide minimal field distortion.<!-- EPO <DP n="23"> --></p><p id="p0060" num="0060">Top level portion 111 has a cylindrical extrusion or boss 112 thereon which encloses the electromagnetic radiation sensor 121. The first side 107 of housing 102 does not have a tapered portion similar to tapered portions 108, 109, 110. First side 107 abuts conductive electronic casing 103. Electrical conductive casing 103 contains electronics similar to those of the personal electromagnetic radiation monitor as depicted in figures 1-7 and as previously described. Conductive electronic casing 103, however, may also contain a battery 122 (shown in Figure 9) within a battery compartment 113. The battery 122 is surrounded by a second backing 114 which can be similar to the graduated lossy material contained within housing 102. Also shown is an alarm test button 115 mounted upon the conductive electronic casing 103.</p><p id="p0061" num="0061">When an alarm electromagnetic radiation threshold is set and that value is exceeded, a piezoelectric horn 117 will sound and a light emitting diode (LED) 116 will illuminate. In a safe environment, the LED 116 can be arranged to flash intermittently, such as once every forty seconds to indicate to the user that the device is currently operating and monitoring the environment. Also, the horn 117 may be arranged to sound intermittently, such as once every forty seconds, if the battery voltage drops below a preset minimum such as 7,5 volts. A failsafe circuit, as previously described, may be included within the electronics so as to produce an alarm state if the sensor opens or fails. The electronics housed within conductive electronic casing 103 may be surrounded by second backing material 114 which also surrounds battery 122.</p><p id="p0062" num="0062">Referring now to Figure 9, a cross-sectional view of the above-described embodiment of the present invention is shown. Figure 9 shows an area (fixed position) electromagnetic radiation monitor 100 including a<!-- EPO <DP n="24"> --> conductive shield 101 upon which is mounted the housing 102 and the conductive electronic casing 103. The boss 112 is shown encasing sensor element 121 which is electrically coupled to conductive electronic casing 103 through conduit 124. It can be seen from the figure that a backing of graduated lossy material 118, 119, 120 extends from conductive shield 101 to the base or vertex of radiation sensor 121. In an alternative embodiment, a second battery 123 may be secured to conductive shield 101 and surrounded by the backing material. Second battery 123, which is shown in Figure 9, is an optional back-up battery.</p><p id="p0063" num="0063">Sensor element 121 consists of 3 mutually orthogonal thin film resistive thermocouple elements similar to those described in U.S. Patents 3.641.439, 3.794.914 and 4.518.912 and similar to the configuration described with regard to the personal electromagnetic radiation monitor. The higher frequency range of the area (fixed position) monitor is provided by the array configuration as described in U.S. Patent No. 4.629.978. Specifically, the vertex of the thermocouple elements is positioned at the outer surface of the highest resistivity backing, which is then tapered at its outer edges. The taper provides a wider incidence angle for reception of incoming energy thereby preventing or minimizing field distortion.</p><p id="p0064" num="0064">The response of radiation sensor 121 is relatively independent of polarization or the direction of propagation of the electromagnetic radiation except when the energy is propagated from behind the sensor unit and through the conductive shield 101. The monitor 100 acts as an isotropic antenna, receiving all electromagnetic energy within the space on the backing side of the plane of the conductive shield surface.</p><p id="p0065" num="0065">Altough illustrative embodiments of the present<!-- EPO <DP n="25"> --> invention have been described herein with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various other changes and modifications may be effected therein by one skilled in the art without departing from the scope of the invention.</p>
EP	0600143	B1	2000-01-19	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>An electromagnetic radiation monitor, which comprises:<claim-text>- an electromagnetic radiation sensor (44; 121);</claim-text><claim-text>- a conductive shield (48; 101), spaced apart from the sensor; and</claim-text><claim-text>- a backing of graduated lossy material, (46; 118, 119, 120), the backing being interposed between the radiation sensor (44; 121) and the conductive shield (48; 101) and having a front surface (60; 118) facing the sensor (44) and an opposite back surface (62; 120) facing the conductive shield (48; 101);<br/>characterized in that the backing is progressively more conductive through the thickness thereof from the front surface (60; 118) to the back surface (62; 120), the radiation monitor further comprising:</claim-text><claim-text>- an audible alarm transducer (6) connected with the electromagnetic radiation sensor (44; 121), and</claim-text><claim-text>- an ear plug assembly (20) in communication with the audible alarm transducer (6; 117), the ear plug assembly (20) being electrically non-conductive to prevent RF energy from being received by the assembly (20) and radiated to the wearer's head.</claim-text><!-- EPO <DP n="27"> --></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein the electromagnetic radiation sensor (44) includes a pair of mutually orthogonally disposed antenna elements (52) residing coplanarly to each other, each antenna element extending along a respective longitudinal axis and including an array of thin film resistive thermocouples (54) arranged along the axis, and a plurality of spaced apart conductive elements (55) of discrete length arranged transversely to the axis of the array, each thermocouple (54) of each antenna element (52) being disposed between adjacent conductive elements (56).</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>An electromagnetic radiation monitor as defined by claim 1, which further includes a sheet (58) of insulating material interposed between the sensor (44) and the backing of graduated lossy material (46).</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein the backing of graduated lossy material (46) comprises a laminate formed from at least first (64) and second (66) layers of lossy material having different resistivities, the first layer (64) having a higher resistivity than the second layer (66).</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein the backing (46) is formed from a lossy material which is continuously more conductive through the thickness thereof from the front surface (60) to the back surface (62).<!-- EPO <DP n="28"> --></claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>An electromagnetic radiation monitor as defined by claim 1, which further includes a housing (2), wherein the sensor (44), backing of graduated lossy material (46) and conductive shield (48) are mounted in the housing.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>An electromagnetic radiation monitor as defined by claim 6, wherein the audible alarm transducer (6) is mounted on a housing side; wherein the housing includes a hook and loop fastener patch (22) mounted on the outer surface of the housing side and positioned in proximity to the transducer (6); and wherein the electrically non-conductive ear plug assembly (20) includes an elongated pneumatic tube (24) having opposite first and second ends, a pneumatic ear plug (26) mounted on the first end of the tube and a hollow housing (28) defining an interior cavity (30) mounted on the second end of the tube, the hollow housing (28) having an opening (32) formed through the thickness thereof and including a second hook and loop fastener patch (34) surrounding the opening (32) and which is adapted to mate with the first hook and loop fastener patch (22) of the monitor housing to allow the hollow housing (28) to be mounted adjacent to the transducer (6), the ear plug (26) being in communication with the transducer (6) through the pneumatic tube (24), cavity and opening when the hollow housing (28) is mounted adjacent to the transducer (6).<!-- EPO <DP n="29"> --></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>An electromagnetic radiation monitor as defined by claim 6, wherein the conductor shield (48) has opposite first and second sides, the lossy material backing (46) being mounted adjacent to the first side of the shield (48); and wherein the monitor further comprises an alarm circuit, the alarm circuit being mounted in the housing (2) on the second side of the shield (48).</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>An electromagnetic radiation monitor as defined by claim 8, wherein the housing defines a battery compartment (40) situated on the second side of the shield (48); and wherein the monitor further includes a battery receptacle (70) situated in the battery compartment (40), and a second layer of graduated lossy material (76) situated in the compartment (40) and at least partially surrounding the battery receptacle, the lossy material (76) being progressively more conductive through its thickness from a backwall (18) of the housing (2) to the shield (48).</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>An electromagnetic radiation monitor as defined by claim 9, wherein the monitor further comprises a latching circuit and a light (8) mounted on the housing (2), the latching circuit being coupled to the alarm circuit and to the light (8), the latching circuit causing the light (8) to illuminate when a predetermined level of radiation is detected by the sensor (44), and further causing the light (8) to remain illuminated when the radiation detected by the sensor (44) falls below the predetermined level.<!-- EPO <DP n="30"> --></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein<claim-text>- the electromagnetic radiation sensor (44) includes a pair of mutually orthogonally disposed antenna elements (52) residing coplanarly to each other, each antenna element extending along a respective longitudinal axis and including an array of thin film resistive thermocouples (54) arranged along the axis, and a plurality of spaced apart conductive elements (56) of discrete length arranged transversely to the axis of the array, each thermocouple (54) of each antenna element being disposed between adjacent conductive elements (56);</claim-text><claim-text>- the conductive shield has opposite first and second sides;</claim-text><claim-text>- the back surface (62) of the backing of graduated lossy material (46) faces the first side of the conductive shield (48);<br/>and wherein said electromagnetic radiation monitor further comprises:</claim-text><claim-text>- a housing (2), the sensor (44) and backing of graduated lossy material (46) and conductive shield (48) being contained within the housing;</claim-text><claim-text>- the audible alarm transducer (6) being mounted on a housing side, the housing (2) including a hook and loop fastener patch (22) mounted on the outer surface of the housing side and positioned in proximity to the transducer (6);</claim-text><claim-text>- the electrically non-conductive ear plug assembly (20), including an elongated pneumatic tube (24) having opposite first and second ends, a pneumatic ear plug (26) mounted on the first end of the tube and a hollow housing (28) defining an interior cavity (30) mounted on the second end of the tube, the hollow housing (28) having an opening formed through the thickness thereof and including a second hook and loop fastening patch (34) surrounding the opening which is adapted to mate with the first hook and loop fastener patch (22) of the monitor housing to allow the hollow housing (28) to be mounted adjacent to the transducer (6), the ear plug (20) being in communication with the transducer (6) through the pneumatic tube (24), cavity and opening<!-- EPO <DP n="31"> --> when the hollow housing (28) is mounted adjacent to the transducer (6);</claim-text><claim-text>- a warning light (8) mounted on the housing (2); and</claim-text><claim-text>- an alarm circuit and a latching circuit, the alarm circuit and the latching circuit being mounted in the housing (2) adjacent to the second side of the shield (48), the alarm circuit being connected to the transducer (6) and being adapted to cause the transducer (6) to emit an audible sound when a predetermined level of radiation is detected by the sensor (44), the latching circuit causing the light (8) to illuminate when the predetermined level of radiation is detected by the sensor (44), and further causing the light (8) to remain illuminated when the radiation detected by the sensor (44) decreases in magnitude to below the predetermined level;</claim-text><claim-text>- the housing defining a battery compartment (40) situated on the second side of the shield (48), the monitor further including a battery receptacle (70) and a second backing of graduated lossy material (76) situated in the compartment and at least partially surrounding the battery receptacle, the lossy material (76) being progressively more conductive through its thickness from a backwall (18) of the housing (2) to the shield (48).</claim-text></claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein the electromagnetic radiation sensor (121) includes three mutually orthogonally disposed antenna elements (52), each antenna element extending from a vertex formed at the front surface of the backing and including an array of thin film resistive thermocouples (54) arranged along the axis of each antenna element (52), and a plurality of spaced apart conductive elements (56) of discrete length arranged transversely to the axis of the array, each thermocouple (54) of each antenna element (52) being disposed between adjacent conductive elements (56).<!-- EPO <DP n="32"> --></claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein the backing of graduated lossy material (46; 118, 119, 120) comprises a laminate formed from at least first (118), second (119) and third (120) layers of lossy material having different resistivities, the first layer (118) having a higher resistivity than the second layer (119), the second layer (119) having a higher resistivity than the third layer (120).</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>An electromagnetic radiation monitor as defined by claim 13, wherein the first (118), second (119) and third (120) layers have volume resistivities of substantially 15kÎ© per cubic centimetre, 600Î© per cubic centimetre and 150Î© per cubic centimetre, respectively, and surface resistances of substantially 20kÎ© per square centimetre, 2kÎ© per square centimetre and 500Î© per square centimetre, respectively.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>An electromagnetic radiation monitor as defined by claim 1, further comprising an electronic control section having an alarm circuit, and a housing (102) mounted on the conductive shield (101) in which the sensor (121) and backing (46; 118, 119, 120) of graduated lossy material are disposed, the electronic control section being contained within a conductive electronic casing (103) and mounted on the conductive shield (101) adjacent to the housing (102); wherein the monitor further includes a visual alarm transducer (116) and an alarm test button (115), all of which are mounted on the conductive electronic casing (103).</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>An electromagnetic radiation monitor as defined by claim 15, wherein the housing (102) is a rectangular shaped extrusion comprising a housing top and four sides, a first side (107) abutting the conductive electronic casing (103), the second (104), third (105) and fourth (106) sides being disposed adjacent to and orthogonal to the edges of the conductive shield (101); and wherein the housing top comprises three tapered portions (108, 109, 110)<!-- EPO <DP n="33"> --> extending up at an angle from each of the second (104), third (105) and fourth (106) sides, each tapered portion being contiguous with a level portion (111) of the housing top upon which is disposed a cylindrical boss (112), the level portion (111) of the housing top also being contiguous with the first side (107).</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>An electromagnetic radiation monitor as defined by claim 15, wherein the conductive electronic casing (103) includes a battery compartment (113) for securing a battery (122) therein, and wherein the battery compartment (113) further includes a battery receptacle situated therein, and a second backing (114) of graduated lossy material situated in the compartment (113) to at least partially surround the battery receptacle.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>An electromagnetic radiation monitor as defined by claim 17, wherein the monitor further comprises a latching circuit mounted on the housing, the latching circuit being coupled to the alarm circuit and to the visual alarm transducer (116), the latching circuit causing the visual alarm transducer (116) to activate when a predetermined level of electromagnetic radiation is detected by the sensor (121), and further causing the visual alarm transducer (116) to remain activated when the radiation level detected by the sensor (121) falls below the predetermined level.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein:<claim-text>- the electromagnetic radiation sensor (121) includes three mutually orthogonally disposed antenna elements (52) extending from a vertex, each antenna element extending along a respective longitudinal axis and including an array of thin film resistive thermocouples (54) arranged along the axis, and a plurality of spaced apart conductive elements (56) of discrete length arranged transversely to the axis of the array, each thermocouple (54) of each antenna element (52) being disposed<!-- EPO <DP n="34"> --> between adjacent conductive elements (56);</claim-text><claim-text>- the conductive shield (101) has opposite first and second sides;</claim-text><claim-text>- the back surface (62) of the backing of graduated lossy material (118, 119, 120) faces the first side of the conductive shield (101) and<br/>wherein said electromagnetic radiation monitor further comprises:</claim-text><claim-text>- a conductive electronic casing (103) attached to the conductive shield (101);</claim-text><claim-text>- a housing (102), the sensor (121) and backing of graduated lossy material (46; 118, 119, 120) being contained within the housing and mounted to the conductive shield (101), at least one side of the housing being adjacent to the conductive electronic casing (103);</claim-text><claim-text>- the audible alarm transducer (117) being mounted on the conductive electronic casing;</claim-text><claim-text>- a visual alarm (116) mounted on the conductive electronic casing (103); and</claim-text><claim-text>- an alarm circuit and a latching circuit, the alarm circuit and the latching circuit being mounted in the conductive electronic casing (103), the alarm circuit being connected to the audible alarm transducer (117) and being adapted to cause the audible alarm transducer (117) to emit an audible sound when a predetermined level of radiation is detected by the sensor, the latching circuit causing the visual alarm transducer (116) to illuminate when the predetermined level of radiation is detected by the sensor (121), and further causing the visual alarm transducer (116) to remain illuminated when the radiation level detected by the sensor (121) decreases in magnitude to below the predetermined level; and</claim-text><claim-text>- the conductive electronic casing (103) having a battery compartment (113) situated therein, and further including a battery receptacle and the casing (103) having a second backing (114) of graduated lossy material situated in the compartment (113) which at least partially surrounds the battery receptacle, the lossy material being progressively more<!-- EPO <DP n="35"> --> conductive through its thickness in a similar manner as in the backing (118, 119, 120).</claim-text></claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>An electromagnetic radiation monitor as defined by claim 15, wherein the alarm circuit, via the audible alarm transducer (117), provides a low battery warning indicating that a battery associated with the monitor is operating at a low level.</claim-text></claim><claim id="c-en-01-0021" num="0021"><claim-text>An electromagnetic radiation monitor as defined by claim 17, further comprising a second battery (B2) for providing power to the visual alarm transducer (116) mounted on the conductive electronic casing (103).</claim-text></claim><claim id="c-en-01-0022" num="0022"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein the electromagnetic radiation sensor (121) includes a pair of mutually orthogonally disposed antenna elements (52), each antenna element extending from a vertex formed at the front surface of the backing and including an array of thin film resistive thermocouples (54) arranged along the axis of each antenna element (52), and a plurality of spaced apart conductive elements (56) of discrete length arranged transversely to the axis of the array, each thermocouple (54) of each antenna element (52) being disposed between adjacent conductive elements (56).</claim-text></claim><claim id="c-en-01-0023" num="0023"><claim-text>An electromagnetic radiation monitor as defined by claim 1, wherein:<claim-text>- the electromagnetic radiation sensor (121) includes a pair of mutually orthogonally disposed antenna elements (52) extending from a vertex, each antenna element extending along a respective longitudinal axis and including an array of thin film resistive thermocouples (54) arranged along the axis, and a plurality of spaced apart conductive elements (56) of discrete length arranged transversely to the axis of the array, each thermocouple (54) of each antenna element (52) being disposed between adjacent conductive elements (56);<!-- EPO <DP n="36"> --></claim-text><claim-text>- the conductive shield (101) has opposite first and second sides;</claim-text><claim-text>- the back surface (62) of the backing of graduated lossy material (118, 119, 120) faces the first side of the conductive shield (101);<br/>and wherein said electromagnetic radiation monitor further comprises:</claim-text><claim-text>- a conductive electronic casing (103) attached to the conductive shield (101);<br/>a housing (102), the sensor (121) and backing of graduated lossy material (46; 118, 119, 120) being contained within the housing and mounted to the conductive shield (101), at least one side of the housing being adjacent to the conductive electronic casing (103);</claim-text><claim-text>- the audible alarm transducer (117) being mounted on the conductive electronic casing;</claim-text><claim-text>- a visual alarm (116) mounted on the conductive electronic casing (103); and</claim-text><claim-text>- an alarm circuit and a latching circuit, the alarm circuit and the latching circuit being mounted in the conductive electronic casing (103), the alarm circuit being connected to the audible alarm transducer (117) and being adapted to cause the audible alarm transducer (117) to emit an audible sound when a predetermined level of radiation is detected by the sensor, the latching circuit causing the visual alarm transducer (116) to illuminate when the predetermined level of radiation is detected by the sensor (121), and further causing the visual alarm transducer (116) to remain illuminated when the radiation level detected by the sensor (121) decreases in magnitude to below the predetermined level; and</claim-text><claim-text>- the conductive electronic casing (103) having a battery compartment (113) situated therein, and further including a battery receptacle and the casing (103) having a second backing (114) of graduated lossy material situated in the compartment (113) which at least partially surrounds the battery receptacle, the lossy material being progressively more conductive through its thickness in a similar manner as in backing (118, 119, 120).</claim-text></claim-text></claim>
EP	0600143	B1	2000-01-19	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, umfassend:<claim-text>- einen Sensor von elektromagnetischer Strahlung (44; 121);</claim-text><claim-text>- einen vom Sensor von elektromagnetischer Strahlung beabstandeten leitfÃ¤higen Schirm (48; 101); und</claim-text><claim-text>- einen abgestuften Halter aus Dissipationsmaterial (46; 118, 119, 120), wobei der Hafer zwischen dem Sensor von elektromagnetischer Strahlung (44; 121) und dem leitfÃ¤higen Schirm (48; 101) zwischengeschaltet ist und eine in Richtung des Sensors von elektromagnetischeer (44) gerichtete VorderflÃ¤che (60; 118) und eine abgewandte, in Richtung des leitfÃ¤higen Schirmes (48; 101) gerichtete RÃ¼ckflÃ¤che (62; 120) aufweist;<br/>dadurch gekennzeichnet, daÃŸ der Halter lÃ¤ngs seiner Dicke von der VorderflÃ¤che (60; 118) bis zur HinterflÃ¤che (62; 120) allmÃ¤hlich leitfÃ¤higer ist, wobei das GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung Ã¼berdies umfaÃŸt:</claim-text><claim-text>- einen mit dem Sensor von elektromagnetischer Strahlung (44; 121) verbundenen Schallalarmwandler (6) und</claim-text><claim-text>- eine mit dem Schallalarmwandler (6; 117) in Verbindung stehende Ohrstopfengruppe (20), die nicht elektrisch leitfÃ¤hig ist, um der Energie RF zu verhindern, daÃŸ sie von der Ohrstopfgruppe (20) empfangen und dem Kopf des TrÃ¤gers abgestrahlt wird.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung nach Anspruch 1, bei dem der Sensor von elektromagnetischer Strahlung (44) ein Paar von zueinander senkrecht angeordneten Antennengliedern (52) umfaÃŸt, die zueinander koplanar sind, wobei jedes Antennenglied sich lÃ¤ngs einer entsprechenden LÃ¤ngsachse erstreckt und eine Schar von Widerstandsthermoelementen<!-- EPO <DP n="38"> --> aus dÃ¼nnem Film (54), die lÃ¤ngs der Achse angeordnet sind, und eine Vielzahl von beabstandeten leitfÃ¤higen Elementen (56) diskreter LÃ¤nge umfaÃŸt, die zur Achse der Schar quer angeordnet sind, wobei jedes Thermoelement (54) eines jeden Antennengliedes (52) zwischen anliegenden, leitfÃ¤higen Elementen (56) angeordnet ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung nach Anspruch 1, das Ã¼berdies eine Folie (58) aus Isoliermaterial umfaÃŸt, die zwischen dem Sensor (44) und dem abgestuften Halter aus Dissipationsmaterial (46) angeordnet ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem der abgestufte Hafer aus Dissipationsmaterial (46) ein Laminat umfaÃŸt, das aus mindestens ersten (64) und zweiten (66) Schichten aus Dissipationsmaterial mit verschiedenem Widerstand besteht, wobei die erste Schicht (64) einen grÃ¶ÃŸeren Widerstand als die zweite Schicht (66) besitzt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem der Halter (46) aus einem Dissipationsmaterial gebildet ist, das durch seine Dicke hindurch von der VorderflÃ¤che (60) bis zur RÃ¼ckflÃ¤che (62) ununterbrochen leitfÃ¤higer wird.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, das Ã¼berdies ein GehÃ¤use (2) umfaÃŸt, bei dem im GehÃ¤use der Sensor von elektromagnetischer Strahlung (44), der abgestufte Halter aus Dissipationsmaterial (46) und der leitfÃ¤hige Schirm (48) eingebaut sind.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 6, bei dem der Schallallarmwandler (6) an einer<!-- EPO <DP n="39"> --> Seite des GehÃ¤uses angebracht ist; bei dem das GehÃ¤use ein angebrachtes BefestigungsstÃ¼ck mit LanglÃ¶chern und Haken (22) umfaÃŸt, das auf der AuÃŸenflÃ¤che seitens des GehÃ¤uses angebracht und in der NÃ¤he des Wandlers (6) positioniert ist; und bei dem die nicht elektrisch leitfÃ¤hige Ohrstopfengruppe (20) ein verlÃ¤ngertes Luftrohr (24), das ein erstes und ein zweites Ende besitzt, die zueinander abgewandt sind, einen pneumatischen Ohrstopfen (26), der am ersten Ende des Rohres angebracht ist, und eine Aufnahme (28) umfaÃŸt, die einen Innenhohlraum (30) festlegt, der am zweiten Ende des Rohres liegt, wobei die Aufnahme (28) eine Ã–ffnung (32) besitzt, die durch ihre Dikke hindurch gebildet ist, und ein zweites angebrachtes BefestigungsstÃ¼ck mit LanglÃ¶chern und Haken (34) umfaÃŸt, das die Ã–ffnung umgibt (32) und fÃ¤hig ist, mit dem ersten angewandten BefestigungsstÃ¼ck mit LanglÃ¶chern und Haken (22) des GehÃ¤uses des GerÃ¤tes zur Ãœberwachung gekoppelt zu werden, um der Aufnahme (28) zu erlauben, am Wandler (6) anliegend angebracht zu werden, wobei der pneumatische Ohrstopfen (26) mit dem Wandler (6) Ã¼ber das Luftrohr (24), den Hohlraum und die Ã–ffnung in Verbindung steht, sobald die Aufnahme (28) am Wandler (6) anliegend angebracht ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 6, bei dem der leitfÃ¤hige Schirm (48) erste und zweite zueinander abgewandte Seiten umfaÃŸt, wobei der Halter aus Dissipationsmaterial (46) an der ersten Seite des Schirms (48) anliegend angebracht ist; und bei dem das GerÃ¤t zur Ãœberwachung Ã¼berdies einen Alarmstromkreis umfaÃŸt, wobei der Alarmstromkreis am GehÃ¤use (2) auf der zweiten Seite des Schirmes (48) angebracht ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 8, bei dem das GehÃ¤use ein Batterienfach (40)<!-- EPO <DP n="40"> --> festlegt, das an der zweiten Seite des Schirms (48) gelegen ist; und bei dem das GerÃ¤t zur Ãœberwachung Ã¼berdies eine im Batterienfach (40) gelegene Batterienaufnahme (70) und eine zweite abgestufte Schicht aus Dissipationsmaterial (76) umfaÃŸt, das im Fach (40) liegt und mindestens teilweise die Batterienaufnahme umgibt, wobei das Dissipationsmaterial (76) lÃ¤ngs seiner Dicke ausgehend von einer RÃ¼ckwand (18) des GehÃ¤uses (2) in Richtung des Schirmes (48) allmÃ¤hlich leitfÃ¤higer wird.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 9, bei dem das GerÃ¤t zur Ãœberwachung Ã¼berdies einen Blockstromkreis und eine am GehÃ¤use (2) angebrachte Lichtanzeige (8) umfaÃŸt, wobei der Blockstromkreis mit dem Alarmstromkreis und mit der Lichtanzeige (8) verbunden ist, wobei der Blockstromkreis derart ausgelegt ist, daÃŸ die Lichtanzeige (8) aufleuchtet, sobald durch den Sensor (44) eine vorgegebene StrahlungshÃ¶he erfaÃŸt wird, und Ã¼berdies derart, daÃŸ die Lichtanzeige (8) leuchtend bleibt, sobald die durch den Sensor (44) erfaÃŸte Strahlung unterhalb ein vorbestimmtes Niveau fÃ¤llt.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem:<claim-text>- der Sensor von elektromagnetischer Strahlung (44) ein Paar von Antennengliedern (52) umfaÃŸt, die zueinander senkrecht und koplanar angeordnet sind, wobei jedes Antennenglied sich lÃ¤ngs einer entsprechenden LÃ¤ngsachse erstreckt und eine Schar von lÃ¤ngs der Achse angeordneten Widerstandsthermoelementen aus einem dÃ¼nnen Film (54) und eine Vielzahl von beabstandeten, leitfÃ¤higen Elementen (56) diskreter LÃ¤nge umfaÃŸt, die quer zur Achse der Schar angeordnet sind, wobei jedes Thermoelement (54) eines jeden Antennengliedes zwischen den angliegenden, leitfÃ¤higen<!-- EPO <DP n="41"> --> Elementen (56) angeordnet ist;</claim-text><claim-text>- der leitfÃ¤hige Schirm erste und zweite abgewandte Seiten besitzt;</claim-text><claim-text>- die RÃ¼ckflÃ¤che (62) des abgestuften Halters aus Dissipationsmaterial (46) in Richtung der ersten Seite des leitfÃ¤higen Schirmes (48) gerichtet ist;<br/>und bei dem das GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung Ã¼berdies umfaÃŸt:</claim-text><claim-text>- ein GehÃ¤use (2), einen Sensor (44) und, wobei der abgestufte Halter aus Dissipationsmaterial (46) und der leitfÃ¤hige Schirm (48) innerhalb des GehÃ¤uses enthalten sind;</claim-text><claim-text>- den Schallalarmwandler (6), der an einer Seite des GehÃ¤uses angebracht ist, wobei das GehÃ¤use (2) ein angewandtes BefestigungsstÃ¼ck mit LanglÃ¶chern und Haken (22), das auf der AuÃŸenseite der Seite des GehÃ¤uses angebracht und in der NÃ¤he des Wandlers (6) positioniert ist;</claim-text><claim-text>- die nicht elektrisch leitfÃ¤hige Ohrstopfengruppe (20), die ein verlÃ¤ngertes Luftrohr (24) mit einem ersten und einem zweiten Ende, die voneinander abgewandt sind, einen pneumatischen Ohrstopfen (26), der am ersten Ende des Rohrs angebracht ist, und eine Aufnahme (28) umfaÃŸt, die einen am zweiten Ende des Rohres vorgesehenen Innenhohlraum (30) festlegt, wobei die Aufnahme (28) eine Ã–ffnung besitzt, die lÃ¤ngs ihrer Dicke gebildet ist, und ein zweites, die Ã–ffnung umgebenes, angewandtes BefestigungsstÃ¼ck mit LanglÃ¶chern und Haken (34) umfaÃŸt, das fÃ¤hig ist, mit dem ersten BefestigungsstÃ¼ck mit LanglÃ¶chern und Haken (22) des GehÃ¤uses des GerÃ¤tes zur Ãœberwachung gekoppelt zu werden, um der Aufnahme (28) zu erlauben, am Wandler anliegend (6) angebracht zu werden, wobei der Ohrstopfen (20) mit dem Wandler (6) Ã¼ber das pneumatische Rohr (24) in Verbindung steht, wobei der Hohlraum und die Ã–ffnung bei angebrachter Aufnahme (28) am Wandler (6) anlegen;<!-- EPO <DP n="42"> --></claim-text><claim-text>- eine Leuchtanzeige (8), die am GehÃ¤use (2) angebracht ist; und</claim-text><claim-text>- einen Alarmstromkreis und einen Blockstromkreis, wobei der Alarmstromkreis und der Blockstromkreis im GehÃ¤use (2) anliegend an der zweiten Seite des Schirmes (48) angebracht sind, wobei der Alarmstromkreis mit dem Wandler (6) verbunden und derart ausgelegt ist, daÃŸ der Wandler (6) einen hÃ¶rbaren Ton abgibt, wenn durch den Sensor (44) ein vorgegebenes Strahlungsniveau erfaÃŸt wird, wobei der Blockstromkreis derart ausgelegt ist, daÃŸ die Leuchtanzeige (8) aufleuchtet, wenn das vorgegebene Strahlungsniveau durch den Sensor (44) erfaÃŸt wird, und Ã¼berdies derart ausgelegt ist, daÃŸ die Leuchtanzeige (8) aufleuchtend bleibt, sobald die durch den Sensor (44) erfaÃŸte Strahlung in der GrÃ¶ÃŸe bis unterhalb des vorgegebenen Niveaus sinkt;</claim-text><claim-text>- wobei das GehÃ¤use ein Batteriefach (40) festlegt, das auf der zweiten Seite des Schirms (48) liegt, wobei das GerÃ¤t zur Ãœberwachung Ã¼berdies eine Batterienaufnahme (70) und einen zweiten, im Batterienfach gelegenen, abgestuften Halter aus Dissipationsmaterial (76) umfaÃŸt, der mindestens teilweise die Batterienaufnahme umgibt, wobei das Dissipationsmaterial (76) lÃ¤ngs seiner Dicke von der RÃ¼ckwand (18) des GehÃ¤uses (2) in Richtung des Schirmes (48) allmÃ¤hlich leitfÃ¤higer wird.</claim-text></claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem der Sensor von elektromagnetischer Strahlung (121) drei zueinander senkrecht angeordnete Antennenglieder (52) umfaÃŸt, wobei jedes Antennenglied sich von einem im Bereich der VorderflÃ¤che des Halters gebildeten Scheitel erstreckt und eine Schar von lÃ¤ngs der Achse eines jeden Antennengliedes (52) angeordneten Widerstandsthermoelementen aus dÃ¼nnem Film (54) und eine Vielzahl von beabstandeten,<!-- EPO <DP n="43"> --> leitfÃ¤higen Elementen (56) diskreter LÃ¤nge umfaÃŸt, die quer zur Achse der Schar angeordnet sind, wobei jedes Thermoelement (54) eines jeden Antennengliedes (52) zwischen anliegenden, leitfÃ¤higen Elementen (56) angeordnet ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem der abgestufte Halter aus Dissipationsmaterial (46; 118, 119, 120) ein Laminat umfaÃŸt, das durch mindestens ersten (118), zweiten (119) und dritten (120) Schichten aus Dissipationsmaterial mit verschiedenen spezifischen WiderstÃ¤nden gebildet ist, wobei die erste Schicht (118) einen spezifischen Widerstand besitzt, der grÃ¶ÃŸer ist als jener der zweiten Schicht (119), wobei die zweite Schicht (119) einen spezifischen Widerstand besitzt, der grÃ¶ÃŸer ist als jener der dritten Schicht (120).</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 13, bei dem die ersten (118), zweiten (119) und dritten (120) Schichten spezifische VolumenwiderstÃ¤nde jeweils im wesentlichen von 15 kÎ© pro Kubikzentimeter, 600 Î© pro Kubikzentimeter und 150 Î© pro Kubikzentimeter und OberflÃ¤chenwiderstÃ¤nde jeweils im wesentlichen von 20 kÎ© pro Quadratzentimeter, 2 kÎ© pro Quadratzentimeter und 500 Î© pro Quadratzentimeter besitzen.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, umfassend Ã¼berdies einen elektronischen Ãœberwachungsabschnitt mit einem Alarmstromkreis und ein am leitfÃ¤higen Schirm (101) angebrachtes GehÃ¤use (102), in dem der Sensor (121) und der abgestufte Halter (46; 118, 119, 120) aus Dissipationsmaterial angeordnet sind, wobei der elektronische Ãœberwachungsabschnitt in einer elektronisch leitfÃ¤higen HÃ¼lle (103) enthalten und auf dem, dem GehÃ¤use (102) anliegenden,<!-- EPO <DP n="44"> --> leitfÃ¤higen Schirm (101) angebracht ist; bei dem das GerÃ¤t zur Ãœberwachung Ã¼berdies einen Sichtalarmwandler (116) und eine AlarmprÃ¼ftaste (115) umfaÃŸt, die alle an der elektronischen leitfÃ¤higen HÃ¼lle (103) angebracht sind.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 15, bei dem das GehÃ¤use (102) ein StrangguÃŸteil rechteckiger Form ist, das einen oberen KÃ¶rperteil und vier Seiten umfaÃŸt, wobei die erste Seite (107) an der elektronischen leitfÃ¤higen HÃ¼lle (103) anschlÃ¤gt, die zweite (104), die dritte (105) und vierte (106) Seite zu den Kanten des leitfÃ¤higen Schirmes (101) anliegen und senkrecht angeordnet sind; und bei dem der obere GehÃ¤useteil drei sich verjÃ¼ngende Abschnitte (108, 109, 110) umfaÃŸt, die sich nach oben unter einem Winkel von jeder der zweiten (104), dritten (105) und vierten (106) Seiten erstrecken, wobei jeder sich verjÃ¼ngende Abschnitt in der NÃ¤he eines Niveauabschnittes (111) des oberen GehÃ¤useteiles liegt, an dem eine zylindrische Nase (112) angeordnet ist, wobei der Niveauabschnitt (111) des oberen GehÃ¤useteiles auch in der NÃ¤he der ersten Seite (107) liegt.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 15, bei dem die elektronisch leitfÃ¤hige HÃ¼lle (103) ein Batterienfach (113) zur Befestigung einer Batterie (122) umfaÃŸt, und bei dem das Batterienfach (113) Ã¼berdies eine dort gelegene Batterienaufnahme und einen zweiten abgestuften Halter (114) aus Dissipationsmaterial umfaÃŸt, der im Batterienfach (113) angeordnet ist, um mindestens teilweise die Batterienaufnahme zu umgeben.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 17, bei dem das GerÃ¤t zur Ãœberwachung Ã¼berdies einen Blockstromkreis umfaÃŸt, der am GehÃ¤use angebracht<!-- EPO <DP n="45"> --> ist, wobei der Blockstromkreis mit dem Alarmstromkreis und mit dem Sichtalarmwandler (116) verbunden ist, wobei der Blockstromkreis derart ausgelegt ist, daÃŸ der Sichtalarmwandler (116) aktiviert wird, sobald durch den Sensor (121) ein vorgegebenes Niveau elektromagnetischer Strahlung erfaÃŸt wird und Ã¼berdies derart ausgelegt ist, daÃŸ der Sichtalarmwandler (116) aktiviert bleibt, wenn das durch den Sensor (121) erfaÃŸte Strahlungsniveau unterhalb einem vorgegebenen Niveau sinkt.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem:<claim-text>- der Sensor von elektromagnetischer Strahlung (121) drei zueinander senkrecht angeordnete Antennenglieder (52), die sich von einem Scheitel erstrecken, wobei jedes Antennenglied sich lÃ¤ngs einer entsprechenden LÃ¤ngsachse erstrecken und eine Schar von lÃ¤ngs der Achse angeordneten Widerstandsthermoelementen aus dÃ¼nnem Film (54) umfassen, und eine Vielzahl von leitfÃ¤higen Elementen (56) umfaÃŸt, die um eine diskrete LÃ¤nge beabstandet und quer zur Achse der Schar angeordnet sind, wobei jedes Thermoelement (54) eines jeden Antennengliedes (52) zwischen den anliegenden, leitfÃ¤higen Elementen (56) angeordnet ist;</claim-text><claim-text>- der leitfÃ¤hige Schirm (101) erste und zweite abgewandte Seiten besitzt;</claim-text><claim-text>- die RÃ¼ckflÃ¤che (62) des abgestuften Halters aus Dissipationsmaterial (118, 119, 120) in Richtung der ersten Seite des leitfÃ¤higen Schirmes (101) gerichtet ist, und bei dem das GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung Ã¼berdies umfaÃŸt:</claim-text><claim-text>- eine am leitfÃ¤higen Schirm (101) angesetzte elektronisch leitfÃ¤hige HÃ¼lle (103);</claim-text><claim-text>- ein GehÃ¤use (102), wobei der Sensor (121) und der abgestufte Halter aus Dissipationsmaterial (46; 118, 119, 120) im<!-- EPO <DP n="46"> --> GehÃ¤use enthalten und am leitfÃ¤higen Schirm (101) angebracht sind, wobei mindestens eine Seite des GehÃ¤uses an der elektronisch leitfÃ¤higen HÃ¼lle (103) anliegend ist;</claim-text><claim-text>- den Schallalarmwandler (117), der an der elektronisch leitfÃ¤higen HÃ¼lle angebracht ist;</claim-text><claim-text>- einen Sichtalarm (116), der an der elektronisch leitfÃ¤higen HÃ¼lle (103) angebracht ist; und</claim-text><claim-text>- einen Alarmstromkreis und einen Blockstromkreis, wobei der Alarmstromkreis und der Blockstromkreis in der elektronisch leitfÃ¤higen HÃ¼lle (113) eingebaut sind, wobei der Alarmstromkreis mit dem Schallalarmwandler (117) verbunden und dazu ausgelegt ist, daÃŸ der Schallalarmwandler (117) einen hÃ¶rbaren Ton abgibt, wenn durch den Sensor ein vorgegebenes Strahlungsniveau erfaÃŸt wird, wobei der Blockstromkreis derart ausgelegt ist, daÃŸ der Sichtalarmwandler (116) aufleuchtet, wenn durch den Sensor (121) das vorgegebene Strahlungsniveau erfaÃŸt wird, und Ã¼berdies derart ausgelegt ist, daÃŸ der Sichtalarmwandler (116) aufleuchtend bleibt, wenn das durch den Sensor (121) erfaÃŸte Strahlungsniveau in der GrÃ¶ÃŸe bis unterhalb des vorgegebenen Niveaus absinkt; und</claim-text><claim-text>- wobei die elektronisch leitfÃ¤hige HÃ¼lle (103) ein dort gelegenes Batterienfach (113) besitzt, und wobei sie Ã¼berdies eine Batterienaufnahme besitzt und die HÃ¼lle (103) einen zweiten, abgestuften, im Batterienfach (113) gelegenen Halter (114) aus Dissipationsmaterial besitzt, der mindestens teilweise die Batterienaufnahme umgibt, wobei das Dissipationsmaterial lÃ¤ngs seiner Dicke auf der gleichen Art und Weise wie im Halter (118, 119, 120) allmÃ¤hlich leitfÃ¤higer wird.</claim-text></claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 15, bei dem der Alarmstromkreis Ã¼ber den Schallalarmwandler (117) eine Warnung bei einer leerlaufenden<!-- EPO <DP n="47"> --> Batterie liefert, die angibt, daÃŸ die dem ÃœberwachungsgerÃ¤t zugeordnete Batterie mit einem tiefen Niveau in Betrieb ist.</claim-text></claim><claim id="c-de-01-0021" num="0021"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 17, umfassend Ã¼berdies eine zweite Batterie (B2) um den Sichtalarmwandler (116) zu speisen, der an der elektronisch leitfÃ¤higen HÃ¼lle (103) angebracht ist.</claim-text></claim><claim id="c-de-01-0022" num="0022"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem der Sensor von elektromagnetischer Strahlung (121) ein Paar von zueinander senkrecht angeordneten Antennengliedern (52) umfaÃŸt, wobei jedes Antennenglied sich von einem in der NÃ¤he der VorderflÃ¤che des Halters gebildeten Scheitels erstreckt und eine Schar von lÃ¤ngs der Achse eines jeden Antennengliedes (52) angeordneten Widerstandsthermoelementen aus dÃ¼nnem Film (54) und eine Vielzahl von beabstandeten, quer zur Achse der Schar angeordneten, leitfÃ¤higen Elementen (56) mit diskreter LÃ¤nge umfaÃŸt, wobei jedes Thermoelement (54) eines jeden Antennengliedes (52) zwischen anliegenden, leitfÃ¤higen Elementen (56) angeordnet ist.</claim-text></claim><claim id="c-de-01-0023" num="0023"><claim-text>GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung, nach Anspruch 1, bei dem:<claim-text>- der Sensor von elektromagnetischer Strahlung (121) ein Paar von zueinander senkrecht angeordneten Antennengliedern (52) umfaÃŸt, die sich von einem Scheitel erstrecken, wobei jedes Antennenglied sich lÃ¤ngs einer entsprechenden LÃ¤ngsachse erstreckt und eine Schar von lÃ¤ngs der Achse angeordneten Widerstandsthermoelementen aus dÃ¼nnem Film (54) und eine Vielzahl von quer zur Achse der Schar angeordneten, beabstandeten, leitfÃ¤higen Elementen (56) mit diskreter LÃ¤nge umfaÃŸt, wobei jedes Thermoelement (54) eines jeden Antennengliedes (52) zwischen den anliegenden, leitfÃ¤higen<!-- EPO <DP n="48"> --> Elementen (56) angeordnet ist;</claim-text><claim-text>- der leitfÃ¤hige Schirm (101) erste und zweite abgewandte Seiten besitzt;</claim-text><claim-text>- die RÃ¼ckflÃ¤che (62) des abgestuften Halters aus Dissipationsmaterial (118, 119, 120) in Richtung der ersten Seite des leitfÃ¤higen Schirmes (101) gerichtet ist;<br/>und bei dem das GerÃ¤t zur Ãœberwachung von elektromagnetischer Strahlung Ã¼berdies umfaÃŸt:</claim-text><claim-text>- eine elektronisch leitfÃ¤hige HÃ¼lle (103), die am leitfÃ¤higen Schirm (101) angesetzt ist;</claim-text><claim-text>- ein GehÃ¤use (102), wobei der Sensor (121) und der abgestufte Halter aus Dissipationsmaterial (46; 118, 119, 120) im GehÃ¤use enthalten und am leitfÃ¤higen Schirm (101) angebracht sind, wobei mindestens eine Seite des GehÃ¤uses an der elektronisch leitfÃ¤higen HÃ¼lle (103) anliegend ist;</claim-text><claim-text>- den Schallallarmwandler (117), der an der elektronisch leitfÃ¤higen HÃ¼lle angebracht ist;</claim-text><claim-text>- einen Sichtalarm (116), der an der elektronisch leitfÃ¤higen HÃ¼lle (103) angebracht ist; und</claim-text><claim-text>- einen Alarmstromkreis und einen Blockstromkreis, wobei der Alarmstromkreis und der Blockstromkreis in der elektronisch leitfÃ¤higen HÃ¼lle (103) eingebaut sind, wobei der Alarmstromkreis mit dem Schallalarmwandler (117) verbunden und derart ausgelegt ist, daÃŸ der Schallalarmwandler (117) einen hÃ¶rbaren Ton abgibt, wenn durch den Sensor ein vorgegebenes Strahlungsniveau erfaÃŸt wird, wobei der Blockstromkreis derart ausgelegt ist, daÃŸ der Sichtalarmwandler (116) aufleuchtet, wenn durch den Sensor (121) das vorgegebene Strahlungsniveau erfaÃŸt wird, und Ã¼berdies derart ausgelegt ist, daÃŸ der Sichtalarmwandler (116) aufleuchtend bleibt, wenn das durch den Sensor (121) erfaÃŸte Strahlungsniveau in der GrÃ¶ÃŸe des unterhalb des vorgegebenen Niveaus sinkt; und<!-- EPO <DP n="49"> --></claim-text><claim-text>- wobei die elektronisch leitfÃ¤hige HÃ¼lle (103) ein dort gelegenes Batterienfach (113) besitzt, und Ã¼berdies eine Batterienaufnahme umfaÃŸt, und wobei die HÃ¼lle (103) einen zweiten abgestuften im Batterienfach (113) angeordneten Halter (114) aus Dissipationsmaterial besitzt, der mindestens teilweise die Batterienaufnahme umgibt, wobei das Dissipationsmaterial lÃ¤ngs seiner Dicke in derselben Weise allmÃ¤hlich leitfÃ¤higer wird, wie im Halter (118, 119, 120).</claim-text></claim-text></claim>
EP	0600143	B1	2000-01-19	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique, comprenant:<claim-text>- un capteur de radiation Ã©lectromagnÃ©tique (44; 121);</claim-text><claim-text>- un Ã©cran conducteur (48; 101) Ã©cartÃ© du capteur; et</claim-text><claim-text>- un renforcement de matÃ©riau dissipatif graduÃ© (46; 118, 119, 120), le renforcement Ã©tant interposÃ© entre le capteur de radiation (44; 121) et l'Ã©cran conducteur (48; 101) et ayant une surface avant (60; 118) en regard du capteur (44) et une surface arriÃ¨re opposÃ©e (62; 120) en regard de l'Ã©cran conducteur (48; 101);</claim-text><claim-text>- caractÃ©risÃ© en ce que le renforcement est progressivement plus conducteur Ã  travers son Ã©paisseur depuis sa surface avant (60; 118) jusqu'Ã  sa surface arriÃ¨re (62; 120), l'appareil pour surveiller la radiation comprenant en outre:</claim-text><claim-text>- un transducteur d'alarme audible (6) reliÃ© au capteur de radiation Ã©lectromagnÃ©tique (44; 121), et</claim-text><claim-text>- un ensemble d'Ã©couteur (20) en communication avec le transducteur d'alarme audible (6; 117), l'ensemble d'Ã©couteur (20) Ã©tant Ã©lectriquement non conducteur pour empÃªcher que l'Ã©nergie RF soit reÃ§ue par l'ensemble (20) et irradiÃ©e Ã  la tÃªte de la personne qui le porte.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel le capteur de radiation Ã©lectromagnÃ©tique (44) comporte une paire d'Ã©lÃ©ments d'antenne (52) disposÃ©s rÃ©ciproquement orthogonaux, lesquels sont coplanaires l'un par rapport Ã  l'autre, chaque Ã©lÃ©ment d'antenne s'Ã©tendant le long d'un axe longitudinal respectif et comprenant une file de thermocouples Ã  rÃ©sistance (54) de pellicule mince disposÃ©s le long de l'axe, et une pluralitÃ© d'Ã©lÃ©ments conducteurs (56) espacÃ©s de longueur discrÃ¨te arrangÃ©s transversalement Ã <!-- EPO <DP n="51"> --> l'axe de la file, chaque thermocouple (54) de chaque Ã©lÃ©ment d'antenne (52) Ã©tant disposÃ© entre des Ã©lÃ©ments conducteurs attenants (56).</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, lequel comporte en outre une feuille (58) de matiÃ¨re isolante interposÃ©e entre le capteur (44) et le renforcement de matÃ©riau dissipatif graduÃ© (46).</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel le renforcement de matÃ©riau dissipatif graduÃ© (46) comporte un laminÃ© se composant d'au moins des premiÃ¨re (64) et deuxiÃ¨me couches (66) de matÃ©riau dissipatif ayant des rÃ©sistances diffÃ©rentes, la premiÃ¨re couche (64) ayant une rÃ©sistance plus Ã©levÃ©e que la deuxiÃ¨me couche (66).</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel le renforcement (46) se compose d'un matÃ©riau dissipatif qui est continuellement plus conducteur Ã  travers son Ã©paisseur, de sa surface avant (60) Ã  sa surface arriÃ¨re (62).</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, lequel comporte en outre un logement (2), dans lequel le capteur (44), le renforcement de matÃ©riau dissipatif graduÃ© (46) et l'Ã©cran conducteur (48) sont montÃ©s dans le logement.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 6, dans lequel le transducteur d'alarme audible (6) est<!-- EPO <DP n="52"> --> montÃ© sur un cÃ´tÃ© du logement; dans lequel le logement comporte une piÃ¨ce appliquÃ©e de fixation Ã  agrafes et oeillets (22) montÃ©e sur la surface extÃ©rieure du cÃ´tÃ© du logement et positionnÃ©e Ã  proximitÃ© du transducteur (6); et dans lequel l'ensemble d'Ã©couteur Ã©lectriquement non conducteur (20) comporte un tube pneumatique allongÃ© (24) ayant une premiÃ¨re et une seconde extrÃ©mitÃ©s opposÃ©es, un Ã©couteur pneumatique (26) montÃ© sur la premiÃ¨re extrÃ©mitÃ© du tube et un siÃ¨ge creux (28) dÃ©finissant une cavitÃ© intÃ©rieure (30) montÃ©e sur la seconde extrÃ©mitÃ© du tube, le siÃ¨ge creux (28) ayant une ouverture (32) formÃ©e Ã  travers son Ã©paisseur et comprenant une deuxiÃ¨me piÃ¨ce appliquÃ©e de fixation Ã  agrafes et oeillets (34) entourant l'ouverture (32) et qui est destinÃ©e Ã  Ã©pouser la premiÃ¨re piÃ¨ce appliquÃ©e de fixation Ã  agrafes et oeillets (22) du siÃ¨ge de l'appareil de surveillance pour permettre que le siÃ¨ge creux (28) puisse Ãªtre montÃ© attenant au transducteur (6), l'Ã©couteur (26) Ã©tant en communication avec le transducteur (6) Ã  travers le tube pneumatique (24), la cavitÃ© et l'ouverture quand le siÃ¨ge creux (28) est montÃ© attenant au transducteur (6).</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 6, dans lequel l'Ã©cran conducteur (48) a des premier et deuxiÃ¨me cÃ´tÃ©s opposÃ©s, le renforcement de matÃ©riau dissipatif (46) Ã©tant montÃ© attenant au premier cÃ´tÃ© de l'Ã©cran (48); et dans lequel l'appareil de surveillance comporte en outre un circuit d'alarme, le circuit d'alarme Ã©tant montÃ© dans le logement (2) sur le deuxiÃ¨me cÃ´tÃ© de l'Ã©cran (48).</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 8, dans lequel le logement dÃ©finit un compartiment de batterie (40) situÃ© sur le deuxiÃ¨me cÃ´tÃ© de l'Ã©cran (48);<!-- EPO <DP n="53"> --> et dans lequel l'appareil de surveillance comporte en outre un rÃ©ceptacle de batterie (70) situÃ© dans le compartiment de batterie (40), et une deuxiÃ¨me couche de matÃ©riau dissipatif graduÃ© (76) situÃ©e dans le compartiment (40) et entourant au moins partiellement le rÃ©ceptacle de batterie, le matÃ©riau dissipatif (76) Ã©tant progressivement plus conducteur Ã  travers son Ã©paisseur depuis la paroi arriÃ¨re (18) du logement (2) vers l'Ã©cran (48).</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 9, dans lequel l'appareil de surveillance comporte en outre un circuit de verrouillage et une alarme lumineuse (8) montÃ©e sur le logement (2), le circuit de verrouillage Ã©tant couplÃ© au circuit d'alarme et Ã  l'alarme lumineuse (8), le circuit de verrouillage amenant l'alarme lumineuse (8) Ã  s'illuminer quand le capteur (44) dÃ©tecte un niveau prÃ©dÃ©terminÃ© de radiation, et amenant en outre l'alarme lumineuse (8) Ã  rester illuminÃ©e quand la radiation dÃ©tectÃ©e par le capteur (44) tombe au-dessous du niveau prÃ©dÃ©terminÃ©.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel:<claim-text>- le capteur de radiation Ã©lectromagnÃ©tique (44) comporte une paire d'Ã©lÃ©ments d'antenne (52) disposÃ©s rÃ©ciproquement orthogonaux, lesquels sont coplanaires l'un par rapport Ã  l'autre, chaque Ã©lÃ©ment d'antenne s'Ã©tendant le long d'un axe longitudinal respectif et comprenant une file de thermocouples Ã  rÃ©sistance (54) de pellicule mince disposÃ©s le long de l'axe, et une pluralitÃ© d'Ã©lÃ©ments conducteurs (56) espacÃ©s de longueur discrÃ¨te arrangÃ©s transversalement Ã  l'axe de la file, chaque thermocouple (54) de chaque Ã©lÃ©ment d'antenne (52)<!-- EPO <DP n="54"> --> Ã©tant disposÃ© entre des Ã©lÃ©ments conducteurs attenants (56);</claim-text><claim-text>- l'Ã©cran conducteur a des premier et deuxiÃ¨me cÃ´tÃ©s opposÃ©s;</claim-text><claim-text>- la surface arriÃ¨re (62) du renforcement de matÃ©riau dissipatif graduÃ© (46) est en regard du premier cÃ´tÃ© de l'Ã©cran conducteur (48); et dans lequel ledit appareil pour surveiller une radiation Ã©lectromagnÃ©tique comporte en outre:</claim-text><claim-text>- un logement (2), le capteur (44) et le renforcement de matÃ©riau dissipatif graduÃ© (46) et l'Ã©cran conducteur (48) Ã©tant contenus dans le logement;</claim-text><claim-text>- le transducteur d'alarme audible (6) Ã©tant montÃ© sur le cÃ´tÃ© du logement, le logement (2) comprenant une piÃ¨ce appliquÃ©e de fixation Ã  agrafes et oeillets (22) montÃ©e sur la surface extÃ©rieure du cÃ´tÃ© du logement et positionnÃ©e Ã  proximitÃ© du transducteur (6);</claim-text><claim-text>- l'ensemble d'Ã©couteur Ã©lectriquement non conducteur (20) comportant un tube pneumatique allongÃ© (24) ayant une premiÃ¨re et une seconde extrÃ©mitÃ©s opposÃ©es, un Ã©couteur pneumatique (26) montÃ© sur la premiÃ¨re extrÃ©mitÃ© du tube et un siÃ¨ge creux (28) dÃ©finissant une cavitÃ© intÃ©rieure (30) montÃ©e sur la seconde extrÃ©mitÃ© du tube, le siÃ¨ge creux (28) ayant une ouverture formÃ©e Ã  travers son Ã©paisseur et comprenant une deuxiÃ¨me piÃ¨ce appliquÃ©e de fixation Ã  agrafes et oeillets (34) entourant l'ouverture et qui est destinÃ©e Ã  Ã©pouser la premiÃ¨re piÃ¨ce appliquÃ©e de fixation Ã  agrafes et oeillets (22) du siÃ¨ge de l'appareil de surveillance pour permettre que le siÃ¨ge creux (28) puisse Ãªtre montÃ© attenant au transducteur (6), l'Ã©couteur (20) Ã©tant en communication avec le transducteur (6) Ã  travers le tube pneumatique (24), la cavitÃ© et l'ouverture quand le siÃ¨ge creux (28) est montÃ© attenant au transducteur (6);</claim-text><claim-text>- une alarme lumineuse (8) montÃ©e sur le logement (2); et</claim-text><claim-text>- un circuit d'alarme et un circuit de verrouillage, le<!-- EPO <DP n="55"> --> circuit d'alarme et le circuit de verrouillage Ã©tant montÃ©s dans le logement (2) en position attenante au deuxiÃ¨me cÃ´tÃ© de l'Ã©cran (48), le circuit d'alarme Ã©tant reliÃ© au transducteur (6) et Ã©tant destinÃ© Ã  amener le transducteur (6) Ã  Ã©mettre un son audible quand le capteur (44) dÃ©tecte un niveau prÃ©dÃ©terminÃ© de radiation, le circuit de verrouillage amenant l'alarme lumineuse (8) Ã  s'illuminer quand le capteur (44) dÃ©tecte le niveau prÃ©dÃ©terminÃ© de radiation, et amenant en outre l'alarme lumineuse (8) Ã  rester illuminÃ©e quand la radiation dÃ©tectÃ©e par le capteur (44) diminue de grandeur jusqu'au-dessous du niveau prÃ©dÃ©terminÃ©;</claim-text><claim-text>- le logement dÃ©finissant un compartiment de batterie (40) situÃ© sur le deuxiÃ¨me cÃ´tÃ© de l'Ã©cran (48), l'appareil de surveillance comprenant en outre un rÃ©ceptacle de batterie (70) et un deuxiÃ¨me renforcement de matÃ©riau dissipatif graduÃ© (76) situÃ© dans le compartiment et entourant au moins partiellement le rÃ©ceptacle de batterie, la matÃ©riau dissipatif (76) Ã©tant progressivement plus conducteur Ã  travers son Ã©paisseur depuis une paroi arriÃ¨re (18) du logement (2) vers l'Ã©cran (48).</claim-text></claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel le capteur de radiation Ã©lectromagnÃ©tique (121) comporte trois Ã©lÃ©ments d'antenne (52) disposÃ©s rÃ©ciproquement orthogonaux, chaque Ã©lÃ©ment d'antenne s'Ã©tendant du sommet formÃ© en correspondant de la surface avant du renforcement et comprenant une file de thermocouples Ã  rÃ©sistance (54) de pellicule mince arrangÃ©s le long de l'axe de chaque Ã©lÃ©ment d'antenne (52), et une pluralitÃ© d'Ã©lÃ©ments conducteurs espacÃ©s (56) de longueur discrÃ¨te disposÃ©s transversalement Ã  l'axe de la file, chaque thermocouple (54) de chaque Ã©lÃ©ment d'antenne (52) Ã©tant disposÃ© entre des Ã©lÃ©ments<!-- EPO <DP n="56"> --> conducteurs attenants (56).</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel le renforcement de matÃ©riau dissipatif graduÃ© (46; 118, 119, 120) comporte un laminÃ© composÃ© d'au moins des premiÃ¨re (118), deuxiÃ¨me (119) et troisiÃ¨me (120) couches de matÃ©riau dissipatif ayant des rÃ©sistances diffÃ©rentes, la premiÃ¨re couche (118) ayant une rÃ©sistance plus Ã©levÃ©e que la deuxiÃ¨me couche (119), la deuxiÃ¨me couche (119) ayant une rÃ©sistance plus Ã©levÃ©e que la troisiÃ¨me couche (120).</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 13, dans lequel les premiÃ¨re (118), deuxiÃ¨me (119) et troisiÃ¨me (120) couches ont des rÃ©sistances de volume respectivement essentiellement de 15 kÎ© par centimÃ¨tre cube, 600 Î© par centimÃ¨tre cube et 150 Î© par centimÃ¨tre cube, et des rÃ©sistances de surface respectivement essentiellement de 20 kÎ© par centimÃ¨tre carrÃ©, 2 kÎ© par centimÃ¨tre carrÃ© et 500 Î© par centimÃ¨tre carrÃ©.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, comprenant en outre une section de contrÃ´le Ã©lectronique ayant un circuit d'alarme, et un logement (102) montÃ© sur l'Ã©cran conducteur (101) dans lequel sont disposÃ©s le capteur (121) et le renforcement (46; 118, 119, 120) de matÃ©riau dissipatif graduÃ©, la section de contrÃ´le Ã©lectronique Ã©tant contenue dans une enveloppe Ã©lectronique conductrice (103) et montÃ©e sur l'Ã©cran conducteur (101) en position attenante au logement (102); dans lequel l'appareil de surveillance comporte en outre un transducteur d'alarme visuelle (116) et un bouton d'essai d'alarme (115), lesquels sont tous montÃ©s sur<!-- EPO <DP n="57"> --> l'enveloppe Ã©lectronique conductrice (103).</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 15, dans lequel le logement (102) est une piÃ¨ce extrudÃ©e de forme rectangulaire comprenant une partie supÃ©rieure et quatre cÃ´tÃ©s, un premier cÃ´tÃ© (107) venant buter contre l'enveloppe Ã©lectronique conductrice (103), les deuxiÃ¨me (104), troisiÃ¨me (105) et quatriÃ¨me (106) cÃ´tÃ©s Ã©tant disposÃ©s attenants et orthogonaux aux bords de l'Ã©cran conducteur (101); et dans lequel la partie supÃ©rieure du logement comporte trois portions Ã  section dÃ©croissante ou effilÃ©es (108, 109, 110) s'Ã©tendant vers le haut de maniÃ¨re angulaire depuis chacun des deuxiÃ¨me (104), troisiÃ¨me (105) et quatriÃ¨me (106) cÃ´tÃ©s, chaque portion effilÃ©e Ã©tant contiguÃ« Ã  une portion principale (111) de la partie supÃ©rieure du logement sur lequel est disposÃ© un ressaut cylindrique (112), la portion principale (111) de la partie supÃ©rieure du logement Ã©tant Ã©galement contiguÃ« au premier cÃ´tÃ© (107).</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 15, dans lequel l'enveloppe Ã©lectronique conductrice (103) comporte un compartiment de batterie (113) pour y fixer une batterie (122), et dans lequel le compartiment de batterie (113) comporte en outre une enveloppe de batterie disposÃ©e Ã  son intÃ©rieur, et un deuxiÃ¨me renforcement (114) de matÃ©riau dissipatif graduÃ© situÃ© dans le compartiment (113) pour entourer au moins partiellement le rÃ©ceptacle de batterie.</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 17, dans lequel l'appareil de surveillance comporte en outre un circuit de verrouillage montÃ© sur le logement, le<!-- EPO <DP n="58"> --> circuit de verrouillage Ã©tant couplÃ© Ã  un circuit d'alarme et Ã  un transducteur de circuit visuelle (116), le circuit d'alarme causant l'activation du transducteur d'alarme visuelle (116) quand le capteur (121) dÃ©tecte un niveau prÃ©dÃ©terminÃ© de radiation Ã©lectromagnÃ©tique, et amenant en outre le transducteur d'alarme visuelle (116) Ã  rester activÃ© quand le niveau de radiation dÃ©tectÃ© par le capteur (121) tombe au-dessous du niveau prÃ©dÃ©terminÃ©.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel:<claim-text>- le capteur de radiation Ã©lectromagnÃ©tique (121) comporte trois Ã©lÃ©ments d'antenne (52) disposÃ©s rÃ©ciproquement orthogonaux, lesquels s'Ã©tendent d'un sommet, chaque Ã©lÃ©ment d'antenne s'Ã©tendant le long d'un axe longitudinal respectif et comprenant une file de thermocouples Ã  rÃ©sistance de pellicule mince (54) arrangÃ©s le long de l'axe, et une pluralitÃ© d'Ã©lÃ©ments conducteurs (56) espacÃ©s de longueur discrÃ¨te arrangÃ©s transversalement Ã  l'axe de la file, chaque thermocouple (54) de chaque Ã©lÃ©ment d'antenne (52) Ã©tant disposÃ© entre des Ã©lÃ©ments conducteurs attenants (56);</claim-text><claim-text>- l'Ã©cran conducteur (101) a des premier et deuxiÃ¨me cÃ´tÃ©s;</claim-text><claim-text>- la surface arriÃ¨re (62) du renforcement de matÃ©riau dissipatif graduÃ© (118, 119, 120) est en regard du premier cÃ´tÃ© de l'Ã©cran conducteur (101) et dans lequel ledit appareil pour surveiller une radiation Ã©lectromagnÃ©tique comporte en outre:</claim-text><claim-text>- une enveloppe Ã©lectronique conductrice (103) attachÃ©e Ã  l'Ã©cran conducteur (101);</claim-text><claim-text>- un logement (102), le capteur (121) et le renforcement de matÃ©riau dissipatif graduÃ© (46; 118, 119, 120) Ã©tant contenu dans le logement et montÃ©s sur l'Ã©cran conducteur (101), au moins un cÃ´tÃ© du logement Ã©tant attenant Ã <!-- EPO <DP n="59"> --> l'enveloppe Ã©lectronique conductrice (103);</claim-text><claim-text>- le transducteur d'alarme audible (117) Ã©tant montÃ© sur l'enveloppe Ã©lectronique conductrice;</claim-text><claim-text>- une alarme visuelle (116) montÃ©e sur l'enveloppe Ã©lectronique conductrice (103); et</claim-text><claim-text>- un circuit d'alarme et un circuit de verrouillage, le circuit d'alarme et le circuit de verrouillage Ã©tant montÃ©s dans l'enveloppe Ã©lectronique conductrice (103), le circuit d'alarme Ã©tant reliÃ© au transducteur d'alarme audible (117) et Ã©tant destinÃ© Ã  amener le transducteur d'alarme audible (117) Ã  Ã©mettre un son audible quand le capteur dÃ©tecte un niveau prÃ©dÃ©terminÃ© de radiation, le circuit de verrouillage amenant le transducteur d'alarme visuelle (116) Ã  s'illuminer quand le capteur (121) dÃ©tecte le niveau prÃ©dÃ©terminÃ© de radiation, et amenant en outre le transducteur d'alarme visuelle (116) Ã  rester illuminÃ© quand la radiation dÃ©tectÃ©e par le capteur (121) diminue de grandeur jusqu'au-dessous du niveau prÃ©dÃ©terminÃ©; et</claim-text><claim-text>- l'enveloppe Ã©lectronique conductrice (103) ayant une compartiment de batterie (113) y situÃ©, et comprenant en outre un rÃ©ceptacle de batterie, et l'enveloppe (103) ayant un deuxiÃ¨me renforcement (114) de matÃ©riau dissipatif graduÃ© situÃ© dans le compartiment (113) qui entoure au moins partiellement le rÃ©ceptacle de batterie, le matÃ©riau dissipatif Ã©tant progressivement plus conducteur Ã  travers son Ã©paisseur de la mÃªme maniÃ¨re que dans le renforcement (118, 119, 120).</claim-text></claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 15, dans lequel le circuit d'alarme, Ã  travers le transducteur d'alarme audible (117) fournit un avertissement de batterie bas indiquant que la batterie associÃ©e Ã  l'appareil de surveillance est en train de fonctionner Ã  un bas niveau.<!-- EPO <DP n="60"> --></claim-text></claim><claim id="c-fr-01-0021" num="0021"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 17, comprenant en outre une deuxiÃ¨me batterie (B2) pour alimenter le transducteur d'alarme visuelle (116) montÃ© sur l'enveloppe Ã©lectronique conductrice (103).</claim-text></claim><claim id="c-fr-01-0022" num="0022"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel le capteur de radiation Ã©lectromagnÃ©tique (121) comporte une paire d'Ã©lÃ©ments d'antenne (52) disposÃ©s de maniÃ¨re orthogonale, chaque Ã©lÃ©ment d'antenne s'Ã©tendant d'un sommet formÃ© en correspondance de la surface avant du renforcement et comprenant une file de thermocouples (54) Ã  rÃ©sistance de pellicule mince arrangÃ©s le long de l'axe de chaque Ã©lÃ©ment d'antenne (52), et une pluralitÃ© d'Ã©lÃ©ments conducteurs (56) espacÃ©s de longueur discrÃ¨te arrangÃ©s transversalement Ã  l'axe de la file, chaque thermocouple (54) de chaque Ã©lÃ©ment d'antenne (52) Ã©tant disposÃ© entre des Ã©lÃ©ments conducteurs attenants (56).</claim-text></claim><claim id="c-fr-01-0023" num="0023"><claim-text>Appareil pour surveiller une radiation Ã©lectromagnÃ©tique comme dÃ©fini dans la revendication 1, dans lequel:<claim-text>- le capteur de radiation Ã©lectromagnÃ©tique (121) comporte une paire d'Ã©lÃ©ments d'antenne disposÃ©s de maniÃ¨re orthogonale (52) lesquels s'Ã©tendent d'un sommet, chaque Ã©lÃ©ment d'antenne s'Ã©tendant le long d'un axe longitudinal respectif et comprenant une file de thermocouples Ã  rÃ©sistance de pellicule mince (54) arrangÃ©s le long de l'axe, et une pluralitÃ© d'Ã©lÃ©ments conducteurs espacÃ©s (56) de longueur discrÃ¨te arrangÃ©s transversalement Ã  l'axe du la file, chaque thermocouple (54) de chaque Ã©lÃ©ment d'antenne (52) Ã©tant disposÃ© entre des Ã©lÃ©ments conducteurs attenants (56);</claim-text><claim-text>- l'Ã©cran conducteur (101) a des premier et deuxiÃ¨me<!-- EPO <DP n="61"> --> cÃ´tÃ©s opposÃ©s;</claim-text><claim-text>- la surface arriÃ¨re (62) du renforcement de matÃ©riau dissipatif graduÃ© (118, 119, 120) se trouve en regard du premier cÃ´tÃ© de l'Ã©cran conducteur (101); et dans lequel ledit appareil pour surveiller une radiation Ã©lectromagnÃ©tique comporte en outre:</claim-text><claim-text>- une enveloppe Ã©lectronique conductrice (103) attachÃ©e Ã  l'Ã©cran conducteur (101); un logement (102), le capteur (121) et le renforcement de matÃ©riau dissipatif graduÃ© (46; 118, 119, 120) Ã©tant contenus dans le logement et montÃ©s sur l'Ã©cran conducteur (101), au moins un cÃ´tÃ© du logement Ã©tant attenant Ã  l'enveloppe Ã©lectronique conductrice (103);</claim-text><claim-text>- le transducteur d'alarme audible (117) Ã©tant montÃ© sur l'enveloppe Ã©lectronique conductrice;</claim-text><claim-text>- une alarme visuelle (116) montÃ©e sur l'enveloppe Ã©lectronique conductrice (103); et</claim-text><claim-text>- un circuit d'alarme et un circuit de verrouillage, le circuit d'alarme et le circuit de verrouillage Ã©tant montÃ©s dans l'enveloppe Ã©lectronique conductrice (103), le circuit d'alarme Ã©tant reliÃ© au transducteur d'alarme audible (117) et Ã©tant destinÃ© Ã  amener le transducteur d'alarme audible (117) Ã  Ã©mettre un son audible quand le capteur dÃ©tecte un niveau prÃ©dÃ©terminÃ© de radiation, le circuit de verrouillage amenant le transducteur d'alarme visuelle (116) Ã  s'illuminer quand le capteur (121) dÃ©tecte un niveau prÃ©dÃ©terminÃ© de radiation, et amenant en outre le transducteur d'alarme visuelle (116) Ã  rester illuminÃ© quand la radiation dÃ©tectÃ©e par le capteur (121) diminue de grandeur jusqu'au-dessous du niveau prÃ©dÃ©terminÃ©; et</claim-text><claim-text>- l'enveloppe Ã©lectronique conductrice (103) ayant un compartiment de batterie (113) y situÃ©, et comprenant en outre un rÃ©ceptacle de batterie et l'enveloppe (103) ayant un deuxiÃ¨me renforcement (114) de matÃ©riau dissipatif graduÃ© situÃ© dans le compartiment (113) qui<!-- EPO <DP n="62"> --> entoure au moins partiellement le rÃ©ceptacle de batterie, le matÃ©riau dissipatif Ã©tant progressivement plus conducteur Ã  travers son Ã©paisseur de la mÃªme maniÃ¨re que dans le renforcement (118, 119, 120).</claim-text></claim-text></claim>
EP	0600143	B1	2000-01-19	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0600143&ki=B1&pd=2000-01-19
EP	0610186	B1	2000-03-29	de	TITLE	1	VERFAHREN ZUR REGENERIEREN VON VERBRAUCHTEM FCC-KATALYSATOR
EP	0610186	B1	2000-03-29	en	TITLE	1	A PROCESS FOR REGENERATING SPENT FLUIDIZED CATALYTIC CRACKING CATALYST
EP	0610186	B1	2000-03-29	fr	TITLE	1	PROCEDE DE REGENERATION D'UN CATALYSEUR USE DE CRAQUAGE CATALYTIQUE FLUIDIFIE
EP	0610186	B1	2000-03-29	en	DESCR	1	<p id="p0001" num="0001">This invention relates to a process for regenerating spent fluidized catalytic cracking catalyst.</p><p id="p0002" num="0002">Catalytic cracking is the backbone of many refineries. It converts heavy feeds to lighter products by cracking large molecules into smaller molecules. Catalytic cracking operates at low pressures, without hydrogen addition, in contrast to hydrocracking, which operates at high hydrogen partial pressures. Catalytic cracking is inherently safe as it operates with very little oil actually in inventory during the cracking process.</p><p id="p0003" num="0003">There are two main variants of the catalytic cracking process: the moving bed process and the far more popular and efficient fluidized bed process.</p><p id="p0004" num="0004">In the fluidized catalytic cracking (FCC) process, catalyst circulates between a cracking reactor and a catalyst regenerator. In the reactor, hydrocarbon feed contacts a source of hot, regenerated catalyst, which vaporizes and cracks the feed at a temperature of 425-600Â°C, usually 460-560Â°C. The cracking reaction deposits carbonaceous hydrocarbons or coke on the catalyst, thereby deactivating the catalyst. The cracked products are separated from the coked catalyst, which is then stripped of volatiles, usually with steam, in a catalyst stripper. The stripped catalyst is then passed to the catalyst regenerator, where coke is burned from the catalyst with oxygen containing gas, usually air. Decoking restores catalyst activity and simultaneously heats the catalyst to, for example, 500-900Â°C, usually 600-750Â°C. This heated catalyst is recycled to the cracking reactor to crack more fresh feed. Flue gas formed by burning coke in the<!-- EPO <DP n="2"> --> regenerator may be treated for removal of particulates and for conversion of carbon monoxide, after which the flue gas is normally discharged into the atmosphere.</p><p id="p0005" num="0005">Catalytic cracking has undergone progressive development since the 1940s, with the trend in fluid catalytic cracking being towards all riser cracking and use of zeolite catalysts.</p><p id="p0006" num="0006">Riser cracking gives higher yields of valuable products than dense bed cracking. Most FCC units now use all riser cracking, with hydrocarbon residence times in the riser of less than 10 seconds, and even less than 5 seconds.</p><p id="p0007" num="0007">Zeolite-containing catalysts having high activity and selectivity are now used in most FCC units. These catalysts work best when coke on the catalyst after regeneration is less than 0.2 wt %, and preferably less than 0.05 wt %.</p><p id="p0008" num="0008">To regenerate FCC catalysts to these low residual carbon levels, and to burn CO completely to CO2 within the regenerator (to conserve heat and minimize air pollution) many FCC operators add a CO combustion promoter metal to the catalyst or to the regenerator.</p><p id="p0009" num="0009">U.S. Patent Nos 4,072,600 and 4,093,535 teach use of combustion-promoting metals such as Pt, Pd, Ir, Rh, Os, Ru and Re in cracking catalysts in concentrations of 0.01 to 50 ppm, based on total catalyst inventory.</p><p id="p0010" num="0010">As the process and catalyst have improved, refiners have attempted to use the process to upgrade a wider range of feedstocks, in particular, feedstocks that are heavier, and also contain more metals and sulfur than have previously been permitted in the feed to a fluid catalytic cracking unit. These heavier, dirtier feeds have placed a growing demand on the regenerator. Processing resids has exacerbated existing problem areas in the regenerator, notably steam, temperature and NOx.<!-- EPO <DP n="3"> --> These problems will each be reviewed in more detail below.</p><heading id="h0001"><u>Steam</u></heading><p id="p0011" num="0011">Steam is always present in FCC regenerators although it is known to cause catalyst deactivation. Steam is not intentionally added, but is invariably present, usually as absorbed or entrained steam from steam stripping of the catalyst or as water of combustion formed in the regenerator. Steam deactivation becomes more of a problem as regenerators get hotter, since higher temperatures accelerate the deactivating effects of steam.</p><heading id="h0002"><u>Temperature</u></heading><p id="p0012" num="0012">Regenerators are being required to operate at higher and higher temperatures. This is because most FCC units are heat balanced, that is, the endothermic heat of the cracking reaction is supplied by burning the coke deposited on the catalyst. With heavier feeds, more coke is deposited on the catalyst than is needed for the cracking reaction. The regenerator gets hotter, and the extra heat is rejected as high temperature flue gas. Many refiners severely limit the amount of resid or similar high CCR feeds to that amount which can be tolerated by the unit. High temperatures are a problem for the metallurgy of many units, but more importantly, are a problem for the catalyst. In the regenerator, the burning of coke and unstripped hydrocarbons leads to much higher surface temperatures on the catalyst than the measured dense bed or dilute phase temperature. This is discussed by Occelli et al in Dual-Function Cracking Catalyst Mixtures, Ch. 12, Fluid Catalytic Cracking, ACS Symposium Series 375, American Chemical Society, Washington, D.C., 1988.<!-- EPO <DP n="4"> --></p><p id="p0013" num="0013">Some regenerator temperature control is possible by adjusting the CO/CO<sub>2</sub> ratio produced in the regenerator. Burning coke partially to CO produces less heat than complete combustion to CO<sub>2</sub>. Control of CO/CO<sub>2</sub> ratios is fairly straightforward in single, bubbling bed regenerators, by limiting the amount of air that is added. It is far more difficult to control CO/CO<sub>2</sub> ratios when multi-stage regeneration is involved.</p><p id="p0014" num="0014">U.S. Patent No. 4,353,812 to Lomas et al discloses cooling catalyst from a regenerator by passing it through the shell side of a heat-exchanger with a cooling medium being passed through the tube side. This approach will remove heat from the regenerator, but will not prevent poorly, or even well, stripped catalyst from experiencing very high surface or localized temperatures in the regenerator.</p><p id="p0015" num="0015">The prior art also uses dense or dilute phase regenerated fluid catalyst heat removal zones or heat-exchangers that are remote from, and external to, the regenerator vessel to cool hot regenerated catalyst for return to the regenerator. Examples of such processes are found in U.S. Patent Nos. 2,970,117 to Harper; 2,873,175 to Owens; 2,862,798 to McKinney; 2,596,748 to Watson et al; 2,515,156 to Jahnig et al; 2,492,948 to Berger; and 2,506,123 to Watson.</p><heading id="h0003"><u>NOx</u></heading><p id="p0016" num="0016">Burning of nitrogenous compounds in FCC regenerators has long led to creation of minor amounts of NOx, which in the past was emitted with the regenerator flue gas. Usually these emissions were not much of a problem because of relatively low temperature, a relatively reducing atmosphere from partial combustion of CO and the absence of catalytic metals like Pt in the regenerator which increase NOx production.<!-- EPO <DP n="5"> --></p><p id="p0017" num="0017">Unfortunately, the trend to heavier feeds usually means that the amount of nitrogen compounds on the coke will increase and that NOx emissions will increase. Higher regenerator temperatures also tend to increase NOx emissions. It would be beneficial, in many refineries, to have a way to burn at least a large portion of the nitrogenous coke in a relatively reducing atmosphere, so that much of the NOx formed could be converted into N<sub>2</sub> within the regenerator. Unfortunately, existing multi-stage regenerator designs can not be run with two stages of regeneration, both operating with partial CO combustion, i.e., with a reducing atmosphere.</p><heading id="h0004"><u>High Efficiency Regenerator</u></heading><p id="p0018" num="0018">Most new FCC units use a high efficiency regenerator, which uses a fast fluidized bed coke combustor to burn most of the coke from the catalyst, and a dilute phase transport riser above the coke combustor to afterburn CO to CO<sub>2</sub> and achieve a limited amount of additional coke combustion. Hot regenerated catalyst and flue gas from the coke combustor are discharged from the transport riser, separated, and the regenerated catalyst collected as a second, bubbling dense bed for return to the FCC reactor and recycle to the coke combustor to heat up incoming spent catalyst.</p><p id="p0019" num="0019">Such regenerators are now widely used. They typically are operated to achieve complete CO combustion within the dilute phase transport riser. They achieve one stage of regeneration, i.e., essentially all of the coke is burned in the coke combustor, with minor amounts being burned in the transport riser. The residence time of the catalyst in the coke combustor is on the order of a few minutes, while the residence time in the transport riser is on the order of a few seconds, so there is generally not enough residence time of catalyst in the<!-- EPO <DP n="6"> --> transport riser to achieve any significant amount of coke combustion.</p><p id="p0020" num="0020">Catalyst regeneration in such high efficiency regenerators is essentially a single stage process in that the catalyst and regeneration gas and produced flue gas remain together from the coke combustor through the dilute phase transport riser. Almost no further regeneration of catalyst occurs downstream of the coke combustor, because very little air is added to the second, bubbling dense bed used to collect regenerated catalyst for recycle to the reactor or the coke combustor. Usually enough air is added to fluff the catalyst, and allow efficient transport of catalyst around the bubbling dense bed. Less than 5 %, and usually less than 1 %, of the coke combustion takes place in the second dense bed.</p><p id="p0021" num="0021">Such units are popular in part because of their efficiency, i.e., the fast fluidized bed, with recycle of hot regenerated catalyst, is so efficient at burning coke that the regenerator can operate with only half the catalyst inventory required in an FCC unit with a bubbling dense bed regenerator.</p><p id="p0022" num="0022">With the trend to heavier feedstocks, the catalyst regenerator is frequently pushed to the limit of its coke burning capacity. Addition of cooling coils, as discussed above in the <u>Temperature</u> discussion, provides some help, but causes additional problems. High efficiency regenerators run best when operated in complete CO combustion mode, so attempts to shift some of the heat of combustion to a downstream CO boiler are difficult to implement.</p><p id="p0023" num="0023">The use of a high efficiency regenerator to achieve staged catalyst regeneration will allow some reduction in NOx emissions, while some recovery of SOx will still be possible. Other benefits also flow from multistage operation, such as reduced steaming of catalyst, because<!-- EPO <DP n="7"> --> of lower average temperatures, and less damage from metals, because at least some of the regeneration is conducted in a somewhat reducing atmosphere which retards formation of highly oxidized forms of vanadium. One such regenerator is disclosed in US 4,849,091, which keeps the air supply to the coke combustor constant, and changes the air supply to the second dense bed based on a dilute phase temperature, which indicates afterburning. There is only partial combustion of coke and CO in the coke combustor, with relatively complete coke and CO combustion in the second dense bed. The reducing flue gas from the coke combustor (with a CO2/CO ratio of 0.7 to 2.0) is combined with the flue gas from the second dense bed, which operates with substantially complete CO combustion to produce a flue gas with at least 0.5% O<sub>2</sub>. The two flue gas streams are combined to form flue gas containing a CO<sub>2</sub>/CO ratio from 1 to 5.</p><p id="p0024" num="0024">The present invention seeks to provide an improved process for effecting high efficiency multi-stage regeneration of spent FCC catalyst in which changes in coke make are dealt with either by changing the coke burning rates in both the coke combustor and the second dense bed, or at least in the coke combustor. This is a preferred arrangement because the coke combustor is the most vigorously fluidized, and most robust place in the regenerator for coke combustion. The fast fluidized bed region is not plagued by the presence of many large bubbles, unlike the second dense bed of many high efficiency regenerators. The fast fluidized bed region is essentially entirely active, while much, and perhaps even a majority, of a bubbling dense phase fluidized bed is inactive. For these reasons, it is preferable to keep the operation of the second stage of regeneration relatively constant, while adjusting coke burning in the fast fluidized bed coke combustor.<!-- EPO <DP n="8"> --></p><p id="p0025" num="0025">Accordingly, the present invention resides in a process for regenerating spent fluidized catalytic cracking catalyst comprising the steps of:<ul id="ul0001" list-style="none" compact="compact"><li>a) partially regenerating said spent cracking catalyst in a primary regeneration zone, comprising a fast fluidized bed coke combustor and a superimposed dilute phase transport riser, by charging said spent catalyst to said fast fluidized bed coke combustor having an inlet for spent catalyst, an inlet for recycled regenerated catalyst and an inlet for primary regeneration gas, to produce partially regenerated catalyst and flue gas comprising at least 1.0 mole % CO, which are passed up into the dilute phase transport riser and discharged therefrom to form a flue gas rich stream comprising at least 1 mole % CO and a catalyst rich stream comprising partially regenerated catalyst; and</li><li>b) completing the regeneration of said partially regenerated catalyst in a secondary regeneration zone comprising a second fluidized bed adapted to receive said partially regenerated catalyst and having means for adding additional regeneration gas to said second fluidized bed in an amount sufficient to complete the regeneration of said catalyst and produce regenerated catalyst and secondary flue gas; wherein:<ul id="ul0002" list-style="none" compact="compact"><li>i) the CO-containing flue gas stream from the said dilute phase transport riser is combined with said secondary flue gas to produce a combined flue gas stream;</li><li>ii) the conditions in said secondary regeneration zone are controlled such that said secondary flue gas contains less than 1 mole % CO and contains sufficient oxygen to react with the CO-containing flue gas stream from the said dilute transport riser;<!-- EPO <DP n="9"> --></li><li>iii) at least one flue gas composition or a differential temperature in said combined flue gas stream is monitored; and</li><li>iv) the amount of primary regeneration gas supplied to said fast fluidized bed coke combustor is controlled so as to maintain constant said monitored flue gas composition or differential temperature.</li></ul></li></ul></p><p id="p0026" num="0026">The invention will now be more particularly described with reference to the accompanying drawings, in which:<ul id="ul0003" list-style="none" compact="compact"><li>Figure 1 is a simplified schematic view of one example of the invention using flue gas composition, or a delta T indicating afterburning, to control air addition to the coke combustor of a multistage FCC high efficiency regenerator.</li><li>Figure 2 is a simplified view of the same regenerator using a flue gas analyzer, or temperature, to control total air flow, and a fluid bed dT controller to apportion air between the fluidized beds.</li><li>Figure 3 shows the same regenerator wherein a flue gas analyzer controller, and/or a delta T controller, changes feed preheat and/or feed rate.</li></ul></p><p id="p0027" num="0027">Referring to the drawings, the FCC reactor section in each example is the same and includes a riser reactor 4, into the lower end of which a heavy feed is charged via line 1. Hot regenerated catalyst is added to the reactor 4 via standpipe 102 and control valve 104 to mix with the feed. Preferably, some atomizing steam is added via line 141 to the base of the riser, usually with the feed. With heavier feeds, e. g. , a resid, 2-10 wt.% steam may be used. A hydrocarbon-catalyst mixture rises as a generally dilute phase through riser 4. Cracked products and coked catalyst are discharged via riser effluent conduit 6 into first stage cyclone 8 in vessel 2. The riser top temperature, the temperature in conduit 6, ranges between 480 and 615Â°C (900 and<!-- EPO <DP n="10"> --> 1150Â°F), and preferably between 538 and 595Â°C (1000 and 1050Â° F). The riser top temperature is usually controlled by adjusting the catalyst to oil ratio in riser 4 or by varying feed preheat.</p><p id="p0028" num="0028">Cyclone 8 separates most of the catalyst from the cracked products and discharges the separated catalyst via dipleg 12 to a stripping zone 30 located in a lower portion of vessel 2. Vapor and minor amounts of catalyst exit cyclone 8 via gas effluent conduit 20 and second stage reactor cyclones 14. The second stage cyclones 14 recover some additional catalyst which is discharged via diplegs to the stripping zone 30.</p><p id="p0029" num="0029">The second stage cyclone overhead stream, cracked products and catalyst fines, pass via effluent conduit 16 and line 120 to product fractionators not shown in Figure 1. Stripping vapors enter the atmosphere of the vessel 2 and may exit this vessel via outlet line 22 or by passing through an annular opening in line 20, not shown, i.e. the inlet to the secondary cyclone can be flared to provide a loose slip fit for the outlet from the primary cyclone.</p><p id="p0030" num="0030">The coked catalyst discharged from the cyclone diplegs collects as a bed of catalyst 31 in the stripping zone 30. Dipleg 12 is sealed by being extended into the catalyst bed 31, whereas the dipleg from the secondary cyclones 14 is sealed by a flapper valve, not shown.</p><p id="p0031" num="0031">Many cyclones, 4 to 8, are usually used in each cyclone separation stage. A preferred closed cyclone system is described in U.S. Patent No. 4,502,947 to Haddad et al.</p><p id="p0032" num="0032">Stripper 30 is a "hot stripper" in that spent catalyst is mixed and heated in bed 31 by hot catalyst from the regenerator. Catalyst from regenerator 80 enters vessel 2 via transfer line 106, and slide valve 108 which controls catalyst flow. Adding hot,<!-- EPO <DP n="11"> --> regenerated catalyst permits first stage stripping at from 55Â°C (100Â°F) above the riser top temperature up to a temperature of 816Â°C (1500Â°F). Preferably, the first stage stripping zone operates at at least 83Â°C (150Â°F) above the riser top temperature, but below 760Â°C (1400Â°F).</p><p id="p0033" num="0033">In bed 31 a stripping gas, preferably steam, flows countercurrent to the catalyst. The stripping gas is preferably introduced into the lower portion of bed 31 by one or more conduits 341. The stripping zone bed 31 preferably contains trays or baffles not shown.</p><p id="p0034" num="0034">High temperature stripping removes coke, sulfur and hydrogen from the spent catalyst. Coke is removed because carbon in the unstripped hydrocarbons is burned as coke in the regenerator. The sulfur is removed as hydrogen sulfide and mercaptans. The hydrogen is removed as molecular hydrogen, hydrocarbons, and hydrogen sulfide. The removed materials also increase the recovery of valuable liquid products, because the stripper vapors can be sent to product recovery with the bulk of the cracked products from the riser reactor. High temperature stripping can reduce coke load to the regenerator by 30 to 50% or more and remove 50-80% of the hydrogen and 35 to 55% of the sulfur, as well as a portion of nitrogen as ammonia and cyanides.</p><p id="p0035" num="0035">Although a hot stripping zone is shown in Figure 1, the present invention may also be used with conventional strippers, or with long residence time steam strippers, or with strippers having internal or external heat exchange means.</p><p id="p0036" num="0036">Although not shown in Figure 1, an internal or external catalyst stripper/cooler, with inlets for hot catalyst and fluidization gas, arid outlets for cooled catalyst and stripper vapor, may also be used where desired to cool the stripped catalyst before it enters the regenerator 80.<!-- EPO <DP n="12"> --></p><p id="p0037" num="0037">The regenerator 80 comprises two regeneration stages, that is a first coke combustor 62/transport riser 83 and a second fluidized bed 82, which is preferably a dense bed or bubbling fluidized bed. Partial CO combustion is maintained in the first stage while the second stage of catalyst regeneration operates in complete CO combustion mode.</p><p id="p0038" num="0038">The stripped catalyst passes through a conduit 42 into regenerator riser 60, where air from line 66 and stripped catalyst combine and pass up through an air catalyst disperser 74 into coke combustor 62. A fast fluidized bed 76 of catalyst is thereby produced in the coke combustor so that combustible materials, such as coke on the catalyst, are burned by contact with air or oxygen containing gas.</p><p id="p0039" num="0039">The amount of air or oxygen containing gas added via line 66, to the base of the riser mixer 60, is preferably constant and preferably restricted to 10-95% of the total air addition to the first stage of regeneration. Additional air, preferably 5-50 % of total air, is added to the coke combustor via line 160 and air ring 167. The partitioning of the first stage air, between the riser mixer 60 and the air ring 167 in the coke combustor, can be fixed or controlled by a differential temperature, e.g., the temperature rise in riser mixer 60. The total amount of air addition to the first stage, i.e., the regeneration in the coke combustor and riser mixer is controlled to maintain only partial coke removal and only partial CO combustion, so that the CO content of the first stage flue gas is in excess of 1 mole%. The control method will be discussed in more detail later.</p><p id="p0040" num="0040">The temperature of fast fluidized bed 76 in the coke combustor 62 may be, and preferably is, increased by recycling some hot regenerated catalyst from the second fluidized bed 82 via line 101 and control valve<!-- EPO <DP n="13"> --> 103. If temperatures in the coke combustor are too high, some heat can be removed via catalyst cooler 48, shown as tubes immersed in the fast fluidized bed in the coke combustor. Very efficient heat transfer can be achieved in the fast fluidized bed 76, so it may be beneficial to both heat the coke combustor (by recycling hot catalyst to it) and to cool the coke combustor (by using catalyst cooler 48) at the same time.</p><p id="p0041" num="0041">In coke combustor 62, the combustion air, regardless of whether added via line 66 or 160, fluidizes the catalyst in bed 76, and subsequently transports the catalyst continuously as a dilute phase through the regenerator riser 83. The dilute phase passes upwardly through the riser 83, through riser outlet 306 into primary regenerator cyclone 308. Catalyst is discharged down through dipleg 84 to form a second relatively dense bed of catalyst 82 located within the regenerator 80.</p><p id="p0042" num="0042">While most of the catalyst passes down through the dipleg 84, the flue gas and some catalyst pass via outlet 310 into the dilute phase region above the second fluidized bed. An additional stage of separation of catalyst from the combined flue gas flue gas streams is achieved in secondary cyclone 486, with catalyst recovered via dipleg 490 and flue gas discharged via gas exhaust line 488 to plenum 520. Flue gas, with a greatly reduced solids content is discharged from the regenerator 80 via line 100.</p><p id="p0043" num="0043">The hot, regenerated catalyst discharged from the various cyclones forms the second fluidized bed 82, which is hotter than any other fluid bed in the regenerator, and hotter than the stripping zone 30. Bed 82 is at least 55Â°C (100Â°F), and preferably at least 83Â°C (150Â°F), hotter than stripping zone 31. The regenerator temperature is preferably no more than 870Â°C (1600Â°F) to prevent deactivating the catalyst.<!-- EPO <DP n="14"> --> Preferably, some hot regenerated catalyst is withdrawn from dense bed 82 and passed via line 106 and control valve 108 into dense bed of catalyst 31 in stripper 30. Hot regenerated catalyst passes through line 102 and catalyst flow control valve 104 for use in heating and cracking of fresh feed.</p><p id="p0044" num="0044">Partial CO combustion is achieved in the first regeneration stage 62, 83 by control of temperature and residence time and by control of the air addition rate. There will always be large amounts of coke on catalyst exiting the riser. Combustion air to the second stage is maintained at a constant rate, or changed only infrequently to suit changing conditions. The second stage flue gas, e.g., CO or O2 content controls the amount of air added to the first stage 62, 83.</p><p id="p0045" num="0045">In the Fig 1 embodiment, air addition to the coke combustor 62 is controlled by a delta T controller 410 which is connected to thermocouples 400 and 405 in the outlet to the transport riser and the dilute phase region above the second fluidized bed respectively. The output from the controller 410 is sent via control line 415 to alter air flow through valve 420 which supplies air to the coke combustor via line 160. The air flow via line 78 to the upper dense bed is fixed, i.e., a conventional control means admits a fixed volume of air.</p><p id="p0046" num="0046">If the CO content of the second stage flue gas increases above 1 mole % CO, or a lower preset maximum CO concentration, in response to a major change in feed characteristics or operating conditions, this means that the second fluidized bed is not able to completely afterburn all the CO produced in the second fluidized bed. The delta T observed by the thermocouples 400, 405 will drop and the dT controller 410 send a signal to the valve 420 to increase the air supply to the coke combustor 62. If second stage flue gas CO content decreases, e.g., to 0.05 mole %, or too much oxygen<!-- EPO <DP n="15"> --> breaks through the second stage, this means the second stage is not being worked hard enough, so the amount of air added to the first stage will be decreased to shift more of the coke burning load to the second stage of regeneration.</p><p id="p0047" num="0047">In an alternative embodiment, shown by the broken lines in Figure 1, a flue gas analyzer 625 is used in place of the dT controller 410 to measure the composition of the flue gas from the second regeneration stage. The flue gas analyzer 625 sends a signal via signal transmission means 615 to valve 420 to control air flow to the coke combustor.</p><p id="p0048" num="0048">The embodiment shown in Figure 1 provides a relatively simple and reliable control scheme (use of a flue gas composition or delta T indicative of a composition of flue gas above the second fluidized bed) which can accommodate normal minor changes in operation, and even be adjusted to deal with major changes in operation.</p><p id="p0049" num="0049">It will be beneficial in many refineries if the relatively large amount of coke burning in both the primary and secondary stage of the regenerator can be directly controlled. The Fig. 2 embodiment provides a way to apportion and control the relative amount of coke burning that occurs in each stage of regeneration.</p><p id="p0050" num="0050">The Fig. 2 embodiment uses most of the hardware from the Fig. 1 embodiment, i.e., the regenerator flue gas streams are combined into a single flue gas stream. The difference in the Fig. 2 embodiment is simultaneous adjustment of both primary and secondary air. This can be seen more easily in conjunction with a review of Figure 2. Elements which correspond to Fig. 1 elements have the same reference numerals, and are not discussed. Fig 2 also includes, besides reference numerals, symbols indicating temperature differences, e.g., dT<sub>12</sub> means<!-- EPO <DP n="16"> --> that a signal is developed indicative of the temperature difference between temperature 1 and temperature 2.</p><p id="p0051" num="0051">The amount of air added to the riser mixer is fixed, for simplicity, but this is merely to simplify the following analysis. The riser mixer air is merely part of the primary air, and could vary with any variations in flow of air to the coke combustor. It is also possible to operate the regenerator with no riser mixer at all, in which case spent catalyst, recycled regenerated catalyst, and primary air are all added directly to the coke combustor. The riser mixer is, however, preferred.</p><p id="p0052" num="0052">The control scheme will first be stated in general terms, then reviewed in conjunction with Fig. 2. The overall amount of combustion air, i.e., the total air to the regenerator, is controlled based on either the composition or temperature of the combined flue gas or a differential temperature indicating afterburning downstream of the second fluidized bed. Controlling or apportioning the air added to each combustion zone allows unit operation to be optimized even when the operator does not know the individual optima for the first and second stages. If the second fluidized bed, typically a bubbling dense bed with fairly poor contacting efficiency, is being called on to do too much afterburning, an increased dT in the flue gas, will occur. The unit can be controlled by increasing the air rate to the coke combustor and decreasing air flow to the second dense bed, and letting the controller keep the relative amount of coke burned in the first and second stages constant regardless of future fluctuations in coke make.</p><p id="p0053" num="0053">In the Fig. 2 embodiment, the control scheme apportions air between the first and second stages of the regenerator. This is a more complicated control method than was used in Figure 1, but will usually allow<!-- EPO <DP n="17"> --> better operation. An operator may specify e.g., that 40 % of the coke will be burned in the first stage and 60 % burned in the second stage, regardless of fluctuations in coke make. Several control loops are needed, basically at least one loop to control total air addition to the regenerator based on a measurement of the flue gas from the unit, and one loop to shift air between the first and second stage to keep the relative amounts of coke combustion in each stage constant.</p><p id="p0054" num="0054">The total air flow in line 358 is controlled by means of a flue gas analyzer 361 or preferably by temperature controller 350 and thermocouple 336 which are in the dilute phase region above the second fluidized bed. Either temperature or flue gas composition can be used to generate a control signal which is transmitted via transmission means 352 or 362 (an air line, or a digital or analogue electrical signal or equivalent signal transmission means) to valve 360 which regulates the total air flow to the regenerator via line 358.</p><p id="p0055" num="0055">The apportionment of air between the primary and secondary stages of regeneration is controlled by the differences in temperature of the two relatively dense phase beds in the regenerator. The temperature (T1) in the coke combustor fast fluidized bed is determined by thermocouple 330. The bubbling dense bed temperature (T2) is determined by thermocouple 332. Both temperature signals are sent to differential temperature controller 338, which generates a signal based on dT12, or the difference in temperature between the two beds. Signals are sent via means 356 to valve 372, which regulates primary air to the coke combustor and via means 354 to valve 72, which regulates secondary air to bubbling dense bed.</p><p id="p0056" num="0056">If the delta T (dT12) becomes too large, it means that not enough coke burning is taking place in the coke<!-- EPO <DP n="18"> --> combustor, and too much coke burning is occurring in the second dense bed. The dT controller 338 will compensate by sending more combustion air to the coke combustor, and less to the bubbling dense bed.</p><p id="p0057" num="0057">There are several other temperature control points which can be used besides the ones shown. Thus the operation of the coke combustor can be measured by the fast fluidized bed temperature (as shown), by the temperature in the dilute phase of the coke combustor or in the dilute phase transport riser, or the temperature measured in the primary cyclone or on a flue gas stream or catalyst stream discharged from the primary cyclone. A flue gas or catalyst composition measurement can also be used to generate a signal indicative of the amount of coke combustion occurring in the fast fluidized bed, but this will generally not be as sensitive as simply measuring the bed temperature in the coke combustor.</p><p id="p0058" num="0058">The designations "primary air" and "secondary air" do not require that a majority of the coke combustion take place in the coke combustor. In most instances, the fast fluidized bed region will be the most efficient place to burn coke, but there are considerations, such as reduced steaming of catalyst if regenerated in the bubbling dense bed, and reduced thermal deactivation of catalyst by delaying as long as possible as much of the carbon burning as possible, which may make it beneficial to burn most of the coke with the "secondary air". This will usually require substantial unit modifications, to increase the size of the second fluidized bed, and to increase the bed superficial vapor velocity so that better fluidization is achieved.</p><p id="p0059" num="0059">It is possible to magnify or to depress the difference in temperature between the coke combustor and the bubbling dense bed by changing the amount of hot regenerated catalyst which is recycled. Operation with large amounts of recycle, i.e., recycling more than 1 or<!-- EPO <DP n="19"> --> 2 weights of catalyst from the bubbling dense bed per weight of spent catalyst, will depress temperature differences between the two regions. Differential temperature control can still be used, but the gain and/or setpoint on the controller may have to be adjusted because recycle of large amounts of catalyst from the second dense bed will increase the temperature in the fast fluidized bed coke combustor.</p><p id="p0060" num="0060">The control method of Fig. 2. will be preferred for most refineries. Another method of control is shown in Fig. 3, which can be used as an alternative to the Fig. 2 method. The Fig. 3 control method retains the ability to apportion combustion air between the primary and secondary stages of regeneration, but adjusts feed preheat, and/or feed rate, rather than total combustion air, to maintain partial CO combustion in the coke combustor and complete CO combustion in the second fluidized bed. The Fig. 3 control method is especially useful where a refiner's air blower capacity is limiting the throughput of the FCC unit. Leaving the air blower at maximum, and adjusting feed preheat and/or feed rate, will maximize the coke burning capacity of the unit by always running the air blower at maximum throughput.</p><p id="p0061" num="0061">In the Fig. 3 embodiment, the total amount of air added via line 358 is controlled solely by the capacity of the compressor or air blower. The apportionment of air between primary and secondary stages of combustion is controlled as in the Fig. 2 embodiment, except that a flue gas dT, rather than a flue gas temperature, is used to adjust coke make. Feed preheat and/or feed rate are adjusted as necessary to keep the coke make in balance with the coke burned in the first stage (partial CO combustion) and in the second stage (complete CO combustion). Each variable changes the coke make of the unit, and each will be reviewed in more detail below.<!-- EPO <DP n="20"> --></p><p id="p0062" num="0062">Feed preheat can control afterburning because of the way FCC reactors are run. The FCC reactor usually operates with a controlled riser top temperature. The hydrocarbon feed in line 1 is mixed with sufficient hot, regenerated catalyst from line 102 to maintain a given riser top temperature. This is the way most FCC units operate. The temperature can be measured at other places in the reactor, as in the middle of the riser, at the riser outlet, cracked product outlet, or a spent catalyst temperature before or after stripping, but usually the riser top temperature is used to control the amount of catalyst added to the base of the riser to crack fresh feed. If the feed is preheated to a very high temperature, and much or all of the feed is added as a vapor, less catalyst will be needed as compared to operation with a relatively cold liquid feed which is vaporized by hot catalyst. High feed preheat reduces the amount of catalyst circulation needed to maintain a given riser top temperature, and this reduced catalyst circulation rate reduces coke make. A constant air supply and a reduced coke make, regardless of the reason for the reduction in coke make, will increase the O2 content of the flue gas.</p><p id="p0063" num="0063">If the O2 content of the flue gas above the bubbling dense bed increases (or if CO content drops) a composition based control signal from analyzer controller 361 may be sent via signal transmission means 384 to feed preheater 380 or to valve 390. Decreasing feed preheat, i.e., a cooler feed, increases coke make. Increasing feed rate increases coke make. Either action, or both together, will increase the coke make, and bring flue gas composition back to the desired point. A differential temperature control 350 may generate an analogous signal, transmitted via means 382 to adjust preheat and/or feed rate.<!-- EPO <DP n="21"> --></p><p id="p0064" num="0064">The air is apportioned between the first and second stages as in the Fig. 2 embodiment, i.e., a dT controller maintains a temperature difference, which indirectly sets the amount of coke burned in each stage.</p><p id="p0065" num="0065">The Fig. 3 embodiment provides a good way to accommodate unusually bad feeds, with CCR levels exceeding 5 or 10 wt %. Partial CO combustion, with downstream combustion of CO, in a CO boiler, and constant maximum air rate maximize the coke burning capacity of the regenerator using an existing air blower of limited capacity.</p><p id="p0066" num="0066">A number of mechanical modifications may be made to the high efficiency regenerator without departing from the scope of the present invention. It is possible to use the control scheme of the present invention even when additional catalyst/flue gas separation means are present. As an example, the riser mixer 60 may discharge into a cyclone or other separation means contained within the coke combustor. The resulting flue gas may be separately withdrawn from the unit, without entering the dilute phase transport riser. Such a regenerator configuration is shown in EP-A-0259115, published on March 9, 1988.</p><p id="p0067" num="0067">Now that the invention has been reviewed in connection with the embodiments shown in the Figures, a more detailed discussion of the different parts of the process and apparatus of the present invention follows. Many elements of the present invention can be conventional, such as the cracking catalyst, or are readily available from vendors, so only a limited discussion of such elements is necessary.</p><heading id="h0005"><u>FCC Feed</u></heading><p id="p0068" num="0068">Any conventional FCC feed can be used. The process of the present invention is especially useful for processing difficult charge stocks, those with high<!-- EPO <DP n="22"> --> levels of CCR material, exceeding 2, 3, 5 and even 10 wt % CCR. The process tolerates feeds which are relatively high in nitrogen content, and which otherwise might produce unacceptable NOx emissions in conventional FCC units, operating with complete CO combustion.</p><p id="p0069" num="0069">The feeds may range from the typical, such as petroleum distillates or residual stocks, either virgin or partially refined, to the atypical, such as coal oils and shale oils. The feed frequently will contain recycled hydrocarbons, such as light and heavy cycle oils which have already been subjected to cracking.</p><p id="p0070" num="0070">Preferred feeds are gas oils, vacuum gas oils, atmospheric resids, and vacuum resids. The present invention is most useful with feeds having an initial boiling point above 343Â°C (650Â°F).</p><heading id="h0006"><u>FCC Catalyst</u></heading><p id="p0071" num="0071">Any commercially available FCC catalyst may be used. The catalyst can be 100% amorphous, but preferably includes some zeolite in a porous refractory matrix such as silica-alumina, clay, or the like. The zeolite is usually 5-40 wt.% of the catalyst, with the rest being matrix. Conventional zeolites include X and Y zeolites, with ultra stable, or relatively high silica Y zeolites being preferred. Dealuminized Y (DEAL Y) and ultrahydrophobic Y (UHP Y) zeolites may be used. The zeolites may be stabilized with Rare Earths, e.g., 0.1 to 10 Wt % RE.</p><p id="p0072" num="0072">Relatively high silica zeolite containing catalysts are preferred for use in the present invention. They withstand the high temperatures usually associated with complete combustion of CO to CO2 within the FCC regenerator.</p><p id="p0073" num="0073">The catalyst inventory may also contain one or more additives, either present as separate additive particles or mixed in with each particle of the cracking catalyst.<!-- EPO <DP n="23"> --> Additives can be added to enhance octane (shape selective zeolites, i.e., those having a Constraint Index of 1-12, preferably ZSM-5), adsorb SOX (alumina), and remove Ni and V (Mg and Ca oxides).</p><heading id="h0007"><u>FCC Reactor Conditions</u></heading><p id="p0074" num="0074">Conventional FCC reactor conditions may be used. The reactor may be either a riser cracking unit or dense bed unit or both. Riser cracking is highly preferred. Typical riser cracking reaction conditions include catalyst/oil ratios of 0.5:1 to 15:1 and preferably 3:1 to 8:1, and a catalyst contact time of 0.5-50 seconds, and preferably 1-20 seconds.</p><p id="p0075" num="0075">It is preferred, but not essential, to use an atomizing feed mixing nozzle in the base of the riser reactor.</p><p id="p0076" num="0076">It is preferred, but not essential, to have a riser acceleration zone in the base of the riser, as shown in Figures 1 and 2.</p><p id="p0077" num="0077">It is preferred, but not essential, to have the riser reactor discharge into a closed cyclone system for rapid and efficient separation of cracked products from spent catalyst. A preferred closed cyclone system is disclosed in US 4,502,947 to Haddad et al.</p><p id="p0078" num="0078">It is preferred but not essential, to rapidly strip the catalyst, immediately after it exits the riser, and upstream of the conventional catalyst stripper. Stripper cyclones disclosed in US 4,173,527, Schatz and Heffley, may be used.</p><p id="p0079" num="0079">It is preferred, but not essential, to use a hot catalyst stripper. Hot strippers heat spent catalyst by adding some hot, regenerated catalyst to spent catalyst. The hot stripper reduces the hydrogen content of the spent catalyst sent to the regenerator and reduces the coke content as well. Thus, the hot stripper helps control the temperature and amount of hydrothermal<!-- EPO <DP n="24"> --> deactivation of catalyst in the regenerator. A good hot stripper design is shown in US 4,820,404 Owen.</p><heading id="h0008"><u>Catalyst Regeneration</u></heading><p id="p0080" num="0080">The process and apparatus of the present invention can use many conventional elements most of which are conventional in FCC regenerators.</p><p id="p0081" num="0081">The present invention uses as its starting point a high efficiency regenerator such as is shown in the Figures. The essential elements of such a regenerator include a coke combustor, a dilute phase transport riser and a second fluidized bed, which is usually a bubbling dense bed. The second fluidized bed can also be a turbulent fluidized bed, or even another fast fluidized bed, but unit modifications will then frequently be required. Preferably, a riser mixer is used. These elements are generally known.</p><p id="p0082" num="0082">Preferably there is quick separation of catalyst from steam laden flue gas exiting the regenerator transport riser. A significantly increased catalyst inventory in the second fluidized bed of the regenerator, and means for adding a significant amount of combustion air for coke combustion in the second fluidized bed are preferably present or added.</p><p id="p0083" num="0083">Each part of the regenerator will be briefly reviewed below, starting with the riser mixer and ending with the regenerator flue gas cyclones.</p><p id="p0084" num="0084">Spent catalyst and some combustion air are charged to the riser mixer 60. Some regenerated catalyst, recycled through the catalyst stripper, will usually be mixed in with the spent catalyst. Some regenerated catalyst may also be directly recycled to the base of the riser mixer 60, either directly or, preferably, after passing through a catalyst cooler. Riser mixer 60 is a preferred way to get the regeneration started. The riser mixer typically burns most of the fast coke<!-- EPO <DP n="25"> --> (probably representing entrained or adsorbed hydrocarbons) and a very small amount of the hard coke. The residence time in the riser mixer is usually very short. The amount of hydrogen and carbon removed, and the reaction conditions needed to achieve this removal are reported below. <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm"/><colspec colnum="2" colname="col2" colwidth="31.50mm"/><colspec colnum="3" colname="col3" colwidth="31.50mm"/><colspec colnum="4" colname="col4" colwidth="31.50mm"/><colspec colnum="5" colname="col5" colwidth="31.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col5" align="center">RISER MIXER CONDITIONS</entry></row><row rowsep="1"><entry namest="col1" nameend="col2"/><entry namest="col3" nameend="col3" align="center">Good</entry><entry namest="col4" nameend="col4" align="left">Preferred</entry><entry namest="col5" nameend="col5" align="center">Best</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" morerows="1" align="left">Inlet Temp.</entry><entry namest="col2" nameend="col2" align="left">Â°F</entry><entry namest="col3" nameend="col3" align="right">900-1200</entry><entry namest="col4" nameend="col4" align="right">925-1100</entry><entry namest="col5" nameend="col5" align="right">950-1050</entry></row><row><entry namest="col2" nameend="col2" align="left">Â°C</entry><entry namest="col3" nameend="col3" align="right">480- 650</entry><entry namest="col4" nameend="col4" align="right">500- 595</entry><entry namest="col5" nameend="col5" align="right">510- 565</entry></row><row><entry namest="col1" nameend="col1" morerows="1" align="left">Temp. Increase,</entry><entry namest="col2" nameend="col2" align="left">Â°F</entry><entry namest="col3" nameend="col3" align="right">10- 200</entry><entry namest="col4" nameend="col4" align="right">25- 150</entry><entry namest="col5" nameend="col5" align="right">50- 100</entry></row><row><entry namest="col2" nameend="col2" align="left">Â°C</entry><entry namest="col3" nameend="col3" align="right">5- 110</entry><entry namest="col4" nameend="col4" align="right">15- 85</entry><entry namest="col5" nameend="col5" align="right">30 - 55</entry></row><row><entry namest="col1" nameend="col2" align="left">Catalyst Residence Time, Seconds</entry><entry namest="col3" nameend="col3" align="right">0.5-30</entry><entry namest="col4" nameend="col4" align="right">1 - 25</entry><entry namest="col5" nameend="col5" align="right">1.5-20</entry></row><row><entry namest="col1" nameend="col1" morerows="1" align="left">Vapor velocity,</entry><entry namest="col2" nameend="col2" align="left">fps</entry><entry namest="col3" nameend="col3" align="right">5- 100</entry><entry namest="col4" nameend="col4" align="right">7 - 50</entry><entry namest="col5" nameend="col5" align="right">10 - 25</entry></row><row><entry namest="col2" nameend="col2" align="left">m/s</entry><entry namest="col3" nameend="col3" align="right">1.5-30</entry><entry namest="col4" nameend="col4" align="right">2.1-15</entry><entry namest="col5" nameend="col5" align="right">3 - 7.5</entry></row><row><entry namest="col1" nameend="col2" align="left">% total air added</entry><entry namest="col3" nameend="col3" align="right">1 - 25</entry><entry namest="col4" nameend="col4" align="right">2 - 20</entry><entry namest="col5" nameend="col5" align="right">3 - 15</entry></row><row><entry namest="col1" nameend="col2" align="left">H2 Removal, %</entry><entry namest="col3" nameend="col3" align="right">5 - 40</entry><entry namest="col4" nameend="col4" align="right">10 -35</entry><entry namest="col5" nameend="col5" align="right">12 - 30</entry></row><row rowsep="1"><entry namest="col1" nameend="col2" align="left">Carbon Removal, %</entry><entry namest="col3" nameend="col3" align="right">1 - 10</entry><entry namest="col4" nameend="col4" align="right">2 - 8</entry><entry namest="col5" nameend="col5" align="right">3 - 7</entry></row></tbody></tgroup></table></tables></p><p id="p0085" num="0085">Although operation with a riser mixer is preferred, it is not essential, and in many units is difficult to implement because there is not enough elevation under the coke combustor in which to fit a riser mixer. Spent, stripped catalyst may be added directly to the coke combustor, discussed next.</p><p id="p0086" num="0086">The coke combustor 62 contains a fast fluidized dense bed of catalyst. It is characterized by relatively high superficial vapor velocity, vigorous<!-- EPO <DP n="26"> --> fluidization, and a relatively low density dense phase fluidized bed. Most of the coke can be burned in the coke combustor. The coke combustor will also efficiently burn "fast coke", primarily unstripped hydrocarbons, on spent catalyst. When a riser mixer is used, a large portion, perhaps most, of the "fast coke" will be removed upstream of the coke combustor. If no riser mixer is used, relatively easy job of burning the fast coke will be done in the coke combustor.</p><p id="p0087" num="0087">The removal of hydrogen and carbon achieved in the coke combustor alone (when no riser mixer is used) or in the combination of the coke combustor and riser mixer, is presented below. The operation of the riser mixer and coke combustor can be combined in this way, because what is important is that catalyst leaving the coke combustor have specified amounts of carbon and hydrogen removed.<!-- EPO <DP n="27"> --> <tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm"/><colspec colnum="2" colname="col2" colwidth="31.50mm"/><colspec colnum="3" colname="col3" colwidth="31.50mm"/><colspec colnum="4" colname="col4" colwidth="31.50mm"/><colspec colnum="5" colname="col5" colwidth="31.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col5" align="center">COKE COMBUSTOR CONDITIONS</entry></row><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="center">Good</entry><entry namest="col4" nameend="col4" align="center">Preferred</entry><entry namest="col5" nameend="col5" align="center">Best</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" morerows="1" align="left">Dense Bed Temp.</entry><entry namest="col2" nameend="col2" align="left">Â°F</entry><entry namest="col3" nameend="col3" align="right">900-1300</entry><entry namest="col4" nameend="col4" align="right">925-1275</entry><entry namest="col5" nameend="col5" align="right">950-1250</entry></row><row><entry namest="col2" nameend="col2" align="left">Â°C</entry><entry namest="col3" nameend="col3" align="right">400- 700</entry><entry namest="col4" nameend="col4" align="right">500- 690</entry><entry namest="col5" nameend="col5" align="right">510- 680</entry></row><row><entry namest="col1" nameend="col2" align="left">Catalyst Residence Time, Seconds</entry><entry namest="col3" nameend="col3" align="right">10- 500</entry><entry namest="col4" nameend="col4" align="right">20- 240</entry><entry namest="col5" nameend="col5" align="right">30- 180</entry></row><row><entry namest="col1" nameend="col1" morerows="1" align="left">Vapor velocity,</entry><entry namest="col2" nameend="col2" align="left">fps</entry><entry namest="col3" nameend="col3" align="right">1- 40</entry><entry namest="col4" nameend="col4" align="right">2 - 20</entry><entry namest="col5" nameend="col5" align="right">3.5-15</entry></row><row><entry namest="col2" nameend="col2" align="left">m/s</entry><entry namest="col3" nameend="col3" align="right">0.3-12</entry><entry namest="col4" nameend="col4" align="right">0.6- 6</entry><entry namest="col5" nameend="col5" align="right">1 - 4.5</entry></row><row><entry namest="col1" nameend="col2" align="left">% primary air added</entry><entry namest="col3" nameend="col3" align="right">40- 100</entry><entry namest="col4" nameend="col4" align="right">50 - 98</entry><entry namest="col5" nameend="col5" align="right">60 - 95</entry></row><row><entry namest="col1" nameend="col2" align="left">% total air added</entry><entry namest="col3" nameend="col3" align="right">30 - 95</entry><entry namest="col4" nameend="col4" align="right">35 - 90</entry><entry namest="col5" nameend="col5" align="right">40 - 80</entry></row><row><entry namest="col1" nameend="col2" align="left">H2 Removal, %</entry><entry namest="col3" nameend="col3" align="right">40 - 98</entry><entry namest="col4" nameend="col4" align="right">45 - 95</entry><entry namest="col5" nameend="col5" align="right">50 - 90</entry></row><row rowsep="1"><entry namest="col1" nameend="col2" align="left">Carbon Removal, %</entry><entry namest="col3" nameend="col3" align="right">25 - 95</entry><entry namest="col4" nameend="col4" align="right">30 - 90</entry><entry namest="col5" nameend="col5" align="right">35 - 75</entry></row></tbody></tgroup></table></tables></p><p id="p0088" num="0088">The dilute phase transport riser 83 forms a dilute phase which efficiently transfers catalyst from the fast fluidized bed through a catalyst separation means to the second dense bed.</p><p id="p0089" num="0089">Additional air can be added to the dilute phase transport riser, but usually it is better to add the air lower down in the regenerator, and speed up coke burning rates.<!-- EPO <DP n="28"> --> <tables id="tabl0003" num="0003"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm"/><colspec colnum="2" colname="col2" colwidth="31.50mm"/><colspec colnum="3" colname="col3" colwidth="31.50mm"/><colspec colnum="4" colname="col4" colwidth="31.50mm"/><colspec colnum="5" colname="col5" colwidth="31.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col5" align="center">TRANSPORT RISER CONDITIONS</entry></row><row rowsep="1"><entry namest="col1" nameend="col2"/><entry namest="col3" nameend="col3" align="center">Good</entry><entry namest="col4" nameend="col4" align="center">Preferred</entry><entry namest="col5" nameend="col5" align="center">Best</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" morerows="1" align="left">Inlet Temp.</entry><entry namest="col2" nameend="col2" align="left">Â°F</entry><entry namest="col3" nameend="col3" align="right">900-1300</entry><entry namest="col4" nameend="col4" align="right">925-1275</entry><entry namest="col5" nameend="col5" align="right">950-1250</entry></row><row><entry namest="col2" nameend="col2" align="left">Â°C</entry><entry namest="col3" nameend="col3" align="right">400- 700</entry><entry namest="col4" nameend="col4" align="right">500- 690</entry><entry namest="col5" nameend="col5" align="right">510- 680</entry></row><row><entry namest="col1" nameend="col1" morerows="1" align="left">Outlet Temp.</entry><entry namest="col2" nameend="col2" align="left">Â°F</entry><entry namest="col3" nameend="col3" align="right">925-1450</entry><entry namest="col4" nameend="col4" align="right">975-1400</entry><entry namest="col5" nameend="col5" align="right">1000-1350</entry></row><row><entry namest="col2" nameend="col2" align="left">Â°C</entry><entry namest="col3" nameend="col3" align="right">500- 790</entry><entry namest="col4" nameend="col4" align="right">25- 760</entry><entry namest="col5" nameend="col5" align="right">540- 730</entry></row><row><entry namest="col1" nameend="col2" align="left">Catalyst Residence Time, Seconds</entry><entry namest="col3" nameend="col3" align="right">1 - 60</entry><entry namest="col4" nameend="col4" align="right">2 - 40</entry><entry namest="col5" nameend="col5" align="right">3 - 30</entry></row><row><entry namest="col1" nameend="col1" morerows="1" align="left">Vapor velocity,</entry><entry namest="col2" nameend="col2" align="left">fps</entry><entry namest="col3" nameend="col3" align="right">6 - 50</entry><entry namest="col4" nameend="col4" align="right">9 - 40</entry><entry namest="col5" nameend="col5" align="right">10 - 30</entry></row><row><entry namest="col2" nameend="col2" align="left">c/s</entry><entry namest="col3" nameend="col3" align="right">2 - 15</entry><entry namest="col4" nameend="col4" align="right">3- -12</entry><entry namest="col5" nameend="col5" align="right">3 - 9</entry></row><row><entry namest="col1" nameend="col2" align="left">% total air in</entry><entry namest="col3" nameend="col3" align="right">0 - 30</entry><entry namest="col4" nameend="col4" align="right">0 - 20</entry><entry namest="col5" nameend="col5" align="right">0 - 5</entry></row><row><entry namest="col1" nameend="col2" align="left">H2 Removal, %</entry><entry namest="col3" nameend="col3" align="right">0 - 20</entry><entry namest="col4" nameend="col4" align="right">1 - 15</entry><entry namest="col5" nameend="col5" align="right">2 - 10</entry></row><row rowsep="1"><entry namest="col1" nameend="col2" align="left">Carbon Removal, %</entry><entry namest="col3" nameend="col3" align="right">0 - 15</entry><entry namest="col4" nameend="col4" align="right">1 - 10</entry><entry namest="col5" nameend="col5" align="right">2 - 5</entry></row></tbody></tgroup></table></tables></p><p id="p0090" num="0090">Rapid separation of flue gas from catalyst exiting the dilute phase transport riser is still the preferred way to operate the unit. This flue gas stream contains a fairly large amount of steam, from adsorbed stripping steam entrained with the spent catalyst and from water of combustion. Many FCC regenerators operate with 35-70 kPa (5-10 psia) steam partial pressure in the flue gas. In the process of the present invention, the dilute phase mixture is preferably quickly separated into a catalyst rich dense phase and a catalyst lean dilute phase.</p><p id="p0091" num="0091">The quick separation of catalyst and flue gas sought in the regenerator transport riser outlet is very<!-- EPO <DP n="29"> --> similar to the quick separation of catalyst and cracked products sought in the riser reactor outlet.</p><p id="p0092" num="0092">The most preferred separation system effects discharge of the regenerator transport riser dilute phase into a closed cyclone system such as that disclosed in US 4,502,947. Such a system rapidly and effectively separates catalyst from steam laden flue gas and isolates and removes the flue gas from the regenerator vessel. This means that catalyst in the regenerator downstream of the transport riser outlet will be in a relatively steam free atmosphere, and the catalyst will not deactivate as quickly as in prior art units.</p><p id="p0093" num="0093">Other methods of effecting a rapid separation of catalyst from steam laden flue gas may also be used, but most of these will not work as well as the use of closed cyclones. Acceptable separation means include a capped riser outlet discharging catalyst down through an annular space defined by the riser top and a covering cap. In older FCC's a reasonably efficient multistage regeneration of catalyst can be achieved by reducing the air added to the coke combustor and increasing the air added to the second fluidized bed. The reduced vapor velocity in the transport riser, and increased vapor velocity immediately above the second fluidized bed, will more or less segregate the flue gas from the transport riser from the flue gas from the second fluidized bed.</p><p id="p0094" num="0094">In a preferred embodiment, the transport riser outlet may be capped with radial arms, not shown, which direct the bulk of the catalyst into large diplegs leading down into the second fluidized bed of catalyst in the regenerator. Such a regenerator riser outlet is disclosed in US Patent 4,810,360.</p><p id="p0095" num="0095">Regardless of the method chosen, at least 90 % of the catalyst discharged from the transport riser<!-- EPO <DP n="30"> --> preferably is quickly discharged into a second fluidized bed, discussed below. At least 90 % of the flue gas exiting the transport riser should be removed from the vessel without further contact with catalyst. This can be achieved to some extent by proper selection of bed geometry in the second fluidized bed, i.e., use of a relatively tall but thin containment vessel 80, and careful control of fluidizing conditions in the second fluidized bed.</p><p id="p0096" num="0096">The second fluidized bed achieves a second stage of regeneration of the catalyst, in a relatively dry atmosphere. The multistage regeneration of catalyst is beneficial from a temperature standpoint alone, i.e., it keeps the average catalyst temperature lower than the last stage temperature. This can be true even when the temperature of regenerated catalyst is exactly the same as in prior art units, because when staged regeneration is used the catalyst does not reach the highest temperature until the last stage. The hot catalyst has a relatively lower residence time at the highest temperature in a multistage regeneration process.</p><p id="p0097" num="0097">The second fluidized bed bears a superficial resemblance to the second dense bed used in prior art, high efficiency regenerators. There are several important differences which bring about profound changes in the function of the second fluidized bed.</p><p id="p0098" num="0098">In prior art second dense beds, the catalyst was merely collected and recycled (to the reactor and frequently to the coke combustor). Catalyst temperatures were typically 680-730Â°C (1250-1350Â°F), with some operating slightly hotter, perhaps approaching 760Â°C (1400Â°F). The average residence time of catalyst was usually 60 seconds or less. A small amount of air, typically around 1 or 2 % of the total air added to the regenerator, was added to the dense bed to keep it fluidized and enable it to flow into collectors for<!-- EPO <DP n="31"> --> recycle to the reactor. The superficial gas velocity in the bed was typically less than 15 cm/s (0.5 fps), usually 3cm/s (0.1 fps). The bed was relatively dense, bordering on incipient fluidization. This was efficient use of the second dense bed as a catalyst collector, but meant that little or no regeneration of catalyst was achieved in the second dense bed. Because of the low vapor velocity in the bed, very poor use would be made of even the small amounts of oxygen added to the bed. Large fluidized beds such as this are characterized, or plagued, by generally poor fluidization, and relatively large gas bubbles.</p><p id="p0099" num="0099">In the present process, the second fluidized bed plays a much more significant role in regenerating the catalyst. To achieve this, the first step is to provide an increased residence time in the second fluidized bed, typically of at least 1 minute, and preferably much longer. This increased residence time can be achieved by adding more catalyst to the unit, and letting it accumulate in the second fluidized bed. In addition, in the present process much more air is added to the second fluidized bed for several reasons. First, more carbon burning occurs in the second fluidized bed, so the air is needed for combustion. Second, to improve fluidization in the second fluidized bed, much higher superficial vapor velocities are necessary. Also the density of the catalyst in the second fluidized bed is decreased. This reduced density is a characteristic of better fluidization, and also somewhat beneficial in that although the present bed may be twice as high as a bed of the prior art it will not have to contain twice as much catalyst.<!-- EPO <DP n="32"> --> <tables id="tabl0004" num="0004"><table frame="all"><tgroup cols="5" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="31.50mm"/><colspec colnum="2" colname="col2" colwidth="31.50mm"/><colspec colnum="3" colname="col3" colwidth="31.50mm"/><colspec colnum="4" colname="col4" colwidth="31.50mm"/><colspec colnum="5" colname="col5" colwidth="31.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col5" align="center">SECOND DENSE BED CONDITIONS</entry></row><row rowsep="1"><entry namest="col1" nameend="col2"/><entry namest="col3" nameend="col3" align="center">Good</entry><entry namest="col4" nameend="col4" align="center">Preferred</entry><entry namest="col5" nameend="col5" align="center">Best</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" morerows="1" align="left">Temperature</entry><entry namest="col2" nameend="col2" align="left">Â°F</entry><entry namest="col3" nameend="col3" align="right">1200-1700</entry><entry namest="col4" nameend="col4" align="right">1300-1600</entry><entry namest="col5" nameend="col5" align="right">1350-1500</entry></row><row><entry namest="col2" nameend="col2" align="left">Â°C</entry><entry namest="col3" nameend="col3" align="right">650 -930</entry><entry namest="col4" nameend="col4" align="right">700 -870</entry><entry namest="col5" nameend="col5" align="right">730 -815</entry></row><row><entry namest="col1" nameend="col2" align="left">Catalyst Residence Time, Seconds</entry><entry namest="col3" nameend="col3" align="right">30 -500</entry><entry namest="col4" nameend="col4" align="right">45 -200</entry><entry namest="col5" nameend="col5" align="right">60 -180</entry></row><row><entry namest="col1" nameend="col1" morerows="1" align="left">Vapor velocity,</entry><entry namest="col2" nameend="col2" align="left">fps</entry><entry namest="col3" nameend="col3" align="right">0.5 -5</entry><entry namest="col4" nameend="col4" align="right">1 - 4</entry><entry namest="col5" nameend="col5" align="right">1.5 3.5</entry></row><row><entry namest="col2" nameend="col2" align="left">m/s</entry><entry namest="col3" nameend="col3" align="right">0.15-1.5</entry><entry namest="col4" nameend="col4" align="right">0.3- 1.2</entry><entry namest="col5" nameend="col5" align="right">0.5 -1.1</entry></row><row><entry namest="col1" nameend="col2" align="left">% total air added</entry><entry namest="col3" nameend="col3" align="right">0 - 90</entry><entry namest="col4" nameend="col4" align="right">2 - 60</entry><entry namest="col5" nameend="col5" align="right">5 - 40</entry></row><row><entry namest="col1" nameend="col2" align="left">H2 Removal, %</entry><entry namest="col3" nameend="col3" align="right">0 - 25</entry><entry namest="col4" nameend="col4" align="right">1 - 10</entry><entry namest="col5" nameend="col5" align="right">1 - 5</entry></row><row rowsep="1"><entry namest="col1" nameend="col2" align="left">Carbon Removal, %</entry><entry namest="col3" nameend="col3" align="right">10 - 70</entry><entry namest="col4" nameend="col4" align="right">5 - 60</entry><entry namest="col5" nameend="col5" align="right">10 - 40</entry></row></tbody></tgroup></table></tables></p><p id="p0100" num="0100">Operating the second fluidized bed with more catalyst inventory, and higher superficial vapor velocity, allows an extra stage of catalyst regeneration, either to achieve cleaner catalyst or to more gently remove the carbon and thereby extend catalyst life. Enhanced stability is achieved because much of the regeneration, and much of the catalyst residence time in the regenerator, is under drier conditions than could be achieved in prior art designs.</p><heading id="h0009"><u>CO COMBUSTION PROMOTER</u></heading><p id="p0101" num="0101">Use of a CO combustion promoter in the regenerator or combustion zone is not essential for the practice of the present invention, however, it may be beneficial. These materials are well-known.</p><p id="p0102" num="0102">U.S. 4,072,600 and U.S. 4,235,754 disclose operation of an FCC regenerator with minute quantities<!-- EPO <DP n="33"> --> of a CO combustion promoter. From 0.01 to 100 ppm Pt metal or enough other metal to give the same CO oxidation, may be used with good results. Very good results are obtained with as little as 0.1 to 10 wt. ppm platinum present on the catalyst in the unit. Pt can be replaced by other metals, but usually more metal is then required. An amount of promoter which would give a CO oxidation activity equal to 0.3 to 3 wt. ppm of platinum is preferred.</p><heading id="h0010"><u>DISCUSSION</u></heading><p id="p0103" num="0103">The control method of the present invention can be readily added to existing high efficiency regenerators. Most of the regenerator can be left untouched, as the modifications to install differential temperature probes in the regenerator cyclones, or flue gas analyzers, are minor. Usually only minor modifications will be needed in the second dense bed to accommodate the additional combustion air, and perhaps to add extra air rings, and new cyclones.</p><p id="p0104" num="0104">The riser mixer (if used), the coke combustor, and the dilute phase transport riser require no modification.</p><p id="p0105" num="0105">The only modification that is strongly recommended for existing high efficiency regenerators is incorporation of a means at the exit of the dilute phase transport riser to rapidly and completely separate catalyst from steam laden flue gas. The steam laden flue gas should be isolated from the catalyst collected in the second fluidized bed. Preferably a closed cyclone system is used to separate and isolate steam laden flue gas from catalyst.</p><p id="p0106" num="0106">Preferably much, and even most, of the coke combustion occurs in the dry atmosphere of the second fluidized bed. Temperatures in the second fluidized bed<!-- EPO <DP n="34"> --> are high, so rapid coke combustion can be achieved even in a bubbling fluidized bed.</p><p id="p0107" num="0107">The process of the present invention permits continuous on stream optimization of the catalyst regeneration process. Achieving a significant amount of coke combustion in the second fluidized bed of a high efficiency regenerator also increases the coke burning capacity of the unit, for very little capital expenditure.</p><p id="p0108" num="0108">The process of the present invention gives refiners a way to achieve the benefits of multi-stage catalyst regeneration in a high efficiency catalyst regenerator. The process accommodates the inevitable changes in coke make that occur in FCC operation by forcing most of the change to be dealt with in the coke combustor, which is the most robust, and controllable, place to burn coke in an FCC regenerator.</p><p id="p0109" num="0109">Both coke combustion and afterburning in the coke combustor can be limited to a great extent by restricting the amount of combustion air added to the coke combustor, provided the unit does not contain excessive amounts of CO combustion promoter.</p><p id="p0110" num="0110">Preferably, the coke burning characteristics of the coke combustor are varied directly, by controllably limiting the amount of hot regenerated catalyst recycled to the coke combustor from the second fluidized bed. In an extreme case, little or no hot regenerated catalyst is recycled to the coke combustor. Because the incoming catalyst is relatively cool, i.e., is merely at the temperature at which it is withdrawn from the catalyst stripper, carbon burning rates are very low even though there is intense fluidization in the coke combustor. At the generally low temperature which prevails in a coke combustor operating without catalyst recycle, there is usually not sufficient residence time to burn more than 10 - 90 % of the coke on the spent catalyst, and usually<!-- EPO <DP n="35"> --> only 20 - 75 % of the coke will be burned in the primary regeneration stage consisting of the coke combustor and the dilute phase transport riser. The relatively low temperatures also hinder to some extent the afterburning of CO to CO2. Thus there will always be a relatively large amount of CO present, whether produced by coke combustion or to a lesser extent by the reaction of CO2 with carbon.</p><p id="p0111" num="0111">For maximum efficiency, refiners will keep relatively constant operation in the second fluidized bed, and make most of the changes to unit operation occur in the coke combustor. It is also possible to change the operation of the primary and secondary stages of regeneration together, so that the relative amounts of coke burning in each stage remain constant.</p><p id="p0112" num="0112">By operating in accordance with the teachings of the present invention, refiners will be able to obtain the benefits of coke burning in a generally reducing atmosphere (less NOx, reduced formation of highly oxidized forms of vanadium, lower temperatures, greater coke burning capacity) while having a reliable and responsive way to control the unit which will deal with upsets and other changes which affect the units coke make.</p>
EP	0610186	B1	2000-03-29	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A process for regenerating spent fluidized catalytic cracking catalyst comprising the steps of:<claim-text>a) partially regenerating said spent cracking catalyst in a primary regeneration zone, comprising a fast fluidized bed coke combustor and a superimposed dilute phase transport riser, by charging said spent catalyst to said fast fluidized bed coke combustor having an inlet for spent catalyst, an inlet for recycled regenerated catalyst and an inlet for primary regeneration gas, to produce partially regenerated catalyst and flue gas comprising at least 1.0 mole % CO, which are passed up into the dilute phase transport riser and discharged therefrom to form a flue gas rich stream comprising at least 1 mole % CO and a catalyst rich stream comprising partially regenerated catalyst; and</claim-text><claim-text>b) completing the regeneration of said partially regenerated catalyst in a secondary regeneration zone comprising a second fluidized bed adapted to receive said partially regenerated catalyst and having means for adding additional regeneration gas to said second fluidized bed in an amount sufficient to complete the regeneration of said catalyst and produce regenerated catalyst and secondary flue gas; wherein:<claim-text>i) the CO-containing flue gas stream from the said dilute phase transport riser is combined with said secondary flue gas to produce a combined flue gas stream;<!-- EPO <DP n="37"> --></claim-text><claim-text>ii) the conditions in said secondary regeneration zone are controlled such that said secondary flue gas contains less than 1 mole % CO and contains sufficient oxygen to react with the CO-containing flue gas stream from the said dilute transport riser;</claim-text><claim-text>iii) at least one flue gas composition or a differential temperature in said combined flue gas stream is monitored; and</claim-text><claim-text>iv) the amount of primary regeneration gas supplied to said fast fluidized bed coke combustor is controlled so as to maintain constant said monitored flue gas composition or differential temperature.</claim-text></claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The process of claim 1 wherein said second fluidized bed comprises a bubbling dense phase fluidized bed.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The process of claim 1 wherein a cyclone separator connected to said dilute phase transport riser outlet is used to separate partially regenerated catalyst from flue gas.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The process of claim 1 wherein the amount of primary regeneration gas supplied to said fast fluidized bed coke combustor and the amount of additional regeneration gas supplied to said second fluidized bed are controlled so as to maintain constant said monitored flue gas composition or differential temperature.<!-- EPO <DP n="38"> --></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The process of claim 1 wherein the amount of regenerated catalyst recycled to the coke combustor from the second fluidized bed is controlled to limit the amount of coke burned in said coke combustor to 10 to 90 % of the coke on said spent catalyst.</claim-text></claim>
EP	0610186	B1	2000-03-29	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zum Regenerieren eines verbrauchten Katalysators vom katalytischen Wirbelschichtcracken, welches die Schritte umfaÃŸt:<claim-text>a) teilweises Regenerieren des verbrauchten Crackkatalysators in einer primÃ¤ren Regenerierungszone, die einen Kokscombustor mit schnell verwirbeltem Bett und einen darÃ¼ber angeordneten FÃ¶rderriser mit verdÃ¼nnter Phase umfaÃŸt, indem der verbrauchte Katalysator dem Kokscombustor mit schnell verwirbeltem Bett zugefÃ¼hrt wird, der einen EinlaÃŸ fÃ¼r verbrauchten Katalysator, einen EinlaÃŸ fÃ¼r rezirkulierten regenerierten Katalysator und einen EinlaÃŸ fÃ¼r primÃ¤res Regenerierungsgas aufweist, wodurch ein teilweise regenerierter Katalysator und Abgas, das mindestens 1,0 Mol-% CO umfaÃŸt, erzeugt werden, die nach oben in den FÃ¶rderriser mit verdÃ¼nnter Phase geleitet und daraus abgegeben werden, wodurch ein an Abgas reicher Strom, der mindestens 1 Mol-% CO umfaÃŸt, und ein an Katalysator reicher Strom erzeugt werden, der teilweise regenerierten Katalysator umfaÃŸt, und</claim-text><claim-text>b)Vollendung der Regenerierung des teilweise regenerierten Katalysators in einer sekundÃ¤ren Regenerierungszone, die ein zweites Wirbelbett umfaÃŸt, das der Aufnahme des teilweise regenerierten Katalysators dient und eine Einrichtung aufweist, um dem zweiten Wirbelbett weiteres Regenerierungsgas in einer ausreichenden Menge zuzufÃ¼hren, damit die Regenerierung<!-- EPO <DP n="40"> --> des Katalysators vollendet wird und regenerierter Katalysator und ein sekundÃ¤res Abgas erzeugt werden, wobei:<claim-text>i) der CO enthaltende Abgasstrom aus dem FÃ¶rderriser mit verdÃ¼nnter Phase mit dem sekundÃ¤ren Abgas gemischt wird, wodurch ein gemischter Abgasstrom erzeugt wird,</claim-text><claim-text>ii) die Bedingungen in der sekundÃ¤ren Regenerierungszone so geregelt werden, daÃŸ das sekundÃ¤re Abgas weniger als 1 Mol-% CO und ausreichend Sauerstoff fÃ¼r die Reaktion mit dem CO enthaltenden Abgasstrom aus dem FÃ¶rderriser mit verdÃ¼nnter Phase enthÃ¤lt,</claim-text><claim-text>iii) mindestens eine Abgaszusammensetzung oder ein Temperaturunterschied im gemischten Abgasstrom Ã¼berwacht wird, und</claim-text><claim-text>iv) die Menge des primÃ¤ren Regenerierungsgases, die dem Kokscombustor mit schnell verwirbeltem Bett zugefÃ¼hrt wird, so geregelt wird, daÃŸ die Ã¼berwachte Abgaszusammensetzung oder der Ã¼berwachte Temperaturunterschied konstant gehalten werden.</claim-text></claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren nach Anspruch 1, wobei das zweite Wirbelbett ein Wirbelbett mit aufwallender dichter Phase umfaÃŸt.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren nach Anspruch 1, wobei ein Zyklonabscheider, der mit dem AuslaÃŸ des FÃ¶rderrisers mit verdÃ¼nnter Phase verbunden ist, verwendet wird, um den teilweise regenerierten Katalysator vom Abgas abzutrennen.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verfahren nach Anspruch 1, wobei die Menge des primÃ¤ren Regenerierungsgases, die dem Kokscombustor mit schnell verwirbeltem Bett zugefÃ¼hrt wird, und die Menge des zusÃ¤tzlichen Regenerierungsgases, die dem zweiten Wirbelbett zugefÃ¼hrt wird, geregelt werden, damit die Ã¼berwachte Abgaszusammensetzung oder der Temperaturunterschied konstant gehalten werden.<!-- EPO <DP n="41"> --></claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verfahren nach Anspruch 1, wobei die Menge des regenerierten Katalysators, die aus dem zweiten Wirbelbett zum Kokscombustor rezirkuliert wird, geregelt wird, um die im Kokscombustor verbrannte Koksmenge auf 10 bis 90 % des Koks auf dem verbrauchten Katalysator zu begrenzen.</claim-text></claim>
EP	0610186	B1	2000-03-29	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Un procÃ©dÃ© de rÃ©gÃ©nÃ©ration de catalyseur de craquage catalytique usÃ© en lit fluidisÃ© comprenant les Ã©tapes suivantes :<claim-text>a) rÃ©gÃ©nÃ©ration partielle dudit catalyseur de craquage usÃ© dans une zone de rÃ©gÃ©nÃ©ration primaire comprenant une installation de combustion du coke en lit fluidisÃ© rapide et un rÃ©acteur superposÃ© de transport ascendant en phase diluÃ©e, en chargeant ledit catalyseur usÃ© dans ladite installation de combustion du coke en lit fluidisÃ© rapide comportant une entrÃ©e pour le catalyseur usÃ©, une entrÃ©e pour le catalyseur rÃ©gÃ©nÃ©rÃ© recyclÃ© et une entrÃ©e pour le gaz de rÃ©gÃ©nÃ©ration primaire, en vue de produire du catalyseur partiellement rÃ©gÃ©nÃ©rÃ© et du gaz effluent comprenant au moins 1,0 mole % de CO, que l'on fait passer au-dessus dans le rÃ©acteur de transport ascendant en phase diluÃ©e et que l'on en Ã©vacue de ce dernier pour former un courant riche en gaz effluent comprenant au moins 1 mole % de CO et un courant riche en catalyseur comprenant du catalyseur partiellement rÃ©gÃ©nÃ©rÃ© et</claim-text><claim-text>b) achÃ¨vement de la rÃ©gÃ©nÃ©ration dudit catalyseur partiellement rÃ©gÃ©nÃ©rÃ© dans une zone de rÃ©gÃ©nÃ©ration secondaire comprenant un second lit fluidisÃ© conÃ§u pour recevoir ledit catalyseur partiellement rÃ©gÃ©nÃ©rÃ© et comportant des moyens d'introduction de gaz de rÃ©gÃ©nÃ©ration supplÃ©mentaire dans ledit second lit fluidisÃ© en quantitÃ© suffisante pour terminer la rÃ©gÃ©nÃ©ration du catalyseur et produire du catalyseur rÃ©gÃ©nÃ©rÃ© et un effluent gazeux secondaire, dans lequel :<claim-text>i) le courant de gaz effluent contenant du CO provenant dudit rÃ©acteur de transport ascendant en phase diluÃ©e est combinÃ© avec ledit effluent gazeux secondaire pour produire un courant d'effluent combinÃ© ;</claim-text><claim-text>ii) les conditions dans ladite zone de rÃ©gÃ©nÃ©ration secondaire sont contrÃ´lÃ©es de faÃ§on que ledit effluent secondaire contienne moins de 1 mole % de CO et contienne suffisamment d'oxygÃ¨ne pour rÃ©agir avec le courant de gaz d'Ã©chappement contenant du CO provenant dudit rÃ©acteur de transport ascendant en phase diluÃ©e ;</claim-text><claim-text>iii) au moins la composition de gaz effluent ou la diffÃ©rentielle de tempÃ©rature dans ledit courant de gaz effluent combinÃ© est surveillÃ©e ; et</claim-text><claim-text>iv) la quantitÃ© de gaz de rÃ©gÃ©nÃ©ration primaire introduite dans ladite installation de coke en lit fluidisÃ© rapide est contrÃ´lÃ©e de faÃ§on Ã  maintenir constante ladite composition ou ladite diffÃ©rentielle de tempÃ©rature de l'effluent gazeux surveillÃ©e.</claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Le procÃ©dÃ© de la revendication 1, dans lequel ledit second lit fluidisÃ© comprend un lit fluidisÃ© Ã  phase dense bouillonnant.<!-- EPO <DP n="43"> --></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Le procÃ©dÃ© de la revendication 1, dans lequel un sÃ©parateur Ã  cyclones raccordÃ© Ã  ladite sortie du rÃ©acteur Ã  transport ascendant en phase diluÃ©e est utilisÃ©e pour sÃ©parer du catalyseur partiellement rÃ©gÃ©nÃ©rÃ© du gaz effluent.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Le procÃ©dÃ© selon la revendication 1, dans laquelle la quantitÃ© de gaz de rÃ©gÃ©nÃ©ration primaire introduite dans ladite installation de combustion du coke en lit fluidisÃ© rapide et la quantitÃ© de gaz de rÃ©gÃ©nÃ©ration supplÃ©mentaire introduite dans ledit second lit fluidisÃ© sont contrÃ´lÃ©es de faÃ§on Ã  maintenir constante ladite composition surveillÃ©e de gaz effluent ou ladite diffÃ©rentielle de tempÃ©rature.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Le procÃ©dÃ© selon la revendication 1, dans lequel la quantitÃ© de catalyseur rÃ©gÃ©nÃ©rÃ© recyclÃ© dans l'installation de combustion du coke Ã  partir du second lit fluidisÃ© est contrÃ´lÃ©e de faÃ§on Ã  limiter la quantitÃ© de coke brÃ»lÃ© dans ladite installation de combustion de coke Ã  une proportion de 10 Ã  90 % du code dÃ©posÃ© sur ledit catalyseur usÃ©.</claim-text></claim>
EP	0610186	B1	2000-03-29	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0610186&ki=B1&pd=2000-03-29
EP	0605418	B1	2000-07-05	de	TITLE	1	AUF BANKAUTOMAT/VERKAUFSSTELLE BASIERTES ELEKTRONISCHES MITTEILUNGSSYSTEM
EP	0605418	B1	2000-07-05	en	TITLE	1	ATMS/POS BASED ELECTRONIC MAIL SYSTEM
EP	0605418	B1	2000-07-05	fr	TITLE	1	SYSTEME DE COURRIER ELECTRONIQUE BASE SUR UN GUICHET AUTOMATIQUE OU UN POINT DE VENTE
EP	0605418	B1	2000-07-05	en	DESCR	1	<heading id="h0001"><u>Technical Field</u></heading><p id="p0001" num="0001">The present invention relates generally to computer data systems for storing and forwarding messages and, more particularly to an adaptation of existing worldwide Automated Teller Machine ("ATM") and Point of Sale ("POS") systems that permits users of such systems to receive and send electronic mail.</p><heading id="h0002"><u>Background Art</u></heading><p id="p0002" num="0002">Over the years, many different types of electronic message transmission devices have been developed. For transmitting spoken messages, one of the oldest, most widely used and convenient of these devices is the telephone. However, until quite recently, the telephone provided only live, real-time communication. Recently, "voice mail" services have become available that permit callers to leave spoken messages for later retrieval and reproduction to their intended recipients. While convenient, the cost of transmitting voice messages over the public phone system is relatively high in comparison with the cost of transmitting messages using surplus capacity that is available in communication systems that have been installed and are maintained in continuous operation for entirely different purposes.</p><p id="p0003" num="0003">Another recently developed message transmission technology is one with the ability to transmit text messages for later retrieval and reproduction by their intended recipient. Such systems are known as electronic mail and utilize an underlying technology known as a "Store And Forward Message Switch". However, most current electronic mail systems are both expensive and must be accessed using special purpose terminals. Presently, there exists no widely available means by which the public can conveniently and inexpensively access electronic mail communication.</p><p id="p0004" num="0004">Yet other recently developed communication systems are the many independently operated ATM systems and POS systems. One of the characteristics of the various ATM and POS systems is<!-- EPO <DP n="2"> --> their interconnection by many clearing house networks. These clearing house networks pass transactions back and forth between terminals on one ATM or POS system and another ATM or POS system on which the user's account identification records reside.</p><p id="p0005" num="0005">It appears desirable to link parts of existing communication systems to provide readily accessible public electronic mail communication that frees users from the need to use a special purpose terminal. Such a combined system facilitates sending and receiving electronic mail and also provides much greater functionality to the exiting voice and data communication systems.</p><p id="p0006" num="0006">In "Review of the Electrical Communication Laboratories" Vol. 32 (1984) Nov, N &amp;, Tokyo, Japan, pages 1036-1043 there is described a method of distributing cryptographic keys to aid in the encryption and decryption of messages over an e-mail network.</p><p id="p0007" num="0007">In "Nachrichtentechnische Zeitschriften" Vol. 36 (1983) Aug.; n8, Berlin, Deutschland, pages 500-504, there is described a means for encrypting communications thereby providing security on videotext networks.</p><p id="p0008" num="0008">Both of these known procedures employ network facilities, including user identity verification and data security facilities to enable services like message delivery and data-base access to be used. In<!-- EPO <DP n="3"> --> particular, the second document discloses the use of such services in a POS system.</p><p id="p0009" num="0009">An object of the present invention is to provide a convenient means by which the public can readily avail themselves of electronic mail services. Another object of the present invention is to provide an economical system for public access to electronic mail services.</p><p id="p0010" num="0010">Another object of the present invention is to provide a secure system for public access to electronic mail services.</p><p id="p0011" num="0011">Yet another object of the present invention is to provide a highly reliable system for public access to electronic mail services.</p><p id="p0012" num="0012">Briefly, the present invention provides an electronic mail system by which users can easily authorise, generate and capture messages and responses. The system uses a debit card, a credit card or other machine readable personal identification card in conjunction with an authorised personal identification number ("PIN") or other valid password security identification to regulate access to the electronic mail service. The system of the present invention employs unique peripherals in conjunction with parts of existing communications networks and devices to provide simple text communications to remote locations. It provides this service by means of a structured link between a store and forward message switch and other<!-- EPO <DP n="4"> --> already installed communication systems. The system of the<!-- EPO <DP n="5"> --> present invention advantageously uses the existing networks of ATM and POS terminals together with the clearing house networks that interconnect the various ATM and POS systems to provide wide public access to electronic mail services.</p><p id="p0013" num="0013">To access this electronic mail service, a user enters their debit, credit, or identification card into either an ATM or POS terminal. That terminal in conjunction with a local processor acquires the user's identity, the user's security information, and the user's desire to retrieve or enter messages. The local ATM or POS processor then passes this information through a processor for the ATM or POS institution to the information processor at the user's financial institution. It is also possible, based on the current state of the art of ATM and POS network systems, that the approval process may take place during an alternate account transaction processing step. This is described in more detail below. Upon receipt of this information, the processor for the user's financial institution confirms the user's identity and authorizes the user to access the electronic mail service. Such identification and authorization procedures are a routine operation on ATM and POS networks.</p><p id="p0014" num="0014">After a user's access to the electronic mail system has been approved by their financial institution, a clearing house processor for the ATM and/or POS networks permits the user to access its electronic mail message service control function. This message service control function differentiates among the various transactions involved in electronic mail communication that are in addition to the financial transactions normally exchanged over the ATM or POS network. The message service control function performed by the clearing house processor also tracks the status and steps required to complete electronic mail transmission.</p><p id="p0015" num="0015">The message service control function on the clearing house processor passes user entered electronic mail control information to a special purpose store and forward message switch for retrieving the user's messages and/or permitting the user to originate or transmit messages to other users. The store and forward message switch then returns messages and/or verification<!-- EPO <DP n="6"> --> of status of messages for other users back through the message service control function of the clearing house processor for transmission back to the user at the ATM or POS terminal. The clearing house processor also separately passes accounting information to the user's financial institution for recording usage of the electronic mail services.</p><heading id="h0003"><u>Brief Description of Drawings</u></heading><p id="p0016" num="0016">Other features and advantages of the invention will become apparent from the following specification which, in association with the attached drawing figures and claims, describe the invention. The figures are annotated with consistent reference numerals throughout.<ul id="ul0001" list-style="none" compact="compact"><li>FIG. 1 is a block diagram depicting an entire system for providing an electronic mail service in accordance with the present invention including its ATM/POS subsystem, the ATM/POS institution processor, a user's financial institution processor, the clearing house processor, and the store and forward message switch;</li><li>FIG. 2 is a block diagram depicting the functional elements included in a terminal of the ATM/POS subsystem illustrated in FIG. 1;</li><li>FIG. 3 is a combined block diagram and flow chart depicting the processor for the ATM or POS institution illustrated in FIG. 1 together with the functions performed by that processor in support of the electronic mail service, in particular the ATM or POS terminal management functions;</li><li>FIG. 4 is a combined block diagram and flow chart depicting the store and forward message switch illustrated in FIG. 1 together with the functions performed by the switch in providing electronic mail services;</li><li>FIG. 5 is a combined block diagram and flow chart depicting the clearing house processor illustrated in FIG. 1 together with the functions performed by that processor in providing electronic mail services including the message service control function; and</li><li>FIG. 6 is a combined block diagram and flow chart depicting the user's financial institution processor system illustrated<!-- EPO <DP n="7"> --> in FIG. 1 together with the functions performed by that processor in providing electronic mail services.</li></ul></p><heading id="h0004"><u>Best Mode for Carrying Out the Invention</u></heading><p id="p0017" num="0017">FIG. 1 depicts a publicly accessible electronic mail system in accordance with the present invention identified by the general reference character 10. The electronic mail system 10 illustrates a generic Automated Teller Machine or Point of Sale ("ATM/POS") system within the dashed line 12. The generic ATM/POS system 12 includes an ATM/POS subsystem enclosed within the dashed line 14, an ATM data communication network 16, and an ATM institution processor 18.</p><p id="p0018" num="0018">The ATM/POS subsystem 14 depicted in FIG. 1 illustrates different techniques routinely employed for connecting various types of ATM terminals 22 and 24 and ATM/POS terminals 26 and 28 to the ATM data communication network 16. In the ATM/POS subsystem 14 depicted in FIG. 1 each of the ATM terminals 22 and 24 include their own microprocessor as depicted in FIG. 2. Consequently, because the terminals 22 and 24 include their own microprocessor, each terminal 22 or 24 is individually capable of communicating directly with the ATM data communication network 16. Alternatively, ATM/POS terminals 26 and 28 illustrate a different technique in which the terminals 26 and 28 are connected to a shared processor 32 through which they communicate with the ATM data communication network 16. The ATM/POS subsystem 14 illustrated in FIG. 1 also depicts a POS terminal 34 that communicates with a POS institution processor 36 via a POS data communication network 38.</p><p id="p0019" num="0019">Because of the similarities among different ATM systems and POS systems when they are incorporated into the electronic mail system 10, for purposes of this disclosure it is possible to illustrate both of these different types of systems by means of a single generic ATM/POS system 12. - If the generic ATM/POS system 12 of FIG. 1 were particularized to only an ATM system, then it would omit the POS terminal 34, the POS processor 36, and the POS data communication network 38, while the ATM/POS terminals 26 and 28 would communicate via the shared processor 32 only with the ATM data communication network 16. The<!-- EPO <DP n="8"> --> ATM/POS system 12 enclosed within its dashed line, when so particularized to only an ATM system, allows a user to perform financial transactions with only the institution(s) whose records reside on the ATM institution processor 18.</p><p id="p0020" num="0020">Alternatively, if the generic ATM/POS system 12 of FIG. 1 were particularized to only a POS system, then it would omit the ATM terminals 22 and 24, the ATM data communication network 16, and the ATM institution processor 18, while the ATM/POS terminals 26 and 28 would communicate via the shared processor 32 only with the POS data communication network 38. The ATM/POS system 12 enclosed within its dashed line, when so particularized to an POS system, allows a user to make transactions with only the merchant(s) whose records reside on the POS institution processor 36.</p><p id="p0021" num="0021">In the illustration of FIG. 1, the shared processor 32 communicates only with the ATM data communication network 16 if the ATM/POS system 12 is particularized to an ATM system. Alternatively, if the ATM/POS system 12 is particularized to a POS system the shared processor 32 communicates only with the POS data communication network 38. The illustration in FIG. 1 of the shared processor 32 as being connected both to the ATM data communication network 16 and to the POS data communication network 38 presently does not exist in any known system. The shared processor 32 is so illustrated in the generic ATM/POS system 12 of FIG. 1 solely for pedagogical reasons to simplify FIG. 1 and to permit it to illustrate the characteristics common to both ATM and POS systems that are relevant to the present invention.</p><p id="p0022" num="0022">The electronic mail system 10 of the present invention envisions a plurality of independently operated ATM/POS systems 12 all intercommunicating simultaneously to provide the entire electronic mail service available to users. A clearing house data communication network 42 interconnects the plurality of ATM institution processors 18 and the plurality of POS institution processors 36 included in the electronic mail system 10 to a clearing house network processor 44. By transferring information among different ATM institution processors 18 operated by various financial institutions and<!-- EPO <DP n="9"> --> among different POS institution processor 36 operated by various merchants, the clearing house data communication network 42 and the clearing house network processor 44 allow users to perform inter-institution transactions such as between one of the ATM/POS systems 12 and a processor 46 operated by a user's financial institution.</p><p id="p0023" num="0023">With the electronic mail system 10 as thus far described, a user begins to receive or transmit electronic mail using the ATM/POS system 12, the clearing house data communication network 42, the clearing house network processor 44, and the user's financial institution processor 46 by inserting a debit or credit card 48 into one of the terminals 22, 24, 26, 28 or 34 operated by one of the plurality of ATM/POS systems 12 included in the electronic mail system 10. Upon insertion of the card 48, the terminal 22, 24, 26, 28 or 36, in conjunction with the local microprocessor, acquires the user's identity and the user's security information. After the user enters a personal identification number ("PIN") or other security password or code, the terminal 22, 24, 26 28 or 34 communicates through its own ATM data communication network 16 and ATM institution processor 18 (or through its own POS data communication network 38 and POS institution processor 36), and the clearing house data communication network 42 with the clearing house network processor 44. The clearing house network processor 44 then interacts with the user's financial institution processor 46 through the clearing house data communication network 42 to access the user's account records, to obtain authorization for the user to access the electronic mail function of the electronic mail system 10, and to acquire appropriate information for charging such use to the user. As mentioned above, this approval process may take place during an alternate processing step and is described in further detail below. In authorizing usage of the electronic mail system 10, the user's financial institution processor 46 returns a message identification ("I.D.") for the user to the clearing house network processor 44.</p><p id="p0024" num="0024">Having received the user's message I.D. the clearing house network processor 44 then activates its message service control<!-- EPO <DP n="10"> --> function to access, via the clearing house data communication network 42, information stored for the user on a store and forward message switch 52. Via the clearing house data communication network 42 and the ATM/POS system 12, the store and forward message switch 52 then sends a group of messages (one transaction) back to the terminal 22, 24, 26, 28 or 34 at which the user entered his request. After completing this transaction, the store and forward message switch 52 updates a status code for the messages delivered to indicate that they have been sent and are awaiting further instructions from the user as to final disposition.</p><p id="p0025" num="0025">By interacting with the terminal 22, 24, 26, 28 or 34 through a keyboard and/or function keys illustrated in FIG. 2, a user directs the ATM/POS subsystem 14 to display the retrieved messages on a display screen, also illustrated in FIG. 2. Using the keyboard and/or function keys of the terminal 22, 24, 26, 28 or 34, the user may request that the terminal 22, 24, 26, 28, or 34 print a copy of a retrieved message on paper 54.</p><p id="p0026" num="0026">The user may respond to or originate messages for storage on the store and forward message switch 52 using the terminal 22, 24, 26, 28 or 34 in the same manner as requesting access to stored messages. The electronic mail system 10 authorizes a user to respond to or originate messages in the same way as described above for retrieving messages. If the ATM/POS subsystem 14 possesses the ability to retain the user's identity and security code information, it is unnecessary for the user to reinsert the debit or credit card 48 and to reenter the security code. A response or a message to be stored on the store and forward message switch 52 may be entered at the terminal 22, 24, 26, 28 or 34 in a variety of different ways. For example, using an ATM/POS subsystem of the type depicted in FIG. 2, the user could respond to or enter a message using either a keyboard or a "pen pad." Alternatively, the terminal 22, 24, 26, 28 or 34 may include an optical character recognition unit (not illustrated in FIG. 2.) to scan a written message 56. A response or new message entered by the user at the terminal 22, 24, 26, 28 or 34 passes through the clearing<!-- EPO <DP n="11"> --> house network processor 44 to the user's financial institution processor 46 which must authorize the response or message's storage on the store and forward message switch 52.</p><p id="p0027" num="0027">Then the store and forward message switch 52 receives a response or a message, it validates the basics of the message, and if they are acceptable, stores the response or message for retransmission. Furthermore, the store and forward message switch 52 provides an acknowledgement to the terminal 22, 24, 26, 28 or 34 that the response or message has been stored. If the store and forward message switch 52 determines that a response or a message is unacceptable, in the same way it transmits a rejection message back to the terminal 22, 24, 26, 28 or 34 together with an explanation of the problem. In addition to the preceding way in which various parts of the electronic mail system 10 of the present invention intercommunicate as described above, the present invention also envisions pathways, other than the clearing house data communication network 42 and the clearing house network processor 44, by which ATM/POS systems 12 may communicate with the user's financial institution processor 46 and the store and forward message switch 52. For example, if the electronic mail system 10 implements the message service control function somewhere other than on the clearing house network processor 44, then the ATM institution processor 18 or the POS institution processor 36 may obtain authorization and other information necessary for a user to access the electronic mail system 10 by communicating directly with the user's financial institution processor 46 via a user authorization data communication network 62. Under such circumstances, the ATM institution processor 18 or the POS institution processor 36 can also exchange user messages directly with the store and forward message switch 52 via a message data communication network 64. Properly implemented, any of the various data communication networks 42, 62 or 64 can provide the message transmission capability necessary for proper operation of the electronic mail system 10.</p><p id="p0028" num="0028">Generally, messages are presented to the store and forward message switch 52 from outside the ATM/POS system 12 by a<!-- EPO <DP n="12"> --> computer terminal entry station 72. The station 72 may be any of several types of terminals that can communicate with electronic mail services. The station 72 could be a standard personal computer ("PC") with the message being created off-line and then transmitted to the store and forward message switch 52. Alternatively, the station 72 could be a terminal connected directly to a mainframe or mini-computer system.</p><p id="p0029" num="0029">The station 72 communicates with the store and forward message switch 52 via a message entry data communication network 74. In storing a message on the store and forward message switch 52, the station 72 identifies the user, either through a directory as normally provide by this type of service, or by knowing the user's electronic mail I.D. Directory services of this type are well known and are associated with many of the current electronic mail systems. A modem 76 may also communicate with the message entry data communication network 74 to provide the electronic mail system 10 with a pager communication service 78 and a facsimile transmission machine 82.</p><p id="p0030" num="0030">The present invention also envisions other ways of storing messages on the store and forward message switch 52. For example, using a telephone 84 individuals without access to an E-Mail Service may call a service bureau that has a station 72 connected to the electronic mail system 10. Such a service bureau will be able to take messages from outside individuals by telephone and store them on the store and forward message switch 52. Similarly, the user can also send messages out to individuals who lack an I.D. on the electronic mail system 10 through a service bureau. Anyone with a phone or mailing address can, in principle, be reached by sending a message to the service bureau for forwarding to the individual with which the user wants to communicate. Such operations would be a normal part of the service bureau function to extend the reach of the message service to the general public.</p><p id="p0031" num="0031">Another way of communicating with individuals who are not themselves users of the electronic mail system 10 is through the facsimile transmission machine 82. The store and forward message switch 52 recognizes when the user enters a facsimile<!-- EPO <DP n="13"> --> telephone number as the destination address for a response or a message. Under such circumstances, the store and forward message switch 52 initiates a telephone call and uses the conventional facsimile transmission process to deliver the message to the intended recipient. After successful facsimile transmission of the message, the message's status is displayed to the user.</p><p id="p0032" num="0032">Furthermore, the electronic mail system 10 may announce to users that a message has been stored for them on the store and forward message switch 52. To announce the storage of a message, the store and forward message switch 52 places a telephone call to the pager communication service 78 thereby activating the user's beeper. Upon being notified of a message's storage, the user proceeds to a terminal 22, 24, 26, 28 or 34 to retrieve it.</p><p id="p0033" num="0033">The link created by the store and forward message switch 52 also allows connection to multiple external E-Mail systems through the industry standard X.400 or custom E-Mail to E-Mail links. Such E-Mail links have already been established by many of these services and are well known in the art. This allows easy physical connection to all of the existing E-Mail services, and provides handy communication to users of the electronic mail system 10 from outside the ATM/POS systems. Generally, all of the standard services provided by the E-Mail system will be the same, and will be available through the electronic mail system 10. However, due to the physical limitations which may practically be imposed on the electronic mail system 10, the scope of the message may be limited in some way. For example such limitations may include, but are not limited to, the size or the detail of the message, or similar limitations.</p><p id="p0034" num="0034">An additional feature of the electronic mail system 10 for individuals who themselves are not users of the system 10 is its ability to capture charge information instead of the normal E-Mail system charges that would be appropriate for those with E-Mail service access. This charge capture capability is a necessary part of providing easy service bureau access to the electronic mail system 10.<!-- EPO <DP n="14"> --></p><heading id="h0005"><u>The Processor That Performs the</u> <u>Message Service Control Function</u></heading><p id="p0035" num="0035">The message service control function, described in greater detail below in connection with FIG. 5, is an essential part of the electronic mail system 10 of the present invention. As indicated above, it is not essential to the operation of the electronic mail system 10 that the message service control function be performed exclusively by the clearing house network processor 44. However, because the message service control function is an essential part of the electronic mail system 10, details in the operations performed respectively on the processors 18, 36, 44 and 46 change slightly depending upon the particular processor that performs the message service control function.</p><p id="p0036" num="0036">The message service control function may be performed on the institution processor 18 or 36 included in the ATM/POS system 12 of the terminal 22, 24, 26, 28 or 34, or on institution processor 18 or 36 that belongs to another ATM/POS system 12, on the clearing house network processor 44, or on the user's financial institution processor 46 which itself may be an institution processor 18 or 36 that belongs to a different ATM/POS system 12. Initially accessing the message service control function differs if the user's account records are maintained on a processor 18, 36, or 46 other than that in the ATM/POS system 12 presently serving the user.</p><p id="p0037" num="0037">After a user has been authorized to use the electronic mail system 10, the message service control function handles all further control relationships with the appropriate terminal 22, 24, 26, 28 or 34 and the store and forward message switch 52. After a user finishes entering a request at the terminal 22, 24, 26, 28 or 34, the ATM/POS subsystem 14 transmits it to the processor 18, 36 or 44 that performs the message service control function to be formatted before it is further transmitted through the networks 42, 62 or 64. The message will be formatted by the processor 18, 36 or 44 in accordance with normal system requirements using the new transaction types and transaction formats unique to the electronic mail system 10.<!-- EPO <DP n="15"> --> Information for providing the message service control function is encoded and included in the message to identify the terminal location, date, time and other information, and becomes an associated part of the message and its audit trail. This message service control information added to each message is used in carrying out the message service control function and in operation of the store and forward message switch 52.</p><p id="p0038" num="0038">The message service control function also processes responses to user requests, and returns the results to the institution processor 18 or 36 for the ATM/POS system 12 controlling the operation of the terminal 22, 24, 26, 28 or 34 serving the user.</p><heading id="h0006"><u>Determining Location/Affiliation</u></heading><p id="p0039" num="0039">Destination can be identified using the normal location/affiliation directory or, as an alternate, a new directory associated with the message transactions alone, whichever is most efficient for network functionality. Furthermore, an alternate location/affiliation approval process may take place on the ATM or POS network during another processing step. Such alternate approval processing is well known in the state of the art of ATM and POS networks and will be readily understood by one skilled in the art.</p><heading id="h0007"><u>ATM/POS Subsystem 14</u></heading><p id="p0040" num="0040">FIG. 2 depicts the functional elements required for one entire terminal 22, 24, 26, 28 or 34 of the ATM/POS subsystem 14 depicted in FIG. 1. As illustrated in FIG. 2, all transactions between the terminal 22, 24, 26, 28 or 34 of the ATM/POS subsystem 14 and the data communication network 16 or 38 pass through a communications controller 110. The communications controller 110 includes an input buffer 112 and an output buffer 114. Within the ATM/POS subsystem 14, the communications controller 110 provides data contained in transactions received from the data communication network 16 or 18 from its input buffer 112 to an input 118 of a microprocessor 120. Analogously, the output buffer 114 of the communications controller 110 receives data from an output 122 of the microprocessor<!-- EPO <DP n="16"> --> 120 for transmission as a transaction over the data communication network 16 or 18.</p><p id="p0041" num="0041">In addition to the input 118 and the output 122, the microprocessor 120 includes a central processing unit ("CPU") 124 that fetches data from the input 118 of the microprocessor 120 and stores data to its output 122. The CPU 124 of the microprocessor 120 also fetches data from and stores data into a memory 126. The microprocessor 120 also includes an arithmetic logical unit ("ALU") 128 that operates upon data received from the CPU 124 and returns the results of such operations to the CPU 124.</p><p id="p0042" num="0042">The ATM/POS subsystem 14 also includes an input/output console 130. The input/output console 130 includes an input buffer 132 that transmits data to the input 118 of the microprocessor 120, and an output buffer 134 that receives data from the output 122 of the microprocessor 120. Included in the input/output console 130 supplying data to the input buffer 132 are various input devices including a debit or credit card reader 136, function keys 138, and a character decoder 142 that receives data both from a keyboard 144 and from a pen pad 146. The input/output console 130 also includes various output devices including a display screen 152, an instruction panel and screen 154, and a status panel 156 that all receive data from the output buffer 134. The status panel 156 may include a number of indicators to inform a user of the various states (or status) of a transaction being performed including problems or errors that are likely to arise. These can be problems encountered by (or status of) the terminal 22, 24, 26, 28 or 34, the microprocessor 120, or errors or status communicated to the ATM/POS subsystem 14 from the processor 18, 36, 44 or 46 or from the store and forward message switch 52. The instruction panel 154 and display screen 152 can be used interchangeably for displaying the same information.</p><p id="p0043" num="0043">In addition to the various output devices included in the input/output console 130, the ATM/POS subsystem 14 includes a printer subsystem 160. The printer subsystem 160 includes an output buffer 162, that receives data from the output 122 of the microprocessor 120, a printer mechanism 164 that receives<!-- EPO <DP n="17"> --> data from the output buffer 162. A printer ejector 166, also included in the printer subsystem 160, receives control signals from the printer mechanism 164.</p><p id="p0044" num="0044">The printer subsystem 160 allows messages retrieved for the user to be sent to the output buffer 162, printed on the paper 54 by the printer mechanism 164, and then provided to the user by expelling the paper 54 through the printer ejector 166. Alternatively the printer subsystem 160 can be used in the same way to print an audit trail of messages entered into the terminal 22, 24, 26, 28 or 34. Use of the printer subsystem 160 can be very valuable where the messages, either entered or retrieved, are instructions to other individuals to take an action, or that require confirmation of an action.</p><p id="p0045" num="0045">In addition to the various input devices included in the input/output console 130, the ATM/POS subsystem 14 includes an optical character recognition ("OCR") subsystem 170. The OCR subsystem 170 includes an output buffer 172 that receives data from the output 122 of the microprocessor 120 and an input buffer 174 that transmits data to the input 118 of the microprocessor 120. The OCR subsystem 170 includes a camera control function 176 that receives data from the output buffer 172 and transmits data to the input buffer 174. The camera control function 176 exchanges control and status signals with a document receiver 182 and a camera 184. The document receiver 182 supplies status signals to the camera 184. The camera 184 supplies data to the input buffer 174 of the OCR subsystem 170 for retransmission to the input 118 of the microprocessor 120.</p><p id="p0046" num="0046">The OCR subsystem 170 is used to capture pre-typed or hand written messages that are not already defined in the electronic mail system 10. To operate the OCR subsystem 170, coded instructions are stored in the output buffer 172 of the OCR subsystem 170. The camera control function 176 interprets the instructions and the document receiver 182 opens to accept the written message 56 from the user. After acceptance, the camera 184 scans the message 56. If no errors are encountered, the scanned image will be placed in the input buffer 174 and further analysis and processing will occur according to the<!-- EPO <DP n="18"> --> normal OCR processing capability of the terminal 22, 24, 26, 28 or 34 and the ATM/POS subsystem 14.</p><p id="p0047" num="0047">While the various elements of the ATM/POS subsystem 14 are described above as though each of the terminals 22, 24, 26, 28 and 34 includes them all, depending upon precise details of the terminal 22, 24, 26, 28 or 34 some of the elements described above may, in fact, be shared among several terminals 22, 24, 26, 28 or 34. For examples, as depicted in FIG. 1, the ATM/POS terminals 26 and 28 are connected to the shared processor 32 through which they communicate with either one or the other of the data communication networks 16 or 38. Thus, the shared processor 32 includes both the communications controller 110 and the microprocessor 120 that are depicted in FIG. 2, and distributes their function to the input/output console 130, the printer subsystem 160, and the OCR subsystem 170 included in each of the ATM/POS terminals 26 and 28.</p><heading id="h0008"><u>Institution Processor 18 or 36</u></heading><p id="p0048" num="0048">FIG. 3 is a combined block diagram and flow chart depicting the ATM or POS institution processor 18 or 36 of FIG. 1. The institution processor 18 or 36 includes a CPU 212 that includes a memory, similar to the memory 126 included in the microprocessor 120 of FIG. 2, and also an ALU, similar to the ALU 128 included in the microprocessor 120. The CPU 212 receives data from an input 214 included in the institution processor 18 or 36 and transmits data to an output 216 also included in the institution processor 18 or 36.</p><p id="p0049" num="0049">A communications controller 220 interfaces between the institution processor 18 or 36 and the data communication networks 16 or 38 and the clearing house data communication network 42. The communications controller 220 includes an input buffer 222 that receives transactions from the communication networks 16, 38 or 42 and transmits them to the input 214 of the institution processor 18 or 36. Similarly, the communications controller 220 includes an output buffer 224 that receives transactions from the output 216 of the institution processor 18 or 36 and transmits them to the communication networks 16, 38 or 42.<!-- EPO <DP n="19"> --></p><p id="p0050" num="0050">In FIG. 3, a dashed line box 230 encloses a flow chart of the computer program executed by the CPU 212 of the institution processor 18 or 36. The flow chart 230 sets forth the various functions performed by the institution processor 18 or 36 which are uniquely required for the operation of the electronic mail system 10. As depicted in the flow chart 230, the first operation performed for every message transaction processed by the institution processor 18 or 36 is a log transaction for recovery function 232. The log transaction for recovery function 232 is a standard function executed by the institution processor 18 or 36 of various different ATM/POS systems 12 in processing standard ATM or POS transactions. The only change needed in the log transaction for recovery functions 232 on existing ATM/POS systems 12 to accommodate the operation of the electronic mail system 10 is adding new record formats for message transactions to those already established for ATM or POS transactions.</p><p id="p0051" num="0051">If the message transaction received by the institution processor 18 or 36 is from a user at one of the terminals 22, 24, 26, 28 or 34 seeking initial access to the electronic mail system 10, the computer program performs a validate user function 234. The validate user function 234 is an existing capability included in all ATM/POS systems 12, though it is not always identified by a system or function name similar to that used here. This standard function remains essentially as it presently exists on the current ATM/POS systems 12, but new message oriented transaction types must be added to the present valid formats to support the electronic mail system 10. If the particular institution processor 18 or 36 that receives a user validation request from one of its terminal 22, 24, 26, 28 or 34 is able to verify the user's authority to access the electronic mail system 10 without communicating with the clearing house network processor 44, then the institution processor 18 or 36 performs a format external message request function 236.</p><p id="p0052" num="0052">The format external message request function 236 handles the special processing associated with message transactions that are unique to the electronic mail system 10. After the<!-- EPO <DP n="20"> --> format external message request function 236 has been performed and the destination affiliation is identified, the transaction will be moved into the normal transaction processing by performing an insert message into output function 238. The insert message into output function 236 forwards the transaction to the appropriate destination which depends on where the message service control function processing occurs for this transaction. Specifically, the format external message request function 236 puts information in the proper format with the necessary structural parameters to allow continued processing by the ATM or POS network. This type of function is common in all state of the art ATM and POS networks.</p><p id="p0053" num="0053">If the particular institution processor 18 or 36 that receives a user validation request is unable to verify the user's authority to access the electronic mail system 10, then it performs a query other financial institutions function 242. The start of the process for accessing another institution through the query other financial institutions function 242 is essentially the same as for all existing or similar transactions processed by the ATM/POS system 12 when the institution processor 18 or 36 is not that of the user's financial institution. Determining location and affiliation of the particular user's account is performed using the standard location/affiliation directory as described above.</p><p id="p0054" num="0054">From this point the transaction will be handled differently if the message service control function is provided by the clearing house network processor 44, or by the user's financial institution processor 46. Once the transaction is processed for local functions, and the destination affiliation is identified, the transaction moves into the standard insert message into output function 238 for transmission to the clearing house network processor 44. The insert message into output function 238 forwards the transaction to the appropriate destination, depending on where message service control function occurs for this transaction. The institution operating each ATM/POS system 12 may choose where it wishes to process message transactions for users being served by its<!-- EPO <DP n="21"> --> terminals 22, 24, 26, 28 and 34 if alternative message service control functions exist.</p><p id="p0055" num="0055">The standard receive messages or timeout function 252 already performed by existing ATM/POS systems 12 need only be modified to handle all normal message transactions for the electronic mail system 10. After the transaction has been processed by the receive messages or timeout function 252, it then proceeds to a format messages for terminal function 254 that performs the formatting required for messages of the electronic mail system 10. The format messages for terminal function 254 uses information provided by the message service control function, the user's account profile, and the store and forward message switch 52 to format the message for presentation to the user at the specific terminal 22, 24, 26, 28 or 34 now serving the user.</p><p id="p0056" num="0056">The response as prepared by the format messages for terminal function 254 is then transferred to a transmit response to terminal function 256 that is a standard function already performed by the institution processor 18 or 36. The present transaction and data exchange protocol performed by the transmit response to terminal function 256 need be modified from that on existing ATM/POS systems 12 only to the extent necessary to process the message transaction formats unique to the electronic mail system 10. The transmit response to terminal function 256 transfers the formatted data to the insert message into output function 238 for transmission to the appropriate one of the terminals 22, 24, 26, 28 or 34.</p><p id="p0057" num="0057">Once the user has entered a valid PIN and has been approved by the system, multiple transactions can be carried out without the need to reenter a PIN and be re-approved by the system.</p><p id="p0058" num="0058">As will be appreciated by those skilled in the art, the ATM/POS system of the present invention will make use of the standard error functions currently available on ATM/POS networks in the prior art. Such error functions and handling, including the new and unique error handling functions necessary for the present invention are described in more detail below.<!-- EPO <DP n="22"> --></p><p id="p0059" num="0059">Security for the electronic mail system 10 is accomplished by the same technique as that normally employed for ATM and/or POS terminals in ATM/POS systems 12. Specifically, security comes from the requirement that a user enter a debit/credit card 48 and security code for each transaction, or by relying on the ATM's ability to retain such information once it has been validated in a preceding transaction. After this user security information has been transmitted to the appropriate institution processor 18, 36 or 46 for verification, that processor's normal error or acceptance procedure occurs. If there is an error, or the user's logon is invalid, the existing normal error process and messages occur.</p><p id="p0060" num="0060">If the user is authorized to access the electronic mail system 10, a Transaction Authorization number is created for the transaction in the same fashion as for all other ATM/POS financial transactions, and processing is allowed to continue. The Transaction Authorization number that is generated for system security purposes in the operation of the electronic mail system 10 uses the standard algorithm and process presently used in ATM/POS systems. That Transaction Authorization number serves the same purpose for message transaction as for all other types of transactions occurring in ATM/POS systems 12.</p><p id="p0061" num="0061">The basic audit trail and recovery oriented processes in the ATM/POS network are not disturbed by the modifications needed to operate the electronic mail system 10. A major advantage of adding the electronic mail system 10 to existing ATM/POS networks in comparison with alternative systems is their relative security due to their existing audit and recovery controls.</p><p id="p0062" num="0062">As described previously, user access to the electronic mail system 10 is accomplished through interaction with one of the terminal 22, 24, 26, 28 or 34. The actual interface that the user experiences may vary from terminal to terminal within a single ATM/POS system 12 and may also vary among various ATM/POS systems 12. The actual interface presented to the user depends upon the particular programs executed by the various processors including those executed by the microprocessor<!-- EPO <DP n="23"> --> 120 for controlling the terminals 22, 24, 26, 28 and 34 shown in FIG. 2, and the operating system and application software of the institution processor 18 or 36 shown in FIG. 3. The basic interaction of these systems and the additional implications of the data communication networks 16, 38, 42, 62, 64 that link them is well known as it already forms the process by which ATM/POS systems 12 perform their existing ATM/POS financial functions.</p><p id="p0063" num="0063">When the terminal 22, 24, 26, 28 or 34 is enabled to allow the user to select a transaction after the user has been allowed access to the electronic mail system 10, the present invention presents the user with a new option in addition to those previously provided by the ATM/POS system 12, that is, the electronic mail capability of the system 10. The electronic mail service choice guides the user through a sequence of steps that allows the creation or retrieval of messages. The electronic mail system 10 also automatically notifies users if messages are waiting for them, without any action required other than the user accessing the ATM/POS system 12 through the terminal 22, 24, 26, 28 or 34. The electronic mail system 10 may automatically display certain types of emergency or high priority messages without the user requesting such display through the terminal 22, 24, 26, 28 or 34.</p><p id="p0064" num="0064">Whichever option a user selects, i.e., creation of a message or retrieval of a message, a display appears on either the display screen 152 or on the instruction panel and screen 154 of the terminal 22, 24, 26, 28 or 34 that allows the user to select from a menu of choices. These choices constitute either additional menus of more detailed choices, or specific transactions to create or retrieve messages. The organization of the electronic mail system 10 allows certain frequently used transactions to be invoked directly and other transactions to be selected after the display of additional menus. The user indicates the desired action either by pressing keys on the keyboard 144, by writing on the pen pad 146 or by pressing specific function keys 138.</p><p id="p0065" num="0065">The following list of three menu options, are set forth here as examples for pedagogical reasons without any implication<!-- EPO <DP n="24"> --> that they are either a specific or a complete set of options that must be provided in implementing the electronic mail system 10.<ul id="ul0002" list-style="none" compact="compact"><li>creating messages</li><li>retrieving/reading messages</li><li>responding to messages</li></ul></p><heading id="h0009"><u>Message Entry</u></heading><p id="p0066" num="0066">When creating messages the user must compose the text of the message. Options for creating a message include, but are not limited to, selecting from pre-coded or pre-defined messages using menus as described previously. Messages appearing on the display screen 152 and on the instruction panel and screen 154 assist the user in understanding the choices and how to use them. The messages displayed on the display screen 152 and on the instruction panel and screen 154 include "fill-in-the-blank" areas which allow the user to customize standard messages. The types of standard pre-coded "fill-in-the-blank" messages which may be invoked by a menu option include, but are not limited to:<ul id="ul0003" list-style="none" compact="compact"><li>identification messages, telling who called, affiliation, the subject of the call, and how to contact them;</li><li>travel messages, describing characteristics of travel such as arrival/departure time, location I.D. (City, State, Country, or Institution such as hotel or business), carrier and the like;</li><li>confirmation messages, confirming such things as stock or bond sales or purchases, approval of reservations, and similar activities; and</li><li>calendar messages, messages to be sent back to the user about scheduled time commitments or actions to be performed, either entered by the user or others, such as a secretary or travel bureau with user granted authority to do so.</li></ul></p><p id="p0067" num="0067">Another menu or instruction option provides selection of a broader range of "pre-coded" messages from a credit, debit, plastic or similar type of card 48 that includes a memory<!-- EPO <DP n="25"> --> and/or a computer. Such cards 48 may include user specific special messages that can be read into the terminal 22, 24, 26, 28 or 34. These types of messages will have the same "fill-in-the-blank" format as the normal "pre-coded" messages of the ATM/POS system 12.</p><p id="p0068" num="0068">The "fill-in-the-blank" messages are typically completed using the keyboard 144 of the terminal 22, 24, 26, 28 or 34. An alternative is using the pen pad 146 or the OCR subsystem 170 for both alphabetic and numeric "fill in the blank" message formats.</p><p id="p0069" num="0069">Another alternative, the composition and entry of complete or complex messages is achieved by scanning the written message 56 with the OCR subsystem 170, or by hand written or printed entry on the pen pad 146. After the message has been scanned by the OCR subsystem 170, using the keyboard 144 or the pen pad 146 the user can correct or improve the message as read. Status or error conditions in the OCR subsystem 170 are reported through the various display methods previously described.</p><p id="p0070" num="0070">A final form of capturing messages, or identifying the intended recipient of a message, is to employ a memory card 48 or access card 48 with on board processing capabilities that stores pre-recorded messages or data bases from which messages can be created, and/or a directory of individuals to whom messages can be sent. Such a card 48 is inserted in the debit or credit card reader 136 and a display of various options appears on the display screen 152. The user then chooses among various options using the entry techniques already described to indicate which individuals and messages are desired, and how they are to be associated and further processed.</p><p id="p0071" num="0071">The user has the option of addressing the message before or after the message text is composed. When addressing the message the user can either enter an addressee mailbox code directly or select an address from a directory of frequently used message destinations stored in a memory or "smart" card 48. At the user's option, addresses may be validated before message transmission. The electronic mail system 10 also allows entry of addresses through the keyboard 144, the pen<!-- EPO <DP n="26"> --> pad 146, or the OCR subsystem 170. After composing the message text and addressing it, message creation is complete.</p><heading id="h0010"><u>Message Retrieval and Response</u></heading><p id="p0072" num="0072">The user can also direct the system to retrieve messages addressed to the user. By interacting with the terminal 22, 24, 26, 28 or 34 through the keyboard 144 and the function keys 138, retrieved messages appear on the display screen 152 of the terminal 22, 24, 26, 28 or 34. A user may choose to have the printer subsystem 160 print a message on the paper 54. The keyboard 144 or the pen pad 146 may be used to control the message appearing the display screen 152 to allow display of sender/source associated information, the text, or selected portions of such information if the screen cannot display all of the information at once.</p><p id="p0073" num="0073">The user responds to messages in a manner similar to composing messages. A response may be sent to the original sender, or to new addressees, or both. The response message is created by the same addressing and composing steps as creating any other message, but a response includes additional information about the original message unless the user intentionally deletes such information.</p><p id="p0074" num="0074">To identify each message for operational and financial purposes, an additional message reference number may be added by the terminal 22, 24, 26, 28 or 34, by the institution processor 18 or 36, or by the processor 18, 36 or 44 providing the message service control function to messages being retrieved from the store and forward message switch 52, or being stored there. If the message comes from an E-Mail system outside the electronic mail system 10, that system's E-Mail reference number can be used on messages stored into the store and forward message switch 52. Furthermore, a system cross reference number may be added if necessary to meet network controls. Such a message reference number may serve the function of identifying each message for operational and financial purposes, and thereby link printed or control documentation to the billing statements that are created by the system.<!-- EPO <DP n="27"> --></p><p id="p0075" num="0075">The characteristics and components of menus and options on the various information displays described above allow the user to create messages or to retrieve waiting messages, and is a unique improvement to the existing capabilities of the ATM/POS subsystem 14.</p><p id="p0076" num="0076">All of the entry techniques can be co-mingled with the memory or processor card options to provide great flexibility in the creation, direction and processing of messages and responses. The memory and processor cards 48 can also be used to capture the addressing and text of messages sent to a user, including information concerning the user's calendar or schedule of activities which can be used to update records in a data base housed in memory on such a card 48. Other special types of messages can also be created to update specific associated data bases in memory on such cards 48.</p><heading id="h0011"><u>Message Errors</u></heading><p id="p0077" num="0077">When errors are encountered, the normal processing for the type of the terminal 22, 24, 26, 28 or 34 in use will be followed. For errors that cannot be corrected at the terminal 22, 24, 26, 28 or 34, the ATM/POS subsystem 14 clears all status and waiting actions and then resets, rejecting all further attempts to process the erroneous transaction. In addition, the normal timeout interval for handling problems such as the occurrence of a network error remains the same.</p><heading id="h0012"><u>Store and Forward Message Switch 52</u></heading><p id="p0078" num="0078">FIG. 4 is a combined block diagram and flow chart depicting the store and forward message switch 52 of FIG. 1. The store and forward message switch 52 includes a CPU 312 that includes a memory, similar to the memory 126 included in the microprocessor 120 of FIG. 2, and also an ALU, similar to the ALU 128 included in the microprocessor 120. The CPU 312 receives data from an input 314 included in the store and forward message switch 52 and transmits data to an output 316 also included in the store and forward message switch 52.</p><p id="p0079" num="0079">A communications controller 320 interfaces between the store and forward message switch 52 and the data communication<!-- EPO <DP n="28"> --> networks 42 or 64. The communications controller 320 includes an input buffer 322 that receives transactions from the communication networks 42 or 64 and transmits them to the input 314 of the store and forward message switch 52. Similarly, the communications controller 320 includes an output buffer 324 that receives transactions from the output 316 of the store and forward message switch 52 and transmits them to the communication networks 42 or 64.</p><p id="p0080" num="0080">In FIG. 4, a dashed line box 330 encloses a flow chart of the computer program executed by the CPU 312 of the store and forward message switch 52. The flow chart 330 sets forth the various functions performed by the store and forward message switch 52. The specific functions depicted in the flow chart 330 support the electronic mail system 10 of the present invention and, illustrate the interrelationship between the electronic mail system 10 and external store and forward or E-Mail systems and the communication networks 42 and 64. The functions depicted in the flow chart 330 also specifically depict the message editing, capture, storage and forwarding capabilities and functions of the electronic mail system 10. It will be understood by those skilled in the art that the functions performed by the store and forward message switch 52 that are needed to support the electronic mail system 10 of the present invention can be developed as a completely new system, or can be obtained by modifying an existing E-Mail or Store and Forward Message Switch system (including its various local and remote components) to perform the required message handling functions.</p><heading id="h0013"><u>Communications with the Store</u> <u>and Forward Message Switch 52</u></heading><p id="p0081" num="0081">The first function performed by the store and forward message switch 52 in processing a transaction is a validate I.D. and password from the financial institution function 332. The validate I.D. and password from the financial institution function 332 is compatible with the message service control function performed by the clearing house network processor 44. The validate I.D. and password from the financial institution<!-- EPO <DP n="29"> --> function 332 allows the store and forward message switch 52 to identify message service users with the transmission of a minimal amount of information about the user that is extracted from their debit/credit card account records or provided by the message service control function of the clearing house network processor 44. The information so transmitted includes the user's account I.D. and password on the store and forward message switch 52. After the validate I.D. and password from the financial institution function 332 determines that a transaction is for a user of the electronic mail system 10, it then performs an origination or retrieval function 334 to determine whether the user has entered a message at the terminal or is requesting that any waiting messages be transmitted.</p><heading id="h0014"><u>Message Retrieval</u></heading><p id="p0082" num="0082">If a transaction specifies that the user is retrieving messages, then the store and forward message switch 52 performs a check mailbox for messages function 336. The check mailbox for messages function 336 queries the users mailbox to determine if there are any messages waiting for delivery. Performing the check mailbox for messages function 336 includes determining the status of all waiting messages and their respective priorities, selecting the next message to be transmitted to the user, and adding to the message being transmitted any additional status information to be sent to the user.</p><p id="p0083" num="0083">After performing the check mailbox for messages function 336, the store and forward message switch 52 performs a format messages for ATM/POS function 338. The format messages for ATM/POS function 338 uses information that accompanies each message retrieval request received from the message service control function on the clearing house network processor 44 to determine how the message should be formatted, and what additional information about other messages (such as their number, emergency nature or degree of priority, etc.) needs to be added to the messages being transmitted to the user at the terminal 22, 24, 26, 28 or 34. Responsive to information<!-- EPO <DP n="30"> --> provided to the store and forward message switch 52 by the message control function performed on the clearing house network processor 44, the format messages for ATM/POS function 338 prepares each message in a format specifically for the particular type of terminal 22, 24, 26, 28 or 34 presently servicing the user.</p><p id="p0084" num="0084">After the store and forward message switch 52 performs the format messages for ATM/POS function 338, it then performs a flag message status function 342. The flag message status function 342 updates records in the user mailbox to identify what messages and other information are being transmitted to the user. This update permits error recovery if validation of message delivery is not received back from The terminal 22, 24, 26, 28 or 34.</p><p id="p0085" num="0085">After performing the flag message status function 342, The store and forward message switch 52 performs an insert message into output function 344. The insert message into output function 344 transmits the message to the message service control function on the clearing house network processor 44 for delivery to the terminal 22, 24, 26, 28 or 34 servicing the user.</p><heading id="h0015"><u>Message Transmission</u></heading><p id="p0086" num="0086">If a transaction specifies that the user is transmitting a message, then after The store and forward message switch 52 performs the origination or retrieval function 334 it performs a validate destination I.D. function 352. The validate destination I.D. function 352 determines The desired destination for the message. This destination can be within the store and forward message switch 52 that is providing the E-Mail capability for the electronic mail system 10, it can be any other E-Mail system connected through industry Standard X.400 links or any other custom E-Mail to E-Mail link, or it can be a facsimile machine. After determining the proper destinations, the validate destination I.D. function 352 routes the message to the appropriate destinations.</p><p id="p0087" num="0087">Once the message has been routed by the validate destination I.D. function 352, the store and forward message switch<!-- EPO <DP n="31"> --> 52 performs a format for mailbox function 354. The format for mailbox function 354 determines the destination mailbox type and rearranges the message as necessary to be acceptable for that mailbox. The format for mailbox function 354 takes certain encrypted information about the message as originated by the user, possibly including data added by the message service control function, and decodes it into text within the message being transmitted. This encrypted information includes, but is not limited to, date, time, location of the terminal 22, 24, 26, 28 or 34 servicing the user, associated information about the original message if this message is a response to a prior message, and directions for further delivery or action by the recipient that are specified for this user as determined by the message service control function performed by the clearing house network processor 44 or by the user's account records. The format for mailbox function 354 may be performed as part of the message service control function if so desired.</p><p id="p0088" num="0088">After performing the format for mailbox function 354, the store and forward message switch 52 performs a flag message status function 356. The flag message status function 356 logs the message, updates the user E-Mail mailbox for information about the transmission of the message, and executes and terminates any external E-Mail links that were established to transmit the message. Alternatively, if the user has specified that the message's recipient is to be a facsimile machine, the store and forward message switch 52 accesses the public telephone system through the modem 76 and the facsimile transmission machine 82 to establish connection with the desired facsimile machine to transmit the message.</p><p id="p0089" num="0089">After completing the flag message status function 356, the store and forward message switch 52 performs a return acknowledgement function 358. The return acknowledgement function 358 completes the message transmission process by providing an audit trail of successful transmission, or it identifies and transmits any standard E-Mail errors that occurred in transmitting the message after the store and forward message switch 52 validated the destination I.D. by performing the<!-- EPO <DP n="32"> --> validate I.D. and password from the financial institution function 332. The return acknowledgement function 358 provides this information that is necessary for further services to this user by the electronic mail system 10 to the message service control function on the clearing house network processor 44. The return acknowledgement function 358 also constructs an appropriate return message and the insert message into output function 344 then transmits the message back through the message service control function on the clearing house network processor 44 for ultimate delivery to the terminal 22, 24, 26, 28 or 34 servicing the user.</p><heading id="h0016"><u>Error Handling</u></heading><p id="p0090" num="0090">Even though validity checks are performed on each request at the user account and request processing levels, certain basic errors are still possible and must be handled. If the store and forward message switch 52 is unable to validate a user's I.D. or password, an appropriate message must be generated by an error messages function 362 and sent back through the message service control function on the clearing house network processor 44 for logging to the user's account and for transmission to the terminal 22, 24, 26, 28 or 34 servicing the user. This logging procedure assures that the electronic mail system 10 can recover in an orderly manner in attempting to remedy any problem. If the check mailbox for messages function 336 determines that there are no messages for a user, this "no messages" condition may be processed as an error through the error messages function 362. If the validate destination I.D. function 352 determines that the user is attempting to send a message to an invalid destination I.D., to maximize the user friendliness of the electronic mail system 10 this type of error is handled in a manner that requires the user to re-enter only the correct destination I.D. necessary to properly resend the message. The error messages function 362 also handles other normal E-Mail errors with specific messages responsive to those errors being transmitted to the terminal 22, 24, 26, 28 or 34 servicing the user.<!-- EPO <DP n="33"> --></p><heading id="h0017"><u>Clearing House Network Processor 44</u></heading><p id="p0091" num="0091">FIG. 5 is a combined block diagram and flow chart depicting the clearing house network processor 44 of FIG. 1. The clearing house network processor 44 includes a CPU 412 that includes a memory, similar to the memory 126 included in the microprocessor 120 of FIG. 2, and also an ALU, similar to the ALU 128 included in the microprocessor 120. The CPU 412 receives data from an input 414 included in the clearing house network processor 44 and transmits data to an output 416 also included in the clearing house network processor 44.</p><p id="p0092" num="0092">A communications controller 420 interfaces between the clearing house network processor 44 and the data communication network 42. The communications controller 420 includes an input buffer 422 that receives transactions from the communication network 42 and transmits them to the input 414 of the clearing house network processor 44. Similarly, the communications controller 420 includes an output buffer 424 that receives transactions from the output 416 of the clearing house network processor 44 and transmits them to the communication network 42.</p><p id="p0093" num="0093">In FIG. 5, a dashed line box 430 encloses a flow chart of the computer program executed by the CPU 412 of the clearing house network processor 44. The flow chart 430 sets forth the various functions performed by the clearing house network processor 44. The specific functions depicted in the flow chart 430 support the electronic mail system 10 and specifically the message service control function of the present invention.</p><heading id="h0018"><u>Standard ATM/POS Network Functions</u></heading><p id="p0094" num="0094">The first step performed by the clearing house network processor 44 in processing message transactions is the standard validation of the account I.D. and PIN. (This function is not depicted in FIG. 5.) This validation function is performed in the manner described above for the validate user function 234 performed by the institution processor 18 or 36. After successful validation, the electronic mail system 10 is then authorized by the approval received back from the user's<!-- EPO <DP n="34"> --> financial institution processor 46 to process message transactions for the user.</p><p id="p0095" num="0095">When the user thereafter transmits a message service request, along with all other transactions, the clearing house network processor 44 validates the authorization code by performing a validate authorization code and institution function 432. After the user's authorization has been validated, the transaction is then logged by a log transaction for recovery function 434. After the message has been logged for recovery, the clearing house network processor 44 performs an identify institution affiliation function 436 to identify the appropriate institution to which the user's charges for using the electronic mail system 10 are to be forwarded.</p><heading id="h0019"><u>Message Service Control Function</u></heading><p id="p0096" num="0096">After the clearing house network processor 44 completes the preceding functions, the message transaction is further processed by the message service control function. Processing of transactions by the message service control function on the clearing house network processor 44 is different than the processing of other non-message service transactions such as financial transactions by the clearing house network processor 44. For each message service transaction, the message service control function creates multiple new message retrieval, message transmission and/or account update transactions that are required to fully perform message transactions The message service control function allows these new transactions to be separated for sequential processing of the message handling transactions and of charging transactions against the user's account on the user's financial institution processor 46.</p><p id="p0097" num="0097">To create these multiple new transactions when a message service request transaction arrives from the terminal 22, 24, 26, 28 or 34, the clearing house network processor 44 performs a process transaction for control function 442. The process transaction for control function 442 logs the existence of message service request and retains sufficient information to track the status and steps required to complete the electronic mail transmission. Logging the message service request allows<!-- EPO <DP n="35"> --> for orderly recovery if a error occurs during subsequent processing of the request. If account validation has not previously occurred, the process transaction for control function 442 invokes this process that is described previously herein. The account validation process acquires information about the validity of message processing for this user, and other information about service scope, address, and the like.</p><p id="p0098" num="0098">After the clearing house network processor 44 performs the process transaction for control function 442, it then performs a process transaction for completion function 444. The process transaction for completion function 444 initiates the message service transaction(s) performed by the store and forward message switch 52 as described above in connection with FIG. 4. Upon completion of the process transaction for completion function 444, a process transaction destination function 446 is carried out. This function performs the proper logic and routing steps to allow processing to continue as well known in the current state of the art in the ATM/POS field.</p><p id="p0099" num="0099">After the process transaction destination function 446 has been performed, the clearing house network processor 44 performs an insert message into output function 448. The insert message into output function 448 transmits message service transactions to the store and forward message switch 52.</p><p id="p0100" num="0100">When a response transaction to a message service transaction returns to the clearing house network processor 44 from the store and forward message switch 52, it is processed through the validate authorization code and institution function 432, the log transaction for recovery function 434 and the identify institution affiliation function 436 to the process transaction for control function 442. Upon receipt of the message service transaction, the process transaction for control function 442 recognizes that it is a response to a message service transaction initiated previously by the clearing house network processor 44. The process transaction for control function 442, therefore, updates the status of its prior request and then forward the transaction to the process transaction for completion function 444. Normally processing<!-- EPO <DP n="36"> --> of the response to a message service transaction by the process transaction for control function 442 satisfies the functional requirements for message transactions other than returning the message to the terminal 22, 24, 26, 28 or 34 servicing the user. However when errors, special circumstances, or complex transactions occur, additional cycles of communication between the clearing house network processor 44 and the store and forward message switch 52 may be required.</p><p id="p0101" num="0101">Before forwarding a message transaction to the terminal 22, 24, 26, 28 or 34, the process transaction for completion function 444 initiates a financial transaction to charge the user for services provided by the electronic mail system 10. This financial transaction is processed in the same manner as other financial transactions from the ATM/POS system 12 that pass through the clearing house network processor 44.</p><p id="p0102" num="0102">When the acknowledgement returns from the user's financial institution processor 46, the message service request will be closed out by the process transaction for control function 442. After the process transaction for control function 442 closes the message service request, the process transaction for completion function 444 transmits the message back to the terminal 22, 24, 26, 28 or 34 servicing the user. The return transaction to the terminal 22, 24, 26, 28 or 34 includes either the status of the messages entered by the user or the messages (if any) that have been retrieved from the store and forward message switch 52. The return transaction to the terminal 22, 24, 26, 28 or 34 also indicates the charges made to the user's account for use of the electronic mail system 10.</p><p id="p0103" num="0103">Error handling and correction will be performed by the error function 501 which, as will be appreciated by those skilled in the art, is well known in the state of the ATM/POS art and currently incorporated in available ATM/POS systems.</p><heading id="h0020"><u>User's Financial Institution Processor 46</u></heading><p id="p0104" num="0104">FIG. 6 is a combined block diagram and flow chart depicting the user's financial institution processor 46 of FIG. 1. The user's financial institution processor 46 includes a CPU<!-- EPO <DP n="37"> --> 512 that includes a memory, similar to the memory 126 included in the microprocessor 120 of FIG. 2, and also an ALU, similar to the ALU 128 included in the microprocessor 120. The CPU 512 receives data from an input 514 included in the user's financial institution processor 46 and transmits data to an output 516 also included in the user's financial institution processor 46.</p><p id="p0105" num="0105">A communications controller 520 interfaces between the user's financial institution processor 46 and the data communication network 42. The communications controller 520 includes an input buffer 522 that receives transactions from the communication network 42 and transmits them to the input 514 of the user's financial institution processor 46. Similarly, the communications controller 520 includes an output buffer 524 that receives transactions from the output 516 of the user's financial institution processor 46 and transmits them to the communication network 42.</p><p id="p0106" num="0106">In FIG. 5, a dashed line box 530 encloses a flow chart of the computer program executed by the CPU 512 of the user's financial institution processor 46. The flow chart 530 sets forth the functions performed by the user's financial institution processor 46 that support the electronic mail system 10, specifically the process by which users are charged for their use of the electronic mail system 10.</p><heading id="h0021"><u>Identifying a Message Service User</u></heading><p id="p0107" num="0107">Upon receiving a financial transaction, the user's financial institution processor 46 performs a log transaction for recovery function 532. The log transaction for recovery function 532 provides the normal audit trail processing for financial transactions that permits recovery if a error occurs during processing.</p><p id="p0108" num="0108">The validate user function 534 will validate the user's account number and determine whether the user has a message on the system.</p><p id="p0109" num="0109">If the ATM/POS system 12 transmits a message initiation and account verification transaction directly to the user's financial institution processor 46 via the user authorization<!-- EPO <DP n="38"> --> data communication network 62, then a format external message request function 536 handles the special processing associated with the new message transaction types. This processing performed by the format external message request function 536 is similar to the processing described above if the terminal 22, 24, 26, 28 or 34 servicing the user is attached to the user's financial institution processor 46. However, when the terminal 22, 24, 26, 28 or 34 servicing the user is different from the user's financial institution processor 46, the user's financial institution processor 46 must communicate information to the message service control function on the clearing house network processor 44 to identify both the institution processor 18 or 36 and the store and forward message switch 52 that are to be involved in responding to this user's requests, including the user's account I.D. and password on the store and forward message switch 52. There are two different ways in which the user's financial institution processor 46 may provide this information.</p><p id="p0110" num="0110">One option will be to transmit forwarding identification information through the format of the transaction in order to minimize the processing differences. When a message transaction is identified it will be forwarded through the network and processed by message service control function, communicating specific account related information necessary to provide the messaging service.</p><p id="p0111" num="0111">In the second alternative, the message service control function is associated with the clearing house data communication network 42. In this second alternative, the response to an account query comes from the format external message request function 536 performed by the institution processor 18 or 36, and the transaction is not further processed by the message service control function on the clearing house network processor 44, but merely satisfies the request of the clearing house network processor 44 for account validation. This second alternative may be chosen by organizations that wish to minimize the impact of the electronic mail system 10 on their financial systems by merely providing billing and account validation to the system 10.<!-- EPO <DP n="39"> --></p><p id="p0112" num="0112">In either case, after approval of a user to use the electronic mail system 10, the message service control function handles all further control relationship with the appropriate institution processor 18 or 36 and the store and forward message switch 52. The appropriate debit or credit to the user's account is the only further transaction required between the clearing house network processor 44 and the user's financial institution processor 46.</p><p id="p0113" num="0113">A third alternative allows billing to be associated with the user's account on the store and forward message switch 52. Under such circumstances, the user's financial institution processor 46 merely validates the user's account I.D. and password on the store and forward message switch 52. In any case, after such processing the insert message into output function 538 then take over placing The message into a condition for appropriate output from the system. This function, as will be appreciated by those skilled in the art, is currently available on ATM and POS systems. Such function will be used in the system of the present invention.</p><heading id="h0022"><u>Billing the User</u></heading><p id="p0114" num="0114">After messages have been processed by the store and forward message switch 52 and are ready to be returned to the terminal 22, 24, 26, 28 or 34 servicing the user, the message service control function on the clearing house network processor 44 transmits the financial transaction to the user's financial institution processor 46. The log transaction for recovery function 532 on the user's financial institution processor 46 logs this financial transaction and forwards it to a receive message charges function 542 for further processing. The receive message charges function 542 identifies the charges and formats them for updating the user's account records. A process account debit function 544 uses the information prepared by the receive message charges function 542 to update all appropriate records by entering the users charges, and to create an audit trail of the financial transactions. After the financial records are updated and the audit trail created, a process message service completion function 546 closes out<!-- EPO <DP n="40"> --> processing on the user's financial institution processor 46 and, through the insert message into output function 538, transmits a transaction acknowledging successful completion to the message service control function on the clearing house network processor 44.</p><heading id="h0023"><u>Correcting Billing Errors</u></heading><p id="p0115" num="0115">If the message service control function on the clearing house network processor 44 is unable to deliver messages to the user at the terminal 22, 24, 26, 28 or 34, either a credit or a reversal of charges must be processed by the electronic mail system 10. This circumstance is handled as an error transaction and processed by an errors function 552 on the user's financial institution processor 46. The user's financial institution processor 46 will provide all appropriate logging and controls as described above to audit such a problem. After proper validation of the circumstances, a process account debit function 554 updates the appropriate records to reverse any charges that have already been recorded for the failed transmission. After the process account debit function 554 has reversed any charges, the errors function 552 sends a transaction indicating this fact back to the message service control function on the clearing house network processor 44 through the insert message into output function 538.</p><p id="p0116" num="0116">All other errors are handled by the error function currently available on state of the art ATM/POS systems; as previously described.</p><heading id="h0024"><b>MESSAGE SERVICE FLOW</b></heading><heading id="h0025"><u>Logging onto the Electronic Mail System 10</u></heading><p id="p0117" num="0117">The process or receiving or sending a message is initiated by a user entering the debit or credit card 48 into the terminal 22, 24, 26, 28 or 34 of the ATM/POS system 12 included in the electronic mail system 10. After the user enters his PIN or other security password, the terminal 22, 24, 26, 28 or 34 captures all data about user identification, security, and the user's desire to retrieve or enter messages. The information captured by the terminal 22, 24, 26, 28 or 34 passes through the institution processor 18 or 36 directly to<!-- EPO <DP n="41"> --> the clearing house network processor 44 via the clearing house data communication network 42. To obtain authorization for the user to use the electronic mail system 10, the message service control function on the clearing house network processor 44 requests such authorization from the user's financial institution processor 46.</p><p id="p0118" num="0118">When the user's financial institution processor 46 receives a request seeking authorization for one of its user to use the electronic mail system 10, it interrogates that user's account records. If the user's account records indicate that the user is allowed to use the system, the user's financial institution processor 46 transmits a transaction back to the message service control function on the clearing house network processor 44 authorizing use of the electronic mail system 10. Once the message service control function on the clearing house network processor 44 receives authorization from the user's financial institution processor 46, the message service control function handles all further control relationships with the appropriate institution processor 18 or 36 and with the store and forward message switch 52.</p><p id="p0119" num="0119">Upon being authorized to use the electronic mail system 10, the user is notified if there are any messages waiting for him on the store and forward message switch 52. At this time the user is prompted to "read" his mail, and is allowed to respond to each messages.</p><heading id="h0026"><u>Retrieving a Message</u></heading><p id="p0120" num="0120">The message service control function of the clearing house network processor 44 also transmits debit or credit transactions to the user's financial institution processor 46.</p><heading id="h0027"><u>Transmitting a Message or Response</u></heading><p id="p0121" num="0121">The message service control function of the clearing house network processor 44 also transmits debit or credit transactions to the user's financial institution processor 46.<!-- EPO <DP n="42"> --></p><heading id="h0028"><u><b>SUMMARY OF SYSTEM OPERATION</b></u></heading><p id="p0122" num="0122">This section of the application will provide an overview and summary of the system operation. This summary will assume the readers knowledge of the details described at length above.</p><heading id="h0029"><u>Logging On To The System</u></heading><p id="p0123" num="0123">The process of receiving or sending a communication is initiated by a user entering a debit or credit card into the terminal 22, 24, 26, 28 or 34 of an institution connected to the system. After the user enters a personal identification number ("PIN") or other security password, the terminal captures all data about identification, security and the desire to retrieve or enter messages.</p><p id="p0124" num="0124">The transaction authorization number generated for system security will utilize the standard algorithm and process used for all transactions in these ATM/POS networks. It will serve the same purpose for this type of transaction as for all other transactions.</p><p id="p0125" num="0125">The information passes through the local information processor which communicates indirectly through the clearing house network processor 44 via an associated ATM or POS processor 18 or 36, and appropriate data communication network, to the user's financial institution processor 46.</p><heading id="h0030"><u>Identifying a Message Service</u></heading><p id="p0126" num="0126">Information about the user's message I.D. is retrieved from his account in the user's financial institution processor 46.</p><p id="p0127" num="0127">When a transaction for message initiation and account verification is transmitted to the user's financial institution processor 46 to invoke approval for the message service control function then the format external message request function 236 will handle the special processing associated with the new message transaction types, after the log transaction for recovery function 232 performs its normal audit trail and recovery processing.</p><p id="p0128" num="0128">After it is determined that the user is approved for the service, the message service control function will handle all further control relationships with the appropriate terminal control processor and the store and forward message switch 52,<!-- EPO <DP n="43"> --> and the debit or credit to the user's account will be the only required additional function of the user's financial institution processor 46 and related components.</p><p id="p0129" num="0129">The ATM/POS user will be told in response to the logon prompt if messages are waiting. When this function is invoked, he will be prompted to "read" his mail, and allowed to respond to each message, if desired.</p><heading id="h0031"><u><b>OPERATING THE TERMINAL</b></u></heading><heading id="h0032"><u>Selecting The Message Options</u></heading><p id="p0130" num="0130">When the user is asked to "select transaction", a new option provided by this invention on the ATM/POS terminal screens will guide the user into a sequence that will allow the creation or retrieval of messages through the functions provided. It will also automatically notify users of the message service if messages are waiting for them, without any action required other than the user logging on to the ATM/POS terminal, as described above. It can also allow certain types of emergency or high priority messages to be automatically displayed.</p><p id="p0131" num="0131">Whichever option is selected, creation or retrieval will cause the terminal system to display on screen 52 or panel 154 further options from which to select. These options will constitute either menus or more detailed choices or specific transactions that will create or retrieve messages. The preferred construction will allow certain frequently used transactions to be invoked directly and other transactions to be selected after further menu display. The user may indicate the desired action by pressing keys on the keyboard 144, writing on the pen/pad 146 or pressing specific function keys 138.</p><heading id="h0033"><u>Creating Messages</u></heading><p id="p0132" num="0132">When creating messages a key function is composing the text. Options for selecting from pre-coded or pre-defined messages will be provided through the techniques described earlier, and the user will be assisted by the simultaneous use of the display screen 152 and the instruction panel 154 to aid<!-- EPO <DP n="44"> --> in understanding the choices and how to use them. These messages may include "fill-in-the-blank" areas to allow the message to be customized.</p><p id="p0133" num="0133">Another menu of instruction option will allow selection of a broader range of "pre-coded" messages from an optional magnetic card which may have on board memory or an on board processor. Such a card can include user specific special messages that can be pulled into the ATM/POS terminal. These messages may have the same "fill-in-the-blank" capability as the terminals normal "pre-coded" messages.</p><p id="p0134" num="0134">The "fill-in-the-blank" messages will normally be completed using the numeric key pad of the ATM/POS terminal. Another option is to allow use of the pen pad 146 or an optical character reader (OCR) for both alphabetic and numeric "fill-in-the-blank" capability.</p><p id="p0135" num="0135">The composition and entry of complete or complex messages may be accomplished by optical character recognition scanning of the message, or by hand written entry on a pen pad such as pen pad 146.</p><p id="p0136" num="0136">The user will have the option of addressing the message before or after the message text is composed. When addressing the message, the user can either enter the addressee mailbox code directly or use a magnetic card, as described above, which includes an on board directory of message destinations that are used frequently, and select from these. At the user's option, addresses may be validated before message transmission. Addressee information may also be captured through the pen pad 146 or the OCR. After composing the message text and addressing it, message creation is complete.</p><heading id="h0034"><u>Retrieving And Reading Messages</u></heading><p id="p0137" num="0137">The user can also direct the system to retrieve messages addressed to the user's mailbox. By interacting with the terminal through its keyboard and function keys, the messages retrieved are displayed on the video display of the terminal At the user's option, each message may be printed out by indicating the desired action through the appropriate keys.<!-- EPO <DP n="45"> --> Reading of a message can be controlled through use of the keyboard and function keys.</p><heading id="h0035"><u>Responding To Messages</u></heading><p id="p0138" num="0138">The user responds to messages through a process similar to composing messages, with the only variation being that addressing the message is a modified process. Response may be to the original sender, or to new addressees, or both. The response message is created by the same addressing and composing steps as creating any normal message. The composing actions are identical to the composing actions during creating a message as described above.</p><heading id="h0036"><u>Complex Message Techniques</u></heading><p id="p0139" num="0139">All of the above entry techniques can be combined with the magnetic card options as described above to provide great flexibility in the creation and direction of messages. The magnetic card can also be used to capture the addressing and text of messages sent to the user, and particularly information about the calendar or schedule of activities which can be used to update recorded records. Other special types of messages can also be created to update specific associated data bases stored on the magnetic card.</p><p id="p0140" num="0140">In addition, it is contemplated that messages may be sent and retrieved through a touch tone telephone. Messages may be sent by calling the messaging system automated terminal which is part of the system and has access to the network. The automated terminal may include a voice response unit and/or a modem with an associated touch tone decoder. The voice response unit and modem combination would attend the call and the touch tone decoder would translate the user responses through a touch tone pad of a standard touch tone telephone. These decoder signals would be used to communicate with an associated computer to send and store messages on the system as previously described for on ATM or POS terminal.</p><p id="p0141" num="0141">In addition, both sending and receiving of messages may take place through a fully automated computer operator. Such a system may function through use of a telephone touch tone pad or may be operated solely through user voice activation and a<!-- EPO <DP n="46"> --> synthesized human voice controlled by the automated operator. This would allow messages to be both sent and received over standard telephone lines.</p><p id="p0142" num="0142">While these automated functions are not specifically illustrated in the drawings, it is contemplated that such an automated system would reside as a node similar to the service bureau and be entered via telephone, such as telephone 84.</p><heading id="h0037"><u><b>MESSAGE TRANSACTION FLOW</b></u></heading><heading id="h0038"><u>Starting Message Service Control</u></heading><p id="p0143" num="0143">When transmitted to the ATM Institution processor by the micro-processor of the ATM/POS terminal in response to completion of the user entry at the terminal, the message transaction will be formatted for transmission through the network. The message service control function will direct the message in accordance with normal system requirements, but using the new transaction types and transaction formats.</p><p id="p0144" num="0144">Invoking the message service control function will be accomplished by the format external message request function 236. This process will handle the special processing associated with the new message transaction types.</p><p id="p0145" num="0145">The destination will be identified using a location/affiliation directory. Information for the message service control function will be encoded and included in the message including an identification of the terminal location, date, time and other information that becomes an associated part of the message function and its audit trail. This information is used by both the message service control function and the store and forward message switch or equivalent E-Mail system.</p><heading id="h0039"><u>Liking The Message Switch To</u> <u>The Message Service Control Function</u></heading><p id="p0146" num="0146">The link between the revised validated I.D. and password from bank process 405 and the message service control function of the clearing house network adds the validation necessary for the new service. This added validation will allow the store and forward message switch 52 to identify system users and<!-- EPO <DP n="47"> --> their password by transmission of a minimal amount of information about the user as extracted from their debit/credit card account records or from message service control function including their E-Mail account I.D. password or PIN. When the store and forward message switch 52 has identified the user as system user, it is then determined by the origination or retrieval function 334 whether the user has entered a message at the terminal, or is requesting that any mail waiting be transmitted. The appropriate control process will then be selected.</p><heading id="h0040"><u>Retrieving Messages From The Users Mailbox</u></heading><p id="p0147" num="0147">When information that the user is approved is passed back to the message service control function from the clearing house network processor 32, message service control function then query's the store and forward message switch 52 for information held in the user's I.D. account or mailbox in that system.</p><p id="p0148" num="0148">If the process required is message retrieval, then the check mailbox for messages function 336 will process the users mailbox to determine if there are any messages waiting for delivery, it will determine, what status exists for all messages, determine priority, and select the next message to be sent. In addition the check mailbox for messages function 336 will determine what other status information needs to be appended to the communication back to the user.</p><p id="p0149" num="0149">The format messages for ATM/POS function 338 will then use information from the message service control function, sent along with the retrieval request, to determine how the message should be formatted, and what associated information about other messages (such as their number, emergency nature or degree or priority, etc.) needs to be attached to the actual messages being returned. The formatting will be specific to the type of terminal that message service control function informs the store and forward message switch 52 is being used by the user.</p><p id="p0150" num="0150">The flag message status function 342 will then update records in the user mailbox to identify what is being transmitted<!-- EPO <DP n="48"> --> to the user. This update will also allow for error recovery if validation of delivery is not received.</p><p id="p0151" num="0151">The insert message into output function 344 will then transmit the message back to the message service control function for delivery to the ATM/POS terminal where the user is located.</p><p id="p0152" num="0152">A group of messages (one transaction) are then passed back to the terminal at which the user has entered his request by the message service control function. The store and forward message switch 52 updates a status code for messages delivered to indicate that they have been sent and are awaiting further instructions from the user as to final disposition.</p><p id="p0153" num="0153">The message service control function will process the response, and return the result to the processor for the ATM or POS terminal where the user is located. This returned transaction will be logged by the log transaction for recovery function 232, exactly as all other traffic within the ATM/POS network.</p><p id="p0154" num="0154">The receive messages or timeout function 252 will process the returning transaction. This standard function will be modified to handle the message transactions for all normal transaction functions, and then route them to format messages for terminal function 254 for the new handling needed. This process will take information from the message service control function, the user's account profile, the E-Mail system or store and forward message switch 52 as required and format the information to be handled by the specific terminal from which the user originated the transaction.</p><p id="p0155" num="0155">Formatted responses will then be fed to the users terminal in association with the capabilities of the terminal, by forwarding them to the transmit response to terminal function 256, a standard process for these networks. The interaction with the terminal will be modified to accept the new message transaction types required by the present invention.</p><heading id="h0041"><u>Sending Messages To a Mailbox from a Terminal</u></heading><p id="p0156" num="0156">When information that the user is approved is passed back to the message service control function by the clearing house<!-- EPO <DP n="49"> --> network processor 44, the message service control function then notifies the store and forward message switch 52 of messages that have been created for delivery to other mailbox holders within the system, or within its addressing window.</p><p id="p0157" num="0157">If the process required is origination of messages, then the validate destination I.D. function will determine the destination of the message desired. This destination can be within the store and forward message switch 52 that is providing the E-Mail capability for the system or it can be any other E-Mail system connected through industry Standard X.400 links, or any other custom E-Mail to E-Mail link, or an external fax machine or modem. This will be determined and the appropriate routing to the E-mail destination mailbox or location established.</p><p id="p0158" num="0158">The format for mailbox function 354 will determine the destination mailbox type and rearrange the message as necessary to be acceptable for that mailbox. It will include taking certain encrypted information about the message as originated by the user, and data added from the message service control function, and turn it into text within the message being transmitted. This information will include, but not be limited to, date, time, location of user or terminal, associated information about the original message if this is itself a response, and directions for further delivery or action by the recipient that are user specific as identified by message service control function or the user's account records.</p><p id="p0159" num="0159">The flag message status function 356 will log the message, update the user E-Mail mailbox for information about the transmission of the message, and execute and terminate any external E-Mail links that were established for transmission purposes.</p><p id="p0160" num="0160">The return acknowledgement function 358 will complete the process by communicating back to the message service control function the audit trail of successful transmission, or identify and transmit any standard E-Mail errors that were encountered in transmission, after the destination I.D. was validated.<!-- EPO <DP n="50"> --></p><p id="p0161" num="0161">The appropriate return message will be constructed and the insert message into output function 344 will then transmit the message back to the message service control function for delivery to the ATM/POS terminal where the user is located.</p><heading id="h0042"><u><b>COMPLETION OF MESSAGE PROCESSING</b></u></heading><heading id="h0043"><u>Final Transmission to the Terminal</u></heading><p id="p0162" num="0162">At the point when the final transaction is being sent back to the terminal, handling will be different than other types of transactions that are either financial or non-financial but not a message service transaction.</p><p id="p0163" num="0163">The functions to handle this include the process transaction for control function 442 and the process transaction for completion function 444. The initial processing occurs when the transaction comes from the terminal. This causes process transaction for control function 442 to log the existence of a message service request, and retain enough information to keep track of the further handling needed.</p><p id="p0164" num="0164">The process transaction for completion function 444 then initiates the first type of the transaction required, the non-financial transaction routed to the store and forward message switch 52 to capture the E-Mail messages that exist, or to send the messages entered by the user, which has been described earlier.</p><p id="p0165" num="0165">When the transaction response returns it passes through the normal validation, logging, and identification processes. The process transaction for control will then recognize that it is a response to its initiated transaction, it will update the status of the request and forward the information to the process transaction for completion function. Normally this will satisfy the functional requirements for processing the non-financial transactions. However, when appropriate due to errors, special circumstances or complex transactions, additional cycles of communicating with the store and forward message switch 52 may be required.</p><p id="p0166" num="0166">The process transaction for completion function 444 then initiates the financial transaction to enter charges to the<!-- EPO <DP n="51"> --> user account. This will adhere to the normal audit controls of the ATM/POS financial network for monetary transactions.</p><p id="p0167" num="0167">The log transaction for recovery function 434 provides the normal audit trial processing for this financial transaction, and the type of transaction causes further processing by the receive message charges function 542. Charges will be identified and formatted for update to the account records of the user. The process account debit function 544 updates all appropriate records to indicate the users charges, and creates the audit trail required by the system. The process message service completion function 546 closes out processing on the user's financial institution processor 46 and transmits acknowledgement of the success through a transaction returned to the message service control function through the standard ATM/POS network capability provided by the message into output function 538.</p><p id="p0168" num="0168">When an acknowledgement returns from the user's financial institution, the message will be closed out by the process transaction for control function 442 and transmitted back to the terminal at which the customer initiated the transaction - by the process transaction for completion function 444. The return transaction to the ATM/POS terminal will include either a status of messages entered by the user or the messages (if any) that are retrieved from the E-Mail function of the store and forward message switch 52, and will also indicate the charges to the customer's account.</p><heading id="h0044"><u>Correcting Billing Errors</u></heading><p id="p0169" num="0169">Under certain circumstances the message service control function will not be able to complete providing the messages to the user at the ATM/POS terminal. Under these extraordinary circumstances, either a credit or a reversal of charges will be processed by the system. This will be identified as an error transaction and handled by the errors function 552. Errors function 552 provides, exactly as all other normal financial errors are handled. After proper validation of the circumstances, the process account debit function 554 will update the appropriate records to reverse the error, and the<!-- EPO <DP n="52"> --> necessary transactions sent back to the message service control function through the insert message into output function 448.</p><heading id="h0045"><u><b>HOW MESSAGES TO/FROM THE USER ARE SENT/RECEIVED</b></u></heading><heading id="h0046"><u>Access To The System</u></heading><p id="p0170" num="0170">The link created by the customized store and forward message switch allows easy physical connection to all of the existing E-Mail services, and results in the ability to easily send messages to users of the new service from outside the ATM/POS systems.</p><p id="p0171" num="0171">Most message creators would be businessmen, secretaries, or spouses with access to some type of computer, allowing the creation of messages with considerable flexibility, and inserting them into the network as easily as using an E-Mail network.</p><p id="p0172" num="0172">A message terminal entry station 72 connected to either the customized store and forward message switch 52 or to any of the linked existing E-Mail systems would be able to send mail by knowing the customers' message service mailbox code. The only restriction will be that the length of the message text which can be processed by an ATM/POS terminal will be constrained.</p><heading id="h0047"><u>Service Bureaus</u></heading><p id="p0173" num="0173">Someone who needs to send a message to a user, who either is not themselves a user, or does not currently have access to a terminal, can call a message in to an operator in a service bureau who enters the message and arranges billing based on what has been authorized by the receiving subscriber. The service bureaus will be able to take messages from outside individuals, usually by phone 84, and insert them into the network on their behalf.</p><p id="p0174" num="0174">The customer can also send messages to individuals without a "mailbox" on the system by use of the service bureaus. Anyone with a phone or mailing address could be reached by sending a message for forwarding to the individual that the customer wanted to reach. Alternatively, the messaging system of the present invention can provide a communicated radio signal activating a pager being carried by the user to inform<!-- EPO <DP n="53"> --> the user that a message has been deposited into his mailbox. The messaging system would, via modem, dial the user's pager and enter a code indicating a message was waiting for the user.</p><heading id="h0048"><u>Fax Output</u></heading><p id="p0175" num="0175">A fax could also be sent from the system directly to a fax machine 82 without manual intervention.</p><heading id="h0049"><u>Industrial Applicability</u></heading><p id="p0176" num="0176">Other alternatives for the electronic mail system 10 include, but are not limited to, varying the number of separate ATM/POS systems 12 capable of accessing the store and forward message switch 52.</p><p id="p0177" num="0177">Though each major component of the electronic mail system 10 is illustrated in the present embodiment as being in communication with a separate processor to perform the necessary system functions, normal computer capabilities allow a single processor to provide all, or any subset, of the functions described above for the electronic mail system 10. For example, the ATM institution processor 18 alone could provide the functions described for it together with the functions for the clearing house network processor 44, for the user's financial institution processor 46, and for the store and forward message switch 52 including interaction with multiple external E-Mail networks. In such a unified electronic mail system 10, the relationships among the various functions remain the same. However, such a unified electronic mail system 10 omits the data communication networks 42, 62 and 64. Other arrangements of processors 18, 36, 44 and 46 are possible depending on the relationship of institutions involved in providing the electronic mail service and their desire to participate in providing part of the network's overall capability.</p><p id="p0178" num="0178">To provide the functions of the electronic mail system 10, an institution having an processor 18 or 36 might place terminals 23, 24, 26, 28 or 34 of the type described in various public and private facilities such as airport or bus terminals, malls, financial institutions, retail merchants, hotels<!-- EPO <DP n="54"> --> or such similar public and private locations, in order to effectively serve the needs of the general public.</p>
EP	0605418	B1	2000-07-05	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>An electronic mail system (10) which is accessible by a user thereof said system comprising:<claim-text>an Automated Teller Machine or Point of Sale (ATM/POS) system (12) and a store and forward message switch (52), the ATM/POS system (12) including (I) a terminal (22, 24, 26, 28, 34) through which the user may request access to said electronic mail system; (II) an ATM/POS data communication network (38); and (III) an ATM/POS institution processor (32) that can intercommunicate with the terminal (22, 24, 26, 28, 34) via the ATM/POS data communication network (38); and wherein, in use,<claim-text>a) the user receives a message that has been stored in said switch (52); said switch (52) transmitting said message to the terminal (22, 24, 26, 28, 34) upon receiving authorisation to do so; and/or,</claim-text><claim-text>b) the user sends a message to be stored in said switch (52); said switch (52) storing said message upon receiving authorisation to do so.</claim-text></claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A system (10) according to claim 1 wherein said switch (52) receives a message from the terminal (22, 24, 26, 28, 34) of said ATM/POS system (12) and stores the received message upon being authorised to do so.<!-- EPO <DP n="56"> --></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A system (10) according to claim 1 or 2 wherein said switch (52) records charges for the user's usage of said electronic mail system (10).</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A system (10) according to claim 2 wherein said switch (52) receives a message for storage from, or transmits the received message to, a station (72) that communicates with said switch (52) over a message entry data communication network (74).</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A system (10) according to claim 2, 3 or 4 wherein said switch (52) transmits the received message to a pager communication service (78) through a modem that communicates with said switch (52) over the message entry data communication network (74).</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A system (10) according to claim 2, 3 or 4 wherein said switch (52) transmits the received message to a facsimile transmission machine (82) through a modem (76) that communicates with said message switch (52) over the message entry data communication network (74)</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A system (10) according to claim 2 wherein a menu is provided at the terminal (22, 24, 26, 28, 34) of said ATM/POS system (12) that permits selection either of message transmission from said switch (52) to the terminal (22, 24, 26, 28, 34), or of message reception by said switch (52) from the terminal (22, 24, 26, 28, 34).<!-- EPO <DP n="57"> --></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A system (10) according to claim 7 wherein the menu provided at the terminal of said ATM/POS system (12) permits selection of the message for transmission from said switch (52) to the terminal(22, 24, 26, 28, 34 from among several messages stored for the user on said switch (52).</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A system (10) according to claim 2 or 7 wherein authorization for said switch (52) to transmit the stored message to, or to receive the received message from, the terminal (22, 24, 26, 28, 34) of said ATM/POS system (12) requires that a debit or credit card (48) be inserted into the terminal (22, 24, 26, 28, 34) after which a personal identification number must be entered into the terminal (22, 24, 26, 28, 34).</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A system (10) according to claim 9 wherein said card (48) inserted into the terminal (22, 24, 26, 28, 34) includes a memory and/or a computer, and stored within the card (48) is a special menu that can be read into the terminal for display thereon.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A system (10) according to claim 9 or 10 wherein said card (48) inserted into the terminal (22, 24, 26, 28, 34) includes a memory and/or a computer, and stored within the card (48) is a directory of individuals to whom the user sends messages.<!-- EPO <DP n="58"> --></claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A system (10) according to claim 9, 10 or 11 wherein said card (48) inserted into the terminal (22, 24, 26, 28, 34) includes a memory and/or a computer, and the message transmitted from said switch (52) to the terminal (22, 24, 26, 28, 34) is stored within the card (48).</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A system (10) according to claim 2 or 7 wherein the terminal (22, 24, 26, 28, 34) includes a pen pad upon which the user may write the message that is received by said switch (52).</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A system (10) according to claim 13 wherein the terminal (22, 24, 26, 28, 34) includes an optical character recognition subsystem for scanning the message that is received by said switch (52).</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A system (10) according to claim 7 further comprising a user's financial institution processor (46) distinct from the ATM/POS institution processor (32), said user's financial institution processor (46) receiving requests from said ATM/POS system (12) that the user be allowed to access said electronic mail system (10) and authorizing such access by properly qualified users, said switch (52) transmitting the stored message to the terminal (22, 24, 26, 28, 34) of said ATM/POS system (12) upon receiving authorization from said user's financial institution processor (46).<!-- EPO <DP n="59"> --></claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>A system (10) according to claim 15 wherein said user's financial institution processor (46) also records charges for the user's usage of said electronic mail system (10).</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>A system (10) according to claim 15 or 16 further comprising a clearing house data communication network (42) that interconnects said ATM/POS system (12) and said user's financial institution processor (46) with a clearing house network processor (44), the clearing house network processor (44) accepting the user's request to access said electronic mail system (10) from said ATM/POS system (12) and transmitting such request to said user's financial institution processor (46).</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>A system (10) according to claim 17 wherein said clearing house network processor (44) also performs a message service control function that tracks the status of and steps required to retrieve the stored message from said switch (52).</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>A method for exchanging electronic mail messages with a terminal (22, 24, 26, 28, 34) included in an ATM/POS system (12) that also includes an ATM/POS institution processor (32), the method comprising the steps of:<claim-text>a. storing a message for a user on a store and forward message switch (52);<!-- EPO <DP n="60"> --></claim-text><claim-text>b. authorizing transmission of the stored message from said switch (52) to the terminal of the ATM/POS system (12) in response to the user's entry of a request therefor into the terminal of the ATM/POS system (12).</claim-text></claim-text></claim>
EP	0605418	B1	2000-07-05	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Elektronisches Mitteilungssystem (10), auf das ein Benutzer davon zugreifen kann, wobei das genannte System folgendes umfaÃŸt:<claim-text>ein Bankautomat- oder Verkaufsstellen- (ATM/POS-) System (12) und eine Speicherungs- und Weiterleitungsnachrichtenzentrale (store and forward message switch) (52), wobei das ATM/POS-System (12) (I) ein EndgerÃ¤t (22, 24, 26, 28, 34) aufweist, durch das der Benutzer Zugang zu dem genannten elektronischen Mitteilungssystem anfordern kann, (II) ein ATM/POS-Datenkommunikationsnetzwerk (38) und (III) einen ATM/POS-Institutsprozessor (32), der mit dem EndgerÃ¤t (22, 24, 26, 28, 34) Ã¼ber das ATM/POS-Datenkommunikationsnetzwerk (38) kommunizieren kann; und wobei im Gebrauch<claim-text>a) der Benutzer eine Nachricht erhÃ¤lt, die in der genannten Zentrale (52) gespeichert wurde, wobei die genannte Zentrale (switch) (52) die genannte Nachricht nach einer entsprechenden Autorisierung zu dem EndgerÃ¤t (22, 24, 26, 28, 34) sendet und/oder</claim-text><claim-text>b) der Benutzer eine in der genannten Zentrale (52) zu speichernde Nachricht sendet, wobei die genannte Zentrale (52) die genannte Nachricht nach dem Erhalt einer entsprechenden Autorisierung speichert.</claim-text></claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>System (10) nach Anspruch 1, bei dem die genannte Zentrale (52) eine Nachricht von dem EndgerÃ¤t (22, 24, 26, 28, 34) des genannten ATM/POS-Systems (12) erhÃ¤lt und die empfangene Nachricht nach einer entsprechenden Autorisierung speichert.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>System (10) nach Anspruch 1 oder 2, bei dem die genannte Zentrale (52) GebÃ¼hren fÃ¼r die Benutzung des genannten elektronischen Mitteilungssystems (10) durch den Benutzer aufzeichnet.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>System (10) nach Anspruch 2, bei dem die genannte Zentrale (52) eine zu speichernde Nachricht von einer Station (72) empfÃ¤ngt oder die empfangene Nachricht zu einer solchen sendet, die mit der genannten Zentrale (52) Ã¼ber ein Nachrichteneingabe-Datenkommunikationssystem (74) kommuniziert.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>System (10) nach Anspruch 2, 3 oder 4, bei dem die genannte Zentrale (52) die empfangene Nachricht zu einem Pager-Kommunikationsdienst (78) durch ein Modem sendet, das mit der genannten Zentrale (52) Ã¼ber das Nachrichteneingabe-Datenkommunikationsnetzwerk (74) kommuniziert.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>System (10) nach Anspruch 2, 3 oder 4, bei dem die genannte Zentrale (52) die empfangene Nachricht zu einer Telefax-Sendemaschine (82) durch ein Modem (76)<!-- EPO <DP n="62"> --> sendet, das mit der genannten Nachrichtenzentrale (52) Ã¼ber das Nachrichteneingabe-Datenkommunikationsnetzwerk (74) kommuniziert</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>System (10) nach Anspruch 2, bei dem ein MenÃ¼ am EndgerÃ¤t (22, 24, 26, 28, 34) des genannten ATM/POS-Systems (12) bereitgestellt wird, Ã¼ber das aus Nachrichtensendung von der genannten Zentrale (52) zu dem EndgerÃ¤t (22, 24, 26, 28, 34) und Nachrichtenempfang von dem EndgerÃ¤t (22, 24, 26, 28, 34) durch die genannte Zentrale (52) ausgewÃ¤hlt werden kann.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>System (10) nach Anspruch 7, bei dem das am EndgerÃ¤t des genannten ATM/POS-Systems (12) bereitgestellte MenÃ¼ die Auswahl der Nachricht zum Senden von der genannten Zentrale (52) zum EndgerÃ¤t (22, 24, 26, 28, 34) aus mehreren fÃ¼r den Benutzer in der genannten Zentrale (52) gespeicherten Nachrichten zulÃ¤ÃŸt.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>System (10) nach Anspruch 2 oder 7, bei dem die Autorisierung fÃ¼r die genannte Zentrale (52) zum Senden der gespeicherten Nachricht zu oder zum Empfangen der empfangenen Nachricht von dem EndgerÃ¤t (22, 24, 26, 28, 34) des genannten ATM/POS-Systems (12) es erfordert, daÃŸ eine Guthaben- oder Kreditkarte (48) in das EndgerÃ¤t (22, 24, 26, 28, 34) eingefÃ¼hrt wird, wonach eine persÃ¶nliche Kennummer (code) in das EndgerÃ¤t (22, 24, 26, 28, 34) eingegeben werden muÃŸ.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>System (10) nach Anspruch 9, bei dem die genannte in das EndgerÃ¤t (22, 24, 26, 28, 34) eingefÃ¼hrte Karte (48) einen Speicher und/oder einen Rechner aufweist und in der Karte (48) ein SpezialmenÃ¼ gespeichert ist, das in das EndgerÃ¤t eingelesen werden kann, um dort angezeigt zu werden.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>System (10) nach Anspruch 9 oder 10, bei dem die genannte in das EndgerÃ¤t (22, 24, 26, 28, 34) eingefÃ¼hrte Karte (48) einen Speicher und/oder einen Rechner aufweist und in der Karte (48) ein Verzeichnis von Einzelpersonen gespeichert ist, zu denen der Benutzer Nachrichten sendet.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>System (10) nach Anspruch 9, 10 oder 11, bei dem die genannte in das EndgerÃ¤t (22, 24, 26, 28, 34) eingefÃ¼hrte Karte (48) einen Speicher und/oder einen Rechner aufweist und die von der genannten Zentrale (52) zu dem EndgerÃ¤t (22, 24, 26, 28, 34) gesendete Nachricht in der Karte (48) gespeichert ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>System (10) nach Anspruch 2 oder 7, bei dem das EndgerÃ¤t (22, 24, 26, 28, 34) ein Schreibpad aufweist, auf das der Benutzer die von der genannten Zentrale (52) empfangene Nachricht schreiben kann.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>System (10) nach Anspruch 13, bei dem das EndgerÃ¤t (22, 24, 26, 28, 34) ein<!-- EPO <DP n="63"> --> optisches Zeichenerkennungssubsystem zum Abtasten der Nachricht beinhaltet, die von der genannten Zentrale (52) erhalten wird.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>System (10) nach Anspruch 7, ferner umfassend einen Benutzer-Finanzinstitutsprozessor (46), der sich von dem ATM/POS-Institutsprozessor (32) unterscheidet, wobei der genannte Benutzer-Finanzinstitutsprozessor (46) Anforderungen von dem genannten ATM/POS-System (12) empfÃ¤ngt, damit es dem Benutzer gestattet wird, auf das genannte elektronische Mitteilungssystem (10) zuzugreifen, und einen solchen Zugriff durch entsprechend qualifizierte Benutzer autorisiert, wobei die genannte Zentrale (52) nach dem Empfang der Autorisierung von dem genannten Benutzer-Finanzinstitutsprozessor (46) die gespeicherte Nachricht zum EndgerÃ¤t (22, 24, 26, 28, 34) des genannten ATM/POS-Systems (12) sendet.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>System (10) nach Anspruch 15, bei dem der genannte Benutzer-Finanzinstitutsprozessor (46) auch GebÃ¼hren fÃ¼r die Benutzung des genannten elektronischen Mitteilungssystems (10) durch den Benutzer aufzeichnet.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>System (10) nach Anspruch 15 oder 16, ferner umfassend ein Clearingstellen-Datenkommunikationsnetzwerk (clearing house network) (42), das das genannte ATM/POS-System (12) und den genannten Benutzer-Finanzinstitutsprozessor (46) mit einem Clearingstellen-Netzwerkprozessor (44) verbindet, wobei der Clearingstellen-Netzwerkprozessor (44) die Benutzeranforderung des Zugangs zu dem genannten elektronischen Mitteilungssystem (10) von dem genannten ATM/POS-System (12) akzeptiert und eine solche Anforderung zu dem genannten Benutzer-Finanzinstitutsprozessor (46) sendet.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>System (10) nach Anspruch 17, bei dem der genannte Clearingstellen-Netzwerkprozessor (44) auch eine Nachrichtendienst-Kontrollfunktion ausfÃ¼hrt, die den Status der gespeicherten Nachricht und die Schritte verfolgt, die notwendig sind, um die gespeicherte Nachricht aus der genannten Zentrale (52) zurÃ¼ckzulesen.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Verfahren zum Austauschen von elektronischen Nachrichten mit einem EndgerÃ¤t (22, 24, 26, 28, 34), das Teil eines ATM/POS-Systems (12) ist, das auch einen ATM/POS-Institutsprozessor (32) umfaÃŸt, wobei das Verfahren die folgenden Schritte umfaÃŸt:<claim-text>a. Speichern einer Nachricht fÃ¼r einen Benutzer in einer Speicher- und Weiterleitungsnachrichtenzentrale (52);</claim-text><claim-text>b. Autorisieren der Sendung der gespeicherten Nachricht von der genannten Zentrale<!-- EPO <DP n="64"> --> (52) zu dem EndgerÃ¤t des ATM/POS-Systems (12) als Reaktion auf die Benutzereingabe einer entsprechenden Anforderung in das EndgerÃ¤t des ATM/POS-Systems (12).</claim-text></claim-text></claim>
EP	0605418	B1	2000-07-05	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>SystÃ¨me de courrier Ã©lectronique (10) qui est accessible par un utilisateur, ledit systÃ¨me comprenant :<claim-text>un systÃ¨me de guichet automatique ou de point de vente (ATM/POS) (12) et un commutateur de stockage et retransmission de messages (store and forward message switch) (52), le systÃ¨me ATM/POS (12) comportant (I) un terminal (22, 24, 26, 28, 34) au moyen duquel l'utilisateur peut demander l'accÃ¨s audit systÃ¨me de courrier Ã©lectronique ; (II) un rÃ©seau de transmission de donnÃ©es ATM/POS (38), et (III) un processeur d'institution ATM/POS (32) qui peut intercommuniquer avec le terminal (22, 24, 26, 28, 34) par l'intermÃ©diaire du rÃ©seau de transmission de donnÃ©es ATM/POS (38) ; et dans lequel, durant l'utilisation,<claim-text>a) l'utilisateur reÃ§oit un message qui a Ã©tÃ© stockÃ© dans ledit commutateur (switch) (52) ; ledit commutateur (52) transmettant ledit message au terminal (22, 24, 26, 28, 34) lorsqu'il en reÃ§oit<!-- EPO <DP n="66"> --> l'autorisation ; et/ou,</claim-text><claim-text>b) l'utilisateur envoie un message devant Ãªtre stockÃ© dans ledit commutateur (52) ; ledit commutateur (52) stockant ledit message lorsqu'il en reÃ§oit l'autorisation.</claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>SystÃ¨me (10) selon la revendication 1, dans lequel ledit commutateur (52) reÃ§oit un message Ã  partir du terminal (22, 24, 26, 28, 34) dudit systÃ¨me ATM/POS (12) et stocke le message reÃ§u lorsqu'il en reÃ§oit l'autorisation.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>SystÃ¨me (10) selon la revendication 1 ou 2, dans lequel ledit commutateur (52) enregistre des trais relatifs Ã  l'utilisation par l'utilisateur dudit systÃ¨me de courrier Ã©lectronique (10).</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>SystÃ¨me (10) selon la revendication 2, dans lequel ledit commutateur (52) reÃ§oit un message Ã  stocker Ã  partir d'un, ou transmet le message reÃ§u Ã  un, poste (72) qui communique avec ledit commutateur (52) sur un rÃ©seau de transmission de donnÃ©es d'entrÃ©e de messages (74).</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>SystÃ¨me (10) selon la revendication 2, 3 ou 4, dans lequel ledit commutateur (52) transmet le message reÃ§u Ã  un service de communication de radiomessagerie (78) Ã  travers un modem qui communique avec ledit commutateur (52) sur le rÃ©seau de transmission de donnÃ©es d'entrÃ©e de messages (74).</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>SystÃ¨me (10) selon la revendication 2, 3 ou 4, dans lequel ledit commutateur (52) transmet le message reÃ§u Ã  une machine de transmission par tÃ©lÃ©copie (82) Ã  travers un modem (76) qui communique avec ledit commutateur de messages (52) sur le rÃ©seau de transmission de donnÃ©es d'entrÃ©e de messages (74).</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>SystÃ¨me (10) selon la revendication 2, dans lequel un menu est fourni au niveau du terminal (22, 24, 26, 28, 34) dudit systÃ¨me ATM/POS (12) qui permet la sÃ©lection<!-- EPO <DP n="67"> --> soit d'une transmission de messages depuis ledit commutateur (52) jusqu'au terminal (22, 24, 26, 28, 34), soit d'une rÃ©ception de messages par ledit commutateur (52) Ã  partir dudit terminal (22, 24, 26, 28, 34).</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>SystÃ¨me (10) selon la revendication 7, dans lequel le menu fourni au niveau du terminal dudit systÃ¨me ATM/POS (12) permet la sÃ©lection du message devant Ãªtre transmis depuis ledit commutateur (52) jusqu'au terminal (22, 24, 26, 28, 34) parmi plusieurs messages stockÃ©s par l'utilisateur dans ledit commutateur (52).</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>SystÃ¨me (10) selon la revendication 2 ou 7, dans lequel l'autorisation dudit commutateur (52) Ã  transmettre le message stockÃ© au, ou Ã  recevoir le message reÃ§u depuis le, terminal (22, 24, 26, 28, 34) dudit systÃ¨me ATM/POS (12) exige qu'une carte de dÃ©bit ou de crÃ©dit (48) soit insÃ©rÃ©e dans le terminal (22, 24, 26, 28, 34) aprÃ¨s quoi un numÃ©ro d'identification (code) personnel doit Ãªtre entrÃ© dans le terminal (22, 24, 26, 28, 34).</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>SystÃ¨me (10) selon la revendication 9, dans lequel ladite carte (48) insÃ©rÃ©e dans le terminal (22, 24, 26, 28, 34) comporte une mÃ©moire et/ou un ordinateur, et oÃ¹ Ã  l'intÃ©rieur de la carte (48) est stockÃ© un menu spÃ©cial qui peut Ãªtre lu dans le terminal en vue d'Ãªtre affichÃ© sur celui-ci.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>SystÃ¨me (10) selon la revendication 9 ou 10, dans lequel ladite carte (48) insÃ©rÃ©e dans le terminal (22, 24, 26, 28, 34) comporte une mÃ©moire et/ou un ordinateur, et oÃ¹ Ã  l'intÃ©rieur de la carte (48) est stockÃ© un rÃ©pertoire des personnes auxquelles l'utilisateur envoie des messages.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>SystÃ¨me (10) selon la revendication 9, 10 ou 11, dans lequel ladite carte (48) insÃ©rÃ©e dans le terminal (22, 24, 26, 28, 34) comporte une mÃ©moire et/ou un<!-- EPO <DP n="68"> --> ordinateur, et oÃ¹ le message transmis Ã  partir dudit commutateur (52) jusqu'au terminal (22, 24, 26, 28, 34) est stockÃ© Ã  l'intÃ©rieur de la carte (48).</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>SystÃ¨me (10) selon la revendication 2 ou 7, dans lequel le terminal (22, 24, 26, 28, 34) comporte une tablette Ã  photostyle sur laquelle l'utilisateur peut Ã©crire le message qui est reÃ§u par ledit commutateur (52).</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>SystÃ¨me (10) selon la revendication 13, dans lequel le terminal (22, 24, 26, 28, 34) comporte un sous-systÃ¨me de reconnaissance optique de caractÃ¨res pour balayer le message qui est reÃ§u par ledit commutateur (52).</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>SystÃ¨me (10) selon la revendication 7, comprenant en outre un processeur de l'institution financiÃ¨re de l'utilisateur (46) distinct du processeur de l'institution ATM/POS (32), ledit processeur de l'institution financiÃ¨re de l'utilisateur (46) recevant dudit systÃ¨me ATM/POS (12) des demandes que l'utilisateur soit autorisÃ© Ã  accÃ©der audit systÃ¨me de courrier Ã©lectronique (10) et autorisant ledit accÃ¨s par des utilisateurs dÃ»ment qualifiÃ©s, ledit commutateur (52) transmettant le message stockÃ© au terminal (22, 24, 26, 28, 34) dudit systÃ¨me ATM/POS (12) lorsqu'il en reÃ§oit l'autorisation par ledit processeur de l'institution financiÃ¨re de l'utilisateur (46).</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>SystÃ¨me (10) selon la revendication 15, dans lequel ledit processeur de l'institution financiÃ¨re de l'utilisateur (46) enregistre Ã©galement des frais relatifs Ã  l'utilisation par l'utilisateur dudit systÃ¨me de courrier Ã©lectronique (10).</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>SystÃ¨me (10) selon la revendication 15 ou 16, comprenant en outre un rÃ©seau de transmission de donnÃ©es de chambre de compensation (clearing house network) (42) qui interconnecte ledit, systÃ¨me ATM/POS (12) et ledit<!-- EPO <DP n="69"> --> processeur de l'institution financiÃ¨re de l'utilisateur (46) avec un processeur de rÃ©seau de chambre de compensation (44), le processeur de rÃ©seau de chambre de compensation (44) acceptant la demande par l'utilisateur d'accÃ©der audit systÃ¨me de courrier Ã©lectronique (10) provenant dudit systÃ¨me ATM/POS (12) et transmettant cette demande audit processeur de l'institution financiÃ¨re de l'utilisateur (46).</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>SystÃ¨me (10) selon la revendication 17, dans lequel ledit processeur de rÃ©seau de chambre de compensation (44) effectue Ã©galement une fonction de contrÃ´le de service de messagerie qui suit l'Ã©tat et les Ã©tapes requises pour extraire le message stockÃ© Ã  partir dudit commutateur (52).</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>ProcÃ©dÃ© d'Ã©change de messages de courrier Ã©lectronique avec un terminal (22, 24, 26, 28, 34) compris dans un systÃ¨me ATM/POS (12) qui comporte aussi un processeur d'institution ATM/POS (32), le procÃ©dÃ© comprenant les Ã©tapes de :<claim-text>a. stockage d'un message d'un utilisateur dans un commutateur de stockage et retransmission de messages (52) ;</claim-text><claim-text>b. autorisation de la transmission du message stockÃ© depuis ledit commutateur (52) jusqu'au terminal du systÃ¨me ATM/POS (12) en rÃ©ponse Ã  l'entrÃ©e par l'utilisateur d'une demande Ã  cet effet dans le terminal du systÃ¨me ATM/POS (12).</claim-text></claim-text></claim>
EP	0605418	B1	2000-07-05	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0605418&ki=B1&pd=2000-07-05
EP	0608223	B1	2000-03-08	de	TITLE	1	BANDAGE
EP	0608223	B1	2000-03-08	en	TITLE	1	BANDAGE
EP	0608223	B1	2000-03-08	fr	TITLE	1	BANDAGE
EP	0608223	B1	2000-03-08	en	DESCR	1	<p id="p0001" num="0001">This invention relates to bandages. In particular, it relates to a bandage which provides flexibility of use and extended scope of application over bandages presently available.</p><p id="p0002" num="0002">US-A-2 096 564 discloses a bandage comprising a flexible strip of tape having an adhesive undersurface and provided with a plurality of spaced rows of elongated apertures.</p><p id="p0003" num="0003">Existing bandages are typically in the form of a strip which is stored in a roll, or in the form of a tube. The tube may be shaped to conform to the particular location at which it is to be used, for example at the ankle joint. A tube, or sleeve, is generally a more convenient form than a strip since it is quick and relatively easy to apply, although its shape and size limit the scope of application.</p><p id="p0004" num="0004">Depending on the circumstances of use, a sleeve, in particular, may suffer the following disadvantages:-<ul id="ul0001" list-style="none" compact="compact"><li>i) it nay be unduly restrictive to movement in a certain direction in which free movement is preferable;</li><li>ii) it may not provide sufficient support, allowing too much movement in a certain direction or directions in which restricted movement is preferable;</li><li>iii) it may be uncomfortable and, in particular, may not fit adequately;</li><li>iv) it may tend to kink when the joint is flexed; or</li><li>v) it may cover an area which needs to remain open or accessible, such as a wound or bed sore.</li></ul></p><p id="p0005" num="0005">According to the invention, there is provided a bandage comprising a flexibly stretchable first member formed of an elastic layer covered on at least one surface by a woven material which is provided with lines or areas of weakness, and a second member formed of a base material less elastic than the first member or inelastic, the second member having upstanding hooked elements for engaging the woven material of the first member; whereby to provide for controlled flexibility over predetermined<!-- EPO <DP n="2"> --> areas of the first member upon engagement therewith.</p><p id="p0006" num="0006">The first member may be easily extensible and the lines or areas of weakness may be local in extent. Such lines or areas of weakness provide means for controlling the stretching of the first member in diverse local areas and in specific directions according to the requirements of a particular application. Lines or areas of weakness are preferably slits or cuts only partially through the first member, but may be made through the entire thickness of the first member. The lines or areas of weakness may be introduced in situ and/or during manufacture. Lines of weakness are preferably generally parallel to the longitudinal axis of the limb to be bandaged. The bandage may thus be adapted to allow easy movement in specific areas and in specific directions since the first member will stretch in a direction generally normal to each slit. The use of a series of lines of weakness in the form of a lattice allows stretching in all directions.</p><p id="p0007" num="0007">In a preferred embodiment, the areas of weakness may be apertures which allow access to a wound site, for example, or which prevent wrinkling of the bandage during flexing of a joint.</p><p id="p0008" num="0008">The second member provides means for fastening the bandage when the hooked elements engage woven material of the first bandage.</p><p id="p0009" num="0009">One or more pieces of the second member may be used to strengthen the bandage by limiting or preventing stretching of the first member. One or more pieces of the second member by also be used to seal unwanted lines or areas of weakness in the first member.<!-- EPO <DP n="3"> --> The elastic layer is preferably of Neoprene or similar material. The woven material is preferably attached to the elastic layer by adhesive, although alternative methods, such as heat sealing for example, may be used.</p><p id="p0010" num="0010">Still more preferably, means for holding inserts in position may be provided. The means may be pockets in the woven material which can hold inserts such as protective pads and plates, or inflatable pads for use with impulse-compression pads for local treatment of joints or tissues or activation of physiological venous pumps, eg. of the hand, foot, calf, knee or thigh.</p><p id="p0011" num="0011">Alternatively, inserts may be located by positioning the inserts next to the first member and fixing in place by one or more pieces of the second member. In this manner inserts may be located on either side of the first member as required.</p><p id="p0012" num="0012">The bandage is suitably manufactured in the form of a sheet, but preferably it is in the form of a tubular bandage of a particular joint shape. Strips of bandage may be obtained by cutting a sheet into the required length and/or width. Tubular bandages may also be made in situ by sealing the ends of a sheet of the first member with one or more strips of the second member. A sheet may thus be closed by the one or more strips of the second member so as to form a cylinder.</p><p id="p0013" num="0013">The bandage may have an adhesive layer on part or all of at least one surface of the first member. Such an adhesive layer would improve protection of damaged ligaments or structural tissue by adhering to the skin surface.<!-- EPO <DP n="4"> --></p><p id="p0014" num="0014">According to a further aspect of the invention, there is provided a method of manufacturing a bandage comprising: manufacturing a flexibly stretchable first member by providing a layer of elastic material, with a layer of woven material attached to at least one surface of said layer and cutting slits through part or all of the first member thus formed; and controlling the flexibility of the first member by fastening one or more pieces of a second member formed of a base material which is inelastic or less elastic than the first member to a predetermined area or areas of the first member by engaging hooked elements upstanding from the second member with the woven material of the first member.</p><p id="p0015" num="0015">Applications of the bandage the subject of the invention include:<ul id="ul0002" list-style="none" compact="compact"><li>i) circumstances where support is required, such as in the protection of damaged ligaments, where appropriately position inhibition means can be used;</li><li>ii) to hold impulse-compression pads inside a tubular bandage for local treatment of joints and tissues;</li><li>iii) where rapid and unskilled placement of dressings with localised pressure is required, such as for preventing the bleeding of a wound in an emergency;</li><li>iv) where ventilation of pressure sores or relief of pressure is required; and</li><li>v) in the constructions of an immobilisation cast for body or limb, with the addition of a quick-setting material such as an alginate or plaster of Paris.</li></ul></p><p id="p0016" num="0016">The thickness of the bandage is not critical to the invention since it should be suited to the particular material used and the specific application envisaged. A typical useful thickness is from 1.5 mm to 8 mm.</p><p id="p0017" num="0017">The numbers, sizes, shapes, locations, orientations and degrees of the areas of elastic inhibition and assistance<!-- EPO <DP n="5"> --> govern the shape and characteristics of the bandage so that the bandage can be tailor-made for a specific application. Thus a bandage can be manufactured for application, not only for a particular site, but also for a particular purpose, and applied with speed and ease even by an unskilled person. Likewise, a bandage can be altered or adjusted before or during fitting to suit a special requirement. The bandage should conform to the particular application in that it must not compromise circulation.</p><p id="p0018" num="0018">The bandage and/or inhibition means may be colour-coded to indicate the degree to which they are elastic.</p><p id="p0019" num="0019">The invention will now be described by way of example with reference to the accompanying drawings, in which:<ul id="ul0003" list-style="none"><li>Fig 1 is a schematic transverse section of a bandage according to the invention;</li><li>Fig 2 is a schematic plan view of another bandage according to the invention;</li><li>Fig 3 is a schematic transverse section of the bandage of Fig 2 viewed in direction A-A;</li><li>Fig 4 is a schematic plan view of a further bandage according to the invention;</li><li>Fig 5 is a schematic plan view of a stretched section of the bandage of Fig 4; and</li><li>Fig 6 is a schematic side view of a yet further bandage according to the invention.</li></ul><!-- EPO <DP n="6"> --></p><p id="p0020" num="0020">In Fig 1, there is shown a bandage 10 comprising a first member 20 and a second member 30. The first member 20 has a layer 40 with a covering layer on each side, the first member 20 being provided with areas or lines of weakness preferably in the form of slits as will be described more clearly in later embodiments of the invention. The covering layer on one side provides a comfort layer 55 for contact with the body and may also be used for location of inflation pads by a further second member. The covering layer 50 on the other side is engaged by hooked elements 70 extending from layer 60 of the second member 30. Layer 40 is an elastic material such as Neoprene with covering layers 50 and 55 being woven material. In use the woven material 50, 55 is attached to the elastic material 40 during manufacture, by adhesive for example, so that the first member 20 can be stretched around the part of the body to be bandaged. Layer 60 is less elastic than the first member or may be inelastic, being a moulded plastics material for example. In use, the hooked, elements 70 engage the woven material 50, preventing stretching of first member 20 at the points of attachment.</p><p id="p0021" num="0021">Figs 2 and 3 show an embodiment in which a bandage 100 has slits 180, 185 cut in its first member 120, and an aperture 190. Slits 180 are partial thickness, being cut through the woven material 150 only. Slits 185 are full thickness, being cut through both layers of the first member 120, comprising woven material 150 and elastic material 140 only in this embodiment.</p><p id="p0022" num="0022">Strips of inelastic material 165 are provided for securing the bandage and pieces of inelastic material 160 is placed around the aperture 190 so as to provide a local inelastic region which prevents unwanted deformation of the bandage.</p><p id="p0023" num="0023">Second member pieces 160, 165 may be Velcro<!-- EPO <DP n="7"> --> (registered trade mark) or other similar inelastic material having hooked elements. The first member is, for example, wetsuit material, which may be 3 mm Neoprene lined with a 0.5 mm thick woven material. It will be appreciated that other materials could be used. In particular woven material 150 could be a piled fabric, such as plush, or could have looped elements which engage with the hooked elements 170.</p><p id="p0024" num="0024">In use, sheets of bandage 100 are placed around the part of the body to be bandaged and are secured in place by strips of inelastic material 165. Slits 180 in the sheet provide lines of weakening, so that the sheet stretches generally normal to these lines. Instead of being manufactured as a sheet, the bandage may be manufactured in the form of a tube. In this case, slits are provided around arcs of the circumference of inelastic material. Unwanted slits may be sealed by strips of pieces of inelastic material. Further strips of inelastic material may be positioned where extra support or strengthening is required, such as along damaged ligaments or across incompletely healed fractures.</p><p id="p0025" num="0025">This example uses inelastic material for securing or strengthening, but it is possible to use material which is less elastic than that of the first member.</p><p id="p0026" num="0026">In another embodiment of the invention, the slits in the first member 120 of the bandage of Fig 3 are in the form of multiple slits 280 arranged in a "bricked" layout in the bandage 200 illustrated in Fig 4. These slits 280 deform when stretched around a limb during application as shown in Fig 5. The multiple slits become a lattice of diamond shapes 285 when stretched as indicated by the arrows. The use of this form enables stretching in all directions. Improved stretching is thereby achieved over the whole of the lattice region.<!-- EPO <DP n="8"> --></p><p id="p0027" num="0027">The bandage 200 may be closed by a longitudinal strip of the second member 265 to form a tubular bandage.</p><p id="p0028" num="0028">The slits are generally closely spaced along the longitudinal axis of the limb to be supported. This weakens the force exerted by the first member so that by itself it exerts only minor constricting force or the limb.</p><p id="p0029" num="0029">Fig 6 shows an embodiment in which the bandage according to the invention has been manufactured in the form of a tubular support bandage 30 and shaped to conform to a knee joint. Slits 380 have been cut in the first member of the bandage in the region where stretching is required and have deformed to a diamond lattice. Further support to ligaments, for instance, is provided in the form of inelastic or less elastic regions obtained by the addition of strips of the second member 330. If necessary, an aperture 390 can prevent wrinkling of the bandage, the aperture being maintained in shape by a piece of the second member 360. The strips 330 may also be used to close a slit 380 if it is not required.</p><p id="p0030" num="0030">A versatile bandage and method of manufacturing a bandage have thus been provided which provide quick and easy application without the requirement of a large range of custom-fit bandages.</p>
EP	0608223	B1	2000-03-08	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A bandage comprising a flexibly stretchable first member (20,120) formed of an elastic layer covered on at least one surface by a woven material (50,15), wherein the first member (20,120) has lines or areas of weakness (180,185), and a second member (30,160) formed of a base material less elastic than the first member (20,120) or inelastic, the second member (30,160) having upstanding hooked elements (70,170) for engaging the woven material of the first member (20,120); whereby to provide for controlled flexibility over predetermined areas of the first member (20,120) upon engagement therewith.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A bandage according to Claim 1 in which the lines or areas of weakness (180,185) are slits through part or all of the first member.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A bandage according to Claim 2 in which the slits (180,280,380) are arranged in a lattice form of staggered rows.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A bandage according to any one of Claims 1 to 3 in which the second member (30,160) provides means for strengthening the bandage.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A bandage according to any one of Claims 1 to 4 in which the elastic layer (20,120) is Neoprene or similar material.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A bandage according to any one of Claims 1 to 5 in which the first member is in the form of a strip, sheet or tube.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A bandage according to any one of Claims 1 to 7 in which the first member (20,120) further comprises an adhesive layer on part or all of at least one surface.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A method of manufacturing a bandage comprising:<claim-text>manufacturing a flexibly stretchable first member (20,120) by providing a layer of elastic material, with a layer of woven material (50,150) attached to at least one surface of said layer and cutting slits<!-- EPO <DP n="10"> --> (180,280,380) through part or all of the first member thus formed; and</claim-text><claim-text>controlling the flexibility of the first member (20,120) by fastening one or more pieces of a second member (30,160) formed of a base material which is inelastic or less elastic than the first member (20,120) to a predetermined area or areas of the first member by engaging hooked elements (70,170) upstanding from the second member (30,160) with the woven material (50,150) of the first member (20,120).</claim-text></claim-text></claim>
EP	0608223	B1	2000-03-08	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Bandage bestehend aus einem flexibel dehnbaren ersten Element (20, 120), welches von einer elastischen Lage gebildet ist, die an wenigstens einer OberflÃ¤chenseite durch ein Gewebe (50, 15) abgedeckt ist, wobei das erste Element (20, 120) SchwÃ¤chungslinien oder -bereiche (180, 185) aufweist, und aus einem zweiten Element (30, 160), welches aus einem Grundmaterial mit einer im Vergleich zum ersten Element (20, 120) geringeren ElastizitÃ¤t oder aus einem nichtelastischen Material hergestellt ist, wobei das zweite Element (30, 160) nach oben wegstehende hakenfÃ¶rmige Elemente (70, 170) fÃ¼r den Eingriff mit dem Gewebematerial des ersten Elementes (20, 120) besitzt, um durch Eingriff eine kontrollierte FlexibilitÃ¤t Ã¼ber vorbestimmte Bereiche des ersten Elementes (20, 120) zu erreichen.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Bandage nach Anspruch 1, dadurch gekennzeichnet, daÃŸ die SchwÃ¤chungslinien oder-bereiche (180, 185) Schlitze sind, die teilweise oder vollstÃ¤ndig durch das erste Element hindurchgehen.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Bandage nach Anspruch 2, dadurch gekennzeichnet, daÃŸ die Schlitze (180, 280, 380) gitterartig in versetzten oder aufeinander folgenden Reihen vorgesehen sind.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Bandage nach einen der AnsprÃ¼che 1 - 3, dadurch gekennzeichnet, daÃŸ das zweite Element (30, 160) Mittel fÃ¼r eine VerstÃ¤rkung der Bandage zur VerfÃ¼gung stellt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Bandage nach einem der AnsprÃ¼che 1 - 4, dadurch gekennzeichnet, daÃŸ die elastische Schicht (20, 120) Neopren oder ein Ã¤hnliches Material ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Bandage nach einem der AnsprÃ¼che 1 - 5, dadurch gekennzeichnet, daÃŸ das erste Element die Form eines Streifens, eines Flachmaterials oder eines Schlauches<!-- EPO <DP n="12"> --> aufweist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Bandage nach einem der AnsprÃ¼che 1 - 7, dadurch gekennzeichnet, daÃŸ das erste Element (20, 120) auf wenigstens einer OberflÃ¤chenseite teilweise oder vollstÃ¤ndig mit einer Klebeschicht versehen ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verfahren zum Herstellen einer Bandage, wobei das Verfahren umfaÃŸt: das Herstellen eines flexibel dehnbaren ersten Elementes (20, 120) durch Bereitstellen einer Schicht eines elastischen Materials, wobei eine Lage aus einem Gewebematerial (50, 150) an wenigstens einer OberflÃ¤chenseite der erwÃ¤hnten Schicht befestigt wird und Schlitze (180, 280, 380) teilweise durchgehend oder vollstÃ¤ndig durchgehend durch das so hergestellte erste Element eingebracht werden; und<claim-text>das Steuern der FlexibilitÃ¤t des ersten Elementes (20, 120), durch Befestigen eines oder mehrerer StÃ¼cke eines zweiten Elementes (30, 160), welches aus einem Grundmaterial gefertigt ist, das nicht elastisch oder eine ElastizitÃ¤t kleiner als die ElastizitÃ¤t des ersten Elementes (20, 120) aufweist, und zwar an einem vorbestimmten Bereich oder an vorbestimmten Bereichen des ersten Elementes durch Verbindung von hakenfÃ¶rmigen Elementen (70, 170), die von dem zweiten Element (30, 160) wegstehen, mit dem Gewebematerial (50, 150) des ersten Elementes (20, 120).</claim-text></claim-text></claim>
EP	0608223	B1	2000-03-08	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Bandage comprenant un premier Ã©lÃ©ment souple Ã©tirable (20, 120) formÃ© d'une couche Ã©lastique recouverte sur au moins une surface par un materiau tisse (50, 15), ledit premier Ã©lÃ©ment (20, 120) comportant des lignes ou des zones de moindre rÃ©sistance (180, 185), et un second Ã©lÃ©ment (30, 160) formÃ© d'un matÃ©riau de base moins Ã©lastique que le premier Ã©lÃ©ment (20, 120), ou inÃ©lastique, et muni de crochets (70, 170) destinÃ©s Ã¢ s'accrocher au matÃ©riau tissÃ© du premier Ã©lÃ©ment (20, 120), afin de'obtenir une souplesse ajustable dans des zones prÃ©dÃ©terminÃ©es du premier Ã©lÃ©ment (20, 120) lors de l'accrochage Ã¢ celui-ci.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Bandage selon la revendication 1, dans lequel les lignes ou zones de moindre rÃ©sistance (180, 185) sont des fontes Ã¢ travers tout ou partie due premier Ã©lÃ©ment.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Bandage selon la revendication 2, dans lequel les fentes (180, 280, 380) sont disposÃ©es sous forme de grilles de rangÃ©es dÃ©calÃ©es.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Bandage selon l'une quelconque des revendications 1 Ã¢ 3, dans lequel le second Ã©lÃ©ment (30, 160) est muni de moyens permettant de consolider le bandage.<!-- EPO <DP n="14"> --></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Bandage selon l'une quelconque des revendications 1 Ã¢ 4, dans luquel la couche Ã©lastique (20, 120) est due NÃ©oprÃ¨ne ou un matÃ©riou similaire.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Bandage selon l'une quelconque des revendications 1 Ã¢ 5, dans lequel le premier Ã©lÃ©ment a la forme d'une bande, d'une feuille ou d'un tube.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Bandage selon l'une quelconque des revendications 1 Ã¢ 6, dans lequel le premier Ã©lÃ©ment (20, 120) comprend en outre une couche adjÃ©sive sur tout ou partie d'au moins une surface.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>ProcÃ©dÃ© de fabrication d'un bandage consistant Ã¢ : fabriquer un premier Ã©lÃ©ment souple Ã©tirable (20, 120) en adjoignant Ã¢ une couche de matÃ©riau Ã©lastique une couche de matÃ©riau tissÃ© (50, 150) fixÃ©e Ã¢ au moins une surface de ladite couche et en coupant des fentes (180, 280, 380) Ã¢ travers tout ou partie du premier Ã©lÃ©ment ainsi formÃ© ; et a ajuster la souplesse du premier Ã©lÃ©ment (20, 120) en fixant un ou plusieurs morceaux d'un second Ã©lÃ©ment (30, 160) fait d'un matÃ©riau de base inÃ©lastique ou moins Ã©lastique que le premier Ã©lÃ©ment (20, 120) sur une ou des zones prÃ©dÃ©terminÃ©es du premier Ã©lÃ©ment, en agrippant des crochets (70, 170) places sur le second Ã©lÃ©ment (30,160) au matÃ©riau tissÃ© (50, 150) du premier Ã©lÃ©ment (20, 120).</claim-text></claim>
EP	0608223	B1	2000-03-08	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0608223&ki=B1&pd=2000-03-08
EP	0632031	B1	2000-05-03	de	TITLE	1	KONDENSIERTE BENZOXA-RINGVERBINDUNG, DEREN HERSTELLUNG SOWIE DIESE ENTHALTENDES ARZNEIMITTEL
EP	0632031	B1	2000-05-03	en	TITLE	1	CONDENSED BENZOXA RING COMPOUND, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP	0632031	B1	2000-05-03	fr	TITLE	1	COMPOSE CYCLIQUE CONDENSE DE BENZOXA, SON PROCEDE DE PRODUCTION, ET COMPOSITION PHARMACEUTIQUE LE CONTENANT
EP	0632031	B1	2000-05-03	en	DESCR	1	<heading id="h0001">TECHNICAL FIELD</heading><p id="p0001" num="0001">The present invention relates to a pharmaceutical composition containing a benzoxa condensed ring compound, and more specifically, it relates to a pharmaceutical composition containing a benzoxazole or 2,3-dihydrobenzofuran compound, which is useful for inhibiting the action of Acyl-Coenzyme A: Cholesterol Acyltransferase (i.e., "ACAT" herein below). Furthermore, the present invention relates to a process for producing the above-mentioned compound and a novel compound belonging to the category of the above-mentioned compound.</p><heading id="h0002">BACKGROUND ART</heading><p id="p0002" num="0002">As is well known in the art, atherosclerosis is a very important factor causative of various cardiovascular diseases, and extensive and intensive studies have been conducted with a view to suppression of the progress of atherosclerosis or regression of atherosclerosis. In particular, the efficacy of a drug for lowering cholesterol in the serum or arterial wall is recognized. However, an ideal drug having a significant clinical effect and less liable to occurrence of an adverse effect has not been realized in the art.</p><p id="p0003" num="0003">In recent years, it has become apparent that the accumulation of a cholesterol ester in an arterial wall is an important factor causative of the progress of atherosclerosis. Therefore, a lowering in the cholesterol level in the blood is useful for suppression of the progress of atherosclerosis and regression of the atherosclerosis.<!-- EPO <DP n="2"> --></p><p id="p0004" num="0004">Cholesterol in foods is esterified in tunica mucosa intestini tenuis and then incorporated as chylomicron in the blood. It is known that ACAT plays an important role in the formation of a cholesterol ester in the tunica mucosa intestini tenuis or arterial wall. Therefore, it is considered that the inhibition of ACAT in the tunica mucosa intestini tenuis and the prevention of the esterification can prevent the absorption of the cholesterol, and the cholesterol level of the blood can be lowered.</p><p id="p0005" num="0005">In the arterial wall, the cholesterol is accumulated as a cholesterol ester. Therefore, it is expected that the inhibition of ACAT in the arterial wall can effectively prevent the accumulation of the cholesterol ester.</p><p id="p0006" num="0006">Thus, an ACAT inhibitor is considered likely to become a drug useful for treating hyperlipidemia and atherosclerosis through the prevention of the cholesterol in intestinum tenue and the accumulation of the cholesterol in the arterial wall.</p><p id="p0007" num="0007">For example, urea derivatives (see, for example, J. Med. Chem., vol. 29, 1131 (1986) and Japanese Unexamined Patent Publication (Kokai) Nos. 63-316761 and 1-93569) and amide derivatives (see, for example, Japanese Examined Patent Publication (Kokoku) No. 63-54718 and Japanese Unexamined Patent Publication (Kokai) No. 63-253060) have hitherto been reported as the above-mentioned ACAT enzyme inhibitor. In all the above-mentioned compounds, although the aromatic nucleus is bonded to a nitrogen atom of a urea or amide portion directly or through an alkylene group, no compound is disclosed wherein a benzoxazole condensed ring, that is, benzoxazole or 2,3-dihydrobenzofuran ring, is directly bonded to a nitrogen atom of the urea or amide portion.<!-- EPO <DP n="3"> --></p><p id="p0008" num="0008">EP 0 297 610 discloses N-[(2,6-disubstituted)phenyl)]-urea and carbamate inhibitors of acyl-CoA:cholesterol acyl-transferase. The phenyl group subsituents are selected from alkyl of from one to six carbon atoms, fluorine, chlorine, bromine, or -OR<sub>3</sub>, where R<sub>3</sub> is alkyl of from one to six carbon atoms, or -CH<sub>2</sub>-phenyl.</p><p id="p0009" num="0009">It is known that some compounds wherein a benzoxazole or 2,3-dihydrobenzofuran ring is directly bonded to a nitrogen atom of an urea or amide portion can be used as<!-- EPO <DP n="4"> --> an intermediate for synthesizing drugs, insecticides, vermifuges, bacteriocides for agriculture and gardening, herbicides, photographic materials, etc. However, it is unknown whether or not they have an ACAT inhibitory activity. Examples of the former compound known in the art include compounds for use as an insecticide, wherein a substituted arylcarbonyl group is bonded to one of the nitrogen atoms of a ureylene group bonded to the benzene ring (see Japanese Unexamined Patent Publication (Kokai) No. 64-42474); compounds for use as a vermifuge, wherein a substituted or unsubstituted phenylamide group<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="44" he="15" img-content="chem" img-format="tif"/></chemistry> is bonded to the benzene ring (see Canadian Patent No. 842258); calcimycin (A-23187) known as Ca ionophore and derivatives thereof (see J. Am. Chem. Soc., <u>104</u>, 1436 (1982); and Japanese Unexamined Patent Publication (Kokai) No. 62-26283) and several derivatives for use as an optomagnetic material and a heat-resistant material (see Journal of The Society of Organic Synthetic Chemistry, vol. 29, p. 717; and Japanese Examined Patent Publication (Kokoku) No. 64-53303). Examples of the latter compound known in the art include compounds for use as a herbicide, wherein a chloroacetamide group is bonded to the benzene ring (see Japanese Patent Unexamined Patent Publication (Kokai) No. 60-109585); compounds for use as a bacteriocide for agriculture and gardening, wherein a substituted phenylamide group is bonded to the benzene ring (see Japanese Unexamined Patent Publication (Kokai) No. 60-215680); compounds for use as a starting compound for a pigment, wherein an acetylacetamide group is bonded to the benzene ring (see Japanese Examined Patent Publication (Kokoku) No. 47-7715); compounds for use as a herbicide, wherein a substituted aryloxyisopropylamide group is bonded to the benzene ring (see Japanese Unexamined PCT Patent<!-- EPO <DP n="5"> --> Publication (Kohyo) No. 61-501991); compounds for use as an antiallergic drug, wherein a tetrazole group is located as an indispensable group at the 2-position and a substituted phenylamide group is bonded to the benzene ring (see Japanese Unexamined Patent Publication (Kokai) No. 2-138242); compounds for use as an analgesic, wherein an acetamide group is bonded to the benzene ring (see Spanish Patent No. 512355); compounds for use as a herbicide, wherein a methyl or cyclopropyl group is bonded to one nitrogen atom of a ureylene group bonded to the benzene ring (see Canadian Patent No. 117860); and compounds for use as a photosensitive material for silver halide color photography, wherein a substituted alkylamide group or a substituted phenylamide group is bonded to the benzene ring (see Japanese Unexamined Patent Publication (Kokai) Nos. 61-250642 and 61-233742). The above-described prior art documents are, however, silent on the fact that benzoxazole or 2,3-dihydrobenzofuran derivatives, including the above-described known compounds, have an ACAT inhibitory activity.</p><heading id="h0003"><u>Disclosure of the Invention</u></heading><p id="p0010" num="0010">Accordingly, an object of the present invention is to provide a pharmaceutical composition having an ACAT enzyme inhibitory activity and capable of exhibiting an excellent therapeutic effect through a lowering in the level of cholesterol in the blood or arterial wall, a novel derivative containing a benzoxa condensed ring capable of exhibiting a significant effect and a process for producing the same.</p><p id="p0011" num="0011">The present inventors have made extensive and intensive studies with a view to providing compounds significantly superior to known anti-hyperlipidemic agents and anti-atheroscleotic agents and, as a result, have unexpectedly found that certain amides or urea derivatives having a benzoxazole or 2,3-dihydrobenzofuran ring have not only a strong ACAT inhibitory activity but<!-- EPO <DP n="6"> --> also strong anti-hyperlipidemic activity and anti-atheroscleotic activity, which has led to the completion of the present invention.</p><p id="p0012" num="0012">In accordance with the present invention, the above-mentioned object of the present invention can be attained by providing a pharmaceutical composition comprising a benzoxa condensed ring compound represented by the following formula (I) or its pharmaceutically acceptable salt in an amount effective for inhibiting the action of Acyl-coenzyme A: Cholesterol Acyltransferase:<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="71" he="33" img-content="chem" img-format="tif"/></chemistry> wherein any one of P, Q, R and S is a group represented by the formula:<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="38" he="16" img-content="chem" img-format="tif"/></chemistry> with the remaining three substituents being independently a group represented by the formula -R<sub>3</sub>,<ul id="ul0001" list-style="none" compact="compact"><li>wherein R<sub>1</sub> stands for a group selected from the group consisting of:<ul id="ul0002" list-style="none" compact="compact"><li>(i) an unsubstituted cycloalkyl or cycloalkenyl group or a cycloalkyl or cycloalkenyl group substituted at a position other than the 1-position with the substituent being a C<sub>1</sub>-C<sub>14</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group;</li><li>(ii) a group represented by the formula:<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="28" he="22" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="7"> --> wherein R<sub>9</sub> and R<sub>10</sub> each independently stands for a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or may combine with each other to form a C<sub>3</sub>-C<sub>7</sub> carbon ring; and R<sub>11</sub> stands for a substituted or unsubstituted C<sub>1</sub>-C<sub>19</sub> alkyl, C<sub>2</sub>-C<sub>19</sub> alkenyl, C<sub>6</sub>-C<sub>10</sub> aryl, C<sub>7</sub>-C<sub>19</sub> arylalkyl or C<sub>1</sub>-C<sub>19</sub> acyl group or acyl group having a C<sub>4</sub>-C<sub>19</sub> aromatic ring, provided that the substituent when said groups are substituted is a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>16</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; or R<sub>11</sub> stands for a group represented by the formula: <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ-A-X-B<br/><br/><ul id="ul0003" list-style="none" compact="compact"><li>wherein A stands for a C<sub>1</sub>-C<sub>12</sub> alkylene chain; X stands for an oxygen atom, a sulfur atom, or a group represented by the formula:<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="17" he="15" img-content="chem" img-format="tif"/></chemistry><ul id="ul0004" list-style="none" compact="compact"><li>wherein R<sub>12</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>-alkyl or acyl group or may combine with B to form a cyclic amine, provided that, when a cyclic amine is formed, an oxygen atom, a sulfur atom, a nitrogen atom or a nitrogen atom substituted with a C<sub>1</sub>-C<sub>6</sub>-alkyl or arylalkyl group may be contained as a constituent member of the ring; and</li></ul> B stands for a substituted or unsubstituted alkyl, aryl or arylalkyl group, provided that the substituent when said groups are substituted is a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>12</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>20</sub> dialkylamino group; and</li></ul><!-- EPO <DP n="8"> --></li><li>(iii) a substituted or unsubstituted aryl group or a group represented by the formula:<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="38" he="35" img-content="chem" img-format="tif"/></chemistry> wherein any one of P<sub>b</sub>, Q<sub>b</sub>, R<sub>b</sub> and S<sub>b</sub> represents a bond with the remaining three substituents independently standing for a group represented by the formula -R<sub>3</sub>, provided that, when the aryl group is substituted, the substituent is present at the o-, m- or p-position and a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>16</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and the alkyl portion of said groups may be interrupted by: -O-, -S-,<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="84" he="15" img-content="chem" img-format="tif"/></chemistry><ul id="ul0005" list-style="none" compact="compact"><li>wherein R<sub>13</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>-alkyl, acyl or arylalkyl group, <br/>arylene or arylenoxy, or 1 to 3 hydrogen atoms on the carbon atom may be substituted with an aryl or aryloxy group, a halogen atom or a cyano group, or the aryl portion as the substituent may be substituted with a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, or a lower alkyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group;</li><li>R<sub>2</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>8</sub> alkyl group;<!-- EPO <DP n="9"> --></li><li>each R<sub>3</sub> independently stands for a hydrogen atom, a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and the alkyl portion of said groups may be interrupted by: -O-, -S-,<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="83" he="14" img-content="chem" img-format="tif"/></chemistry></li><li>wherein R<sub>13</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>- alkyl, acyl or arylalkyl group,<br/>arylene or arylenoxy, or 1 to 3 hydrogen atoms on the carbon atom may be substituted with an aryl or aryloxy group, a halogen atom or a cyano group, or the aryl portion as the substituent may be substituted with a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and</li><li>Z stands for a linking group which combines with an O atom, a carbon atom of the benzene ring, to which the O atom is bonded, and a carbon atom adjacent to said carbon atom to form a five-membered ring and is represented by the formula:<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="76" he="22" img-content="chem" img-format="tif"/></chemistry></li><li>wherein R<sub>4</sub> stands for a hydrogen atom, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkenyl or alkynyl group, or a substituted or unsubstituted aryl group, provided that the substituent when the aryl group is substituted is a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl<!-- EPO <DP n="10"> --> or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and</li><li>R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> each independently stand for a hydrogen atom or a C<sub>1</sub>-C<sub>20</sub> alkyl group, or R<sub>5</sub> and R<sub>6</sub> or R<sub>7</sub> and R<sub>8</sub> combine with a carbon atom bonded thereto to form a C<sub>5</sub>-C<sub>7</sub> carbon ring; and n is 0 or 1.</li></ul></li></ul></li></ul></p><p id="p0013" num="0013">Further, the present invention provides a novel benzoxa condensed ring compound represented by the following formula (I<sub>a</sub>) or its pharmaceutically acceptable salt which constitutes a preferred embodiment of the above-described pharmaceutical composition:<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="78" he="36" img-content="chem" img-format="tif"/></chemistry> wherein P<sub>a</sub>, Q<sub>a</sub> and R<sub>a</sub> each independently stand for a hydrogen atom, a halogen atom, or an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and the alkyl portion of said groups may be interrupted by: -O-, -S-,<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="81" he="13" img-content="chem" img-format="tif"/></chemistry><ul id="ul0006" list-style="none" compact="compact"><li>wherein R<sub>13</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>-alkyl, acyl or arylalkyl group,<br/>arylene or arylenoxy, or 1 to 3 hydrogen atoms on the carbon atom may be substituted with an aryl or aryloxy group, a halogen atom or a cyano group, and the aryl portion as the substituent may be substituted with a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group, provided that R<sub>a</sub> stands for a<!-- EPO <DP n="11"> --> group other than the hydrogen atom among the groups described above in connection with the definition of Ra; and</li><li>R<sub>1</sub>, R<sub>2</sub>, Z and n are as defined above;<!-- EPO <DP n="12"> --></li><li>wherein the compound 2,3-dihydro-2,2-dimethyl-7-acetoacetamido benzofuran and the dihydrobenzofuran compound wherein R<sub>a</sub>, Q<sub>a</sub>, P<sub>a</sub>, R<sup>7</sup> and R<sup>8</sup> are hydrogen atoms, Z is -CHR<sup>5</sup>R<sup>6</sup>-CHR<sup>7</sup>R<sup>8</sup> with R<sup>5</sup> and R<sup>6</sup> being a methyl group, n is 0 and R<sup>1</sup> is an orthomethylphenyl group are excluded.</li></ul></p><p id="p0014" num="0014">These compounds are disclosed in DE 19 31 213 as a intermediate for the preparation of azo compounds and in JP-A-61 280 460 as a derivative having fungicidal activity.<!-- EPO <DP n="13"> --></p><p id="p0015" num="0015">Further, the present invention provides the following processes for producing compounds represented by the formula (I), that is,<ul id="ul0007" list-style="none" compact="compact"><li>(A) a process for producing a compound represented by the formula (I) wherein n is 1, and its pharmaceutically acceptable salt, comprising reacting an isocyanate represented by the following formula (II):<chemistry id="chem0012" num="0012"><img id="ib0012" file="imgb0012.tif" wi="77" he="33" img-content="chem" img-format="tif"/></chemistry><ul id="ul0008" list-style="none" compact="compact"><li>wherein m is an integer of 0 to 3; and</li><li>R<sub>3</sub> and Z are as defined above, with an isocyanate represented by the following formula (III):<chemistry id="chem0013" num="0013"><img id="ib0013" file="imgb0013.tif" wi="72" he="18" img-content="chem" img-format="tif"/></chemistry></li><li>wherein R<sub>1</sub> and R<sub>2</sub> are as defined above, and optionally converting the reaction product to a salt;</li></ul></li><li>(B) a process for producing a compound represented by the formula (I) wherein n is 1, and its pharmaceutically acceptable salt, comprising reacting an amine represented by the following formula (IV):<chemistry id="chem0014" num="0014"><img id="ib0014" file="imgb0014.tif" wi="74" he="33" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="14"> --><ul id="ul0009" list-style="none" compact="compact"><li>wherein m, R<sub>3</sub> and Z are as defined above, with an isocyanate represented by the following formula (V): <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒO=C=N-R<sub>1</sub>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(V)<br/><br/></li><li>wherein R<sub>1</sub> is as defined above, and optionally converting the reaction product to a salt; and</li></ul></li><li>(C) a process for producing a compound represented by the above-mentioned formula (I) wherein n is 0, and its pharmaceutically acceptable salt, comprising reacting an amine represented by the formula (IV) with a carboxylic acid represented by the following formula (VI) or its reactive derivative: <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒR<sub>1</sub>COOHâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(VI)<br/><br/><ul id="ul0010" list-style="none" compact="compact"><li>wherein R<sub>1</sub> is as defined above, and optionally converting the reaction product to a salt.</li></ul></li></ul></p><p id="p0016" num="0016">Other objects and advantage of the present invention will be apparent from the following description.</p><heading id="h0004">BEST MODE FOR CARRYING OUT THE INVENTION</heading><p id="p0017" num="0017">In accordance with to the present invention, there is provided a pharmaceutical composition comprising a compound, which partially includes a known compound, for use in the treatment of diseases developed by the action of ACAT, which compounds are unknown to have an ACAT inhibitory activity and to be useful for treating the diseases. In the present invention, the term "treatment" is used in such a concept that the compound represented by the formula (I) is used for any of therapeutic and preventive purposes.</p><p id="p0018" num="0018">Furthermore, in accordance with the present invention, there is provided a novel compound which can be used particularly advantageously for the treatment of the above-mentioned diseases.</p><p id="p0019" num="0019">In the description in connection with the compounds and derivatives in the present specification, the term "lower" is used in such meaning that, in groups to which<!-- EPO <DP n="15"> --> the term is affixed, for example, alkyl, alkenyl, alkynyl, alkoxy, acylamino, mono- or di-alkylamino, acyl and acyloxy groups and the alkyl, alkenyl or alkynyl portion of arylalkyl groups may take any of chain (straight-chain or branched) and cyclic forms having a 1 to 6 carbon atoms, unless otherwise specified. Accordingly, specific examples of the lower alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl, hexyl, cyclopropyl, cyclohexyl and cyclopropylmethyl.</p><p id="p0020" num="0020">Also when the above-described groups have a larger number of carbon atoms, they are used in such meaning that they may take any of chain (straight-chain or branched) and cyclic forms, unless otherwise specified.</p><p id="p0021" num="0021">The expression "the alkyl portion is interrupted by: -O-, -S-,<chemistry id="chem0015" num="0015"><img id="ib0015" file="imgb0015.tif" wi="18" he="15" img-content="chem" img-format="tif"/></chemistry> or the like" is intended to mean that a suitable carbon-carbon bond of the alkyl chain may take a bonding form, such as carbon-O-carbon.</p><p id="p0022" num="0022">In the compounds of the formula (I) used for attaining the object of the present invention, Z in the formula combines with an oxygen atom bonded to the benzene ring, a carbon atom of the benzene ring, to which the oxygen atom is bonded, and a carbon atom adjacent to said carbon atom to form a five-membered ring, and the compounds of the formula (I) are roughly classified into groups of compounds, that is, benzoxazole derivatives (i.e., Z being a linking group represented by the formula:<chemistry id="chem0016" num="0016"><img id="ib0016" file="imgb0016.tif" wi="31" he="15" img-content="chem" img-format="tif"/></chemistry> and 2,3-dihydrobenzofuran derivatives (i.e., Z being a linking group represented by the formula:<!-- EPO <DP n="16"> --><chemistry id="chem0017" num="0017"><img id="ib0017" file="imgb0017.tif" wi="44" he="18" img-content="chem" img-format="tif"/></chemistry> and further classified into amide derivatives wherein each n is 0, and urea derivatives wherein n is 1.</p><p id="p0023" num="0023">More specifically, the benzoxa condensed ring compounds belonging to the first group of compounds according to the present invention are benzoxazole derivatives represented by the following formula (I-1):<chemistry id="chem0018" num="0018"><img id="ib0018" file="imgb0018.tif" wi="63" he="39" img-content="chem" img-format="tif"/></chemistry> wherein P, Q, R, S and R<sub>4</sub> are as defined above, and the second group of compounds are 2,3-dihydrobenzofuran derivatives represented by the following formula (I-2):<chemistry id="chem0019" num="0019"><img id="ib0019" file="imgb0019.tif" wi="75" he="34" img-content="chem" img-format="tif"/></chemistry> wherein P, Q, R, S, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are as defined above.</p><p id="p0024" num="0024">In the formulae (I-1) and (I-2), the groups Q to S are of equal significance from the viewpoint of the object of the present invention, and any one of these groups stands for a group represented by the formula:<chemistry id="chem0020" num="0020"><img id="ib0020" file="imgb0020.tif" wi="39" he="15" img-content="chem" img-format="tif"/></chemistry> with the remaining substituents each independently standing for a group R<sub>3</sub>. Therefore, the group<!-- EPO <DP n="17"> --> represented by the above-described formula may be bonded to any of the 4- to 7-positions (P, Q, R, S) in the benzene ring of the compounds represented by the formulae (I-1) and (I-2). However, compounds wherein the group represented by the above-mentioned formula is bonded to the 7-position (S) is particularly preferred from the viewpoint of the intended drug efficacy and are important also because most of them are novel compounds.</p><p id="p0025" num="0025">In the formulae (I-1) and (I-2), the R<sub>1</sub> stands for (i) an unsubstituted cycloalkyl or cycloalkenyl group, or a cycloalkyl or cycloalkenyl group substituted at its position other than the 1-position; a group represented by the formula:<chemistry id="chem0021" num="0021"><img id="ib0021" file="imgb0021.tif" wi="23" he="22" img-content="chem" img-format="tif"/></chemistry> a substituted or unsubstituted aryl group or a group represented by the formula:<chemistry id="chem0022" num="0022"><img id="ib0022" file="imgb0022.tif" wi="87" he="39" img-content="chem" img-format="tif"/></chemistry> wherein the bonding group substitutes for the group:<chemistry id="chem0023" num="0023"><img id="ib0023" file="imgb0023.tif" wi="38" he="15" img-content="chem" img-format="tif"/></chemistry> with the remaining groups being as defined above.</p><p id="p0026" num="0026">In the R<sub>1</sub>, favorable specific examples of the unsubstituted cycloalkyl or cycloalkenyl group or cycloalkyl or cycloalkenyl group substituted at its position other than the 1-position include cyclopentyl,<!-- EPO <DP n="18"> --> cyclohexyl, cycloheptyl, 1-cyclohexen-1-yl, 4-hexylcyclohexyl and 4-decyloxycyclohexyl.</p><p id="p0027" num="0027">When the R<sub>1</sub> stands for a group represented by the formula:<chemistry id="chem0024" num="0024"><img id="ib0024" file="imgb0024.tif" wi="25" he="21" img-content="chem" img-format="tif"/></chemistry> the R<sub>9</sub> and R<sub>10</sub> each independently stand for a hydrogen atom or a lower alkyl group, or combine with each other to form a C<sub>3</sub>-C<sub>7</sub> carbon ring.</p><p id="p0028" num="0028">Examples of the lower alkyl group include those described above, and when the R<sub>9</sub> and R<sub>10</sub> combine with each other to form a C<sub>3</sub>-C<sub>7</sub> carbon ring, examples of the R<sub>1</sub> include a group represented by the following formula:<chemistry id="chem0025" num="0025"><img id="ib0025" file="imgb0025.tif" wi="46" he="18" img-content="chem" img-format="tif"/></chemistry></p><p id="p0029" num="0029">In the R<sub>11</sub>, favorable examples of the substituted or unsubstituted C<sub>1</sub>-C<sub>19</sub> alkyl include, besides the above-described lower alkyls, isohexyl, octyl, decyl, undecyl, dodecyl, tridecyl, pentadecyl, hexadecyl, heptadecyl, nonadecyl, icosyl, 1,1-dimethylhepthyl, 1,1-dimethylundecyl, 1,1,12,12-tetramethyltridecyl, 1-methyltridecyl, 1-decylcyclohexyl, 1-decylcyclopentyl, 1-dodecylcyclopropyl, 1-cyclohexyl-1-methylethyl, 1-ethyloctyl and 10,10-dimethylundecyl.</p><p id="p0030" num="0030">In the R<sub>11</sub>, examples of the C<sub>2</sub>-C<sub>19</sub> alkenyl include vinyl, allyl, butenyl, hexenyl, 8-tridecenyl, 8-heptadecenyl, 9-octadecenyl, 8,11-heptadecanedienyl, 1,1-dimethyl-8-nonenyl, cyclohexenylmethyl, 2-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 3-cyclohexen-1-yl and 2,5-cyclohexadien-1-yl.</p><p id="p0031" num="0031">Specific examples of the R<sub>11</sub> when the R<sub>11</sub> stands for a C<sub>6</sub>-C<sub>10</sub> aryl group include phenyl, naphthyl, pyridyl<!-- EPO <DP n="19"> --> and thienyl. Accordingly, in this case, specific examples of the R1 include benzyl, 1-phenylcyclopentyl, 1-phenylethyl and 1-methyl-1-(2-pyridyl)ethyl. Favorable specific examples of the R<sub>1</sub> when the R<sub>11</sub> stands for a C<sub>7</sub>-C<sub>19</sub> aryl alkyl include 2-phenylethyl, 8-phenyloctyl, 1,1-dimethyl-11-phenylundecyl, 1-benzylcyclopentyl, (1-phenylcyclopentyl)methyl, 1,1-dimethyl-4-(1-methyl-1,2,3,4-tetrahydroquinolin-6-yl)butyl, 1,1-dimethyl-7-pyridylheptyl, 2,2-diphenylethyl, 1,1-dimethyl-6-phenylhexyl, 1,1-dimethyl-7-phenylheptyl, 1,1-dimethyl-5-phenylpentyl and 1,1-dimethyl-4-phenylbutyl.</p><p id="p0032" num="0032">Favorable examples of the R<sub>11</sub> when the R<sub>11</sub> stands for a C<sub>1</sub>-C<sub>19</sub> chain acyl group, C<sub>4</sub>-C<sub>19</sub> cyclic hydrocarbon acyl group or a acyl group having a aromatic ring include groups wherein a carbonyl group is bonded to a favorable group of the above-described alkyl, cyclic alkyl, chain alkenyl, cyclic alkenyl, aryl and arylalkyl groups.</p><p id="p0033" num="0033">The R<sub>11</sub> embraces also groups wherein one or more hydrogen atoms, preferably 1 to 3 hydrogen atoms, on carbon(s) in the chain or on carbons constituting the ring are substituted with halogen atoms (for example, fluorine, chlorine, bromine and iodine, preferably fluorine and chlorine), amino, nitro, cyano, carboxyl and hydroxyl groups and further C<sub>1</sub>-C<sub>16</sub> alkyl (as described above), alkoxy (for example, lower alkoxy, such as methoxy, ethoxy and propoxy, pentadecanoxy, decyloxy and octyloxy), acylamino (for example, lower acylamino, such as acetamide, propionylamino, butyrylamino and heptanoylamino, and lauroylamino and palmitoylamino), mono- or di-alkylamino (for example, methylamino, ethylamino, dimethylamino, diethylamino and decanylamino), alkyloxycarbonyl (for example, groups wherein a carbonyl group is bonded to the above-described alkoxy, such as methoxycarbonyl and ethoxycarbonyl), acyl (formyl, acetyl, propionyl, isovaleryl, pivaloyl, myristoyl, palmitoyl, etc.), and acyloxy (acetyloxy, pivaloyloxy, myristoyloxy, etc.). Specific examples of<!-- EPO <DP n="20"> --> the R<sub>1</sub> having R<sub>11</sub> substituted with the above-described groups include 1,1-dimethyl-11-chloroundecyl, 1,1-dimethyl-7-bromoheptyl, 9-ethoxycarbonylnonyl, 1,1-dimethyl-11-hydroxyundecyl, 1,1-dimethyl-10-carboxyldecyl, 1-(4-dimethylaminophenyl)cyclopentyl, 1-methyl-1-(4-chlorophenyl)ethyl, 1-methyl-1-(4-octyloxyphenyl)ethyl, [1-(4-chloro)phenylcyclopentyl]methyl, [1-(4-dimethylamino)phenylcyclopentyl]methyl, 1,1-dimethyl-4-(4-isobutyl)phenylbutyl, 1,1-dimethyl-4-(4-hexyloxy)phenylbutyl, 1,1-dimethyl-2-(4-decyloxy)phenylethyl, 1,1-dimethyl-2-(4-decylamino)phenylethyl and 1,1-dimethyl-7-(4-chloro)phenylheptyl groups.</p><p id="p0034" num="0034">Alternatively, the R<sub>11</sub> may stand for a group represented by the formula -A-X-B wherein A stands for a C<sub>1</sub>-C<sub>12</sub> alkylene chain; X stands for an oxygen atom, a sulfur atom, or a group represented by the formula:<chemistry id="chem0026" num="0026"><img id="ib0026" file="imgb0026.tif" wi="18" he="14" img-content="chem" img-format="tif"/></chemistry> wherein R<sub>12</sub> stands for a hydrogen atom or a lower alkyl or acyl group or may combine with B to form a cyclic amine, provided that, when a cyclic amine is formed, an oxygen atom, a sulfur atom, a nitrogen atom or a nitrogen atom substituted with a lower alkyl or arylalkyl group may be contained as a constituent member of the ring; and B stands for a substituted or unsubstituted alkyl, aryl or arylalkyl group. The alkylene in the A is a divalent group formed by further eliminating one hydrogen atom from the alkyl group, and examples thereof include those corresponding to the alkyl groups specifically described above. Examples of the lower alkyl and acyl groups in the R<sub>12</sub> include the same groups as those described above in connection with the lower alkyl group and acyl group. Favorable specific examples of the cyclic amine when R<sub>12</sub> combines with B to form a cyclic amine include 1-pyrrolidinyl,<!-- EPO <DP n="21"> --> piperidino, morpholino, thiomorpholino, 4-methyl-1-piperazinyl and 4-benzyl-1-piperazinyl. The alkyl group and axylalkyl group in the B have the same meaning as the alkyl group and arylalkyl group defined above, and preferred examples thereof are also the same as those of the alkyl group and arylalkyl group described above.</p><p id="p0035" num="0035">Also when the R<sub>11</sub> stands for a group represented by the formula -A-X-B, each group may be substituted in the same manner as that described above in connection with each group of R<sub>11</sub>. Favolable specific examples of the R<sub>1</sub> having R<sub>11</sub> substituted with the above-described groups include 6-isobutoxyhexyl, 6-p-chlorophenoxyhexyl, 5-p-dimechylaminophenoxypentyl, 5-isohexyloxy-1,1-dimethylpentyl, 7-isohexyloxy-1,1-dimethylheptyl, 7-isobutoxy-1,1-dimethylheptyl, 7-neopentyloxy-1,1-dimethylheptyl, 5-p-chlorophenoxy-1,1-dimethylpentyl, 6-p-chlorophenoxy-1,1-dimethylhexyl, 7-p-chlorophenoxy-1,1-dimethylheptyl, 1,1-dimethyl-7-p-tolyloxyheptyl, 5-(p-tert-butylphenoxypentyl, 1,1-dimethyl-6-p-dimethylaminophenoxyhexyl, 1,1-dimethyl-7-p-dimethylaminophenoxyheptyl, 7-isopropylamino-1,1-dimethylheptyl, 7-benzylamino-1,1-dimethylheptyl, 7-(N-benzyl-N-methylamino)-1,1-dimethylheptyl, 7-(N-p-chlorobenzyl-N-methylamino)-1,1-dimethylheptyl, 7-(N-p-chlorophenyl-N-methylamino)-1,1-dimethylheptyl, 1,1-dimethyl-7-piperidinoheptyl, 1,1-dimethyl-7-(4-methyl-1-piperazinyl)heptyl, 7-(4-benzyl-1-piperazinyl)-1,1-dimethylheptyl, 5-(4-benzyl-1-piperazinyl)-1,1-dimethylpentyl, 6-(p-chlorophenylthio)-1,1-dimethylhexyl, 1,1-dimethyl-6-p-nitrophenoxyhexyl, 1,1-dimethyl-6-p-fluorophenoxyhexyl, 1,1-dimethyl-6-p-aminophenoxyhexyl, 1,1-dimethyl-6-(2,4-dichloro)phenoxyhexyl, 1,1-dimethyl-7-p-fluorophenoxyheptyl, 1,1-dimethyl-6-p-hexyloxyphenyloxyhexyl, 1,1-dimethyl-7-morpholinoheptyl and 1,1-dimethyl-6-cyclohexylethylhexyl.<!-- EPO <DP n="22"> --></p><p id="p0036" num="0036">When the R<sub>1</sub> stands for a substituted or unsubstituted aryl group, the aryl group has the same meaning as the aryl group defined above in connection with the R<sub>11</sub>, except that the aryl group is bonded to the carbon atom of the carbonyl group or the nitrogen atom of the group represented by the formula<chemistry id="chem0027" num="0027"><img id="ib0027" file="imgb0027.tif" wi="18" he="13" img-content="chem" img-format="tif"/></chemistry> of an amide or urea portion of the formula (I-1) or (I-2). The substituted aryl group has a suitable substituent at the o-, m- or p-position relative to the site of bonding to the amide or urea (ureylene) portion. Preferred specific examples of these substituents include the same groups as those described above in connection with the R<sub>11</sub>. When these substituents have a particularly long chain alkyl portion, the alkyl portion may be interrupted by: -O-, -S-,<chemistry id="chem0028" num="0028"><img id="ib0028" file="imgb0028.tif" wi="88" he="15" img-content="chem" img-format="tif"/></chemistry> (wherein R<sub>13</sub> stands for a hydrogen atom or a lower alkyl, acyl or arylalkyl group), arylene or arylenoxy. The term "arylene" used herein is intended to mean a divalent group formed by eliminating one hydrogen atom from an aryl group, and specific examples thereof include those formed by eliminating one hydrogen atom from the aryl group specifically described above. The alkyl portion and aryl (or arylene) portion of these substituents as well may be substituted with one or more substituents, preferably 1 to 3 substituents, as described above connection with the R<sub>11</sub>. Among them, particularly preferred examples include p-fluorophenyl, p-decylphenyl, p-methoxyphenyl, p-isohexyloxyphenyl, p-decyloxyphenyl, p-butyrylaminophenyl, p-(N-butyl-N-methylamino, phenyl, p-valeryloxyphenyl, m-heptanoylphenyl, 4-[6-(4-chlorophenyloxy)hexyloxy]phenyl, 4-decylaminophenyl, 4-decanamidephenyl, m-decyloxyphenyl, 4-[6-(4-dimethylaminophenyloxy)-hexyloxy]phenyl, 3-chloro-4-decyloxyphenyl,<!-- EPO <DP n="23"> --> 4-[6-(N-methyl-N-benzylamino)hexyloxy]phenyl and 3-dimethylamino-4-decyloxyphenyl groups.</p><p id="p0037" num="0037">Further examples of the R<sub>1</sub> include a group represented by the formula:<chemistry id="chem0029" num="0029"><img id="ib0029" file="imgb0029.tif" wi="37" he="36" img-content="chem" img-format="tif"/></chemistry> wherein P<sub>b</sub> to S<sub>b</sub> and Z have the same meaning the corresponding P<sub>a</sub> to S<sub>b</sub> and Z described above, except that one of the P<sub>b</sub> to S<sub>b</sub> stands for a linking group instead of the group represented by the formula:<chemistry id="chem0030" num="0030"><img id="ib0030" file="imgb0030.tif" wi="45" he="20" img-content="chem" img-format="tif"/></chemistry></p><p id="p0038" num="0038">When the R<sub>1</sub> has the above-described group, examples of the compound represented by the formula (I) include compounds comprising combination of the following moieties.<chemistry id="chem0031" num="0031"><img id="ib0031" file="imgb0031.tif" wi="117" he="39" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="24"> --><chemistry id="chem0032" num="0032"><img id="ib0032" file="imgb0032.tif" wi="121" he="52" img-content="chem" img-format="tif"/></chemistry></p><p id="p0039" num="0039">Therefore, the compound represented by the formula (I) include also a compound having such a structure that the above-described individual moieties are linked together through the divalent linking group of the ureylene group or amide group indicated at the center of the above-described structural formulae and the linking group of the left and right condensed ring moieties.</p><p id="p0040" num="0040">The R<sub>2</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>8</sub> alkyl group. Favorable examples of the alkyl group include, besides the above-described specific examples of the lower alkyl group, heptane, octane, cyclohexylmethyl and cyclohexylethyl.</p><p id="p0041" num="0041">When P, Q, R and S in the formulae (I-1) and (I-2) stand for a group other than the group represented by the formula:<chemistry id="chem0033" num="0033"><img id="ib0033" file="imgb0033.tif" wi="46" he="17" img-content="chem" img-format="tif"/></chemistry> the remaining three groups each independently stand for a hydrogen atom, a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and the alkyl portion of these groups may be interrupted by: -O-, -S-,<chemistry id="chem0034" num="0034"><img id="ib0034" file="imgb0034.tif" wi="88" he="17" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="25"> --> wherein R<sub>13</sub> stands for a hydrogen atom or a lower alkyl, acyl or arylalkyl group,<br/>â€ƒâ€ƒâ€ƒarylene or arylenoxy, or 1 to 3 hydrogen atoms on the carbon atom may be substituted with an aryl or aryloxy group, a halogen atom or a cyano group, or the aryl portion as the substituent may be substituted with a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group.</p><p id="p0042" num="0042">The meaning and specific examples of these groups are the same as the meaning and specific examples of the corresponding groups described above in connection with the R<sub>1</sub>. More preferably, when any three of the groups P, Q, R and S stand for a group other than the group represented by the formula:<chemistry id="chem0035" num="0035"><img id="ib0035" file="imgb0035.tif" wi="39" he="16" img-content="chem" img-format="tif"/></chemistry> although these three groups may be the same or different, if the R<sub>1</sub> stands for a group having a large number of constituent atoms (number of carbon atoms: 10 to 20), these groups preferably comprise a group having a small number of constituent atoms, for example, a hydrogen atom, a halogen atom (particularly, fluorine, chlorine or bromine), an amino, nitro, cyano, carboxy or hydroxyl group, a lower alkyl group (particularly, methyl, ethyl, propyl or isopropyl), a lower alkyloxy group (particularly, methoxy, ethoxy or propoxy), a lower acylamino group (particularly, acetamide or propionylamide), a mono- or di-lower alkylamino group (particularly, methylamino, ethylamino or dimethylamino), a lower alkyloxycarbonyl group (particularly, methoxycarbonyl or ethoxycarbonyl), a lower acyl group (particularly, acetyl, propionyl or butyryl), or a lower<!-- EPO <DP n="26"> --> acyloxy group (particularly, acetyloxy or propionyloxy). On the other hand, when the R<sub>1</sub> is a group having a small number of constituent atoms (number of carbon atoms: 6 or less), it is preferred that at least one group among the P, Q, R and S except for the group represented by the formula:<chemistry id="chem0036" num="0036"><img id="ib0036" file="imgb0036.tif" wi="37" he="13" img-content="chem" img-format="tif"/></chemistry> be a group having a large number of constituent atoms. Specific examples of the group having a large number of constituent atoms include decyloxy, decanoylamide, dodecyloxy, 4-decyloxybenzoylamide, decyl, decylamino, 2,2-dimethyldodecanamido, 6-(4-chlorophenyl)hexyloxy, 4-(6-phenyloxy)hexyloxybenzoyl and 6-(N-methyl-N-4-chlorobenzyl)aminohexyloxy.</p><p id="p0043" num="0043">As described above, the compound represented by the formula (I) wherein a group represented by the formula:<chemistry id="chem0037" num="0037"><img id="ib0037" file="imgb0037.tif" wi="39" he="15" img-content="chem" img-format="tif"/></chemistry> is bonded to the 7-position (S) is particularly preferred from the viewpoint of drug efficacy. In this case, it is still preferred for the 6-position (R) to be a group other than a hydrogen atom from the viewpoint of the drug efficacy. In particular, when the R<sub>1</sub> contained in the group bonded to the 7-position stands for a group having a large number of constituent atoms, it is preferred for the substituent at the 6-position to be a lower alkyl, a lower alkoxy or a halogen.</p><p id="p0044" num="0044">When the R<sub>4</sub> in the formula (I-1) stands for a C<sub>1</sub>-C<sub>20</sub> alkyl group, specific examples of such an alkyl group are the same as those of the alkyl group described above in connection with the definition of P, Q, R and S. When the R<sub>4</sub> stands for an alkenyl group, the alkenyl group is preferably a lower alkenyl group and examples thereof include vinyl, propenyl and cyclohexenyl. When the R<sub>4</sub><!-- EPO <DP n="27"> --> stands for an alkyl group, the alkynyl group is preferably a lower alkynyl group and examples thereof include ethynyl and propynyl. When the R<sub>4</sub> stands for a substituted or unsubstituted aryl group, examples of the substituent are the same as those of the substituent at the site of the aryl in the definition of the R<sub>11</sub> and preferred examples thereof include a halogen atom, a lower alkyl, a lower alkoxy, a lower acyl, a lower alkylamino or a lower alkyloxycarbonyl. When the R<sub>4</sub> stands for the above-described aryl group, favorable specific examples of the aryl group include phenyl, pyridyl, thienyl, 4-methylphenyl, 4-chlorophenyl, 4-methoxyphenyl, 4-decanoxyphenyl and 3-nitrophenyl.</p><p id="p0045" num="0045">When the R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> in the formula (I-2) stand for a C<sub>1</sub>-C<sub>20</sub> alkyl group, specific examples of such an alkyl group are the same as those of the alkyl group described in connection with the R<sub>4</sub>. Among them, a lower alkyl, such as methyl, ethyl, propyl and isopropyl, are particularly preferred. These four groups may be the same or different. It is preferred that the R<sub>5</sub> and R<sub>6</sub> stand for a hydrogen atom with the R<sub>7</sub> and R<sub>8</sub> standing for a lower alkyl group. When R<sub>5</sub> and R<sub>6</sub> or R<sub>7</sub> and R<sub>8</sub> combine with a carbon atom bonded thereto to form a C<sub>5</sub>-C<sub>7</sub> carbon ring, favorable specific examples of such a carbon ring include C<sub>5</sub>-C<sub>7</sub> carbon rings described above in connection with the R<sub>11</sub>.</p><p id="p0046" num="0046">Compounds represented by the formula (Ia), more specifically, benzoxazole compounds represented by the following formula (Ia-1):<chemistry id="chem0038" num="0038"><img id="ib0038" file="imgb0038.tif" wi="84" he="42" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="28"> --> wherein P<sub>a</sub>, Q<sub>a</sub>, R<sub>a</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> and n are as defined above, provided that R<sub>a</sub> stands for a group other than a hydrogen atom, and 2,3-dihydrobenzofuran compounds represented by the following formula (Ia-2):<chemistry id="chem0039" num="0039"><img id="ib0039" file="imgb0039.tif" wi="87" he="40" img-content="chem" img-format="tif"/></chemistry> wherein P<sub>a</sub>, Q<sub>a</sub>, R<sub>a</sub>, R<sub>1</sub>, R<sub>2</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub> and n are as defined above, provided that R<sub>a</sub> stands for a group other than a hydrogen atom, are novel compounds not described in any conventional technical literature. Further, when the structural formula representing the compound of the present invention has an asymmetric carbon, the compound of the present invention includes all possible optical isomers.</p><p id="p0047" num="0047">Examples of compounds comprising specific combinations of groups will now be described for the purpose of more specifically describing the compounds and novel compounds used in the pharmaceutical composition of the present invention. In the following synoptical tables, code G is used according to need to represent the formula:<chemistry id="chem0040" num="0040"><img id="ib0040" file="imgb0040.tif" wi="44" he="19" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="29"> --><tables id="tabl0001" num="0001"><img id="ib0041" file="imgb0041.tif" wi="113" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="30"> --><tables id="tabl0002" num="0002"><img id="ib0042" file="imgb0042.tif" wi="128" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="31"> --><tables id="tabl0003" num="0003"><img id="ib0043" file="imgb0043.tif" wi="73" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="32"> --><tables id="tabl0004" num="0004"><img id="ib0044" file="imgb0044.tif" wi="105" he="210" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="33"> --><tables id="tabl0005" num="0005"><img id="ib0045" file="imgb0045.tif" wi="121" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="34"> --><tables id="tabl0006" num="0006"><img id="ib0046" file="imgb0046.tif" wi="95" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="35"> --><tables id="tabl0007" num="0007"><img id="ib0047" file="imgb0047.tif" wi="127" he="213" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="36"> --><tables id="tabl0008" num="0008"><img id="ib0048" file="imgb0048.tif" wi="126" he="204" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="37"> --><tables id="tabl0009" num="0009"><img id="ib0049" file="imgb0049.tif" wi="113" he="209" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="38"> --><tables id="tabl0010" num="0010"><img id="ib0050" file="imgb0050.tif" wi="117" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="39"> --><tables id="tabl0011" num="0011"><img id="ib0051" file="imgb0051.tif" wi="73" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="40"> --><tables id="tabl0012" num="0012"><img id="ib0052" file="imgb0052.tif" wi="116" he="215" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="41"> --><tables id="tabl0013" num="0013"><img id="ib0053" file="imgb0053.tif" wi="105" he="211" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="42"> --><tables id="tabl0014" num="0014"><img id="ib0054" file="imgb0054.tif" wi="90" he="215" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="43"> --><tables id="tabl0015" num="0015"><img id="ib0055" file="imgb0055.tif" wi="128" he="199" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="44"> --><tables id="tabl0016" num="0016"><img id="ib0056" file="imgb0056.tif" wi="128" he="212" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="45"> --><tables id="tabl0017" num="0017"><img id="ib0057" file="imgb0057.tif" wi="129" he="204" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="46"> --><tables id="tabl0018" num="0018"><img id="ib0058" file="imgb0058.tif" wi="123" he="201" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="47"> --><tables id="tabl0019" num="0019"><img id="ib0059" file="imgb0059.tif" wi="62" he="201" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="48"> --><tables id="tabl0020" num="0020"><img id="ib0060" file="imgb0060.tif" wi="128" he="214" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="49"> --><tables id="tabl0021" num="0021"><img id="ib0061" file="imgb0061.tif" wi="129" he="205" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="50"> --><tables id="tabl0022" num="0022"><img id="ib0062" file="imgb0062.tif" wi="131" he="202" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="51"> --><tables id="tabl0023" num="0023"><img id="ib0063" file="imgb0063.tif" wi="130" he="213" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="52"> --><tables id="tabl0024" num="0024"><img id="ib0064" file="imgb0064.tif" wi="131" he="211" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="53"> --><tables id="tabl0025" num="0025"><img id="ib0065" file="imgb0065.tif" wi="129" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="54"> --><tables id="tabl0026" num="0026"><img id="ib0066" file="imgb0066.tif" wi="130" he="214" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="55"> --><tables id="tabl0027" num="0027"><img id="ib0067" file="imgb0067.tif" wi="124" he="213" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="56"> --><tables id="tabl0028" num="0028"><img id="ib0068" file="imgb0068.tif" wi="130" he="204" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="57"> --><tables id="tabl0029" num="0029"><img id="ib0069" file="imgb0069.tif" wi="129" he="201" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="58"> --><tables id="tabl0030" num="0030"><img id="ib0070" file="imgb0070.tif" wi="129" he="214" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="59"> --><tables id="tabl0031" num="0031"><img id="ib0071" file="imgb0071.tif" wi="132" he="204" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="60"> --><tables id="tabl0032" num="0032"><img id="ib0072" file="imgb0072.tif" wi="129" he="203" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="61"> --><tables id="tabl0033" num="0033"><img id="ib0073" file="imgb0073.tif" wi="129" he="203" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="62"> --></p><p id="p0048" num="0048">The compounds having the above-mentioned formula (I) include some known compounds and novel compounds represented by the formula (Ia). The novel compounds can also be produced according to production processes used in the production of the known compounds. Preferably, they can be produced by a novel production process proposed as one aspect of the present invention.</p><p id="p0049" num="0049">For example, the compounds having the formula (I) can be produced by the following respective reaction schemes.<chemistry id="chem0041" num="0041"><img id="ib0074" file="imgb0074.tif" wi="140" he="144" img-content="chem" img-format="tif"/></chemistry> wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, Z and m are as defined above.</p><p id="p0050" num="0050">The reactions represented by the reaction schemes (i) and (ii) can be practiced by reacting the<!-- EPO <DP n="63"> --> corresponding amine compound represented by the formula (III) or (IV) with an isocyanate compound represented by the formula (II) or (V) in the absence or presence of a solvent.</p><p id="p0051" num="0051">Most of the compounds represented by the formulae (II) to (VI) are known compounds and can be produced by known processes. The novel compounds can be produced according to the processes for producing the known compounds. For example, 2,3-dihydrobenzofuranylamine which is a compound belonging to the compounds represented by the formula (IV) can be produced a process described in Chem. Abst., <u>66</u>, 463196 (1969).</p><p id="p0052" num="0052">In general, with respect to the amount ratio of reactants (starting compounds) used in the reaction, the amount of the amine compound and the amount of the isocyanate compound are preferably set so as to be equivalent to each other. However, the optimal amount ratio varies depending upon the reactants used. A person having ordinary skill in the art can learn the optimal amount ratio through a simple small-scale experiment. In general, the amount of the isocyanate compound can be varied in the range of from 0.2 to 5 equivalents based on one equivalent of the amine compound.</p><p id="p0053" num="0053">The reaction solvent may be any type of solvent so far as it has no adverse effect on the reaction. Examples of the solvent generally used in the reaction include halogenated hydrocarbons, such as dichloromethane and chloroform, aromatic hydrocarbons, such as benzene and toluene, ethers, such as diethyl ether and tetrahydrofuran, esters, such as ethyl acetate, and aprotic polar solvents, such as dimethylformamide and dimethylsulfoxide.</p><p id="p0054" num="0054">With respect to the reaction conditions, the reaction temperature is in the range of from -20 to 150Â°C, preferably in the range of from room temperature to 100Â°C, and the reaction time is usually 72 hrs or less.<!-- EPO <DP n="64"> --></p><p id="p0055" num="0055">After the completion of the reaction, the reaction mixture may be subjected to conventional separation and purification procedure, that is, extraction, recrystallization, chromatography, etc. to isolate an intended benzoxa condensed ring compound represented by the formula (I-b) or (I-c). Further, the product can be converted to a pharmaceutically acceptable salt by a conventional method.</p><p id="p0056" num="0056">The reaction corresponding to the reaction scheme (iii) is a reaction of an amine compound represented by the formula (IV) with a reactive derivative of a carboxylic acid represented by the formula (IV). Among the compounds represented by the formula (I), compounds belonging to the above-mentioned amide derivatives can be efficiently produced by this reaction.</p><p id="p0057" num="0057">This reaction can be practiced according to a known reaction of an amino compound with a carboxylic acid or a reactive derivative of the carboxylic acid. The reactive derivative of a carboxylic acid used in the invention embraces all reactive derivatives of carboxylic acids usually known in the field of organic synthesis including acid anhydrides, acid halides and mixed acid anhydrides of the corresponding carboxylic acids.</p><p id="p0058" num="0058">Accordingly, the above-mentioned reaction can be practiced by reacting the amine compound with 1 to 5 equivalents of the corresponding carboxylic acid chloride or acid anhydride in the presence of a solvent.</p><p id="p0059" num="0059">The reaction temperature is in the range of from -20 to 150Â°C, preferably in the range of from -10 to 100Â°C, and the reaction time is usually 72 hrs or less.</p><p id="p0060" num="0060">Examples of the reaction solvent include halogenated hydrocarbons, such as dichloromethane and chloroform, aromatic hydrocarbons, such as benzene and toluene, ethers, such as diethyl ether and tetrahydrofuran, esters, such as ethyl acetate, and aprotic polar solvents, such as dimethylformamide and dimethylsulfoxide. In this case, 0.1 to 10 equivalents<!-- EPO <DP n="65"> --> of a basic amine compound, for example, triethylamine, pyridine or 4-dimethylaminopyridine, may be added to the reaction system.</p><p id="p0061" num="0061">After the completion of the reaction, the reaction mixture may be subjected to conventional separation and purification procedure, that is, extraction, recrystallization, chromatography, etc. to isolate an intended benzoxa condensed ring compound represented by the formula (I-d).</p><p id="p0062" num="0062">As specifically mentioned above, the compound represented by the formula (I) or the compound represented by the formula (Ia) can bear, in its molecule, an amino group or a carboxyl group. Therefore, if necessary, these compounds can be converted to their acid addition salts or alkali addition salts by a conventional salt forming reaction.</p><p id="p0063" num="0063">For example, with respect to the compound bearing an amino group represented by the formula (I), a salt forming reaction can be practiced by simply mixing the corresponding compound represented by the formula (I) with an inorganic acid or an organic acid in the absence or presence of a suitable solvent. The inorganic acid or organic acid used in the salt forming reaction may be any one so far as it can produce a pharmaceutically acceptable salt upon being reacted with the compound represented by the formula (I). Favorable examples of the inorganic acid or organic acid include mineral acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid and carbonic acid, and organic acids, such as citric acid, malic acid, oxalic acid, tartaric acid, fumaric acid and methanesulfonic acid.</p><p id="p0064" num="0064">The compound represented by the formula (I) and its pharmaceutically acceptable salt provided by the present invention have an ACAT enzyme inhibitory activity and an excellent pharmacological activity for lowering the total cholesterol and LDL levels of the blood, liver and arterial wall, which renders them useful for the<!-- EPO <DP n="66"> --> suppression of the progress or regression of hyperlipidemia and atherosclerosis.</p><p id="p0065" num="0065">The benzoxa condensed ring compound and its pharmaceutically acceptable salt according to the present invention can be blended with a pharmacologically acceptable carrier to provide a pharmaceutical composition. Although the content of the active ingredient in the pharmaceutical composition is not particularly limited, it is usually in the range of from 5 to 70 % by weight.</p><p id="p0066" num="0066">The compound represented by the formula (I) and its pharmaceutically acceptable salt provided by the present invention can be orally administered.</p><p id="p0067" num="0067">Examples of dosage forms of the oral preparation include a tablet, a powder, granules and a capsule.</p><p id="p0068" num="0068">These dosage forms can be shaped according to a conventional method through the use of, for example, an excipient, such as lactose, starch or crystalline cellulose, a binder, such as carboxymethylcellulose, methyl cellulose or polyvinyl pyrrolidone, and a disintegrator, such as sodium alginate, sodium hydrogencarbonate or sodium laurate. The powder and granules as well can be shaped in a similar manner. The capsule can be shaped by filling a capsule, such as gelatin, with a powder or granules. Examples of parenteral preparations include percutaneous preparations, such as a suppository, a patch and an injection.</p><p id="p0069" num="0069">Although the dose of the compound represented by the formula (I) and its pharmaceutically acceptable salt provided by the present invention varies depending upon the severity of disease, age and sex of patient, it is usually about 1 to 500 mg/day/adult.</p><heading id="h0005"><u>EXAMPLES</u></heading><p id="p0070" num="0070">The present invention will now be described in more detail with reference to, but is by no means limited to, the following Examples.<!-- EPO <DP n="67"> --></p><heading id="h0006"><u>Reference Example 1</u></heading><heading id="h0007"><u>Synthesis of 2-amino-6-nitrophenol</u></heading><p id="p0071" num="0071">100 ml of methanol was added to 5.0 g of 2,6-dinitrophenol in a vessel. The inside of the vessel was purged with argon. About 1.5 g of 10 % palladium-carbon was added thereto, the inside of the vessel was purged with argon and then with hydrogen, and the reaction mixture was stirred at room temperature overnight.</p><p id="p0072" num="0072">After the completion of the reaction, the palladium-carbon was removed by filtration with Celite, and the filtrate was concentrated to provide 4.1 g of the title compound, that is, 2-amino-6-nitrophenol.<ul id="ul0011" list-style="none" compact="compact"><li><sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ (ppm):<br/>10.70 (s, 1H, OH), 7.46(dd, J=2.0Hz, 8.2Hz, 1H, ArH), 6.94(dd, J=2.0Hz, 7.7Hz, 1H, ArH), 6.76(dd, J=8.2Hz, 7.7Hz, 1H, ArH), 3.70-4.50(br, 2H, NH<sub>2</sub>)</li></ul></p><heading id="h0008"><u>Reference Example 2</u></heading><heading id="h0009"><u>Preparation of trimethylsilyl polyphosphate solution (PPSE)</u></heading><p id="p0073" num="0073">50 ml of 1,2-dichlorobenzene was added to 10 g of phosphorus pentaoxide, and 25 ml of hexamethyldisiloxane was added to the mixture with stirring. The mixture was allowed to react under reflux for 10 min and cooled to room temperature to prepare the title solution.</p><heading id="h0010"><u>Reference Example 3</u></heading><heading id="h0011"><u>Synthesis of 7-nitro-2-(3-pyridyl)benzoxazole</u></heading><p id="p0074" num="0074">15 ml of the trimethylsilyl polyphosphate solution prepared in Reference Example 2 was placed in a vessel purged with argon, and 1.06 g of 2-amino-6-nitrophenol prepared in Reference Example 1 and 0.62 g of nicotinic acid. The mixture was allowed to react under reflux for 3 hr. After the completion of the reaction, 50 ml of a 1 N aqueous sodium hydroxide solution was added to the reaction mixture. The intended product was extracted with dichloromethane (50 ml x 3), and the organic layer was washed with water and then dried. The organic<!-- EPO <DP n="68"> --> solvent was removed by evaporation, and the resultant concentrate was purified by silica gel column chromatography (hexane : ethyl acetate = 6 : 4) to provide 0.49 g of the title compound.<ul id="ul0012" list-style="none" compact="compact"><li><sup>1</sup>H NMR (CDCl<sub>3</sub>) Î´ (ppm):<br/>9.40(d, J=1.5Hz, 1H, ArH), 8.87(dd, J=4.8Hz, 1.5Hz, 1H, ArH), 8.58(ddd, J=1.8Hz, 2.2Hz, 7.9Hz, 1H, ArH), 8.34(dd, J=2.2Hz, 1.1Hz, 1H, ArH), 8.27(d, J=1.1Hz, 1H, ArH), 7.58-8.24(m, 2H, ArH)</li></ul></p><heading id="h0012"><u>Reference Example 4</u></heading><heading id="h0013"><u>Synthesis of 7-amino-2-(3-pyridyl)benzoxazole</u></heading><p id="p0075" num="0075">4 ml of 10 % acetic acid was added to 7-nitro-2-(3-pyridyl)benzoxazole prepared in Reference Example 3, and 200 mg of powdered iron was added by portions with stirring at room temperature. The mixture was heated to 100Â°C in an oil bath and stirred for 2 hr. The reaction mixture was filtered through Celite and washed with a small amount of dilute hydrochloric acid. The filtrate was neutralized with an aqueous sodium hydroxide solution, the product was extracted with ethyl acetate, and the organic layer was dried. The organic solvent was removed by evaporation to provide 153 mg of the intended title compound.<ul id="ul0013" list-style="none" compact="compact"><li><sup>1</sup>H NMR (Î´/ppm, d<sub>6</sub>-DMSO)<br/>9.37(dd, J=0.9Hz, 2.2Hz, 1H, ArH), 8.78(dd, J=1.8Hz, 4.8Hz, 1H, ArH), 8.59(ddd, J=1.8Hz, 2.2Hz, 8.1Hz, 1H, ArH), 7.63(ddd, J=0.9Hz, 4.8Hz, 8.1Hz, 1H, ArH), 6.92-7.10(m, 2H, ArH), 6.67(dd, J=1.8Hz, 7.3Hz, 1H, ArH), 5.59(s, 2H, NH<sub>2</sub>)</li></ul></p><heading id="h0014"><u>Reference Example 5</u></heading><heading id="h0015"><u>Synthesis of 2-phenylbenzoxazolyl-7-isocyanate</u></heading><p id="p0076" num="0076">137 mg of 7-amino-2-phenylbenzoxazole was suspended in 5 ml of 1,2-dichlorobenzene, and the mixture was stirred under reflux for 10 min. The reaction mixture was somewhat cooled. 129 mg of triphosgene and 132 mg of triethylamine were added thereto, and the mixture, as such, was stirred for 20 min.<!-- EPO <DP n="69"> --></p><p id="p0077" num="0077">After the completion of the reaction, the reaction mixture was filtered through Celite to remove insolubles. The solvent was removed by evaporation to provide 154 mg of the intended title compound.</p><heading id="h0016"><u>Example 1</u></heading><heading id="h0017"><u>Synthesis of 1-(2-phenylbenzoxazol-7-yl)-3-[(1- phenylcyclopentyl)methyl]urea (105)</u></heading><p id="p0078" num="0078"><chemistry id="chem0042" num="0042"><img id="ib0075" file="imgb0075.tif" wi="66" he="49" img-content="chem" img-format="tif"/></chemistry></p><p id="p0079" num="0079">A 77 mg amount of 2-phenylbenzoxazolyl-7-isocyanate prepared in Reference Example 5 was dissolved in 3 ml of ethyl acetate, 57 mg of 1-phenylcyclopentylmethylamine was added thereto, and the mixture was stirred at room temperature overnight.</p><p id="p0080" num="0080">After the completion of the reaction, the solvent was removed by evaporation. The resultant precipitate was recrystallized from hexane-ethyl acetate to provide 71 mg of the intended title compound.<ul id="ul0014" list-style="none" compact="compact"><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>8.16-8.27(m, 2H, ArH), 7.44-7.59(m, 4H, ArH), 7.13-7.41 (m, 9H, ArH), 6.35(s, 1H, NH), 4.49(br, 1H, NH), 3.47(d, J=5.7Hz, 2H, -CH<sub>2</sub>-), 1.70-2.10(br, 8H, -CH<sub>2</sub>-)</li><li>m.p.: 214-215Â°C</li></ul></p><heading id="h0018"><u>Example 2</u></heading><heading id="h0019"><u>Synthesis of N-[2-(3-pyridyl)benzoxazol-7-yl]-1- decylcyclopentanecarboxamide (207)</u></heading><!-- EPO <DP n="70"> --><p id="p0081" num="0081"><chemistry id="chem0043" num="0043"><img id="ib0076" file="imgb0076.tif" wi="60" he="45" img-content="chem" img-format="tif"/></chemistry></p><p id="p0082" num="0082">A 65 mg amount of 1-decylcyclopentanecarboxylic acid chloride was added to a solution of 51 mg of 7-amino-2-(3-pyridyl)benzoxazole and 0.034 ml of triethylamine in 2.5 ml of dichloromethane, and the mixture was stirred at room temperature for 9 hrs.</p><p id="p0083" num="0083">A saturated aqueous potassium hydrogensulfate solution (10 ml) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 ml x 2).</p><p id="p0084" num="0084">The extract was dried over anhydrous magnesium sulfate, filtered, concentrated and then purified by thin-layer chromatography (hexane : ethyl acetate = 1 : 1) to provide 35 mg of the intended title compound.<ul id="ul0015" list-style="none" compact="compact"><li>Property Values:</li><li><sup>1</sup>N NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>9.45(dd, J=2.2Hz, 0.7Hz, 1H, ArH), 8.79(dd, J=4.8Hz, 1.8Hz, 1H, ArH), 8.51(ddd, J=7.9Hz, 2.2Hz, 1.8Hz, 1H, ArH), 8.08(dd, J=7.9Hz, 1.3Hz, 1H, ArH), 7.34-7.63(m, 4H, ArH, ArNH), 2.20-2.34(br-t, J =6.4Hz, 2H, -CH<sub>2</sub>-), 1.53-1.90(m, 8H, -CH<sub>2</sub>-), 1.20-1.47(m, 16H, -CH<sub>2</sub>-), 0.84(t, J=5.1Hz, -CH<sub>3</sub>)</li></ul></p><heading id="h0020"><u>Reference Example 6</u></heading><heading id="h0021"><u>Synthesis of 5-chloro-2,2,4,6-tetramethyl-7-nitro- 2,3-dihydrobenzofuran</u></heading><p id="p0085" num="0085">A 50 g amount of 4-chloro-3,5-xylenol was dissolved in 50 ml of dry methanol. A 73.9 g amount of sodium methoxide (28 % methanol solution) and 43.4 g of 3-chloro-2-methyl-1-propene was added thereto, and the mixture was heated under reflux with stirring for 28 hrs. The reaction mixture was cooled, the solvent was removed<!-- EPO <DP n="71"> --> by evaporation, 300 ml of water was added to the residue, and the mixture was extracted with ethyl acetate (150 ml x three times). The organic layer was washed with a 5 N aqueous sodium hydroxide solution (70 ml x two times), water and brine and dried over anhydrous magnesium sulfate, and the solvent was removed by evaporation to provide 66.6 g of a pale yellow oleaginous substance. A 25 g amount of anhydrous magnesium chloride was added to the oleaginous substance, and the mixture was heated at 200Â°C with stirring for 24 hrs. The reaction mixture was cooled, 500 ml of water was added thereto, and the mixture was extracted with methylene chloride (250 ml x three times). The organic layer was washed with a 5 N aqueous sodium hydroxide solution (100 ml), a 1 N aqueous hydrochloric acid solution (100 ml) and brine in that order and dried over anhydrous magnesium sulfate, and the solvent was removed by evaporation to provide 64.8 g of a pale green oleaginous substance.</p><p id="p0086" num="0086">Then, this product was dissolved in 300 ml of acetic anhydride, and 29.09 g of nitric acid (70 %) was slowly added thereto under ice cooling. The stirring was continued for additional one hour to precipitate crystal. The reaction was allowed to proceed at room temperature for additional 2 hr, the reaction mixture was poured into 500 ml of water, and the mixture was extracted with ethyl acetate (300 ml x 3 times). The organic layer was washed with an aqueous sodium hydroxide solution (2 N, 200 ml x 2 times), water and saturated saline in that order and dried over anhydrous magnesium sulfate, and the solvent was removed by evaporation to provide pale brown crystals. This crystal was dissolved in 350 ml of hexane with heating, insolubles were removed by filtration, and the filtrate was subjected to recrystallization. The resultant crystals were further recrystallized from ethanol to provide 31.4 g of the intended compound (5-chloro-2,2,4,6-tetramethyl-7-nitro-2,3-dihydrobenzofuran)<!-- EPO <DP n="72"> --> as pale yellow crystals (yield: 38.5 %). The melting point (m.p.) was 111 to 112Â°C.</p><heading id="h0022"><u>Reference Example 7</u></heading><heading id="h0023"><u>Synthesis of 7-amino-2,2,4,6-tetramethyl-2,3-dihydrobenzofuran hydrochloride</u></heading><p id="p0087" num="0087">A 20.00 g amount of 5-chloro-2,2,4,6-tetramethyl-7-nitro-2,3-dihydrobenzofuran was dissolved in 300 ml of ethyl acetate, 2.0 g of Pd-C (10 %) was added thereto, and the mixture was subjected to hydrogenation at room temperature under a hydrogen gas pressure of one atm with vigorous stirring. After 24 hrs from the initiation of the hydrogenation, the consumption of hydrogen gas was about 6 liters. A 30 ml amount of triethylamine, 4.0 g of Pd-C (10 %) and 100 ml of ethanol were added thereto, and the hydrogenation was continued for additional 24 hrs. After the completion of the reaction was confirmed by TLC, Pd-C was removed by filtration and the solvent was removed by evaporation. A 300 ml amount of water was added to the resultant solid, and the mixture was extracted with ethyl acetate (150 ml x 3 times). The organic layer was washed with an aqueous sodium hydroxide solution (1 N, 100 ml x 2 times), water (100 ml) and brine (50 ml) in that order and dried over anhydrous magnesium sulfate, the solvent was removed by evaporation, and the residue was sufficiently dried to provide pale brown crystals. These crystals were dissolved in 100 ml of ethanol, about 40 ml of an ethanol solution (7 N) of hydrochloric acid was added thereto, and the solvent was removed by distillation to provide a crude hydrochloride. The crude hydrochloride was dissolved in 50 ml of methylene chloride with heating, insolubles were removed by filtration, and 400 ml of ethyl acetate was added to the filtrate with heating to effect recrystallization. The resultant crystal was collected by filtration, washed with a small amount of ethyl acetate and then dried to provide 14.47 g of the<!-- EPO <DP n="73"> --> intended product, i.e., 7-amino-2,2,4,6-tetramethyl-2,3-dihydrobenzofuran hydrochloride. The yield was 72 %.<ul id="ul0016" list-style="none" compact="compact"><li>Colorless plate crystal</li><li>m.p.: 176 - 178Â°C (sublimable)</li><li>1H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.45 (s, 1H), 3.47(s, 3H), 2.91(s, 2H), 2.57(s, 3H), 2.13(s, 3H), 1.49(s, 6H)</li></ul></p><heading id="h0024"><u>Reference Example 8</u></heading><heading id="h0025"><u>Synthesis of 2,2,6-trimethyl-2,3-dihydrobenzofuran-7-yl isocyanate</u></heading><p id="p0088" num="0088">A 400 mg amount of 7- amino-2,2,6-trimethyl-2,3-dihydrobenzofuran was dissolved in 10 ml of carbon tetrachloride, and 246 mg of triphosgene was added thereto. The reaction solution was heated to 80Â°C, and 229 mg of triethylamine was slowly added thereto with stirring. Further, the mixture was heated under reflux for 1.5 hr. The reaction mixture was filtered through Celite to remove insolubles. The solvent was removed by evaporation to provide 461 mg of the title compound.<ul id="ul0017" list-style="none" compact="compact"><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.82(d, 1H, J=7.5Hz), 6.59(d, 1H, J=7.5Hz), 3.02(s, 2H), 2.24(s, 3H), 1.50(s, 6H)</li></ul></p><heading id="h0026"><u>Example 3</u></heading><heading id="h0027"><u>Synthesis of 1-[(1-phenylcyclopentyl)methyl-3-(2,2,6-trimethyl-2,3-dihydrobenzofuran-7-yl)urea (309)</u></heading><p id="p0089" num="0089"><chemistry id="chem0044" num="0044"><img id="ib0077" file="imgb0077.tif" wi="68" he="44" img-content="chem" img-format="tif"/></chemistry></p><p id="p0090" num="0090">A 60 mg amount of (1-phenycyclopentyl)methylamine was added to a solution of 70 mg of 2,2,6-trimethyl-2,3-dihydrobenzofuran-7-yl isocyanate in 2 ml of ethyl<!-- EPO <DP n="74"> --> acetate, and the mixture was stirred at room temperature for 15 hrs. The solvent was removed by evaporation under reduced pressure, and the residue was subjected to recrystallization to provide 65 mg of the intended title compound.<ul id="ul0018" list-style="none" compact="compact"><li>Property values</li><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>7.0-7.2(m, 5H), 6.95(d, 1H, J=9Hz), 6.65(d, 1H, J=9Hz), 5.4(br-s, 1H), 4.3(br-s, 1H), 3.2-3.4(m, 2H), 2.93(s, 3H), 2.14(3, 3H), 1.5-2.1(m, 8H), 1.52(s, 6H)</li><li>m.p. : 186-186.5Â°C</li></ul></p><heading id="h0028"><u>Example 4</u></heading><heading id="h0029"><u>Synthesis of N-(2,2,6-trimethyl-2,3-dihydrobenzofuran-7-yl)hexadecaneamide (429)</u></heading><p id="p0091" num="0091"><chemistry id="chem0045" num="0045"><img id="ib0078" file="imgb0078.tif" wi="138" he="38" img-content="chem" img-format="tif"/></chemistry></p><p id="p0092" num="0092">A 171 mg amount of hexadecanecarboxylic acid chloride was added to a solution of 100 mg of 7-amino-2,2,6-trimethyl-2,3-dihydrobenzofuran and 63 mg of triethylamine in 2 ml of dichloromethane, and the mixture was stirred at room temperature for one hour. A 10 ml amount of a saturated sodium hydrogencarbonate solution was added thereto, and the mixture was extracted twice with 20 ml of ethyl acetate.</p><p id="p0093" num="0093">The extract was dried over anhydrous magnesium sulfate, filtered, concentrated and purified by column chromatography (hexane/ethyl acetate) to provide 193 mg of the intended title compound.<ul id="ul0019" list-style="none" compact="compact"><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.95(d, 1H, J=9Hz), 6.68(d, 1H, J=9Hz), 6.7(br-s, 1H), 2.99(s, 2H), 2.4(br-s, 2H), 2.19(s, 3H),<!-- EPO <DP n="75"> --> 1.66(br-t, 2H, J=9Hz), 1.44(s, 6H), 1.05-1.5(m, 24H), 0.89(br-t, 3H, J=5Hz)</li><li>m.p. 76-76.5Â°C</li></ul></p><heading id="h0030"><u>Example 5</u></heading><heading id="h0031"><u>Synthesis of N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (434)</u></heading><p id="p0094" num="0094"><chemistry id="chem0046" num="0046"><img id="ib0079" file="imgb0079.tif" wi="120" he="41" img-content="chem" img-format="tif"/></chemistry></p><p id="p0095" num="0095">A 233 mg amount of 7-amino-2,2,4,6-tetramethyl-2,3-dihydrobenzofuran hydrochloride was dissolved in 3 ml of dichloromethane, and 0.28 ml of triethylamine was added thereto. 248 mg of 2,2-dimethyldodecanecarboxylic acid chloride was slowly added thereto, and the mixture was stirred at room temperature for 15 hrs. A 15 ml amount of 2 N hydrochloric acid was added thereto, the resultant dichloromethane layer was separated, and the water layer was further extracted with ethyl acetate (25 ml x three times). The organic layers were combined with each other and washed with water and brine in that order. Anhydrous magnesium sulfate was added thereto to dry the washed organic layer. The solvent was removed by evaporation to provide 413 mg of the title compound. This product was purified by silica gel chromatography (hexane/ethyl acetate) to provide 370 mg of a colorless crystal. The yield was 92 %.<ul id="ul0020" list-style="none" compact="compact"><li>1H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.79(bs, 1H), 6.50(s, 1H), 2.89(s, 2H), 2.14(s, 3H), 2.13(s, 3H), 1.5-1.6(m, 2H), 1.43(s, 6H), 1.2-1.5(m, 22H), 0.88(t, 3H, J=6.6Hz)</li><li>m.p.: 57-58.5Â°C</li></ul><!-- EPO <DP n="76"> --></p><heading id="h0032"><u>Example 6</u></heading><heading id="h0033"><u>Synthesis of N-(2,2,4,6-tetramethyl-5-nitro-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (485)</u></heading><p id="p0096" num="0096"><chemistry id="chem0047" num="0047"><img id="ib0080" file="imgb0080.tif" wi="119" he="40" img-content="chem" img-format="tif"/></chemistry></p><p id="p0097" num="0097">A 64 mg amount of N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (434) was dissolved in 0.5 ml of acetic anhydride, and 24 mg of nitric acid was slowly added to the solution while cooling the solution to 0Â°C. The mixture, as such, was allowed to react at 0Â°C for one hour with stirring. The reaction solution was diluted with 5 ml of ice-cold water, 10 ml of a saturated aqueous sodium hydrogencarbonate solution was added thereto to effect neutralization, and the mixture was extracted with ethyl acetate (20 ml x twice). The organic layer was washed with water and brine in that order and dried over anhydrous magnesium sulfate. The solvent was removed by evaporation, and 72 mg of the resultant crude product was purified by silica gel column chromatography (hexane/ethyl acetate) to provide 56 mg of the intended tittle compound. The yield was 78 %.<ul id="ul0021" list-style="none" compact="compact"><li>1H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.80(br-s, 1H), 2.97(s, 2H), 2.15(s, 3H), 2.11(s, 3H), 1.5-1.6(m, 2H), 1.47(s, 6H), 1.2-1.5(m, 22H), 0.88(t, 3H, J=6.5Hz)</li><li>Pale yellow crystal</li><li>m.p.: 88 - 90Â°C (recrystallized from hexane)</li></ul></p><heading id="h0034"><u>Example 7</u></heading><!-- EPO <DP n="77"> --><heading id="h0035"><u>Synthesis of N-(5-amino-2,2,4,6-tetramethyl-2,3- dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (486)</u></heading><p id="p0098" num="0098"><chemistry id="chem0048" num="0048"><img id="ib0081" file="imgb0081.tif" wi="120" he="38" img-content="chem" img-format="tif"/></chemistry></p><p id="p0099" num="0099">A 2.0 g amount of N-(2,2,4,6-tetramethyl-5-nitro-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (485) was dissolved in 30 ml of ethanol, 600 mg of Pd-C (10 %) was added thereto, and the mixture was subjected to hydrogenation at room temperature with vigorous stirring. After 24 hrs from the initiation of the hydrogenation, the reaction was completed. Pd-C was removed by filtration with Celite, and the solvent was removed by evaporation to provide 1.75 g of the intended title compound as a solid. The yield was 94 %.<ul id="ul0022" list-style="none" compact="compact"><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.86(br-s, 1H), 3.26(br-s, 2H), 2.92(s, 2H), 2.15(s, 3H), 2.04(s, 3H), 1.5-1.65(m, 2H), 1.40(s, 6H), 1.2-1.5(m, 22H), 0.88(t, 3H, J=6.5Hz)</li><li>m.p.: 125Â°C (recrystallized from hexane and dichloromethane)</li></ul></p><heading id="h0036"><u>Example 8</u></heading><heading id="h0037"><u>Synthesis of N-(5-dimethylamino-2,2,4,6- tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (490)</u></heading><p id="p0100" num="0100"><chemistry id="chem0049" num="0049"><img id="ib0082" file="imgb0082.tif" wi="125" he="41" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="78"> --></p><p id="p0101" num="0101">A 1.75 g amount of N-(5-amino-2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (486) was dissolved in 30 ml of ethanol, 4.26 g of a formaldehyde solution (37 %) and 600 mg of platinum dioxide were added thereto, and the mixture was subjected to hydrogenation at room temperature. After 7 hrs from the initiation of the hydrogenation, the catalyst was removed by filtration with Celite, and the solvent was removed by evaporation. A 50 ml amount of water was added to the residue, and the mixture was extracted with ethyl acetate (30 ml x three times). The organic layer was washed with water and brine and dried over anhydrous magnesium sulfate. The solvent was removed by distillation to provide 2.25 g of a light brown oleaginous substance. The oleaginous substance was purified by silica gel column chromatography (hexane/ethyl acetate) to provide 1.33 g of the intended title compound. The yield was 71.4 %.<ul id="ul0023" list-style="none" compact="compact"><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.82(br-s, 1H), 2.89(s, 2H), 2.79(s, 6H), 2.10(s, 3H), 2.09(s, 3H), 1.5-1.65(m, 2H), 1.42(s, 6H), 1.2-1.5(m, 22H), 0.88(t, 3H, J=6.6Hz) Colorless crystal</li><li>m.p.: 84.5 - 85Â°C</li></ul></p><heading id="h0038"><u>Example 9</u></heading><heading id="h0039"><u>Synthesis of N-(5-dimechylamino-2,2,4,6- tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2- dimethyldodecaneamide hydrochloride (490 hydrochloride)</u></heading><p id="p0102" num="0102">A 452 mg amount of free base of the compound (490) prepared in Example 8 was dissolved in 3 ml of ethanol, and 1 ml of ethanol saturated with hydrochloric acid was added thereto to convert the compound to a hydrochloride. The solvent was removed by evaporation, and the resultant crystal was recrystallized from ethyl acetate to provide 313 mg of the intended title compound.<ul id="ul0024" list-style="none" compact="compact"><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/><!-- EPO <DP n="79"> -->6.85(br-s, 1H), 3.4(br-s, 6H), 2.97(s, 2H), 2.65(br-s, 3H), 2.42(br-s, 3H), 1.2-1.65(m, 30H), 0.88(t, 3H, J=6.5Hz) Colorless crystal</li><li>m.p.: 107-110Â°C</li></ul></p><heading id="h0040"><u>Example 10</u></heading><heading id="h0041"><u>Synthesis of N-(2,2,4,6-tetramethyl-2,3- dihydrobenzofuran-7-yl)-[2,2-dimethyl-7-(4-nitroopenyloxy)]heptaneamide (462)</u></heading><p id="p0103" num="0103"><chemistry id="chem0050" num="0050"><img id="ib0083" file="imgb0083.tif" wi="119" he="42" img-content="chem" img-format="tif"/></chemistry></p><p id="p0104" num="0104">A 410 mg amount of N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-(2,2-dimethyl-7-bromo)heptaneamide prepared according to a method described in Example 5 was dissolved in 10 ml of acetonitrile together with 139 mg of p-nitrophenol and 138 mg of potassium carbonate, and the resultant solution was heated under reflux for 2.5 hr. The solvent was removed by evaporation, 30 ml of a 5 N aqueous sodium hydroxide solution was added to the residue, and the mixture was extracted with 100 ml of ethyl acetate. The organic layer was washed with 5 N sodium hydroxide, 1 N hydrochloric acid, water and brine in that order and then dried over anhydrous magnesium sulfate. The solvent was removed by evaporation to provide 484 mg of an oleaginous substance which was then purified by silica gel column chromatography to provide 354 mg of the intended title compound.<ul id="ul0025" list-style="none" compact="compact"><li>Pale yellow crystal</li><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/><!-- EPO <DP n="80"> -->8.17(d, 2H, J=9.3Hz), 6.91(d, 2H, J=9.3Hz), 6.8(br-s, 1H), 6.49(br-s, 1H), 4.04(t, 2H, J=6.5Hz), 2.88(s, 2H), 2.13(s, 6H), 1.25-2.0(m, 20H)</li><li>m.p. : 93-94Â°C</li></ul></p><heading id="h0042"><u>Example 11</u></heading><heading id="h0043"><u>Synthesis of N-(2,2,4,6-tetramethyl-2,3- dihydrobenzofuran-7-yl)-2,2-dimethyl-8-(N-isopropyl)aminooctaneamide (469)</u></heading><p id="p0105" num="0105"><chemistry id="chem0051" num="0051"><img id="ib0084" file="imgb0084.tif" wi="110" he="42" img-content="chem" img-format="tif"/></chemistry></p><p id="p0106" num="0106">A 203 mg amount of N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyl-8-bromooctaneamide and 150 my of potassium carbonate were added to 7 ml of isopropylamine, and the mixture was allowed to react under reflux for 14 hrs.</p><p id="p0107" num="0107">After the completion of the reaction, excess isopropylamine was removed by distillation under reduced pressure. Ethyl acetate and 2 N hydrochloric acid were added to the residue, followed by separation. A 2 N aqueous sodium hydroxide solution was added the water layer to render the solution basic, and the liberated compound was extracted with ethyl acetate.</p><p id="p0108" num="0108">The organic solvent was removed by distillation under reduced pressure to provide 54 my of the title compound.<ul id="ul0026" list-style="none" compact="compact"><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.79(br, 1H), 6.48(s, 1H), 3.19(br, 1H), 2.88(s, 2H), 2.61(t, J=7.0Hz 2H), 2.13(s, 6H), 1.42(s, 6H), 1.27(s, 6H), 1.28-1.65(m, 10H), 1.10(d, J=6.2Hz 6H)</li></ul></p><heading id="h0044"><u>Preparation of hydrochloride</u></heading><!-- EPO <DP n="81"> --><p id="p0109" num="0109">Hydrochloric acid/ether was added to 54 mg of the title compound until a precipitate did not occur any longer. The precipitate was collected by filtration and subjected to recrystallization from ethyl acetate to provide 30 mg of a hydrochloride of the title compound.<ul id="ul0027" list-style="none" compact="compact"><li>Property value</li><li>m.p.: 129-130Â°C</li></ul></p><heading id="h0045"><u>Examples 12 to 86</u></heading><p id="p0110" num="0110">Compounds of the present invention were synthesized in the sane manner as that of Examples 1 to 11, except that respective corresponding starting compounds and reactants were used. Property values thus produced are given in the following Table 1. Compound Nos. described in Table I represent respective numbers given to the compounds listed above as favorable specific examples.<!-- EPO <DP n="82"> --><tables id="tabl0034" num="0034"><img id="ib0085" file="imgb0085.tif" wi="133" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="83"> --><tables id="tabl0035" num="0035"><img id="ib0086" file="imgb0086.tif" wi="137" he="215" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="84"> --><tables id="tabl0036" num="0036"><img id="ib0087" file="imgb0087.tif" wi="138" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="85"> --><tables id="tabl0037" num="0037"><img id="ib0088" file="imgb0088.tif" wi="125" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="86"> --><tables id="tabl0038" num="0038"><img id="ib0089" file="imgb0089.tif" wi="140" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="87"> --><tables id="tabl0039" num="0039"><img id="ib0090" file="imgb0090.tif" wi="139" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="88"> --><tables id="tabl0040" num="0040"><img id="ib0091" file="imgb0091.tif" wi="130" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="89"> --><tables id="tabl0041" num="0041"><img id="ib0092" file="imgb0092.tif" wi="143" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="90"> --><tables id="tabl0042" num="0042"><img id="ib0093" file="imgb0093.tif" wi="131" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="91"> --><tables id="tabl0043" num="0043"><img id="ib0094" file="imgb0094.tif" wi="139" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="92"> --><tables id="tabl0044" num="0044"><img id="ib0095" file="imgb0095.tif" wi="138" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="93"> --><tables id="tabl0045" num="0045"><img id="ib0096" file="imgb0096.tif" wi="149" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="94"> --><tables id="tabl0046" num="0046"><img id="ib0097" file="imgb0097.tif" wi="123" he="215" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="95"> --><tables id="tabl0047" num="0047"><img id="ib0098" file="imgb0098.tif" wi="139" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="96"> --><tables id="tabl0048" num="0048"><img id="ib0099" file="imgb0099.tif" wi="129" he="216" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="97"> --><tables id="tabl0049" num="0049"><img id="ib0100" file="imgb0100.tif" wi="128" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="98"> --><tables id="tabl0050" num="0050"><img id="ib0101" file="imgb0101.tif" wi="134" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="99"> --><tables id="tabl0051" num="0051"><img id="ib0102" file="imgb0102.tif" wi="115" he="217" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="100"> --></p><heading id="h0046"><u>Example 87</u></heading><heading id="h0047"><u>Synthesis of N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-4-(4-chlorobenzyloxy)benzoylamide (408)</u></heading><p id="p0111" num="0111"><chemistry id="chem0052" num="0052"><img id="ib0103" file="imgb0103.tif" wi="100" he="50" img-content="chem" img-format="tif"/></chemistry></p><p id="p0112" num="0112">A 62 my amount of N-(2,2,4,6-tetramethyldihydro-1-benzofuran-7-yl)-4-hydroxybenzoylamide was dissolved in 2 ml of acetonitrile. A 38 my amount of 4-chlorobenzyl chloride and 41 my of potassium carbonate were added thereto, and the mixture was allowed to react under reflux for 10 hrs.</p><p id="p0113" num="0113">After the completion of the reaction, potassium carbonate was removed, the residue was concentrated by removing the solvent, and the concentrate was purified by preparative thin-layer chromatography (hexane : ethyl acetate = 4 : 6) to provide 72 my of the title compound.<ul id="ul0028" list-style="none" compact="compact"><li>Property values</li><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>7.89(br, 2H), 7.37(s, 4H), 7.25(br, 1H), 7.01(br-d, J=8.7Hz, 2H), 6.56(s, 1H), 2.92(s, 2H), 2.21(s, 3H), 2.16(s, 3H), 1.44(s, 6H)</li><li>m.p. : 148-150Â°C</li></ul></p><heading id="h0048"><u>Example 88</u></heading><heading id="h0049"><u>Synthesis of N-(2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)3-(4-decyloxyphenyl)-3-oxopropaneamide (479)</u></heading><!-- EPO <DP n="101"> --><p id="p0114" num="0114"><chemistry id="chem0053" num="0053"><img id="ib0104" file="imgb0104.tif" wi="140" he="41" img-content="chem" img-format="tif"/></chemistry></p><p id="p0115" num="0115">A 1.36 ml amount of a 1.6 M n-butyl lithium hexane solution was added by portions to a solution of 304 Âµl of diisopropylamine in 5 ml of dry tetrahydrofuran at -78Â°C, and the mixture was stirred at that temperature for 30 min. Subsequently, a solution of 500 mg of 4-decyloxyacetophenone in 5 ml of dry tetrahydrofuran was added at 0Â°C, and the mixture was stirred at that temperature for 15 min and then at room temperature for one hour.</p><p id="p0116" num="0116">Separately, 2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl isocyanate was prepared from 412 mg of 2,2,4,6-tetramethyl-7-aminodihydro-1-benzofuran according to the reference examples. The above-described stirred solution was added to a solution of the 2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl isocyanate in 5 ml of dry tetrahydrofuran at room temperature.</p><p id="p0117" num="0117">The mixture was allowed to react for 15 hrs. An aqueous potassium hydrogensulfate was added to the reaction mixture, and the mixture was extracted with ethyl acetate.</p><p id="p0118" num="0118">The extract was concentrated by removing the organic solvent, and the concentrate was purified by silica gel column chromatography (hexane : ethyl acetate = 6 : 4). The product was further recrystallized from hexane to provide 440 mg of the title compound.<ul id="ul0029" list-style="none" compact="compact"><li>Property values</li><li><sup>1</sup>H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>8.31(br, 1H), 8.02(d, J=8.9Hz, 2H), 6.95(d, J=8.9Hz, 2H), 6.50(s, 1H), 4.09(s, 2H), 4.03(t,<!-- EPO <DP n="102"> --> J=6.6Hz, 2H), 2.89(s, 2H), 2.13(s, 3H), 2.11(s, 3H), 1.81(tt, J=6.6Hz, J=6.9Hz, 2H), 1.28-1.55(m, 14H), 0.88(t, J=6.6Hz, 3H)</li><li>m.p.: 118.5-119Â°C</li></ul></p><heading id="h0050"><u>Example 89</u></heading><heading id="h0051"><u>Synthesis of N-(5-dodecaneamide-2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (535)</u></heading><p id="p0119" num="0119"><chemistry id="chem0054" num="0054"><img id="ib0105" file="imgb0105.tif" wi="145" he="41" img-content="chem" img-format="tif"/></chemistry></p><p id="p0120" num="0120">A 42 my amount of N-(5-amino-2,2,4,6-tetramethyl-2,3-dihydrobenzofuran-7-yl)-2,2-dimethyldodecaneamide (486) was dissolved in 2.0 ml of dichloromethane, and 13 mg of triethylamine was added thereto. Further, 22 my of n-dodecanoyl chloride was added thereto, and the mixture was allowed to react at room temperature with stirring for 5 hr. The reaction solution was poured into 20 ml of water, and the mixture was extracted with ethyl acetate (10 ml x three times). The organic layer was washed with water and brine in that order and dehydrated over anhydrous magnesium sulfate, and the solvent was removed by distillation. The resultant crystal was purified by silica gel column chromatography to provide 40 my of the intended title compound. The yield was 67.6 %.<ul id="ul0030" list-style="none" compact="compact"><li>1H NMR(CDCl<sub>3</sub>) Î´ (ppm):<br/>6.86(br-s, 1H), 6.70(br-s, 1H), 2.92(s, 2H), 2.39(t, 2H, J=7.9Hz), 2.02(s, 3H), 2.00(s, 3H), 1.56(br-t, 4H, J=6Hz), 1.1-1.5(m, 32H), 0.88(t, 6H, J=7.6Hz)</li></ul></p><heading id="h0052"><u>Example 90</u></heading><!-- EPO <DP n="103"> --><heading id="h0053"><u>Measurement of ACAT enzyme inhibitory activity (measurement of ACAT enzyme inhibitory activity of rabbit intestinal mucosa)</u></heading><p id="p0121" num="0121">Preparation of a domestic rabbit intestinal mucosa microsome and measurement of the ACAT enzyme activity were conducted by slightly modifying a method established by Salone and Field (see Biochemica et Biophysica, vol. 712, 557 (1982).</p><p id="p0122" num="0122">The domestic rabbit intestinal mucosa was homogenized by using a 40 mM phosphate buffer having a pH value of 7.4 (buffer A) containing 30 mM EDTA, 50 mM KCl and 0.1 M sucrose and centrifuged at 10,000 x g and a temperature of 4Â°C for 30 mm to provide a supernatant. The supernatant was further centrifuged at 105,000 x g and a temperature of 4Â°C for one hour to provide a precipitate. The precipitate was resuspended in the buffer A to provide a microsome fraction.</p><p id="p0123" num="0123">A 1 %v/v dimethylsulfoxide solution of each specimen compound in a predetermined concentration was added to the buffer A containing 43 ÂµM serum albumin and 0.5 mg/ml microsome fraction, and the mixture was heated at 37Â°C for 5 min.</p><p id="p0124" num="0124">Then, 43 ÂµM oleoyl CoA containing [1-<sup>14</sup>C] oleoyl CoA (3.7 kB) was added thereto, the mixture was heated at 37Â°C for 10 min, and chloroform/methanol (2/1) containing 10 mg/ml cholesteryl oleate was added thereto to terminate the reaction.</p><p id="p0125" num="0125">0.111 kB of [<sup>3</sup>H] cholesteryl oleate and 1 N hydrochloric acid were added thereto, and the mixture was stirred. The cholesteryl oleate extracted into the chloroform layer was isolated by thin-layer chromatography, and the radioactivity was measured as the ACAT activity. The results are given in Table 2.<!-- EPO <DP n="104"> --><tables id="tabl0052" num="0052"><img id="ib0106" file="imgb0106.tif" wi="153" he="164" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="105"> --><tables id="tabl0053" num="0053"><img id="ib0107" file="imgb0107.tif" wi="154" he="161" img-content="table" img-format="tif"/></tables><!-- EPO <DP n="106"> --><tables id="tabl0054" num="0054"><img id="ib0108" file="imgb0108.tif" wi="152" he="160" img-content="table" img-format="tif"/></tables></p><p id="p0126" num="0126">All the test compounds had a LD<sub>50</sub> value of 2 g/kg or more (mouse).</p><heading id="h0054"><u>Example 91</u></heading><heading id="h0055"><u>Measurement of percentage change of serum cholesterol</u></heading><p id="p0127" num="0127">Male Wistar rats having a weight of 200 g were preliminarily bred for 7 days while they freely ingested a normal feed (CE-2 manufactured by CLEA Japan Inc.).</p><p id="p0128" num="0128">Thereafter, they were bred for 3 days while they freely ingested a feed enriched with cholesterol and fat<!-- EPO <DP n="107"> --> (2 % cholesterol, 1 % cholic acid, 20 % casein, 45 % fine granulated sugar, 12 % coconut oil, 4 % KC flock, 1 % mixed vitamin, 7 % mixed mineral and 8 % dried fish powder; a product of CLEA Japan Inc.). During the cholesterol loading period, the test compound of the present invention was orally administered to the above test animals at a dose of 0.1 to 10 mg per kg of the weight once a day for three days. On the other hand, the excipient alone was administered to the control animals.</p><p id="p0129" num="0129">After 8 hrs from the last administration, the test animals were fasted. 16 hr after the initiation of the fasting, these test animals were slaughtered. The serum cholesterol level was measured for each animal.</p><p id="p0130" num="0130">The results were compared with those of the control and are given as percentage serum cholesterol (%) in Table 3.<maths id="math0001" num=""><math display="block"><mrow><mtext>Percentage change of serum cholesterol (%) = {(A - B)/B} x 100</mtext></mrow></math><img id="ib0109" file="imgb0109.tif" wi="121" he="5" img-content="math" img-format="tif"/></maths> wherein A represents the total cholesterol level of serum in the group of rats to which the test compound was administered; and B represents the total cholesterol level of serum in the control group of rats.<!-- EPO <DP n="108"> --> <tables id="tabl0055" num="0055"><table frame="all"><title>Table 3</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Test Compound</entry><entry namest="col2" nameend="col2" align="center">Dose in Oral Administration (mg/kg)</entry><entry namest="col3" nameend="col3" align="center">Percentage Change of Serum Cholesterol (%)</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Compound of Ex. 5</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-61</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex. 8</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-71</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.20</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">-46</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.29</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-23</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.36</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">-52</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.42</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-44</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.45</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-58</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.49</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-50</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.50</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">-54</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.53</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">-50</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.58</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">-27</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.59</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-43</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.61</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-64</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.62</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-18</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.68</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-75</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.71</entry><entry namest="col2" nameend="col2" align="right">1</entry><entry namest="col3" nameend="col3" align="right">-49</entry></row><row><entry namest="col1" nameend="col1" align="left">Compound of Ex.78</entry><entry namest="col2" nameend="col2" align="right">10</entry><entry namest="col3" nameend="col3" align="right">-43</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Compound of Ex.94</entry><entry namest="col2" nameend="col2" align="right">3</entry><entry namest="col3" nameend="col3" align="right">-55</entry></row></tbody></tgroup></table></tables></p><heading id="h0056"><u>Example 92</u></heading><heading id="h0057"><u>Preparation of Tablet</u></heading><p id="p0131" num="0131">A tablet containing 30 mg of the compound of Example 5 was prepared according to the following formulation. <tables id="tabl0056" num="0056"><table frame="all"><tgroup cols="2" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="78.75mm"/><colspec colnum="2" colname="col2" colwidth="78.75mm"/><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Compound Ex. 5</entry><entry namest="col2" nameend="col2" align="right">30 mg</entry></row><row><entry namest="col1" nameend="col1" align="left">Lactose</entry><entry namest="col2" nameend="col2" align="right">87 mg</entry></row><row><entry namest="col1" nameend="col1" align="left">Starch</entry><entry namest="col2" nameend="col2" align="right">30 mg</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Magnesium stearate</entry><entry namest="col2" nameend="col2" align="right">3 mg</entry></row></tbody></tgroup></table></tables></p><heading id="h0058"><u>Utilization in Industry</u></heading><p id="p0132" num="0132">The present invention provides a pharmaceutical composition for use as an ACAT inhibitor and treating hyperlipidemia and atherosclerosis, which pharmaceutical composition contains a benzoxazole compound and a 2,3-dihydrobenzofuran<!-- EPO <DP n="109"> --> compound. Further, it provides novel benzoxazole and 2,3-dihydrobenzofuran compounds which can be particularly usefully used in the above-described pharmaceutical composition.</p>
EP	0632031	B1	2000-05-03	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A pharmaceutical composition comprising a benzoxa condensed ring compound represented by the following formula (I) or its pharmaceutically acceptable salt in an amount effective for inhibiting the action of Acyl-coenzyme A: Cholesterol Acyltransferase:<chemistry id="chem0055" num="0055"><img id="ib0110" file="imgb0110.tif" wi="76" he="33" img-content="chem" img-format="tif"/></chemistry> wherein any one of P, Q, R and S is a group represented by the formula:<chemistry id="chem0056" num="0056"><img id="ib0111" file="imgb0111.tif" wi="35" he="15" img-content="chem" img-format="tif"/></chemistry> with the remaining three substituents being independently a group represented by the formula -R<sub>3</sub>,<claim-text>wherein R<sub>1</sub> stands for a group selected from the group consisting of:<claim-text>(i) an unsubstituted cycloalkyl or cycloalkenyl group or a cycloalkyl or cycloalkenyl group substituted at a position other than the 1-position with the substituent being a C<sub>1</sub>-C<sub>14</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group;</claim-text><claim-text>(ii) a group represented by the formula:<chemistry id="chem0057" num="0057"><img id="ib0112" file="imgb0112.tif" wi="22" he="20" img-content="chem" img-format="tif"/></chemistry> wherein R<sub>9</sub> and R<sub>10</sub> each independently stand for a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>-alkyl group, or may combine with each other to form a C<sub>3</sub>-C<sub>7</sub> carbon ring; and R<sub>11</sub> stands for a substituted or unsubstituted C<sub>1</sub>-C<sub>19</sub> alkyl, C<sub>2</sub>-C<sub>19</sub> alkenyl, C<sub>6</sub>-C<sub>10</sub> aryl, C<sub>7</sub>-C<sub>19</sub><!-- EPO <DP n="111"> --> arylalkyl, C<sub>1</sub>-C<sub>19</sub> acyl or acyl group having a C<sub>4</sub>-C<sub>19</sub> aromatic ring, provided that the substituent when said groups are substituted is a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>16</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; or R<sub>11</sub> stands for a group represented by the formula: <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ-A-X-B<br/><br/><claim-text>wherein A stands for a C<sub>1</sub>-C<sub>12</sub> alkylene chain; X stands for an oxygen atom, a sulfur atom, or a group represented by the formula:<chemistry id="chem0058" num="0058"><img id="ib0113" file="imgb0113.tif" wi="18" he="14" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein R<sub>12</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub>-alkyl or acyl group or may combine with B to form a cyclic amine, provided that, when a cyclic amine is formed, an oxygen atom, a sulfur atom, a nitrogen atom or a nitrogen atom substituted with a C<sub>1</sub>-C<sub>6</sub>-alkyl or arylalkyl group may be contained as a constituent member of the ring; and</claim-text></claim-text><claim-text>B stands for a substituted or unsubstituted alkyl, aryl or arylalkyl group, provided that the substituent when said groups are substituted is a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>12</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>20</sub> dialkylamino group; and</claim-text></claim-text><claim-text>(iii) a substituted or unsubstituted aryl group or a group represented by the formula:<!-- EPO <DP n="112"> --><chemistry id="chem0059" num="0059"><img id="ib0114" file="imgb0114.tif" wi="36" he="33" img-content="chem" img-format="tif"/></chemistry> wherein any one of P<sub>b</sub>, Q<sub>b</sub>, R<sub>b</sub> and S<sub>b</sub> represents a bond with the remaining three substituents independently standing for a group represented by the formula -R<sub>3</sub>, provided that, when the aryl group is substituted, the substituent is present at the o-, m- or p-position and a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>16</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and the alkyl portion of said groups may be interrupted by: -O-, -S-,<chemistry id="chem0060" num="0060"><img id="ib0115" file="imgb0115.tif" wi="83" he="16" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein R<sub>13</sub> stands for a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub>-alkyl, acyl or arylalkyl group, arylene or arylenoxy, or 1 to 3 hydrogen atoms on the carbon atoms may be substituted with an aryl or aryloxy group, a halogen atom or a cyano group, or the aryl portion as the substituent may be substituted with a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, or a C<sub>1</sub>-C<sub>6</sub>-alkyl, alkoxy, monoalkylamino, dialkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group;</claim-text><claim-text>R<sub>2</sub> stands for a hydrogen atom or a C<sub>1</sub>-C<sub>8</sub> alkyl group;</claim-text><claim-text>each R<sub>3</sub> independently stands for a hydrogen atom, a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy,<!-- EPO <DP n="113"> --> acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and the alkyl portion of said groups may be interrupted by: -O-, -S-,<chemistry id="chem0061" num="0061"><img id="ib0116" file="imgb0116.tif" wi="83" he="18" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sub>13</sub> stands for a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub>-alkyl, acyl or arylalkyl group, arylene or arylenoxy, or 1 to 3 hydrogen atoms on the carbon atoms may be substituted with an aryl or aryloxy group, a halogen atom or a cyano group, or the aryl portion as the substituent may be substituted with a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, monoalkylamino, acylamino,<br/>alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and</claim-text><claim-text>Z stands for a linking group which combines with an O atom, a carbon atom of the benzene ring, to which the O atom is bonded, and a carbon atom adjacent to said carbon atom to form a five-membered ring and is represented by the formula:<chemistry id="chem0062" num="0062"><img id="ib0117" file="imgb0117.tif" wi="78" he="21" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sub>4</sub> stands for a hydrogen atom, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkenyl or alkynyl group, or a substituted or unsubstituted aryl group, provided that the substituent when the aryl group is substituted is a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and<!-- EPO <DP n="114"> --></claim-text><claim-text>R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> each independently stand for a hydrogen atom or a C<sub>1</sub>-C<sub>20</sub> alkyl group, or R<sub>5</sub> and R<sub>6</sub> or R<sub>7</sub> and R<sub>8</sub> combine with a carbon atom bonded thereto to form a C<sub>5</sub>-C<sub>7</sub> carbon ring; and</claim-text><claim-text>n is 0 or 1.</claim-text></claim-text></claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A pharmaceutical composition according to claim 1, wherein the substituent S stands for a group represented by the formula:<chemistry id="chem0063" num="0063"><img id="ib0118" file="imgb0118.tif" wi="39" he="16" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A pharmaceutical composition according to claim 1, which is used for treating hyperlipidemia and atherosclerosis.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A benzoxa condensed ring compound represented by the following formula (Ia) or its pharmaceutically acceptable salt:<chemistry id="chem0064" num="0064"><img id="ib0119" file="imgb0119.tif" wi="78" he="36" img-content="chem" img-format="tif"/></chemistry> wherein P<sub>a</sub>, Q<sub>a</sub> and R<sub>a</sub> each independently stand for a hydrogen atom, a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and the alkyl portion of said groups may be interrupted by: -O-, -S-,<chemistry id="chem0065" num="0065"><img id="ib0120" file="imgb0120.tif" wi="85" he="13" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein R<sub>13</sub> stands for a hydrogen atom, a C<sub>1</sub>-C<sub>6</sub>-alkyl, acyl or arylalkyl group,<br/>arylene or arylenoxy, or 1 to 3 hydrogen atoms on the carbon atom may be substituted with an aryl or aryloxy<!-- EPO <DP n="115"> --> group, a halogen atom or a cyano group, and the aryl portion as the substituent may be substituted with a halogen atom, an amino, nitro, cyano, carboxyl or hydroxyl group, a C<sub>1</sub>-C<sub>20</sub> alkyl, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyl, acyl or acyloxy group, or a C<sub>2</sub>-C<sub>26</sub> dialkylamino group; and</claim-text><claim-text>R<sub>1</sub>, R<sub>2</sub>, Z and n are as defined in claim 1;<!-- EPO <DP n="116"> --> the benzoxa condensed ring compound not including 2,3-dihydro-2,2-dimethyl-7-acetoacetamidobenzofuran and the compound (Ia) wherein R<sub>a</sub>, Q<sub>a</sub>, P<sub>a</sub>, R<sup>7</sup> and R<sup>8</sup> are hydrogen atoms, Z is -CHR<sup>5</sup>R<sup>6</sup>-CHR<sup>7</sup>R<sup>8</sup>- with R<sup>5</sup> and R<sup>6</sup> being a methyl group, n is O and R<sup>1</sup> is an ortho-methylphenyl group.</claim-text><!-- EPO <DP n="117"> --></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 4, wherein the n value is 1.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 5, wherein the R<sub>2</sub> stands for a hydrogen atom.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 4, wherein the n value is 0 (zero).</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 7, wherein the substituent Z stands for a group represented by the following formula:<chemistry id="chem0066" num="0066"><img id="ib0121" file="imgb0121.tif" wi="28" he="14" img-content="chem" img-format="tif"/></chemistry> wherein the R<sub>4</sub> is as defined in claim 1.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 7, wherein the substituent z stands for a group represented by the following formula:<chemistry id="chem0067" num="0067"><img id="ib0122" file="imgb0122.tif" wi="33" he="22" img-content="chem" img-format="tif"/></chemistry> wherein the R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> are as defined in claim 1.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 8, wherein the R<sub>a</sub> stands for a group other than a hydrogen atom.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 9, wherein the R<sub>a</sub> stands for a group other than a hydrogen atom.<!-- EPO <DP n="118"> --></claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 11, wherein the R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> and R<sub>8</sub> each independently stand for a hydrogen atom or a methyl group.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 10, wherein the R<sub>1</sub> stands for a group represented by the formula:<chemistry id="chem0068" num="0068"><img id="ib0123" file="imgb0123.tif" wi="22" he="19" img-content="chem" img-format="tif"/></chemistry> wherein the R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> are as defined in claim 1.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A compound and its pharmaceutically acceptable salt according to claim 11, wherein the R<sub>1</sub> stands for a group represented by the formula:<chemistry id="chem0069" num="0069"><img id="ib0124" file="imgb0124.tif" wi="22" he="21" img-content="chem" img-format="tif"/></chemistry> wherein the R<sub>9</sub>, R<sub>10</sub> and R<sub>11</sub> are as defined in claim 1.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A process for producing a compound represented by the formula (I), wherein n is 1, and its pharmaceutically acceptable salt, comprising reacting an isocyanate represented by the following formula (II):<chemistry id="chem0070" num="0070"><img id="ib0125" file="imgb0125.tif" wi="78" he="31" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein m is an integer of 0 to 3, each R<sub>3</sub> is independently defined as in claim 1 when n is 2 or 3, and z is as defined in claim 1,<br/>with an amine compound represented by the following formula (III):<!-- EPO <DP n="119"> --><chemistry id="chem0071" num="0071"><img id="ib0126" file="imgb0126.tif" wi="73" he="16" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>wherein R<sub>1</sub> and R<sub>2</sub> are as defined above, and optionally converting the reaction product to a salt.</claim-text></claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>A processes for producing a compound represented by the formula (I), wherein n is 1, and its pharmaceutically acceptable salt, comprising reacting an amine represented by the following formula (IV):<chemistry id="chem0072" num="0072"><img id="ib0127" file="imgb0127.tif" wi="70" he="30" img-content="chem" img-format="tif"/></chemistry><claim-text>wherein m, R<sub>3</sub> and Z are as defined above, with an isocyanate represented by the following formula (V): <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒO=C=N-R<sub>1</sub>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(V)<br/><br/></claim-text><claim-text>wherein R<sub>1</sub> is as defined above,<br/>and optionally converting the reaction product to a salt.</claim-text></claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>A process for producing a compound according to claim 4, wherein n is 0, and its pharmaceutically acceptable salt, comprising reacting an amine represented by the formula (IV) with a carboxylic acid represented by the following formula (VI) or its reactive derivative: <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒR<sub>1</sub>COOHâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(VI)<br/><br/><claim-text>wherein R<sub>1</sub> is as defined in claim 1,<br/>and optionally converting the reaction product to a salt.</claim-text></claim-text></claim>
EP	0632031	B1	2000-05-03	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Pharmazeutische Zusammensetzung, umfassend eine Benzoxakondensierte Ringverbindung, welche durch die folgende Formel (I) oder ihr pharmazeutisch geeignetes Salz in einer Menge, die ausreichend ist, um die Wirkung von AcylCoenzym A: Cholesterol Acyltransferase zu inhibieren:<chemistry id="chem0073" num="0073"><img id="ib0128" file="imgb0128.tif" wi="87" he="38" img-content="chem" img-format="tif"/></chemistry> worin irgendeiner der Buchstaben P, Q, R und S eine Gruppe der Formel reprÃ¤sentiert:<chemistry id="chem0074" num="0074"><img id="ib0129" file="imgb0129.tif" wi="44" he="20" img-content="chem" img-format="tif"/></chemistry> wobei die verbleibenden drei Substituenten unabhÃ¤ngig voneinander eine Gruppe der Formel -R<sub>3</sub> reprÃ¤sentieren,<claim-text>worin R<sub>1</sub> eine Gruppe bedeutet, welche ausgewÃ¤hlt ist aus<claim-text>(i) einer unsubstituierten Cycloalkyl- oder Cycloalkenylgruppe oder einer Cycloalkyl- oder Cycloalkenylgruppe, welche in einer Stellung, die von der 1-Position verschieden ist, mit einem Substituenten substituiert ist, welcher eine C<sub>1</sub>-C<sub>14</sub>-Alkyl-, Alkoxy-, Acylamino-,<!-- EPO <DP n="121"> --> Monoalkylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder eine C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe ist;</claim-text><claim-text>(ii)einer Gruppe, welche durch die Formel reprÃ¤sentiert wird:<chemistry id="chem0075" num="0075"><img id="ib0130" file="imgb0130.tif" wi="28" he="22" img-content="chem" img-format="tif"/></chemistry><claim-text>worin R<sub>9</sub> und R<sub>10</sub> jeder unabhÃ¤ngig voneinander fÃ¼r ein Wasserstoffatom oder eine C<sub>1</sub>-C<sub>6</sub>-Alkylgruppe stehen oder miteinander kombiniert sein kÃ¶nnen, um einen C<sub>3</sub>-C<sub>7</sub>-Kohlenstoffring zu bilden;</claim-text><claim-text>und worin R<sub>11</sub> fÃ¼r eine substituierte oder unsubstituierte C<sub>1</sub>-C<sub>19</sub>-Alkyl-, C<sub>2</sub>-C<sub>19</sub>-Akenyl-, C<sub>6</sub>-C<sub>10</sub>-Aryl-, C<sub>7</sub>-C<sub>19</sub>-Arylalkyl-, C<sub>1</sub>-C<sub>19</sub>-Acyl- oder eine Acylgruppe steht, welche einen C<sub>4</sub>-C<sub>19</sub>-aromatischen Ring aufweist, vorausgesetzt, daÃŸ der Substituent, wenn die Gruppen substituiert sind, ein Halogenatom, eine Aminogruppe, eine Nitrogruppe, eine Cyanogruppe, eine Carboxyl- oder Hydroxylgruppe, eine C<sub>1</sub>-C<sub>16</sub>-Alkyl-, Alkoxy-, Acylamino-, Monoalkylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder eine C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe ist; oder worin R<sub>11</sub> fÃ¼r eine Gruppe der folgenden Formel steht: <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ-A-X-B<br/><br/></claim-text><claim-text>worin A fÃ¼r eine C<sub>1</sub>-C<sub>12</sub>-Alkylenkette steht; worin X fÃ¼r ein Sauerstoffatom, ein Schwefelatom oder eine Gruppe der folgenden Formel steht:<chemistry id="chem0076" num="0076"><img id="ib0131" file="imgb0131.tif" wi="18" he="23" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>worin R<sub>12</sub> fÃ¼r ein Wasserstoffatom oder eine C<sub>1</sub>-C<sub>6</sub>-Alkyl- oder Acylgruppe steht oder mit B kombiniert sein<!-- EPO <DP n="122"> --> kann, um ein cyclisches Amin zu bilden, wobei gilt, daÃŸ, wenn ein cyclisches Amin gebildet wird, ein Sauerstoffatom, ein Schwefelatom, ein Stickstoffatom oder ein mit einem C<sub>1</sub>-C<sub>6</sub>-Alkyl- oder Aralkylrest substituiertes Stickstoffatom als ein Bestandteil des Rings enthalten sein kann;</claim-text><claim-text>und worin B fÃ¼r eine substituierte oder unsubstituierte Alkyl-, Aryl- oder Arylalkylgruppe steht, wobei gilt, daÃŸ, falls Gruppen substituiert sind, der Substituent ein Halogenatom, eine Amino-, eine Nitro-, eine Cyano-, eine Carboxyl- oder Hydroxylgruppe, eine C<sub>1</sub>-C<sub>12</sub>-Alkyl-, eine Alkoxy-, Monoalkylamino-, Acylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder eine C<sub>2</sub>-C<sub>20</sub>-Dialkylaminogruppe ist; und</claim-text></claim-text><claim-text>(iii) einer substituierten oder unsubstituierten Arylgruppe oder einer Gruppe der Formel:<chemistry id="chem0077" num="0077"><img id="ib0132" file="imgb0132.tif" wi="37" he="35" img-content="chem" img-format="tif"/></chemistry><claim-text>worin irgendeiner der Reste P<sub>b</sub>, Q<sub>b</sub>, R<sub>b</sub> und S<sub>b</sub> eine Bindung reprÃ¤sentiert, wobei die verbleibenden drei Substituenten unabhÃ¤ngig voneinander eine Gruppe reprÃ¤sentieren, welche durch die Formel -R<sub>3</sub> reprÃ¤sentiert ist, wobei gilt, daÃŸ, wenn die Arylgruppe substituiert ist, der Substituent an der o-, m- oder p-Stellung vorhanden ist und ein Halogenatom, eine Amino-, eine Nitro-, eine Cyano-, eine Carboxyl- oder eine Hydroxylgruppe, eine C<sub>1</sub>-C<sub>16</sub>-Alkyl-, Alkoxy-, Monoalkylamino-, Acylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder eine C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe ist;<!-- EPO <DP n="123"> --></claim-text><claim-text>und worin die Alkylanteile dieser Gruppen unterbrochen sein kÃ¶nnen durch: -O-, -S-,<chemistry id="chem0078" num="0078"><img id="ib0133" file="imgb0133.tif" wi="84" he="17" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>worin R<sub>13</sub> fÃ¼r ein Wasserstoffatom, eine C<sub>1</sub>-C<sub>16</sub>-Alkyl-, Acyl- oder Arylalkylgruppe, eine Arylen- oder Arylenoxygruppe steht oder worin 1 bis 3 Wasserstoffatome an den Kohlenstoffatomen mit einer Aryl- oder Aryloxygruppe, einem Halogenatom oder einer Cyanogruppe substituiert sein kÃ¶nnen, oder der Arylanteil als Substituent mit einem Halogenatom, einer Amino-, Nitro-, Cyano-, Carboxyl- oder Hydroxylgruppe oder einer C<sub>1</sub>-C<sub>6</sub>-Alkyl-, Alkoxy-, Monoalkylamino-, Dialkylamino-, Acylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe substituiert sein kann;</claim-text><claim-text>worin R<sub>2</sub> fÃ¼r ein Wasserstoffatom oder eine C<sub>1</sub>-C<sub>8</sub>-Alkylgruppe steht;</claim-text><claim-text>wobei jeder Rest -R<sub>3</sub> unabhÃ¤ngig von den anderen fÃ¼r ein Wasserstoffatom, ein Halogenatom, eine Amino-, Nitro-, Cyano-, Carboxyl- oder Hydroxylgruppe, eine C<sub>1</sub>-C<sub>20</sub>-Alkyl-, Alkoxy-, Acylamino-, Monoalkylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder eine C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe steht; und wobei der Alkylanteil dieser Gruppen unterbrochen sein kann durch: -O-, -S-,<chemistry id="chem0079" num="0079"><img id="ib0134" file="imgb0134.tif" wi="83" he="19" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>worin R<sub>13</sub> fÃ¼r ein Wasserstoffatom, eine C<sub>1</sub>-C<sub>6</sub>-Alkyl-, Acyl- oder Arylalkyl-Gruppe, eine Arylen- oder Arylenoxygruppe steht, oder worin 1 bis 3 Wasserstoffatome<!-- EPO <DP n="124"> --> an den Kohlenstoffatomen durch einen Aryl- oder Aryloxyrest, ein Halogenatom oder eine Cyanogruppe substituiert sein kÃ¶nnen, oder worin der Arylrest als Substituent mit einem Halogenatom, einer Amino-, Nitro-, Cyano-, Carboxyl- oder Hydroxylgruppe, einer C<sub>1</sub>-C<sub>20</sub>-Alkyl-, Alkoxy-, Monoalkylamino-, Acylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder einer C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe substituiert sein kann; und</claim-text><claim-text>worin Z fÃ¼r eine verknÃ¼pfende Gruppe steht, welche kombiniert mit einem Sauerstoff, einem Kohlenstoffatom des Benzolrings, an den das Sauerstoffatom gebunden ist, und einem Kohlenstoffatom benachbart zu dem Kohlenstoffatom einen fÃ¼nfgliedrigen Ring bildet, und reprÃ¤sentiert ist durch die Formeln:<chemistry id="chem0080" num="0080"><img id="ib0135" file="imgb0135.tif" wi="74" he="25" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>worin R<sub>4</sub> fÃ¼r ein Wasserstoffatom, eine C<sub>1</sub>-C<sub>20</sub>-Alkyl-, Alkenyl- oder Alkinylgruppe oder eine substituierte oder eine unsubstituierte Arylgruppe steht, wobei gilt, daÃŸ, wenn die Arylgruppe substituiert ist, der Substituent ein Halogenatom, eine Amino-, Nitro-, Cyano-, Carboxyl- oder Hydroxylgruppe, eine C<sub>1</sub>-C<sub>20</sub>-Alkyl-, Alkoxy-, Monoalkylamino-, Acylamino-, Alkyloxycarbonyl-, Acyl-, oder Acyloxygruppe oder eine C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe darstellt; und</claim-text><claim-text>worin R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> und R<sub>8</sub> jeweils unabhÃ¤ngig voneinander fÃ¼r ein Wasserstoffatom oder eine C<sub>1</sub>-C<sub>20</sub>-Alkylgruppe stehen oder worin R<sub>5</sub> und R<sub>6</sub> oder R<sub>7</sub> und R<sub>8</sub> kombiniert mit einem daran gebundenen Kohlenstoffatom einen C<sub>5</sub>-C<sub>7</sub>-Kohlenstoffring bilden; und worin n gleich 0 oder 1 ist.</claim-text></claim-text></claim-text><!-- EPO <DP n="125"> --></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 1, worin der Substituent S fÃ¼r eine Gruppe gemÃ¤ÃŸ der Formel steht:<chemistry id="chem0081" num="0081"><img id="ib0136" file="imgb0136.tif" wi="39" he="16" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 1, welche zur Behandlung von HyperlipidÃ¤mie und Arteriosklerose verwendet wird.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Benzoxakondensierte Ringverbindung gemÃ¤ÃŸ der folgenden Formel (Ia) oder ihre pharmazeutisch geeigneten Salze:<chemistry id="chem0082" num="0082"><img id="ib0137" file="imgb0137.tif" wi="79" he="38" img-content="chem" img-format="tif"/></chemistry><claim-text>worin P<sub>a</sub>, Q<sub>a</sub> und R<sub>a</sub> jeweils unabhÃ¤ngig voneinander fÃ¼r ein Wasserstoffatom, ein Halogenatom, eine Amino-, Nitro-, Cyano-, Carboxyl- oder Hydroxylgruppe, eine C<sub>1</sub>-C<sub>20</sub>-Alkyl-, Alkoxy-, Acylamino-, Monoalkylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder eine C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe stehen; und der Alkylanteil dieser Gruppe unterbrochen sein kann durch: -O-, -S-,<chemistry id="chem0083" num="0083"><img id="ib0138" file="imgb0138.tif" wi="84" he="22" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>worin R<sub>13</sub> fÃ¼r ein Wasserstoffatom, eine C<sub>1</sub>-C<sub>6</sub>-Alkyl-, Acyl- oder Arylalkylgruppe, eine Arylen- oder Arylenoxygruppe steht, oder worin 1 bis 3 Wasserstoffatome an dem Kohlenstoffatom mit einer Aryl- oder Aryloxygruppe, einem Halogenatom oder einer Cyanogruppe substituiert sein kÃ¶nnen,<!-- EPO <DP n="126"> --> und worin der Arylanteil als Substituent substituiert sein kann mit einem Halogenatom, einer Amino-, einer Nitro-, einer Cyano-, einer Carboxyl- oder Hydroxylgruppe, einer C<sub>1</sub>-C<sub>20</sub>-Alkyl-, Alkoxy-, Monoalkylamino-, Acylamino-, Alkyloxycarbonyl-, Acyl- oder Acyloxygruppe oder einer C<sub>2</sub>-C<sub>26</sub>-Dialkylaminogruppe;</claim-text><claim-text>und worin R<sub>1</sub>, R<sub>2</sub>, Z und n wie oben in Anspruch 1 definiert sind;</claim-text><claim-text>wobei die benzoxakondensierte Ringverbindung 2,3-Dihydro-2,2-dimethyl-7-acetoacetamidobenzofuran und die Verbindung (Ia) nicht einschlieÃŸt, bei der R<sub>a</sub>, Q<sub>a</sub>, P<sub>a</sub>, R<sup>7</sup> und R<sup>8</sup> Wasserstoffatome sind und Z gleich -CHR<sup>5</sup>R<sup>6</sup>-CHR<sup>7</sup>R<sup>8</sup>- mit der Bedeutung von R<sup>5</sup> und R<sup>6</sup> als eine Methylgruppe, n gleich 0 und R<sup>1</sup> eine ortho-Methylphenylgruppe.</claim-text></claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Eine Verbindung oder ihr pharmazeutisch geeignetes Salz nach Anspruch 4, worin n den Wert 1 hat.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Eine Verbindung oder ihr pharmazeutisch geeignetes Salz nach Anspruch 5, worin R<sup>2</sup> fÃ¼r ein Wasserstoffatom steht.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Eine Verbindung oder ihr pharmazeutisch geeignetes Salz nach Anspruch 4, worin der Wert fÃ¼r n gleich null ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Eine Verbindung oder ihr pharmazeutisch geeignetes Salz nach Anspruch 7, worin der Substituent Z fÃ¼r eine Gruppe steht, die durch die folgende Formel reprÃ¤sentiert ist:<chemistry id="chem0084" num="0084"><img id="ib0139" file="imgb0139.tif" wi="30" he="17" img-content="chem" img-format="tif"/></chemistry> worin der Rest R<sub>4</sub> wie in Anspruch 1 definiert ist.<!-- EPO <DP n="127"> --></claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verbindung und deren pharmazeutisch geeignetes Salz nach Anspruch 7, worin der Substituent Z fÃ¼r eine Gruppe steht, welche durch die folgende Formel reprÃ¤sentiert ist:<chemistry id="chem0085" num="0085"><img id="ib0140" file="imgb0140.tif" wi="36" he="24" img-content="chem" img-format="tif"/></chemistry> worin R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> und R<sub>8</sub> wie in Anspruch 1 definiert sind.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verbindung und deren pharmazeutisch geeignetes Salz nach Anspruch 8, worin R<sub>a</sub> fÃ¼r eine Gruppe steht, die von einem Wasserstoffatom verschieden ist.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verbindung und deren pharmazeutisch geeignetes Salz nach Anspruch 9, worin R<sub>a</sub> fÃ¼r eine Gruppe steht, die von einem Wasserstoffatom verschieden ist.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verbindung und deren pharmazeutisch geeignetes Salz nach Anspruch 11, worin die Reste R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> und R<sub>8</sub> jeweils unabhÃ¤ngig voneinander fÃ¼r ein Wasserstoffatom oder eine Methylgruppe stehen.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verbindung und deren pharmazeutisch geeignetes Salz nach Anspruch 10, worin der Rest R<sub>1</sub> fÃ¼r eine Gruppe der folgenden Formel steht:<chemistry id="chem0086" num="0086"><img id="ib0141" file="imgb0141.tif" wi="24" he="26" img-content="chem" img-format="tif"/></chemistry> worin die Reste R<sub>9</sub>, R<sub>10</sub> und R<sub>11</sub> wie in Anspruch 1 definiert sind.<!-- EPO <DP n="128"> --></claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verbindung und deren pharmazeutisch geeignetes Salz nach Anspruch 10, worin der Rest R<sub>1</sub> fÃ¼r eine Gruppe der Formel steht:<chemistry id="chem0087" num="0087"><img id="ib0142" file="imgb0142.tif" wi="25" he="26" img-content="chem" img-format="tif"/></chemistry> worin die Reste R<sub>9</sub>, R<sub>10</sub> und R<sub>11</sub> wie in Anspruch 1 definiert sind.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Verfahren zur Herstellung einer Verbindung gemÃ¤ÃŸ der Formel (I), worin n gleich 1 ist und deren pharmazeutisch geeignetes Salz, umfassend das Reagierenlassen eines Isocyanats gemÃ¤ÃŸ der folgenden Formel (II):<chemistry id="chem0088" num="0088"><img id="ib0143" file="imgb0143.tif" wi="75" he="33" img-content="chem" img-format="tif"/></chemistry><claim-text>worin m eine ganze Zahl von 0 bis 3 ist, wobei jeder der Reste R<sub>3</sub> unabhÃ¤ngig voneinander wie in Anspruch 1 definiert ist, wenn n gleich 2 oder 3 ist, und worin Z wie in Anspruch 1 definiert ist,</claim-text><claim-text>mit einer Aminverbindung, welche durch die folgende Formel (III) reprÃ¤sentiert ist:<chemistry id="chem0089" num="0089"><img id="ib0144" file="imgb0144.tif" wi="78" he="23" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>worin R<sub>1</sub> und R<sub>2</sub> wie oben definiert sind,<!-- EPO <DP n="129"> --></claim-text><claim-text>und gegebenenfalls Umwandeln des Reaktionsproduktes in ein Salz.</claim-text></claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Verfahren zur Herstellung einer Verbindung gemÃ¤ÃŸ der Formel (I), worin n gleich 1 ist, und deren pharmazeutisch geeignetes Salz, umfassend das Reagierenlassen eines Amins gemÃ¤ÃŸ der folgenden Formel (IV):<chemistry id="chem0090" num="0090"><img id="ib0145" file="imgb0145.tif" wi="71" he="32" img-content="chem" img-format="tif"/></chemistry><claim-text>worin m, R<sub>3</sub> und Z wie oben definiert sind,</claim-text><claim-text>mit einem Isocyanat gemÃ¤ÃŸ der folgenden Formel (V): <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒO=C=N-R<sub>1</sub>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(V)<br/><br/></claim-text><claim-text>worin R<sub>1</sub> wie oben definiert ist,</claim-text><claim-text>und gegebenenfalls Umwandeln des Reaktionsproduktes in ein Salz.</claim-text></claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Verfahren zur Herstellung einer Verbindung nach Anspruch 4, worin n gleich 0 ist, und dessen pharmazeutisch geeignetes Salz, umfassend das Reagierenlassen eines Amins gemÃ¤ÃŸ der Formel (IV) mit einer CarbonsÃ¤ure, welche durch die folgende Formel (VI) reprÃ¤sentiert ist, oder deren reaktives Derivat: <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒR<sub>1</sub>COOHâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(VI)<br/><br/><claim-text>worin R<sub>1</sub> wie in Anspruch 1 definiert ist,<!-- EPO <DP n="130"> --></claim-text><claim-text>und gegebenenfalls Umwandeln des Reaktionsproduktes in ein Salz.</claim-text></claim-text></claim>
EP	0632031	B1	2000-05-03	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Composition pharmaceutique comprenant un composÃ© Ã  cycle benzoxa condensÃ© reprÃ©sentÃ© par la formule (I) suivante ou son sel acceptable sur le plan pharmaceutique dans une quantitÃ© efficace pour inhiber l'action de l'acyl-coenzyme A : cholestÃ©rol acyltransfÃ©rase :<chemistry id="chem0091" num="0091"><img id="ib0146" file="imgb0146.tif" wi="98" he="38" img-content="chem" img-format="tif"/></chemistry><claim-text>dans laquelle l'un quelconque des radicaux P, Q, R et S est un groupe reprÃ©sentÃ© par la formule :<chemistry id="chem0092" num="0092"><img id="ib0147" file="imgb0147.tif" wi="47" he="21" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>les trois substituants restants Ã©tant indÃ©pendamment des groupes reprÃ©sentÃ©s par la formule -R<sub>3</sub>, dans laquelle R<sub>1</sub> reprÃ©sente un groupe choisi dans le groupe consistant en :<claim-text>(i) un groupe cycloalkyle ou cycloalkÃ©nyle non substituÃ© ou un groupe cycloalkyle ou cycloalkÃ©nyle substituÃ© dans une position diffÃ©rente de la position 1, le substituant Ã©tant un groupe alkyle, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>14</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ;</claim-text><claim-text>(ii) un groupe reprÃ©sentÃ© par la formule :<chemistry id="chem0093" num="0093"><img id="ib0148" file="imgb0148.tif" wi="26" he="24" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="132"> --><claim-text>dans laquelle les radicaux R<sub>9</sub> et R<sub>10</sub> reprÃ©sentent chacun indÃ©pendamment un atome d'hydrogÃ¨ne ou un groupe alkyle en C<sub>1</sub> Ã  C<sub>6</sub>, ou peuvent se combiner pour former un cycle carbonÃ© en C<sub>3</sub> Ã  C<sub>7</sub> ;</claim-text><claim-text>et R<sub>11</sub> reprÃ©sente un groupe, substituÃ© ou non substituÃ©, alkyle en C<sub>1</sub> Ã  C<sub>19</sub>, un groupe alkÃ©nyle en C<sub>2</sub> Ã  C<sub>19</sub>, un groupe aryle en C<sub>6</sub> Ã  C<sub>10</sub>, un groupe arylalkyle en C<sub>7</sub> Ã  C<sub>19</sub>, un groupe acyle en C<sub>1</sub> Ã  C<sub>19</sub> ou un groupe acyle comportant un cycle aromatique en C<sub>4</sub> Ã  C<sub>19</sub>, Ã  condition que le substituant, lorsque les dits groupes sont substituÃ©s, est un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>16</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ; ou R<sub>11</sub> reprÃ©sente un groupe reprÃ©sentÃ© par la formule : <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ-A-X-B<br/><br/></claim-text><claim-text>dans laquelle A reprÃ©sente une chaÃ®ne alkylÃ¨ne en C<sub>1</sub> Ã  C<sub>12</sub> ; X reprÃ©sente un atome d'oxygÃ¨ne, un atome de soufre, ou un groupe reprÃ©sentÃ© par la formule :<chemistry id="chem0094" num="0094"><img id="ib0149" file="imgb0149.tif" wi="23" he="16" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>dans laquelle R<sub>12</sub> reprÃ©sente un atome d'hydrogÃ¨ne ou un groupe alkyle ou acyle en C<sub>1</sub> Ã  C<sub>6</sub>, ou peut se combiner avec le radical B pour former une amine cyclique, Ã  condition que, lorsqu'une amine cyclique est formÃ©e, un atome d'oxygÃ¨ne, un atome de soufre, un atome d'azote ou un atome d'azote substituÃ© par un groupe alkyle ou arylalkyle en C<sub>1</sub> Ã  C<sub>6</sub> puisse Ãªtre contenu dans le cycle en tant qu'un membre constitutif de celui-ci ; et</claim-text><claim-text>B reprÃ©sente un groupe alkyle, aryle ou arylalkyle substituÃ© ou non substituÃ©, Ã  condition que le substituant, lorsque les dits groupes sont substituÃ©s, soit un atome d'hydrogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyle,<!-- EPO <DP n="133"> --> acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>12</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>20</sub> ;</claim-text></claim-text><claim-text>(iii) un groupe aryle substituÃ© ou non substituÃ© ou un groupe reprÃ©sentÃ© par la formule :<chemistry id="chem0095" num="0095"><img id="ib0150" file="imgb0150.tif" wi="43" he="41" img-content="chem" img-format="tif"/></chemistry><claim-text>dans laquelle l'un quelconque des radicaux P<sub>b</sub>, Q<sub>b</sub>, R<sub>b</sub> et S<sub>b</sub> reprÃ©sente une liaison avec les trois substituants restants reprÃ©sentant indÃ©pendamment un groupe reprÃ©sentÃ© par la formule -R<sub>3</sub>, Ã  condition que, lorsque le groupe aryle est substituÃ©, le substituant est prÃ©sent dans la position o, m, ou p, et un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>16</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ; et la partie alkyle des dits groupes puisse Ãªtre interrompue par : -O-, -S-,<chemistry id="chem0096" num="0096"><img id="ib0151" file="imgb0151.tif" wi="96" he="22" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>dans lesquelles R<sub>13</sub> reprÃ©sente un atome d'hydrogÃ¨ne, un groupe alkyle, acyle ou arylalkyle en C<sub>1</sub> Ã  C<sub>6</sub>, un groupe arylÃ¨ne ou arylÃ©noxy, ou 1 Ã  3 atomes d'hydrogÃ¨ne sur les atomes de carbone peuvent Ãªtre substituÃ©s par un groupe aryle ou aryloxy, un atome d'halogÃ¨ne ou un groupe cyano, ou la partie aryle en tant que le substituant peut Ãªtre substituÃ©e par un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, monoalkylamino, dialkylamino, acylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>6</sub> ;<!-- EPO <DP n="134"> --></claim-text><claim-text>R<sub>2</sub> reprÃ©sente un atome d'hydrogÃ¨ne ou un groupe alkyle en C<sub>1</sub> Ã  C<sub>8</sub> ;</claim-text><claim-text>chaque radical R<sub>3</sub> reprÃ©sente indÃ©pendamment un atome d'hydrogÃ¨ne, un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>20</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ; et la partie alkyle des dits groupes puisse Ãªtre interrompue par : -O-, -S-,<chemistry id="chem0097" num="0097"><img id="ib0152" file="imgb0152.tif" wi="90" he="17" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>dans lesquelles R<sub>13</sub> reprÃ©sente un atome d'hydrogÃ¨ne, un groupe alkyle, acyle ou arylalkyle en C<sub>1</sub> Ã  C<sub>6</sub>, un groupe arylÃ¨ne ou arylÃ©noxy, ou 1 Ã  3 atomes d'hydrogÃ¨ne sur les atomes de carbone peuvent Ãªtre substituÃ©s par un groupe aryle ou aryloxy, un atome d'halogÃ¨ne ou un groupe cyano, ou la partie aryle en tant que le substituant peut Ãªtre substituÃ©e par un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>20</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ; et</claim-text><claim-text>z reprÃ©sente un groupe de liaison qui se combine avec un atome d'oxygÃ¨ne, un atome de carbone du cycle benzÃ¨ne, auquel l'atome d'oxygÃ¨ne est liÃ©, et un atome de carbone adjacent au dit atome de carbone pour former un cycle Ã  cinq membres et est reprÃ©sentÃ© par la formule :<chemistry id="chem0098" num="0098"><img id="ib0153" file="imgb0153.tif" wi="81" he="28" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="135"> --></claim-text><claim-text>dans laquelle R<sub>4</sub> reprÃ©sente un atome d'hydrogÃ¨ne, un groupe alkyle, alkÃ©nyle ou alkynyle en C<sub>1</sub> Ã  C<sub>20</sub>, ou un groupe aryle substituÃ© ou non substituÃ©, Ã  condition que le substituant, lorsque le groupe aryle est substituÃ©, soit un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>20</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ; et</claim-text><claim-text>les radicaux R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> et R<sub>8</sub> reprÃ©sentent chacun indÃ©pendamment un atome d'hydrogÃ¨ne ou un groupe alkyle en C<sub>1</sub> Ã  C<sub>20</sub>, ou R<sub>5</sub> et R<sub>6</sub> ou R<sub>7</sub> et R<sub>8</sub> se combinent avec un atome de carbone liÃ© Ã  ceux-ci pour former un cycle carbonÃ© en C<sub>5</sub> Ã  C<sub>7</sub> ;</claim-text><claim-text>n est Ã©gal Ã  0 ou 1.</claim-text></claim-text></claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composition pharmaceutique selon la revendication 1, dans laquelle le substituant S reprÃ©sente un groupe reprÃ©sentÃ© par la formule :<chemistry id="chem0099" num="0099"><img id="ib0154" file="imgb0154.tif" wi="42" he="15" img-content="chem" img-format="tif"/></chemistry></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composition pharmaceutique selon la revendication 1 qui est utilisÃ©e pour traiter l'hyperlipidÃ©mie et l'athÃ©rosclÃ©rose.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>ComposÃ© Ã  cycle benzoxa condensÃ© reprÃ©sentÃ© par la formule (Ia) suivante ou son sel acceptable sur le plan pharmaceutique :<chemistry id="chem0100" num="0100"><img id="ib0155" file="imgb0155.tif" wi="121" he="43" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="136"> --><claim-text>dans laquelle les radicaux P<sub>a</sub>, Q<sub>a</sub> et R<sub>a</sub> reprÃ©sentent chacun indÃ©pendamment un atome d'hydrogÃ¨ne, un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, acylamino, monoalkylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>20</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ; et la partie alkyle des dits groupes peut Ãªtre interrompue par : -O-, -S-,<chemistry id="chem0101" num="0101"><img id="ib0156" file="imgb0156.tif" wi="95" he="21" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>dans lesquelles R<sub>13</sub> reprÃ©sente un atome d'hydrogÃ¨ne, un groupe alkyle, acyle ou arylalkyle en C<sub>1</sub> Ã  C<sub>6</sub>, un groupe arylÃ¨ne ou arylÃ©noxy, ou 1 Ã  3 atomes d'hydrogÃ¨ne sur l'atome de carbone peuvent Ãªtre substituÃ©s par un groupe aryle ou aryloxy, un atome d'halogÃ¨ne ou un groupe cyano, et la partie aryle en tant que le substituant peut Ãªtre substituÃ©e par un atome d'halogÃ¨ne, un groupe amino, nitro, cyano, carboxyle ou hydroxyle, un groupe alkyle, alkoxy, monoalkylamino, acylamino, alkyloxycarbonyle, acyle ou acyloxy en C<sub>1</sub> Ã  C<sub>20</sub>, ou un groupe dialkylamino en C<sub>2</sub> Ã  C<sub>26</sub> ; et</claim-text><claim-text>R<sub>1</sub>, R<sub>2</sub>, Z et n sont tels que dÃ©finis dans la revendication 1 ; le composÃ© Ã  cycle benzoxa condensÃ© ne comprenant pas le 2,3-dihydro-2,2-dimÃ©thyl-7-acÃ©toacÃ©tamidobenzofuranne, et le composÃ© (Ia) dans lequel R<sub>a</sub>, Q<sub>a</sub>, P<sub>a</sub>, R<sub>7</sub> et R<sub>8</sub> sont des atomes d'hydrogÃ¨ne, Z reprÃ©sentant -CHR<sub>5</sub>R<sub>6</sub>-CHR<sub>7</sub>R<sub>8</sub>-, R<sub>5</sub> et R<sub>6</sub> reprÃ©sentant un groupe mÃ©thyle, n Ã©tant Ã©gal Ã  0 et R<sub>1</sub> Ã©tant un groupe ortho-mÃ©thylphÃ©nyle.</claim-text></claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 4, dans lesquels la valeur de n est 1.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 5, dans lesquels R<sub>2</sub> reprÃ©sente un atome d'hydrogÃ¨ne.<!-- EPO <DP n="137"> --></claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 4, dans lesquels la valeur de n est 0 (zÃ©ro).</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 7, dans lesquels le substituant Z reprÃ©sente un groupe reprÃ©sentÃ© par la formule suivante :<chemistry id="chem0102" num="0102"><img id="ib0157" file="imgb0157.tif" wi="33" he="18" img-content="chem" img-format="tif"/></chemistry> dans laquelle R<sub>4</sub> est tel que dÃ©fini dans la revendication 1.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 7, dans lesquels le substituant Z reprÃ©sente un groupe reprÃ©sentÃ© par la formule suivante :<chemistry id="chem0103" num="0103"><img id="ib0158" file="imgb0158.tif" wi="40" he="27" img-content="chem" img-format="tif"/></chemistry> dans laquelle R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> et R<sub>8</sub> sont tels que dÃ©finis dans la revendication 1.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 8, dans lesquels le radical R<sub>a</sub> reprÃ©sente un groupe diffÃ©rent de l'atome d'hydrogÃ¨ne.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 9, dans lesquels le radical R<sub>a</sub> reprÃ©sente un groupe diffÃ©rent d'un atome d'hydrogÃ¨ne.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 11, dans lesquels R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub> et R<sub>8</sub> reprÃ©sentent chacun indÃ©pendamment un atome d'hydrogÃ¨ne ou un groupe mÃ©thyle.<!-- EPO <DP n="138"> --></claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 10, dans lesquels le radical R<sub>1</sub> reprÃ©sente un groupe reprÃ©sentÃ© par la formule :<chemistry id="chem0104" num="0104"><img id="ib0159" file="imgb0159.tif" wi="25" he="26" img-content="chem" img-format="tif"/></chemistry> dans laquelle R<sub>9</sub>, R<sub>10</sub> et R<sub>11</sub> sont tels que dÃ©finis dans la revendication 1.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>ComposÃ© et son sel acceptable sur le plan pharmaceutique selon la revendication 11, dans lesquels le radical R<sub>1</sub> reprÃ©sente un groupe reprÃ©sentÃ© par la formule :<chemistry id="chem0105" num="0105"><img id="ib0160" file="imgb0160.tif" wi="23" he="25" img-content="chem" img-format="tif"/></chemistry> dans laquelle R<sub>9</sub>, R<sub>10</sub> et R<sub>11</sub> sont tels que dÃ©finis dans la revendication 1.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>ProcÃ©dÃ© de prÃ©paration d'un composÃ© reprÃ©sentÃ© par la formule (I), dans laquelle n est Ã©gal Ã  1, et de son sel acceptable sur le plan pharmaceutique, comprenant la mise en rÃ©action d'un isocyanate reprÃ©sentÃ© par la formule (II) suivante :<chemistry id="chem0106" num="0106"><img id="ib0161" file="imgb0161.tif" wi="107" he="35" img-content="chem" img-format="tif"/></chemistry><claim-text>dans laquelle m est un nombre entier de 0 Ã  3, chaque radical R<sub>3</sub> reprÃ©sente indÃ©pendamment un groupe tel que dÃ©fini dans la revendication 1 lorsque n est Ã©gal Ã  2 ou 3,</claim-text><claim-text>et Z est tel que dÃ©fini dans la revendication 1,<!-- EPO <DP n="139"> --></claim-text><claim-text>avec un composÃ© amine reprÃ©sentÃ© par la formule (III) suivante :<chemistry id="chem0107" num="0107"><img id="ib0162" file="imgb0162.tif" wi="97" he="27" img-content="chem" img-format="tif"/></chemistry></claim-text><claim-text>dans laquelle R<sub>1</sub> et R<sub>2</sub> sont tels que dÃ©finis ci-dessus, et la conversion facultative du produit de la rÃ©action en un sel.</claim-text></claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>ProcÃ©dÃ© de prÃ©paration d'un composÃ© reprÃ©sentÃ© par la formule (I), dans laquelle n est Ã©gal Ã  1, et de son sel acceptable sur le plan pharmaceutique, comprenant la mise en rÃ©action d'une amine reprÃ©sentÃ©e par la formule (IV) suivante :<chemistry id="chem0108" num="0108"><img id="ib0163" file="imgb0163.tif" wi="101" he="35" img-content="chem" img-format="tif"/></chemistry><claim-text>dans laquelle m, R<sub>3</sub> et Z sont tels que dÃ©finis ci-dessus, avec un isocyanate reprÃ©sentÃ© par la formule (V) suivante : <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒO=C=N-R<sub>1</sub>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(V)<br/><br/></claim-text><claim-text>dans laquelle R<sub>1</sub> est tel que dÃ©fini ci-dessus, et la conversion facultative du produit de la rÃ©action en un sel.</claim-text></claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>ProcÃ©dÃ© de prÃ©paration d'un composÃ© selon la revendication 4, dans laquelle n est Ã©gal Ã  0, et de son sel acceptable sur le plan pharmaceutique, comprenant la mise en rÃ©action d'une amine reprÃ©sentÃ©e par la formule (IV) avec un acide carboxylique reprÃ©sentÃ© par la formule (VI) suivante ou son dÃ©rivÃ© rÃ©actif : <br/><br/>â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒR<sub>1</sub>COOHâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒ(VI)<br/><br/><!-- EPO <DP n="140"> --> dans laquelle R<sub>1</sub> est tel que dÃ©fini dans la revendication 1, et la conversion facultative du produit de la rÃ©action en un sel.</claim-text></claim>
EP	0632031	B1	2000-05-03	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0632031&ki=B1&pd=2000-05-03
EP	0612463	B2	2000-05-24	de	TITLE	1	ANORDNUNG ZUR HERSTELLUNG EINES FILMS AUF DIE LOECHERWAENDE IN GEDRUCKTEN SCHALTUNGEN
EP	0612463	B2	2000-05-24	en	TITLE	1	DEVICE FOR FORMATION OF A FILM ON THE WALLS OF HOLES IN PRINTED CIRCUIT BOARDS
EP	0612463	B2	2000-05-24	fr	TITLE	1	DISPOSITIF DE FORMATION D'UNE COUCHE SUR LES PAROIS DE TROUS MENAGES DANS LES CARTES A CIRCUITS IMPRIMES
EP	0612463	B2	2000-05-24	en	DESCR	1	<p id="p0001" num="0001">The invention concerns a device for formation of a film on the walls of small holes in boards for printed circuits.</p><p id="p0002" num="0002">A device for the formation of such films, according to the preamble of claim 1, is disclosed in EP-A-0 424 798. The circuit boards are immersed in a special bath so that a protective or antioxidizing film, or some film to improve surface quality, may be formed on said boards and especially on the walls of the holes bored through them. The components of said bath determine chemical reactions on the copper surfaces forming what is known as chemical tin or chemical copper or other products.</p><p id="p0003" num="0003">In mass production methods the boards follow each other through the bath moved along by some means of transport. This is clearly a lengthy process partly because the film deposited must be as uniform as possible.</p><p id="p0004" num="0004">The major difficulty arises over forming the film on the walls of the very small holes made in these boards since passage of the liquid through them is hindered by their minute diameters and also because their walls lie orthogonally<!-- EPO <DP n="2"> --> to the direction in which the boards move especially if this movement is parallel to their greater surfaces.</p><p id="p0005" num="0005">While the horizontal disposition of the boards may be optimum from the structural and functional standpoints, it does not facilitate action by gravity of the chemical agents on the sides of the above holes which, as said above, lie orthogonally to the surfaces of the boards.</p><p id="p0006" num="0006">Purpose of the present invention is to shorten working times and also to ensure the best possible formation of film inside the holes, as will be explained below.</p><p id="p0007" num="0007">Subject of the invention is a device for forming a film on the walls of small holes bored in printed circuit boards by immersion of said boards in a tank containing a specific liquid product.</p><p id="p0008" num="0008">One or more sets of nozzles, orthogonal to board movement, are placed in the tank in a position corresponding to that of the boards, said tank also containing a pump that continually takes up liquid and returns it to the bath under pressure applied through said nozzles.</p><p id="p0009" num="0009">In this way currents of liquid are made to flow through said holes.</p><p id="p0010" num="0010">The chemical reaction between the bath's components and the copper sides of the holes can result in formation of a film of chemical tin, chemical copper or of some other substance, as the case may be.</p><p id="p0011" num="0011">A special mechanism causes the boards to move along continuously on a level parallel to their greater surface and to the free surface of the liquid.</p><p id="p0012" num="0012">Preferably the tank contains sets of 'suction' nozzles through which liquid is taken from the bath, said sets<!-- EPO <DP n="3"> --> alternating with other sets of pressure nozzles, also orthogonal to movement of the boards and in a position corresponding to that of said boards, through which second responding to that of said boards, through which second set the liquid is returned to the bath.</p><p id="p0013" num="0013">Entry point of a pump is connected to the suction nozzles and its exit point to the pressure nozzles.</p><p id="p0014" num="0014">The nozzles of each set are fed on a plane which is orthogonal and transversal to movement of the boards.</p><p id="p0015" num="0015">In this way currents of liquid, alternating in one direction and in the opposite direction, will pass through the holes and in doing so speed up and improve formation of the desired film.</p><p id="p0016" num="0016">The nozzles consist of thin rectangular openings, each set being aligned transversally to the direction in which the boards move, the purpose of this being to set up laminar currents transversal to this movement.</p><p id="p0017" num="0017">In one execution each set of nozzles consists of several longitudinal slit-like mouths, placed along the top of horizontal cylindrical tubes.</p><p id="p0018" num="0018">These tubes are parallel, transversal to movement of the boards, some being joined by vertical connections to a longitudinal tube fixed to the entry side of the pump, and others to another tube, parallel to the first one, fixed to the exit side of the pump.</p><p id="p0019" num="0019">The invention offers some evident advantages. The currents of liquid in the tank flowing in opposite directions and passing back and forth inside the holes in the boards moving along the tank, increase the amount of movement between said liquid and the walls of the holes. This signifies an increase in the speed at which particles of liquid are deposited and in the chemical reactions that give rise to formation of film on the walls of said holes.<!-- EPO <DP n="4"> --></p><p id="p0020" num="0020">Not only does the invention achieve this but it also reduces costs of manufacturing printed circuits and improves their quality.</p><p id="p0021" num="0021">Characteristics and purposes of the invention will be made still clearer by the example of its execution here following illustrated by diagrammatic figures.</p><heading id="h0001"><u>Examples of execution</u></heading><p id="p0022" num="0022"><dl id="dl0001" compact="compact"><dt>Fig. 1</dt><dd>Perspective view of an apparatus for printed circuits with the device subject of the invention.</dd><dt>Fig. 2</dt><dd>Detailed view of the 'suction' nozzles.</dd><dt>Fig. 3</dt><dd>Detailed view of the pressure nozzles.</dd></dl></p><p id="p0023" num="0023">The device 10 comprises the frame 11 and tank 12 for holding the liquid product 13 that gives a chemical reaction on the boards 20 of printed circuits.</p><p id="p0024" num="0024">Said boards 20 are made to slide on a horizontal geometrical plane, indicated by XX, by means of two sets of motor-driven wheels 21 and 22 one above and the other below said plane.</p><p id="p0025" num="0025">The sets of transversal parallel manifolds 30 and 31, respectively alternated, are placed at established intervals below said plane XX.</p><p id="p0026" num="0026">Aligned on the upper side of said manifolds are the rectangular nozzles, 32 and 33 respectively.</p><p id="p0027" num="0027">The manifolds 30 are joined by connections 28 to the longitudinal tube 34 while manifolds 31 are joined by connections 29 to the longitudinal tube 35 parallel to the first one.</p><p id="p0028" num="0028">The tube 34 is connected to the exit side 36 of the pump 50 while the tube 35 is connected to the entry side 37 of said pump.</p><p id="p0029" num="0029">By means of this pump the liquid 13 contained in the tank 12 is continually recycled since it is sucked up through<!-- EPO <DP n="5"> --> the nozzles 32 and returned through nozzles 33 with the current 40 flowing upward and thus towards the printed circuit boards 20, and the current 41 caused by said boards to flow downward.</p><p id="p0030" num="0030">Penetration of said current 40 inside the holes 42 in the printed circuit boards and current 41 flowing out from said holes 42, increases the movement of liquid in relation to the walls of the holes and this in turn increases and potentiates the chemical reaction that leads to gradual formation of the film 43, especially of chemical tin or chemical copper on said walls.</p>
EP	0612463	B2	2000-05-24	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>Device (10) for formation of a film (43) on the walls of small holes (42) in boards (20) for printed circuits by chemical reaction obtained during their immersion in a liquid product (13) contained in a bath (12), wherein the device comprises at least one set of suction nozzles and at least one set of pressure nozzles orthogonally to said boards during said immersion and aligned in a position transversely to said moving direction of said boards and comprises a pump (50) that continually takes up liquid (13) from the bath (12) through said set of suction nozzles (32) and returns it under pressure to said bath (12) through said set of pressure nozzles (33) creating currents (40, 41) of said liquid passing directly from said nozzles to said boards through the holes (42) back and forth therein to increase movement between the liquid (13) and the walls of said holes (42) to accelerate and improve formation of the film (43).<!-- EPO <DP n="7"> --></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>Device (10) as in claim 1<br/>characterized in that the film (43) is of chemical tin.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>Device as in claim 1<br/>characterized in that the film (43) is of chemical copper.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>Device (10) as in claim 1<br/>characterized in that specially provided mechanisms (21) (22) determine continuous translation,on the level,of the boards (20), parallel to themselves and to the free surface of the liquid (13).</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>Device (10) as in claim 1<br/>characterized in that a specially provided mechanism (21) (22) determines continuous translation, on the level, of the boards (20), parallel to their greater surface and to the free surface of the liquid (13), there being one or more sets of suction nozzles (32) by which the liquid (13) is drawn up from the bath (12), alternating with other sets of pressure nozzles (33) by means of which the pump (50)<!-- EPO <DP n="8"> --> returns the liquid (13) to the bath (12), this setting up inside the holes (42) in the translating boards (20), currents (41) of liquid (13) moving in one direction and currents (40) of liquid moving in the opposite direction, the purpose of this being to accelerate and further improve formation of the film (43).</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>Device (10) as in claim 5<br/>characterized in that the nozzles (32) (33) have thin rectangular mouths aligned,in each set, transversal to the moving direction the boards (20) in order to determine laminar currents transversal to said direction of the boards.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>Device (10) as in claim 5<br/>characterized in that a pump (50) is connected at its entry side (37) to the suction nozzles (32) and at its exit side (36) to the pressure nozzles (33), said pump (50) therefore simultaneously sucking up the liquid (13) from the bath (12) and returning it thereto.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>Device (10) as in claim 5<br/>characterized in that each set of nozzles (32) (33) is obtained from a quantity of longitudinal slit-like mouths aligned and made in the top of horizontal cylindrical manifolds (30) (31), parallel and transversal to the moving direction of the boards (20), some being joined by vertical connections (28) (29) to one longitudinal tube (35) fixed to the entry side (37) of the pump (50) and others to another tube (34) parallel to the first one and connected to the exit side (36) of the pump (50).</claim-text></claim>
EP	0612463	B2	2000-05-24	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Vorrichtung (10) fÃ¼r die Herstellung eines Films (43) auf den WÃ¤nden kleiner LÃ¶cher (42) in Platten (20) fÃ¼r gedruckte Schaltungen durch eine chemische Reaktion, welche wÃ¤hrend deren Eintauchen in ein flÃ¼ssiges Produkt (13) erhalten wird, welches in einem Becken (12) enthalten ist, wobei die Vorrichtung mindestens eine Reihe von SaugdÃ¼sen und mindestens eine Reihe von DruckdÃ¼sen umfaÃŸt, welche wÃ¤hrend des Eintauchens orthogonal zu den Platten sind und in einer Position transversal zu der Bewegungsrichtung der Platten ausgerichtet sind, und eine Pumpe (50) umfaÃŸt, welche kontinuierlich FlÃ¼ssigkeit (13) aus dem Becken (12) durch die Reihe von SaugdÃ¼sen (32) entnimmt und sie unter Druck Ã¼ber die Reihe von DruckdÃ¼sen (33) in das Becken (12) zurÃ¼ckfÃ¼hrt, wobei StrÃ¶mungen (40, 41) der FlÃ¼ssigkeit erzeugt werden, welche direkt von den DÃ¼sen zu den Platten durch die LÃ¶cher (42), darin hin und her, verlaufen, um die Bewegung zwischen der FlÃ¼ssigkeit (13) und den WÃ¤nden der LÃ¶cher (42) zu steigern, um die Bildung des Films (43) zu beschleunigen und zu verbessern.<!-- EPO <DP n="10"> --></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Vorrichtung (10) gemÃ¤ÃŸ Anspruch 1), dadurch gekennzeichnet, daÃŸ der Film (43) aus chemischem Zinn ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Vorrichtung gemÃ¤ÃŸ Anspruch 1), dadurch gekennzeichnet, daÃŸ der Film (43) aus chemischem Kupfer ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Vorrichtung (10) gemÃ¤ÃŸ Anspruch 1), dadurch gekennzeichnet, daÃŸ ein entsprechender Kinematismus (21), (22) die stÃ¤ndige, waagerechte Translation der Platten (20) parallel zu sich selbst und dem freien Spiegel der FlÃ¼ssigkeit (13) verursacht.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Vorrichtung (10) laut Anspruch 1), dadurch gekennzeichnet, daÃŸ ein entsprechender Kinematismus (21), (22) die stÃ¤ndige, waagerechte Translation der Platten (20) parallel zu deren grÃ¶ÃŸerer OberflÃ¤che und dem freien Spiegel der FlÃ¼ssigkeit (13) verursacht, wobei eine oder mehrere Reihen sogenannter SaugdÃ¼sen (32) vorgesehen sind, von denen die FlÃ¼ssigkeit (13) aus dem Becken (12) gesaugt wird, und zwar abwechselnd mit anderen DÃ¼senreihen (33), sogenannten DruckdÃ¼sen, durch die die Pumpe (50) die FlÃ¼ssigkeit (13) wieder in das Becken (12) lÃ¤ÃŸt, wodurch in den kleinen LÃ¶chern (42) der sich verschiebenden Platten (20) FlÃ¼ssigkeits-(13) StrÃ¶me (41), die in einer Richtung, und FlÃ¼ssigkeits- (13) StrÃ¶me (40) gebildet werden, die in der entgegengesetzten Richtung verlaufen, und zwar um die Bildung des Films (43) zu beschleunigen und zu verbessern.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Vorrichtung (10) gemÃ¤ÃŸ Anspruch 5), dadurch gekennzeichnet, daÃŸ die Dosen (32), (33) schmale rechteckige Ã–ffnungen aufweisen, die bei jeder Reihe quer zur Translationsrichtung der Platten (20) ausgerichtet sind, und zwar um quer zu dieser Translation verlaufende laminare StrÃ¶me zu erzeugen.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Vorrichtung (10) gemÃ¤ÃŸ Anspruch 5), dadurch gekennzeichnet, daÃŸ eine Pumpe (50) an ihrem EinlaÃŸ (37) mit den SaugdÃ¼sen (32) und an ihrem AuslaÃŸ (36) mit den DruckdÃ¼sen (33) verbunden ist, wobei diese Pumpe (50) gleichzeitig fÃ¼r die Ansaugung des FlÃ¼ssigkeit (13) aus dem Becken (12) und deren WiedereinlaÃŸ in dasselbe sorgt.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Vorrichtung (10) gemÃ¤ÃŸ Anspruch 5), dadurch gekennzeichnet, daÃŸ eine Reihe Dosen (32), (33), die durch eine Vielfalt von schlitzfÃ¶rmigen LÃ¤ngsÃ¶ffnungen gebildet wird, die an der Spitze von Sammlern (30), (31) ausgerichtet und angeordnet sind, die zylindrisch und horizontal sind und parallel und quer<!-- EPO <DP n="11"> --> zur Translation der Platten (20) verlaufen, und mit senkrechten AnschluÃŸstÃ¼cken (28), (29) zum Teil an eine LÃ¤ngsleitung (35) und an den EinlaÃŸ (37) der Pumpe (50) angeschlossen sind, und zum Teil mit einer zweiten Leitung (34) verbunden sind, die parallel zur ersten verlÃ¤uft und an den AuslaÃŸ (36) der Pumpe (50) angeschlossen ist.</claim-text></claim>
EP	0612463	B2	2000-05-24	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Dispositif (10) pour la formation d'une pellicule (43) sur les parois de petits trous (42) dans des plaques (20) pour circuits imprimÃ©s par rÃ©action chimique obtenue pendant l'immersion dans un produit liquide (13) contenu dans un bain (12) dans lequel le dispositif comprend au moins une sÃ©rie de buses d'aspiration et au moins une sÃ©rie de buses de pression perpendiculairement auxdites plaques pendant ladite immersion et alignÃ©es dans une position transversalement Ã  ladite direction de dÃ©placement desdites plaques et comprend une pompe (50) qui prÃ©lÃ¨ve continuellement du liquide (13) du bain (12) par l'intermÃ©diaire de ladite sÃ©rie de buses d'aspiration (32) et qui le rÃ©introduit sous pression dans ledit bain (12) par l'intermÃ©diaire de ladite sÃ©rie de buse de pression (33) en crÃ©ant des courants (40, 41) dudit liquide passant directement desdites buses auxdites plaques Ã  travers les trous (42) en aller et retour dedans pour augmenter le mouvement entre le liquide (13) et les parois desdits trous (42) pour accÃ©lÃ©rer et amÃ©liorer la formation de la pellicule (43).<!-- EPO <DP n="13"> --></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Dispositif (10) conformÃ©ment Ã  la revendication 1), caractÃ©risÃ© par le fait que la pellicule (43) est en Ã©tain chimique.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Dispositif conformÃ©ment Ã  la revendication 1), caractÃ©risÃ© par le fait que la pellicule (43) est en cuivre chimique.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Dispositif (10) conformÃ©ment Ã  la revendication 1), caractÃ©risÃ© par le fait qu'un cinÃ©matisme spÃ©cial (21), (22) dÃ©termine la translation en continuitÃ© des plaques (20) Ã  plat, parallÃ¨lement Ã  celles-ci et au fil libre du liquide (13).</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Dispositif (10) conformÃ©ment Ã  la revendication 1), caractÃ©risÃ© par le fait qu'un cinÃ©matisme spÃ©cial (21), (22) dÃ©termine la translation en continuitÃ© des plaques (20) Ã  plat, parallÃ¨lement Ã  leur surface majeure et au fil libre du liquide (13),Ã©tant prÃ©disposÃ©es une ou plusieurs sÃ©ries de buses (32) appelÃ©es d'aspiration, d'oÃ¹ le liquide (13) est aspirÃ© par la cuve (12), alternÃ©es Ã  d'autres sÃ©ries de buses (33) appelÃ©es de pression, Ã  travers lesquelles la pompe (50) admet de nouveau le liquide (13) dans la cuve (12), se dÃ©terminant par consÃ©quent dans les petits trous (42) des plaques (20) de translation, des courants (41) de liquide (13) orientÃ©es dans un sens et des courants (40) de liquide orientÃ© dans le sens opposÃ© et cela dans le but d'accÃ©lÃ©rer et d'amÃ©liorer<!-- EPO <DP n="14"> --> ultÃ©rieurement la formation de la pellicule (43).</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Dispositif (10) conformÃ©ment Ã  la revendication 5), caractÃ©risÃ© par le fait que les buses (32), (33) ont des ouvertures rectangulaires fines, alignÃ©es dans chaque sÃ©rie, transversalement Ã  la direction de translation des plaques (20) et cela dans le but de dÃ©terminer des courants laminaires transversaux Ã  cette translation.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Dispositif (10) conformÃ©ment Ã  la revendication 5), caractÃ©risÃ© par le fait qu'une pompe (50) est reliÃ©e Ã  son entrÃ©e (37) aux buses (32) appelÃ©es d'admission et Ã  sa sortie (36) par des buses (33) appelÃ©es de pression, cette pompe (50) effectuant donc simultanÃ©ment l'aspiration du liquide (13) de la cuve (12) et l'admettant de nouveau dans celle-ci.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Dispositif (10) conformÃ©ment Ã  la revendication 5), caractÃ©risÃ© par le fait que chaque sÃ©rie de buses (32), (33), obtenue par une pluralitÃ© de bouches en fente longitudinales, alignÃ©es et prÃ©disposÃ©es au sommet de collecteurs (30), (31) cylindriques horizontaux, parallÃ¨les et transversaux Ã  la translation des plaques (20) et reliÃ©s par des raccords (28), (29) verticaux, en partie Ã  une tuyauterie (35) longitudinale et reliÃ©e Ã  l'entrÃ©e (37) de la pompe (50), et en partie Ã  une seconde conduite (34), parallÃ¨le Ã  la premiÃ¨re, reliÃ©e Ã  la sortie (35) de la pompe (50).</claim-text></claim>
EP	0612463	B2	2000-05-24	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0612463&ki=B2&pd=2000-05-24
EP	0615422	B1	2000-01-19	de	TITLE	1	GERÃ„T ZUM MESSEN DES DRUCKES IM VORHOF DES HERZENS
EP	0615422	B1	2000-01-19	en	TITLE	1	APPARATUS FOR THE MEASUREMENT OF ATRIAL PRESSURE
EP	0615422	B1	2000-01-19	fr	TITLE	1	APPAREIL DE MESURE DE LA PRESSION ATRIALE
EP	0615422	B1	2000-01-19	en	DESCR	1	<p id="p0001" num="0001">The present invention relates generally to the measurement of blood pressure and, more specifically, to the determination of mean left atrial blood pressure. Many invasive methods of determining mean left atrial pressure are known, but the invention aims to provide a less invasive technique (without requiring puncturing of an artery) for monitoring mean left atrial pressure.</p><p id="p0002" num="0002">US-A-4,409,986 discloses an esophageal cardiac pulse probe for monitoring cardiac pulse wave forms. The apparatus is intended for monitoring sounds from the heart and lungs, but is not disclosed as being suitable for measuring mean left atrial pressure. The apparatus comprises a sensing probe including and inflatable balloon, means for inserting said sensing probe into an esophogus, and inflation means for inflating said ballon and means for measuring the balloon pressure.</p><p id="p0003" num="0003">The invention provides apparatus as set out in Claim 1,</p><p id="p0004" num="0004">Thus, the<!-- EPO <DP n="2"> --> invention seeks to non-invasively and easily obtain a determination of a person's mean left atrial transmural pressure.</p><p id="p0005" num="0005">In order to non-invasively determine a person's mean left atrial pressure safely, accurately, and reliably, in accordance with the present invention a balloon is inserted into the person's esophagus and positioned adjacent the left atrium and inflated, and the mean balloon pressure is measured when the amplitude of balloon pressure oscillations effected by the left atrial pressure is at a peak. This peak amplitude is indicative of resonating of the balloon pressure at a pressure effected by the person's mean left atrial pressure, in accordance with the oscillometric principle. This pressure is thus determinative approximately of mean left atrial pressure. The mean left atrial transmural pressure may be determined by subtracting therefrom the pleural pressure, i.e., the pressure on the outside of the heart. It is envisioned that further refinements of this method may lead to the ability to determine other left atrial pressure values such as diastolic and systolic left atrial pressures or other pressures associated therewith.</p><p id="p0006" num="0006">The above and other aims, features, and advantages of the present invention will be apparent in the following description, provided purely by way of example, when read in conjunction with the accompanying drawings in which like reference numerals denote the same or similar parts throughout the several views.</p><p id="p0007" num="0007">In the drawings:-<ul id="ul0001" list-style="none" compact="compact"><li>Fig. 1 is a side view of a combination of a balloon-containing catheter and an<!-- EPO <DP n="3"> --> electrode-containing catheter in accordance with the present invention with the balloon inflated;</li><li>Fig. 2 is an enlarged side sectional view of the balloon of Fig. 1;</li><li>Fig. 3 is a partial left lateral sectional view of the human body taken along the mid-sagittal plane and showing the balloon of Fig. 1 within the esophagus and adjacent the left atrium of the heart;</li><li>Fig. 4 is a front sectional view of the human body illustrating the position of the heart</li><li>Fig. 5 is a top sectional view of the human body, taken along lines 5-5 of Fig. 4, at the level of the seventh thoracic vertebra and with the balloon of Fig. 1 in the esophagus :</li><li>Fig. 6 is a schematic view of apparatus, including the balloon-containing catheter of Fig. 1, which embodies the present invention;</li><li>Fig. 7 is a pressure trace of the left atrial pressure during one cardiac cycle as sensed by the balloon of Fig. 1 when adjacent the left atrium;</li><li>Fig. 8 is a graph of an esophageal electrocardiogram of the left atrium during one cardiac cycle;</li><li>Fig. 9 is a pressure trace of an unfiltered signal of balloon pressure with respiratory and cardiac effected oscillations when the balloon of Fig. 1 is adjacent the left atrium, as the balloon is gradually pressurized;</li><li>Fig. 10 is a pressure trace of mean balloon pressure for the pressure trace of Fig. 1;</li><li>Fig. 11 is a pressure trace of amplified cardiac signal on a steady baseline which signal is derived from the balloon pressure trace of Fig. 9 and covers the same time period as that of Figs. 9 and 10;</li><li>Fig. 12 is a graph of an electrocardiogram<!-- EPO <DP n="4"> --> taken simultaneously with the pressure traces of Figs. 9, 10 and 11;</li><li>Fig. 13 is a schematic view of an alternative embodiment of the present invention, it being understood that this embodiment is meant to include the portion of apparatus of FIg. 6 which is connected to line 60:</li><li>Fig. 14 is a schematic view of an alternative embodiment of the present invention, it being understood that this embodiment is meant to include the portion of apparatus of Fig. 6 which is connected to line 60;</li><li>Fig. 15 is a view similar to that of Fig. 1 of the catheter apparatus of Fig. 14; and</li><li>Fig. 16 is a view similar to that of Fig. 3 of an alternative means for sensing position of an esophageal balloon adjacent the left atrium.</li></ul></p><p id="p0008" num="0008">Referring to Figs. 1 and 2, there is illustrated generally at 19 catheter apparatus including a hollow catheter 20 comprising a length of flexible tubing 22 having a bore or lumen 23 and on one end of which is attached a balloon 24 for flow communication with the lumen 23 for pressurization of the balloon and for sensing the pressure thereof. An electrode 21 may be positioned just above the balloon 24 for obtaining an esophageal electrocardiogram and an electrical lead 25, within a second catheter 27, provided thereto, as will be discussed in greater detail hereinafter.</p><p id="p0009" num="0009">Referring to Fig. 3, there is illustrated the placement of the balloon 24 within the esophagus 26 of a human body for the purpose of sensing the mean pressure of the left atrium 28 of the heart 30. The catheter 20 is inserted balloon first through nasal<!-- EPO <DP n="5"> --> passage 32, pharynx 34, then into the esophagus 26. If desired, the balloon may alternatively be inserted through the mouth. As shown in Fig. 3, the outer wall of the left atrium 28 is adjacent and essentially in direct contact with the outer wall of the esophagus 26, and advantage is taken of this relationship to determine mean left atrium pressure by means of the balloon 24 thusly inserted non-invasively into the esophagus 26 and positioned therealong adjacent the left atrium so as to be sufficiently affected thereby to sense left atrium pressure, as will be discussed in greater detail hereinafter.</p><p id="p0010" num="0010">The tubing 22 may be composed of any suitable flexible, chemically inert, non-toxic material such as polyvinyl chloride for withstanding operating pressures without significant expansion. A preferred tubing is a TygonÂ® brand polyvinyl Chloride tubing having an inner diameter of approximately 1.3mm (0.050") which is a product of Cole-Parmer Instrument Co., 7425 North Oak Park Avenue, Chicago, Illinois 60648-9930, as shown on page 636 of the Cole-Parmer 1989-90 Catalog. The tubing 22 has a suitable length which may be perhaps 80 cm. The tubing 22 may desirably have markings (not shown) along the length thereof to indicate distance therealong so that the balloon 24 may be initially positioned approximately adjacent the left atrium 28. The tubing may contain a portion 18 which extends over the length of the balloon 24 and a portion 15 which extends from the balloon. Portions 15 and 18 are connected by means of a stainless steel ferrule 44 over which the tubing is press fit. The distal end of the balloon is closing by plugging by a cylindrical plug 42 of stainless steel or the like over which tubing portion 18 is<!-- EPO <DP n="6"> --> press fit. At each balloon end, a sleeve 43 is fitted over the tubing portion 18 to provide a larger diameter for securing the balloon fabric. Each balloon end is then sealed by surgical thread 38 and/or silicone cement. A plurality of apertures 46 are provided in the tubing (portion 18) wall over a distance from the closed end 42 equal to less than the balloon length to provide flow communication between the tubing 22 and the interior of the balloon 24 for inflating the balloon and for sensing pressure therein. The balloon 24 fits over the tubing portion 18 containing the apertures 46 and is attached to the tubing 22 at end portion 42 and at ferrule or second portion 44 between which portions are the apertures 46, as illustrated in Fig. 2. Pressurization and sensing lines may be attached at the end 40, which is opposite the balloon end 42, as will be discussed in greater detail hereinafter.</p><p id="p0011" num="0011">However, other suitable means may be used for such attachment. For example, the balloon may be fixed over the end of a catheter the end of which is plugged. The balloon 24 may be constructed of any suitable flexible non-toxic film which can withstand operating pressures without rupture or irreversible deformation. The balloon 24 may have a capacity of perhaps about 2 milliliters. When inflated within the pressure range for measuring mean left atrial pressure, the balloon 24 takes on a generally cylindrical shape, as illustrated in Figs. 1 and 2. The thickness of the material of which the balloon 24 is made is perhaps about 0.013mm (0.0005"). The balloon 24 should function properly in any rotational orientation around the longitudinal catheter axis. The balloon 24 may, for example, be constructed of low density polyethylene film such as ExtrelÂ® SF brand polyethylene film, a product of Exxon Chemical<!-- EPO <DP n="7"> --> Co., Polymers Group, Division of Exxon Corp., 351 North Oakwood Road, Lake Zurich, Illinois 60047-1562.</p><p id="p0012" num="0012">Referring to Figs. 4 and 5, it should be noted that the esophagus 26 is sandwiched between the left atrium 28 and the vertebral column 48 so that when the balloon 24 is positioned adjacent the left atrium 28 the vertebral column 48 acts similarly as an anvil for effective action of the left atrium pressure on the balloon 24 to affect the pressure therein as will be described hereinafter. The esophagus 26 is flanked by the left and right lungs 50 and 52 respectively. The aorta 54 is positioned generally between the esophagus 26 and the left lung 50 and in proximity to the vertebral column 48, as shown in Fig. 5.</p><p id="p0013" num="0013">Referring to Fig. 6, there is illustrated generally at 56 apparatus for pressurizing the balloon 24 and for sensing the pressure therein. For the purpose of precisely positioning the balloon 24 adjacent the left atrium 28, the balloon 24 is first statically filled with a predetermined quantity of perhaps 1.4 milliliter of air via syringe 58, with stop cock or valve 96 suitably open for passage of the air therefrom through line 60 to tubing 22 to which line 60 is suitably attached at the end portion 40.</p><p id="p0014" num="0014">The balloon pressure is transmitted from line 60 through line 62 to four-way stop cock or valve 64 which transmits the pressure through line 66 to one side 74 of the diaphragm 86 of a differential pressure transducer 68 and through line 70 to filter 72. Transducer 68 may, for example, be a Validyne model DP7 differential pressure transducer provided by Validyne Engineering Corp., 8626 Wilbur Avenue, Northridge, California 91324. Pressure from the<!-- EPO <DP n="8"> --> filter 72 is transmitted through line 76 and stop cock or valve 78 to the other side 80 of the transducer 68. The transducer 68 converts the net pressure signal acting on the diaphragm 86 to an electrical signal which is transmitted through line 82 to a first signal processor 84. Processor 84 may be any suitable conventional electronic signal processing circuit which amplifies and otherwise processes and conditions the electrical signal representations of pressure and communicates these signals to a display means 85 via line 87. Display means 85 may be a digital display, a strip chart recorder, a cathode ray tube, or any other suitable device for displaying or utilizing the signals from processor 84.</p><p id="p0015" num="0015">The balloon 24 will not only sense atrial pressure but will also record normal peristaltic waves from swallowing as well as pressure excursions from normal breathing. Peristaltic waves are easily distinguished by their high amplitude (up to 10 kPa (100 cm of water)) and relative infrequency and can therefore be ignored. Respiratory excursions (typically from - 1 kPa to + 1kPa (-10 to +10 cm of water)) at frequencies of 0.1 to 0.8 Hertz) can interfere with left atrial pressure wave form and measurement. They are therefore filtered out during signal processing as described hereinafter.</p><p id="p0016" num="0016">Filter 72 is a low pass mechanical filter such as, for example, a NuproÂ® micrometer needle valve connected as shown in Fig. 6, a product of Nupro Company of 4800 East 345th Street, Willoughby, Ohio 44094. The unprocessed signal carrying both the higher frequency cardiac wave form (generally 1.5 to 9.0 Hertz) effected by left atrial pressure and the lower frequency respiratory wave form (generally 0.1 to 0.8 Hertz) goes directly to the first side 74 of<!-- EPO <DP n="9"> --> the differential pressure transducer 68 via line 66. An identical signal is also transmitted to the variable control valve 72. By restricting an orifice (not shown) in filter 72, in accordance with principles commonly known to those of ordinary skill in the art to which this invention pertains, the balloon pressure wave is filtered to selectively pass the lower frequency component, which includes respiratory artifact, through line 76 and valve 78 to the other side 80 of the differential transducer 68, and the higher frequency component is excluded. This in effect allows the respiratory artifact arriving almost in phase on both sides of the transducer diaphragm 86 to cancel itself out so that the cardiac wave form is recovered and outputted as an electrical signal through line 82 to the first signal processor 84.</p><p id="p0017" num="0017">With the balloon inflated, it is precisely positioned adjacent the left atrium 28 by moving it up or down the esophagus 26 by withdrawing or inserting the catheter 20 at the nose until a typical left atrial pressure wave form, illustrated at 88 in Fig. 7, is seen on the pressure trace from the first signal processor 84. As previously discussed, this wave form 88 comprises the balloon pressure signal with the lower frequency respiratory wave form filtered out. This wave form 88 may be confirmed as being a typical left atrial pressure wave form by comparison with a simultaneous esophageal electrocardiogram, illustrated at 140 in Fig. 8, which is recorded by a conventional electrocardiograph, illustrated at 92 in Fig. 6. Electrocardiogram 140 is obtained by the use of a stainless steel electrode, illustrated at 21, which is suitably attached to the catheter 20 just above the balloon 24. However, the electrode 21 may be<!-- EPO <DP n="10"> --> otherwise adjacent the balloon 24. For example, an electrode for this purpose could comprise conductive material on the surface of the balloon. An electrical lead 25 is attached to the electrode and extends within a second catheter 27 and to electrocardiograph 92 for transmitting the signals picked up by the electrode 21 for processing therein. The lead 25 may, for example, be silvered 30 AWG wire-wrapping wire provided by OK Industries, 4 Executive Plaza, Yonkers, New York 10701. The catheters 20 and 27 may be held together by suitable securing means such as, for example, cyclohexanone glue 16. Alternatively, a double-lumen catheter of pre-formed polyvinyl chloride may be used. The electrode 21 is preferably in the shape of a ring which encircles catheter tubing 22 so as to insure that it will be suitably positioned without interference by tubing 22 for sensing left atrial electrical activity. In accordance with conventional practice, it may be required that skin electrodes 94 also be hooked-up to the subject. The wave form 140 is characterized by a wave portion (which heralds atrial depolarization) which reaches a high voltage and becomes bi-phasic with a sharp upstroke and shows an intrinsicoid deflection. Thus, points A, C, and V, shown on wave form 88 in Fig. 7, are three essential components of the left atrial pressure wave, and these points are known to correspond to points P, R, and T respectively on the electrocardiogram 140 of Fig. 8 thus confirming that the wave form 88 is a typical left atrial pressure wave form.</p><p id="p0018" num="0018">When, as the balloon and esophageal electrode are moved up and down the esophagus, a typical left atrial wave form, similar to wave form 88, is sensed on the pressure trace from the first signal<!-- EPO <DP n="11"> --> processor 84, which indicates that the balloon 24 is suitably positioned adjacent the left atrium 28, the balloon 24 is then fixed in place by applying tape over the catheter 20 and onto the upper lip just beneath the nose. The distinctiveness of this wave form, confirmed by use of electrode 21, may desirably reduce the level of skill required for proper positioning of the balloon. Alternatively, a conventional surface or skin electrocardiogram may be obtained, by use of electrodes 94 on the subject's body and wired to electrocardiograph 92, for comparison with wave form 88 to determine when the balloon is correctly positioned. However, the use of the esophageal electrocardiogram 140 for this purpose is considered preferable since it may provide a more distinctive wave form which is more easily recognized. The use of either the esophageal or skin electrodes for positioning the balloon is advantageously suitable for use with the wide range of body size from premature neonates to adult men.</p><p id="p0019" num="0019">Other means for suitably positioning the sensing balloon may alternatively be used. For example, as illustrated in Fig. 16, a positioning balloon 200 may be positioned on a catheter 210 to contact the esophago-gastric junction 204 at the stomach 212 of an adult and a sensing balloon 206 positioned on a separate catheter 202 (since the positioning balloon 200 must be inflated before inflation of the sensing balloon 206 is begun) and at a distance from the positioning balloon 200 which approximates the relatively constant distance, illustrated at 208, in an adult between the esophago-gastric junction 204 and the left atrium 28. This distance 208 is of course relatively constant in adults but not in premature neonates and infants.<!-- EPO <DP n="12"> --></p><p id="p0020" num="0020">As previously discussed, the pressure wave form 88 is insufficient for determining mean left atrial pressure due to its amplitude being a function of the elasticity of the system, the amount of gas in the balloon, and the initial pressure within it, as well as the intra-atrial pressure and the surrounding tissue pressure. With the balloon 24 precisely positioned, processing can begin for accurately and non-invasively determining the mean left atrial pressure, as discussed hereinafter.</p><p id="p0021" num="0021">After proper placement has been accomplished, sensing balloon 24 is initially evacuated to perhaps - 1 kPa to - 1.2 kPa (-10 to -12 cm of water) pressure, less than the minimum expected pressure to be measured, using syringe 58, with the stop cock 96 open thereto. This purges the system of any gas, prior to beginning a measurement, to insure consistency, accuracy, and reliability of pressure measurements. The system is similarly also purged of any residual gases between measurements.</p><p id="p0022" num="0022">After the balloon 24 has been properly placed adjacent the left atrium 28 and evacuated, it is gradually inflated with air or another suitable inert gas such as, for example, nitrogen gas or a suitable liquid such as, for example, water for the purpose of determining mean left atrial pressure as hereinafter described. The use of a liquid may provide enhanced gain. If a liquid is used, it may be provided to line 60 by means of a liquid-filled syringe to which is attached a suitable mechanical or hydraulic pressurization device. The use of air may simplify the equipment and its use and may therefore be preferred for this purpose. A source of air under a sufficient pressure such as, for example, 276 kPa (40 psi) for inflating the balloon 24 is illustrated at 100. With stop cocks or valves 96<!-- EPO <DP n="13"> --> and 102 opened to connect the metering gas supply valve 98 with the line 60 and with syringe 58 closed to line 60 by valve 96, the gas from source 100 is routed through line 104 to the metering valve 98 where it is released to line 106 and through stop cocks 102 and 96 and line 60 to catheter 20 in metered quantity for gradually inflating the balloon 24. As used herein and in the claims, the term "line", unless otherwise specified, is meant to refer to tubing, a catheter, an electrically conductive wire, or other suitable means for transmitting a pressure or electrical signal. Valve 98 is a NuproÂ® brand micrometer needle valve, a product of Nupro Company of 4800 East 345th Street, Willoughby, Ohio 44094, which is constructed to allow a broad range of near constant flow rates against back pressures to a maximum of about 5 kPa (50 cm water or 0.74 psi). It is precalibrated to provide gas flows up to about 4 milliliters per minute on average. Other suitable valves may alternatively be provided. Metering valve 98 is thus opened to provide a suitable gas flow such as a flew of approximately 1.0 milliliter per minute for gradually filling the sensing balloon 24 at a constant rate.</p><p id="p0023" num="0023">While not wishing to be bound by theory here or elsewhere in this specification, the following is believed to occur as the sensing balloon 24 is pressurized. The gradual filling of the sensing balloon 24 causes the pressure therein to increase at a generally slow steady rate which, in accordance with the theory of the previously discussed oscillometric effect, is affected by the atrial pressure causing oscillations therein as well as by respiratory waves. As the mean balloon pressure approaches the mean left atrial pressure, the atrial<!-- EPO <DP n="14"> --> pressure oscillations of balloon pressure increase in intensity or amplitude until the balloon pressure resonates maximally, i.e. reaches a peak amplitude, when the mean balloon pressure approximates the mean left atrial pressure. Thereafter, as the mean balloon pressure continues to increase, the amplitude of oscillations due to the atrial pressure decreases. More specifically, the balloon pressure oscillates maximally when its expansion has increased the pressure in the tissue surrounding the left atrium to the point where the mean tissue pressure equals mean left atrial pressure (MLAP).</p><p id="p0024" num="0024">Figs. 9 to 12 are illustrations of four electronic displays or tracings used to record and display the absolute balloon pressure wave form 108 (Fig. 9), the mean balloon pressure wave form 110 (Fig. 10), the differential signal 112 with added gain from the signal processor 84 (Fig. 11), and a simultaneous electrocardiogram 114 (Fig. 12). Vertical line 116 in each of Figs. 9 to 12 represents the same point in time. A comparison of the electrocardiograms 140 and 114 in Figs. 8 and 12 respectively indicates that the time scale for Figs. 7 and 8 is greatly expanded relative to the time scale for Figs. 9 to 12, i.e., the wave form 140 in Fig. 8 covers a period of about a second, and a multitude of such waves over a multitude of seconds is shown in Fig. 12.</p><p id="p0025" num="0025">The absolute balloon pressure wave form 108 is obtained from a suitable transducer 118 connected to line 60 via line 120. The transducer 118 may, for example, be a Cobe CDX III transducer provided by Cobe Laboratories, Inc., 1185 Oak Street, Lakewood, Colorado 80215. The transducer 118 converts the balloon pressure signal in line 120 to an electrical signal which is transmitted through line 122 to<!-- EPO <DP n="15"> --> second signal processor 124, which is a suitable conventional electronic signal processing circuit which suitably processes and conditions the electrical signal representations of pressure and transmits these signals to a suitable display means 142, which may be similar to display means 85, via line 144. The processor 124 amplifies the signal for display as shown by tracing 108 in Fig. 9. Signal processor 124 also suitably processes the signal, in accordance with principles commonly known to those of ordinary skill in the art to which this invention pertains, to provide an electronic mean thereof as shown by tracing 110 in Fig. 10. The transducer 118 is referenced to one atmosphere of pressure absolute (101.3 kPa).</p><p id="p0026" num="0026">It should be recognized that ether suitable analog or digital electronic signal processing means can be employed to filter, amplify, compare, and otherwise process the signals. Both pressure transducers 68 and 118 are suitably calibrated against a water manometer prior to use.</p><p id="p0027" num="0027">A suitable relief valve 130 is provided in line 60 to protect the system 56 and the patient from over-pressurization. The relief valve 130 is set to open at a suitable pressure of perhaps 5 kPa (50 cm of water pressure) to vent the tubing and balloon to atmosphere in order to prevent dangerously high pressure such as might cause the balloon to rupture.</p><p id="p0028" num="0028">The absolute balloon pressure wave form 108 is comprised of low amplitude high frequency oscillations effected by left atrial pressure which are superimposed on high amplitude low frequency respiratory oscillations which are in turn superimposed on the gradual increase in balloon pressure provided by gas supply valve 98. The mean balloon pressure wave form is shown at 110 in Fig.<!-- EPO <DP n="16"> --> 10. By "mean balloon pressure" is meant, for the purposes of this specification and the claims, the balloon pressure at the mean of each of the high frequency (greater than about 0.8 Hertz) oscillations. Stated another way, the "mean balloon pressure" wave form 110 is the absolute balloon pressure wave form 108 with the high frequency oscillations removed therefrom. When a signal is filtered, waves which are removed therefrom do not appear in the output while those which are passed or extracted do appear in the output. The abrupt slope change indicated at 200 from a fast to a slowed rate of pressure increase is indicative of the equalization of balloon pressure with the surrounding tissue pressure prior to balloon expansion.</p><p id="p0029" num="0029">The differential signal 112 is provided by the signal processor 84 after low frequency oscillations representing the respiratory artifact are filtered out by the differential pressure transducer 68 so that the left atrial pressure wave form is recovered. In addition, the rising absolute pressure due to the gradual inflation of the balloon 24 (which is treated by the filter 72 similarly as a low frequency oscillation and thus passed to transducer side 80) is also cancelled out by the differential transducer 68 so that the pressure signal 112 processed by signal processor 84 is on a steady base line. The signal 112 is then further filtered electronically, amplified, and displayed by the signal processor 84 on display 85.</p><p id="p0030" num="0030">Wave form 112 may alternatively be obtained by electronically inverting the mean balloon pressure wave form 110 and adding the inverted wave form to the absolute balloon pressure wave form 108 and amplifying the oscillations obtained.<!-- EPO <DP n="17"> --></p><p id="p0031" num="0031">The use of a bias balloon 150 for alternatively eliminating respiratory artifact to obtain signal 112 is illustrated in Fig. 13. The pressure in balloon 24 is transmitted through lines 60, 62, and 66 to one side 74 of differential pressure transducer 68 similarly as illustrated in Fig. 6. This pressure, which is also transmitted through line 120 to transducer 118 and converted to an electrical signal which is processed and displayed on display 142, includes the effects of respiratory artifact as well as atrial pressure. The bias balloon 150, similar to balloon 24 and similarly inserted by means of a catheter 152, which may be similar to catheter 20, may also be pressurized via line 60 as hereinafter discussed. Bias balloon 150 is inserted into the esophagus intermediate the position of the left atrium and the nasal or mouth passage, i.e., perhaps 3 or 4 cm. or more above the position of balloon 24, so that the pressure therein is not affected by left atrial pressure. But bias balloon 150 does sense respiratory artifact, i.e., pressure swings generated by respiration, and therefore may be said to reflect esophageal pressure and thus record the respiration induced fluctuation in esophageal pressure. The bias balloon pressure is transmitted through lines 154 and 156 to the other side 80 of differential pressure transducer 68. Thus, a pressure effected by absolute left atrial pressure plus respiratory artifact is applied to one side 74 of transducer 68, and a pressure effected by respiratory artifact is applied to the other side 80. The difference, representative of left atrial pressure without the respiratory artifact, is outputted as an electrical signal through line 82 to signal processor 84 which transmits a suitably processed signal of the<!-- EPO <DP n="18"> --> resulting difference wave through line 87 to signal display 85, which may be similar to display 142. One advantage of bias balloon 150 is that its use will eliminate respiratory artifacts regardless of their frequency. If desired, the bias balloon 150 could also be used to independently measure simultaneous esophageal pressure by transmitting the bias balloon pressure from line 154 via line 158 to transducer 160, which may be similar to transducer 118, which converts the pressure to an electrical signal which is then transmitted via line 162 to signal processor 164, which may be similar to processor 124, in which the signal is suitably processed and transmitted via line 166 to display 168, which may be similar to display 142.</p><p id="p0032" num="0032">As shown in Figs. 9 and 10, the low frequency oscillations representative of respiratory artifact decrease in amplitude as the pressure in the balloon 24 increases. In order that the same amplitude of respiratory wave at each point in time may be supplied to both sides of the pressure transducer 68 so that effective cancellation of respiratory artifact may be achieved, balloons 150 and 24 are both connected to gas supply 100 via line 60. Thus, lines 61 and 155 connect line 60 to line 154 for inflation of balloon 150. In order to prevent the cardiac signals from appearing on the bias balloon signal, a suitable low pass filter 157, which may be similar to filter 72, is connected so that line 61 extends from line 60 to input pressure from pressure source 100 to filter 157, and the output of filter 157, with the cardiac waves removed, is transmitted via lines 155 and 154 to balloon 150. In accordance with an alternative (not shown), two separate gas supplies may be provided for balloons 24 and 150 to prevent signal<!-- EPO <DP n="19"> --> contamination with suitable pressure transducers and electronic feedback means to automatically maintain the mean pressure in the bias balloon 150 equal to the mean pressure in the sensing balloon 24. In accordance with another alternative (not shown), two separate gas supplies may be provided with a pressure regulator on the bias balloon side which is referenced to the mean sensing balloon pressure and such that cardiac oscillations are not conducted across the regulator.</p><p id="p0033" num="0033">It should be understood that other means, for example, analog or digital filtering techniques applied directly to the absolute balloon pressure to remove low frequency artifacts such as from respiration or peristalsis may be used for deriving wave form 112 from the absolute balloon pressure, and such other means are meant to come within the scope of the present invention.</p><p id="p0034" num="0034">The wave form 112 is thus an oscillating signal of varying amplitude on a steady baseline. These oscillations, derived from absolute balloon pressure, are in response to the driving pressure of the left atrium.</p><p id="p0035" num="0035">By noting the peak resonant amplitude of the wave form 112 (Fig. 11) and comparing it to the simultaneous mean balloon pressure 110 (Fig. 10), the mean left atrial pressure can be determined. Thus, in accordance with the oscillometric principle, the mean balloon pressure approximates the mean left atrial pressure when the oscillations of wave form 112 are at a peak, i.e., the peak or highest amplitude oscillations in the wave form 112 occur at the time 116 the balloon pressure is equal to mean left atrial pressure. The mean left atrial pressure is thus determined from the example of Figs. 9 to 12 to be a pressure, illustrated at 128, of about 300 Pa (3 cm water).<!-- EPO <DP n="20"> --></p><p id="p0036" num="0036">It should be recognized that mean left atrial pressure may alternatively be approximated by reference to the absolute balloon pressure wave form 108. Thus, the relatively small amplitude of the high frequency oscillations on wave form 108 would permit one to estimate the mean balloon pressure from which an estimation of mean left atrial pressure may be obtained.</p><p id="p0037" num="0037">It should be understood that it is not essential to the present invention that the wave forms in Figs. 9 to 12 be actually obtained in graph or tracing form. For example, an electronic peak detector may alternatively be used to sense the maximum or peak amplitude, and associated electronics may then determine and display the corresponding mean left atrial pressure in accordance with principles commonly known to those of ordinary skill in the art to which this invention pertains.</p><p id="p0038" num="0038">The relaxed diameter of the normal adult esophagus is about 2.5 cm. The inflated balloon diameter should be less than this in order to avoid stretching the esophagus since, if this were to happen, not all of the balloon pressure would be applied to the left atrial wall with the result that the balloon pressure at peak oscillation would be higher than the mean left atrial pressure. In addition, if the balloon is too large, its inflation may trigger secondary peristalsis. On the other hand, if the inflated balloon diameter is too small, it will not be able to exert adequate pressure against the left atrium during inflation, nor will it have optimal contact area to optimize pulse transmission. The balloon length should be adequate to provide optimal longitudinal contact with the left atrium and pulmonary veins in which the mean<!-- EPO <DP n="21"> --> pressure equals mean left atrial pressure, but should not extend too far beyond the left atrium where it could pick up pressure artifacts from the aorta or lower esophageal sphincter. In accordance with the above requirements, for use in adults, the balloon 24 preferably has an inflated diameter, illustrated at 132 in Fig. 2, which is between about 0.9 and 1.5 cm and an inflated length, illustrated at 134 in Fig. 1, which is between about 3.0 and 4.0 cm. More preferably, the balloon 24 has an inflated diameter 132 of about 1 cm and an inflated length 134 of about 3.5 cm providing a volume of about 2 milliliters. This diameter still allows the vertebral column to serve as an anvil since the esophagus is normally collapsed. For children and neonates the above sizes will be suitably reduced.</p><p id="p0039" num="0039">Maximum oscillation of balloon pressure may coincidently occur just before the balloon reaches its full volume after which the balloon pressure may rise very sharply, as indicated at 196 in Fig. 10. Sometimes this sharp rise may obscure the point of maximum balloon oscillation. In order to allow better control of balloon pressure filling for smoother balloon inflation near the point of maximum oscillation, in accordance with a preferred embodiment, illustrated in Figs. 14 and 15, a balloon with an exhaust line for exhausting the balloon outside the body is used to slow such a rapid pressure rise. In this embodiment, a pair of catheters 170 and 172 containing lumens 171 and 173 respectively are attached to esophageal balloon 174. Catheter 170 is attached to line 60. Though not shown in Fig. 14 for ease of illustration, the equipment attached to line 60 in Fig. 6 should also be understood to be attached to line 60 in Fig. 14. Catheter 172 is connected via line 176 to a four-way<!-- EPO <DP n="22"> --> stopcock 178 or other suitable valve and subsequently via line 180 to a Nupro controlled exhaust valve 182 which exhausts through line 184 to atmosphere. Exhaust valve 182 may be of any suitable type such as, for example, one which is similar to control valve 98.</p><p id="p0040" num="0040">As discussed previously with respect to the embodiment of Fig. 6, when an exhaust valve is not used the control valve 98 is set at a constant flow rate and then left alone to gradually fill the balloon. However, with the stopcock 178 open to connect the exhaust valve 182 to the balloon 174, the exhaust valve 182 is set to a position which is determined by experience, and which can be determined by one of ordinary skill in the art to which this invention pertains without undue experimentation, and control valve 98 is used for balloon pressure control. The balloon 174 is pressurized by steadily opening the control valve 98 and using the exhaust valve 182, which is set at the fixed setting and left alone, to provide back pressure. The control valve 98 is thus continuously opened to increase the flow through the balloon 174 with the pressure gradually rising. At some point, in accordance with the oscillometric principle the balloon oscillates maximally, as effected by left atrial pressure, after which the oscillations decrease as the balloon pressure increases further. The exhaust valve 182 is provided to achieve finer supply gas control so that the peak of oscillations may be more precisely determined. Thus, as the pressure in the balloon 174 increases, it is believed that the flow through the exhaust valve 182 increases, thus slowing and stabilizing the pressure rise, without affecting the relative amplitudes of oscillations effected by left atrial pressure<!-- EPO <DP n="23"> --> whereby the peak in such oscillations may still occur at the same balloon pressure value from which mean left atrial pressure can be determined. An esophageal electrode wire 186 for an electrode 188, which may be similar to electrode 21, is routed through the exhaust line catheter 172 to thereby alleviate the need for a separate catheter for the wire 186. As seen in Fig. 15, the catheter 172 suitably extends into the interior of balloon 174 and has an open end 190 for receiving exhaust. By closing the stopcock 178, the embodiment of Fig. 14 can, if desired, be reverted for use without the exhaust line, similarly as discussed with respect to the embodiment of Fig. 6.</p><p id="p0041" num="0041">If desired, lumens 171 and 173 may be provided within a single catheter. In accordance with another alternative embodiment, a single lumen catheter may be provided with a side port which has a vent valve that could provide some back pressure during filling but which would attentuate the abrupt pressure rise when the balloon reaches its maximum volume. Yet another means for attenuating this abrupt pressure rise may be to throttle the flow-control valve as maximum balloon volume is reached so that filling toward the end stages is slowed.</p><p id="p0042" num="0042">In certain body positions such as supine and semi-recumbent, the heart weight bears on the esophagus. In other body positions such as standing, sitting, lying on the side, or prone, the heart weight would not bear on the esophagus. It is presently believed that the pressure effect of heart weight per se against the esophagus has little if any effect on the peak balloon oscillation pressure irregardless of the body position of the patient. However, in order to insure a measurement of peak<!-- EPO <DP n="24"> --> balloon oscillation pressure uninfluenced by heart weight, it is preferred that the determination of mean left atrial pressure, as hereinbefore described, be made while the patient is positioned standing, sitting, lying on the side, prone, or in any other position wherein the heart weight does not bear on the esophagus.</p><p id="p0043" num="0043">A physiologically and medically important pressure, the mean left atrial transmural pressure, can also be determined with information available from the catheter. This pressure is the difference between the mean left atrial pressure and the pleural pressure (the pressure of the tissue immediately surrounding the heart). It is important to know this transmural pressure because it can influence the degree to which fluid will leave the pulmonary capillaries and enter the lung tissue, causing pulmonary edema or "wet lungs".</p><p id="p0044" num="0044">The pleural pressure can be determined by measuring the mean esophageal pressure in the esophagus at a location above and away from the heart, i.e., at least about 3 or 4 cm above the heart, such as to be unaffected by pressure in the heart, using principles commonly known to those of ordinary skill in the art to which this invention pertains.</p><p id="p0045" num="0045">The mean esophageal pressure can be determined by moving the sensing balloon away from under the heart after peak oscillation measurement or by the use of a second balloon-tipped catheter. For example, bias balloon 150 of Fig. 13 may be used to obtain esophageal pressure, uninfluenced by heart weight, which is determined by measuring the balloon pressure at a slope change, which may be similar to slope change 200, from a fast to a slowed rate of pressure increase indicative of equalization of<!-- EPO <DP n="25"> --> balloon pressure with the surrounding tissue pressure, i.e., mean esophageal pressure, prior to balloon expansion. Alternatively, the mean esophageal pressure may be determined by evacuating balloon 150, then adding a small volume of gas (slightly greater than the dead space volume of the catheter and connecting tubing), and taking the mean of the resulting esophageal pressure wave form.</p><p id="p0046" num="0046">The apparatus of the present invention may be used for providing precise determination of mean left atrial pressure for patients connected to respirators. However, when a patient is connected to a breathing machine which uses positive end expiratory pressure (PEEP), the patient's pulmonary capillary wedge pressure (PCWP) and mean left atrial pressure (MLAP) may be elevated as a result, since all intra-thoracic structures are exposed to varying degrees to this pressure. Since mean esophageal pressure reflects intra-pleural pressure (a good measure of the pressure environment in the chest), the mean esophageal pressure will provide a measure of the effect of PEEP on thoracic structures. Thus, the mean left atrial transmural pressure, as provided by the catheter, provides an excellent means to understand the physiologic and clinical impact of PEEP on the heart and lungs since it takes into account simultaneous pressure changes induced in both the left atrium and the esophagus by the imposition of PEEP.</p><p id="p0047" num="0047">Using the apparatus of the present invention, as illustrated in Fig. 6 and using a surface electrocardiogram for positioning the balloon 24, average mean left atrial pressure measurements were obtained for two healthy adults with the catheter in these persons sitting upright dry or immersed to the neck in thermoneutral water. The results were as follows:<!-- EPO <DP n="26"> --> <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="3" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" rowsep="0" align="center">Subject</entry><entry namest="col2" nameend="col3" align="left">Average Mean Left Atrial Pressure</entry></row><row><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="center">Dry</entry><entry namest="col3" nameend="col3" align="center">Immersed</entry></row></thead><tbody valign="top"><row rowsep="0"><entry namest="col1" nameend="col1" align="left">No. 1</entry><entry namest="col2" nameend="col2" align="right">-343 Pa(-3.5 cm H<sub>2</sub>O)</entry><entry namest="col3" nameend="col3" align="char" char=".">+ 1.3 kPa (+13 cm H<sub>2</sub>O)</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">No.2</entry><entry namest="col2" nameend="col2" align="right">0 Pa</entry><entry namest="col3" nameend="col3" align="char" char=".">+ 1.5 kPa(+15cm H<sub>2</sub>O)</entry></row></tbody></tgroup></table></tables></p><p id="p0048" num="0048">A paper entitled <u>Hemodynamic Changes in Man during Immersion with the Head Above Water</u>, Aerospace Medicine, June, 1972, pp 592-598, shows data from subjects with intracardiac monitoring subjected to similar conditions. While the paper indicates that mean left atrial pressures were not measured, both mean right atrial and pulmonary artery diastolic pressures were measured. These pressures are known to be roughly similar to mean left atrial pressures in young healthy adults. As indicated in Table 1, p. 594, of the paper, the average values were: <tables id="tabl0002" num="0002"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="center">Dry</entry><entry namest="col3" nameend="col3" align="center">Immersed</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">Mean right a trial pressure</entry><entry namest="col2" nameend="col2" align="right">- 266 Pa (-2 mm Hg)</entry><entry namest="col3" nameend="col3" align="right">+ 2133 Pa (+16 mm Hg)</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Pulmonary artery diastolic pressure</entry><entry namest="col2" nameend="col2" align="right">-400 Pa (+3 mm Hg)</entry><entry namest="col3" nameend="col3" align="right">+ 2666 Pa (+20 mm Hg)</entry></row></tbody></tgroup></table></tables></p><p id="p0049" num="0049">Note that 1 mm Hg = 1.3 cm H<sub>2</sub>O = 133,3 Pa. These results indicate that the values of average mean left atrial pressure obtained, in accordance with the present invention, are within the expected range, i.e., both studies showed a 2 percent increase in pressures during immersion when referenced to one atmosphere in the corresponding units of measurement: 1000 cm H<sub>2</sub>0 or 760 mm or 101.3 kPa.</p><p id="p0050" num="0050">It should be understood that while the present invention has been described in detail herein, the<!-- EPO <DP n="27"> --> invention can be embodied otherwise without departing from the principles thereof. Such other embodiments are meant to come within the scope of the present invention as defined by the appended claims.</p>
EP	0615422	B1	2000-01-19	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>Apparatus for determining mean left atrial pressure comprising a sensing probe (24) including an inflatable balloon (24), means (20) for inserting said sensing probe (24) into an esophagus (26) adjacent the left atrium (28), and determining means (56) comprising inflation means (58) for inflating said balloon (24) and means (68) for measuring the balloon pressure when the amplitude of balloon pressure oscillations effected by the left atrial pressure when the balloon (24) is adjacent the left atrium (28) is at a peak to determine mean left atrial pressure from the effect of left atrial pressure on said probe (24).</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>Apparatus according to Claim 1, further including filtering means (72) for filtering the balloon pressure to remove oscillations thereof effected by respiratory waves whereby oscillations effected by the left atrial pressure may be passed substantially free of the effects of respiratory waves.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>Apparatus according to Claim 1 or Claim 2, wherein the inflation means (96,100,102,104,106) is adapted to gradually inflate said balloon (24) while the balloon (24) is adjacent the left atrium (28) so that balloon pressure oscillations are effected by left atrial pressure and respiratory waves as said balloon (24) is inflated and said determining means (56) is adapted to filter the balloon pressure and provide an output indicating the amplitude of oscillations effected by the left atrial pressure so that the mean left atrial pressure may be determined, in accordance with the oscillometric principle, from the mean balloon pressure when the indicated amplitude of the oscillations effected by the left atrial pressure is at a peak.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>Apparatus according to any of the preceeding claims, wherein said determining means (56) comprises transducer means (68) for converting the balloon pressure to an electrical signal, the transducer means (68) comprising a differential transducer means (68) having a diaphragm (86) for application of pressures on opposite sides (74,80) thereof for converting the difference in the applied pressures<!-- EPO <DP n="29"> --> to an electrical signal, means (84) for converting said electrical signal to an electrical signal of mean balloon pressure, means (66) for applying balloon pressure to one side (74) of said diaphragm (86), and means (70,72,76) for applying balloon pressure oscillations having a frequency less than about 0.8 Hertz to the other side of said diaphragm (86) whereby balloon pressure oscillations having a frequency greater than about 0.8 Hertz effected by the left atrial pressure are converted to an electrical signal having a steady baseline by the differential transducer means (68) and whereby the mean left atrial pressure may be determined in accordance with the oscillometric principle by reference to the mean balloon pressure when the amplitude of said balloon pressure oscillations effected by the left atrial pressure is at a peak.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>Apparatus according to any of the preceding claims wherein the balloon (24) is in association with a catheter (20), the apparatus further comprising means (84, 21) for sensing a position of the balloon (24) adjacent the left atrium (28).</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>Apparatus according to Claim 5 wherein said position sensing means (84,21) comprises electrode means (21) on said catheter (20) adjacent said balloon (24) for obtaining an esophageal electrocardiogram of the left atrium (28).</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>Apparatus according to Claim 5 or 6 wherein said balloon position sensing means (84,21) comprises another balloon (200) positioned on said catheter (20) so that the distance between said balloons (24,200) is equal to about the distance in an adult between the esophagogastric junction and the left atrium (28).</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>Apparatus according to Claim 5, 6 or 7, wherein said balloon position sensing means (84,21) comprises means (72) for filtering balloon pressure to remove oscillations thereof having a frequency less than about 0.8 Hertz and means (84) for comparing oscillations passed by said filtering with a skin electrocardiogram.<!-- EPO <DP n="30"> --></claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>Apparatus according to Claim 2, or any of Claims 3 to 7 when dependent on Claim 2, wherein said filtering means (72) is adapted to remove oscillations from the balloon pressure which are greater than about 0.8 Hertz.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>Apparatus according to any preceding claim wherein said balloon (24) is provided in association with one catheter (20) and the balloon pressure measuring means (68) includes another catheter (210) which includes another balloon (200) insertable into an esophagus for positioning said another balloon intermediate the left atrium and the entrance of said another catheter to the esophagus, a differential pressure transducer means, and means for transmitting the pressures in said balloons to respectively opposite sides of said differential transducer means so that respiration effected pressure oscillations are substantially cancelled and a signal of balloon pressure oscillations effected by left atrial pressure may be outputted.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>Apparatus according to any of the preceding claims further comprising means (130) for exhausting fluid from said sensing probe for slowing rapid pressure rises of said probe.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>Apparatus according to any preceding claim wherein said balloon (24) has an inflated diameter which is between about 0.9 and 1.5 cm, and is preferably about 1 cm.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>Apparatus according to any preceding claim, wherein said balloon (24) has an inflated length which is between about 3 and 4 cm.</claim-text></claim>
EP	0615422	B1	2000-01-19	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Vorrichtung zur Bestimmung eines mittleren linken aterialen Drucks, umfassend eine FÃ¼hlsonde (24) beinhaltend einen aufbiasbaren Ballon (24), Mittel (20) zum EinfÃ¼hren besagter FÃ¼hlsonde (24) in eine SpeiserÃ¶hre (26), die an den linken Vorhof (28) angegrenzt, und eine Bestimmungseinrichtung (56), umfassend Aufbiasmittel (58) zum Aufbiasen des Ballons (24) und Mittel (68) zum Messen des Ballondrucks, wenn die Amplitude von Ballondruckoszillationen, die durch den linken aterialen Druck erzeugt werden, wenn der Ballon (24) an den linken Vorhof (28) angrenzt, einen Peak hat, um den mittleren linken aterialen Druck aus der Wirkung des linken aterialen Drucks auf die Sonde (24) zu bestimmen.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Vorrichtung nach Anspruch 1, zusÃ¤tzlich beinhaltend Filtermittel (72) zum Filtern des Ballondrucks, um dessen Oszillationen zu entfernen, die erzeugt werden durch Atmungswellen, wobei Oszillationen hervorgerufen durch den linken aterialen Druck im wesentlichen frei von den Effekten der Atmungswellen weitergegeben werden kÃ¶nnen.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Vorrichtung gemÃ¤ÃŸ Anspruch 1 oder 2, dadurch gekennzeichnet, dass das Aufblasmittel (96, 100, 102, 104, 106) angepasst ist, um den Ballon (24) allmÃ¤hlich aufzublasen, wÃ¤hrend der Ballon (24) an den linken Vorhof (28) angrenzend angeordnet ist, so dass die Ballondruckoszillationen hervorgerufen werden durch den linken aterialen Druck und Atmungswellen, wenn der Ballon (24) aufgeblasen wird, und dass die Bestimmungseinrichtung (56) angepasst ist, den Ballondruck zu filtern und einen Output zur VerfÃ¼gung zu stellen, der die Amplitude der Oszillationen, die durch den linken aterialen Druck hervorgerufen werden, anzeigt, so dass der mittlere linke ateriale Druck bestimmt werden kann,<!-- EPO <DP n="32"> --> in Ãœbereinstimmung mit dem oszillometrischen Prinzip, aus dem mittleren Ballondruck, wenn die angezeigte Amplitude der Oszillationen, die durch den linken aterialen Druck hervorgerufen werden, einen Peak hat.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Vorrichtung gemÃ¤ÃŸ einem der vorhergehenden AnsprÃ¼che, dadurch gekennzeichnet, dass die Bestimmungseinrichtung (56) ein Wandlermittel (68) zum Konvertieren des Ballondrucks in ein elektrisches Signal umfasst, wobei das Wandlermittel (68) ein differentielles Wandlermittel (68) umfasst, das ein Diaphragma (86) mm Aufbringen von DrÃ¼cken auf entgegenliegenden Seiten (74, 80) aufweist, zum Konvertieren des Unterschieds in den aufgebrachten DrÃ¼cken in ein elektrisches Signal, Mittel (84) zum Konvertieren des besagten elektrischen Signais in ein elektrisches Signal des mittleren Ballondrucks, Mittel (66) zum Aufbringen eines Ballondrucks auf eine Seite (74) des Diaphragmas (86), und Mittel (70, 72, 76) zum Aufbringen von Ballondruckoszillationen, die eine Frequenz von weniger als ungefÃ¤hr 0,8 Hz haben, auf die andere Seite des Diaphragmas (86), wobei Ballondruckoszillationen, die eine Frequenz grÃ¶ÃŸer als ungefÃ¤hr 0,8 Hz haben, erzeugt durch den linken aterialen Druck, durch das differentielle Wandlermittel (68) zu einem elektrischen Signal konvertiert werden, welches eine gleichbleibende Grundlinie hat und wobei der mittlere linke ateriale Druck bestimmt werden kann in Ãœbereinstimmung mit dem oszillometrischen Prinzip durch das Beziehen auf den mittleren Ballondruck, wenn die Amplitude der besagten Ballondruckoszillationen, erzeugt durch den linken aterialen Druck, einen Peak hat.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Vorrichtung gemÃ¤ÃŸ einem der vorherigen AnsprÃ¼che, dadurch gekennzeichnet, dass der Ballon (24) in Wirkverbindung mit einem Katheter (20) ist und die Vorrichtung ferner Mittel (84, 21) zum FÃ¼hlen einer Position des an den linken Vorhof (28) angrenzenden Ballons (24) umfasst.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Vorrichtung gemÃ¤ÃŸ Anspruch 5, dadurch gekennzeichnet, dass das positionsfÃ¼hlende Mittel (84, 21) ein Elektrodenmittel (21) auf besagtem Katheter<!-- EPO <DP n="33"> --> (20) angrenzend an den Ballon (24) umfasst zum Erhalt eines Ã¶sophagealen Elektrokardiogramms von dem linken Vorhof (28).</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Vorrichtung gemÃ¤ÃŸ Anspruch 5 oder 6, dadurch gekennzeichnet, dass das die Ballonposition fÃ¼hlende Mittel (84, 21) einen anderen Ballon (200) umfasst, der auf dem Katheter (20) positioniert ist, so dass der Abstand zwischen den Ballonen (24, 200) ungefÃ¤hr gleich dem Abstand zwischen dem SpeiserÃ¶hremagenÃ¼bergang und dem linken Vorhof (28) bei einem Erwachsenen ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Vorrichtung gemÃ¤ÃŸ Anspruch 5, 6 oder 7, dadurch gekennzeichnet, dass das die Ballonposition fÃ¼hlende Mittel (84, 21) Mittel (72) zum Filtern des Ballondrucks, um Oszillationen daraus zu entfernen, die eine Frequenz von weniger als ungefÃ¤hr 0,8 Hz haben, und Mittel (84) umfasst zum Vergleichen von Oszillationen, die durch das Filtern mit einem Hautelektrokardiogramm gelangen.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Vorrichtung gemÃ¤ÃŸ Anspruch 2 oder einem der AnsprÃ¼che 3 bis 7, wenn diese sich auf Anspruch 2 beziehen, dadurch gekennzeichnet, dass das Filtermittel (72) angepasst ist, um Oszillationen von dem Ballondruck zu entfernen, die grÃ¶ÃŸer sind als ungefÃ¤hr 0,8 Hz.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Vorrichtung gemÃ¤ÃŸ einem der vorhergehenden AnsprÃ¼che, dadurch gekennzeichnet, dass der Ballon (24) vorgesehen wird in Verbindung mit einem Katheter (20) und das Ballondruckmessungsmittel (68) einen anderen Katheter (210), welcher einen anderen Ballon (200) aufweist, der in eine SpeiserÃ¶hre einfÃ¼hrbar ist zum Positionieren des besagten anderen Ballons zwischen dem linken Vorhof und dem Eingang des besagten anderen Katheters in die SpeiserÃ¶hre, differentiale Druckwandlermittel und Mittel zum Ãœbermitteln der DrÃ¼cke in den Ballonen zu jeweils entgegenliegenden Seiten des differentialen Wandlermittels aufweist, so dass durch Atmung erzeugte Druckoszillationen im wesentlichen gelÃ¶scht werden und ein Signal der Ballondruckoszillationen erzeugt durch linken aterialen Druck ausgegeben werden kann.<!-- EPO <DP n="34"> --></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Vorrichtung gemÃ¤ÃŸ einem der vorherigen AnsprÃ¼che zusÃ¤tzlich umfassend Mittel (130) zum AusstoÃŸen von Fluid von der FÃ¼hlsonde, um schnelle Druckanstiege der Sonde zu verlangsamen.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Vorrichtung gemÃ¤ÃŸ einem der vorherigen AnsprÃ¼che, dadurch gekennzeichnet, dass der Ballon (24) im aufgeblasenen Zustand einen Durchmesser hat, welcher zwischen ungefÃ¤hr 0,9 und 1,5 cm und vorzugsweise ungefÃ¤hr 1 cm ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Vorrichtung gemÃ¤ÃŸ einem der vorherigen AnsprÃ¼che, dadurch gekennzeichnet, dass der Ballon (24) im aufgeblasenen Zustand eine LÃ¤nge hat, die zwischen ungefÃ¤hr 3 und 4 cm ist.</claim-text></claim>
EP	0615422	B1	2000-01-19	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Appareil pour dÃ©terminer une pression moyenne atriale comprenant une sonde de dÃ©tection (24) comprenant un ballon gonflable (24), un moyen (22) pour insÃ©rer ladite sonde de dÃ©tection (24) dans un oesophage (26) adjacent Ã  l'atrium gauche (28), et un moyen de dÃ©termination (56) comprenant un moyen de gonflage (58) pour gonfler ledit ballon (24) et un moyen (68) pour mesurer la pression de ballon lorsque l'amplitude des oscillations de pression de ballon effectuÃ©e par la pression atriale gauche lorsque le ballon (24) est adjacent de l'atrium gauche (28) est une crÃªte pour dÃ©terminer une pression moyenne atriale gauche Ã  partir de l'effet de la pression atriale gauche sur ladite sonde (24).</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Appareil selon la revendication 1, comprenant en outre un moyen de filtrage (72) pour filtrer la pression de ballon pour enlever des oscillations de celle-ci effectuÃ©es par des ondes respiratoires de sorte que des oscillations effectuÃ©es par la pression atriale gauche peuvent Ãªtre passÃ©e substantiellement sans les effets des ondes respiratoires.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Appareil selon la revendication 1 ou la revendication 2, dans lequel le moyen de gonflage (96, 100, 102, 104, 106) est adaptÃ© pour gonfler progressivement ledit ballon (24) alors que le ballon (24) est adjacent de l'atrium gauche (23) de sorte que des oscillations de pression de ballon sont effectuÃ©es<!-- EPO <DP n="36"> --> par des ondes de pression et respiratoires atriales gauches lorsque ledit ballon (24) est gonflÃ© et ledit moyen de dÃ©termination (56) est adaptÃ© pour filtrer la pression de ballon et fournir une sortie indiquant l'amplitude des oscillations effectuÃ©es par la pression atriale gauche de sorte que la pression moyenne atriale gauche peut Ãªtre dÃ©terminÃ©e, selon le principe oscillomÃ©trique, Ã  partir de la pression moyenne de ballon lorsque l'amplitude indiquÃ©e des oscillations effectuÃ©es par la pression atriale gauche est une crÃªte.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Appareil selon une quelconque des revendications prÃ©cÃ©dentes, dans lequel ledit moyen de dÃ©termination (56) comprend un moyen de transducteur (68) pour convertir la pression de ballon en un signal Ã©lectrique, le moyen de transducteur (68) comprenant un moyen de transducteur diffÃ©rentiel (68) ayant un diaphragme (86) pour l'application de pressions sur des cÃ´tÃ©s opposÃ©s (74, 80) de celui-ci pour convertir la diffÃ©rence des pressions appliquÃ©es en un signal Ã©lectrique, un moyen (84) pour convertir ledit signal Ã©lectrique en un signal Ã©lectrique de pression de ballon moyen, un moyen (66) pour appliquer une pression de ballon Ã  un cÃ´tÃ© (74) dudit diaphragme (86), et un moyen (70, 72, 76) pour appliquer des oscillations de pression de ballon ayant une frÃ©quence plus petite qu'environ 0,8 Hertz Ã  l'autre cÃ´tÃ© dudit diaphragme (86) de sorte que des oscillations de pression de ballon ayant une frÃ©quence plus Ã©levÃ©e que 0,8 Hertz environ effectuÃ©es par la pression atriale gauche sont<!-- EPO <DP n="37"> --> converties en un signal Ã©lectrique ayant une ligne de base rÃ©guliÃ¨re par ledit moyen transducteur diffÃ©rentiel (68) et de sorte que la pression moyenne atriale gauche peut Ãªtre dÃ©terminÃ©e selon le principe oscillomÃ©trique en rÃ©fÃ©rence Ã  la pression moyenne de ballon lorsque l'amplitude desdites oscillations de pression de ballon effectuÃ©e par la pression atriale gauche est une crÃªte.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Appareil selon l'une quelconque des revendications prÃ©cÃ©dentes dans lequel le ballon (24) est en association avec un cathÃ©ter (20), l'appareil comprenant en outre un moyen (84, 21) pour dÃ©tecter une position du ballon (24) adjacent Ã  l'atrium gauche (28).</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Appareil selon la revendication 5 dans lequel ledit moyen de dÃ©tection de position (84, 21) comprend un moyen d'Ã©lectrode (21) sur ledit cathÃ©ter (20) adjacent audit ballon (24) pour obtenir un Ã©lectrocardiogramme oesophagial de l'atrium gauche (28).</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Appareil selon la revendication 5 ou 6 dans lequel ledit moyen de dÃ©tection de position de ballon (84, 21) comprend un autre ballon (200) positionnÃ© sur ledit cathÃ©ter (20) de sorte que la distance entre lesdits ballons (24, 200) est Ã©gale Ã  environ la distance chez un adulte entre la jonction oesophagogastrique et l'atrium gauche (28).<!-- EPO <DP n="38"> --></claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Appareil selon la revendication 5, 6 ou 7, dans lequel ledit moyen de dÃ©tection de position de ballon (84, 21) comprend un moyen (72) pour filtrer la pression de ballon pour enlever des oscillations de celle-ci ayant une frÃ©quence infÃ©rieure Ã  0,8 Hertz environ et un moyen (84) pour comparer des oscillations passÃ©es par ledit filtrage avec un Ã©lectrocardiogramme de peau.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Appareil selon la revendication 2, ou une quelconque des revendications 3 Ã  7 lorsqu'elles dÃ©pendent de la revendication 2, dans lequel ledit moyen de filtrage (72) est adaptÃ© pour enlever des oscillations de la pression de ballon qui sont supÃ©rieures Ã  0,8 Hertz environ.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Appareil selon l'une quelconque des revendications prÃ©cÃ©dentes dans lequel ledit ballon (24) est fourni en association avec un cathÃ©ter (20) et le moyen de mesure de pression de ballon (68) comprend un autre cathÃ©ter (210) qui comprend un autre ballon (200) insÃ©rable dans un oesophage pour positionner ledit autre ballon entre l'atrium gauche et l'entrÃ©e dudit autre cathÃ©ter dans l'oesophage, un moyen de transducteur diffÃ©rentiel de pression, et un moyen pour transmettre les pressions dans lesdits ballons aux cÃ´tÃ©s opposÃ©s respectivement dudit moyen transducteur diffÃ©rentiel de sorte que les oscillations de pression effectuÃ©es par la respiration sont substantiellement annulÃ©es et un signal des oscillations de pression de<!-- EPO <DP n="39"> --> ballon effectuÃ©es par la pression atriale gauche peut Ãªtre fournie.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Appareil selon l'une quelconque des revendications prÃ©cÃ©dentes comprenant en outre un moyen (130) pour faire Ã©chapper du fluide de ladite sonde de dÃ©tection pour ralentir des augmentations rapides de pression de ladite sonde.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Appareil selon une quelconque des revendications prÃ©cÃ©dentes dans lequel ledit ballon (24) a un diamÃ¨tre gonflÃ© qui est entre environ 0,9 et 1,5 cm, et est prÃ©fÃ©rablement d'environ 1 cm.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Appareil selon l'une quelconque des revendications prÃ©cÃ©dentes, dans lequel ledit ballon (24) a une longueur gonflÃ©e qui est entre environ 3 et 4 cm.</claim-text></claim>
EP	0615422	B1	2000-01-19	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0615422&ki=B1&pd=2000-01-19
EP	0619020	B1	2000-11-08	de	TITLE	1	BESTIMMUNG TRIZYKLISCHER ANTIDEPRESSIVA IN GEGENWART STÃ–RENDER SUBSTANZEN
EP	0619020	B1	2000-11-08	en	TITLE	1	DETERMINATION OF TRICYCLIC ANTIDEPRESSANT DRUGS IN THE PRESENCE OF INTERFERING SUBSTANCES
EP	0619020	B1	2000-11-08	fr	TITLE	1	DETECTION DE MEDICAMENTS ANTIDEPRESSEURS TRICYCLIQUES EN PRESENCE DE SUBSTANCES D'INTERFERENCE
EP	0619020	B1	2000-11-08	en	DESCR	1	<heading id="h0001"><u>FIELD OF THE INVENTION</u></heading><p id="p0001" num="0001">The present invention relates to the determination of a tricyclic antidepressant drug which does not contain a sulfur moiety in a test sample also containing one or more analytically interfering substances. In particular, the present invention relates to the pretreatment of a test sample to permit the analytical determination of a tricyclic antidepressant drug which does not contain a sulfur moiety in the presence of one or more interfering substances.</p><heading id="h0002"><u>Background of the Invention</u></heading><p id="p0002" num="0002">The determination of analytes has become very useful in a variety of fields such as biochemical research, environmental and industrial testing, and especially medical diagnostics. The monitoring of therapeutic drug levels and other analytes in biological fluids such as serum, plasma, whole blood, urine, and the like, has become very useful to provide physicians with information to aid in patient management. The monitoring of such drug levels enables adjustment of patient dosage to achieve optimal therapeutic effects, and helps avoid either subtherapeutic or toxic levels.<!-- EPO <DP n="2"> --></p><p id="p0003" num="0003">A test sample may contain one or more detectable compounds having chemical structures which are substantially similar to, or which resemble, or which could resemble, and therefore be indistinguishable from, the desired analyte of interest. For example, in the area of medical diagnostics where it is important to monitor the level of therapeutic drugs, a number of drugs having substantially similar chemical structures may be administered to a patient wherein a test sample from such patient could contain detectable levels thereof.</p><p id="p0004" num="0004">In such instances, the analytical determination of the desired analyte may be interfered with by the presence of such one or more additional substances having substantially similar chemical structures to the chemical structure of the analyte of interest to thereby produce inconsistent and inaccurate results. In particular, where the analytical determination involves immunoassay techniques employing antibodies capable of binding to the analyte of interest, such antibodies may also bind or crossreact with such other substances having substantially similar chemical structures. Similarly, where the analytical determination involves high pressure liquid chromatography techniques or thin layer chromatography techniques, the elution profile of the analyte of interest may be indistinguishable from the elution profile of such other substances having substantially similar chemical structures.<!-- EPO <DP n="3"> --></p><p id="p0005" num="0005">U.S. Patent No. 4,810,635 discloses a fluorescence energy transfer immunoassay for the detection of digoxin in a serum sample in which interfering endogenous fluorescence has been eliminated by treatment of the sample with a strong oxidizing agent. U.S. Patent No. 4,668,620 discloses an enzyme-label immunoassay in which a serum sample has been treated with a peracid compound to reduce or eliminate background interference contributed by serum components. U.S. Patent No. 4,829,012 discloses an immunoassay for IgM antibodies in a liquid sample, such as a biological fluid, in which interfering IgG antibodies are modified by the binding of the IgG antibodies to anti-IgG antibodies. Alltech Associates, Inc. Chromatography Catalog #150, issued 1988, pages 58 and 258-263 discloses various chromatography assays for different analyte families involving the pre-treatment with a derivatization agent which allows the differential analysis of a predetermined member(s) of a selected substance family in the presence of other member(s) of the same family. Chemical Abstracts, vol. 106, no. 17, issued 27 April 1987, (Y.H. Cho et al., Arch. Pharmacal. Res. 1986, 9(3), 131-8) discloses the determination of barbiturates such as thiopental in plasma by gas chromatography-flame photometric detector after N,N'-dimethylthiomethyl derivatization. Chemical Abstracts, vol. 98, no. 7, issued 14 February 1983 (K.E. Karlsson, J. Chromatography 1981, 219(3), 373-8) discloses differential analysis of secondary and tertiary amine amitryptiline (a parent compound and its structurally similar metabolites) by gas chromatography following a two-phase derivatization to carbamates. Biological Abstracts, vol. 68, no. 9, issued 01 November 1979 (H.F. Proelss et al., Clin. Chem. 24(11):1948-1953, 1978) discloses a high-performance liquid chromatographic simultaneous determination of five commonly used tricyclic antidepressants (doxepin, desipramine, nortriptyline, imipramine and amitriptyline) in serum in which interference from drugs such as phenothiazines occurs. Aldrich Chemical Company, Inc. Catalog, issued 1986, pages 283, 1194 and 1196 discloses oxidizing agents such as Chloramine-B and Chloramine T which are useful in the present invention.<!-- EPO <DP n="4"> --></p><heading id="h0003"><u>Summary of the Invention</u></heading><p id="p0006" num="0006">The present invention relates to an<ul id="ul0001" list-style="none" compact="compact"><li>immunoassay method for determining the amount of a tricyclic antidepressant drug in a biological test sample, wherein said tricyclic antidepressant drug does not contain a sulfur moiety and wherein said biological test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and is immunologically crossreactive with an antibody to said antidepressant drug, said method comprising the steps of:<ul id="ul0002" list-style="none" compact="compact"><li>(a) forming a pretreatment solution by contacting said biological test sample with an oxidative reagent capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby crossreactive binding of said antibody to said tricyclic antidepressant drug to said modified sulfur-containing compound is reduced;</li><li>(b) contacting said pretreatment solution with (i) a labeled reagent comprising said tricyclic antidepressant drug or derivative thereof labeled with a fluorescent moiety, and (ii) said antibody capable of binding to said labeled reagent and said tricyclic antidepressant drug from said biological test sample to form a reaction solution therewith, said labeled reagent capable of producing a detectable fluorescence polarization response to the presence of said antibody; and</li><li>(c) detecting the fluorescence polarization response to said reaction solution as a function of the amount of said tricyclic antidepressant drug present in said test sample.</li></ul></li></ul><!-- EPO <DP n="5"> --></p><p id="p0007" num="0007">The present invention also relates to a<ul id="ul0003" list-style="none" compact="compact"><li>high pressure liquid chromatography (HPLC) method for determining the amount of a tricyclic antidepressant drug in a biological test sample, wherein said tricyclic antidepressant drug does not contain a sulfur moiety and wherein said biological test sample includes a sulfur-containing compound having a chemical structure similar to the chemical structure of said tricyclic antidepressant drug and an elution profile which interferes with the elution profile of said tricyclic antidepressant drug, said method comprising the steps of:<ul id="ul0004" list-style="none" compact="compact"><li>(a) forming an admixture of an aliquot of said biological test sample and an internal standard;</li><li>(b) forming a pretreatment solution by contacting said admixture with an oxidative reagent capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby the elution profile of said modified sulfur-containing compound does not interfere with the elution profile of said tricyclic antidepressant drug;</li><li>(c) contacting said pretreatment solution to an HPLC stationary phase and eluting therefrom with a mobile phase; and</li><li>(d) measuring elution times and absorbances of said internal standard and said tricyclic antidepressant drug as they elute from the stationary phase in order to determine the amount of said tricyclic antidepressant drug in said biological test sample.</li></ul></li></ul><!-- EPO <DP n="6"> --></p><p id="p0008" num="0008">Accordingly, by chemically modifying one of such compounds as described by the present invention, methods previously required to permit the selective detection as described above are no longer necessary.</p><p id="p0009" num="0009">The pretreatment reagent is an oxidative reagent which is useful for the derivatization of sulfur-containing compounds which may be present in a test sample, particularly for the fluorescent polarization immunoassay determination of tricyclic antidepressant drugs in the presence of phenothiazines. As would be understood by one skilled in the art, phenothiazines are often co-prescribed to a patient being treated with a tricyclic antidepressant drug wherein a test sample from such patient would therefore contain levels of both drugs. According to such preferred embodiment, such test sample is contacted with an oxidative reagent, preferably chloramine-T (sodium salt of N-chloro-4-methylbenzene sulfonamide) or chloramine-B (sodium salt of N-chlorobenzene sulfonamide), to selectively modify the chemical structure of the phenothiazines whereby the phenothiazines present in the test sample are selectively oxidized to their corresponding sulfoxides or sulfones. After such pretreatment of the test sample, determination of the tricyclic antidepressant drug can be accomplished<!-- EPO <DP n="7"> --><ul id="ul0005" list-style="none" compact="compact"><li>preferably according to fluorescent polarization immunoassay techniques<br/>wherein crossreactivity of the modified phenothiazine with the antibody to the tricyclic antidepressant drug is substantially reduced.</li></ul></p><heading id="h0004"><u>Brief Description of the Drawings</u></heading><p id="p0010" num="0010"><ul id="ul0006" list-style="none" compact="compact"><li>Fig. 1 is a chromatogram which illustrates the elution profiles of tricyclic antidepressant drugs (desipramine and imipramine) and a phenothiazine (desmethylchlorpromazine) prior to [Fig. 1(a)] and subsequent [Fig. 1(b)] to modification of the chemical structure of the phenothiazine according to the present invention.</li><li>Fig. 2 is a chromatogram which illustrates the elution profiles of tricyclic antidepressant drugs [amitriptyline (AMI), 10-hydroxyamitriptyline (10-OH AMI), and nortriptyline (NOR)] and phenothiazines [desmethylchlorpromazine (DM-CPZ) and chlorpromazine (CPZ)] prior to [Fig. 2(a)] and subsequent to [Fig. 2(b)] modification of the chemical structure of the phenothiazines according to the present invention.</li></ul><!-- EPO <DP n="8"> --></p><heading id="h0005"><u>Detailed Description of the Invention</u></heading><p id="p0011" num="0011">The present invention is useful for the determination of a tricyclic antidepressant drug which does not contain a sulfur moiety present in a test sample also containing one or more interfering substances which is a sulfur-containing compound having substantially similar chemical structures to, or chemical structures which resemble or could resemble, the analyte of interest. It is to be understood that the analyte of interest and such interfering substances could be substantially dissimilar but, at the same time, could have conformational aspects in which they resemble each other.</p><p id="p0012" num="0012">In particular, analytes of interest include, but are not intended to be limited to, tricyclic antidepressant drugs such as amitriptyline, nortriptyline, imipramine, desipramine, protriptyline, doxepin, clomipramine and desdoxepin; and benzodiazepines such as diazepam.</p><p id="p0013" num="0013">In particular, interfering substances include, but are not intended to be limited to phenothiazines such as chloropromazine, desmethylchloropromazine, thioridazine, desmethylthioridazine, sulforidazine and mesoridazine, and thioxanthines such as thiothixene.</p><p id="p0014" num="0014">According to the present invention, the pretreatment reagent is specific for and is capable of selectively modifying the chemical structure at one or more sites or positions of one or more interfering substances present in a test sample.<!-- EPO <DP n="9"> --></p><p id="p0015" num="0015">It is to be appreciated that once the chemical structure of the interfering substance has been modified according to the present invention, the analytical determination of the analyte can be made. Also according to the present invention, the pretreatment reagent can be selected from a variety of oxidative reagents capable of substantially modifying the chemical structure of the interfering substance. Such reagents include, but are not intended to be limited to N-chlorosulfonamides such as chloramine-T and chloramine-B; hypochlorites such as sodium hypochlorite and hypochlorous acid; hypobromites such as sodium hypobromite and hypobromous acid; peroxides such as sodium hydroperoxide; peracids such as perselenic acid and 3-chloroperbenzoic acid; and oxidative enzymes such as catalase, peroxidase and microperoxidase. For sulfur-containing interfering substances, such as phenothiazines, the pretreatment reagent is preferably selected from the group<!-- EPO <DP n="10"> --> consisting of sodium hypochlorite, catalase, and perselenic acid, more preferably chloramine-T.</p><p id="p0016" num="0016">As would be understood by one skilled in the art apprised of the foregoing considerations and as will be described in greater detail in the specific embodiments and examples hereinbelow, selection of a particular pretreatment reagent will depend upon the chemical structure of the analyte of interest and the chemical structure of interfering substances which may be present in a test sample. It is to be understood that in addition to being added or introduced into a test sample from an external source, the oxidative reagent can alternatively be generated or otherwise formed <u>in</u> <u>situ</u>, such as the generation of hydrogen peroxide. For example, in the case of an analytical system containing the analyte of interest, an interfering substance as described herein, selenium dioxide, and glucose oxidase, to which glucose is added, hydrogen peroxide is formed <u>in</u> <u>situ</u>. This is particularly useful for the packaging of reagents in that the packaging and shipment of strong oxidizing agents can be avoided by providing reagents which can form, <u>in</u> <u>situ</u>, the oxidative reagent for use as described herein. In addition, the pretreatment reagent can be presented as a liquid reagent, a dry reagent, or immobilized to a solid support material according to methods known in the art.<!-- EPO <DP n="11"> --></p><p id="p0017" num="0017">Although the pretreatment reagent can be employed in the analytical systems as described above, the pretreatment reagent according to the present invention is especially useful in a fluorescent polarization immunoassay (FPIA) system. For example, in a competitive protein binding or immunoassay, a substance being measured, often referred to as a ligand, competes with a substance of close structural similarity coupled to a detectable moiety, often referred to as a tracer, for a limited number of binding sites on antibodies specific to the portion or portions of the ligand and tracer with structural similarity, shared with an immunogen employed to produce such antibodies. In a fluorescent polarization immunoassay, the detectable moiety component of the tracer is a fluorescent moiety selected from the group consisting of fluoresceins, aminofluoresceins, carboxyfluoresceins, fluoresceinamines, and the like.</p><p id="p0018" num="0018">According to such FPIA format, the amount of tracer bound to the antibody varies inversely to the amount of ligand present in either the test sample or standard calibrator solution in a predictable manner. The relative, and therefore characteristic, binding affinities of the ligand and the tracer to the antibody binding site, are important parameters of the assay system. In particular, FPIA techniques are based on the principle that a fluorescent tracer, when excited by plane polarized light of<!-- EPO <DP n="12"> --> a characteristic wavelength, will emit light at another characteristic wavelength (i.e., fluorescence) that retains a degree of the polarization relative to the incident stimulating light that is inversely related to the rate of rotation of the tracer in a given medium. As a consequence of this property, a tracer substance with constrained rotation, such as in a viscous solution phase or when bound to another solution component with a relatively lower rate of rotation, will retain a relatively greater degree of polarization of emitted light than if in free solution. Therefore, within the time frame in which the ligand and tracer compete for binding to the antibody, the tracer and ligand binding rates should yield an appropriate proportion of free and bound tracer with the preservation of important performance parameters such as selectivity, sensitivity, and precision.</p><p id="p0019" num="0019">For example, for the FPIA determination of imipramine, a test sample is contacted with the pretreatment reagent according to the present invention and with imipramine antiserum in the presence of an appropriately selected fluorescein derivative thereof which is capable of producing a detectable fluorescence polarization response to the presence of imipramine antiserum. Plane polarized light is then passed through the solution to obtain a fluorescent polarization response and the response is detected as a measure of the amount of imipramine present in the test<!-- EPO <DP n="13"> --> sample when compared to the response of standard calibrators prepared from the native compound.</p><p id="p0020" num="0020">As described herein, the test sample containing the analyte of interest and such other interfering substances is a biological test sample such as whole blood, serum, plasma, urine, feces, saliva, cerebrospinal fluid and brain tissue.</p><p id="p0021" num="0021">According to the present invention, there is provided a test kit useful for the fluorescent polarization immunoassay determination of a tricyclic antidepressant drug present in a test sample, wherein said antidepressant drug does not contain a sulfur moiety and wherein said test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and is immunologically crossreactive with an antibody to said antidepressant drug, said test kit comprising (a) an oxidative reagent, or reagents which can generate hydrogen peroxide as an oxidative reagent in the test sample, said oxidative reagent being capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby crossreactive binding of said antibody to said tricyclic antidepressant drug to said modified sulfur-containing compound is reduced and (b) all essential additional reagents for performing the fluorescent polarization immunoassay determination including an antibody to said tricyclic antidepressant drug and a suitable fluorescent tracer compound.<!-- EPO <DP n="14"> --></p><p id="p0022" num="0022">According to the present invention, there is also provided a test kit useful for the chromatographic determination of a tricyclic antidepressant drug present in a test sample, wherein said antidepressant drug does not contain a sulfur moiety and wherein said test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and an elution profile which interferes with the elution profile of said tricyclic antidepressant drug, said test kit comprising (a) an oxidative reagent, or reagents which can generate hydrogen peroxide as an oxidative reagent in the test sample, said oxidative reagent being capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby the elution profile of said modified sulfur-containing compound does not interfere with the elution profile of said tricyclic antidepressant drug; and (b) all essential additional reagents for performing the chromatographic determination including an internal standard. Such test kit may be useful in a high pressure liquid chromatographic determination of said drug or useful in a thin layer chromatographic determination of said drug. The test kit is<!-- EPO <DP n="15"> --> presented in a commercially packaged form as a combination of one or more containers holding the necessary reagents, as a composition or admixture where the compatibility of the reagents will allow. Particularly preferred is a test kit for the fluorescent polarization immunoassay determination of tricyclic antidepressant drugs, comprising the appropriate pretreatment reagent according to the present invention, an appropriate fluorescent tracer compound, and an appropriate antibody reagent as described above. It is to be understood that the test kit can, of course, include other materials as are known in the art and which may be desirable from a commercial user standpoint, such as buffers, diluents, standards, and the like.</p><p id="p0023" num="0023">The present invention will now be illustrated, but is not intended to be limited, by the following examples:</p><heading id="h0006"><u>EXAMPLE 1</u></heading><heading id="h0007">Fluorescent Polarization Immunoassay For Imipramine and Desipramine</heading><p id="p0024" num="0024">In a fluorescent polarization immunoassay (FPIA) using an Abbott TDxÂ® analytical system for imipramine (IMI) or desipramine (DMI), phenothiazines such as chlorpromazine may interfere with the determination of IMI and DMI. In particular, antibodies directed to IMI may recognize<!-- EPO <DP n="16"> --> chlorpromazine or desmethylchlorpromazine as well as imipramine when present in a patient sample. In order to prevent the error in quantitation that would result, the sample is treated with chloramine-T to oxidatively modify the structure of the chlorpromazine or desmethylchlorpromazine to a form much less well recognized by this antitricyclic immune serum.</p><p id="p0025" num="0025">For the determination of imipramine, the sample (0.100 mL) was rendered basic by the addition of 0.100 mL of 0.25 M NaOH and dissociated from serum proteins by the addition of 0.025 mL of isoamyl alcohol. The mixture was allowed to stand for up to 5.0 minutes, after which time 0.50 mL of decane was added and the sample vortexed vigorously for 1.0 minute. The sample/decane biphasic mixture was then centrifuged for up to 5.0 minutes to clarify those phases. In the case of imipramine, 0.100 mL of the decane upper phase was transferred to a tube containing 0.100 mL of acidic buffer, pH 3, to which 0.010 mL of 20 microgram per mL of chloramine-T had been added. This amount of chloramine-T can completely modify up to 1.0 microgram of chlorpromazine in the original sample. Variations in the quantity of chloramine-T may be made to accommodate differing ranges of phenothiazine concentrations expected to be present in the sample. Table I below illustrates a typical example of results obtained from comparing the analysis of a sample containing, as in this case, 300 ng/mL<!-- EPO <DP n="17"> --> of chlorpromazine and 128 ng/mL of imipramine, employing an Abbott TDx analytical system. Chlorpromazine crossreacts with the antibody used in the FPIA for imipramine. This quantity of chlorpromazine yielded a significant overestimate of the amount of imipramine actually present in the sample (171%). Treatment of the sample extract with chloramine-T modifies the structure of the chlorpromazine in such a fashion that it is no longer an assay interferant. Inclusion of the chloramine-T treatment removed this overestimate entirely. <tables id="tabl0001" num="0001"><table frame="all"><title>TABLE I</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" align="center">Removal Of Chlorpromazine Interferant In FPIA For Imipramine</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Sample</entry><entry namest="col2" nameend="col2" align="left">Treatment</entry><entry namest="col3" nameend="col3" align="left">Mass</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">IMI</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="right">128 ng/mL</entry></row><row><entry namest="col1" nameend="col1" align="left">IMI+300 ng CPZ</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="right">219 ng/mL</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">IMI+300 ng CPZ</entry><entry namest="col2" nameend="col2" align="left">Chloramine-T</entry><entry namest="col3" nameend="col3" align="right">130 ng/mL</entry></row></tbody></tgroup></table></tables></p><p id="p0026" num="0026">The procedure described above could also be followed for the analysis of desipramine in the presence of phenothiazines to achieve the elimination of interfering substances as described herein.<!-- EPO <DP n="18"> --></p><heading id="h0008"><u>EXAMPLE 2</u></heading><heading id="h0009">High Pressure Liquid Chromatography Determination of Imipramine and Desipramine</heading><p id="p0027" num="0027">In the HPLC analysis of tricyclic antidepressants such as imipramine and desipramine, phenothiazines such as chlorpromazine or its metabolite, desmethylchlorpromazine, may interfere with the analysis of the tricyclic antidepressants or one of their metabolites.</p><p id="p0028" num="0028">A 1.0 mL sample to which an internal standard substance was added was rendered basic by the addition of 0.200 mL of 1.0 M NaOH followed by the addition of 0.200 mL of isoamyl alcohol to inhibit analyte/protein interaction. Ten mL of heptane was then added and the biphasic mixture shaken for 1.0 hour followed by 30 minutes of centrifugation at about 2000 x g. The heptane layer was then transferred in its entirety to a test tube containing 1.0 mL of an acidic buffer, pH 3, to which 0.100 mL of 100 micrograms/mL chloramine-T had been added. The acidic buffer was then made basic by the addition of 0.200 mL of 1 M NaOH followed by 0.100 mL of isoamyl alcohol. To this solution, 5.0 mL of pentane was added and the biphasic mixture was shaken for 30 minutes followed by centrifugation at about 2000 x g. The pentane was pipetted into a small vial, reduced to dryness with a stream of nitrogen and reconstituted in HPLC mobile phase. An aliquot was then analyzed by HPLC utilizing a spectrophotometric ultraviolet detector. Compounds of<!-- EPO <DP n="19"> --> interest in this case were quantified by observation at 254 nm.</p><p id="p0029" num="0029">HPLC analysis may be accomplished with many different mobile phases. The example tracings presented in Figure 1 utilized a 3 Âµm silica stationary phase in a column of 6 mm x 15 cm. The mobile phase consisted of a mixture of 80 parts of 25 mM NaH<sub>2</sub>PO<sub>4</sub>, pH 3.0, 20 parts of acetonitrile, and was doped with 21 mM n-nonylamine. The column exhibited approximately 150,000 theoretical plates per meter in a test system used by the manufacturer. Figure 1 illustrates that desmethylchlorpromazine, a metabolite of chlorpromazine, elutes in the area of the chromatogram in which the analytes and internal standard elute. Treatment with chloramine-T completely eliminated the desmethylchlorpromazine as an interfering substance.</p><heading id="h0010"><u>EXAMPLE 3</u></heading><heading id="h0011">Fluorescent Polarization Immunoassay For Total Doxepins In The Presence Of Phenothiazines</heading><p id="p0030" num="0030">The present example illustrates that chlorpromazine (CPZ) is significantly recognized in the immunoassay for doxepin and desdoxepin (Total DOX) and gives incorrect readings for the quantitation of Total DOX (Table II). These data also show that including chloramine-T in the procedure removes the recognition of CPZ in the immunoassay for Total DOX.<!-- EPO <DP n="20"> --></p><p id="p0031" num="0031">To a 0.25 mL solution containing Total DOX and CPZ was added 0.90 mL of heptane:isoamyl alcohol (35:1, v/v) solution and 0.100 mL of sodium carbonate solution. After vortexing for 60 seconds and centrifuging for 30 seconds, 0.50 mL of the upper phase (heptane:isoamyl alcohol phase) was transferred to a clean tube. Next, 0.100 mL of HCl (0.05 N) and 0.040 mL of either distilled water or chloramine-T (0.040 mg/mL) in distilled water were added. After vortexing for 30 seconds, waiting 120 seconds, and centrifuging for 30 seconds, 0.085 mL of the lower phase (aqueous phase of HCl and water with or without chloramine-T) was transferred for quantitation by immunoassay for Total DOX employing an Abbott TDx analytical system.</p><p id="p0032" num="0032">In a sample containing Total DOX at 100 ng/mL and CPZ at 1000 ng/mL, the concentration in the immunoassay without the addition of chloramine-T was 232 ng/mL or an error of more than twofold as shown in Table II below. The addition of chloramine-T removed the recognition of CPZ by the immunoassay for Total DOX and a value of 95 ng/mL was obtained. This procedure allows quantitation of Total DOX by immunoassay in samples containing CPZ.<!-- EPO <DP n="21"> --> <tables id="tabl0002" num="0002"><table frame="all"><title>TABLE II</title><tgroup cols="4" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="39.37mm"/><colspec colnum="2" colname="col2" colwidth="39.37mm"/><colspec colnum="3" colname="col3" colwidth="39.37mm"/><colspec colnum="4" colname="col4" colwidth="39.37mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col4" align="center">Removal of Chlorpromazine Interferant In Abbott TDx Total DOX FPIA</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" rowsep="0" align="center">Amount Total DOX Added</entry><entry namest="col2" nameend="col2" rowsep="0" align="center">Amount CPZ Added</entry><entry namest="col3" nameend="col4" align="center">Concentration of Total DOX when the procedure includes:</entry></row><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2"/><entry namest="col3" nameend="col3" align="center">Water</entry><entry namest="col4" nameend="col4" align="center">Chloramine-T</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="right">0</entry><entry namest="col2" nameend="col2" align="right">1000</entry><entry namest="col3" nameend="col3" align="right">143</entry><entry namest="col4" nameend="col4" align="right">7</entry></row><row><entry namest="col1" nameend="col1" align="right">0</entry><entry namest="col2" nameend="col2" align="right">2000</entry><entry namest="col3" nameend="col3" align="right">197</entry><entry namest="col4" nameend="col4" align="right">10</entry></row><row><entry namest="col1" nameend="col1" align="right">50</entry><entry namest="col2" nameend="col2" align="right">1000</entry><entry namest="col3" nameend="col3" align="right">181</entry><entry namest="col4" nameend="col4" align="right">49</entry></row><row><entry namest="col1" nameend="col1" align="right">75</entry><entry namest="col2" nameend="col2" align="right">1000</entry><entry namest="col3" nameend="col3" align="right">199</entry><entry namest="col4" nameend="col4" align="right">83</entry></row><row><entry namest="col1" nameend="col1" align="right">100</entry><entry namest="col2" nameend="col2" align="right">1000</entry><entry namest="col3" nameend="col3" align="right">232</entry><entry namest="col4" nameend="col4" align="right">95</entry></row><row><entry namest="col1" nameend="col1" align="right">100</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">104</entry><entry namest="col4" nameend="col4" align="right">101</entry></row><row><entry namest="col1" nameend="col1" align="right">125</entry><entry namest="col2" nameend="col2" align="right">500</entry><entry namest="col3" nameend="col3" align="right">223</entry><entry namest="col4" nameend="col4" align="right">135</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="right">150</entry><entry namest="col2" nameend="col2" align="right">1000</entry><entry namest="col3" nameend="col3" align="right">274</entry><entry namest="col4" nameend="col4" align="right">155</entry></row><row rowsep="1"><entry namest="col1" nameend="col4" align="justify">[all concentrations in ng/mL]</entry></row></tbody></tgroup></table></tables></p><heading id="h0012"><u>EXAMPLE 4</u></heading><heading id="h0013">Fluorescent Polarization Immunoassay For Amitriptyline and Nortriptyline</heading><p id="p0033" num="0033">Chlorpromazine (CPZ) crossreacts with the antibodies used in the FPIA determinations of amitriptyline (AMI) and nortriptyline (NOR), which lead to significant overestimations of AMI and NOR levels. Treatment of a test sample with chloramine-T according to the present invention modifies oxidatively the structure of chlorpromazine in such<!-- EPO <DP n="22"> --> a fashion that it no longer crossreacts in either immunoassay.</p><p id="p0034" num="0034">A test sample (0.200 mL) was made basic by the addition of 0.050 mL of 1 N NaOH and dissociated from serum proteins by addition of 0.050 mL isoamyl alcohol; this mixture was briefly mixed and allowed to stand for at least 5.0 minutes, after which time 0.500 mL of n-heptane was added and the sample vortexed vigorously for 30 seconds. The sample/n-heptane biphasic mixture was centrifuged at 10,000 x g for 1 minute to clarify the phases. A measured 0.400 mL aliquot of the upper (n-heptane) phase was then transferred to a new tube with 0.400 mL of 0.1 M glycyl-glycine buffer (pH 3) and vortexed vigorously for 30 sec. Forty microliters (0.040 mL) of chloramine-T solution (100 ug/mL) was then added to the biphasic mixture (chloramine-T treatment as shown in Table III); in the control condition (no treatment), 0.040 mL of extraction buffer was added in place of chloramine-T. Samples were centrifuged at 10,000 x g for 1 minute, with the bottom (glycyl-glycine) phase taken for analysis. Treated and untreated samples were run in duplicate on the Abbott TDx analytical system, and concentrations were determined using stored calibration curves for either AMI or NOR.<!-- EPO <DP n="23"> --> <tables id="tabl0003" num="0003"><table frame="all"><title>TABLE III</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" align="center">Removal of Chlorpromazine Interferant In Abbott TDx Amitriptyline and Nortriptyline FPIA</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">SAMPLE</entry><entry namest="col2" nameend="col2" align="left">TREATMENT</entry><entry namest="col3" nameend="col3" align="center">CONCENTRATION</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">AMI</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="right">75 ng/mL</entry></row><row><entry namest="col1" nameend="col1" align="left">AMI + CPZ</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="right">300 ng/mL</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">AMI + CPZ</entry><entry namest="col2" nameend="col2" align="left">Chloramine-T</entry><entry namest="col3" nameend="col3" align="right">78 ng/mL</entry></row><row><entry namest="col1" nameend="col1" align="left">NOR</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="right">65 ng/mL</entry></row><row><entry namest="col1" nameend="col1" align="left">NOR + CPZ</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="right">101 ng/mL</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">NOR + CPZ</entry><entry namest="col2" nameend="col2" align="left">Chloramine-T</entry><entry namest="col3" nameend="col3" align="right">73 ng/mL</entry></row><row rowsep="1"><entry namest="col1" nameend="col3" align="justify">[CPZ concentration = 1,000 ng/mL]</entry></row></tbody></tgroup></table></tables></p><p id="p0035" num="0035">Accordingly, treatment with chloramine-T allowed for the correct determination of AMI and NOR levels in the presence of high concentrations of chlorpromazine.</p><heading id="h0014"><u>EXAMPLE 5</u></heading><heading id="h0015">High Pressure Liquid Chromatography Determination of Amitriptyline and Nortriptyline</heading><p id="p0036" num="0036">In the HPLC analysis of tricyclic antidepressants such as amitriptyline and nortriptyline, phenothiazine drugs such as chlorpromazine or its metabolite desmethylchlorpromazine may interfere with analysis of these antidepressant drugs or<!-- EPO <DP n="24"> --> their hydroxylated metabolites. Individual 0.400 mL aliquots containing nortriptyline, 10-hydroxyamitriptyline, amitriptyline, desmethylchlorpromazine, and chlorpromazine were treated with either 0.040 mL of chloramine-T solution (100 ug/mL) or 0.040 mL of water (Figure 2). In each instance, the total sample (0.440 mL) was made basic by the addition of 0.050 mL of 1N sodium hydroxide, and 1.0 mL of n-pentane was then added. The biphasic mixture was vortexed vigorously for 1 minute and centrifuged at 10,000 x g for 1 minute. The pentane layer was transferred in its entirety to a conical test tube, reduced to dryness with a stream of nitrogen and reconstituted in HPLC mobile phase. An aliquot was then analyzed by HPLC using spectrophotometric ultraviolet detection at 254 nm. The solid- and mobile-phase constituents for this HPLC analytical procedure were as described in Example 2 above.</p><heading id="h0016"><u>EXAMPLE 6</u></heading><heading id="h0017">Removal of Chlorpromazine Interferant By Selenium Dioxide In The Presence of Hydrogen Peroxide</heading><p id="p0037" num="0037">A test sample (0.100 mL) containing imipramine was rendered basic by the addition of 0.100 mL of 0.25 M NaOH and dissociated from serum proteins by the addition of 0.025 mL of isoamyl alcohol. The mixture was allowed to stand for up to 5.0 minutes, after which time 0.50 mL of nonane was added and the sample vortexed vigorously for 1.0 minute.<!-- EPO <DP n="25"> --> The mixture was then centrifuged for up to 5.0 minutes at approximately 2000 x g to clarify the phases. A 0.100 mL aliquot of the nonane upper phase was then transferred to a tube containing 0.100 mL of an acidic buffer containing 100 ug/mL of selenium dioxide (SeO<sub>2</sub>). To this biphasic mixture, 20 uL of a 30% aqueous solution of H<sub>2</sub>O<sub>2</sub> was added and the mixture was vortexed, ninety microliters (0.090 mL) of the lower aqueous phase was then transferred to the sample wells and analyzed by the Abbott TDx analytical system (Table IV). Treatment of the sample extract with selenium dioxide and hydrogen peroxide modified the chemical structure of chlorpromazine such that it was no longer an assay interferant whereas selenium dioxide in the absence of hydrogen peroxide did not cause the conversion of chlorpromazine to chlorpromazine sulfoxide or sulfone. <tables id="tabl0004" num="0004"><table frame="all"><title>TABLE IV</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" align="center">Removal Of Chlorpromazine Interferant In FPIA For Imipramine</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Sample</entry><entry namest="col2" nameend="col2" align="left">Treatment</entry><entry namest="col3" nameend="col3" align="center">Mass Measured</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">IMI</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="char" char=".">15 ng/mL</entry></row><row><entry namest="col1" nameend="col1" align="left">IMI+312 ng CPZ</entry><entry namest="col2" nameend="col2" align="left">NONE</entry><entry namest="col3" nameend="col3" align="char" char=".">98 ng/mL</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">IMI+312 ng CPZ</entry><entry namest="col2" nameend="col2" align="left">SeO<sub>2</sub> + H<sub>2</sub>O<sub>2</sub></entry><entry namest="col3" nameend="col3" align="char" char=".">14.7 ng/mL</entry></row></tbody></tgroup></table></tables></p>
EP	0619020	B1	2000-11-08	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>An immunoassay method for determining the amount of a tricyclic antidepressant drug in a biological test sample, wherein said tricyclic antidepressant drug does not contain a sulfur moiety and wherein said biological test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and is immunologically crossreactive with an antibody to said antidepressant drug, said method comprising the steps of:<claim-text>(a) forming a pretreatment solution by contacting said biological test sample with an oxidative reagent capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby crossreactive binding of said antibody to said tricyclic antidepressant drug to said modified sulfur-containing compound is reduced;</claim-text><claim-text>(b) contacting said pretreatment solution with (i) a labeled reagent comprising said tricyclic antidepressant drug or derivative thereof labeled with a fluorescent moiety, and (ii) said antibody capable of binding to said labeled reagent and said tricyclic antidepressant drug from said biological test sample to form a reaction solution therewith, said labeled reagent capable of producing a detectable fluorescence polarization response to the presence of said antibody; and</claim-text><claim-text>(c) detecting the fluorescence polarization response to said reaction solution as a function of the amount of said tricyclic antidepressant drug present in said test sample.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A high pressure liquid chromatography (HPLC) method for determining the amount of a tricyclic antidepressant drug in a biological test sample, wherein said tricyclic antidepressant drug does not contain a sulfur moiety and<!-- EPO <DP n="27"> --> wherein said biological test sample includes a sulfur-containing compound having a chemical structure similar to the chemical structure of said tricyclic antidepressant drug and an elution profile which interferes with the elution profile of said tricyclic antidepressant drug, said method comprising the steps of:<claim-text>(a) forming an admixture of an aliquot of said biological test sample and an internal standard;</claim-text><claim-text>(b) forming a pretreatment solution by contacting said admixture with an oxidative reagent capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby the elution profile of said modified sulfur-containing compound does not interfere with the elution profile of said tricyclic antidepressant drug;</claim-text><claim-text>(c) contacting said pretreatment solution to an HPLC stationary phase and eluting therefrom with a mobile phase; and</claim-text><claim-text>(d) measuring elution times and absorbances of said internal standard and said tricyclic antidepressant drug as they elute from the stationary phase in order to determine the amount of said tricyclic antidepressant drug in said biological test sample.</claim-text></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The method of Claim 1 or 2 wherein said biological test sample is selected from the group consisting of whole blood, urine, serum, plasma, cerebrospinal fluid and saliva.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The method of Claim 1 or 2 wherein said oxidative reagent is hydrogen peroxide which is generated <u><i>in situ</i></u>.<!-- EPO <DP n="28"> --></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The method of Claim 1 or 2 wherein said oxidative reagent is selected from the group consisting of N-chlorosulfonamides, hypochlorites, hypobromites, peroxides, peracids, and oxidative enzymes.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The method of Claim 1 or 2 wherein said oxidative reagent is a sodium salt of N-chloro-4-methylbenzene sulfonamide.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The method of Claim 1 or 2 wherein said tricyclic antidepressant drug is selected from the group consisting of amitriptylene, nortriptylene, imipramine, desipramine, protriptyline, doxepin, desdoxepin, and clomipramine.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The method of Claim 1 or 2 wherein said sulfur-containing substance is a phenothiazine selected from the group consisting of chloropromazine, desmethylchloropromazine, thioridazine, desmethylthioridazine, sulforidazine, and mesoridazine.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A test kit useful for the fluorescent polarization immunoassay determination of a tricyclic antidepressant drug present in a test sample, wherein said antidepressant drug does not contain a sulfur moiety and wherein said test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and is immunologically crossreactive with an antibody to said antidepressant drug, said test kit comprising (a) an oxidative reagent, or reagents which can generate hydrogen peroxide as an oxidative reagent in the test sample, said oxidative reagent being capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby crossreactive binding of said antibody to said tricyclic antidepressant drug to said modified sulfur-containing compound is reduced and (b) all essential additional reagents for performing the fluorescent polarization immunoassay<!-- EPO <DP n="29"> --> determination including an antibody to said tricyclic antidepressant drug and a suitable fluorescent tracer compound.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A test kit useful for the chromatographic determination of a tricyclic antidepressant drug present in a test sample, wherein said antidepressant drug does not contain a sulfur moiety and wherein said test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and an elution profile which interferes with the elution profile of said tricyclic antidepressant drug, said test kit comprising (a) an oxidative reagent, or reagents which can generate hydrogen peroxide as an oxidative reagent in the test sample, said oxidative reagent being capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby the elution profile of said modified sulfur-containing compound does not interfere with the elution profile of said tricyclic antidepressant drug; and (b) all essential additional reagents for performing the chromatographic determination including an internal standard.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The test kit of Claim 10 useful in a high pressure liquid chromatographic determination of said drug; or useful in a thin layer chromatographic determination of said drug.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The test kit of any one of Claims 9-11 wherein said oxidative reagent is selected from the group consisting of N-chlorosulfonamides, hypochlorites, hypobromites, peroxides, peracids and oxidative enzymes.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The test kit of any one of Claims 9-11 wherein said oxidative reagent is selected from the group consisting of sodium hypochlorite, catalase, perselenic acid and a sodium salt of N-chloro-4-methylbenzene sulfonamide.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The test kit of any one of Claims 9-11 wherein said oxidative reagent is a sodium salt of N-chloro-4-methylbenzene sulfonamide or a sodium salt of N-chlorobenzene sulfonamide.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The test kit of any one of Claims 9-11 wherein said sulfur-containing substances are phenothiazines.</claim-text></claim>
EP	0619020	B1	2000-11-08	en	CLAIM	2	<claim id="c-en-02-0001" num="0001"><claim-text>An immunoassay method for determining the amount of a tricyclic antidepressant drug in a biological test sample, wherein said tricyclic antidepressant drug does not contain a sulfur moiety and wherein said biological test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and is immunologically crossreactive with an antibody to said antidepressant drug, said method comprising the steps of:<claim-text>(a) forming a pretreatment solution by contacting said biological test sample with an oxidative reagent capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby crossreactive binding of said antibody to said tricyclic antidepressant drug to said modified sulfur-containing compound is reduced;</claim-text><claim-text>(b) contacting said pretreatment solution with (i) a labeled reagent comprising said tricyclic antidepressant drug or derivative thereof labeled with a fluorescent moiety, and (ii) said antibody capable of binding to said labeled reagent and said tricyclic antidepressant drug from said biological test sample to form a reaction solution therewith, said labeled reagent capable of producing a detectable fluorescence polarization response to the presence of said antibody; and</claim-text><claim-text>(c) detecting the fluorescence polarization response to said reaction solution as a function of the amount of said tricyclic antidepressant drug present in said test sample.</claim-text></claim-text></claim><claim id="c-en-02-0002" num="0002"><claim-text>A high pressure liquid chromatography (HPLC) method for determining the amount of a tricyclic antidepressant drug in a biological test sample, wherein said tricyclic antidepressant drug does not contain a sulfur moiety and<!-- EPO <DP n="31"> --> wherein said biological test sample includes a sulfur-containing compound having a chemical structure similar to the chemical structure of said tricyclic antidepressant drug and an elution profile which interferes with the elution profile of said tricyclic antidepressant drug, said method comprising the steps of:<claim-text>(a) forming an admixture of an aliquot of said biological test sample and an internal standard;</claim-text><claim-text>(b) forming a pretreatment solution by contacting said admixture with an oxidative reagent capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby the elution profile of said modified sulfur-containing compound does not interfere with the elution profile of said tricyclic antidepressant drug;</claim-text><claim-text>(c) contacting said pretreatment solution to an HPLC stationary phase and eluting therefrom with a mobile phase; and</claim-text><claim-text>(d) measuring elution times and absorbances of said internal standard and said tricyclic antidepressant drug as they elute from the stationary phase in order to determine the amount of said tricyclic antidepressant drug in said biological test sample.</claim-text></claim-text></claim><claim id="c-en-02-0003" num="0003"><claim-text>The method of Claim 1 or 2 wherein said biological test sample is selected from the group consisting of whole blood, urine, serum, plasma, cerebrospinal fluid and saliva.</claim-text></claim><claim id="c-en-02-0004" num="0004"><claim-text>The method of Claim 1 or 2 wherein said oxidative reagent is hydrogen peroxide which is generated <u><i>in situ</i></u>.<!-- EPO <DP n="32"> --></claim-text></claim><claim id="c-en-02-0005" num="0005"><claim-text>The method of Claim 1 or 2 wherein said oxidative reagent is selected from the group consisting of N-chlorosulfonamides, hypochlorites, hypobromites, peroxides, peracids, and oxidative enzymes.</claim-text></claim><claim id="c-en-02-0006" num="0006"><claim-text>The method of Claim 1 or 2 wherein said oxidative reagent is a sodium salt of N-chloro-4-methylbenzene sulfonamide.</claim-text></claim><claim id="c-en-02-0007" num="0007"><claim-text>The method of Claim 1 or 2 wherein said tricyclic antidepressant drug is selected from the group consisting of amitriptylene, nortriptylene, imipramine, desipramine, protriptyline, doxepin, desdoxepin, and clomipramine.</claim-text></claim><claim id="c-en-02-0008" num="0008"><claim-text>The method of Claim 1 or 2 wherein said sulfur-containing substance is a phenothiazine selected from the group consisting of chloropromazine, desmethylchloropromazine, thioridazine, desmethylthioridazine, sulforidazine, and mesoridazine.</claim-text></claim><claim id="c-en-02-0009" num="0009"><claim-text>Use of a test kit for the fluorescent polarization immunoassay determination of a tricyclic antidepressant drug present in a test sample, wherein said antidepressant drug does not contain a sulfur moiety and wherein said test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and is immunologically crossreactive with an antibody to said antidepressant drug, said test kit comprising (a) an oxidative reagent, or reagents which can generate hydrogen peroxide as an oxidative reagent in the test sample, said oxidative reagent being capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby crossreactive binding of said antibody to said tricyclic antidepressant drug to said modified sulfur-containing compound is reduced and (b) all essential additional reagents for performing the fluorescent polarization immunoassay<!-- EPO <DP n="33"> --> determination including an antibody to said tricyclic antidepressant drug and a suitable fluorescent tracer compound.</claim-text></claim><claim id="c-en-02-0010" num="0010"><claim-text>Use of a test kit for the chromatographic determination of a tricyclic antidepressant drug present in a test sample, wherein said antidepressant drug does not contain a sulfur moiety and wherein said test sample includes a sulfur-containing compound having a chemical structure which is similar to said tricyclic antidepressant drug and an elution profile which interferes with the elution profile of said tricyclic antidepressant drug, said test kit comprising (a) an oxidative reagent, or reagents which can generate hydrogen peroxide as an oxidative reagent in the test sample, said oxidative reagent being capable of modifying the chemical structure of said sulfur-containing compound by selectively oxidizing the sulfur moiety of said sulfur-containing compound without modifying the chemical structure of said tricyclic antidepressant drug, whereby the elution profile of said modified sulfur-containing compound does not interfere with the elution profile of said tricyclic antidepressant drug; and (b) all essential additional reagents for performing the chromatographic determination including an internal standard.</claim-text></claim><claim id="c-en-02-0011" num="0011"><claim-text>The use of Claim 10 in a high pressure liquid chromatographic determination of said drug; or in a thin layer chromatographic determination of said drug.</claim-text></claim><claim id="c-en-02-0012" num="0012"><claim-text>The use of any one of Claims 9-11 wherein said oxidative reagent is selected from the group consisting of N-chlorosulfonamides, hypochlorites, hypobromites, peroxides, peracids and oxidative enzymes.</claim-text></claim><claim id="c-en-02-0013" num="0013"><claim-text>The use of any one of Claims 9-11 wherein said oxidative reagent is selected from the group consisting of sodium hypochlorite, catalase, perselenic acid and a sodium salt of N-chloro-4-methylbenzene sulfonamide.</claim-text></claim><claim id="c-en-02-0014" num="0014"><claim-text>The use of any one of Claims 9-11 wherein said oxidative reagent is a sodium salt of N-chloro-4-methylbenzene sulfonamide or a sodium salt of N-chlorobenzene sulfonamide.</claim-text></claim><claim id="c-en-02-0015" num="0015"><claim-text>The use of any one of Claims 9-11 wherein said sulfur-containing substances are phenothiazines.</claim-text></claim>
EP	0619020	B1	2000-11-08	de	CLAIM	3	<claim id="c-de-01-0001" num="0001"><claim-text>Ein Immunoassayverfahren zur Bestimmung der Menge eines trizyklischen Antidepressivums in einer biologischen Testprobe, worin das trizyklische Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die biologische Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur hat, die dem trizyklischen Antidepressivum Ã¤hnlich ist und immunologisch kreuzreaktiv ist mit einem AntikÃ¶rper zu dem Antidepressivum, wobei das Verfahren folgende Schritte umfaÃŸt:<claim-text>(a) Bilden einer VorbehandlungslÃ¶sung, indem die biologische Testprobe mit einem oxidativen Reagens in Kontakt gebracht wird, das in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung zu modifizieren, indem die Schwefelkomponente der schwefelenthaltenden Verbindung selektiv oxidiert wird, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizieren, wobei die kreuzreaktive Bindung des AntikÃ¶rpers zu dem Antidepressivum gegenÃ¼ber der modifizierten schwefelenthaltenden Verbindung reduziert ist;</claim-text><claim-text>(b) In-Kontakt-Bringen der VorbehandlungslÃ¶sung mit (i) einem markierten Reagenz, das das trizyklische Antidepressivum oder ein Derivat davon, markiert mit einer fluoreszierenden Komponente, enthÃ¤lt und (ii) wobei der AntikÃ¶rper in der Lage ist, das markierte Reagenz und das trizyklische Antidepressivum aus der biologischen Testprobe zu binden, damit eine ReaktionslÃ¶sung gebildet wird, wobei das markierte Reagens in der Lage ist, eine detektierbare Fluoreszenzpolarisationsantwort auf die Anwesenheit des AntikÃ¶rpers zu geben; und</claim-text><claim-text>(c) Detektieren der Fluoreszenzpolarisationsantwort auf die ReaktionslÃ¶sung als eine Funktion der Menge des trizyklischen Antidepressivums, die in der Testprobe vorhanden ist.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Ein HochleistungsflÃ¼ssigchromatographieverfahren (HPLC)<!-- EPO <DP n="35"> --> zur Bestimmung der Menge eines trizyklischen Antidepressivums in einer biologischen Testprobe, worin das trizyklische Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die biologische Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur Ã¤hnlich der chemischen Struktur des trizyklischen Antidepressivums hat, und ein Elutionsprofil, das das Elutionsprofil des trizyklischen Antidepressivums beeinfluÃŸt, wobei das Verfahren folgende Schritte umfaÃŸt:<claim-text>(a) Bilden einer Mischung aus einem Aliquot der biologischen Testprobe und einem internen Standard;</claim-text><claim-text>(b) Bilden einer VorbehandlungslÃ¶sung, indem die Mischung mit einem oxidativen Reagens in Kontakt gebracht wird, das in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung durch selektive Oxidation der Schwefelkomponente der schwefelenthaltenden Verbindung zu modifizieren, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizieren, durch das Elutionsprofil der modifizierten schwefelenthaltenden Verbindung das Elutionsprofil des trizyklischen Antidepressivums nicht beeinfluÃŸt;</claim-text><claim-text>(c) In-Kontakt-Bringen der VorbehandlungslÃ¶sung mit einer HPLC stationÃ¤ren Phase und daraus Eluieren mit einer mobilen Phase; und</claim-text><claim-text>(d) Messen von Elutionszeiten und Absorptionen von dem internen Standard und dem trizyklischen Antidepressivum wÃ¤hrend sie von der stationÃ¤ren Phase eluieren, um die Menge des trizyklischen Antidepressivums in der biologischen Testprobe zu bestimmen.</claim-text></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin die biologische Testprobe gewÃ¤hlt ist aus der Gruppe bestehend aus Vollblut, Urin, Serum, Plasma, CerebrospinalflÃ¼ssigkeit und Speichel.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das oxidative Reagens Wasserstoffperoxid ist, das <u><i>in situ</i></u> hergestellt wird.<!-- EPO <DP n="36"> --></claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das oxidative Reagens gewÃ¤hlt ist aus der Gruppe bestehend aus N-Chlorsulfonamid, Hypochloriten, Hypobromiten, Peroxiden, Peraciden und oxidativen Enzymen.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das oxidative Reagens ein Natriumsalz von N-Chlor-4-methylbenzensulfonamid ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das trizyklische Antidepressivum gewÃ¤hlt ist aus der Gruppe bestehend aus Amitriptylen, Nortriptylen, Imipramin, Desipramin, Protriptylin, Doxepin, Desdoxepin und Clomipramin.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin die schwefelenthaltende Substanz ein Phenothiazin ist, gewÃ¤hlt aus der Gruppe bestehend aus Chlorpromazin, Desmethylchlorpromazin, Thioridazin, Desmethylthioridazin, Sulforidazin und Mesoridazin.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Ein Testkit, nÃ¼tzlich fÃ¼r die Fluoreszenzpolarisationsimmunoassaybestimmung eines trizyklischen Antidepressivums, das in einer Testprobe enthalten ist, worin das Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur hat, die dem trizyklischen Antidepressivum Ã¤hnlich ist und immunologisch kreuzreaktiv mit einem AntikÃ¶rper zu dem Antidepressivum ist, wobei der Testkit folgendes enthÃ¤lt (a) ein oxidatives Reagens oder Reagenzien, die Wasserstoffperoxid als oxidatives Reagens in der Testprobe erzeugen kÃ¶nnen, wobei das oxidative Reagens in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung durch selektive Oxidation der Schwefelkomponente der schwefelenthaltenden Verbindung zu modifizieren, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizeren, wobei kreuzreaktives Binden des AntikÃ¶rpers zu dem trizyklischen Antidepressivum gegenÃ¼ber der modifizierten schwefelenthaltende Verbindung reduziert ist und<!-- EPO <DP n="37"> --> wobei (b) alle wesentlichen zusÃ¤tzlichen Reagenzien zur DurchfÃ¼hrung der Fluoreszenzimmunoassaybestimmung einen AntikÃ¶rper zu dem trizyklischen Antidepressivum und eine passende Fluoreszenztracerverbindung einschlieÃŸen.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Ein Testkit, nÃ¼tzlich zur chromatographischen Bestimmung eines trizyklischen Antidepressivums, das in einer Testprobe vorhanden ist, worin das Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur hat, die dem trizyklischen Antidepressivum Ã¤hnlich ist, und ein Elutionsprofil, das das Elutionsprofil des trizyklischen Antidepressivums beinfluÃŸt, wobei das Testkit folgendes enthÃ¤lt (a) ein oxidatives Reagens oder Reagenzien, die Wasserstoffperoxid als oxidatives Reagens in der Testprobe erzeugen kÃ¶nnen, wobei das oxidative Reagenz in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung durch selektive Oxidation der Schwefelkomponente der schwefelenthaltenden Verbindung zu modifizieren, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizieren, wodurch das Elutionsprofil der modifizierten schwefelenthaltenden Verbindung das Elutionsprofil des trizyklischen Antidepressivums nicht beinfluÃŸt; und wobei (b) alle wesentlichen zusÃ¤tzlichen Reagenzien zur DurchfÃ¼hrung der chromatographischen Bestimmung, einen internen Standard einschlieÃŸen.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Das Testkit nach Anspruch 10, nÃ¼tzlich in einer hochdruckflÃ¼ssigchromatographischen Bestimmung des Arzneimittels; oder nÃ¼tzlich in einer dÃ¼nnschichtchromatographischen Bestimmung des Arzneimittels.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Das Testkit nach irgendeinem der AnsprÃ¼cke 9-11, worin das oxidative Reagens gewÃ¤hlt ist aus der Gruppe bestehend aus N-Chlorsulfonamiden, Hypochloriten, Hypobromiten, Peroxiden, Peraciden und oxidativen Enzymen.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Das Testkit nach irgendeinem der AnsprÃ¼che 9-11, worin<!-- EPO <DP n="38"> --> das oxidative Reagens gewÃ¤hlt ist aus der Gruppe bestehend aus Natriumhypochlorit, Katalase, PerselensÃ¤ure und einem Natriumsalz von N-Chlor-4-methylbenzensulfonamid.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Das Testkit nach igendeinem der AnsprÃ¼che 9-11, worin das oxidative Reagens ein Natriumsalz von N-Chlor-4-methylbenzensulfonamid ist oder ein Natriumsalz von N-Chlorbenzensulfonamid.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Das Testkit nach irgendeinem der AnsprÃ¼che 9-11, worin die schwefelenthaltenden Substanzen Phenothiazine sind.</claim-text></claim>
EP	0619020	B1	2000-11-08	de	CLAIM	4	<claim id="c-de-02-0001" num="0001"><claim-text>Ein Immunoassayverfahren zur Bestimmung der Menge eines trizyklischen Antidepressivums in einer biologischen Testprobe, worin das trizyklische Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die biologische Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur hat, die dem trizyklischen Antidepressivum Ã¤hnlich ist und immunologisch kreuzreaktiv ist mit einem AntikÃ¶rper zu dem Antidepressivum, wobei das Verfahren folgende Schritte umfaÃŸt:<claim-text>(a) Bilden einer VorbehandlungslÃ¶sung, indem die biologische Testprobe mit einem oxidativen Reagens in Kontakt gebracht wird, das in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung zu modifizieren, indem die Schwefelkomponente der schwefelenthaltenden Verbindung selektiv oxidiert wird, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizieren, wobei die kreuzreaktive Bindung des AntikÃ¶rpers zu dem Antidepressivum gegenÃ¼ber der modifizierten schwefelenthaltenden Verbindung reduziert ist;</claim-text><claim-text>(b) In-Kontakt-Bringen der VorbehandlungslÃ¶sung mit (i) einem markierten Reagenz, das das trizyklische Antidepressivum oder ein Derivat davon, markiert mit einer fluoreszierenden Komponente, enthÃ¤lt und (ii) wobei der AntikÃ¶rper in der Lage ist, das markierte Reagenz und das trizyklische Antidepressivum aus der biologischen Testprobe zu binden, damit eine ReaktionslÃ¶sung gebildet wird, wobei das markierte Reagens in der Lage ist, eine detektierbare Fluoreszenzpolarisationsantwort auf die Anwesenheit des AntikÃ¶rpers zu geben; und</claim-text><claim-text>(c) Detektieren der Fluoreszenzpolarisationsantwort auf die ReaktionslÃ¶sung als eine Funktion der Menge des trizyklischen Antidepressivums, die in der Testprobe vorhanden ist.</claim-text></claim-text></claim><claim id="c-de-02-0002" num="0002"><claim-text>Ein HochleistungsflÃ¼ssigchromatographieverfahren (HPLC) zur Bestimmung der Menge eines trizyklischen Antidepressivums in einer biologischen Testprobe, worin das trizyklische<!-- EPO <DP n="40"> --> Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die biologische Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur Ã¤hnlich der chemischen Struktur des trizyklischen Antidepressivums hat, und ein Elutionsprofil, das das Elutionsprofil des trizyklischen Antidepressivums beeinfluÃŸt, wobei das Verfahren folgende Schritte umfaÃŸt:<claim-text>(a) Bilden einer Mischung aus einem Aliquot der biologischen Testprobe und einem internen Standard;</claim-text><claim-text>(b) Bilden einer VorbehandlungslÃ¶sung, indem die Mischung mit einem oxidativen Reagens in Kontakt gebracht wird, das in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung durch selektive Oxidation der Schwefelkomponente der schwefelenthaltenden Verbindung zu modifizieren, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizieren, durch das Elutionsprofil der modifizierten schwefelenthaltenden Verbindung das Elutionsprofil des trizyklischen Antidepressivums nicht beeinfluÃŸt;</claim-text><claim-text>(c) In-Kontakt-Bringen der VorbehandlungslÃ¶sung mit einer HPLC stationÃ¤ren Phase und daraus Eluieren mit einer mobilen Phase; und</claim-text><claim-text>(d) Messen von Elutionszeiten und Absorptionen von dem internen Standard und dem trizyklischen Antidepressivum wÃ¤hrend sie von der stationÃ¤ren Phase eluieren, um die Menge des trizyklischen Antidepressivums in der biologischen Testprobe zu bestimmen.</claim-text></claim-text></claim><claim id="c-de-02-0003" num="0003"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin die biologische Testprobe gewÃ¤hlt ist aus der Gruppe bestehend aus Vollblut, Urin, Serum, Plasma, CerebrospinalflÃ¼ssigkeit und Speichel.</claim-text></claim><claim id="c-de-02-0004" num="0004"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das oxidative Reagens Wasserstoffperoxid ist, das <u><i>in situ</i></u> hergestellt wird.</claim-text></claim><claim id="c-de-02-0005" num="0005"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das<!-- EPO <DP n="41"> --> oxidative Reagens gewÃ¤hlt ist aus der Gruppe bestehend aus N-Chlorsulfonamid, Hypochloriten, Hypobromiten, Peroxiden, Peraciden und oxidativen Enzymen.</claim-text></claim><claim id="c-de-02-0006" num="0006"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das oxidative Reagens ein Natriumsalz von N-Chlor-4-methylbenzensulfonamid ist.</claim-text></claim><claim id="c-de-02-0007" num="0007"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin das trizyklische Antidepressivum gewÃ¤hlt ist aus der Gruppe bestehend aus Amitriptylen, Nortriptylen, Imipramin, Desipramin, Protriptylin, Doxepin, Desdoxepin und Clomipramin.</claim-text></claim><claim id="c-de-02-0008" num="0008"><claim-text>Das Verfahren nach Anspruch 1 oder 2, worin die schwefelenthaltende Substanz ein Phenothiazin ist, gewÃ¤hlt aus der Gruppe bestehend aus Chlorpromazin, Desmethylchlorpromazin, Thioridazin, Desmethylthioridazin, Sulforidazin und Mesoridazin.</claim-text></claim><claim id="c-de-02-0009" num="0009"><claim-text>Ein Testkit, nÃ¼tzlich fÃ¼r die Fluoreszenzpolarisationsimmunoassaybestimmung eines trizyklischen Antidepressivums, das in einer Testprobe enthalten ist, worin das Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur hat, die dem trizyklischen Antidepressivum Ã¤hnlich ist und immunologisch kreuzreaktiv mit einem AntikÃ¶rper zu dem Antidepressivum ist, wobei der Testkit folgendes enthÃ¤lt (a) ein oxidatives Reagens oder Reagenzien, die Wasserstoffperoxid als oxidatives Reagens in der Testprobe erzeugen kÃ¶nnen, wobei das oxidative Reagens in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung durch selektive Oxidation der Schwefelkomponente der schwefelenthaltenden Verbindung zu modifizieren, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizeren, wobei kreuzreaktives Binden des AntikÃ¶rpers zu dem trizyklischen Antidepressivum gegenÃ¼ber der modifizierten schwefelenthaltende Verbindung reduziert ist und wobei (b) alle wesentlichen zusÃ¤tzlichen Reagenzien zur DurchfÃ¼hrung der Fluoreszenzimmunoassaybestimmung einen AntikÃ¶rper zu<!-- EPO <DP n="42"> --> dem trizyklischen Antidepressivum und eine passende Fluoreszenztracerverbindung einschlieÃŸen.</claim-text></claim><claim id="c-de-02-0010" num="0010"><claim-text>Ein Testkit, nÃ¼tzlich zur chromatographischen Bestimmung eines trizyklischen Antidepressivums, das in einer Testprobe vorhanden ist, worin das Antidepressivum keine Schwefelkomponente enthÃ¤lt und worin die Testprobe eine schwefelenthaltende Verbindung enthÃ¤lt, die eine chemische Struktur hat, die dem trizyklischen Antidepressivum Ã¤hnlich ist, und ein Elutionsprofil, das das Elutionsprofil des trizyklischen Antidepressivums beinfluÃŸt, wobei das Testkit folgendes enthÃ¤lt (a) ein oxidatives Reagens oder Reagenzien, die Wasserstoffperoxid als oxidatives Reagens in der Testprobe erzeugen kÃ¶nnen, wobei das oxidative Reagenz in der Lage ist, die chemische Struktur der schwefelenthaltenden Verbindung durch selektive Oxidation der Schwefelkomponente der schwefelenthaltenden Verbindung zu modifizieren, ohne die chemische Struktur des trizyklischen Antidepressivums zu modifizieren, wodurch das Elutionsprofil der modifizierten schwefelenthaltenden Verbindung das Elutionsprofil des trizyklischen Antidepressivums nicht beinfluÃŸt; und wobei (b) alle wesentlichen zusÃ¤tzlichen Reagenzien zur DurchfÃ¼hrung der chromatographischen Bestimmung, einen internen Standard einschlieÃŸen.</claim-text></claim><claim id="c-de-02-0011" num="0011"><claim-text>Das Testkit nach Anspruch 10, nÃ¼tzlich in einer hochdruckflÃ¼ssigchromatographischen Bestimmung des Arzneimittels; oder nÃ¼tzlich in einer dÃ¼nnschichtchromatographischen Bestimmung des Arzneimittels.</claim-text></claim><claim id="c-de-02-0012" num="0012"><claim-text>Das Testkit nach irgendeinem der AnsprÃ¼cke 9-11, worin das oxidative Reagens gewÃ¤hlt ist aus der Gruppe bestehend aus N-Chlorsulfonamiden, Hypochloriten, Hypobromiten, Peroxiden, Peraciden und oxidativen Enzymen.</claim-text></claim><claim id="c-de-02-0013" num="0013"><claim-text>Das Testkit nach irgendeinem der AnsprÃ¼che 9-11, worin das oxidative Reagens gewÃ¤hlt ist aus der Gruppe bestehend aus Natriumhypochlorit, Katalase, PerselensÃ¤ure und einem<!-- EPO <DP n="43"> --> Natriumsalz von N-Chlor-4-methylbenzensulfonamid.</claim-text></claim><claim id="c-de-02-0014" num="0014"><claim-text>Das Testkit nach igendeinem der AnsprÃ¼che 9-11, worin das oxidative Reagens ein Natriumsalz von N-Chlor-4-methylbenzensulfonamid ist oder ein Natriumsalz von N-Chlorbenzensulfonamid.</claim-text></claim><claim id="c-de-02-0015" num="0015"><claim-text>Das Testkit nach irgendeinem der AnsprÃ¼che 9-11, worin die schwefelenthaltenden Substanzen Phenothiazine sind.</claim-text></claim>
EP	0619020	B1	2000-11-08	fr	CLAIM	5	<claim id="c-fr-01-0001" num="0001"><claim-text>MÃ©thode de dosage immunologique pour la dÃ©termination de la quantitÃ© d'un mÃ©dicament antidÃ©presseur tricyclique dans un Ã©chantillon biologique Ã  tester, dans laquelle ledit mÃ©dicament antidÃ©presseur tricyclique ne contient pas de fragment soufre et dans laquelle ledit Ã©chantillon biologique Ã  tester contient un composÃ© contenant du soufre ayant une structure chimique similaire audit mÃ©dicament antidÃ©presseur tricyclique et prÃ©sentant une rÃ©action immunologique croisÃ©e avec un anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur, ladite mÃ©thode comprenant les Ã©tapes de :<claim-text>(a) la formation d'une solution de prÃ©traitement par la mise en contact dudit Ã©chantillon biologique Ã  tester avec un rÃ©actif oxydant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, ce qui rÃ©duit la fixation par rÃ©action croisÃ©e dudit anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur tricyclique audit composÃ© contenant du soufre modifiÃ© ;</claim-text><claim-text>(b) la mise en contact de ladite solution de prÃ©traitement avec (i) un rÃ©actif marquÃ© contenant ledit mÃ©dicament antidÃ©presseur tricyclique ou un de ses dÃ©rivÃ©s marquÃ© avec un fragment fluorescent et (ii) ledit anticorps capable de se fixer audit rÃ©actif marquÃ© et audit mÃ©dicament antidÃ©presseur tricyclique dudit Ã©chantillon biologique Ã  tester pour former avec eux une solution rÃ©actionnelle, ledit rÃ©actif marquÃ© Ã©tant capable de produire une rÃ©ponse de polarisation de fluorescence dÃ©tectable en prÃ©sence dudit anticorps ; et</claim-text><claim-text>(c) la dÃ©tection de la rÃ©ponse de polarisation de fluorescence de ladite solution rÃ©actionnelle en fonction de la quantitÃ© dudit mÃ©dicament antidÃ©presseur tricyclique prÃ©sent dans ledit Ã©chantillon Ã  tester.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>MÃ©thode de chromatographie liquide haute pression (HPLC) pour dÃ©terminer la quantitÃ© d'un mÃ©dicament antidÃ©presseur tricyclique dans un Ã©chantillon biologique Ã  tester, dans laquelle ledit mÃ©dicament antidÃ©presseur tricyclique ne contient pas de fragment soufre et dans laquelle ledit Ã©chantillon biologique Ã  tester contient un composÃ© contenant du soufre ayant une structure chimique similaire Ã  la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique et prÃ©sentant un profil d'Ã©lution<!-- EPO <DP n="45"> --> interfÃ©rant avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique, ladite mÃ©thode comprenant les Ã©tapes de :<claim-text>(a) la formation d'un mÃ©lange d'une partie aliquote dudit Ã©chantillon biologique Ã  tester et d'un Ã©talon interne ;</claim-text><claim-text>(b) la formation d'une solution de prÃ©traitement par la mise en contact dudit mÃ©lange avec un rÃ©actif oxydant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, le profil d'Ã©lution dudit composÃ© contenant du soufre modifiÃ© n'interfÃ©rant ainsi pas avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique ;</claim-text><claim-text>(c) la mise en contact de ladite solution de prÃ©traitement avec une phase stationnaire de HPLC et son Ã©lution avec une phase mobile ; et</claim-text><claim-text>(d) la mesure des durÃ©es d'Ã©lution et des absorbances dudit Ã©talon interne et dudit mÃ©dicament antidÃ©presseur tricyclique quand ils Ã©luent de la phase stationnaire pour dÃ©terminer la quantitÃ© dudit mÃ©dicament antidÃ©presseur tricyclique dans ledit Ã©chantillon biologique Ã  tester.</claim-text></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit Ã©chantillon biologique Ã  tester est choisi dans le groupe constituÃ© par le sang total, l'urine, le sÃ©rum, le plasma, le fluide cÃ©rÃ©bro-spinal et la salive.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit rÃ©actif oxydant est du peroxyde d'hydrogÃ¨ne gÃ©nÃ©rÃ© <i>in situ</i>.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit rÃ©actif oxydant est choisi dans le groupe constituÃ© par les N-chlorosulfonamides, les hypochlorites, les hypobromites, les peroxydes, les peracides et les enzymes oxydantes.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit rÃ©actif oxydant est le sel de sodium du N-chloro-4-mÃ©thylbenzÃ¨nesulfonamide.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit mÃ©dicament antidÃ©presseur tricyclique est choisi dans le groupe constituÃ© par l'amitripyline, le nortriptyline, l'imipramine, la dÃ©sipramine, la protriptyline, la doxÃ©pine, la desdoxÃ©pine et la clomipramine.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle la substance contenant du soufre est une phÃ©nothiazine choisie dans le groupe constituÃ© par la chloropromazine, la desmÃ©thylchloropromazine, la thioridazine, la desmÃ©thylthioridazine, la sulforidazine et la mÃ©soridazine.<!-- EPO <DP n="46"> --></claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Kit de test utile pour la dÃ©termination par dosage immunologique par polarisation de fluorescence d'un mÃ©dicament antidÃ©presseur tricyclique prÃ©sent dans un Ã©chantillon Ã  tester, ledit mÃ©dicament antidÃ©presseur ne contenant pas de fragment soufre et ledit Ã©chantillon Ã  tester contenant un composÃ© contenant du soufre ayant une structure chimique similaire audit mÃ©dicament antidÃ©presseur tricyclique et prÃ©sentant une rÃ©action immunologique croisÃ©e avec un anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur, ledit kit de test comprenant (a) un rÃ©actif oxydant, ou des rÃ©actifs capables de gÃ©nÃ©rer du peroxyde d'hydrogÃ¨ne en tant que rÃ©actif oxydant dans l'Ã©chantillon Ã  tester, ledit rÃ©actif oxydant Ã©tant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, ce qui rÃ©duit la fixation par rÃ©action croisÃ©e dudit anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur tricyclique audit composÃ© contenant du soufre modifiÃ© et (b) tous les autres rÃ©actifs essentiels pour la rÃ©alisation d'un dosage immunologique par polarisation de fluorescence incluant un anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur tricyclique et un composÃ© traceur fluorescent appropriÃ©.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Kit de test utile pour le dosage chromatographique d'un mÃ©dicament antidÃ©presseur tricyclique prÃ©sent dans un Ã©chantillon Ã  tester, ledit mÃ©dicament antidÃ©presseur ne contenant pas de fragment soufre et ledit Ã©chantillon Ã  tester contenant un composÃ© contenant du soufre ayant une structure chimique similaire audit mÃ©dicament antidÃ©presseur tricyclique et un profil d'Ã©lution interfÃ©rant avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique, ledit kit de test comprenant (a) un rÃ©actif oxydant, ou des rÃ©actifs capables de gÃ©nÃ©rer du peroxyde d'hydrogÃ¨ne en tant que rÃ©actif oxydant dans l'Ã©chantillon Ã  tester, ledit rÃ©actif oxydant Ã©tant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, le profil d'Ã©lution dudit composÃ© contenant du soufre modifiÃ© n'interfÃ©rant ainsi pas avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique ; et (b) tous les autres rÃ©actifs essentiels pour la rÃ©alisation d'un dosage chromatographique incluant un Ã©talon interne.<!-- EPO <DP n="47"> --></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Kit de test selon la revendication 10 utile dans le dosage dudit mÃ©dicament par chromatographie liquide Ã  haute pression ; ou utile dans le dosage dudit mÃ©dicament par chromatographie sur couche mince.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Kit de test selon une quelconque des revendications 9 - 11, dans lequel ledit rÃ©actif oxydant est choisi dans le groupe constituÃ© par les N-chlorosulfonamides, les hypochlorites, les hypobromites, les peroxydes, les peracides et les enzymes oxydantes.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Kit de test selon une quelconque des revendications 9 - 11, dans lequel ledit rÃ©actif oxydant est choisi dans le groupe constituÃ© par l'hypochlorite de sodium, une catalase, l'acide persÃ©lÃ©nique et le sel de sodium du N-chloro-4-mÃ©thylbenzÃ¨nesulfonamide.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Kit de test selon une quelconque des revendications 9 - 11, dans lequel ledit rÃ©actif oxydant est le sel de sodium du N-chloro-4-mÃ©thylbenzÃ¨nesulfonamide ou le sel de sodium du N-chlorobenzÃ¨nesulfonamide.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Kit de test selon une quelconque des revendications 9 - 11, dans lequel les substances contenant du soufre sont des phÃ©nothiazines.</claim-text></claim>
EP	0619020	B1	2000-11-08	fr	CLAIM	6	<claim id="c-fr-02-0001" num="0001"><claim-text>MÃ©thode de dosage immunologique pour la dÃ©termination de la quantitÃ© d'un mÃ©dicament antidÃ©presseur tricyclique dans un Ã©chantillon biologique Ã  tester, dans laquelle ledit mÃ©dicament antidÃ©presseur tricyclique ne contient pas de fragment soufre et dans laquelle ledit Ã©chantillon biologique Ã  tester contient un composÃ© contenant du soufre ayant une structure chimique similaire audit mÃ©dicament antidÃ©presseur tricyclique et prÃ©sentant une rÃ©action immunologique croisÃ©e avec un anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur, ladite mÃ©thode comprenant les Ã©tapes de :<claim-text>(a) la formation d'une solution de prÃ©traitement par la mise en contact dudit Ã©chantillon biologique Ã  tester avec un rÃ©actif oxydant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, ce qui rÃ©duit la fixation par rÃ©action croisÃ©e dudit anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur tricyclique audit composÃ© contenant du soufre modifiÃ© ;</claim-text><claim-text>(b) la mise en contact de ladite solution de prÃ©traitement avec (i) un rÃ©actif marquÃ© contenant ledit mÃ©dicament antidÃ©presseur tricyclique ou un de ses dÃ©rivÃ©s marquÃ© avec un fragment fluorescent et (ii) ledit anticorps capable de se fixer audit rÃ©actif marquÃ© et audit mÃ©dicament antidÃ©presseur tricyclique dudit Ã©chantillon biologique Ã  tester pour former avec eux une solution rÃ©actionnelle, ledit rÃ©actif marquÃ© Ã©tant capable de produire une rÃ©ponse de polarisation de fluorescence dÃ©tectable en prÃ©sence dudit anticorps ; et</claim-text><claim-text>(c) la dÃ©tection de la rÃ©ponse de polarisation de fluorescence de ladite solution rÃ©actionnelle en fonction de la quantitÃ© dudit mÃ©dicament antidÃ©presseur tricyclique prÃ©sent dans ledit Ã©chantillon Ã  tester.</claim-text></claim-text></claim><claim id="c-fr-02-0002" num="0002"><claim-text>MÃ©thode de chromatographie liquide haute pression (HPLC) pour dÃ©terminer la quantitÃ© d'un mÃ©dicament antidÃ©presseur tricyclique dans un Ã©chantillon biologique Ã  tester, dans laquelle ledit mÃ©dicament antidÃ©presseur tricyclique ne contient pas de fragment soufre et dans laquelle ledit Ã©chantillon biologique Ã  tester contient un composÃ© contenant du soufre ayant une structure chimique similaire Ã  la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique et prÃ©sentant un profil d'Ã©lution<!-- EPO <DP n="49"> --> interfÃ©rant avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique, ladite mÃ©thode comprenant les Ã©tapes de :<claim-text>(a) la formation d'un mÃ©lange d'une partie aliquote dudit Ã©chantillon biologique Ã  tester et d'un Ã©talon interne ;</claim-text><claim-text>(b) la formation d'une solution de prÃ©traitement par la mise en contact dudit mÃ©lange avec un rÃ©actif oxydant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, le profil d'Ã©lution dudit composÃ© contenant du soufre modifiÃ© n'interfÃ©rant ainsi pas avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique ;</claim-text><claim-text>(c) la mise en contact de ladite solution de prÃ©traitement avec une phase stationnaire de HPLC et son Ã©lution avec une phase mobile ; et</claim-text><claim-text>(d) la mesure des durÃ©es d'Ã©lution et des absorbances dudit Ã©talon interne et dudit mÃ©dicament antidÃ©presseur tricyclique quand ils Ã©luent de la phase stationnaire pour dÃ©terminer la quantitÃ© dudit mÃ©dicament antidÃ©presseur tricyclique dans ledit Ã©chantillon biologique Ã  tester.</claim-text></claim-text></claim><claim id="c-fr-02-0003" num="0003"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit Ã©chantillon biologique Ã  tester est choisi dans le groupe constituÃ© par le sang total, l'urine, le sÃ©rum, le plasma, le fluide cÃ©rÃ©bro-spinal et la salive.</claim-text></claim><claim id="c-fr-02-0004" num="0004"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit rÃ©actif oxydant est du peroxyde d'hydrogÃ¨ne gÃ©nÃ©rÃ© <i>in situ</i>.</claim-text></claim><claim id="c-fr-02-0005" num="0005"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit rÃ©actif oxydant est choisi dans le groupe constituÃ© par les N-chlorosulfonamides, les hypochlorites, les hypobromites, les peroxydes, les peracides et les enzymes oxydantes.</claim-text></claim><claim id="c-fr-02-0006" num="0006"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit rÃ©actif oxydant est le sel de sodium du N-chloro-4-mÃ©thylbenzÃ¨nesulfonamide.</claim-text></claim><claim id="c-fr-02-0007" num="0007"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle ledit mÃ©dicament antidÃ©presseur tricyclique est choisi dans le groupe constituÃ© par l'amitripyline, le nortriptyline, l'imipramine, la dÃ©sipramine, la protriptyline, la doxÃ©pine, la desdoxÃ©pine et la clomipramine.</claim-text></claim><claim id="c-fr-02-0008" num="0008"><claim-text>MÃ©thode selon la revendication 1 ou 2, dans laquelle la substance contenant du soufre est une phÃ©nothiazine choisie dans le groupe constituÃ© par la chloropromazine, la desmÃ©thylchloropromazine, la thioridazine, la desmÃ©thylthioridazine, la sulforidazine et la mÃ©soridazine.<!-- EPO <DP n="50"> --></claim-text></claim><claim id="c-fr-02-0009" num="0009"><claim-text>Utilisation d'un kit de test pour la dÃ©termination par dosage immunologique par polarisation de fluorescence d'un mÃ©dicament antidÃ©presseur tricyclique prÃ©sent dans un Ã©chantillon Ã  tester, ledit mÃ©dicament antidÃ©presseur ne contenant pas de fragment soufre et ledit Ã©chantillon Ã  tester contenant un composÃ© contenant du soufre ayant une structure chimique similaire audit mÃ©dicament antidÃ©presseur tricyclique et prÃ©sentant une rÃ©action immunologique croisÃ©e avec un anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur, ledit kit de test comprenant (a) un rÃ©actif oxydant, ou des rÃ©actifs capables de gÃ©nÃ©rer du peroxyde d'hydrogÃ¨ne en tant que rÃ©actif oxydant dans l'Ã©chantillon Ã  tester, ledit rÃ©actif oxydant Ã©tant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, ce qui rÃ©duit la fixation par rÃ©action croisÃ©e dudit anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur tricyclique audit composÃ© contenant du soufre modifiÃ© et (b) tous les autres rÃ©actifs essentiels pour la rÃ©alisation d'un dosage immunologique par polarisation de fluorescence incluant un anticorps dirigÃ© contre ledit mÃ©dicament antidÃ©presseur tricyclique et un composÃ© traceur fluorescent appropriÃ©.</claim-text></claim><claim id="c-fr-02-0010" num="0010"><claim-text>Utilisation d'un kit de test pour la dÃ©termination chromatographique d'un mÃ©dicament antidÃ©presseur tricyclique prÃ©sent dans un Ã©chantillon Ã  tester, ledit mÃ©dicament antidÃ©presseur ne contenant pas de fragment soufre et ledit Ã©chantillon Ã  tester contenant un composÃ© contenant du soufre ayant une structure chimique similaire audit mÃ©dicament antidÃ©presseur tricyclique et un profil d'Ã©lution interfÃ©rant avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique, ledit kit de test comprenant (a) un rÃ©actif oxydant, ou des rÃ©actifs capables de gÃ©nÃ©rer du peroxyde d'hydrogÃ¨ne en tant que rÃ©actif oxydant dans l'Ã©chantillon Ã  tester, ledit rÃ©actif oxydant Ã©tant capable de modifier la structure chimique dudit composÃ© contenant du soufre par oxydation sÃ©lective du fragment soufre dudit composÃ© contenant du soufre sans modifier la structure chimique dudit mÃ©dicament antidÃ©presseur tricyclique, le profil d'Ã©lution dudit composÃ© contenant du soufre modifiÃ© n'interfÃ©rant ainsi pas avec le profil d'Ã©lution dudit mÃ©dicament antidÃ©presseur tricyclique ; et (b) tous les autres rÃ©actifs essentiels pour la rÃ©alisation d'un dosage chromatographique incluant un Ã©talon interne.<!-- EPO <DP n="51"> --></claim-text></claim><claim id="c-fr-02-0011" num="0011"><claim-text>Utilisation selon la revendication 10, dans le dosage dudit mÃ©dicament par chromatographie liquide Ã  haute pression ; ou dans le dosage dudit mÃ©dicament par chromatographie sur couche mince.</claim-text></claim><claim id="c-fr-02-0012" num="0012"><claim-text>Utilisation selon une quelconque des revendications 9 - 11, dans laquelle ledit rÃ©actif oxydant est choisi dans le poupe constituÃ© par les N-chlorosulfonamides, les hypochlorites, les hypobromites, les peroxydes, les peracides et les enzymes oxydantes.</claim-text></claim><claim id="c-fr-02-0013" num="0013"><claim-text>Utilisation selon une quelconque des revendications 9 - 11, dans laquelle ledit rÃ©actif oxydant est choisi dans le groupe constituÃ© par l'hypochlorite de sodium, une catalase, l'acide persÃ©lÃ©nique et le sel de sodium du N-chloro-4-mÃ©thylbenzÃ¨nesulfonamide.</claim-text></claim><claim id="c-fr-02-0014" num="0014"><claim-text>Utilisation selon une quelconque des revendications 9 - 11, dans laquelle ledit rÃ©actif oxydant est le sel de sodium du N-chloro-4-mÃ©thylbenzÃ¨nesulfonamide ou le sel de sodium du N-chlorobenzÃ¨nesulfonamide.</claim-text></claim><claim id="c-fr-02-0015" num="0015"><claim-text>Utilisation selon une quelconque des revendications 9 - 11, dans laquelle les substances contenant du soufre sont des phÃ©nothiazines.</claim-text></claim>
EP	0619020	B1	2000-11-08	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0619020&ki=B1&pd=2000-11-08
EP	0612246	B1	2000-08-30	de	TITLE	1	PHARMAZEUTISCHE ZUSAMMENSETZUNGEN VON GALLIUM-KOMPLEXEN VON 3-HYDROXY-4-PYRONEN
EP	0612246	B1	2000-08-30	en	TITLE	1	PHARMACEUTICAL COMPOSITIONS OF GALLIUM COMPLEXES OF 3-HYDROXY-4-PYRONES
EP	0612246	B1	2000-08-30	fr	TITLE	1	COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES COMPLEXES AU GALLIUM DE 3-HYDROXY-4-PYRONES
EP	0612246	B1	2000-08-30	en	DESCR	1	<heading id="h0001"><b>BACKGROUND OF THE INVENTION</b></heading><heading id="h0002">1. <u>Field of the Invention</u></heading><p id="p0001" num="0001">This invention relates to pharmaceutical gallium compositions, particularly those having enhanced oral bioavailability relative to simple gallium salts and methods for their use. Gallium has demonstrated pharmaceutical value for the treatment of many human and animal disorders, including hypercalcemia, cancer, and especially certain widespread degenerative or metabolic bone diseases such as osteoporosis and Paget's disease.</p><heading id="h0003">2. <u>References</u></heading><p id="p0002" num="0002">The following references are cited in this application as superscript numbers at the relevant portion of the application:<ul id="ul0001" list-style="none" compact="compact"><li>1. Hart and Adamson, Proceedings of the National Academy of Sciences, U.S.A., <u>68</u>:1623-1626 (1971)</li><li>2. Collery, U.S. Patent No. 4,596,710</li><li>3. Adamson et al., Chemotherapy Reports, <u>59</u>:599-610 (1975)</li><li>4. Warrell, Jr. et al., U.S. Patent No. 4,529,593</li><li>5. Bockman et al., U.S. Patent No. 4,704,277</li><li>6. Warrell, Jr. et al., "Gallium in the Treatment of Hypercalcemia and Bone Metastasis", in "Important Advances in Oncology 1989", DeVita, Jr., Editor, J.P. Lippincott Company, Philadelphia, PA<!-- EPO <DP n="2"> --></li><li>7. Porter, "The Use of Opadry, Coateric, and Surelease in the Aqueous Film Coating of Pharmaceutical Oral Dosage Forms", at pp. 317-362 of "Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms", McGinity, Editor, Marcel Decker, Inc., New York, NY (1989)</li><li>8. Nagai et al., "Applications of HPMC and HPMCAS Aqueous Film Coatings of Pharmaceutical Dosage Forms", at pp. 81-152 of "Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms", McGinity, Editor, Marcel Decker, Inc., New York, NY (1989)</li><li>9. Jones, "Production of Enteric Coated Capsules", Manufacturing Chemist &amp; Aerosol News, <u>41</u>:43-57 (1970)</li><li>10. Messora, U.S. Patent No. 3,927,195</li><li>11. Porter, "Coating of Pharmaceutical Dosage Forms", at Chapter 91, pp. 1633-1643, of "Remington's Pharmaceutical Sciences", Gennaro et al., Editors, 17th Ed. (1985)</li><li>12. Windholz et al., The Merck Index, 9th Edition, pp. 741-742, Merck &amp; Company, Rahway, New Jersey (1976)</li><li>13. Foster et al., "Gallium Nitrate: The Second Metal With Clinical Activity", Cancer Treatment Reports, <u>70</u>:1311-1319 (1986)</li><li>14. Hider et al., U.S. Patent No. 4,575,502</li><li>15. Finnegan et al., Inorganic Chemistry, <u>26</u>:2171-2176 (1987)</li><li>16. Farrar et al., Food and Chemical Toxicology, <u>26</u>:523-525 (1988)</li><li>17. Ott, International Journal of Artificial Organs, <u>6</u>:173-175 (1983)</li></ul><!-- EPO <DP n="3"> --></p><heading id="h0004">3. <u>State of the Art</u></heading><p id="p0003" num="0003">Gallium is known to accumulate in certain tumors, inflamed tissue, and bone tissue by mechanisms that are largely unknown. Binding of gallium to transferrins, particularly lactoferrin, is thought to be responsible for some of the transport of gallium in the body, and for the concentration of gallium in certain tumors and inflamed tissues. Radioactive <sup>67</sup>Ga citrate compositions are used in patients to diagnose certain malignancies and infections, including those in bone tissue. Non-radioactive gallium compositions, and compositions containing other Group IIIa elements, have been found effective in treating some tumors in animals and humans. Gallium is thought to be the most effective of these Group IIIa elements<sup>1,3,4</sup>. The art recognizes that gallium is useful for the treatment and prevention of many human and other mammalian diseases, including hypercalcemia, cancer, and certain degenerative or metabolic bone diseases such as osteoporosis and Paget's disease<sup>2-6,13</sup>. Gallium itself appears to be the active agent; the form in which the gallium is administered (e.g. as the nitrate, sulfate, or chloride) does not appear to affect its activity to any significant extent<sup>3,6</sup>.</p><p id="p0004" num="0004">Gallium is particularly useful in the treatment and prevention of hypercalcemia and certain bone diseases. Treatable bone diseases include such widespread conditions as osteoporosis, osteopenia, Paget's disease, malignant bone disease, bone degeneration due to hyperparathyroidism, and other conditions associated with increased bone resorption or turnover in humans or animals<sup>4,6</sup>. In addition to the above, it has been found that gallium increases calcium accretion in bone and decreases bone resorption<sup>5</sup>.<!-- EPO <DP n="4"> --></p><p id="p0005" num="0005">Specifically, Warrell et al.<sup>4,6</sup> and Bockman et al.<sup>5</sup> disclose treatments using gallium salts, preferably gallium nitrate, for regulating the resorption of calcium from bone in certain bane diseases and hypercalcemia, and for increasing the mass and tensile strength of bone. Warrell et al.<sup>4</sup> discloses that such regulation entails the generation of plasma gallium concentrations in the patient of from about 0.9 to 2.0 Âµg/ml whereas Bockman et al.<sup>5</sup> recite the generation of plasma gallium concentrations in the patient of from about 0.1 to 5.0 Âµg/ml.</p><p id="p0006" num="0006">Treatment of cancer with gallium nitrate is disclosed by Foster et al.<sup>13</sup> which teaches the administration (by infusion) of gallium nitrate at 700-750 mg/m<sup>2</sup> by short infusion every 2-3 weeks; 300 mg/m<sup>2</sup>/day by short infusion for three consecutive days, to be repeated every 2 weeks; and 300 mg/m<sup>2</sup>/day by continuous infusion for 7 consecutive days, to be repeated every 3-5 weeks. Specific cancers treated in this reference include, by way of example, refractory lymphomas, small cell lung carcinoma, genitourinary malignancies (renal, bladder, prostate, testicular), and multiple myeloma.</p><p id="p0007" num="0007">On the other hand, Collery<sup>2</sup> discloses the treatment of cancer by the oral administration of a dose of from 200 mg to 1 gram of gallium chloride per day for at least 2 months.</p><p id="p0008" num="0008">However, in spite of its established utility, the use of gallium in the treatment of such diseases is hampered by the fact that ionic gallium lacks high bioavailability when delivered orally. In fact, ionic gallium is a form of gallium which is poorly absorbed by the gastrointestinal tract. In this regard, Warrell et al.<sup>4</sup> disclose that when a composition of gallium nitrate is administered orally to a dog, only 0.5 to 2% of the gallium is absorbed from the gastrointestinal<!-- EPO <DP n="5"> --> tract, into the bloodstream and then excreted into the urine. The percent absorption of other Ga<sup>+3</sup> salts is not likely to be significantly different, as such salts dissociate in aqueous solutions to produce mainly trivalent gallium ions in a similar manner to gallium nitrate.</p><p id="p0009" num="0009">The low bioavailability of orally delivered gallium salts (i.e., ionic gallium) and the need to generate blood plasma gallium concentrations in the patient of from 0.1 to 5 Âµg/ml of plasma gallium concentration (and preferably 0.5 to 2 Âµg/ml) for the treatment of hypercalcemia or excessive bone resorption<sup>5</sup> requires that either impractically large doses of orally delivered gallium be administered to the patient or that the gallium be administered via non-oral means (e.g., intravenous delivery). The oral delivery of such gallium salts is not believed to be practical particularly with widespread, chronic conditions such as osteoporosis and the like.</p><p id="p0010" num="0010">The present invention is directed to the discovery that gallium bioavailability via oral administration is greatly enhanced by using electrostatically neutral gallium chelates of certain 3-hydroxy-4-pyrones. The present invention is directed to the further discoveries that because such neutral gallium chelates decompose in the acidic conditions commonly present in the stomach, pharmaceutical compositions of orally delivered neutral gallium chelates must contain means to inhibit dissociation of the neutral gallium chelates under such acidic conditions.</p><p id="p0011" num="0011">In regard to the above, it is noted that Finnegan et al.<sup>15</sup> disclose the preparation of aluminum and gallium complexes of some 3-hydroxy-4-pyrones, including maltol. This reference recites that the aluminum maltol complex is highly neurotoxic when injected intracranially into rabbits, and suggests<!-- EPO <DP n="6"> --> further neurotoxicity experiments with the aluminum and gallium complexes. This reference further recites nuclear magnetic resonance spectroscopy (NMR) experiments that demonstrated significant differences between the aqueous behavior of the complexes of aluminum and gallium, i.e., experiments to determine the stability of gallium complexes as a function of pH could not be performed, whereas such experiments were readily performed on aluminum complexes.</p><p id="p0012" num="0012">Further regarding the significant differences between aluminum and gallium, aluminum is well known in the art to be a cause of degenerative bone disease<sup>17</sup> as well as being neurotoxic. Contrarily and as previously discussed, gallium is known in the art as effective in the treatment of degenerative bone disease and has shown no reported evidence of neurotoxicity.</p><p id="p0013" num="0013">Farrar et al.<sup>16</sup> disclose the preparation of an aqueous solution containing 10 mM maltol, 1 mM Ga(NO<sub>3</sub>)<sub>3</sub>, and a trace of GaCl<sub>3</sub> labelled with radioactive <sup>67</sup>Ga for administration to rats by oral gavage. However, it is not established in this reference that this solution contains a significant amount of the neutral 3:1 complex. In any event, Farrar et al. completely fail to even consider the possibility that pH might affect the stability of a Ga-maltol complex. This reference also completely fails to realize, suggest, or imply any method to increase gallium absorption in fed animals. Additionally, this reference fails to suggest combining such gallium complexes with means to inhibit dissociation of the complex in a mammalian stomach.</p><p id="p0014" num="0014">Lastly, Hider et al.<sup>14</sup> disclose orally deliverable pharmaceutical compositions containing neutral iron complexes of 3-hydroxy-4-pyrones and means to inhibit dissociation of such complexes under acidic conditions. However, the teachings of this reference are expressly limited to iron and it is art recognized that gallium<!-- EPO <DP n="7"> --> is not equivalent to iron. Further in this regard, iron is a Group VIII metal that is easily oxidized and reduced between its +2 and +3 valences at physiologic conditions, whereas gallium is a Group IIIa semi-metal be that exists only with a +3 valence state at physiologic conditions.</p><heading id="h0005"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0015" num="0015">In view of the above, the present invention is directed to methods for increasing the bioavailability of gallium into the bloodstream as well as to pharmaceutical compositions employed to achieve such methods.</p><p id="p0016" num="0016">Particularly, a primary object of the present invention is to provide the pharmaceutical composition defined in the appended claims.</p><p id="p0017" num="0017">In one of its aspects the present invention is directed to a composition for administering gallium to a mammalian patient (e.g., human patient) which comprises the oral ingestion of a sufficient amount of a pharmaceutical composition comprising<ul id="ul0002" list-style="none" compact="compact"><li>(a) a neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone wherein said 3-hydroxy-4-pyrone has the formula<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="51" he="35" img-content="chem" img-format="tif"/></chemistry> wherein each R is independently selected from the group consisting of hydrogen and alkyl of from 1 to 6 carbon atoms; and</li><li>(b) means to inhibit dissociation of said complex under acidic conditions of the gastro portion of said gastrointestinal tract<br/>so as to provide a blood plasma gallium concentration of from about 0.1 to about 5 Âµg/ml.</li></ul><!-- EPO <DP n="8"> --></p><p id="p0018" num="0018">In another aspect, the present invention is directed to a pharmaceutical composition for increasing calcium accretion in bone or for decreasing calcium resorption in a mammal (e.g., a human) comprising<ul id="ul0003" list-style="none" compact="compact"><li>(a) a neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone wherein said 3-hydroxy-4-pyrone has the formula<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="52" he="34" img-content="chem" img-format="tif"/></chemistry> wherein each R is independently selected from the group consisting of hydrogen, and alkyl of from 1 to 6 carbon atoms; and</li><li>(b) means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the gastrointestinal tract.</li></ul></p><p id="p0019" num="0019">Such a composition can be in a solid dosage form for oral administration.<!-- EPO <DP n="9"> --></p><p id="p0020" num="0020">The compositions of this invention are useful for orally delivering gallium to humans and other mammals for a wide variety of medical and veterinary applications, including, by way of example, the treatment of bone diseases relating to the increased resorption of calcium into the bloodstream.<!-- EPO <DP n="10"> --></p><heading id="h0006"><b>DETAILED DESCRIPTION OF THE INVENTION</b></heading><p id="p0021" num="0021">As noted above, the present invention is directed to methods and compositions for enhancing the bioavailability of gallium from orally delivered pharmaceutical compositions containing gallium. However, prior to discussing this invention in further detail, the following terms will first be defined. Unless defined below, the terms used herein have their normally accepted meanings.</p><heading id="h0007">1. <u>Definitions</u></heading><p id="p0022" num="0022">As used herein, the following terms have the definitions given below:</p><p id="p0023" num="0023">The term "neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone" refers to an electrostatically neutral complex of Ga<sup>+3</sup> and 3 equivalents of the anionic form of 3-hydroxy-4-pyrone which complex is represented by the formula [Ga<sup>+3</sup>(py<sup>-1</sup>)<sub>3</sub>] wherein py<sup>-1</sup> represents the anionic form of 3-hydroxy-4-pyrone which is defined below. Because such complexes do not dissociate to any significant extent in aqueous solutions maintained at a pH of from about 5 to about 9, these complexes remain predominantly electrostatically neutral in such solutions.</p><p id="p0024" num="0024">In this regard, these complexes are deemed "electrostatically neutral" because there are equal numbers of positive and negative charges in the complex.</p><p id="p0025" num="0025">Also, it is apparent that the anionic form of the 3-hydroxy-4-pyrone acts as a chelating agent to the gallium and as such, the complex is sometimes referred to herein as "neutral gallium chelates of 3-hydroxy-4-pyrones". It being understood that this latter term is<!-- EPO <DP n="11"> --> synonymous with the term "neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone".</p><p id="p0026" num="0026">The term "a 3-hydroxy-4-pyrone" refers to a compound of the Formula 1:<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="83" he="33" img-content="chem" img-format="tif"/></chemistry> wherein each R is independently selected from hydrogen atoms and alkyl of from one to six carbon atoms.</p><p id="p0027" num="0027">Specific compounds encompassed by the term "a 3-hydroxy-4-pyrone" are represented by the Formulas 2-5 below:<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="144" he="69" img-content="chem" img-format="tif"/></chemistry> where in each R' is independently alkyl of from 1 to 6 carbon atoms.</p><p id="p0028" num="0028">The unsubstituted form of 3-hydroxy-4-pyrone (Formula 2, also called pyromeconic acid) contains three hydrogen atoms that are bound only to ring carbon atoms.<!-- EPO <DP n="12"> --> The locations of a few possible substitutions are presented in Formulas 3-5, in which R' is an alkyl group (including methyl, ethyl, isopropyl, and n-propyl). The groups are preferably acyclic and are preferably unbranched. Groups containing six or fewer carbon atoms, particularly of one through three carbon atoms, especially methyl or ethyl, are preferred. Single substitution is preferred; a substitution at either the 6-position or especially the 2-position is preferred. Some examples of specific compounds whose gallium complexes may be used in compositions comprised by the invention are: 3-hydroxy-2-methyl-4-pyrone (Formula 3, R' = CH<sub>3</sub> -- sometimes referred to as maltol or larixinic acid) and 3-hydroxy-2-ethyl-4-pyrone (Formula 3, R' = C<sub>2</sub>H<sub>5</sub> -- sometimes referred to as ethyl maltol or ethylpyromeconic acid), both of which are preferred for use in this invention, especially 3-hydroxy-2-methyl-4-pyrone. Other preferred compounds include 3-hydroxy-4-pyrone (Formula 2 -- sometimes referred to as pyromeconic acid); and 3-hydroxy-6-methyl-4-pyrone (Formula 4, R' = CH<sub>3</sub>).</p><p id="p0029" num="0029">The term "an anion of a 3-hydroxy-4-pyrone" refers to a compound defined in Formulas 2-5 above wherein the hydroxyl proton has been removed so as to provide for the anionically charged form of these compounds.</p><p id="p0030" num="0030">The terms "oral administration" and "oral ingestion" refer to all conventional forms for the oral delivery of a pharmaceutical composition to a patient (e.g., human) and that result in the deposition of the pharmaceutical composition into the gastrointestinal tract (including the gastro portion of the gastrointestinal tract, i.e., the stomach) of the patient. Accordingly, oral administration and oral<!-- EPO <DP n="13"> --> ingestion include, by way of example, actual ingestion of a solid or liquid pharmaceutical composition, oral gavage, and the like.</p><p id="p0031" num="0031">The term "inhibit dissociation" means that at least 20%, preferably at least 50% and more preferably at least 80%, of the complex is not dissociated under acidic conditions (e.g., about pH 2-4) for a period of at least 1 hr and preferably at least 3 hours.</p><heading id="h0008">2. <u>Synthesis and Methodology</u></heading><p id="p0032" num="0032">This invention includes methods for the preparation of neutral 3:1 gallium complexes of 3-hydroxy-4-pyrone or 3-hydroxy-4-pyrones of formula 1. Such methods comprise reacting such hydroxypyrones with gallium ions and isolating, at least in part, the resulting complex or complexes.</p><p id="p0033" num="0033">Specifically, the neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone is prepared by the reaction of gallium ions and the 3-hydroxy-4-pyrones in solution. Gallium ions can be derived from a gallium salt, such as a gallium halide, particularly gallium chloride, or a gallium nitrate compound, especially a hydrated gallium nitrate. The gallium nitrate compounds are often preferable as they are easier to work with than gallium halides, which may be highly irritating and may react violently with many solvents, including water. Using the proper safeguards, a variety of gallium salts can be used. The reaction is conveniently effected in a mutual solvent, including but not limited to mixtures containing water, ethanol, methanol, and, chloroform. Pure water may be used in many cases, though the purification of the gallium hydroxypyrone complexes may<!-- EPO <DP n="14"> --> be difficult if it is used. A preferable method, if it is desired to separate at least a major part of reaction by-products such as sodium nitrates, sodium chloride, and sodium carbonates, is to use a mixture containing roughly equal parts of ethanol and chloroform, with a trace of water. The reaction by-products mentioned above have very low solubilities in this mixture and can be removed readily by filtration.</p><p id="p0034" num="0034">To produce the preferred neutral 3:1 hydroxypyrone:gallium complex, the hydroxypyrone and the gallium ions are mixed in 3:1 molar proportions, preferably with a slight excess of hydroxypyrone to insure a great preponderance of the 3:1 complex over the 2:1 and 1:1 complexes. The proportions of the particular complexes formed are dependent upon the pH of the solution. When a gallium salt such as a halide or nitrate is dissolved, the resulting solution will generally have a low pH. To form a preponderance of the preferred neutral 3:1 complex, a pH of from 5 to 9, preferably 7 through 8, is used. If a more acidic solution is used, a preponderance of the less preferred 2:1 and 1:1 complexes may instead be formed, even if a large excess of hydroxypyrone is present. Under highly basic conditions, poorly soluble gallium hydroxides may precipitate. It is preferable to regulate the pH with materials other than hydroxides such as sodium hydroxide, as the use of such hydroxides may cause the precipitation of poorly soluble gallium hydroxides, which are not wanted, and the pH may actually be buffered at a low level by this precipitation. The use of a carbonate, especially sodium carbonate, is preferred to regulate the pH. The use of sodium carbonate in a solvent mixture containing ethanol and chloroform, for example, can result in the precipitation of sodium nitrates that are very slightly soluble in this mixture, and which can be filtered off<!-- EPO <DP n="15"> --> if desired to help purify the solution containing the desired pharmaceutical compositions.</p><p id="p0035" num="0035">The reaction to form the hydroxypyrone-gallium complex in solution is generally complete within about five minutes at about 20Â°C. Gentle stirring or other agitation of the solution promotes a uniform, rapid reaction. Longer reaction times may be used if found necessary. Following the separation, if desired, of reaction by-products such as sodium nitrates, sodium chloride, and sodium carbonates (depending on the solvents and reactants used), the reaction mixture may be evaporated slowly in air or, more rapidly, through the use of a rotary evaporator or by freeze drying, as examples. After drying, the gallium complex or complexes will remain in solid form. Recrystallization can be accomplished, if desired, using a suitable solvent, including but not limited to chloroform, alcohols such as ethanol and methanol, ether, water, acetone, and mixtures containing such solvents. Suitable solvents will depend upon which particular gallium complex(es) and impurities are present, upon the impurities to be separated, and upon the temperature and other physical conditions.</p><p id="p0036" num="0036">It is noted that the mentioned methods are not the only ones that can produce hydroxypyrones and gallium complexes with hydroxypyrones and that various alternative methods may be used as will be apparent to those skilled in the art. Additionally, in preparing the neutral 3:1 complexes of gallium with 3-hydroxy-4-pyrone, a single 3-hydroxy-4-pyrone or a mixture of 3-hydroxy-4-pyrones can be used. However, preferably, only a single 3-hydroxy-4-pyrone is employed.</p><p id="p0037" num="0037">With regard to the preparation of 3-hydroxy-4-pyrones which are used as starting materials in the preparation of the neutral 3:1 complexes of gallium with 3-hydroxy-4-pyrones, certain of these compounds<!-- EPO <DP n="16"> --> occur naturally and may be obtained by extraction from the natural sources. For example, maltol is found in the bark of the young larch tree (<i>Larix decidua</i> Mill.), and in pine needles, chicory, wood tars and oils, and roasted malt<sup>12</sup>. Certain of the 3-hydroxy-4-pyrones are available commercially, including maltol and ethyl maltol. Others can be made from pyromeconic acid as a starting material, which can be derived from the decarboxylation of meconic acid. Methods for preparing such other 3-hydroxy-4-pyrones are well known in the art. Additionally, it is noted that maltol and ethyl maltol are in widespread use as flavoring and fragrance-enhancing agents for foods, and have very low toxicities when taken orally.</p><heading id="h0009">3. <u>Pharmaceutical Compositions</u></heading><p id="p0038" num="0038">The methods of this invention are achieved by using a pharmaceutical composition comprising a neutral 3:1 complex of gallium with 3-hydroxy-4-pyrone and means to inhibit dissociation of said complex under acidic conditions in the gastro (stomach) portion of the gastrointestinal tract.</p><p id="p0039" num="0039">As noted above, this invention is directed in part to the discovery that while the neutral 3:1 complex of gallium with 3-hydroxy-4-pyrones delivers gallium to the bloodstream from the gastrointestinal tract, this complex will dissociate under acidic conditions (generally at a pH of about 4 or less) such as those which can be present in the stomach to the less absorbable 2:1 and 1:1 complexes, together with free hydroxypyrone and ionic gallium. Accordingly, in order to maintain the orally delivered gallium in a form which is highly absorbable in the gastrointestinal tract, the pharmaceutical compositions of this invention are formulated to contain a means to inhibit<!-- EPO <DP n="17"> --> dissociation of this complex when exposed to the acidic conditions of the stomach.</p><p id="p0040" num="0040">Means to inhibit or prevent dissociation of this complex when exposed to the acidic conditions of the stomach include the following preferred methods:<ul id="ul0004" list-style="none" compact="compact"><li>(1) Addition of a sufficient amount of a pharmaceutically compatible buffering agent to the 3:1 complex that would bring the pH of the stomach fluids to a range of from about 5-9 and preferably from about 6-7 so that the stomach fluids would no longer disrupt the 3:1 hydroxypyrone:Ga complex. <br/>Pharmaceutically compatible buffering agents are those which, while acting as a buffering agent, do not significantly alter the ability of the neutral 3:1 gallium complex to deliver gallium to the bloodstream of the patient and are not toxic either alone or in combination with the neutral gallium complex. The particular pharmaceutically compatible buffering agent employed is not critical. Examples of preferred pharmaceutically compatible buffering agents include, by way of example, calcium carbonate (CaCO<sub>3</sub>), sodium bicarbonate (NaHCO<sub>3</sub>) and the like. On the other hand, aluminum hydroxide, Al(OH)<sub>3</sub>, and other aluminum-containing compounds, by way of example, should be avoided. Other pharmaceutically compatible buffering agents are well known in the art and are recited in standard pharmaceutical manufacturing textbooks (e.g., Remington's Pharmaceutical Sciences by Mack Publishing Company).</li><li>(2) Adding to the pharmaceutical composition containing the 3:1 complex an excess of free hydroxypyrone (or a salt thereof containing a physiologically acceptable cation), particularly the one used to make the 3:1 complex. Such a mixture, when dissolved in the stomach, has the effect of shifting<!-- EPO <DP n="18"> --> the equilibrium among the 1:1, 2:1, and 3:1 complexes towards a preponderance of the 3:1 complex. In this embodiment, the weight of the free hydroxypyrone incorporated into the formulation is preferably 0.1 to 100 times the weight of the 3:1 complex employed in the formulation, and more preferably 0.1 to 10 times. This method, by itself, is not highly preferred but may be used in conjunction with other methods to inhibit dissociation.</li><li>(3) Formulating the pharmaceutical composition that contains the 3:1 complex in delayed release form, so that a preponderance of the complex is not released until the intestinal tract is reached. An example of such a composition is to formulate the 3:1 complex with certain gels, preferably hydrogels such as a polymerized polyethylene glycol hydrogel, that adsorb the 3:1 complex and then release it after ingestion only very slowly while in the stomach. The preparation of such delayed release formulations, particularly those using hydrogels, is well known in the art.</li><li>(4) Most preferably, formulating or packaging the 3:1 complex in such a way that the release of the 3:1 complex is prevented or inhibited until the basic, or less acidic, conditions of the intestinal tract are reached. Specific preferred methods include:<ul id="ul0005" list-style="none" compact="compact"><li>(a) Encapsulating the 3:1 complex in a material that is resistant to dissolution until the intestinal tract is reached, most preferably using a tablet or capsule that is enteric coated, or granules that are enteric coated, to inhibit or prevent release of the 3:1 complex until a pH greater than about 5 or 6 is reached. Enteric coating of tablets, capsules, and granules is well known in the art.</li><li>(b) Microencapsulating the 3:1 complex within liposomes, preferably made from phospholipids, that do not dissociate under the acidic conditions of the<!-- EPO <DP n="19"> --> stomach, but that will release the 3:1 complex in the higher pH conditions of the intestinal tract. Such liposomes are also well known in the art.</li></ul></li></ul></p><p id="p0041" num="0041">The most preferred method, enteric coating tablets, granules or especially capsules, is well known in the art. Such methods are described, for example, by Porter<sup>7</sup>, by Nagai et al.<sup>8</sup>, by Jones<sup>9</sup>, by Messora<sup>10</sup>, and by Porter<sup>11</sup>. Preferred materials for the enteric coating include, by way of example, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, poly(vinyl acetate phthalate), hydroxypropyl methylcellulose acetate succinates, poly(meth)acrylates, and, preferably, cellulose acetate phthalate/diethylphthalate. When capsules are coated, a plasticizer should be used (such as hydroxypropyl methylcellulose acetate succinates/triethyl citrate or especially cellulose acetate phthalate/diethylphthalate) to minimize brittleness in the coating and to inhibit cracking of the coating. Tablets and granules can also be used.</p><p id="p0042" num="0042">In addition to the above, two or more means to inhibit dissociation of these complexes can be employed in combination so as to enhance the level of inhibition, i.e., a pharmaceutically compatible buffer can be employed in combination with an excess of free 3-hydroxy-4-pyrone.</p><p id="p0043" num="0043">When used for oral administration, which is preferred, the gallium complex may be formulated in a variety of ways. It will preferably be in solid form, and may optionally and conveniently be used in compositions containing a pharmaceutically inert carrier including conventional solid carriers such as lactose, starch, or dextrin, which are conveniently presented in tablet or capsule form. Materials and methods to enhance gallium absorption, including those<!-- EPO <DP n="20"> --> mentioned in the preceding paragraph, may be incorporated; the use of enteric coated tablets or capsules, as previously discussed, is preferred. In this regard, the complex itself, with or without additional hydroxypyrone, buffers, or other active ingredients, may also be used without the addition of inert pharmaceutical carriers, particularly for use in capsule form. In this embodiment, the capsule serves as the means to inhibit dissociation of the complex.</p><p id="p0044" num="0044">Compositions including a liquid pharmaceutically inert carrier (e.g., water) may also be considered for oral administration that comprise an appropriate means for inhibiting dissociation of the 3:1 complex in the acidic conditions of the stomach, preferably through the use of a pharmaceutically compatible buffer, preferably CaCO<sub>3</sub> or NaHCO<sub>3</sub>. The use of such buffers is well known in the art.</p><p id="p0045" num="0045">Doses are selected to provide pharmaceutically active plasma gallium concentrations for the treatment of excessive resorption of calcium from bone (e.g., arising from hypercalcemia, osteoporosis, osteopenia, Paget's disease or cancer), which are established to be about 0.1-5.0 Âµg/ml, preferably about 0.9-2.0 Âµg/ml<sup>4,5</sup>. To obtain such physiologically active gallium levels in the patient, compositions for oral administration provide about 0.1-200 mg/m<sup>2</sup>/day gallium (delivered as a 3:1 complex with hydroxypyrone in the composition) and preferably about 1-30 mg/m<sup>2</sup>/day.</p><p id="p0046" num="0046">For the 3:1 complexes containing maltol or ethyl maltol, this corresponds to a daily dose, preferably given in unit dose form, of about 0.9-1800 mg of the complex for a 50 kg individual, preferably about 9-360 mg. The compositions, when formulated according to the preferred methods described above, may be effectively administered at any time, though preferably two or more hours after meals.<!-- EPO <DP n="21"> --></p><p id="p0047" num="0047">The pharmaceutical compositions described herein generally comprise from about 1 to about 99 weight percent of a neutral 3:1 complex of gallium with 3-hydroxy-4-pyrone. Preferably, when an inert pharmaceutical carrier is employed in the compositions of this invention, the compositions contain from about 1 to about 99 weight percent of the pharmaceutically inert carrier. The compositions also contain a sufficient amount of a means to inhibit dissociation of the complex under the acidic conditions of the stomach. Preferably, when such means include a buffer or an excess of hydroxypyrones, the composition comprising such means is incorporated into the pharmaceutical composition at no more than about 98 weight percent of the composition.</p><p id="p0048" num="0048">Formulations may also be considered for other modes of administration, for example per rectum, transdermally, and by intravenous, subcutaneous, and intramuscular injection. These formulations may contain a liquid carrier that may be oily, aqueous, emulsified, or contain certain solvents suitable to the mode of administration. Compositions may be formulated in unit dose form, which is preferred, or in multiple or sub-unit doses.</p><p id="p0049" num="0049">Formulations may also be produced that contain active ingredients other than the gallium complexes. These may include other agents to regulate calcium resorption from bone, for example, but other active agents may also be incorporated.</p><p id="p0050" num="0050">When treating cancer, established doses for gallium nitrate delivery are from 300 mg/m<sup>2</sup>/day to 700 mg/m<sup>2</sup>/day<sup>13</sup> which can be extrapolated for the administration of a 3:1 neutral complex of 3-hydroxy-4-pyrone and gallium.<!-- EPO <DP n="22"> --></p><heading id="h0010">4. <u>Utility</u></heading><p id="p0051" num="0051">As noted previously, the art recognizes that gallium is useful in treating conditions such as hypercalcemia, cancer [e.g., refractory lymphomas, small cell lung carcinoma, genitourinary malignancies (renal, bladder, prostate, testicular), multiple mysloma, and the like] and degenerative bone diseases. For example, the art recognizes that blood plasma levels of from about 0.1 to about 5 Âµg/ml are effective in treating hypercalcemia; for treating other degenerative bone diseases; and for increasing the mass and tensile strength of bone<sup>5</sup>.</p><p id="p0052" num="0052">The compositions and methods of this invention are useful in providing enhanced bioavailability of gallium to the patient's bloodstream as compared to the bioavailability of gallium achieved with gallium salt compositions heretofore employed. Accordingly, on equal weight of gallium basis, pharmaceutical compositions containing a complex of this invention together with means to prevent dissociation of the complex in the patient's stomach deliver significantly greater quantities of gallium to the bloodstream of a patient as compared to the amount of gallium delivered to the bloodstream by pharmaceutical compositions containing prior art gallium salts. Such enhanced delivery of gallium by pharmaceutical compositions containing neutral 3:1 gallium complexes permit the use of less gallium per unit dose as compared to pharmaceutical compositions containing gallium salts while still providing efficacious blood plasma gallium concentrations. The use of less gallium while still achieving the requisite blood plasma gallium concentrations by the compositions of this invention provides a practical method for the oral delivery of gallium. Additionally, because the amount of gallium<!-- EPO <DP n="23"> --> ingested is reduced, side effects from gallium ingestion are expected to be reduced.</p><p id="p0053" num="0053">Notwithstanding the fact that gallium is administered as a neutral complex, the present invention is also based on the discovery that gallium is nevertheless transported <u>in</u> <u>vivo</u> into the bloodstream of the patient.</p><p id="p0054" num="0054">The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention.</p><p id="p0055" num="0055">In these examples, the following abbreviations have the following meanings:<dl id="dl0001" compact="compact"><dt>Ã…</dt><dd>= Ã…ngstrom</dd><dt>C</dt><dd>= Centigrade</dd><dt>kg</dt><dd>= kilogram</dd><dt>M</dt><dd>= Molar</dd><dt>mg</dt><dd>= milligram</dd><dt>ml</dt><dd>= milliliter</dd><dt>mm</dt><dd>= millimeter</dd><dt>N</dt><dd>= Normal</dd><dt>nm</dt><dd>= nanometers</dd></dl></p><p id="p0056" num="0056">Also, in X-ray fluorescence and diffraction data given in Example 1, the numbers in parentheses after the value reported represent the estimated standard deviation in the last digit.</p><heading id="h0011"><b>EXAMPLES</b></heading><heading id="h0012">Example 1 -- <u>Preparation of gallium ethyl maltol</u></heading><p id="p0057" num="0057">A 1.5M solution of ethyl maltol in chloroform is mixed with an equal volume of a 0.5M solution of gallium nitrate nonohydrate in ethanol to provide a 3:1 molar ratio of ethyl maltol to gallium ions in the<!-- EPO <DP n="24"> --> mixture. The mixture is stirred for 7 minutes at 22Â°C. Solid anhydrous sodium carbonate is then added in a 10 molar excess, and stirring continues for an additional ten minutes. When the sodium carbonate is added, a trace of water may sometimes need to be added to facilitate the reaction, which is evidenced by some effervescence. The mixture is then filtered and the filtrate evaporated to give the solid 3:1 complex of ethyl maltol and gallium.</p><p id="p0058" num="0058">The complex as so produced contains 14.3(1) weight percent gallium by x-ray fluorescence analysis, as predicted for Ga(C<sub>7</sub>H<sub>6</sub>O<sub>3</sub>)<sub>3</sub>. The material forms white to pale beige monoclinic crystals with unit cell parameters of about <i>a</i> = 7.899(1)Ã…, <i>b</i> = 8.765(1)Ã…, <i>c</i> = 31.626(2)Ã…, beta = 103.253(7) degrees, <i>V</i> = 2131 Ã…<sup>3</sup>, based on powder x-ray diffraction analysis. The solubility of this compound is measured as about 5 millimolar in distilled deionized water at 23Â°C. Crystallization from other solvents or under other conditions may produce other crystal structures. Under some conditions, water may also be incorporated into the structure.</p><heading id="h0013">Example 2 -- <u>Bioavailability study in rabbits</u></heading><p id="p0059" num="0059">A test of the oral bioavailability of the 3:1 ethyl maltol:gallium complex in rabbits was conducted. In this test, the complex was given to rabbits and compared to a solution of gallium nitrate. Six female New Zealand white rabbits weighing between 2.68 and 2.91 kg were used, and were not fed for 18 hours before starting the experiment. A suspension of the 3:1 gallium ethyl maltol complex in double distilled water was prepared with a concentration of 10 mg elemental gallium per 4 ml of suspension. A solution of gallium nitrate nonohydrate dissolved in double distilled water<!-- EPO <DP n="25"> --> was also prepared, which had a concentration of 10 mg elemental gallium per 4 ml of solution. A small amount of solid sodium carbonate was added to the latter solution to bring the pH up to about 6. Each of the two solutions was given to three rabbits by oral gavage (through a tube inserted through the mouth to the stomach) in the amount of 4 ml per kg of body weight. The stomach tubes were flushed by three ml of water following administration of the solutions.</p><p id="p0060" num="0060">Six ml of blood was taken from each rabbit at 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours following administration of the solutions, and the serum separated and frozen. Control samples of blood were taken 24 hours earlier. The frozen serum samples were then sent to an independent testing laboratory for determination of the gallium contents by graphite furnace atomic absorption analysis. The testing laboratory received numbered serum samples, and never had any knowledge of the experimental conditions used to produce the samples. The results of the analyses are indicated in Table 1. Due to uncertainties in the analytical procedures for gallium in serum, the relative proportions of gallium in the serum samples are considered more significant than the actual reported concentrations.</p><p id="p0061" num="0061">It is seen from Table 1 that the gallium ethyl maltol suspension was absorbed in significantly higher amounts than the gallium nitrate suspension of equal volume and gallium concentration. It is important to note that no attempt was made to counteract the adverse effects of the 3:1 gallium ethyl maltol complex being exposed to the acidic conditions of the stomach. This study should therefore be considered to give a minimal value for the oral bioavailability of the gallium ethyl maltol complex compared to gallium nitrate.<!-- EPO <DP n="26"> --> <tables id="tabl0001" num="0001"><table frame="all"><title>Table 1</title><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" align="center">Mean gallium content of rabbit serum (ng/ml).</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" rowsep="0"/><entry namest="col2" nameend="col3" align="center">Rabbits treated with</entry></row><row rowsep="1"><entry namest="col1" nameend="col1"/><entry namest="col2" nameend="col2" align="center">Composition A (3 animals)</entry><entry namest="col3" nameend="col3" align="center">Composition B (3 animals)</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">pro-treatment</entry><entry namest="col2" nameend="col2" align="right">0</entry><entry namest="col3" nameend="col3" align="right">0</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">1 hour</entry><entry namest="col2" nameend="col2" align="right">90</entry><entry namest="col3" nameend="col3" align="right">51</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">2 hours</entry><entry namest="col2" nameend="col2" align="right">274</entry><entry namest="col3" nameend="col3" align="right">99</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">4 hours</entry><entry namest="col2" nameend="col2" align="right">260</entry><entry namest="col3" nameend="col3" align="right">118</entry></row><row><entry namest="col1" nameend="col1" align="char" char=".">8 hours</entry><entry namest="col2" nameend="col2" align="right">212</entry><entry namest="col3" nameend="col3" align="right">103</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="char" char=".">24 hours</entry><entry namest="col2" nameend="col2" align="right">84</entry><entry namest="col3" nameend="col3" align="right">64</entry></row><row rowsep="1"><entry namest="col1" nameend="col3" align="justify">Composition A = Gallium ethyl maltol suspension<br/>Composition B = Gallium nitrate solution</entry></row></tbody></tgroup></table></tables></p><heading id="h0014">Example 3 -- <u>Preparation of gallium maltol</u></heading><p id="p0062" num="0062">Maltol is dissolved in chloroform to form a 0.75M solution, and gallium nitrate nonohydrate is dissolved in ethanol to form a 0.5M solution. To 20 ml of the 0.75M maltol solution in chloroform is slowly added, with continuous stirring, 10ml of the 0.5M gallium nitrate nonohydrate solution in ethanol. The resulting solution is stirred for 5 minutes at 23Â°C. About 5.5 grams of powdered anhydrous sodium carbonate are added, and stirring continues for an additional 12 minutes. The mixture is filtered to remove all solids, and the filtrate is evaporated in a rotary evaporator. The remaining crystalline solid is the 3:1 maltol:gallium composition. This composition is analyzed using powder x-ray diffraction and found to consist of orthorhombic crystals with unit cell dimensions of about <i>a</i> = 18.52(1)Ã…, <i>b</i> = 16.94(1)Ã…, <i>c</i> = 12.02(1)Ã…. The solubility of this composition is measured as about 24 millimolar in distilled deionized water at 23Â°C.<!-- EPO <DP n="27"> --></p><p id="p0063" num="0063">The stability of the neutral 3:1 maltol:gallium complex was studied in aqueous solutions at various pH values. The complex was studied at two concentrations in double distilled deionized water: 2.5 X 10<sup>-6</sup> M and 1.0 X 10<sup>-2</sup> M. The pH was adjusted by adding either 1N HCl or 1N Na<sub>2</sub>CO<sub>3</sub>. The stability of the complex was determined using ultraviolet spectroscopy over the region 200-450 nm at 25Â°C. Several absorption peaks are observed in this range, including those at about 212-217 nm, 248 nm, 273 nm, 318 nm, and 385 nm. An isobesic point occurs over much of the pH range at about 290 nm. In the very dilute solutions (2.5 X 10<sup>-6</sup> M), the neutral 3:1 complex appears to be stable from about pH 4.5 to 9.5. For the less dilute solutions (1.0 X 10<sup>-2</sup> M), the determination was more difficult due to the very high absorbance. The stability region appears very similar to that of the highly dilute solution, possibly slightly wider.</p><heading id="h0015">Example 4 -- <u>Preparation of enteric coated capsule formulation</u></heading><p id="p0064" num="0064">The 3:1 maltol:gallium composition is prepared as described in Example 3. Into a standard size 3 hard gelatin capsule (about 15.5 mm long and 5.8 mm diameter) is added 40 mg of the 3:1 maltol:gallium composition, 10 mg of maltol, and about 190 mg of starch. The capsule is closed and is then coated with a layer of cellulose acetate phthalate/diethyl phthalate using a pilot-scale procedure described by Jones<sup>9</sup>. Acetone is used as a solvent, and a coating thickness of about 35 micrometers is obtained. Such a capsule inhibits the release of its contents (the 3:1 maltol:gallium composition) in the acidic conditions of the stomach, but releases its contents in the small intestine, where the pH is greater than about 5.5.<!-- EPO <DP n="28"> --></p><p id="p0065" num="0065">Other materials well known in the art can be used to enteric coat the capsule by merely substituting for the cellulose acetate phthalate/diethyl phthalate employed in Example 4 above. Such other materials include, by way of example, cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, poly (vinyl acetate phthalate), hydroxypropyl methylcellulose acetate succinates, poly(meth)acrylates, and the like.</p><heading id="h0016">Example 5 -- <u>Preparation of Capsules Containing a Pharmaceutically Acceptable Buffer</u></heading><p id="p0066" num="0066">The purpose of this example is to demonstrate the preparation of an orally deliverable pharmaceutical composition containing a neutral complex of gallium and a 3-hydroxy-4-pyrone wherein the means to inhibit dissociation of the complex in the acidic conditions of the stomach is the use of a pharmaceutically acceptable buffer. Specifically, 40 mg of the 3:1 maltol:gallium composition, from about 50 to about 1000 mg (preferably 500 mg) of calcium carbonate, and the balance starch, are added to a standard gelatin capsule. The capsule is then closed to provide a composition of this invention. Such a capsule will inhibit the dissociation of the 3:1 maltol:gallium composition in the acidic conditions of the stomach by raising the pH of the fluid in the stomach.</p><p id="p0067" num="0067">In view of the above, other neutral complexes of gallium and 3-hydroxy-4-pyrones could be prepared in the methods described above by merely substituting such other 3-hydroxy-4-pyrones for maltol and for ethyl maltol described in the above examples. Similarly, other means to prevent dissociation of the neutral complex could be employed by merely substituting such other means for the means exemplified above.<!-- EPO <DP n="29"> --></p><p id="p0068" num="0068">Specifically, from about 50 to about 1000 mg of other pharmaceutically acceptable buffers can be employed in place of calcium carbonate in the capsules of Example 5. Such other pharmaceutically acceptable buffers include, by way of example, sodium bicarbonate, sodium carbonate and the like.</p>
EP	0612246	B1	2000-08-30	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A pharmaceutical composition in a solid dosage form for oral administration for use in treating excessive resorption of calcium from bone which composition comprises gallium complexes of a 3-hydroxy-4-pyrone wherein said 3-hydroxy-4-pyrone has the formula (1):<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="41" he="37" img-content="chem" img-format="tif"/></chemistry> wherein each R is independently selected from the group consisting of hydrogen, and alkyl of from 1 to 6 carbon atoms, in said gallium complexes the neutral 3:1 formula 1-gallium complex has preponderance.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The pharmaceutical composition according to Claim 1, further including a means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the gastrointestinal tract.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The pharmaceutical composition according to either of Claims 1 or 2 wherein the amount of complex in the composition is such that following oral administration of the composition to an individual, a blood plasma gallium concentration of about 0.1 to about 5Âµg/l is provided.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The pharmaceutical composition according to any one of Claims 1 to 3 wherein said excessive resorption of calcium from bone arises from hypercalcemia, osteoporosis, osteopenia, Paget's disease or cancer.<!-- EPO <DP n="31"> --></claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The pharmaceutical composition according to any one of Claims 1 to 4 which further comprises a pharmaceutically inert carrier.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The pharmaceutical composition according to any one of Claims 1 to 3 wherein said alkyl group is an acyclic group of from 1 to 3 carbon atoms.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The pharmaceutical composition according to Claim 6 wherein said acyclic alkyl group is either methyl or ethyl.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The pharmaceutical composition according to claim 6 wherein said 3-hydroxy-4-pyrone has a single alkyl substituent at either the 2- or 6-position.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The pharmaceutical composition according to any one of Claims 1 to 3 wherein the said 3-hydroxy-4-pyrone is selected from the group consisting of 3-hydroxy-4-pyrone, 3 -hydroxy-2-methyl-4-pyrone, 3-hydroxy-2-ethyl-4-pyrone, and 3-hydroxy-6-methyl-4-pyrone.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The pharmaceutical composition according to Claim 9 wherein said 3-hydroxy-4-pyrone is selected from the group consisting of 3-hydroxy-2-methyl-4-pyrone and 3-hydroxy-2-ethyl-4-pyrone.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The pharmaceutical composition according to Claim 10 wherein said 3-hydroxy-4-pyrone is 3-hydroxy-2-methyl-4-pyrone.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The pharmaceutical composition according to Claim 10 wherein said 3-hydroxy-4-pyrone is 3-hydroxy-2-ethyl-4-pyrone.<!-- EPO <DP n="32"> --></claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>The pharmaceutical composition according to Claim 2 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract are selected from the group consisting of (a) formulating said pharmaceutical composition in delayed release form; (b) adding a buffering agent to said pharmaceutical composition; (c) formulating said pharmaceutical composition in a form biased towards release in basic rather than acidic conditions; (d) encapsulating said complex in material that is resistant to dissolution until the small intestine is reached; and (e) further incorporating into said pharmaceutical composition the same hydroxypyrone as employed in said complex, or a salt thereof containing a physiologically acceptable cation, in uncomplexed form.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The pharmaceutical composition according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises formulating said pharmaceutical composition in delayed release form.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>The pharmaceutical composition according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises adding a buffering agent to said pharmaceutical composition.<!-- EPO <DP n="33"> --></claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>The pharmaceutical composition according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises formulating said pharmaceutical composition in a form biased towards release in basic rather than in acidic conditions.</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>The pharmaceutical composition according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises encapsulating said complex in material that is resistant to dissolution until the small intestine is reached.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>The pharmaceutical composition according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises further incorporating into said pharmaceutical composition the same hydroxypyrone as employed in said complex, or a salt thereof containing a physiologically acceptable cation, in uncomplexed form.<!-- EPO <DP n="34"> --></claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>A pharmaceutical composition for increasing calcium accretion in bone or for decreasing calcium resorption in a mammal, comprising<claim-text>(a) a neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone wherein said 3-hydroxy-4-pyrone has the formula<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="49" he="31" img-content="chem" img-format="tif"/></chemistry> wherein each R is independently selected from the group consisting of hydrogen, and alkyl of from 1 to 6 carbon atoms; and</claim-text><claim-text>(b) means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the gastrointestinal tract.</claim-text></claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>A pharmaceutical composition according to Claim 19 which is in a solid dosage form suitable for oral administration.</claim-text></claim>
EP	0612246	B1	2000-08-30	en	CLAIM	2	<claim id="c-en-02-0001" num="0001"><claim-text>Process for preparing a pharmaceutical composition in a solid dosage form for oral administration which comprises mixing or encapsulating gallium complexes of a 3-hydroxy-4-pyrone wherein said 3-hydroxy-4-pyrone has the formula:<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="41" he="37" img-content="chem" img-format="tif"/></chemistry> wherein each R is independently selected from the group consisting of hydrogen, and alkyl of from 1 to 6 carbon atoms, in said gallium complexes the neutral 3:1 formula 1-gallium complex having preponderance, with or in a pharmaceutically acceptable carrier.</claim-text></claim><claim id="c-en-02-0002" num="0002"><claim-text>The process according to Claim 1, including a means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the gastrointestinal tract.</claim-text></claim><claim id="c-en-02-0003" num="0003"><claim-text>The process according to either of Claims 1 or 2 wherein the amount of complex in the composition is such that following oral administration of the composition to an individual, a blood plasma gallium concentration of about 0.1 to about 5Âµg/l is provided.</claim-text></claim><claim id="c-en-02-0004" num="0004"><claim-text>The process according to any one of Claims 1 to 3 wherein said pharmaceutical composition is for use in treating excessive resorption of calcium from bone.<!-- EPO <DP n="36"> --></claim-text></claim><claim id="c-en-02-0005" num="0005"><claim-text>The process according to Claim 4 wherein said excessive resorption of calcium from bone arises from hypercalcemia, osteoporosis, osteopenia, Paget's disease or cancer.</claim-text></claim><claim id="c-en-02-0006" num="0006"><claim-text>The process according to any one of Claims 1 to 5 wherein said alkyl group is an acyclic group of from 1 to 3 carbon atoms.</claim-text></claim><claim id="c-en-02-0007" num="0007"><claim-text>The process according to Claim 6 wherein said acyclic alkyl group is either methyl or ethyl.</claim-text></claim><claim id="c-en-02-0008" num="0008"><claim-text>The process according to Claim 6 wherein said 3-hydroxy-4-pyrone has a single alkyl substituent at either the 2- or 6-position.</claim-text></claim><claim id="c-en-02-0009" num="0009"><claim-text>The process according to any one of Claims 1 to 3 wherein said 3-hydroxy-4-pyrone is selected from the group consisting of 3-hydroxy-4-pyrone, 3-hydroxy-2-methyl-4-pyrone, 3-hydroxy-2-ethyl-4-pyrone, and 3-hydroxy-6-methyl-4-pyrone.</claim-text></claim><claim id="c-en-02-0010" num="0010"><claim-text>The process according to Claim 9 wherein said 3-hydroxy-4-pyrone is selected from the group consisting of 3-hydroxy-2-methyl-4-pyrone, and 3-hydroxy-2-ethyl-4-pyrone.</claim-text></claim><claim id="c-en-02-0011" num="0011"><claim-text>The process according to Claim 9 wherein said 3-hydroxy-4-pyrone is 3-hydroxy-2-methyl-4-pyrone.</claim-text></claim><claim id="c-en-02-0012" num="0012"><claim-text>The process according to Claim 9 wherein said 3-hydroxy-4-pyrone is 3-hydroxy-2-ethy-4-pyrone</claim-text></claim><claim id="c-en-02-0013" num="0013"><claim-text>The process according to Claim 2 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's<!-- EPO <DP n="37"> --> gastrointestinal tract are selected from the group consisting of (a) formulating said pharmaceutical composition in delayed release form; (b) adding a buffering agent to said pharmaceutical composition; (c) formulating said pharmaceutical composition in a form biased towards release in basic rather than acidic conditions; (d) encapsulating said complex in material that is resistant to dissolution until the small intestine is reached; and (e) further incorporating into said pharmaceutical composition the same hydroxypyrone as employed in said complex, or a salt thereof containing a physiologically acceptable cation, in uncomplexed form.</claim-text></claim><claim id="c-en-02-0014" num="0014"><claim-text>The process according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises formulating said pharmaceutical composition in delayed release form.</claim-text></claim><claim id="c-en-02-0015" num="0015"><claim-text>The process according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises adding a buffering agent to said pharmaceutical composition.</claim-text></claim><claim id="c-en-02-0016" num="0016"><claim-text>The process according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises formulating said pharmaceutical composition in a form biased towards release in basic rather than in acidic conditions.</claim-text></claim><claim id="c-en-02-0017" num="0017"><claim-text>The process according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's<!-- EPO <DP n="38"> --> gastrointestinal tract comprises encapsulating said complex in material that is resistant to dissolution until the small intestine is reached.</claim-text></claim><claim id="c-en-02-0018" num="0018"><claim-text>The process according to Claim 13 wherein said means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the patient's gastrointestinal tract comprises further incorporating into said pharmaceutical composition the same hydroxypyrone as employed in said complex, or a salt thereof containing a physiologically acceptable cation, in uncomplexed form.</claim-text></claim><claim id="c-en-02-0019" num="0019"><claim-text>A process for preparing a pharmaceutical composition for increasing calcium accretion in bone or for decreasing calcium resorption in a mammal, comprising formulating:<claim-text>(a) a neutral 3:1 gallium complex of a 3-hydroxy-4-pyrone wherein said 3-hydroxy-4-pyrone has the formula:<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="40" he="31" img-content="chem" img-format="tif"/></chemistry> wherein each R is independently selected from the group consisting of hydrogen, and alkyl of from 1 to 6 carbon atoms; with</claim-text><claim-text>(b) means to inhibit dissociation of said complex under acidic conditions of the gastro portion of the gastrointestinal tract.</claim-text></claim-text></claim><claim id="c-en-02-0020" num="0020"><claim-text>A process according to Claim 19 wherein the pharmaceutical composition is in a solid dosage form suitable for oral administration.</claim-text></claim>
EP	0612246	B1	2000-08-30	de	CLAIM	3	<claim id="c-de-01-0001" num="0001"><claim-text>Pharmazeutische Zusammensetzung in einer festen Dosierungsform fÃ¼r die orale Verabreichung fÃ¼r die Verwendung zur Behandlung einer Ã¼bermÃ¤ÃŸigen Resorption von Calcium aus Knochen, wobei die Zusammensetzung umfaÃŸt Gallium-Komplexe eines 3-Hydroxy-4-pyrons, worin das genannte 3-Hydroxy-4-pyron die Formel (1) hat:<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="39" he="37" img-content="chem" img-format="tif"/></chemistry> worin die Reste R jeweils unabhÃ¤ngig voneinander ausgewÃ¤hlt werden aus der Gruppe, die besteht aus Wasserstoff und Alkyl mit 1 bis 6 Kohlenstoffatomen, wobei in den genannten Gallium-Komplexen der neutrale 3:1-Formel(1)-Gallium-Komplex Ã¼berwiegt.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 1, die auÃŸerdem ein Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts enthÃ¤lt.<!-- EPO <DP n="40"> --></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 1 oder 2, worin die Menge des Komplexes in der Zusammensetzung so groÃŸ ist, daÃŸ nach der oralen Verabreichung der Zusammensetzung an ein Individuum eine Blutplasma-Galliumkonzentration von etwa 0,1 bis etwa 5 Âµg/l erzielt wird.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Pharmazeutische Zusammensetzung nach einem der AnsprÃ¼che 1 bis 3, worin die genannte Ã¼bermÃ¤ÃŸige Resorption von Calcium aus Knochen eine Folge von HypercalcÃ¤mie, Osteoporose, Osteopenie, Paget-Syndrom oder Krebs ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Pharmazeutische Zusammensetzung nach einem der AnsprÃ¼che 1 bis 4, die auÃŸerdem einen pharmazeutisch inerten TrÃ¤ger umfaÃŸt.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Pharmazeutische Zusammensetzung nach einem der AnsprÃ¼che 1 bis 3, worin die genannte Alkylgruppe eine acyclische Gruppe mit 1 bis 3 Kohlenstoffatomen ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 6, worin die genannte acyclische Alkylgruppe Methyl oder Ethyl ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 6, worin das genannte 3-Hydroxy-4-pyron einen einzelnen Alkyl-Substituenten in der 2- oder 6-Position aufweist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Pharmazeutische Zusammensetzung nach einem der AnsprÃ¼che 1 bis 3, worin das genannte 3-Hydroxy-4-pyron ausgewÃ¤hlt wird aus der Gruppe, die besteht aus 3-Hydroxy-4-pyron, 3-Hydroxy-2-methyl-4-pyron, 3-Hydroxy-2-ethyl-4-pyron und 3-Hydroxy-6-methyl-4-pyron.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 9, worin das genannte 3-Hydroxy-4-pyron ausgewÃ¤hlt wird aus der Gruppe, die besteht aus 3-Hydroxy-2-methyl-4-pyron und 3-Hydroxy-2-ethyl-4-pyron.<!-- EPO <DP n="41"> --></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 10, worin das genannte 3-Hydroxy-4-pyron das 3-Hydroxy-2-methyl-4-pyron ist.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 10, worin das genannte 3-Hydroxy-4-pyron das 3-Hydroxy-2-ethyl-4-pyron ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 2, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten ausgewÃ¤hlt wird aus der Gruppe, die besteht aus (a) der Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form mit verzÃ¶gerter Freisetzung; (b) der Zugabe eines Puffermittels zu der genannten pharmazeutischen Zusammensetzung; (c) der Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form die eher unter basischen Bedingungen als unter sauren Bedingungen freigesetzt wird; (d) der Einkapselung des genannten Komplexes in einem Material, das gegen AuflÃ¶sung bestÃ¤ndig ist, bis der DÃ¼nndarm erreicht ist; und (e) der weiteren Einarbeitung des gleichen Hydroxypyrons wie es in dem genannten Komplex verwendet worden ist, oder eines Salzes davon, das ein physiologisch akzeptables Kation enthÃ¤lt, in nicht komplex gebundener Form in die genannte pharmazeutische Zusammensetzung.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form mit verzÃ¶gerter Freisetzung umfaÃŸt.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten<!-- EPO <DP n="42"> --> die Zugabe eines Puffermittels zu der genannten pharmazeutischen Zusammensetzung umfaÃŸt.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form, die eher eine Freisetzung unter basischen als unter sauren Bedingungen ergibt, umfaÃŸt.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 13, worin das genannte Mitte! zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die Einkapselung des genannten Komplexes in einem Material umfaÃŸt, das gegen AuflÃ¶sung bestÃ¤ndig ist, bis der DÃ¼nndarm erreicht ist.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die weitere Einarbeitung des gleichen Hydroxypyrons, wie es in dem genannten Komplex verwendet worden ist, oder eines Salzes davon, das ein physiologisch akzeptables Kation enthÃ¤lt, in nicht komplex gebundener Form in die genannte pharmazeutische Zusammensetzung umfaÃŸt.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>Pharmazeutische Zusammensetzung zur ErhÃ¶hung der Calciumakkretion in den Knochen oder zur Verringerung der Calciumresorption bei einem SÃ¤ugetier, die umfaÃŸt<claim-text>(a) einen neutralen 3:1 Gallium-Komplex eines 3-Hydroxy-4-pyrons, worin das genannte 3-Hydroxy-4-pyron die Formel hat<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="51" he="35" img-content="chem" img-format="tif"/></chemistry><!-- EPO <DP n="43"> --> worin die Reste R jeweils unabhÃ¤ngig voneinander ausgewÃ¤hlt werden aus der Gruppe, die besteht aus Wasserstoff und Alkyl mit 1 bis 6 Kohlenstoffatomen, und</claim-text><claim-text>(b) ein Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts der Magendarmtrakts.</claim-text></claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>Pharmazeutische Zusammensetzung nach Anspruch 19, die in einer festen Dosierungsform vorliegt, die fÃ¼r die orale Verabreichung geeignet ist.</claim-text></claim>
EP	0612246	B1	2000-08-30	de	CLAIM	4	<claim id="c-de-02-0001" num="0001"><claim-text>Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung in einer festen Dosierungsform fÃ¼r die orale Verabreichung, das umfaÃŸt das Mischen oder Einkapseln von Gallium-Komplexen eines 3-Hydroxy-4-pyrons, worin das genannte 3-Hydroxy-4-pyron die Formel hat:<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="42" he="39" img-content="chem" img-format="tif"/></chemistry> worin die Reste R jeweils unabhÃ¤ngig voneinander ausgewÃ¤hlt werden aus der Gruppe, die besteht aus Wasserstoff und Alkyl mit 1 bis 6 Kohlenstoffatomen, wobei bei den genannten Gallium-Komplexen der neutrale 3:1-Formel(1)-Galiium-Komplex Ã¼berwiegt, mit einem bzw. in einem pharmazeutisch akzeptablen TrÃ¤ger.</claim-text></claim><claim id="c-de-02-0002" num="0002"><claim-text>Verfahren nach Anspruch 1, das ein Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts enthÃ¤lt.</claim-text></claim><claim id="c-de-02-0003" num="0003"><claim-text>Verfahren nach Anspruch 1 oder 2, worin die Menge des Komplexes in der Zusammensetzung so groÃŸ ist, daÃŸ nach der oralen Verabreichung der Zusammensetzung an ein Individuum eine Blutplasma-Galliumkonzentration von etwa 0,1 bis etwa 5 Âµg/l erzielt wird.<!-- EPO <DP n="45"> --></claim-text></claim><claim id="c-de-02-0004" num="0004"><claim-text>Verfahren nach einem der AnsprÃ¼che 1 bis 3, worin die genannte pharmazeutische Zusammensetzung zur Behandlung einer Ã¼bermÃ¤ÃŸigen Resorption von Calcium aus den Knochen verwendet wird.</claim-text></claim><claim id="c-de-02-0005" num="0005"><claim-text>Verfahren nach Anspruch 4, worin die genannte Ã¼bermÃ¤ÃŸige Resorption von Calcium aus den Knochen eine Folge von HypercalcÃ¤mie, Osteoporose, Osteopenie, Paget-Syndrom oder Krebs ist.</claim-text></claim><claim id="c-de-02-0006" num="0006"><claim-text>Verfahren nach einem der AnsprÃ¼che 1 bis 5, worin die genannte Alkylgruppe eine acyclische Gruppe mit 1 bis 3 Kohlenstoffatomen ist.</claim-text></claim><claim id="c-de-02-0007" num="0007"><claim-text>Verfahren nach Anspruch 6, worin die genannte acyclische Alkylgruppe Methyl oder Ethyl ist.</claim-text></claim><claim id="c-de-02-0008" num="0008"><claim-text>Verfahren nach Anspruch 6, worin das genannte 3-Hydroxy-4-pyron einen einzelnen Alkyl-Substituenten in der 2- oder 6-Position aufweist.</claim-text></claim><claim id="c-de-02-0009" num="0009"><claim-text>Verfahren nach einem der AnsprÃ¼che 1 bis 3, worin das genannte 3-Hydroxy-4-pyron ausgewÃ¤hlt wird aus der Gruppe, die besteht aus 3-Hydroxy-4-pyron, 3-Hydroxy-2-methyl-4-pyron, 3-Hydroxy-2-ethyl-4-pyron und 3-Hydroxy-6-methyl-4-pyron.</claim-text></claim><claim id="c-de-02-0010" num="0010"><claim-text>Verfahren nach Anspruch 9, worin das genannte 3-Hydroxy-4-pyron ausgewÃ¤hlt wird aus der Gruppe, die besteht aus 3-Hydroxy-2-methyl-4-pyron und 3-Hydroxy-2-ethyl-4-pyron.</claim-text></claim><claim id="c-de-02-0011" num="0011"><claim-text>Verfahren nach Anspruch 9, worin das genannte 3-Hydroxy-4-pyron das 3-Hydroxy-2-methyl-4-pyron ist.</claim-text></claim><claim id="c-de-02-0012" num="0012"><claim-text>Verfahren nach Anspruch 9, worin das genannte 3-Hydroxy-4-pyron das 3-Hydroxy-2-ethyl-4-pyron ist.<!-- EPO <DP n="46"> --></claim-text></claim><claim id="c-de-02-0013" num="0013"><claim-text>Verfahren nach Anspruch 2, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten ausgewÃ¤hlt wird aus der Gruppe, die besteht aus (a) der Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form mit verzÃ¶gerter Freisetzung; (b) der Zugabe eines Puffermittels zu der genannten pharmazeutischen Zusammensetzung; (c) der Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form die eher unter basischen Bedingungen als unter sauren Bedingungen freigesetzt wird; (d) der Einkapselung des genannten Komplexes in einem Material, das gegen AuflÃ¶sung bestÃ¤ndig ist, bis der DÃ¼nndarm erreicht ist; und (e) der weiteren Einarbeitung des gleichen Hydroxypyrons, wie es in dem genannten Komplex verwendet worden ist, oder eines Salzes davon, das ein physiologisch akzeptables Kation enthÃ¤lt, in nicht komplex gebundener Form in die genannte pharmazeutische Zusammensetzung.</claim-text></claim><claim id="c-de-02-0014" num="0014"><claim-text>Verfahren nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form mit verzÃ¶gerter Freisetzung umfaÃŸt.</claim-text></claim><claim id="c-de-02-0015" num="0015"><claim-text>Verfahren nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die Zugabe eines Puffermittels zu der genannten pharmazeutischen Zusammensetzung umfaÃŸt.</claim-text></claim><claim id="c-de-02-0016" num="0016"><claim-text>Verfahren nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die Formulierung der genannten pharmazeutischen Zusammensetzung in einer Form, die eher<!-- EPO <DP n="47"> --> eine Freisetzung unter basischen als unter sauren Bedingungen ergibt, umfaÃŸt.</claim-text></claim><claim id="c-de-02-0017" num="0017"><claim-text>Verfahren nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die Einkapselung des genannten Komplexes in einem Material umfaÃŸt, das gegen AuflÃ¶sung bestÃ¤ndig ist, bis der DÃ¼nndarm erreicht ist.</claim-text></claim><claim id="c-de-02-0018" num="0018"><claim-text>Verfahren nach Anspruch 13, worin das genannte Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts des Patienten die weitere Einarbeitung des gleichen Hydroxypyrons, wie es in dem genannten Komplex verwendet worden ist, oder eines Salzes davon, das ein physiologisch akzeptables Kation enthÃ¤lt, in nicht komplex gebundener Form in die genannte pharmazeutische Zusammensetzung umfaÃŸt.</claim-text></claim><claim id="c-de-02-0019" num="0019"><claim-text>Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung zur ErhÃ¶hung der Calciumakkretion in den Knochen oder zur Verringerung der Calciumresorption bei einem SÃ¤ugetier, das umfaÃŸt die Formulierung<claim-text>(a) eines neutralen 3:1 Gallium-Komplexes eines 3-Hydroxy-4-pyrons, worin das genannte 3-Hydroxy-4-pyron die Formel hat<chemistry id="chem0012" num="0012"><img id="ib0012" file="imgb0012.tif" wi="41" he="29" img-content="chem" img-format="tif"/></chemistry> worin die Reste R jeweils unabhÃ¤ngig voneinander ausgewÃ¤hlt werden aus der Gruppe, die besteht aus Wasserstoff und Alkyl mit 1 bis 6 Kohlenstoffatomen, mit</claim-text><claim-text>(b) einem Mittel zur Inhibierung der Dissoziation des genannten Komplexes unter den sauren Bedingungen des Magenabschnitts des Magendarmtrakts.</claim-text><!-- EPO <DP n="48"> --></claim-text></claim><claim id="c-de-02-0020" num="0020"><claim-text>Verfahren nach Anspruch 19, worin die pharmazeutische Zusammensetzung in einer festen Dosierungsform vorliegt, die fÃ¼r die orale Verabreichung geeignet ist.</claim-text></claim>
EP	0612246	B1	2000-08-30	fr	CLAIM	5	<claim id="c-fr-01-0001" num="0001"><claim-text>Composition pharmaceutique dans une forme pharmaceutique solide pour administration orale pour utilisation dans le traitement de la rÃ©sorption excessive du calcium des os, ladite composition comprenant des complexes de gallium d'une 3-hydroxy-4-pyrone, dans laquelle ladite 3-hydroxy-4-pyrone possÃ¨de la formule (1) :<chemistry id="chem0013" num="0013"><img id="ib0013" file="imgb0013.tif" wi="38" he="30" img-content="chem" img-format="tif"/></chemistry> dans laquelle chaque R est indÃ©pendamment sÃ©lectionnÃ© parmi le groupe composÃ© de l'hydrogÃ¨ne et d'alkyles de 1 Ã  6 atomes de carbone, le complexe gallium-formule (1) neutre 3:1 Ã©tant prÃ©pondÃ©rant parmi lesdits complexes de gallium.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composition pharmaceutique selon la revendication 1, comprenant Ã©galement un moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composition pharmaceutique selon la revendication 1 ou 2, dans laquelle la quantitÃ© de complexe dans la composition est telle qu'aprÃ¨s administration orale de la composition Ã  un individu, une concentration de gallium dans le plasma sanguin d'environ 0,1 Ã  environ 5 Âµg/l est obtenue.<!-- EPO <DP n="50"> --></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composition pharmaceutique selon l'une quelconque des revendications 1 Ã  3, dans laquelle ladite rÃ©sorption excessive du calcium des os est due Ã  une hypercalcÃ©mie, une ostÃ©oporose, une ostÃ©opÃ©nie, la maladie de Paget ou un cancer.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Composition pharmaceutique selon l'une quelconque des revendications 1 Ã  4, qui comprend Ã©galement un support pharmaceutiquement inerte.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Composition pharmaceutique selon l<sup>'</sup>une quelconque des revendications 1 Ã  3, dans laquelle ledit groupe alkyle est un groupe acyclique de 1 Ã  3 atomes de carbone.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Composition pharmaceutique selon la revendication 6, dans laquelle ledit groupe alkyle acyclique est un mÃ©thyle ou un Ã©thyle.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Composition pharmaceutique selon la revendication 6, dans laquelle ladite 3-hydroxy-4-pyrone comprend un seul substituant alkyle en position 2 ou 6.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Composition pharmaceutique selon l'une quelconque des revendications 1 Ã  3, dans laquelle ladite 3-hydroxy-4-pyrone est sÃ©lectionnÃ©e parmi le groupe composÃ© de la 3-hydroxy-4-pyrone, la 3-hydroxy-2-mÃ©thyl-4-pyrone, la 3-hyclroxy-2-Ã©thyl-4-pyrone et la 3-hydroxy-6-mÃ©thyl-4-pyrone.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Composition pharmaceutique selon la revendication 9, dans laquelle ladite 3-hydroxy-4-pyrone<!-- EPO <DP n="51"> --> est sÃ©lectionnÃ©e parmi le groupe composÃ© de la 3-hydroxy-2-mÃ©thyl-4-pyrone et la 3-hydroxy-2-Ã©thyl-4-pyrone.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Composition pharmaceutique selon la revendication 10, dans laquelle ladite 3-hydroxy-4-pyrone est la 3-hydroxy-2-mÃ©thyl-4-pyrone.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Composition pharmaceutique selon la revendication 10, dans laquelle ladite 3-hydroxy-4-pyrone est la 3-hydroxy-2-Ã©thyl-4-pyrone.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Composition pharmaceutique selon la revendication 2, dans laquelle ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient est sÃ©lectionnÃ© parmi le groupe composÃ© de (a) la formulation de ladite composition pharmaceutique sous une forme Ã  libÃ©ration retardÃ©e ; (b) l'ajout d'un agent tampon Ã  ladite composition pharmaceutique ; (c) la formulation de ladite composition pharmaceutique dans une forme orientÃ©e vers la libÃ©ration dans des conditions basiques plutÃ´t qu'acides ; (d) l'encapsulation dudit complexe dans un matÃ©riau qui est rÃ©sistant Ã  la dissolution jusqu'Ã  ce que l'intestin grÃªle soit atteint ; et (e) l'incorporation supplÃ©mentaire dans ladite composition pharmaceutique de la mÃªme hydroxypyrone que celle utilisÃ©e dans ledit complexe, ou d'un sel de celle-ci contenant un cation physiologiquement acceptable, sous forme non complexÃ©e.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Composition pharmaceutique selon la revendication 13, dans laquelle ledit moyen d'inhiber<!-- EPO <DP n="52"> --> la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastrointestinales du patient comprend la formulation de ladite composition pharmaceutique sous une forme Ã  libÃ©ration retardÃ©e.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Composition pharmaceutique selon la revendication 13, dans laquelle ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient comprend l'ajout d'un agent tampon Ã  ladite composition pharmaceutique.</claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Composition pharmaceutique selon la revendication 13, dans laquelle ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastrointestinales du patient comprend la formulation de ladite composition pharmaceutique dans une forme orientÃ©e vers la libÃ©ration dans des conditions basiques plutÃ´t qu'acides.</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>Composition pharmaceutique selon la revendication 13, dans laquelle ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastrointestinales du patient comprend l'encapsulation dudit complexe dans un matÃ©riau qui est rÃ©sistant Ã  la dissolution jusqu'Ã  ce que l'intestin grÃªle soit atteint.</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>Composition pharmaceutique selon la revendication 13, dans laquelle ledit moyen d'inhiber<!-- EPO <DP n="53"> --> la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastrointestinales du patient comprend l'incorporation supplÃ©mentaire dans ladite composition pharmaceutique de la mÃªme hydroxypyrone que celle utilisÃ©e dans ledit complexe, ou d'un sel de celle-ci contenant un cation physiologiquement acceptable, sous forme non complexÃ©e.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>Composition pharmaceutique pour augmenter l'accrÃ©tion du calcium dans les os ou pour diminuer la rÃ©sorption du calcium chez un mammifÃ¨re, comprenant<claim-text>(a) un complexe de gallium neutre 3:1 d'une 3-hydroxy-4-pyrone dans lequel ladite 3-hydroxy-4-pyrone possÃ¨de la formule :<chemistry id="chem0014" num="0014"><img id="ib0014" file="imgb0014.tif" wi="38" he="29" img-content="chem" img-format="tif"/></chemistry> dans laquelle chaque R est indÃ©pendamment sÃ©lectionnÃ© parmi le groupe composÃ© de l'hydrogÃ¨ne et d'alkyles de 1 Ã  6 atomes de carbone ; et</claim-text><claim-text>(b) un moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales.</claim-text></claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>Composition pharmaceutique selon la revendication 19, qui est dans une forme pharmaceutique solide adaptÃ©e pour l'administration orale.</claim-text></claim>
EP	0612246	B1	2000-08-30	fr	CLAIM	6	<claim id="c-fr-02-0001" num="0001"><claim-text>ProcÃ©dÃ© de prÃ©paration d'une composition pharmaceutique dans une forme pharmaceutique solide pour administration orale qui comprend le mÃ©lange ou l'encapsulation de complexes de gallium d'une 3-hydroxy-4-pyrone, dans laquelle ladite 3-hydroxy-4-pyrone possÃ¨de la formule :<chemistry id="chem0015" num="0015"><img id="ib0015" file="imgb0015.tif" wi="38" he="35" img-content="chem" img-format="tif"/></chemistry> dans laquelle chaque R est indÃ©pendamment sÃ©lectionnÃ© parmi le groupe composÃ© de l'hydrogÃ¨ne et d'alkyles de 1 Ã  6 atomes de carbone, le complexe gallium-formule (I) neutre 3:1 Ã©tant prÃ©pondÃ©rant parmi lesdits complexes de gallium, avec ou dans un support pharmaceutiquement acceptable.</claim-text></claim><claim id="c-fr-02-0002" num="0002"><claim-text>ProcÃ©dÃ© selon la revendication 1, comprenant un moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales.</claim-text></claim><claim id="c-fr-02-0003" num="0003"><claim-text>ProcÃ©dÃ© selon la revendication 1 ou 2, dans lequel la quantitÃ© de complexe dans la composition est telle qu'aprÃ¨s administration orale de la composition Ã  un individu, une concentration de gallium dans le plasma sanguin d'environ 0,1 Ã  environ 5 Âµg/l est obtenue.<!-- EPO <DP n="55"> --></claim-text></claim><claim id="c-fr-02-0004" num="0004"><claim-text>ProcÃ©dÃ© selon la revendication 1 ou 2, dans lequel ladite composition pharmaceutique est pour utilisation dans le traitement de la rÃ©sorption excessive du calcium des os.</claim-text></claim><claim id="c-fr-02-0005" num="0005"><claim-text>ProcÃ©dÃ© selon la revendication 4, dans lequel ladite rÃ©sorption excessive du calcium des os est due Ã  une hypercalcÃ©mie, une ostÃ©oporose, une ostÃ©opÃ©nie, la maladie de Paget ou un cancer.</claim-text></claim><claim id="c-fr-02-0006" num="0006"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 1 Ã  5, dans lequel ledit groupe alkyle est un groupe acyclique de 1 Ã  3 atomes de carbone.</claim-text></claim><claim id="c-fr-02-0007" num="0007"><claim-text>ProcÃ©dÃ© selon la revendication 6, dans lequel ledit groupe alkyle acyclique est un mÃ©thyle ou un Ã©thyle.</claim-text></claim><claim id="c-fr-02-0008" num="0008"><claim-text>ProcÃ©dÃ© selon la revendication 6, dans lequel ladite 3-hydroxy-4-pyrone comprend un seul substituant alkyle en position 2 ou 6.</claim-text></claim><claim id="c-fr-02-0009" num="0009"><claim-text>ProcÃ©dÃ© selon l'une quelconque des revendications 1 Ã  3, dans lequel ladite 3-hydroxy-4-pyrone est sÃ©lectionnÃ©e parmi le groupe composÃ© de la 3-hydroxy-4-pyrone, la 3-hydroxy-2-mÃ©thyl-4-pyrone, la 3-hydroxy-2-Ã©thyl-4-pyrone et la 3-hydroxy-6-mÃ©thyl-4-pyrone.</claim-text></claim><claim id="c-fr-02-0010" num="0010"><claim-text>ProcÃ©dÃ© selon la revendication 9, dans lequel ladite 3-hydroxy-4-pyrone est sÃ©lectionnÃ©e parmi le groupe composÃ© de la 3-hydroxy-2-mÃ©thyl-4-pyrone et la 3-hydroxy-2-Ã©thyl-4-pyrone.<!-- EPO <DP n="56"> --></claim-text></claim><claim id="c-fr-02-0011" num="0011"><claim-text>ProcÃ©dÃ© selon la revendication 9, dans lequel ladite 3-hydroxy-4-pyrone est la 3-hydroxy-2-mÃ©thyl-4-pyrone.</claim-text></claim><claim id="c-fr-02-0012" num="0012"><claim-text>ProcÃ©dÃ© selon la revendication 9, dans lequel ladite 3-hydroxy-4-pyrone est la 3-hydroxy-2-Ã©thyl-4-pyrone.</claim-text></claim><claim id="c-fr-02-0013" num="0013"><claim-text>ProcÃ©dÃ© selon la revendication 2, dans lequel ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient est sÃ©lectionnÃ© parmi le groupe composÃ© de (a) la formulation de ladite composition pharmaceutique dans une formule Ã  libÃ©ration retardÃ©e ; (b) l'ajout d'un agent tampon Ã  ladite composition pharmaceutique ; (c) la formulation de ladite composition pharmaceutique dans une forme orientÃ©e vers la libÃ©ration dans des conditions basiques plutÃ´t qu'acides ; (d) l'encapsulation dudit complexe dans un matÃ©riau qui est rÃ©sistant Ã  la dissolution jusqu'Ã  ce que l'intestin grÃªle soit atteint ; et (e) l'incorporation supplÃ©mentaire dans ladite composition pharmaceutique de la mÃªme hydroxypyrone que celle utilisÃ©e dans ledit complexe, ou un sel de celle-ci contenant un cation physiologiquement acceptable, sous forme non complexÃ©e.</claim-text></claim><claim id="c-fr-02-0014" num="0014"><claim-text>ProcÃ©dÃ© selon la revendication 13, dans lequel ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient comprend la formulation de ladite composition pharmaceutique dans une forme Ã  libÃ©ration retardÃ©e.<!-- EPO <DP n="57"> --></claim-text></claim><claim id="c-fr-02-0015" num="0015"><claim-text>ProcÃ©dÃ© selon la revendication 13, dans lequel ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient comprend l'ajout d'un agent tampon Ã  ladite composition pharmaceutique.</claim-text></claim><claim id="c-fr-02-0016" num="0016"><claim-text>ProcÃ©dÃ© selon la revendication 13, dans lequel ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient comprend la formulation de ladite composition pharmaceutique dans une forme orientÃ©e vers la libÃ©ration dans des conditions basiques plutÃ´t qu'acides.</claim-text></claim><claim id="c-fr-02-0017" num="0017"><claim-text>ProcÃ©dÃ© selon la revendication 13, dans lequel ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient comprend l'encapsulation dudit complexe dans un matÃ©riau qui est rÃ©sistant Ã  la dissolution jusqu'Ã  ce que l'intestin grÃªle soit atteint.</claim-text></claim><claim id="c-fr-02-0018" num="0018"><claim-text>ProcÃ©dÃ© selon la revendication 13, dans lequel ledit moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales du patient comprend l'incorporation supplÃ©mentaire dans ladite composition pharmaceutique de la mÃªme hydroxypyrone que celle utilisÃ©e dans ledit complexe, ou d'un sel de celle-ci contenant un cation physiologiquement acceptable, sous forme non complexÃ©e.<!-- EPO <DP n="58"> --></claim-text></claim><claim id="c-fr-02-0019" num="0019"><claim-text>ProcÃ©dÃ© de prÃ©paration d'une composition pharmaceutique pour augmenter l'accrÃ©tion du calcium dans les os ou pour diminuer la rÃ©sorption du calcium chez un mammifÃ¨re, comprenant la formulation de :<claim-text>(a) un complexe de gallium neutre 3:1 d'une 3-hydroxy-4-pyrone dans lequel ladite 3-hydroxy-4-pyrone possÃ¨de la formule :<chemistry id="chem0016" num="0016"><img id="ib0016" file="imgb0016.tif" wi="39" he="29" img-content="chem" img-format="tif"/></chemistry> dans lequel chaque R est indÃ©pendamment sÃ©lectionnÃ© parmi le groupe composÃ© de l'hydrogÃ¨ne et d'alkyles de 1 Ã  6 atomes de carbone ; avec</claim-text><claim-text>(b) un moyen d'inhiber la dissociation dudit complexe dans les conditions acides de la partie gastrique des voies gastro-intestinales.</claim-text></claim-text></claim><claim id="c-fr-02-0020" num="0020"><claim-text>ProcÃ©dÃ© selon la revendication 19, dans lequel la composition pharmaceutique est dans une forme pharmaceutique solide adaptÃ©e pour l'administration orale.</claim-text></claim>
EP	0612246	B1	2000-08-30	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0612246&ki=B1&pd=2000-08-30
EP	0636181	B1	2000-11-29	de	TITLE	1	VERWENDUNG EINES GENS, DAS FÃœR OXALAT OXIDASE KODIERT ZUR TRANSFORMATION VON PFLANZEN
EP	0636181	B1	2000-11-29	en	TITLE	1	USE OF A GENE ENCODING OXALATE OXIDASE FOR THE TRANSFORMATION OF PLANTS
EP	0636181	B1	2000-11-29	fr	TITLE	1	UTILISATION D' UN GENE ENCODANT OXALATE OXYDASE POUR LA TRANSFORMATON DES PLANTES
EP	0636181	B1	2000-11-29	en	DESCR	1	<p id="p0001" num="0001">This invention relates to the genetic improvement of plants by the use of recombinant DNA techniques. Particularly, but not exclusively, the invention relates to the improvement of the tolerance of plants to disease.</p><p id="p0002" num="0002">From the beginning of agriculture humans have been confronted with the problem of plant disease. Throughout history many strides have been made against plant diseases as exemplified through the use of hybrid plants, pesticides and improved agricultural practices. However, as any farmer, home gardener, or house plant devotee can attest, the problems of plant disease are an ongoing and constant problem in plant cultivation. This invention constitutes a major step forward in solving the problem of plant disease by exploiting a long known fact regarding the method by which certain microbes, especially fungi, attack plants. Specifically, this invention addresses a means by which the etiologic (disease causing) agent is slowed or prevented from actually entering into the plant tissue, thereby preventing disease. Alternatively, in instances where complete invasion is not prevented the present invention confers upon plants a means for reducing the effects of infection thereby reducing or preventing plant mortality due to the disease.</p><p id="p0003" num="0003">In order for a plant pathogen to infect a plant, it must be able to gain access into and subsequently throughout the plant. Plant pathogens accomplish this in various ways. Generally, this is accomplished by the secretion of chemical substances that affect certain component and/or metabolic mechanisms of the plant to be attacked, i.e., the host for the pathogen. The main groups of compounds that are secreted by plant pathogens and that are related to the disease-causing mechanism are toxins, enzymes, polysaccharides and/or other effectors of growth. One such chemical compound is oxalic acid or oxalate which can be degraded by the enzyme oxalate oxidase. Although the reaction catalysed by oxalate oxidase is well-known, the physico-chemical attributes of the enzyme as exemplified by barley oxalate oxidase are incorrectly reported in the literature.</p><p id="p0004" num="0004">The secretion of oxalic acid as a means by which plant pathogens attack plant hosts is commonly found in a plurality of fungal genera and especially in the genera Sclerotinia, Sclerotium, Aspergillus, Streptomyces, Penicillium, Pythium, Paxillus, Mycena, Leucostoma, Rhizoctonia and Schizophyllum. These genera of fungi, especially those fungi of the genus Sclerotinia, are known to cause destructive and fatal diseases of numerous highly cultivated plants including field crops such as sunflower, soybean, beans in general, rape/canola, alfalfa, flax, safflower, peanut and clover, vegetable crops such as lettuce, tomato, cucurbits, potato, carrot, radish, pea, lentils, cabbage, broccoli and brussel sprouts, flowers such as petunia and pyrethrum and tree species such as peach.</p><p id="p0005" num="0005">The diseases include not only pre-harvest diseases in the field but also post-harvest diseases during shipping and storage.</p><p id="p0006" num="0006">The symptoms caused by the aforementioned fungal genera vary with the host plant and the parts of the host plant infected with the disease, as well as being dependent upon environmental conditions at the time of pathogen attack. For example, a feature of all Sclerotinia disease is wilting and collapse of the leaves<!-- EPO <DP n="2"> --> whereupon the fungus rapidly invades the "heart" of the plant and throughout the stem. The disease is fatal.</p><p id="p0007" num="0007">In liquid cultures of Sclerotinia levels of oxalic acid ranging from a thousand to ten thousand parts per million, depending upon growth media, age of the culture and other parameters have been observed. Certain plant tissue such as leaves of bean and sunflower exposed to low concentrations of oxalic acid readily show signs of wilting and cell death suggesting the importance of oxalic acid in later stages of disease. The precise mechanism of the disease causing function of oxalic acid after infection is unknown although theories range from chelation of divalent metals interfering with plant cell walls and/or key metabolic enzymes to providing an optimum micro-environment for the action of hydrolytic enzymes secreted by these fungi. Regardless, it is clear from extant evidence that oxalic acid is an integral component of pathogenic attack. Evidence for this conclusion has been obtained by several studies including investigations with oxalate-minus Sclerotinia mutants that appear to possess the normal complement of hydrolytic enzymes and other factors but do not produce disease symptomology. Revertants of these oxalate minus mutants demonstrated normal disease development and characteristics.</p><p id="p0008" num="0008">The high degree of virulence of diseases associated with the aforementioned fungal genera are well-known. For example, leaves of greenhouse grown sunflower plants infected with Sclerotinia sclerotorum frequently exhibit wilting and interveinal necrosis three to five days after inoculation. Study of these plants has shown a wilt inducing substance in water extracts of hypocotyl (the part of the axis of a plant embryo or seedling below the cotyledon) lesions. Chemical tests including thin layer chromatography and gas-liquid chromatography have demonstrated that this wilt inducing substance contained oxalic acid and that wilted leaves from infected plants contained over fifteen times more oxalic acid than leaves of healthy plants. As already noted, the oxalic acid moves systemically through the plant to cause disease symptoms in tissues that are both distant from the initial point of infection and not necessarily infected with fungal hyphae.</p><p id="p0009" num="0009">With this backdrop, the inventors realised that appropriate identification, isolation and expression of an oxalate degrading enzyme such as an oxalate oxidase, oxalate decarboxylase or similar enzyme by a plant might well diminish the pathogenicity of fungi which secrete oxalic acid as a key component of pathogenicity. Accordingly, the inventors set out and achieved the goal of properly identifying and isolating a gene for a protein that is suitable for the introduction of oxalate oxidase activity into plants and microbes using the techniques of genetic engineering.</p><p id="p0010" num="0010">Oxalates also occur commonly in some plant species as products naturally produced by the plant itself. Naturally-occurring oxalate accumulates in some green leaf vegetables such as spinach and rhubarb and in some forage legumes.</p><p id="p0011" num="0011">Although such crops species potential sources of dietary vitamins and minerals, ingestion of large amounts is toxic to humans where it binds with calcium ion and precipitates, as insoluble calcium oxalate in the kidneys leading to hyperoxaluria and degradation of renal tissue.</p><p id="p0012" num="0012">It is also known that oxalic acid may react with other plant metabolites to form oxalate derivatives which are highly toxic. In one example the compound b-N-oxalyl-L-a-b-diaminopropionic acid is formed which is a neurotoxin.</p><p id="p0013" num="0013">Thus, the presence of oxalic acid in some plant species rules out their use as human or animal food.<!-- EPO <DP n="3"> --></p><p id="p0014" num="0014">In particular, the inventors have characterised an enzyme useful in thwarting pathogenicity involving oxalic acid. This uniquely characterised oxalate oxidase enzyme catalyzes or otherwise contributes to a reaction involving the oxidative degradation of oxalate to produce carbon dioxide and hydrogen peroxide. The general form of this reaction is:<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="80" he="9" img-content="chem" img-format="tif"/></chemistry></p><p id="p0015" num="0015">The study of this enzyme has resulted not only in its identification, isolation and expression, but, also in its characterisation and its cloning so that a gene for expression of the enzyme is extant, can be introduced into plants, and expressed by plants thereby conferring disease resistance to fungi in which oxalic acid is a critical component. Such plant transformation would protect the transformed plants against the deleterious disease causing effects of oxalic acid.</p><p id="p0016" num="0016">It will be appreciated that the applications of the aforementioned inventions are not limited to plant pathogenesis. Still another benefit of this invention is the introduction of an oxalate oxidase gene into a plant to produce a low oxalic acid plant. This could be especially beneficial in high oxalate plants such as peanuts, beets, spinach, rhubarb, barley, cocoa, and many grasses. See, Libert and Franceschi (1987), J/ Agric. Food Chem., 35:926-938. Also, the invention has application for the large scale production of oxalate degrading enzymes. The need for such large scale oxalate degrading enzymes is known in a variety of fields including the need for their use in assay kits to determine the presence and/or amount of oxalic acid and for use in the degradation of oxalic acid present in foodstuffs, beverages and commercial processes. For example, the microbial oxalate decarboxylase has been used by the brewing industry (U.S. Patent No. 4,652,452) and as set forth herein oxalate can also be degraded using oxalate oxidase.</p><p id="p0017" num="0017">An object of the present invention is to provide means for the degradation of oxalic acid in plants.</p><p id="p0018" num="0018">According to the present invention there is provided a method of imparting the ability to degrade oxalate to a plant comprising inserting into the genome of the said plant by genetic transformation a gene encoding an oxalate oxidase.</p><p id="p0019" num="0019">Preferably the the plant genome is transformed by a gene construct having a promoter sequence, a transit peptide, a structural gene sequence encoding said oxalate oxidase enzyme and a gene terminator sequence.</p><p id="p0020" num="0020">In a preferred embodiment the structural gene sequence comprises the DNA sequence of Figure 1.</p><p id="p0021" num="0021">The present invention also provides a method of combating plant pathogenesis by infection with a fungus which secretes oxalic acid, comprising stably incorporating into the genome of said plant by transformation a gene encoding oxalate oxidase.</p><p id="p0022" num="0022">The said fungus may be of a genus selected from the group of oxalic acid secreting fungi comprising Sclerotinia, Sclerotium, Aspergillus, Streptomyces, Penicillium, Pythium, Paxillus, Mycena, Leucostoma, Rhizoctonia, and Schizophyllum.</p><p id="p0023" num="0023">Most preferably the fungus is <i>Sclerotinia sclerotorum</i>.</p><p id="p0024" num="0024">In a preferred application of the invention the plant is sunflower <i>(Helianthus annuus)</i><!-- EPO <DP n="4"> --></p><p id="p0025" num="0025">The invention also provides a plant derived therefrom having stably incorporated within its genome by transformation a gene encoding oxalate oxidase and also a plant cell having stably incorporated within its genome by transformation a gene encoding oxalate oxidase.</p><p id="p0026" num="0026">Thus, in general terms, the present invention is broadly directed to the understanding and appreciation of the use of an oxalate degrading enzyme as exemplified by oxalate oxidase for commercial uses such as in the brewing industry or for agronomic uses such as to reduce susceptibility of a plant to oxalic acid or to reduce the endogenous oxalic acid concentration in a plant. The inventors have come to appreciate and teach herein, particularly for agronomic application, the use of oxalate degrading enzymes to reduce plant mortality or destruction from diseases or other phenomenon in which oxalic acid plays a critical invasive role. The inventors have also appreciated that use of this invention can result in the prevention of plant mortality and infection from diseases in which oxalic acid is critical. Such diseases are particularly caused by, among others, the specific genera of fungi set forth herein.</p><p id="p0027" num="0027">The appreciation of the inventor's novel uses of oxalate degrading enzymes is especially enhanced by the realisation and invention of the inventors that the physico-chemical properties of barley oxalate oxidase as reported in the literature was inaccurate. Accordingly, the inventors have substantially purified and characterised on oxalate oxidase enzyme not heretofore described. Indeed, the purported substantial purifications of the enzyme as set forth in the literature are shown herein to be incorrect. Specifically, the inventors disclose a substantially pure oxalate oxidase having a particular total amino acid composition, shown in Figure 2, a pH optimum of 3.5, a neutral isoelectric point, a positive heat stability, protease stability and a single subunit of approximately 25 kilodaltons.</p><p id="p0028" num="0028">Also set forth herein is the invention of substantially all of a substantially pure gene encoding an oxalate oxidase enzyme with a specific DNA sequence as shown in Figure 1. The gene encodes the oxalate oxidase enzyme having the characteristics as set forth above. In particular the gene encodes an enzyme exhibiting oxalate oxidase activity having a single subunit of approximately 25 kilodaltons, that reacts specifically with antibodies raised against purified barley oxalate oxidase, and has an amino acid sequence shown in Figure 2.</p><p id="p0029" num="0029">A transformed plant cell is also disclosed herein, which cell is transformed by a gene encoding the expression of oxalate oxidase or another oxalate degrading enzyme. The gene encoding such enzyme can include the DNA sequence set forth in Figure 1, which substantially corresponds to the oxalate oxidase enzyme substantially purified by the inventors.</p><p id="p0030" num="0030">The purified oxalate oxidase of this invention, its use as an agent to fight pathogenesis and its use in plant cell transformation provide an innovative and unique approach to the control of plant diseases in which oxalic acid plays a critical component either during pathogenesis or at the invasive stage. It is, of course, well-known that the activity of the enzyme oxalate oxidase is that it contributes to the degradation of oxalic acid. However, it was the current inventors who first appreciated that by attacking the oxalic acid by chemical degradation, for example by enzymatic degradation, a significant agricultural benefit in conferring disease resistance against those diseases in which oxalic acid plays a critical role would result. This invention holds special promise because a major scourge in the commercial<!-- EPO <DP n="5"> --> cultivation of agronomically important plants, for example crops such as sunflowers, is caused by fungal species such as Sclerotinia that secrete oxalic acid.</p><p id="p0031" num="0031">Although the prior art reportedly purified oxalate oxidase and characterised it, the inventors have discovered that such literature reports were inaccurate and that the enzyme was, in fact, never properly purified and characterised. It will be appreciated that as used herein, "oxalate oxidase" refers to the purified and characterised form of the enzyme as set forth herein unless stated otherwise. The differences between the extant literature reports and the purified and characterised enzyme of the current invention are set forth in detail herein and can be briefly gleaned from Table 1.</p><p id="p0032" num="0032">The impurity of commercially available oxalate oxidase preparations as well as the improper characterisation of the enzyme in the literature was evident when the inventors first purified oxalate oxidase from barley seedling root. Two procedures were used. In one instance purification of the barley seedling root oxalate oxidase involved homogenisation of frozen tissue in 1 to 4 volumes of water and purification from the aqueous extract following filtration though cheesecloth to remove debris. The solution was further purified by centrifugation at 18,000 g for 30 minutes followed by heat treatment at 80Â°C for 3 minutes with the precipitates at both steps being discarded; protein precipitation from the supernatant between 30% and 70% saturation with respect to ammonium sulphate (NH4)2SO4 was collected by centrifugation and was dialyzed against water. Protein resolubilizing from the ammonium sulphate precipitation step was fractionated on a Pharmacia FPLC using a Mono S 10/10 column equilibrated with 25 mM potassium acetate pH 4.8 eluted with a 0.0 to 0.4 M NaCl gradient in the same buffer. Oxalate oxidase activity was measured by the method of Sugiura, et al (1979), Chem. Pharma. Bull. 27(9):2003. Peak fractions of oxalate oxidase activity were combined, equilibrated with the low salt potassium acetate pH 4.8 buffer and re-chromatographed on the FPLC using a Mono S 5/5 column eluted with the buffers and NaCl gradient as above. Peak fractions from the Mono S 5/5 step were combined, equilibrated with 25 mM Tris-Cl, pH 7.6 applied to a Mono Q 5/5 column and eluted with a 0.0 to 0.4 m NaCl gradient. Sodium dodecyl sulphate polyacrylamide gel electrophoresis of peak oxalate oxidase activity fractions showed prominent protein bands upon silver staining at approximately 25 and 38-40 kilodaltons.</p><p id="p0033" num="0033">Subsequent size fractionated of the native protein on a Superose-12 gel filtration column (equilibrated with 50 mM potassium acetate, pH 4.8) on the FPLC showed a well-defined peak of activity eluting at a time corresponding with the molecular weight of about 25,000. No oxalate oxidase activity was found eluting in any other fractions associated with other molecular weights.</p><p id="p0034" num="0034">A second method involved the use of detergent extraction. Four to seven day old barley seedling roots were powdered in the presence of liquid nitrogen and stored at -80Â°C. Storage under these conditions resulted in no apparent loss of activity. The stored tissue was homogenised with distilled water containing 0.5% taurodeoxycholate sodium salt, filtered and centrifuged. Oxalate oxidase assays on the two fractions (supernatant and pellet) reveal that both fractions possessed activity. Accordingly, the pellet was extracted with distilled water containing 0.5% taurodeoxycholate. Following exhaustive dialysis against distilled water, ammonium sulphate was added to concentrate and fractionate the soluble supernatant probe. The precipitated proteins (30-70% ammonium sulphate fractions) were then resuspended in a small volume of distilled water containing detergent and desalted on a small gel<!-- EPO <DP n="6"> --> permeation column (Sephadex G25). The active fraction was applied to an anion exchange column (DEAE) using a Tris-HCl, pH 7.5 buffer and elution of bound protein effected using a sodium chloride gradient. The enzymatically active fraction was concentrated, desalted and then applied to a Mono-Q column (Pharmacia). A sodium chloride gradient was again employed to elute the proteins. Activity assays showed that the oxalate oxidase was concentrated in 3 fractions. Upon analysis of these fractions by SDS polyacrylamide gel electrophoresis, the activity was determined to be associated with a polypeptide of about 25 kilodalton molecular weight.</p><p id="p0035" num="0035">Following purification, characterisation of the purified, homogeneous oxalate oxidase preparation was effectuated. As already indicated and as shown in Table 1 the properties of the protein resulting from this purification plainly differ from that described in the literature. This suggests that despite attempts by others skilled in the art to purify the oxalate oxidase enzyme, it was not until the present efforts of the inventors that this enzyme was properly described and fingerprinted through the elucidation of its physico-chemical properties. The results of the physico-chemical characterisation undertaken by the inventors are set forth in Table 1. By way of comparison, the previously reported literature characterisation of the enzyme is also set forth. <tables id="tabl0001" num="0001"><table frame="all"><title>TABLE 1</title><tgroup cols="3" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col3" align="center"><b>OXALATE OXIDASE PROPERTIES</b></entry></row><row><entry namest="col1" nameend="col1" align="left">Property</entry><entry namest="col2" nameend="col2" align="left"><b>Literature</b></entry><entry namest="col3" nameend="col3" align="left"><b>Invention</b></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">pH optimum</entry><entry namest="col2" nameend="col2" align="left">3.5</entry><entry namest="col3" nameend="col3" align="left">3.5</entry></row><row><entry namest="col1" nameend="col1" align="left">Heat Stability</entry><entry namest="col2" nameend="col2" align="left">+</entry><entry namest="col3" nameend="col3" align="left">+</entry></row><row><entry namest="col1" nameend="col1" align="left">Subunit No.</entry><entry namest="col2" nameend="col2" align="left">2</entry><entry namest="col3" nameend="col3" align="left">1</entry></row><row><entry namest="col1" nameend="col1" align="left">Size</entry><entry namest="col2" nameend="col2" align="left">75k</entry><entry namest="col3" nameend="col3" align="left">25k</entry></row><row><entry namest="col1" nameend="col1" align="left">pI</entry><entry namest="col2" nameend="col2" align="left">2.8</entry><entry namest="col3" nameend="col3" align="left">approx. 7</entry></row><row><entry namest="col1" nameend="col1" align="left">Cofactors</entry><entry namest="col2" nameend="col2" align="left">-</entry><entry namest="col3" nameend="col3" align="left">-</entry></row><row><entry namest="col1" nameend="col1" align="left">Protease Sta</entry><entry namest="col2" nameend="col2" align="left">unknown</entry><entry namest="col3" nameend="col3" align="left">+</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">Membrane association</entry><entry namest="col2" nameend="col2" align="left">unclear</entry><entry namest="col3" nameend="col3" align="left">+</entry></row></tbody></tgroup></table></tables></p><p id="p0036" num="0036">Further establishing the distinctiveness of the inventors' enzyme exhibiting oxalate oxidase activity can be seen in Table 2. As Table 2 plainly evidences this invention establishes an amino acid composition different than reported in the literature. See, Chiriboga, J. (1966) Archives of Biochemistry and Biophysics 116, 516-523. <tables id="tabl0002" num="0002"><table frame="all"><title>TABLE 2</title><tgroup cols="3" colsep="1" rowsep="1"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row><entry namest="col1" nameend="col1" align="center"><b>Amino acid</b></entry><entry namest="col2" nameend="col2" align="center"><b>Invention</b></entry><entry namest="col3" nameend="col3" align="center"><b>Literature</b></entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left"><b>Asx</b></entry><entry namest="col2" nameend="col2" align="char" char=".">12.53</entry><entry namest="col3" nameend="col3" align="char" char=".">8.44</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Ser</b></entry><entry namest="col2" nameend="col2" align="char" char=".">8.65</entry><entry namest="col3" nameend="col3" align="char" char=".">6.50</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Gly</b></entry><entry namest="col2" nameend="col2" align="char" char=".">13.31</entry><entry namest="col3" nameend="col3" align="char" char=".">10.75</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Glx</b></entry><entry namest="col2" nameend="col2" align="char" char=".">7.42</entry><entry namest="col3" nameend="col3" align="char" char=".">6.80</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Thr</b></entry><entry namest="col2" nameend="col2" align="char" char=".">8.10</entry><entry namest="col3" nameend="col3" align="char" char=".">5.18</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Ala</b></entry><entry namest="col2" nameend="col2" align="char" char=".">7.93</entry><entry namest="col3" nameend="col3" align="char" char=".">7.85</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Val</b></entry><entry namest="col2" nameend="col2" align="char" char=".">8.41</entry><entry namest="col3" nameend="col3" align="char" char=".">6.40</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Met</b></entry><entry namest="col2" nameend="col2" align="char" char=".">2.85</entry><entry namest="col3" nameend="col3" align="char" char=".">0</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Tyr</b></entry><entry namest="col2" nameend="col2" align="char" char=".">0.98</entry><entry namest="col3" nameend="col3" align="char" char=".">0.93</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Ile</b></entry><entry namest="col2" nameend="col2" align="char" char=".">2.15</entry><entry namest="col3" nameend="col3" align="char" char=".">6.39</entry></row><!-- EPO <DP n="7"> --><row><entry namest="col1" nameend="col1" align="left"><b>Leu</b></entry><entry namest="col2" nameend="col2" align="char" char=".">9.36</entry><entry namest="col3" nameend="col3" align="char" char=".">-</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Phe</b></entry><entry namest="col2" nameend="col2" align="char" char=".">6.89</entry><entry namest="col3" nameend="col3" align="char" char=".">-</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>His</b></entry><entry namest="col2" nameend="col2" align="char" char=".">1.79</entry><entry namest="col3" nameend="col3" align="char" char=".">1.68</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Lys</b></entry><entry namest="col2" nameend="col2" align="char" char=".">5.98</entry><entry namest="col3" nameend="col3" align="char" char=".">4.90</entry></row><row><entry namest="col1" nameend="col1" align="left"><b>Trp</b></entry><entry namest="col2" nameend="col2" align="char" char="."><b>-</b></entry><entry namest="col3" nameend="col3" align="char" char="."><b>-</b></entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left"><b>Arg</b></entry><entry namest="col2" nameend="col2" align="char" char=".">3.65</entry><entry namest="col3" nameend="col3" align="char" char=".">3.48</entry></row></tbody></tgroup></table></tables></p><p id="p0037" num="0037">Partially purified barley seed root oxalate oxidase was solubilized, subjected to cation exchange chromatography using a Mono S column (25 mM potassium acetate, pH 4.8, and eluted with a 0 to 400 millimolar potassium chloride gradient in the same buffer). The recovered enzymatically active protein was further purified by preparative sodium dodecyl sulphate polyacrylamide gel electrophoresis. A single protein band of about 25 kilodalton molecular weight band was detected and subsequently sliced from the gel.</p><p id="p0038" num="0038">The wet gel slices were fragmented, mixed with Freund's adjuvant and injected intramuscularly into the rear of the thigh muscle near the hip of the rabbits. The rabbits were boosted with additional quantities of protein and sample bleeds monitored to assure the production of oxalate oxidase specific antibodies. After about four months the animals were exsanguinated. The polyclonal rabbit antibodies produced were of very high titer.</p><p id="p0039" num="0039">The gene encoding for barley-derived oxalate oxidase having the structure shown in Figure 1, was cloned as shown in Figure 4 using a cDNA library constructed from barley root. Total RNA was prepared from barley root. Polyadenylated RNA was then recovered from total RNA and used for the synthesis of cDNA. Both total and polyadenylated RNA were prepared using commercially available RNA extraction and mRNA purification kits according to the standard instructions provided with the kits (Pharmacia LKB Biotechnology Inc). Construction of the library was commercially performed (Clontech Laboratories). The vector chosen for the library was lambda gt 22. Use of this expression vector was selected based on the high titer and specificity of the oxalate oxidase antiserum. Whatever the expression vector selected for use with this conversion, it is advantageous for the vector to permit the use of an immunological screen for the protein product of oxalate oxidase cDNA clones. Base on the average insert size of 1.8 kilobases for the cDNA library and good representation as far as number of independent clones (1.7 x 106), it was deduced that the library should contain a cDNA clone for the oxalate oxidase protein approximately 25 kilodaltons in size.</p><p id="p0040" num="0040">The initial screen of the library was performed with antiserum to oxalate oxidase according to standard procedures as, for example, set forth in Huynh, T., et al., (1985) DNA Cloning Techniques: A Practical Approach, D. Glover, ed. IRL Press, Oxford. Since information on the N-terminal amino acid sequence of the mature oxalate oxidase protein had been obtained (except for the N-terminal residue), the N-terminal sequence was also used to confirm the identity of any cDNA clones recovered as positive in the initial immunological screen. 1.2 x 106 plaques from the cDNA library were screened with the antiserum. Fourteen potentially positive signals were obtained one of which was much stronger than the others. Two sequential rounds of re-screening with the antiserum were performed on these fourteen clones in order to obtain confirmed positive, single plaque isolates which would be<!-- EPO <DP n="8"> --> characterised at the molecular level. Plaque number 12 again gave the strongest signal throughout these subsequent screens. Plaque number 12 was then used to purify the oxalate oxidase antibody as a test of the specificity of the plaque signal, according to the standard procedure as described, for example, in Hunyh, T. et al., supra. Antibody purified from plaque 12 was used as a probe on a Western blot of an acrylamide gel of oxalate oxidase protein. The plaque-purified antibody reacted specifically with oxalate oxidase, showing a pattern identical to that seen with purified antibody as a probe. The insert (cDNA product cloned into the vector lambda gt 22) from plaque 12</p><p id="p0041" num="0041">was recovered using standard polymerase chain reaction (PCR) methods as exemplified in Ausubel, F.M. et al., eds., (1988). "The Polymerase Chain Reaction", in Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, New York, pp. 15.0.1-15.4.6. The insert in plaque number 12 was estimated to be 650-750 base pairs. The size of the insert in plaque 12 was consistent with a protein of about 25 kd. Based on the initial size estimate for the cDNA insert and the result from plaque purification of the antibody, plaque number 12 was considered to be the best candidate for further molecular analysis. The number 12 insert prepared by PCR was then recloned into a plasmid vector more amenable to analysis. The cDNA insert from clone 12 was also used as a probe to a Northern blot of barley root RNA to estimate the size of the mRNA for oxalate oxidase. Formaldehyde gel electrophoresis and transfer to a nylon membrane were carried out according to the procedures recommended by the commercial supplier of the membranes, Schleicher and Schuell. The number 12 probe hybridised to a single mRNA species approximately 800-850 bases long.</p><p id="p0042" num="0042">Dideoxy nucleotide sequencing was performed on the recloned plaque 12 insert. A commercially available T7 sequencing kit (Pharmacia LKB Biotechnology Inc.) and the manufacturer's recommended procedure were used. The barley cDNA insert was determined to be approximately 690 bases long with some uncertainty in two small regions covering no more than ten base pairs each, the c terminus and the identity of the three N terminal bases. The nucleotide sequence of the clone 12 insert is shown schematically in Figure 1. The partial protein sequence was then predicted from the nucleotide sequence of clone 12 and compared to the N-terminal amino acid sequence obtained directly from the purified oxalate oxidase. This comparison is shown in Figure 3.</p><p id="p0043" num="0043">The gene having the structure shown in Figure 1 containing the coding sequence for the mature oxalate oxidase enzyme would be attached to genetic regulatory elements which are needed for the expression of the structural gene in a defined host cell. The first type of regulatory element required is a gene promoter region, which contains DNA sequences recognised by the biological machinery of the plant cell and which induces transcription of the DNA sequence into messenger RNA (mRNA). The mRNA is then translated into the protein produce codes for by the structural gene region. The promoter is attached in front of or 5' to the gene for oxalate oxidase, which can be performed according to standard methods know in the art. See, for example, T Maniatis, et al., (1982) Molecular Cloning, Cold Spring Harbor Laboratory, New York, pp. 104-106. Promoter regions which could be used for expression of the oxalate oxidase gene in plant cells include promoters which are active in a wide range of different plant tissues. For example, the 35S promoter from the cauliflower mosaic virus may be suitable for this purpose. Another type of<!-- EPO <DP n="9"> --> promoter that could be used in plant cells is one which expresses under more restricted conditions. Included in this class would be promoters active only in certain tissue(s) of the plant and/or induced to be active by certain stimuli like wounding. An example of this kind of promoter would be the 5' regulatory region from the gene for phenylalanine ammonia lyase (PAL). This type of promoter is discussed in Liang, X. et al., (1989), PNAS, USA, 8:9284-9288. Expression of the oxalate oxidase gene in microbial hosts could be achieved by use of promoters obtained from microbial sources. Examples of such promoters would include the trp promoter for expression in bacteria such as E. Coli as exemplified in Amann, E., et al., (1983) Gene, 25: 167-178, or the glyceraldehyde phosphate dehydrogenase (GAPD) promoter for expression in yeast as exemplified in Edens, L. et al, (1984), "Synthesis and Processing of the Plant Protein Thaumatin in Yeast," Cell 37:629-633. The gene promoter sequences may also be derived in part or in whole from promoter sequences found in cells unlike those of the host cell as long as they meet the above criteria for transcription and translation.</p><p id="p0044" num="0044">A second genetic regulatory element which desirably could be, but need not be, attached to the oxalate oxidase gene is a terminator or polyadenylation sequence which promotes effective termination of transcription of the gene and, in eukaryotes, also promotes polyadenylation, ie, the addition of any number of adenosine nucleotides at the 3' end of the mRNA. Standard methods known in the art can be used to attach the terminator region behind or 3' to the gene. (See, for example, T. Maniatis, et al, supra, pp. 104-106). An example of such a terminator/polyadenylation sequence for expression in plants would be that from the octopine synthase gene from an <i>Agrobacterium tumefaciens</i> Ti plasmid as enuciated in H. DeGreve et al., (1982), "Nucleotide sequence and transcript map of the <i>Agrobacterium tumefaciens</i> Ti plasmid-encoded octopine synthase gene", J. Mol. Appl. Genet., 1:499-511. An example of such a terminator for expression in microbial hosts is the rho-independent transcription terminator sequence from <i>Salmonella typhimurium</i>. See, for example, M.E. Winkler, (1987), "<i>Escherichia coli</i> and <i>Salmonella typhimurium</i>: Cellular and Molecular Biology", F.C. Neidhardt, ed-in-chef; American Society for Microbiology. The gene terminator sequences may also be derived in part or in whole from terminator sequences found in cells unlike those of the host cell, as long as they meet the above criteria for transcription termination and polyadenylation required by the host cell.</p><p id="p0045" num="0045">Another type of regulatory element which may be attached to the gene for oxalate oxidase is a DNA sequence coding for a signal peptide. The signal peptide is attached to the amino terminus of the protein and permits the protein to be localised to the cell wall or secreted from the host cell. During this localisation process, the signal peptide is cleaved off, producing a protein product with the sequence of the mature protein. The DNA sequence for the signal peptide is inserted between the promoter and the coding region. Standard methods known in the art may be used to attach the DNA sequence for the signal peptide (See, for example, Maniatis, T., et al., supra, pp. 104-106). Examples of such signal sequences would include the signal peptide from an extension gene of plants (Chen, J. and Varner, J.E., an extracellular matrix protein in plants: characterization of a genomic clone for carrot extension". EMBO J 4:2145-2151, 1985) from the bacterial pelB (pectate lyase) gene of <i>Erwinia carotovora</i> (Lei, S.P. et al., (1987), J. Bacteriol. 169 4379) and from perpro factor of yeast (Smith, R.A., et al., Science 229:1219-1229, 1985). The signal peptide sequences may also be<!-- EPO <DP n="10"> --> derived in whole or in part from terminator sequences found in cells unlike those of the host cell, as long as they meet the above criteria for processing and localisation of the protein in the host cell.</p><p id="p0046" num="0046">Any of the various methods known for introducing foreign genes into plants could be used for insertion of the oxalate oxidase gene into a host plant. The methodology chosen to accomplish plant transformation with the oxalate oxidase gene would vary depending on the host plant. By way of example, one well-characterized methodology that would be useful for plant transformation with the oxalate oxidase gene would be Agrobacterium mediated transformation.</p><p id="p0047" num="0047">Agrobacterium mediated transformation using the oxidase gene follows the procedures well-known for this methodology. First, a gene cassette suitable for expression in plants is introduced into a disarmed strain of <i>Agrobacterium tumefaciens</i> as an intermediate host. The oxalate oxidase gene cassette is introduced into the T-DNA region of a recombinant plasmid containing a selectable marker gene such as a gene encoding for neomycin phosphotransferese II, phosphinothricin acetyl transferase or the like. This methodology is set forth in many literature publications including Horsch, et al., (1985),. "A Simple and General Method for Transferring Genes Into Plants", Science 227:1229-1231. Pieces of plant tissue, eg leaf, cotyledon or hypocotyl are co-incubated with the bacteria for 2-3 days before the bacteria are killed using antibiotics such as carbenicillin. Additional antibiotics corresponding to the selectable marker gene employed are included in the plant tissue culture medium such that only transformed plant cells will grow.</p><p id="p0048" num="0048">Plants regenerated from the transformed cells are then tested for the presence and expression of the oxalate oxidase gene. Immuno assays and test for oxalate oxidase activity can be used to identify individual transformants. Tolerance to exogenous oxalic acid can also be used as a functional test of intact tissues.</p><p id="p0049" num="0049">As noted, several other methodologies are available for plant transformation apart from Agrobacterium transformation. Examples of these other DMA delivery methods include electroporation, ie chemically induced delivery into protoplasts, micro-injected, biolostics as well as others. An example of a type of plant that is not especially suitable for Agrobacterium-mediated transformation are soybean and certain cereals including maize. These plants would plainly benefit from plant transformation attempts using methodologies other than Agrobacterium-mediated transformation.</p><p id="p0050" num="0050">The drawings which accompany this description are as follows:<ul id="ul0001" list-style="none" compact="compact"><li>Figure 1 shows a cDNA sequence reverse engineered from the mRNA coding for barley seedling oxalate oxidase.</li><li>Figure 2 shows the amino acid sequence translated from the cDNA shown in Figure 1.</li><li>Figure 3 shows diagrammatically the cloning strategy used to clone the oxalate oxidase gene and described in detail in Examples 1 and 2 hereinbelow.</li><li>Figure 4 shows diagrammatically the cloning strategy described in Examples 3 and 4 below.</li><li>Figure 5 shows the structure of plasmid pVB1, and,</li><li>Figure 6 shows the structure of plasmid pBin19i.</li></ul></p><p id="p0051" num="0051">The invention will now be described, by way of illustration, in the following Examples.<!-- EPO <DP n="11"> --></p><heading id="h0001"><b>EXAMPLE 1</b></heading><p id="p0052" num="0052"><b>Construction of an oxalate oxidase non-secretion vector for tomato transformation.</b></p><heading id="h0002"><b>(a) Reconstruction of a full length oxalate oxidase open reading frame (ORF).</b></heading><p id="p0053" num="0053">Oligonucleotides 1219901A and 1219901A(compl) were designed and synthesised to form a linker with a HindIII site at the 5' end and a BsaI site at the 3' end.oligo 1219901A:5'-<img id="ib0002" file="imgb0002.tif" wi="151" he="21" img-content="dna" img-format="tif"/></p><p id="p0054" num="0054">The oligonucleotides were annealed and cloned into clone #22 cut with HindIII and partially with BsaI to produce the clone pOXOX1 containing the mature oxalate oxidase ORF as indicated by peptide sequencing.</p><p id="p0055" num="0055">After cloning of the HindIII/BsaI linked into clone #22, the integrity of the mature oxalate oxidase ORF was confirmed by DNA sequencing.</p><heading id="h0003"><b>(b) Insertion of the oxalate oxidase ORF into an expression vector.</b></heading><p id="p0056" num="0056">The mature oxalate oxidase coding region was isolated from agarose as a 700 bp HindIII/BamHI fragment and the ends were made blunt with T4 DNA polymerase. pNB33A was cut with XbaI and PstI, the vector fragment was isolated from agarose and the ends made blunt with T4 polymerase.</p><p id="p0057" num="0057">These two blunt ended fragments were ligated together to produce the clone pNBOXOX1. The correct orientation of the oxalate oxidase coding region in pNBOXOX1 was confirmed by DNA sequencing.</p><heading id="h0004"><b>(c) Transfer of the oxalate oxidase expression cassette into pBin19Ri.</b></heading><p id="p0058" num="0058">pBNOXOX1 was cut with HindIII and partially with EcoRI. The 1.9 kb expression cassette was isolated from agarose and cloned into pBin19Ri (Figure 6) cut with EcoRI and HindIII to give clone pNOX1.</p><p id="p0059" num="0059">The presence of the oxalate oxidase expression cassette in clone pNOX1 was confirmed by restriction of plasmid DNA with EcoRI and HindIII.</p><heading id="h0005"><b>EXAMPLE 2</b></heading><p id="p0060" num="0060"><b>Construction of an oxalate oxidase non-secretion vector for sunflower transformation.</b></p><heading id="h0006"><b>(a) Transfer of the oxalate oxidase expression cassette into pVB1.</b></heading><p id="p0061" num="0061">The 2.1 kb EcoRI/HindIII fragment containing the oxalate oxidase expression cassette isolated from pNBOXOX1, described in Example 1 above, was cloned into pVB1 (Figure 5) cut with EcoRI and HindIII to give clone pVBOX1.</p><p id="p0062" num="0062">The presence of the oxalate oxidase expression cassette in clone pVBOX1 was confirmed by restriction of plasmid DNA with EcoRI and HindIII.</p><heading id="h0007"><b>(b) Insertion of the Hygromycin resistance gene into pVBOX1.</b></heading><p id="p0063" num="0063">A 2.3 kb HindIII fragment containing the Hygromycin resistance cassette was isolated from p19HYG and cloned into pVBOX1 cur with HindIII to give clone pHOX1.</p><p id="p0064" num="0064">The presence and orientation of the Hygromycin cassette in clone pHOX1 was confirmed by digestion of plasmid DNA with EcoRI.</p><heading id="h0008"><b>EXAMPLE 3</b></heading><p id="p0065" num="0065"><b>Construction of an oxalate oxidase secretion vector for tomato transformation.</b><!-- EPO <DP n="12"> --></p><heading id="h0009"><b>(a) Production of an extensin transit peptide/oxalate oxidase fusion by PCR.</b></heading><p id="p0066" num="0066">In order to fuse the mature oxalate oxidase to an extensin transit peptide, oligonucleotides EXTOX-5 and EXTOX-3 were designed and synthesised.EXTOX-55'-<img id="ib0003" file="imgb0003.tif" wi="150" he="21" img-content="dna" img-format="tif"/></p><p id="p0067" num="0067">The oligonucleotides were used as PCR primers with pNBOX1 as template. The resulting 771bp EXTOX PCR product containing a 23 amino acid extensin transit peptide fused in frame to the mature oxalate oxidase coding region was cut with KpnI.</p><heading id="h0010"><b>(b) Insertion of the EXTOX PCR product into pJR1(pUC).</b></heading><p id="p0068" num="0068">The KpnI digested EXTOX PCR product described above was cloned into pJR1(pUC) cut with KpnI to give the clone pJEXTOX1. The orientation and sequence of the EXTOX PCR product in pJEXTOX1 was confirmed by DNA sequencing.</p><heading id="h0011"><b>(c) Transfer of the EXTOX expression cassette into pBin19i.</b></heading><p id="p0069" num="0069">The extensin/oxalate oxidase expression cassette was isolated from pJEXTOX1 as a 1.5 kb EcoRI/HindIII fragment and cloned into pBin19i cut with EcoRI and HindIII to produce the clone pNEXTOX1.</p><p id="p0070" num="0070">The presence of the expression cassette in pNEXTOX1 was confirmed by digestion of plasmid DNA with EcoRI and HindIII.</p><heading id="h0012"><b>EXAMPLE 4</b></heading><p id="p0071" num="0071"><b>Construction of an oxalate oxidase secretion vector for sunflower transformation.</b></p><heading id="h0013"><b>(a) Isolation of the secretion expression cassette and insertion into pVB1.</b></heading><p id="p0072" num="0072">The extensin/oxalate oxidase expression cassette was isolated from pJEXTOX1 as a 1.5 kb EcoRI/HindIII fragment and cloned into pVB1 cut with EcoRI and HindIII to produced the clone pVEXTOX1.</p><p id="p0073" num="0073">The presence of the expression cassette in pVEXTOX1 was confirmed by digestion of plasmid DNA with EcoRI and HindIII.</p><heading id="h0014"><b>(b) Insertion of the Hygromycin resistance gene into pVEXTOX1.</b></heading><p id="p0074" num="0074">A 2.3 kb HindIII fragment containing the Hygromycin resistance cassette was isolated from p19HYG and cloned into pVEXTOX1 cur with HindIII to give clone pHEXTOX1.</p><p id="p0075" num="0075">The presence and orientation of the Hygromycin cassette in clone pHEXTOX1 was confirmed by digestion of plasmid DNA with EcoRI.</p>
EP	0636181	B1	2000-11-29	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A method of imparting the ability to degrade oxalate to a plant comprising inserting into the genome of the said plant by genetic transformation a gene encoding an oxalate oxidase.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A method as claimed in claim 1, in which the plant genome is transformed by a gene construct having a promoter sequence, a transit peptide, a structural gene sequence encoding said oxalate oxidase enzyme and a gene terminator sequence.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A method as claimed in claim 2 in which the structural gene sequence comprises the DNA sequence of Figure 1.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A method of combating plant pathogenesis by infection with a fungus which secretes oxalic acid, comprising stably incorporating into the genome of said plant by transformation a gene encoding oxalate oxidase.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A method as claimed in claim 4 in which the fungus is of a genus selected from the group of oxalic acid secreting fungi comprising Sclerotinia, Selerotium, Aspergillus, Streptomyces, Penicillium, Pythium, Paxillus, Mycena, Leucostoma, Rhizoctonia, and Schizophyllum.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A method as claimed in claim 5 in which the fungus is <u><i>Sclerotinia sclerotorum.</i></u></claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A method as claimed in claim 5 or 6 in which the plant is sunflower (<i><u>Helianthus</u> an<u>nuus</u></i>)</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A plant having stably incorporated within its genome by transformation a gene encoding oxalate oxidase.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A plant cell having stably incorporated within its genome by transformation a gene encoding oxalate oxidase.</claim-text></claim>
EP	0636181	B1	2000-11-29	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zum Ãœbertragen der FÃ¤higkeit zum Abbau von Oxalat auf eine Pflanze, umfassend das Insertieren eines Gens, das eine Oxalatoxidase kodiert, in das Genom der Pflanze durch genetische Transformation.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 1, worin das Pflanzengenom durch ein Genkonstrukt mit einer Promotorsequenz, einem Transitpeptid, einer Strukturgen-Sequenz, die das das Oxalatoxidase-Enzym kodiert, und einer Genterminator-Sequenz transformiert wird.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 2, worin die Strukturgen-Sequenz die DNA-Sequenz der Figur 1 umfaÃŸt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verfahren zur BekÃ¤mpfung von Pflanzenpathogenese durch Infektion mit einem Pilz, der OxalsÃ¤ure absondert, umfassend das stabile Einbauen eines Oxalatoxidase kodierenden Gens durch Transformation in das Genom der Pflanze.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 4, worin der Pilz aus einer Gattung stammt, die aus der Gruppe OxalsÃ¤ure absondernder Pilze ausgewÃ¤hlt ist, umfassend Sclerotinia, Sclerotium, Aspergillus, Streptomyces, Penicillium, Pythium, Paxillus, Mycena, Leucostoma, Rhizoctonia und Schizophyllum.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 5, worin der Pilz Sclerotinia sclerotorum ist.<!-- EPO <DP n="15"> --></claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verfahren gemÃ¤ÃŸ Anspruch 5 oder 6, worin die Pflanze die Sonnenblume ist (Helianthus annuus).</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Pflanze mit einem in ihrem Genom durch Transformation stabil eingebauten, Oxalatoxidase kodierenden Gen.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Pflanzenzelle mit einem in ihrem Genom durch Transformation stabil eingebauten, Oxalatoxidase kodierenden Gen.</claim-text></claim>
EP	0636181	B1	2000-11-29	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>ProcÃ©dÃ© pour confÃ©rer l'aptitude Ã  dÃ©grader un oxalate Ã  une plante comprenant l'insertion dans le gÃ©nome de ladite plante par transformation gÃ©nÃ©tique d'un gÃ¨ne codant une oxalate oxydase.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>ProcÃ©dÃ© suivant la revendication 1, dans lequel le gÃ©nome de la plante est transformÃ© avec une construction de gÃ¨ne ayant une sÃ©quence promoteur, un peptide transitoire, une sÃ©quence de gÃ¨ne structurale codant ladite enzyme oxalate oxydase et une sÃ©quence terminateur du gÃ¨ne.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>ProcÃ©dÃ© suivant la revendication 2, dans lequel la sÃ©quence de gÃ¨ne structurale comprend la sÃ©quence d'ADN de la figure 1.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>ProcÃ©dÃ© pour combattre une pathogenÃ¨se vÃ©gÃ©tale par infection avec un champignon qui sÃ©crÃ¨te de l'acide oxalique, comprenant l'incorporation de faÃ§on stable dans le gÃ¨ne de ladite plante par transformation d'un gÃ¨ne codant une oxalate oxydase.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>ProcÃ©dÃ© suivant la revendication 4, dans lequel le champignon est un genre choisi dans le groupe de champignons sÃ©crÃ©tant de l'acide oxalique comprenant <i>Sclerotinia, Sclerotium, Aspergillus, Streptomyces, Penicillium, Pythium, Paxillus, Mycena, Leucostoma, Rhizoctonia</i> et <i>Schizophyllum.</i></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>ProcÃ©dÃ© suivant la revendication 5, dans lequel le champignon est <i>Sclerotinia sclerotorum.</i></claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>ProcÃ©dÃ© suivant les revendications 5 ou 6, dans lequel la plante est le tournesol (<i>Helianthus annuus</i>).</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Plante dans le gÃ©nome de laquelle est incorporÃ© de faÃ§on stable par transformation un gÃ¨ne codant une oxalate oxydase.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Cellule vÃ©gÃ©tale dans le gÃ©nome de laquelle est incorporÃ© de faÃ§on stable par transformation un gÃ¨ne codant une oxalate oxydase.</claim-text></claim>
EP	0636181	B1	2000-11-29	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0636181&ki=B1&pd=2000-11-29
EP	0605422	B1	2000-03-08	de	TITLE	1	SICHERHEITSEINRICHTUNG FÃœR SPRITZE MIT RADIAL DEFORMIERBAREM KÃ–RPER
EP	0605422	B1	2000-03-08	en	TITLE	1	SAFETY SYRINGE ASSEMBLY WITH RADIALLY DEFORMABLE BODY
EP	0605422	B1	2000-03-08	fr	TITLE	1	ASSEMBLAGE DE SERINGUE DE SECURITE AVEC CORPS DEFORMABLE RADIALEMENT
EP	0605422	B1	2000-03-08	en	DESCR	1	<heading id="h0001">BACKGROUND OF THE INVENTION</heading><p id="p0001" num="0001">The need for preventing inadvertent needle sticks has been recognized for many years. For example, U.S. Patent No. 2,571,653 to Bastien shows a syringe in which the barrel of the syringe is mounted within a protective sheath. The sheath can be placed at different axial positions relative to the barrel, one exposing the needle for use and one covering the needle for safety. Many other safety syringe assemblies have been developed as well (see in particular document GB-A-2202747). However, one of the problems with the prior art safety syringe assemblies is that they generally cannot be used with conventional syringes, are awkward to use and make calibrations and volume graduations difficult to see clearly. Also, existing safety syringe assemblies often are not economical to produce; this is especially true when the syringe structures are intended to be disposable.</p><heading id="h0002">SUMMARY OF THE INVENTION</heading><p id="p0002" num="0002">The present invention is directed to a syringe assembly, particularly useful for use with conventional prefilled pharmaceutical cartridge-needle units, including a hollow body housing the cartridge-needle unit or other syringe structure. The hollow body and the syringe structure include mating positioning elements to permit the syringe structure to be secured at one or more axial positions within the body. The positioning elements are preferably radially extending recesses and extensions. The hollow body typically has at least two internal recesses sized and positioned to engage a radially extending member carried by the syringe structure so that the<!-- EPO <DP n="2"> --> needle can be partially or totally exposed for use and then withdrawn into the body for safety. The body is configured so that when the user squeezes the body at positions diametrically adjacent the recess, the radially extending member becomes disengaged from the recess due to the deformation of the body. This frees the needle permitting it to be repositioned within the body.</p><p id="p0003" num="0003">The body is constructed so that the body may be deformed to permit the radially extending member to freely move from the recess to permit the syringe structure and body to move axially relative to one another. This may be achieved by constructing the body with an elliptical cross-sectional shape and forming pairs of the recesses through the walls of the body while constructing the radially extending member as an annular, outwardly extending ring carried by the syringe structure. The radially extending member can be disengaged from the recesses by squeezing the body to deform the body from the generally elliptical shape to a generally circular shape. Preferably, three sets (or four sets to permit one molded body to accommodate both short and long needle lengths) of axially spaced-apart recesses are provided. One recess near the distal end of the body for I.M. (IntraMuscular) injections. An intermediate recess (or two to accommodate both long and short needle cannula) such that the tip of the needle is within the interior of the body may be used for safer disposal. Also, this position may be used for I.V. (IntraVenous) port injection. By properly sizing the opening at the distal end of the body, the body may be placed over the injection valve of an I.V. port, permitting the sharpened point of the needle cannula to pierce the membrane port only after this sharpened point has been shielded from human contact. This permits I.V. port injection with a high degree of safety and efficacy. The recess or recesses closest to the plunger end of the body are used to ensure the needle tip is well within the body for safe disposal of the syringe structures.</p><p id="p0004" num="0004">One of the primary advantages of the invention is that it permits the needle of a syringe structure to be safely housed within the body in an extremely simple and cost<!-- EPO <DP n="3"> --> effective manner. In addition, although the invention can be used with conventional syringes, the invention finds particular utility when used with prefilled pharmaceutical cartridge-needle units. In such case, the body can be part of an enclosure unit, the enclosure unit acting as both the protective packaging for the cartridge-needle unit, and also as a part of the operational syringe assembly itself.</p><p id="p0005" num="0005">Other features and advantages will appear from the following description in which the preferred embodiments have been set forth in detail in conjunction with the accompanying drawings.</p><heading id="h0003">BRIEF DESCRIPTION OF THE DRAWINGS</heading><p id="p0006" num="0006"><ul id="ul0001" list-style="none" compact="compact"><li>FIG. 1 is a side cross-sectional view of an enclosure unit made according to the invention;</li><li>FIG. 2 is an isometric view of a set of the enclosure units of FIG. 1;</li><li>FIG. 3 shows the enclosure unit of FIG. 1 after the adapter has been driven into the body section at the needle end of the body section;</li><li>FIG. 4 illustrates a syringe assembly made according to the invention by mounting a cartridge-needle unit mounted within the body section of the enclosure unit of FIG. 3 with the cap at the end section used to plug the end section to maintain the cartridge-needle unit within the enclosure unit and help prevent tampering;</li><li>FIG. 5 illustrates the syringe assembly of FIG. 4 after the end unit has been separated from the body section and discarded and the stem section has been separated from the adapter and mounted to the piston at the plunger end of the barrel of the cartridge-needle unit;</li><li>FIG. 6 illustrates the syringe assembly of FIG. 5 after the sheath has been removed from the needle and the plunger has been depressed, injecting the contents of the barrel through the needle;</li><li>FIG. 7A is a cross-sectional view taken along line 7-7 of FIG. 6 showing the elliptical cross-sectional shape of the body section and the engagement of the adapter ring with<!-- EPO <DP n="4"> --> the circumferential extending body slots formed in the body section at the needle end of the body section;</li><li>FIG. 7B illustrates the syringe assembly of FIG. 7A after the user has deformed the body section by squeezing the body section as indicated to disengage the adapter ring from the body slots to permit the cartridge-needle unit to be moved axially within the body section;</li><li>FIG. 8 illustrates the movement of the cartridge-needle unit from the use position of FIG. 6, with the needle exposed, to the safe position of FIG. 8, with the needle fully housed within the body section, and also illustrates how the syringe assembly of FIGS. 6 and 8 could be used to inject a medicine into, or remove a sample from, an injection arm of an IV port while keeping the sharpened tip of the needle in a safe position;</li><li>FIG. 9A is an enlarged view taken along line 9A of FIG. 8 illustrating the engagement of a standard adapter ring within a body slot;</li><li>FIG. 9B shows an alternative embodiment of the adapter ring of FIG. 9A in which the plunger facing surface of the ring provides a ramp effect to enhance movement of the cartridge-needle unit towards the plunger end of the body section;</li><li>FIG. 10 illustrates the syringe assembly of FIG. 6 in which the adapter ring is positioned within the body slots adjacent the plunger end of the body section to accommodate longer needles than used with the embodiment of FIG. 8;</li><li>FIGS. 11 and 12a illustrate alternative embodiments of the syringe structure of FIG. 8 adapted for use with different length needles and including different width body slots to accommodate different width adapter rings so the same body section can be used with needles of different lengths and still maintain the proper position of the tip of the needle for IV port use;</li><li>FIG. 12b is a partial side view of the syringe structure of FIG. 12a;</li><li>FIGS. 13 and 14 illustrate a further alternative embodiment of the invention in which the adapter ring does not<!-- EPO <DP n="5"> --> extend completely around the adapter to engage the appropriately positioned body slot for a short needle version of the cartridge needle unit;</li><li>FIGS. 15 and 16 show the embodiment of FIGS. 13 and 14 with a long needle version of the cartridge-needle unit and with an adapter ring positioned to the opposite side of the body section as in the embodiment of FIG. 13, so that the adapter ring of the embodiments of FIGS. 13 and 15 engage the appropriately intermediate position body slots located at different axial positions along the body section according to the lengths of the needles;</li><li>FIG. 17 illustrates a further embodiment of the invention in which the outer surface of the body section is normally cylindrical with the inner surface having internal flanges which engage a circumferential slot formed in an adapter mounted to the hub of the cartridge-needle unit;</li><li>FIG. 18A is a cross-sectional view of the syringe assembly of FIG. 17 taken along line 18-18 illustrating the engagement of the flanges into the annular slot;</li><li>FIG. 18B illustrates the syringe assembly of FIG. 18A after the body section has been deformed causing the flanges to disengage from the annular slot to permit the cartridge-needle unit to move axially within the body section;</li><li>FIG. 19 illustrates an alternative embodiment of the invention in which the syringe assembly of FIG. 4 has been modified to eliminate the need for a separate adapter by using a cartridge-needle unit in which the hub of the cartridge-needle unit is modified to include its own adapter ring;</li><li>FIG. 20 shows a further embodiment of the invention for use with smaller sized cartridge-needle units; and</li><li>FIG. 21 is a cross-sectional view taken along line 21-21 of FIG. 20.</li></ul></p><heading id="h0004">DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT</heading><p id="p0007" num="0007">FIG. 1 illustrates a one-piece molded enclosure unit 2, preferably made from clear polypropylene or polyethylene. Enclosure unit 2 includes elongate, substantially hollow body section 4 having a needle end 6, a<!-- EPO <DP n="6"> --> plunger end 8 and defining an interior 10 therein. Unit 2 also includes an end section 12 frangibly connected to plunger end 8 at frangible connections 14. End section 12 includes a cap 16 connected to the remainder of end section 12 by an integral hinge 18 to permit the end 20 of end section 12 to be oriented and sealed as suggested in FIG. 4.</p><p id="p0008" num="0008">Enclosure unit 2 also includes an adapter 22 extending from needle end 6 and attached thereto by frangible connections 24. Adapter 22 has a circumferentially extending adapter ring 26 sized to engage specially positioned pairs of body slots 28, 29, 30 formed in body section 4. The method and purpose for doing so will be discussed below. Finally, enclosure unit 2 also includes a hollow stem section 32 frangibly attached to adapter 22 by frangible connections 34. Stem section 32 is hollow to accommodate a sheathed (typically sterile) needle (see FIG. 4) and also has a threaded tip 36 to permit stem section 32, once removed from adapter 22, to be secured to a piston to create a plunger as suggested in FIG. 5. Adapter 22 is moved from the position of Fig. 1 to that of Fig. 3 by forcing stem section 32 in the direction of arrow 35, thus severing frangible connections 24, until ring 26 engages slots 28. Body section 4 includes a shoulder 37 at needle end 6. Shoulder 37 helps to keep adapter 22 from inadvertently passing back out of interior 10. Shoulder 37 may be a continuous shoulder, or it may be formed as diametrically opposed segments.</p><p id="p0009" num="0009">FIG. 2 illustrates a set 38 of enclosure units 2 molded as a one-piece item and secured to one another through frangible connections 40 at needle end 6 of body section 4 and by frangible connections (not shown) extending between the finger grips 42 at plunger ends 8. As discussed in the above-referenced application, set 38 of enclosure units 2 acts as both the protective shipping and storage container for cartridge-needle units 46, shown in Fig. 4, as well as providing other functions as discussed below.</p><p id="p0010" num="0010">FIG. 4 illustrates enclosure unit 2 with a conventional cartridge-needle unit 46, such as one made by Wyeth-Ayerst Laboratories of Radnor, Pennsylvania, under the<!-- EPO <DP n="7"> --> trademark TUBEX, mounted therein to create a syringe assembly 48 in its as-shipped condition. Cartridge-needle unit 46 is of the type including a barrel 50 containing a flowable material, typically a liquid, and having a piston 52, typically initially at the plunger end 54 of barrel 50. A needle assembly 56 is mounted to the needle end 58 of barrel 50. Needle assembly 56 includes a needle 60, having a sharpened tip 62, and a hub 64 used to mount needle 62 barrel 50. An elastomeric sheath 65 is used to cover needle 60 and seal tip 62. Hub 64 is secured within the interior 66 of adapter 22 through the engagement of a lip 68 (see FIG. 3) with the plunger facing edge 70 of hub 64. As suggested by arrow 72, once cartridge-needle unit 46 is mounted within enclosure unit 2, cap 16 is pivoted to close end 20 and is sealed in place, such as with an irreversible mechanical lock which is also tamper-resistent and tamper-evident, an adhesive or with heat or ultrasonic welding techniques. The thickness of cap 16 is sufficient to resist tampering with the contents of barrel 50 while syringe assembly 48 is in its as-shipped condition of FIG. 4. To further inhibit tampering, an internal metal shield could be used.</p><p id="p0011" num="0011">To use syringe assembly 48, stem section 32 is fractured from adapter 22, typically with a twisting action, and tip 36 is secured to piston 52, typically with a threading action as suggested by arrow 74 in FIG. 5. Next, sheath 65 is removed and the injection is given by driving plunger 76, made up of stem 32, piston 52 and thumb plate 53, as shown by arrow 78 of FIG. 6.</p><p id="p0012" num="0012">The present invention permits needle 60 to be withdrawn back into body section 4 in a simple, straightforward manner. As shown in FIG. 7A, body section 4 has an elliptical cross-sectional shape with body slots 28 positioned through the walls of body 4. This permits the outer circumference of adapter ring 26 to enter body slots 28 so long as body section 4 is in its normal, typically undeformed condition of FIG. 7A. To disengage adapter ring 26 from body slots 28 thereby permitting its axial movement, the user 79 squeezes body 4 as suggested by arrows 80 in FIG. 7B opposite body slot 28. The appropriate place to squeeze body section 4 is further aided by<!-- EPO <DP n="8"> --> the provision of three different sets of tactile bumps 82, 83, 84, shown in FIG. 2, opposite body slots 28, 29 and 30. Once body section 4 has been sufficiently deformed to release adapter ring 26, cartridge-needle unit 46 can be moved axially relative to body section 4 from the I.M. injection position of FIG. 6 to the I.V. injection position of FIG. 8, at which adapter ring 26 engages body slots 29. As can be seen in FIG. 8, body slots 29 are positioned so that tip 62 of needle 60 is within interior 10 of body section 4, but near needle end 6. Doing so permits syringe assembly 48 to be easily and safely used to inject a liquid into or withdraw a liquid from a membrane valve 86 of a conventional I.V. port 88 as shown in FIG. 8. The opening at needle end 6 is sized to properly guide injector arm 86 while eliminating any substantial possibility of an inadvertent needle stick during such a procedure.</p><p id="p0013" num="0013">FIG. 9A illustrates the engagement of adapter ring 26 within body slot 29. At FIG. 9B a modified adapter ring 26a is shown with a tapered plunger-facing surface 90. The use of surface 90 keeps adapter ring 26 snug within body slot 29 and also provides a ramp effect to make movement of adapter ring 26a towards plunger end 8 of body section 4 easier.</p><p id="p0014" num="0014">FIG. 10 illustrates a syringe assembly 48a identical to syringe assembly 48 but with a needle 60a being longer than needle 60. To properly position tip 62 relative to needle end 6, adapter 22 is positioned along body section 4 until adapter ring 26 engages body slots 30 rather than body slots 29.</p><p id="p0015" num="0015">FIGS. 12a and 11 illustrate further embodiments providing for the proper positioning of tips 62 of needles 60, 60a (the short and long needle versions, respectively). Short needle 60 is used with a conventional width adapter ring 26 as in FIG. 8. However, with syringe assembly 48b, shown in FIG. 11, extra width adapter ring 26b is used. Adapter ring 26b will engage body slots 28a, 29a and 30a but will not engage narrow width body slots 29. However, normal width adapter ring 26 can engage all of the body slots 28a, 29, 29a and 30a. Therefor, adapter ring 26b is repositioned from body slots 28a, past body slots 29 and into engagement with body slots 29a so to properly position tip 62. With syringe assembly 48c, shown<!-- EPO <DP n="9"> --> in FIG. 12, adapter ring 26 is initially positioned within body slots 29a (although somewhat loosely). Movement of adapter ring 26 from body slot 28a towards plunger end 8 allows adapter ring 26 to engage body slots 29 and thus properly position tip 62 in this case as well. FIG. 12b shows the use of an I.V. drip visual indicator 91 between body slots 29, 29a to show the user which body slot is to be used for use with an I.V. port 88. Other visual indicators or markings could be used adjacent the body slots used for I.M. injections and safe disposal.</p><p id="p0016" num="0016">FIGS. 13-16 illustrate another method by which different length needles can be accommodated, and also demonstrate that adapter ring 26 need not be a full circle. Syringe assembly 48d, illustrated in FIG. 13, uses a short length needle 60 while syringe assembly 48e uses long length needle 60a while both use a body section 4b. Body section 4b includes a pair of body slots 28, a single body slot 29b, a single body slot 29c and a pair of body slots 30b formed in a plunger end 8a. As can be seen in FIG. 14, adapter ring 26c is generally C-shaped and is sized to substantially impede or prevent rotation of adapter 22b within interior 10 of body section 4b when engaged within the body slot 29b. The axial and rotary position of body slot 29b is chosen to properly position tip 62 of needle 60. Similarly, with reference to FIGS. 15 and 16, adapter 22c has its adapter ring 26d positioned 180Â° from adapter ring 26c of FIG. 14 so that adapter ring 26d engages body slot 29c rather than slot 29b so tip 62 of needle 60a is also properly positioned relative to needle end 6 of body section 4b.</p><p id="p0017" num="0017">In both embodiments of FIGS. 13 and 15, plunger end 8a is thickened or strengthened. This helps to rigidify body section 4b at body slots 30a so that once adapter rings 26c, 26d enter body slots 30a, it will be quite difficult to squeeze plunger end 8a of body section 4b with sufficient force to disengage the adapter ring from the body slot.</p><p id="p0018" num="0018">FIGS. 17, 18A and 18B illustrates a situation in which the body slots 28, 29 and 30 are replaced by flanges 92, 93, 94 which engage an annular slot 96 formed in adapter 22d. The disengagement of flanges 92 from slot 96 occurs in the same<!-- EPO <DP n="10"> --> manner as discussed with reference to FIGS. 7A and 7B. That is, the user squeezes body section 4c as shown by arrows 80 to cause the disengagement of flanges 92 from slot 96. This permits the relative axial movement of adapter 22d within body section 4c so to reposition needle 60 within the interior 10 of the body section.</p><p id="p0019" num="0019">FIG. 19 illustrates a still further alternative embodiment of the syringe assembly 48 of FIG. 4. Syringe assembly 48f is similar to syringe assembly 48 except that adapter 22 is replaced by providing an adapter ring 26e as an integral part of hub 64a. This eliminates the need for adapter 22, but likely requires modification of a conventional cartridge-needle unit.</p><p id="p0020" num="0020">Turning now to FIGS. 20 and 21, a syringe assembly 48g is shown adapted for use with a smaller sized cartridge-needle unit 46a. One distinction between syringe assembly 48g and syringe assembly 48 is the use of an extended length adapter 22e, a portion 98 of which extends past finger grips 42 to permit user 79 to grasp portion 98 when placing the assembly into an I.V. injection or a safe disposal condition.</p><p id="p0021" num="0021">Body section 4c of syringe assembly 48g includes a pair of inwardly biased fingers 100 having protrusions 102 shaped to conform to the outer surface of portion 98 of adapter 22e. This helps to center adapter 22e, and cartridge-needle unit 46a therewith, within interior 10 of body section 4c. Fingers 100 could also be used to center and stabilize cartridge-needle unit 46 in the other embodiments.</p><p id="p0022" num="0022">Other modifications and variations can be made to disclosed embodiments without departing from the subject of the invention as defined in the following claims. For example, the invention is particularly adapted for use with a cartridge-needle unit. However, the invention is also adaptable for use with syringes and can be used with separately packaged cartridges and cartridge-needle units as well. While most of the disclosed embodiments use an elliptically shaped body section, the body section could, however, be another shape, such as generally triangular, as well. The deformation of the body section could also be created by twisting or rotating the<!-- EPO <DP n="11"> --> adapter ring (or other radially extending member) to cause the radially extending member to disengage from a body slot. However, doing so would require the appropriate rotary manipulation of the pieces in addition to axial manipulation. While enclosure unit 2 is, in the preferred embodiment, a one-piece molded structure, it may be desireable to make it from two or more pieces. For example, it may be desireable to make adapter 22 and cap 16 as separate pieces. Also, it may be desired to mount adapter 22 to hub 64 prior to positioning the cartridge-needle unit within the body section.</p>
EP	0605422	B1	2000-03-08	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>Syringe assembly comprising:<claim-text>a syringe structure;</claim-text><claim-text>the syringe structure including a first positioning element;</claim-text><claim-text>a hollow body (4) housing at least a portion of the syringe structure; and</claim-text><claim-text>the body (4) including an inner surface having a second positioning element formed thereat, the first and second positioning elements sized for mating engagement when aligned so to prevent relative axial movement of the body and the syringe structure;</claim-text><claim-text>characterized in that one of the first and second positioning elements includes a radially extending circumferential member (26) extending around a substantial portion of the circumference thereof and the other of the first and second positioning elements includes at least one recess (28, 29,30) sized to accept the radially extending member (26) regardless of the relative rotary orientation of the syringe structure and the body;</claim-text><claim-text>the body (4) including means for permitting at least a part of the body to be deformed radially when the radially extending circumferential member (26) is to be removed from said at least one recess (28,29,30) to allow relative axial movement of the body and the syringe structure.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>Assembly according to claim 1 wherein the first positioning element includes said radially extending circumferential member (26).</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>Assembly according to claim 1 wherein the second positioning element includes said radially extending circumferential member (26).</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>Assembly according to any of claims 1 to 3 wherein the syringe structure includes a cartridge-needle unit (46) having a barrel (50), a piston (52) mounted within the barrel, and a needle assembly (56) mounted to the barrel.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>Assembly according to claim 4 wherein the syringe structure includes an adapter (22) mounted to the cartridge-needle unit, the adapter including the first positioning member.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>Assembly according to any of claims 1 to 5 wherein the radially extending member includes an annular ring (26).</claim-text></claim>
EP	0605422	B1	2000-03-08	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Ein Spritzenaufbau, der folgendes umfaÃŸt:<claim-text>eine Spritzenvorrichtung;</claim-text><claim-text>wobei die Spritzenvorrichtung ein erstes Positionierungselement einschlieÃŸt:</claim-text><claim-text>einen hohlen KÃ¶rper (4), der mindestens einen Abschnitt der Spritzenvorrichtung unterbringt; und</claim-text><claim-text>wobei der KÃ¶rper (4) eine InnenflÃ¤che einschlieÃŸt, die Ã¼ber ein daran ausgebildetes zweites Positionierungselement verfÃ¼gt, wobei das erste und zweite Positionierungselement fÃ¼r einen zusammenpassenden Eingriff dimensioniert sind, sobald sie ausgerichtet sind, um so die relative axiale Bewegung des KÃ¶rpers und der Spritzenvorrichtung zu verhindern;</claim-text><claim-text>dadurch gekennzeichnet, daÃŸ eines der ersten und zweiten Positionierungselemente ein sich radial erstreckendes Umfangsglied (26) einschlieÃŸt, das sich um einen wesentlichen Abschnitt des Umfangs davon erstreckt, und das andere der ersten und zweiten Positionierungselemente mindestens einen Einschnitt (28, 29, 30) einschlieÃŸt, der dimensioniert ist, um unabhÃ¤ngig von der relativen Drehausrichtung der Spritzenvorrichtung und des KÃ¶rpers das sich radial erstreckende Glied (26) aufzunehmen;</claim-text><claim-text>wobei der KÃ¶rper (4) ein Mittel einschlieÃŸt, um mindestens einem Teil des KÃ¶rpers zu erlauben, radial verformt zu werden, wenn das sich radial erstreckende Umfangsglied (26) aus dem mindestens einen Einschnitt (28, 29, 30) entfernt werden soll, um die relative axiale Bewegung des KÃ¶rpers und der Spritzenvorrichtung zu gestatten.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Der Aufbau nach Anspruch 1, worin das erste Positionierungselement das sich radial erstreckende Umfangsglied (26) einschlieÃŸt.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Der Aufbau nach Anspruch 1, worin das zweite Positionierungselement<!-- EPO <DP n="14"> --> das sich radial erstreckendes Umfangsglied (26) einschlieÃŸt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Der Aufbau nach irgendeinem der AnsprÃ¼che 1 bis 3, worin die Spritzenvorrichtung eine Patronennadeleinheit (46) einschlieÃŸt, die Ã¼ber ein Kolbenrohr (50), einen innerhalb, des Kolbenrohrs angebrachten Kolben (52) und einen am Kolbenrohr angebrachten Nadelaufbau (56) verfÃ¼gt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Der Aufbau nach Anspruch 4, worin die Spritzenvorrichtung einen an der Patronennadeleinheit angebrachten Adapter (22) einschlieÃŸt, wobei der Adapter das erste Positionierungselement einschlieÃŸt.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Der Aufbau nach irgendeinem der AnsprÃ¼che 1 bis 5, worin das sich radial erstreckende Glied einen ringfÃ¶rmigen Ring (26) einschlieÃŸt.</claim-text></claim>
EP	0605422	B1	2000-03-08	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Ensemble formant seringue, comportant:<claim-text>une structure de seringue;</claim-text><claim-text>la structure de seringue (4) incluant un premier Ã©lÃ©ment de positionnement;</claim-text><claim-text>un corps creux (4) logeant au moins une partie de la structure de seringue; et</claim-text><claim-text>le corps (4) incluant une surface intÃ©rieure prÃ©sentant un second Ã©lÃ©ment de positionnement qui y est formÃ©, le premier et le second Ã©lÃ©ments de positionnement Ã©tant dimensionnÃ©s pour s'associer en venant en prise lorsqu'ils sont alignÃ©s de faÃ§on Ã  empÃªcher un mouvement axial relatif du corps et de la structure de seringue.</claim-text><claim-text>caractÃ©risÃ© par le fait que l'un des deux, du premier et du second Ã©lÃ©ments de positionnement, comporte un Ã©lÃ©ment circonfÃ©rentiel (26) s'Ã©tendant radialement et s'Ã©tendant autour d'une portion substantielle de sa circonfÃ©rence, et que l'autre des deux Ã©lÃ©ments de positionnement inclut au moins un Ã©videment (28, 29, 30) dimensionnÃ© pour recevoir l'Ã©lÃ©ment (26) s'Ã©tendant radialement, quelle que soit l'orientation angulaire relative de la structure de seringue et du corps;</claim-text><claim-text>le corps (4) incluant des moyens pour permettre de dÃ©former radialement au moins une partie du corps lorsqu'il faut sortir l'Ã©lÃ©ment circonfÃ©rentiel (26) s'Ã©tendant radialement hors dudit Ã©videment (28, 29, 30), dont il y a au moins un, pour permettre un mouvement axial relatif du corps et de la structure de seringue.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Ensemble selon la revendication 1, dans lequel c'est le premier Ã©lÃ©ment de positionnement qui inclut ledit Ã©lÃ©ment circonfÃ©rentiel (26) s'Ã©tendant radialement.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Ensemble selon la revendication 1, dans lequel c'est le second Ã©lÃ©ment de positionnement qui inclut ledit Ã©lÃ©ment circonfÃ©rentiel (26) s'Ã©tendant radialement.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Ensemble selon l'une quelconque des revendications 1 Ã  3, dans lequel la structure de seringue inclut un sous-ensemble cartouche-aiguille (46) comportant un cylindre (50), un piston (52)<!-- EPO <DP n="16"> --> montÃ© dans le cylindre, et un ensemble formant aiguille (56) montÃ© sur le cylindre.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Ensemble selon la revendication 4, dans lequel la structure de seringue inclut un adaptateur (22) montÃ© sur le sous-ensemble cartouche-aiguille, l'adaptateur incluant le premier Ã©lÃ©ment de positionnement.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Ensemble selon l'une quelconque des revendications 1 Ã  5, dans lequel, l'Ã©lÃ©ment s'Ã©tendant radialement inclut une bague annulaire (26).</claim-text></claim>
EP	0605422	B1	2000-03-08	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0605422&ki=B1&pd=2000-03-08
EP	0614422	B1	2000-03-22	de	TITLE	1	DOPPELKOLBENFEDERBEIN
EP	0614422	B1	2000-03-22	en	TITLE	1	DUAL PISTON STRUT
EP	0614422	B1	2000-03-22	fr	TITLE	1	JAMBE D'AMORTISSEUR A DEUX PISTONS
EP	0614422	B1	2000-03-22	en	DESCR	1	<p id="p0001" num="0001">This invention relates generally to suspension systems for land vehicles and, in a preferred embodiment thereof, to a liquid spring suspension system in which the spring and damping characteristics of each liquid spring are computer adjusted, during vehicle operation, in response to sensed variations in liquid spring and vehicle operating parameters.</p><p id="p0002" num="0002">Various proposals have been made for replacing the conventional hydraulic shock absorber and exterior coil spring assemblies in vehicular suspension systems with more compact devices known as liquid springs. A conventional liquid spring includes a cylindrical housing having an internal chamber with a compressible liquid therein, a piston reciprocally disposed in the chamber, a rod structure secured to the piston and axially movable into and out of the chamber, and having an external strut projecting outwardly of one of the housing ends. With the liquid spring operatively interconnected between the vehicle frame and an associated wheel support structure, the compressible working liquid generates both spring and damping forces in the suspension system in response to relative axial translation between the rod structure and housing of the<!-- EPO <DP n="2"> --> liquid spring caused by relative vertical displacement between the wheel and the frame.</p><p id="p0003" num="0003">The compressible working liquid permits the system to exhibit a non-linear force/deflection curve. This non-linear behavior is important because it offers lower spring rates during normal operation and higher spring rates when the vehicle strikes a bump. Non-linearity in the system is provided by the compressibility of the silicone-based working liquid, which is approximately 1.5 to 2 times more compressible than conventional hydraulic fluid. In operation, the non-linear system provides a spring rate which increases exponentially when the strut moves from its normal static position to full compression. This increase permits the suspension unit to absorb sharp bumps without bottoming out. In contrast, if the spring rate were linear, a substantially greater piston stroke would be required to enable the suspension unit to absorb comparable bounce forces.</p><p id="p0004" num="0004">Conventional liquid spring suspensions can be tuned and readily adjusted for differing vehicle weights (springing force) and different ride characteristics (dampening). It will be appreciated that non-linear struts that utilize a compressible working liquid for both springing and dampening have a potential for superior performance.</p><p id="p0005" num="0005">Various arrangements have been proposed for selectively adjusting the spring force and/or damping force characteristics of liquid springs to settings which remain essentially constant during vehicle operation until readjusted when the vehicle is at rest. These essentially fixed spring force and damping force characteristics represent at best compromise settings adapted to handle an often wide range of road conditions and vehicle operational inputs (such as steering input, braking forces, vehicle<!-- EPO <DP n="3"> --> speed and the like) encountered during operation of the vehicle.</p><p id="p0006" num="0006">Conventional non-linear suspension systems, for example gas-over-oil systems, are too bulky and heavy for certain commercial and military vehicles. There is a continuing interest in reducing the size and weight of such non-linear suspension systems, as well as improving the operational performance.</p><p id="p0007" num="0007">Examples of the general structure and operation of a liquid spring incorporated in a vehicular suspension system are disclosed in the following U.S. patents:<ul id="ul0001" list-style="none" compact="compact"><li>4,741,516â€ƒâ€ƒâ€ƒ4,877,222</li><li>4,735,402â€ƒâ€ƒâ€ƒ4,652,008</li></ul></p><p id="p0008" num="0008">UK Patent Application No. 2,159,604 discloses an adjustable hydraulic damper having a working chamber divided into upper and lower chambers. The upper and lower chambers are permitted bypass flow to a compensating chamber when an extension phase valve is extended. A modulation chamber is coupled to an external pressure source for modulating the pressure of the various chambers. There is a fixed tube which guides a piston assembly, but its upper end is not sealed against a control tube partially filled with compressed gas and oil. The working chamber is not divided into bounce and rebound chambers, as defined in Applicant's described<!-- EPO <DP n="4"> --> embodiments.</p><p id="p0009" num="0009">The principal object of the present invention is to provide an improved liquid spring vehicular suspension system in which the spring force and damping force characteristics of the liquid springs are automatically adjusted, during vehicle operation, to compensate for variations in both road conditions, vehicle load changes and vehicle operational inputs, or any combination thereof.</p><p id="p0010" num="0010">In a particular embodiment, illustrative of the present invention, and to be described below, by way of example, the spring and damping force characteristics of each liquid spring of a vehicular suspension system are continuously computer adjusted during vehicle operation in response to sensed variations in either or both liquid spring and vehicle operating parameters.</p><p id="p0011" num="0011">Each liquid spring of the particular embodiment has a main cylinder housing having a pressure chamber formed therein in which a dual piston assembly is reciprocally disposed and axially divides the main pressure chamber into bounce and rebound chambers. The dual piston assembly includes a support piston secured to the main housing and<!-- EPO <DP n="5"> --> coaxially disposed within the main pressure chamber. A separation piston head is coaxially secured to the static support piston and is slidably and sealingly engaged against the main housing chamber bore for axial movement relative thereto into and out of the pressure chamber. The separation piston head is secured to a tubular piston which includes a tubular strut portion which projects outwardly of the housing and which has a longitudinal bore defining a pressure modulation chamber.</p><p id="p0012" num="0012">A compressible working liquid is disposed within the bounce and rebound chambers and within the pressure modulation chamber of the tubular piston. An annular flow passage is defined in the annulus between the static support piston and the tubular piston. Flow transfer ports are formed radially through the tubular piston closely adjacent the rebound chamber side of the separator piston head, and radially extending flow transfer ports are formed through the static support piston in communication with the bounce and rebound chambers, respectively. The static support piston is intersected by a longitudinal flow passage which is coupled in flow communication with the bounce and rebound chambers by the flow transfer ports. A rotary metering valve is interposed between the bounce and rebound chambers and is independently operable to respectively meter compressible liquid flow therebetween. The piston modulation chamber is coupled in flow communication with the bounce chamber through a check valve.</p><p id="p0013" num="0013">Each of the liquid springs has its cylinder housing piston secured to an associated wheel structure, and has its strut secured to the vehicle frame in a manner such that vertical deflection of the wheel structure relative to the frame causes relative axial displacement between the rod structure and the housing and causes the compressible working liquid to exert spring and dancing forces that yieldingly and reactively resist vertical wheel displacement. Control means are provided and are respectively operable to selectively and independently operate the rotary metering valve to meter compressible liquid flow through the piston rod ports, to selectively vary the effective volume of<!-- EPO <DP n="6"> --> the compressible liquid and to selectively vary the pressure of the compressible liquid in the bounce and rebound chambers by modulating the pressure of the compressible liquid in the modulation chamber.</p><p id="p0014" num="0014">Means are provided for generating liquid spring operating parameter signals including a first signal indicative of the relative axial position of the piston within the housing chamber, and a second signal indicative of the compressible liquid pressure in the bounce chamber. Additionally, means are provided for generating vehicle operating parameter signals which representatively include signals indicative of the sense and magnitude of steering input to the vehicle, the speed of the vehicle, and the braking force being exerted on the vehicle.</p><p id="p0015" num="0015">Computer means receive the liquid spring operating parameter signals, and the vehicle operating parameter signals, and responsively generate output signals that are used to operate the metering valve and a proportional flow control valve in a manner automatically adjusting the spring and damping characteristics of each liquid spring to maintain a desired ride height deflection and optimum damping force to maximize ride performance characteristics.</p><p id="p0016" num="0016">The following description and drawings disclose, by means of an example, the invention which is characterised in the appended claims, whose terms determine the extent<!-- EPO <DP n="7"> --> of the protection conferred hereby.</p><p id="p0017" num="0017">In the drawings:-<ul id="ul0002" list-style="none" compact="compact"><li>Figure 1 is a longitudinal view, and full section, of a dual piston strut constructed according to the teachings of the present invention;</li><li>Figure 2 is an enlarged view, partially broken away, showing the relative position of the dual piston components in the maximum ride height deflection position;</li><li>Figure 3 is similar to Figure 2 showing the relative positions of the dual piston components illustrating the relative positions of the dual piston components in response to bounce extension of the main tubular piston relative to the static support piston;</li><li>Figure 4 is a simplified electrical, hydraulic and mechanical schematic diagram which illustrates interconnection of the various components of a liquid spring suspension system constructed according to a preferred embodiment of the present invention;</li><li>Figure 5 is a simplified sectional view of a metering valve taken through the line 5-5 of Figure 3; Figure 6 is a performance curve which illustrates strut deflection as a function of dynamic loading;</li><li>Figure 7 is a simplified schematic diagram showing the liquid spring of Figure 1 in a double wishbone (A-frame) assembly;</li><li>Figure 8 is a sectional view of the double wishbone<!-- EPO <DP n="8"> --> (A-frame) assembly of Figure 7 taken along the line 8-8.</li></ul></p><p id="p0018" num="0018">In the description which follows, like parts are marked throughout the specification and drawings with the same reference numerals, respectively. The drawing figures are not necessarily drawn to scale and the proportions of certain parts have been exaggerated for purposes of clarity.</p><p id="p0019" num="0019">Referring now to Figure 1 and Figure 4, an improved liquid spring vehicular suspension system 10 incorporates a generally vertically oriented dual piston liquid spring 12 at each wheel 14 of the vehicle. The liquid spring 12 is adapted for attachment at its upper end to a vehicle frame F, and at its lower end to the axle spindle 16 of its associated wheel 14. The liquid spring 12 is operable to provide the requisite suspension spring and damping<!-- EPO <DP n="9"> --> forces at each wheel location. As described below, the liquid spring 12 is controlled by a computer 18 which continuously and automatically adjusts key operational aspects of the liquid spring 12 in response to sensed variations in selected vehicle and liquid spring operating parameters.</p><p id="p0020" num="0020">The liquid spring 12 includes an elongated main cylinder housing 20 having an upper housing end 20A and a lower housing end 20B. A spherical bearing 22 is secured to the lower housing end 20B and is connected to the wheel support structure 16 as shown in Figure 4. A spherical bearing 24 is secured to a cylindrical housing boot 26 in which the main housing 20 is telescopically received. The spherical bearing assembly 24 is adapted for attachment to a vehicle frame (not shown). An annular gland member 28 is connected into the upper housing end 20A of the main cylinder housing 20 by a threaded union T. Interposed between the gland 28 and the upper housing sidewall 20A is an annular, elastomer seal 30. The main cylinder housing 20 has a cylindrical bore 22 which defines a pressure chamber 34 for receiving compressible silicone-based working liquid.</p><p id="p0021" num="0021">A dual piston assembly 36 is reciprocally disposed in and axially divides the main pressure chamber 34 into a bounce chamber 38 and a rebound chamber 40. The dual piston assembly 36 includes a static support piston 42 which is secured to the lover end 20B of the main housing 20 and is coaxially disposed within the main pressure chamber 34. A separation piston head 44 is coaxially secured to the static support piston 42 and is slidingly and sealingly engaged against the main housing chamber bore 32 for axial extension and retraction movement relative thereto into and out of the pressure chamber 34. The separation piston head 44 is sealed against the main housing chamber bore 32 by an annular seal 46. The separation piston head 44 is attached to a tubular piston 48 having a longitudinal bore 50 defining a pressure modulation chamber 52. The tubular piston 48 has a tubular strut portion 485 projecting outwardly of the main cylinder housing 20 and is mechanically connected to the housing boot 26 and the spherical<!-- EPO <DP n="10"> --> bearing 24.</p><p id="p0022" num="0022">The upper end of the support piston 42 is received in telescoping engagement within the bore 50 of the tubular piston 48. As can best be seen in Figure 3, a damping flow annulus 54 is formed between the overlapping end portions of the static support piston 42 and the tubular piston 48. The annulus 54 between the static support piston and the tubular piston is sealed by an annular gland seal 56. The tubular piston 48 is sealed against the bore of the annular housing gland 28 by an annular gland seal 58. A flow port 60 is formed through the head of the tubular piston 48 and is engaged by a hydraulic fitting 62 for permitting the flow of compressible working liquid into and out of the pressure modulation chamber as indicated by the double arrow 64.</p><p id="p0023" num="0023">The tubular piston 48 and separator piston head 44 are thus extendable into and retractable out of the main cylinder chamber 34 in response to differential pressure conditions which are imposed within the bounce chamber 38 relative to the rebound chamber 40, and relative to the pressure modulation chamber 52.</p><p id="p0024" num="0024">The deflection position of the separation piston head 44 is detected by a position sensor 66 which is mounted onto the housing boot 26. The position sensor 66 carries a conductor which forms one plate of a capacitor, while the second plate of the capacitor is formed by a tapered conductive strip 68 attached to the external side surface of the main cylinder housing 20. The capacitance produced by the sensor plate and the tapered conductor strip 68 varies substantially linearly as the sensor head is moved along the tapered strip. The effective capacitor value produced by this arrangement forms a portion of an electronic bridge circuit which generates an electrical analog output signal 70 which is directly proportional to the radial displacement of the sensor head 66 from the tapered strip 68. Since the strip 68 has a linear taper, the radial displacement of the sensor plate is directly proportional to axial displacement of the sensor head from a reference position D<sub>0</sub> (Figure 2). The analog electrical output signal 70 forms one of the vehicle operating parameter<!-- EPO <DP n="11"> --> signals which is input to the computer 18.</p><p id="p0025" num="0025">Interchamber flow communication between the bounce chamber 38 and the rebound chamber 40 is provided by flow transfer ports 72 which are formed radially through the static support piston closely adjacent the lower housing end portion 20B on the bounce chamber side of the piston, and by flow transfer ports 74 which are formed radially through the static support piston closely adjacent the upper housing end portion 20A on the rebound chamber side of the separator piston head 44. The upper flow transfer ports 74 are in flow communication with the damping flow annulus 54. The flow transfer ports 76 are formed radially through the tubular piston 48 closely adjacent to the rebound chamber side of the separator piston head, in flow communication with the rebound chamber 40 and with the damping flow annulus 54. The static support piston 42 is intersected by a longitudinal flow passage 78 which is in flow communication with the radial flow ports 72 and the bounce chamber 38, and also in flow communication with the upper flow transfer ports 74 and damping flow annulus 54.</p><p id="p0026" num="0026">According to one aspect of the invention, a variable flow restrictor 80 is interposed between the bounce chamber 38 and the rebound chamber 40. Preferably, the variable flow restrictor 80 is a rotary metering valve which is independently operable to meter compressible liquid flow from the bounce chamber 38 to the rebound chamber 40, and from the rebound chamber 40 to the bounce chamber 38, respectively. The metering valve 80 includes a D.C. electrical stepping motor 82 having a rotor 82R mounted for rotation about a tubular mandrel 84.</p><p id="p0027" num="0027">Connected to the rotor 82R for rotation on the tubular mandrel 84 is a metering valve body 86 having axially extending peripheral passages 86A, 86B which, upon appropriate rotation of the rotor 82R, may be moved into and out of metering registration with the flow transfer ports 74 to thereby selectively meter compressible liquid flow between the bounce chamber 38 and the rebound chamber 40. The rotor 82R of the stepping motor 82 is rotatable through nine step increments of ten degrees each so that<!-- EPO <DP n="12"> --> the valve body metering passages are selectively positionable from partially open (maximum damping), as shown in Figure 5, to fully open (minimum damping).</p><p id="p0028" num="0028">The tubular mandrel 84 has a central bore 88 disposed in flow communication with the flow passage 78 and extends longitudinally through the support piston 42. The metering valve 80 is mounted within a counterbore 90 which is formed in the upper end of the static support piston 42. The metering valve assembly 80 is confined within the counter bore 90 by a threaded retainer cap 92. D.C. electrical power for operating the stepping motor 82 is provided by a conductor 94 which is routed through a longitudinal bore 96 formed through the sidewall of the support piston 42. The piston rod 42 and the main housing cylinder 20 form the D.C. return conductor.</p><p id="p0029" num="0029">A check valve 98 is mounted within a pocket in the retainer cap and is spring loaded to close a discharge flow passage 100 and is yieldable to connect the pressure modulation chamber 52 in fluid communication with the central bore 88 of the tubular mandrel 84 in response to a predetermined pressure differential. According to this arrangement, a positive pressure differential in the pressure modulation chamber 52 relative to the bounce chamber 38 causes the check valve 98 to open and thereby permit the bounce chamber 38 to be pressurized to the pressure level of the pressure modulation chamber 52. The check valve 98 is thus operable to permit one way interchamber flow from the modulation chamber to the bounce chamber 38, but blocks reverse flow.</p><p id="p0030" num="0030">The tubular piston 48 is slidably and sealingly engaged against the annular housing gland 28, and the slidable union is further sealed by an annular wiper seal 102. The rebound chamber is further sealed by an O-ring seal 104 which is mounted in an annular slot 106 formed in the housing gland 28. Impact forces applied by the separator piston 44 against the annular housing gland 28 are reacted by a resilient bounce pad 108.</p><p id="p0031" num="0031">When the vehicle is at rest, the portion of its weight supported by the wheel structure and the liquid spring 12 exerts<!-- EPO <DP n="13"> --> a downward axial force on the tubular piston 48 which tends to force the separator head 44 further into the main pressure chamber 34, thereby reducing the volume of the bounce chamber 38. Downward movement of the separator piston also reduces the volume of the pressure modulation chamber, thereby compressing and pressurizing the working liquid within the pressure modulation chamber 52.</p><p id="p0032" num="0032">As the separator piston 44 strokes downwardly, the compressible working liquid is forced through the flow ports 72 upwardly through the flow passage 78 where it is discharged through the rotary metering valve 80 into the flow transfer ports 74, 76. When the net upwardly directed fluid pressure on the face of the static support piston 42 and on the face of the separator piston 44 equals the load of the vehicle weight born by its wheel structure, the tubular piston 48 is at a vertical equilibrium deflection paint D<sub>1</sub> within the main pressure chamber 34 (Figure 3). This equilibrium point established the ride height of the vehicle when it is at rest or travelling along essentially level terrain.</p><p id="p0033" num="0033">When an additional, upwardly directed bounce force is imposed on the wheel structure, the main cylinder housing 20 is moved further upwardly along the tubular piston 48 and the flow of compressible working liquid is metered through the metering valve 80 to equalize the pressures in the bounce and rebound chambers. According to an important feature of the invention, the pressure of the bounce chamber 38 is modulated by flow from the pressure modulation chamber 52 to restore the deflection of the separator piston 44 to a desired ride height D<sub>1</sub>. This is accomplished by the computer 18 which receives the analog signal 70 which is representative of the instantaneous ride height deflection. In response to the ride height deflection signal 70, as well as other vehicle operation parameters, the computer 18 directs an increase or decrease in the pressure of the pressure modulation chamber 52 by directing the flow of compressible working liquid from a accumulator through a proportional flow control valve 112 and a<!-- EPO <DP n="14"> --> directional flow control valve 114. The accumulator 110 is charged from a compressible liquid reservoir 115 by a hydraulic intensifier 117.</p><p id="p0034" num="0034">Referring now to Figure 6, the load deflection response of the liquid spring 12 is illustrated. In this example, the piston of the liquid spring 12 is at a vertical equilibrium deflection point A, which corresponds with a stroke deflection D<sub>1</sub> of three inches, and a precharged pressure level P of about 1800 psi in the bounce and rebound chambers. In response to a bounce impact, and in the absence of a modulating pressure, the tubular piston 48 will stroke through the main pressure chamber 34, with the operating point following along the non-linear load deflection curve X. Without pressure modulating compensation, the piston will continue its stroke until bottoming occurs. However, upon the application of a high pressure boost of compressible liquid from the pressure modulation chamber 52 through the check valve 98 into the bounce chamber 38, the piston stroke is reversed at point B, with the tubular piston 48 being retracted until equilibrium is reached at the desired ride height deflection D<sub>1</sub> at point C on the load deflection curve Y. As the bounce forces are reacted, the pressure within the bounce chamber equalizes with the pressure in the rebound chamber, thereby causing the operating point to return to point A on the load deflection curve X. The load deflection curves X, Y generally define the limits of an operational load deflection envelope. The operating point A can be established and maintained at any point within the operational envelope by appropriate modulation of the pressure level within the modulation pressure chamber 52.</p><p id="p0035" num="0035">The proportioning flow control valve 112 is controlled by a flow rate control signal 116 generated by the computer 18. The proportioning control valve is driven by a pilot actuator 118. The pilot actuator 118 moves a shuttle within the valve to provide flow rate proportioning control of compressible liquid from the reservoir 110 to the directional control valve 114 from a first position in which its inputs are fully blocked, to a second<!-- EPO <DP n="15"> --> position in which both input ports are fully open to receive pressurized working liquid from the reservoir 110, to a third position which one output port is vented and one output port is blocked. The three position, four way proportioning control valve 112 is also operable to provide continuously variable flow rate control from fully closed (blocked) to fully open (vented).</p><p id="p0036" num="0036">The directional flow control valve 114 is responsive to computer control signals 120, 122 for selectively charging the bottom port 124 which is in flow communication with the bounce chamber 38, while venting the top port 60 which is in flow communication with the modulation chamber 52 in a first position, and is movable to a second position in which the bounce chamber 38 is blocked and the modulation chamber 52 is open to receive pressurized working liquid from the accumulator 110, and movable to a third position in which the pressure modulation chamber 52 is charged and the bounce chamber 38 is vented to permit pressurized working fluid to be returned to the hydraulic supply reservoir 110.</p><p id="p0037" num="0037">According to this arrangement, the directional control valve 114 is operable to switch the flow through the hydraulic conduits 62, 126 so that the pressure modulation chamber 52 can be switched from charge to discharge, and the bounce chamber 38 can be switched from charge to discharge according to computer control. Moreover, both the pressure modulation chamber 52 and the bounce chamber 38 may be charged at the same time and both can be blocked at the same time. The pressure modulation chamber 52 and the bounce chamber 38 can be selectively blocked or opened for charging and venting, as determined by the vehicle operating parameters.</p><p id="p0038" num="0038">The vehicle operating parameters include input signals developed by a manually/automatic settable ride height controller 128, a vehicle speed transducer 132, a steering transducer 134, a braking force transducer 136 and a manually settable damping controller 138. The ride height controller 128, the vehicle speed transducer, steering transducer, brake transducer, ride height<!-- EPO <DP n="16"> --> sensor and manual damping controller each produce analog signals which are subsequently digitized by an analog-to-digital converter (ADC) for input to the computer 18. The computer 18 receives these analog and digital vehicle operating parameter signals and generates control signals to the proportioning flow controller 112 and the directional flow controller 114, as well as a D.C. metering control signal 140 which is electrically connected to the power conductor 94 by a connector 142 (Figure 1) and applied to the electrical stepping motor of the metering valve 80 for automatically adjusting the spring and damping characteristics of the liquid spring 12 to maintain a desired ride height deflection.</p><p id="p0039" num="0039">The use of the proportioning flow control valve 112 and directional flow control valve 120 in conjunction with the pressure modulation chamber 52 and the bounce chamber 38 permits the bounce and rebound damping characteristics of the liquid spring 12 to be selectively, independently and quickly varied over a wide adjustment range. For example, with the metering valve 80 rotated to its maximum position relative to the flow control ports 74, 76 the damping forces on the static support piston 42 and the tubular piston 48 are at their minimum magnitudes, with the valve body 86 being positioned at its least restrictive setting. At the other extreme of the damping range, when the metering valve body 86 is in its fully closed position as shown in Figure 5, the available bounce and rebound damping forces are maximized. Between those two extremes are an infinite number of relative valve positions and correspondingly available bounce and rebound damping force settings.</p><p id="p0040" num="0040">Not only may the metering flow be variably restricted by the metering valve 80, but the pressure modulation chamber 52 and the bounce chamber 38 may be selectively charged or vented and opened or closed with respect to the output of the proportioning flow controller valve 112, whereby the bounce chamber 38 can be modulated instantaneously by pressure changes in the pressure modulation chamber 52 to further modify the damping<!-- EPO <DP n="17"> --> characteristics of the liquid spring 12. This permits the pressure modulation chamber 52 to be used, for example, to store compression energy as the housing 20 is deflected in one vertical direction, and to release the stored compression energy as the housing deflects in the opposite vertical direction.</p><p id="p0041" num="0041">Operation of the liquid spring 12 is uniquely controlled during vehicle operation by the control input signals 128 (ride height setting), 132A (vehicle speed), 134A (steering), 136A (braking rate), 138A (manual damping) and 70 (deflection height). The deflection signal 70 which is transmitted tram the position sensor 66 has a magnitude which is proportional to the deflection distance D<sub>1</sub> (Figure 3) as measured from the fully extended position D<sub>0</sub>, and is therefore indicative of the axial position of the piston head 44 relative to the opposite ends of the main cylinder pressure chamber 34.</p><p id="p0042" num="0042">According to this embodiment, both the spring force characteristics and the bounce and rebound damping characteristics of the liquid spring 12 are continuously monitored and automatically varied in response to variations in the vehicle operating parameters and the deflection operating parameter of the liquid spring itself. For example, the previously described continuous sensing of the deflection position of the piston head 44 enables the computer 18 to compute, at any given instant, the direction of relative travel of the piston 48, its velocity, and its acceleration relative to the main cylinder housing 20, and responsively vary the controller signals 116, 120 to the proportioning flow control valve 112 and the flow direction control valve 114 to substantially instantaneously adjust the effective piston velocity and/or acceleration during either a bounce or rebound stroke of the wheel 14. It will be appreciated that the suspension system 10 may be conveniently utilized to continuously and automatically adjust the spring and damping characteristics of the liquid spring 12 to generally optimize the suspension performance over a wide range of road conditions the vehicle may encounter at any given instant.<!-- EPO <DP n="18"> --></p><p id="p0043" num="0043">The suspension system 10 takes full advantage of the instantaneous compliance and compressibility of the silicone compressible working liquid. Because of the compressible nature of the silicone working liquid, the suspension system 10 can respond faster to bounce impulses than gas/oil systems because the silicone working liquid does not require hydraulic flow before compliance can occur. The instantaneous reaction and greater damping power reduces not only the magnitude of impact but also significantly reduces the number of sequential impact cycles transmitted to the frame, which improves all aspects of handling and ride comfort. Moreover, the improved suspension system 10 is characterized by lighter mass weight and package size, thereby providing lighter unsprung weight which further enhances ride handling characteristics.</p><p id="p0044" num="0044">The improved suspension system 10 is thus capable of carrying a wide range of loads and of varying the load force relationship of the liquid spring slowly and instantaneously to permit a vehicle to travel over rough courses with the suspended chassis remaining stable and comfortable. The system thus accommodates large variations of static and dynamic loading with reduced dynamic affect on the suspended chassis. The suspension system has the ability to sense the movement of the piston strut 48 including its direction, its instantaneous position and acceleration, and modifies the damping function and bounce or rebound to maximize its reduction of transmitted force to the chassis and thereby improve ride comfort.</p><p id="p0045" num="0045">The ride height sensor signals are read by the computer which generates appropriate output signals the proportional flow controller and the directional flow controller valves to produce the desired pressure force and the required damping level to optimize the chassis ride. For a four wheeled vehicle, the outputs of the four load ride height deflection sensors represent the chassis dynamic motions and describe the heave, pitch, roll and warp modes of the chassis relative to the road. The suspension system 10 uses the damping force to counteract the<!-- EPO <DP n="19"> --> acceleration forces and produces an increase or decrease in the modulation of the spring forces to reduce or increase the displacement at the appropriate strut to affect a more stable ride over an uneven course.</p><p id="p0046" num="0046">The liquid spring suspension units function both as a spring and as a shock absorber in which both functions are capable of modulation within desired ranges to increase or decrease damping to provide harder or softer performance and increase or decrease the spring force to respond to dynamic road conditions, unsprung mass and chassis motions to effectively reduce the chassis dynamic motions and to produce a smoother, more comfortable ride. The signal from the ride height sensors at each strut are sensed by direction and position in relation to a desired ride height, thereby providing real time adjustment by the computer. The ride height position signals are continuously monitored and are used in the control system to compare to other struts indicating chassis, heave, roll and warp modes of operation and corrective damping and spring forces are instantaneously modified within the struts to obtain the desired ride and vehicle control.</p><p id="p0047" num="0047">It will be appreciated that the suspension system 10 provides greater damping force capability and the ability to change spring force rapidly. This provides improved performance capability over prior art suspension systems. Moreover, the suspension system of the present invention simplifies assembly by reducing both the numbers and complexity of the liquid spring components. The overall system cost and weight are reduced correspondingly. Moreover, improved ride quality is provided over a greater load variation, thereby reducing friction and improving reliability. Consequently, many of the factors which have impeded the development of practical dynamic ride control suspension systems have been overcome. The suspension system of the present<!-- EPO <DP n="20"> --> invention is adaptable to a wide variety or applications, in which the following capabilities are provided:<ul id="ul0003" list-style="none" compact="compact"><li>a. provide fast compliance for levelling system</li><li>b. able to bank into corners</li><li>c. level ride on a curve</li><li>d. reduce nose dive when braking</li><li>e. reduce nose rise when accelerating</li><li>f. decrease chassis pitch</li><li>g. decrease chassis roll</li><li>h. reduce chassis bounce cycles</li><li>i. reduce peak bounce forces transmitted to the chassis</li><li>j. since the spring force is riding on compressible liquid, the steering bearing reaction thereby eliminating a separate bearing which would otherwise be required for conventional steel spring reaction and rotation.</li><li>k. riding on compressible fluid reduces noise and high frequency vibration to the chassis by better isolation</li><li>l. electronic damping control can tune the damping forces to provide optimum system requirement for a smooth ride with damping differential in bounce and rebound</li><li>m. electronic hydraulic pressure in flow control provides spring force changes in real time so that forces can be modulated for chassis pitch, roll, and vertical (heave) motion cancellation</li><li>n. reduced stroke length provides a better ride than conventional suspension since there is no required stroke to accommodate changes in load capacity of the vehicle</li></ul></p><p id="p0048" num="0048">It should be noted that the suspension system 10 shown in Figure 4 is representative for a single wheel assembly in a McPherson configuration, and that except for common components such as the computer and hydraulic reservoir, accumulator and intensifier, corresponding components including the liquid spring are required for each wheel. The liquid spring of the present<!-- EPO <DP n="21"> --> invention may be installed in other suspension configuration, such as the double wishbone (A-frame) configuration of Figure 7. The sensing of the piston deflection position may be achieved by other means, for example by a photoelectric position sensor, a magnetoresistive sensor, or an inductive sensor. It is therefore contemplated that the appended claims are intended to cover all embodiments of inventions and modifications thereof which do not depart from the sphere and scope of the invention.</p>
EP	0614422	B1	2000-03-22	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A compressible liquid spring suspension strut assembly with adjustable spring and damping characteristics including a main cylinder housing (20) adapted for attachment to a wheel assembly (14), the main cylinder housing (20) having a bore (32) defining a pressure chamber (34), a tubular piston (48) adapted for attachment to a vehicle frame, the tubular piston (48) having a bore (50) defining a pressure modulation chamber (52), an inlet port (60) for admitting a compressible liquid into the pressure modulation chamber (52), and an annular head (44) disposed in slidable, sealing engagement against the main cylinder housing bore (32), the annular head (44) dividing the main cylinder housing pressure chamber (34) into a bounce chamber (38) and a rebound chamber (40), a piston (42) mounted on the main cylinder housing (20) and projecting coaxially with and through the main cylinder housing chamber (34) into slidable, sealing engagement against the bore (50) of the tubular piston (48) thereby forming a dual piston assembly disposed within the main pressure chamber (34), the piston (42) and the tubular piston (48) being intersected by flow passages (72,74,76) for connecting the bounce chamber (38) into flow communication with the rebound chamber (40) and valve apparatus (80,86,98) coupled in fluid communication between the bounce chamber (38), the rebound chamber (40) and the modulation chamber (52) for restricting and controlling the flow of compressible liquid from one chamber to another.<!-- EPO <DP n="23"> --></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A strut as claimed in claim 1 wherein the valve apparatus includes a variable flow restrictor (80) interposed between the bounce chamber (38) and the rebound chamber (40) for adjusting the rate of flow of compressible liquid from the bounce chamber to the rebound chamber and from the rebound chamber to the bounce chamber, respectively, and, a check valve (98) interposed between the pressure modulation chamber (52) and the bounce chamber (38) for permitting one way flow of compressible liquid from the pressure modulation chamber (52) into the bounce chamber (38), and for blocking reverse flow thereof.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A strut as defined in claim 2, wherein the variable flow restrictor includes a rotary metering valve (82R) having flow passages (86A,86B) which are rotatable into and out of flow communication with the bounce chamber and the rebound chamber.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A strut as defined in claim 2, wherein the piston rod (42) is intersected by a longitudinal bore (78) and radial flow transfer portions (72,74) providing flow communication between the bounce chamber and the rebound chamber, and the variable flow restrictor (80,<!-- EPO <DP n="24"> --> 82R) is interposed between the longitudinal flow passage (78) and the radial flow ports.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A strut as defined in claim 1, including a tubular mandrel (84) connecting the pressure modulation chamber (52) in flow communication with the bounce chamber, and including a variable flow restrictor (80) mounted for rotation on the tubular mandrel, the variable flow restrictor being operably interposed between the bounce chamber and the rebound chamber.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A strut as claimed in claim 1 including means for generating a vehicle operating parameter signal, and wherein the annular head (44) includes a dual piston assembly disposed within the main pressure chamber, the dual piston assembly including the piston rod (42) attached to the main cylinder and the tubular piston (48) movably mounted on the piston rod, the pressure modulation chamber (52) having the inlet port (60) for admitting a compressible liquid into the pressure modulation, and wherein the control apparatus controls the bounce chamber pressure, pressure modulation chamber pressure and interchamber flow rate in response to a sensed variation in a vehicle operating parameter signal.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A strut as defined in claim 6, wherein the control apparatus includes means for generating a liquid<!-- EPO <DP n="25"> --> spring operating parameter signal, and, a computer coupled to the liquid spring and vehicle operating parameter signals and to the control apparatus for adjusting the bounce chamber pressure, modulation chamber pressure and interchamber flow rate in response to a sensed variation in the vehicle operating parameter signal and in response to a sensed variation in the liquid spring operating parameter signal.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A strut as defined in claim 7 wherein the liquid spring operating parameter generating means is operable to produce a signal indicative of the position of the moveable piston head relative to the piston rod within the housing chamber.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A strut as defined in claim 6 wherein the vehicle operating parameter generating means includes a manually operable controller being operable to produce an adjustable output signal indicative of the desired ride height deflection of the vehicle.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A strut as defined in claim 6 wherein the vehicle operating parameter generating means includes a transducer operable to produce an output signal proportional to the steering input to the vehicle.<!-- EPO <DP n="26"> --></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A strut as defined in claim 6 wherein the vehicle operating parameter includes a transducer operable to produce an output signal proportional to the speed of the vehicle.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>A strut as defined in claim 6 wherein the vehicle operating parameter generating means includes a transducer operable to produce an output signal proportional to the braking force exerted on the vehicle.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A strut as defined in claim 6 wherein the vehicle operating parameter generator means includes a manual controller operable to produce an adjustable output signal indicative of a predetermined damping factor.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>A strut as defined in claim 6 and including a tubular housing having a main chamber disposed therein for containing a compressible liquid, with the tubular piston (48) reciprocally disposed in the chamber and having the head portion dividing the main chamber into bounce and rebound chambers, a pressure modulation chamber having the flow port (60) through which the compressible liquid may be flowed into and out of the pressure modulation chamber, and a damping flow annulus (54) defined between the bounce and rebound chambers, means for operatively associating the liquid spring with<!-- EPO <DP n="27"> --> the frame and the wheel structure in a manner such that relative vertical movement between the frame and the wheel structure causes relative axial translation between the tubular piston and the housing, and whereby, the means for adjustably restricting interchamber flow between the bounce and rebound chambers in response to variation in at least one vehicle operating parameter, to selectively varies the damping force of the liquid spring.</claim-text></claim>
EP	0614422	B1	2000-03-22	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>DruckflÃ¼ssigkeits-Federbeinanordnung mit einstellbarer Feder- und DÃ¤mpfungskennlinie, mit einem HauptzylindergehÃ¤use (20), ausgebildet zur Anbringung an einer RadaufhÃ¤ngung (14), wobei das HauptzylindergehÃ¤use (20) eine eine Druckkammer (34) bildende Bohrung (32) aufweist, einem rohrfÃ¶rmigen Kolben (48), der an einem Fahrgestell eines Fahrzeugs anbringbar ist und eine Bohrung (50) aufweist, die eine Druckmodulationskammer (52) definiert, einer EinlaÃŸÃ¶ffnung (60) zum Einleiten einer komprimierbaren FlÃ¼ssigkeit in die Druckmodulationskammer (52), und einem ringfÃ¶rmigen Kopf (44), der in gleitender, abdichtender Anlage an der HauptzylindergehÃ¤use-Bohrung (32) liegt, wobei der ringfÃ¶rmige Kopf (44) die HauptzylindergehÃ¤use-Druckkammer (34) unterteilt in eine StoÃŸkammer (38) und eine RÃ¼ckstoÃŸkammer (40), einem Kolben (42), der an dem HauptzylindergehÃ¤use (20) gelagert ist und koaxial mit und durch die HauptzylindergehÃ¤use-Kammer (34) in verschieblicher, abdichtender Anlage an der Bohrung (50) des rohrfÃ¶rmigen Kolbens (48) steht, um dadurch ein Doppelkolbenanordnung zu bilden, die im Inneren der Hauptdruckkammer (34) angeordnet ist, wobei der Kolben (42) und der rohrfÃ¶rmige Kolben (48) von StrÃ¶mungskanÃ¤len (72, 74, 76) gekreuzt werden, um die StoÃŸkammer (38) mit der RÃ¼ckstoÃŸkammer (40) in StrÃ¶mungsverbindung zu bringen, und einer Ventilanordnung (80, 86, 98), die in Fluidverbindung zwischen die StoÃŸkammer (38), die RÃ¼ckstoÃŸkammer (40) und die Modulationskammer (52) gekoppelt ist, um den Strom komprimierbarer FlÃ¼ssigkeit von der einen Kammer zu der anderen zu beschrÃ¤nken.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Federbein nach Anspruch 1, bei dem die Ventilanordnung eine verÃ¤nderliche StrÃ¶mungsdrossel (80) aufweist, die zwischen der StoÃŸkammer (38) und der RÃ¼ckstoÃŸkammer (40) liegt, um den Durchsatz an<!-- EPO <DP n="29"> --> komprimierbarer FlÃ¼ssigkeit aus der StoÃŸkammer in die RÃ¼ckstoÃŸkammer und aus der RÃ¼ckstoÃŸkammer in die StoÃŸkammer einzustellen, wobei auÃŸerdem zwischen der Druckmodulationskammer (52) und der StoÃŸkammer (38) ein RÃ¼ckschlagventil (98) liegt, um einen Einwegestrom komprimierbarer FlÃ¼ssigkeit aus der Druckmodulationskammer (52) in die StoÃŸkammer (38) zu ermÃ¶glichen, einen entgegengesetzten Strom jedoch zu sperren.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Federbein nach Anspruch 2, bei dem die verÃ¤nderliche StrÃ¶mungsdrossel ein DrehmeÃŸventil (82R) mit StrÃ¶mungskanÃ¤len (86A, 86B) aufweist, die in und aus der StrÃ¶mungsverbindung zwischen StoÃŸkammer und RÃ¼ckstoÃŸkammer drehbar sind.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Federbein nach Anspruch 2, bei dem die Kolbenstange (42) von einer LÃ¤ngsbohrung (78) und radialen StrÃ¶mungstransferabschnitten (72, 74) durchsetzt wird, die eine StrÃ¶mungsverbindung zwischen der StoÃŸkammer und der RÃ¼ckstoÃŸkammer bilden, wobei die verÃ¤nderliche StrÃ¶mungsdrossel (80, 82R) zwischen dem LÃ¤ngsstrÃ¶mungskanal (78) und den radialen StrÃ¶mungsÃ¶ffnungen liegt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Federbein nach Anspruch 1, mit einem rohrfÃ¶rmigen Dorn (84), der die Druckmodulationskammer (52) in StrÃ¶mungsverbindung mit der StoÃŸkammer bringt, und mit einer verÃ¤nderlichen StrÃ¶mungsdrossel (80), die drehbar an dem rohrfÃ¶rmigen Dorn gelagert ist, und die betrieblich zwischen die StoÃŸkammer und die RÃ¼ckstoÃŸkammer gekoppelt ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Federbein nach Anspruch 1, mit einer Einrichtung zum Erzeugen eines Fahrzeugbetriebsparametersignals, wobei der ringfÃ¶rmige Kopf (44) eine Doppelkolbenanordnung innerhalb der Hauptdruckkammer enthÃ¤lt, wobei die Doppelkolbenanordnung die an dem Hauptzylinder befestigte Kolbenstange (42) und den beweglich an der Kolbenstange gelagerten rohrfÃ¶rmigen Kolben (48) enthÃ¤lt, wobei die Druckmodulationskammer (52) die EinlaÃŸÃ¶ffnung (60) zum ZufÃ¼hren einer komprimierbaren FlÃ¼ssigkeit zu der Druckmodulation aufweist, und wobei die<!-- EPO <DP n="30"> --> Steuereinrichtung den StoÃŸkammerdruck, den Druckmodulationskammerdruck und den Zwischenkammer-StrÃ¶mungsdurchsatz ansprechend auf eine ermittelte Ã„nderung eines Fahrzeugbetriebsparametersignals steuert.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Federbein nach Anspruch 6, bei dem die Steuereinrichtung Mittel enthÃ¤lt, um ein FlÃ¼ssigkeitsfeder-Betriebsparametersignal zu erzeugen, auÃŸerdem einen an die FlÃ¼ssigkeitsfeder- und Fahrzeugbetriebsparametersignale sowie an die Steuervorrichtung gekoppelten Rechner zum Einstellen des StoÃŸkammerdrucks, des Modulationskammerdrucks und des Zwischenkammer-StrÃ¶mungsdurchsatzes in AbhÃ¤ngigkeit einer ermittelten Ã„nderung des Fahrzeugbetriebsparametersignals und in AbhÃ¤ngigkeit einer ermittelten Ã„nderung des FlÃ¼ssigkeitsfeder-Betriebsparametersignals.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Federbein nach Anspruch 7, bei dem die Einrichtung zum Erzeugen eines FlÃ¼ssigkeitsfeder-Betriebsparameters ein Signal erzeugt, welches kennzeichnend ist fÃ¼r die Stellung des beweglichen Kolbenkopfs in Bezug auf die Kolbenstange innerhalb der GehÃ¤usekammer.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Federbein nach Anspruch 6, bei dem die Einrichtung zum Erzeugen eines Fahrzeugbetriebsparameters einen manuell betÃ¤tigbaren Regler aufweist, der betÃ¤tigbar ist, um ein einstellbares Ausgangssignal zu erzeugen, welches den gewÃ¼nschten HÃ¶henhub beim Fahren des Fahrzeugs angibt.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Federbein nach Anspruch 6, bei dem die Einrichtung zum Erzeugen eines Fahrzeugbetriebsparameters einen Wandler enthÃ¤lt, der betreibbar ist, um ein Ausgangssignal zu erzeugen, welches proportional zum Lenkeinschlag des Fahrzeugs ist.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Federbein nach Anspruch 6, bei dem der Fabrzeugbetriebsparameter einen Wandler enthÃ¤lt, der betreibbar ist, um ein Ausgangssignal proportional zur Fahrzeuggeschwindigkeit zu erzeugen.<!-- EPO <DP n="31"> --></claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Federbein nach Anspruch 6, bei dem die Einrichtung zum Erzeugen eines Fahrzeugbetriebsparameters einen Wandler enthÃ¤lt, der betreibbar ist, um ein Ausgangssignal zu erzeugen, welches proportional zu der auf das Fahrzeug ausgeÃ¼bten Bremskraft ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Federbein nach Anspruch 6, bei dem die Einrichtung zum Erzeugen eines Fahrzeugbetriebsparameters einen manuellen Regler enthÃ¤lt, der bedienbar ist, um ein einstellbares Ausgangssignal zu erzeugen, welches einen vorbestimmten DÃ¤mpfungsfaktor angibt.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Federbein nach Anspruch 6, mit einem rohrfÃ¶rmigen GehÃ¤use, in welchem sich eine Hauptkammer zur Aufnahme einer komprimierbaren FlÃ¼ssigkeit befindet, wobei der rohrfÃ¶rmige Kolben (48) hin- und herbeweglich in der Kammer angeordnet ist, wobei der Kopfabschnitt die Hauptkammer in StoÃŸ- und RÃ¼ckstoÃŸkammer unterteilt, eine Druckmodulationskammer die StrÃ¶mungsÃ¶ffnung (60) enthÃ¤lt, durch die die komprimierbare FlÃ¼ssigkeit in die und aus der Druckmodulationskammer strÃ¶men kann, und zwischen der StoÃŸ- und der RÃ¼ckstoÃŸkammer ein DÃ¤mpfungsstrom-Ringraum (54) definiert ist, eine Einrichtung vorhanden ist, die die FlÃ¼ssigkeitsfeder betrieblich dem Fahrgestell und der RadaufhÃ¤ngung in der Weise zuordnet, daÃŸ eine Relativ-Vertikalbewegung zwischen Fahrgestell und RadaufhÃ¤ngung zu einer relativen axialen Translation zwischen dem rohrfÃ¶rmigen Kolben und dem GehÃ¤use fÃ¼hrt, wodurch die Einrichtung zum einstellbaren Drosseln des Zwischenkammerstroms zwischen der StoÃŸ- und der RÃ¼ckstoÃŸkammer ansprechend auf eine Ã„nderung mindestens eines Fahrzeugbetriebsparameters selektiv die DÃ¤mpfungskraft der FlÃ¼ssigkeitsfeder variiert.</claim-text></claim>
EP	0614422	B1	2000-03-22	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>SystÃ¨me de jambe de suspension d'amortisseur hydraulique compressible avec des caractÃ©ristiques rÃ©glables d'Ã©lasticitÃ© et d'amortissement comprenant un cylindre principal (20) prÃ©vu pour Ãªtre fixÃ© Ã  une roue (14), le cylindre principal (20) ayant sa surface interne (32) qui dÃ©finit une chambre de pression (34), un piston tubulaire (48) Ã  fixer au chÃ¢ssis du vÃ©hicule, le piston tubulaire (48) comportant un alÃ©sage (50) qui dÃ©finit une chambre de modulation de pression (52), une entrÃ©e (60) pour l'admission d'un liquide compressible dans la chambre de modulation de pression (52), et une tÃªte annulaire (44) prÃ©vue en contact Ã©tanche, tout en pouvant glisser contre la surface latÃ©rale interne (32) du cylindre principal, la tÃªte annulaire (44) divisant la chambre de pression (34) du cylindre principal en une chambre de bondissement (38) et une chambre de rebondissement (40), un piston (42) montÃ© sur le cylindre principal (20) et faisant saillie en position coaxiale dans la chambre (34) du cylindre principal en contact Ã©tanche, tout en pouvant glisser contre l'alÃ©sage (50) du piston tubulaire (48) et formant ainsi un systÃ¨me Ã  deux pistons dans la chambre de pression principale (34), le piston (42) et le piston tubulaire (48) croisant des passages d'Ã©coulement (72, 74, 76) pour relier la chambre de bondissement (38) en communication fluidique avec la chambre de rebondissement (40), et un ensemble de soupapes (80, 86, 98) reliÃ©es en communication fluidique entre la chambre de bondissement (38), la chambre de rebondissement (40) et la chambre de modulation (52) pour restreindre et contrÃ´ler le dÃ©bit de liquide compressible d'une chambre Ã  l'autre.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Amortisseur suivant la revendication 1, dans lequel l'ensemble de soupapes comprend un limiteur variable de dÃ©bit (80) interposÃ© entre la chambre de bondissement (38) et la chambre de rebondissement (40) pour rÃ©gler le dÃ©bit du liquide compressible respectivement allant de la chambre de bondissement Ã  la chambre de rebondissement, et allant de la chambre de rebondissement Ã  la chambre de bondissement, et une soupape d'arrÃªt (98) interposÃ©e entre la chambre de<!-- EPO <DP n="33"> --> modulation de pression (52) et la chambre de bondissement (38) pour permettre un Ã©coulement unilatÃ©ral de liquide compressible de la chambre de modulation de pression (52) vers la chambre de bondissement (38), et pour bloquer l'Ã©coulement inverse.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Amortisseur suivant la revendication 2, dans lequel le limiteur variable de dÃ©bit comprend une soupape rotative de dosage (82R) comportant des passages d'Ã©coulement (86A, 86B) qui peuvent Ãªtre tournÃ©s en communication fluidique ou non avec la chambre de bondissement et la chambre de rebondissement.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Amortisseur suivant la revendication 2, dans lequel la tige de piston (42) comporte un alÃ©sage longitudinal (78) et croise des portions radiales (72, 74) de transfert d'Ã©coulement fournissant une communication fluidique entre la chambre de bondissement et la chambre de rebondissement, et le limiteur variable (80, 82B) d'Ã©coulement est interposÃ© entre le passage longitudinal (78) et les trous radiaux d'Ã©coulement.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Amortisseur suivant la revendication 1, comprenant un axe tubulaire (84) reliant la chambre de modulation de pression (52) en communication fluidique avec la chambre de bondissement, et comprenant un limiteur variable d'Ã©coulement (80) montÃ© pour tourner sur l'axe tubulaire, le limiteur variable Ã©tant, en fonctionnement, interposÃ© entre la chambre de bondissement et chambre de rebondissement.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Amortisseur suivant la revendication 1, comprenant un moyen destinÃ© Ã  engendrer un signal de paramÃ¨tre de fonctionnement du vÃ©hicule, et dans lequel une tÃªte annulaire (44) comprend un ensemble Ã  double piston dans la chambre principale de pression, l'ensemble Ã  double piston comprenant la tige de piston (42) fixÃ©e au cylindre principal et le piston tubulaire (48) montÃ© mobile sur la tige de piston, la chambre de modulation de pression (52) comportant une entrÃ©e (60) pour admettre<!-- EPO <DP n="34"> --> un liquide compressible dans la chambre de modulation de pression, et dans lequel l'appareil de commande la pression de la chambre de bondissement, la pression de la chambre de modulation de pression et le dÃ©bit entre les chambres en rÃ©ponse Ã  une variation dÃ©tectÃ©e dans un signal de paramÃ¨tre de fonctionnement du vÃ©hicule.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Amortisseur suivant la revendication 6, dans lequel l'appareil de commande comprend un moyen destinÃ© Ã  engendrer un signal de paramÃ¨tre de fonctionnement d'un liquide Ã©lastique, et un calculateur couplÃ© aux signaux de paramÃ¨tres de fonctionnement du liquide Ã©lastique et du vÃ©hicule, et Ã  l'appareil de commande pour rÃ©gler la pression de la chambre de bondissement, la pression de la chambre de rebondissement et le dÃ©bit entre les chambres en rÃ©ponse Ã  une variation dÃ©tectÃ©e dans le signal de paramÃ¨tre du fonctionnement du vÃ©hicule et en rÃ©ponse Ã  une variation dÃ©tectÃ©e dans le signal de paramÃ¨tre de fonctionnement du liquide Ã©lastique.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Amortisseur suivant la revendication 7, dans lequel le moyen d'engendrer le paramÃ¨tre de fonctionnement du liquide Ã©lastique peut fonctionner pour produire un signal indicatif de la position de la tÃªte de piston mobile par rapport Ã  la tige de piston dans la chambre de l'enveloppe.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Amortisseur suivant la revendication 6, dans lequel le moyen d'engendrer le paramÃ¨tre de fonctionnement du vÃ©hicule comprend un dispositif de commande que l'on peut actionner manuellement pour produire un signal rÃ©glable de sortie indicatif de la dÃ©flexion de hauteur dÃ©sirÃ©e de conduite du vÃ©hicule.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Amortisseur suivant la revendication 6, dans lequel le moyen d'engendrer le paramÃ¨tre de fonctionnement du vÃ©hicule comprend un transducteur que l'on peut faire fonctionner pour produire un signal de sortie proportionnel Ã  l'entrÃ©e de braquage du vÃ©hicule.<!-- EPO <DP n="35"> --></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Amortisseur suivant la revendication 6, dans lequel le moyen d'engendrer le paramÃ¨tre de fonctionnement du vÃ©hicule comprend un transducteur que l'on peut faire fonctionner pour produire un signal de sortie proportionnel Ã  la vitesse du vÃ©hicule.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Amortisseur suivant la revendication 6, dans lequel le moyen d'engendrer le paramÃ¨tre de fonctionnement du vÃ©hicule comprend un transducteur que l'on peur faire fonctionner pour produire un signal de sortie proportionnel Ã  la force de freinage exercÃ©e sur le vÃ©hicule</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Amortisseur suivant la revendication 6, dans lequel le moyen d'engendrer le paramÃ¨tre de fonctionnement du vÃ©hicule comprend un dispositif de commande manuel que l'on peut faire fonctionner pour produire un signal rÃ©glable de sortie indicatif d'un facteur d'amortissement prÃ©dÃ©terminÃ©.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Amortisseur suivant la revendication 6, et comprenant une enveloppe tubulaire comportant une chambre principale qui y est logÃ©e pour contenir un liquide compressible, avec le piston tubulaire (48) prÃ©vu pour des mouvements alternatifs dans la chambre et ayant une partie tÃªte divisant la chambre principale en chambre de bondissement et chambre de rebondissement, une chambre de modulation de pression ayant un orifice d'Ã©coulement (60) par lequel le liquide compressible peut entre et sortir de la chambre de modulation de pression, et un anneau d'amortissement d'Ã©coulement (54) dÃ©fini entre les chambre de bondissement et chambre de rebondissement, un moyen pour associer en fonctionnement le liquide Ã©lastique au chÃ¢ssis et Ã  la structure des roues d'un maniÃ¨re telle qu'un mouvement vertical relatif entre le chÃ¢ssis et la structure des roues entraÃ®ne une translation axiale entre le piston tubulaire et l'enveloppe, et de maniÃ¨re que le moyen pour limiter d'une faÃ§on rÃ©glable l'Ã©coulement entre la chambre de bondissement et la chambre de rebondissement en<!-- EPO <DP n="36"> --> rÃ©ponse Ã  une variation d'au moins un paramÃ¨tre de fonctionnement du vÃ©hicule fasse varier sÃ©lectivement la force d'amortissement du liquide Ã©lastique.</claim-text></claim>
EP	0614422	B1	2000-03-22	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0614422&ki=B1&pd=2000-03-22
EP	0674732	B1	2000-08-16	de	TITLE	1	ZUSAMMENGESETZTER BLOCK UND VERFAHREN ZUR HERSTELLUNG
EP	0674732	B1	2000-08-16	en	TITLE	1	COMPOSITE BLOCK AND PROCESS FOR MANUFACTURING
EP	0674732	B1	2000-08-16	fr	TITLE	1	BLOC COMPOSITE ET PROCEDE DE FABRICATION
EP	0674732	B1	2000-08-16	en	DESCR	1	<p id="p0001" num="0001">This invention relates to composite blocks such as paving blocks used to construct roads, parking lots, driveways and the like, and preformed slabs used for buildings and the like.</p><p id="p0002" num="0002">In North America, and indeed in most of the civilized and populated areas of the world, roads have become an integral part of cities, towns, suburbs, and so on. Indeed, most towns and cities contain hundreds or thousands of miles of roads within their boundaries, and also driveways or parking lots for virtually every building within a city or town.</p><p id="p0003" num="0003">The conventional way and indeed the most popular way to provide roads, driveways, and parking lots with a top surface is to use asphalt for the top surface. A best estimate is that several million miles of roads and several million acres of parking lots within North America are surfaced with asphalt.</p><p id="p0004" num="0004">However, there are two fundamental problems with asphalt. One problem is that asphalt is oil based, or at least largely so, and therefore a raw material that is in limited supply is being used when it could be being used for other purposes. Secondly, there is a question of durability, which is now generally recognized as a very significant problem. Many existing roadways and parking lots, even very new ones, are degraded considerably largely due to broken asphalt, and cracks or potholes can be found at any given time. The amount of asphalt roadway in North America that has asphalt damage is quite extensive. Most of the damage is caused by weather cycles, which cause expansion and contraction of the asphalt. Any roadway that does not have asphalt damage has most likely been constructed or repaired in the last few years. This is generally unsightly and also quite expensive. Further, oil and other fluids that drip from vehicles while the vehicle is parked or in motion also cause a<!-- EPO <DP n="2"> --> significant problem. The amount of damage that is done by oil and other fluids from vehicles is considerable. This damage can be seen in virtually every parking lot, driveway, and roadway intersection in North America. Not only does the oil, or whatever fluid that might be leaking from a vehicle, leave a very unsightly stain on the asphalt surface of a roadway, parking lot or driveway, the asphalt surface in time will start to degrade to a point where it is crumbling and needs to be replaced.</p><p id="p0005" num="0005">While it is possible to replace small portions of the asphalt surface, at least in most cases, this leaves an unsightly patch -- or indeed several patches -- of new asphalt.</p><p id="p0006" num="0006">One alternative that has been recently fairly widely accepted in North America as an alternative for resurfacing driveways and small parking lots is interlocking blocks. Interlocking blocks are made of a cementitious or a cement based material having a small relatively constant sized aggregate therein. These blocks come in various shapes and sizes. Basically, these blocks interfit with one another such that the blocks can be installed on a surface to completely cover the surface. The blocks may need to be cut around the perimeter of a surface in order to fit exactly to the outline of the surface. Among the advantages of interlocking blocks are that they do not require the same heavy equipment to install as it takes to create a surface of asphalt, they are easy to replace, only the damaged blocks need replacing which can be done relatively quickly and inexpensively, and they last much longer than an asphalt surface and are much more resistant to damage -- including weathering, impact, and leaking oil. They are, however, more expensive to install initially than an asphalt surface, although the cost factor can be spread over many more years since interlocking blocks are much more durable than asphalt. Further, it generally takes longer to install a given area of interlocking blocks than to pave the same area with asphalt, which adds to the initial cost. Largely because of the lower initial cost, many parking lots and driveways are still paved with asphalt instead of surfaces with interlocking blocks. However,<!-- EPO <DP n="3"> --> because of the long term cost benefits, it is becoming more and more acceptable to use interlocking blocks even where cost is an important and an accountable factor, such as in municipal roads and parking lots or shopping mall and office complex parking lots.</p><p id="p0007" num="0007">Another advantage of interlocking blocks is that they can, in most cases, allow for ground movement without breaking. The blocks merely shift slightly with respect to one another or in some cases separate slightly from one another, which is usually acceptable. Further, moisture can pass between interlocking blocks which means that normal water seepage into the ground is not interfered with significantly.</p><p id="p0008" num="0008">Another problem with the present interlocking blocks is that they are concrete based and therefore somewhat porous. This means that they can absorb water which tends to cause them to crack or break during the winter.</p><p id="p0009" num="0009">The prior art includes basically asphalt surfaces and interlocking paving blocks made mainly of cement based materials.</p><p id="p0010" num="0010">However, several patents relating generally to the subject matter hereof are discussed below, for the record:</p><p id="p0011" num="0011">U.S. Patent 1,740,212 discloses a bituminous composition and the manufacture thereof. This bituminous composition comprises an admixture of rubber with bituminous cement. Further, an admixture of fibre is added thereto.</p><p id="p0012" num="0012">U.S. Patent 3,253,521 a flexible paving composition wherein to surface a roadway, a rubberized bituminous adhesive is applied to the surface and then a cover of paving composition is applied thereto, while the adhesive is in a condition to adhere the composition to the surface. The paving composition comprises a mixture of rubberized bitumen and particulated rubber.</p><p id="p0013" num="0013">U.S. Patent 3,891,585 discloses an elastomeric pavement repair composition wherein asphalt is heated and rubber is combined therewith. The resulting<!-- EPO <DP n="4"> --> composition is mixed to form a hot jellied composition which can be applied to cracked or distressed pavements.</p><p id="p0014" num="0014">U.S. Patent 4,284,366 discloses an elastomeric composite pavement wherein a molded paving unit is formed as a composite of a resilient base material and a friction aggregate. The particles of the aggregate are disposed in the base material throughout the thickness of the paving unit. The resilient base material includes a binder material such as rubber -- more specifically EPDM. Alternate layers of friction aggregate and elastomeric binder material are laid into a cavity to form the molded paving unit.</p><p id="p0015" num="0015">U.S. Patent 4,427,818 discloses a thermoplastic polymer concrete structure and method wherein a thermoplastic polymer concrete block is constructed of contaminated thermoplastic resin scrap, and fill material. The fill material may include sand particles, fibrous particles such as threads, and other waste materials such as metal chips. The mixture is heated and mixed and then placed into molds of a desired shape, and ultimately cooled.</p><p id="p0016" num="0016">U.S. Patent 4,868,233 discloses a polyethylene modified asphalt wherein certain linear polyethylene compounds are added to an asphalt that is low in asphaltenes but relatively high in saturates. The resulting composition has excellent storage stability, face compatibility and creep resistance relative to unmodified asphalts. The improved asphaltic composition is particularly well suited for use as a binder in paving materials and as a coating or saturant for roofing products.</p><p id="p0017" num="0017">In U.S. Patent 4,873,275 it is disclosed that paving asphalts (especially of the hot mix, hot laid type) may be modified so as to have improved stability and rheological properties by the addition of certain co-polymers of ethylene with a vinyl acetate or lower alkyl esters of acrylic acid and methacrylic acid to the asphalt, provided the asphalt has an<!-- EPO <DP n="5"> --> asphaltene content below a critical level. More specifically, an asphalt cement or binder having both enhanced storage stability and creep resistance relative to conventional binders is formed when the asphalt used in the binder has an asphaltene content of about 7% (by weight) or less, based on percentage of weight of the asphalt. One embodiment disclosed provides an improvement in paving structures wherein the binder in the structures comprises an asphalt containing about 7% (by weight) or less asphaltenes and from about 3.5% to about 10% (by weight) of a co-polymer of ethylene, and from 3% to about 30% (by weight) vinyl-acetate, alkyl acrylate or alkyl methacrylate. Another embodiment of the invention incorporates into the asphalt used in the binders, from about 3.5% to about 10% by weight of a co-polymer of ethylene which contains from 3% to about 30% (by weight) vinyl-acetate, alkyl acrylate or alkyl methacrylate. The composition disclosed in the patent is said to be particularly suitable for use as a binder in the load bearing course as well as the top or surface course of pavement structures, particularly hot mix pavement structures.</p><p id="p0018" num="0018">U.S. Patent 4,882,373 discloses that an asphaltic composition comprising a mineral acid, a thermoplastic elastomer and an unsaturated functional monomer, has improved tensile properties relative to that obtained in the absence of the unsaturated functional monomer.</p><p id="p0019" num="0019">Japanese Patent Publication 57-66206 discloses a method of manufacturing asphalt by using a hot asphalt mixture combined with a pasty rubber composition. The rubber composition consists of a 2:1 to 1:3 mixture of a rubber latex and a powdery polyolefinic polymer, having a melt index of 20 to 400 and a grain size of 0.3 m.m. or less.</p><p id="p0020" num="0020">In the prior art, it is not disclosed to use both an elastomeric material and a polyethylene material in the same asphalt mix. Further, the use of a fibre material interspersed within the asphalt the polyethylene mixture is not contemplated. Moreover, the prior art does not contemplate to use the materials in the prior art to form blocks or the like to use as elements for paving or similar.<!-- EPO <DP n="6"> --></p><p id="p0021" num="0021">The present invention provides a moulded block which can be used in the surfacing and re-surfacing of roads, parking lots, sidewalks and other walkways, airport runways and tarmacs, and the like. The moulded blocks of the present invention are to be used substantially in the same manner as presently available interlocking blocks.</p><p id="p0022" num="0022">According to a first aspect of the invention there is provided composite blocks comprising asphalt in a proportion of about 25% to about 55% by volume, polyethylene in a proportion of about 10% to about 40% by volume, monofilament fibre material in a proportion of about 5% to about 35% by volume, and elastomeric material in a proportion of 5% to about 30% by volume.</p><p id="p0023" num="0023">The proportion of the materials that make up the composite material must of course add up to 100%.</p><p id="p0024" num="0024">Use of these components to form a resulting composite material provides a block that is extremely strong, durable, resistant to cracking and chipping, and so on.</p><p id="p0025" num="0025">Preferably, the moulded paving blocks of the present invention will be in the shape of a rectangular prism -- basically the same shape as a typical brick that is used in the construction of a building. Other shapes can of course be manufactured and used.</p><p id="p0026" num="0026">The materials used are preferably previously used materials such as reclaimed asphalt, recycled plastic such as polyethylene containers, reclaimed elastomeric material such as rubber from scrap tyres, and reclaimed monofilament fibre material such as nylon, rayon, or KEVLARâ„¢ cords from scrap tyres. The materials<!-- EPO <DP n="7"> --> may also be new materials. There are many advantages of using reclaimed or recycled materials such as reduction of waste and also lower cost of raw materials.</p><p id="p0027" num="0027">The preferred proportional amounts of materials include asphalt in a proportion of about 40% by volume, polyethylene in a proportion of about 25% by volume, monofilament fibre material in a proportion of about 20% by volume, and elastomeric material in a proportion of about 15% by volume.</p><p id="p0028" num="0028">The asphalt should generally be the main or prevalent constituent of the composite material that forms the composite block of the present invention. The asphalt provides the mass and strength of the composite material due to the aggregate within the asphalt. Further, the asphalt contains resins composed largely of hydrocarbons. These hydrocarbons intermingle and bond with the plastic, which is preferably polyethylene, thus creating a binding agent within the material. Further, the plastic physically stabilizes the asphalt and therefore precludes deformation due to extreme temperatures. The monofilament fibres act to reinforce the binding agent thereby providing additional strength to the composite material. The elastomeric material --typically rubber -- acts as a flexural extender and thereby provides a measure of resilience to the composite material. It is also quite acceptable to use flexible polyvinylchloride in place of rubber as the elastomeric material. The enhanced resilience lessens the chance of the composite block cracking or breaking due to extreme temperatures or due to high loads or impact forces.</p><p id="p0029" num="0029">According to a second aspect of the present invention, the composite blocks are, paving blocks, and in this case the polyethylene is replaced by phenolic resin.<!-- EPO <DP n="8"> --></p><p id="p0030" num="0030">In addition, the present invention provides a process for manufacturing blocks a process for manufacturing composite blocks, comprising placing asphalt and polyethylene, or phenolic resin where the block is a paving block, according to the features of claims 6,7,9 and 10.<!-- EPO <DP n="9"> --></p><p id="p0031" num="0031">Further the invention provides a construction material comprising asphalt in a proportion of about 25% to about 55% by volume, polyethylene in a proportion of about 10% to about 40% by volume monofilament fibre material in a proportion of about 5% to about 35% by volume; and elastomeric material in a proportion of about 5% to above 30% by volume.<!-- EPO <DP n="10"> --></p><p id="p0032" num="0032">In one embodiment of the invention, the composite material is entered into the heating oven in separate portions of a pre-determined weight. The portions are separated to the correct weight of a paving block of desired site by a computer controlled batch dispensing system.</p><p id="p0033" num="0033">In another embodiment the composite material is entered into the heating oven as a continuous ribbon of material. Upon exiting the oven, the material is pre-plasticized and extruded and is then cut into portions of precise volume. These portions of composite material are then deposited to the molding system.</p><p id="p0034" num="0034">An embodiment of the invention will now be described with reference to the accompanying drawings, in which:<ul id="ul0001" list-style="none" compact="compact"><li>Figure 1 is a schematic diagram of a first process used to produce the molded paving block of the present invention;</li><li>Figure 2 is a schematic diagram of a second process used to produce the molded paving block of the present invention; and</li><li>Figure 3 is a partially cutaway view of the molded paving block of the present invention.</li></ul></p><p id="p0035" num="0035">Reference will now be made to Figure 1 which provides a schematic representation of a first preferred process used to form the composite paving block of the present invention. At the start of a production line 20, there is a blending drum 22. The various materials that are the components of the resulting composite material are entered into the blending drum 22, generally one at a time. In the preferred process, the blending drum 22 contains a mixture of asphalt, plastic, monofilament fibre material and elastomeric material. This mixture is blended in the rotating blending drum 22 until the various component materials are suitably blended together, as will be described in more detail subsequently.</p><p id="p0036" num="0036">The asphalt is preferably reclaimed asphalt that has been crushed and subsequently screened such the that the pieces are of a size of -4 mesh. The mesh measurement used is an industry<!-- EPO <DP n="11"> --> standard Tyler mesh. The term -4 mesh refers to fragmented or particulate material having a particle size of less than a 4 mesh.</p><p id="p0037" num="0037">The plastic is preferably recycled crushed plastic and should be of a size of -30 mesh. The plastic material is polyethylene or Phenolic resin. It is common to reclaim several types of plastic through recycling programs, with polyethylene. Inclusion of these other types of plastics in a small amount is not detrimental to the properties of the resulting end material that ultimately forms the paving block. Unexpectedly, it has been found that inclusion of other types of plastics in fairly large proportions -- even as much as 90% of the entire plastic content, with the rest being polyethylene -- has produced an acceptable resulting end material. Tests have shown that paving blocks made of such material merely have a lower strength, but in general retain a similar structural integrity to those blocks containing virtually 100% polyethylene as the plastic material.</p><p id="p0038" num="0038">The monofilament fibre material is preferably reclaimed monofilament fibre material that has been reclaimed from sources such as scrap tyres and is typically recovered from the tyres by a cryogenic process. Preferably, the material is chosen from the group of rayon, nylon, and similar polyesters. Further, the monofilament fibre material should have a strand length preferably between 1/8"(approx 3,2mm) and 3,8"(approx 9.5mm) with the ideal strand length being around 1/4"(approx 6,4mm). The monofilament strands recovered from scrap tires may be cut to this length by use of a suitable grinder. The monofilament fibre material is blown into the blending drum when the other component materials, or at least most of the other component materials, are in the blending drum 22 and while the blending drum 22 is rotating in order to achieve proper dispersion.</p><p id="p0039" num="0039">The elastomeric material is preferably reclaimed rubber that has been reclaimed from sources such as scrap tires. The preferred process for producing such reclaimed rubber is a cryogenic process, which is well known in the industry. The rubber that is produced by a suitable cryogenic process or a suitable ambient reduction<!-- EPO <DP n="12"> --> process, is preferably crumb rubber that is free from other materials found in the tires. The particles of crumb rubber should be of a size of -12 mesh. It is also quite acceptable to use flexible polyvinylchloride as the elastomeric material.</p><p id="p0040" num="0040">These materials are entered into the blending drum 22 through a receiving hatch 24. The asphalt, polyethylene, and elastomeric material can be deposited separately from one another, or all together, as is convenient. It is preferable, as stated previously, to have the monofilament fibre material blown into the blending drum. It is important that the materials be in certain proportions within the blending drum 22. The preferred proportions are about 40% asphalt, about 25% plastic, about 20% monofilament fibre material and about 15% elastomeric material. These percentages are all expressed in terms of percent by volume. An acceptable range for each of these materials is from about 25% to about 55% asphalt, from about 10% to about 40% plastic, from about 5% to about 35% monofilament fibre material and from about 5% to about 30% elastomeric material. The percentages of course add up to 100%.</p><p id="p0041" num="0041">After all of the materials have been placed in the blending drum 22, the blending drum 22 is rotated in order to blend the materials together into a uniformly distributed mixture. The blending drum 22 is heated in order to drive off excess moisture in the plastic, asphalt and the elastomeric material. It has been found that a temperature of about 130Â°F(approx 55Â°C)is useful in providing the proper heat for causing the excess moisture to be vapourized. It is useful in terms of energy efficiency to have water removed at this stage so that it will not absorb heat energy in a subsequent heating stage. Some fluidizing of the mixture occurs, but the mixture does not reach complete fluidity. The drum 22 must be rotated at a speed of between 10 r.p.m. and 35 r.p.m. in order to blend the materials properly such that they are evenly dispersed throughout the mixture. It has been found that the blending drum 22 should not be rotated faster than 35 r.p.m. because the drum 22 then acts as a centrifuge and causes the materials to separate, or at least to not blend properly, due to centrifugal force.<!-- EPO <DP n="13"> --></p><p id="p0042" num="0042">The mixture is thoroughly blended in the blending drum 22, so that the materials become evenly dispersed to form a composite material that will be properly stabilized -- with respect to chemistry and dimensions -- when a paving block is ultimately formed. The composite material is removed from the heated blending drum through a discharge port 26, and is fed by gravity into a heated holding drum 30 through a receiving hatch 32. The heated blending drum 22 is stopped so that the material can be removed. Alternatively, it is possible to use a continuous extractor, such as a screw feed type extractor, to remove the composite material from the blending drum 22 through an opening in the end thereof, while the blending drum 22 is either stopped or rotating.</p><p id="p0043" num="0043">The holding drum 30 preferably rotates during the processing operation in order to keep the various components in the composite material from separating. The preferred rotational speed of the holding drum 30 is generally in the same speed range as the blending drum 22, or in a slightly slower speed range, below 10 r.p.m.</p><p id="p0044" num="0044">The composite material is removed from the holding drum 30 generally on a continuous basis, either as the holding drum 30 is rotating or when it is stopped. The holding drum 30 acts as a physical buffer for the composite material so that a generally continuous supply of the composite material can be provided to the remainder of the system. The overall process described herein will of course work without the holding drum 30, but the output in terms of number of blocks per unit time will not be maximized.</p><p id="p0045" num="0045">From the holding drum 30, the composite material is metered through a discharge port 26 into a receiving hopper 34 of a computer controlled batch dispensing system. The batch dispensing system continuously measures the amount of the composite material in the receiving hopper 34. When the proper amount of material for forming one moulded paving block has been received by the receiving hopper 34 the material is removed from the receiving hopper as a discrete portion of composite material 36, and is<!-- EPO <DP n="14"> --> deposited into a continuous feed heating oven 40. The continuous feed oven 40 is shown in ghost outline so that the components therein may be more clearly seen.</p><p id="p0046" num="0046">The portions of composite material 36 are deposited on a PTFE coated steel belt 42 in the continuous feed oven 40. It is preferable that the portions of composite material 36 deposited on the PTFE coated steel belt 42 be about one-half inch thick so that subsequent heating of the portions of material 36 can take place rapidly. In order to accomplish this, the portions of composite material 36 are leveled to the desired height of 1/2"(approx 12,7mm) by a bridge as they enter the continuous feed oven 40.</p><p id="p0047" num="0047">The subsequent heating of the portions of composite material 36 occurs in the following manner. Within the continuous feed oven 40, there is a first series 44 of gas fired radiant heaters 48 located above the portion of the PTFE coated steel belt 42 that carries the portions of material 36 through the oven 40. This first series 44 of heaters 48 directly heats the mixture from above. There is also a second series 46 of heaters 48 below the lower portion of the PTFE coated steel belt 42. This second series of heaters 48 heat the portions of composite material 36 through the two layers of steel belt 42. The heaters in both the first series 44 and second series 46 of heaters 48 are preferably evenly spaced along the belt 42 with the number of heaters 48 being such that the heaters are placed close to one another so as to ensure even heating along the entire length of the belt 42.</p><p id="p0048" num="0048">After each portion of composite material 36 has passed through the continuous feed oven 40, they reach an outlet opening 50 and are removed from the steel belt 42 preferably by a computer controlled plough 52. The plough 52 removes each portion of material 36 from the belt 42 and directs each portion of material 36 into a heated receiving hopper 54 of an automatic batch discharge system. The amount of material in each portion 36 is, of course, the desired amount for forming the resulting molded paving block.</p><p id="p0049" num="0049">The portion of composite material 36 is then dumped from the receiving hopper 54 into a molding system where it is molded into a<!-- EPO <DP n="15"> --> paving block. The molding system includes a mold 56, which in turn comprises a mold cavity 57 and mold plate 58. The mold cavity 57 receives the pardon of composite material 36 therein when it is in position 57A. The mold cavity 57 is then moved underneath the mold plate 58 to position 57B. The mold plate 58 is introduced to the mold cavity 57 by a hydraulic ram and a seal is formed between the two. The mold plate 58 directly contacts the portion of material 36 therein. A pressure of about 750p.s.i.(approx 51x10<sup>4</sup>kp/m<sup>2</sup>) applied in order that the material is formed properly into the desired shape of a molded paving block. The mold cavity 57 is then moved to position 57C where the molded paving block is discharged onto a water bath cooling conveyor 59, where they are quickly cooled for handling purposes. The resulting paving block has a compressive strength of about 7000p.s.i.(approx 48x10<sup>5</sup>kp/m<sup>2</sup>). As can be seen in Figure 3, the preferred shape of the paving block is a rectangular prism, with the preferred sites of these rectangular prism paving blocks being 200 mm long x 100 mm wide x 60 mm deep, and 200 mm long x 100 mm wide x 80 mm deep. With these rectangular prism paving blocks, a herringbone pattern can be created. A herringbone pattern has been found to be a preferable pattern for forming a road or other surface from rectangular prism blocks. Of course, virtually any suitable size block could be produced by the method disclosed herein.</p><p id="p0050" num="0050">Reference will now be made to Figure 2 which shows a second preferred process used to form the composite paving block of the present invention at production line 70. In this second preferred process, the composite material is discharged from the holding drum 30 in the form of a continuous ribbon of composite material. This continuous ribbon of composite material is deposited onto the travelling belt of the heating oven 40, wherein the composite material is allowed to temperature stabilize at a temperature of about 325Â°F(approx 163Â°C) to about 375Â°F(approx 191Â°C). The continuous ribbon of material is then discharged into an extruder 104 through an opening 106 in the top thereof. The composite material is extruded through a die 108 from the extruder 104 on a continuous basis. The extruded material is cut into slugs<!-- EPO <DP n="16"> --> 110 of a desired size by a computer controlled cutting blade 111. The extruder 104 is preferably a linear extruder (as shown) with the piston of the extruder 104 being driven by hydraulic power. The extruder may also be a screw extruder, as dictated by performance and cost considerations. The main reason for the extruder is to pre-plasticize the composite material and force any gases from the material, before the pressurization in the mold.</p><p id="p0051" num="0051">The extruder is also preferably heated to the mixture at a temperature of about 325Â°F(approx 163Â°C) to about 375Â°F(approx 191Â°C) thereby allowing it to be more easily extruded. In any event, the extruder is preferably heated to keep the portion of composite material 36 at a proper temperature.</p><p id="p0052" num="0052">The slug 110 is then taken from the die 108 and placed into a mold 56 and is molded and subsequently cooled as described in the first preferred embodiment.</p><p id="p0053" num="0053">The paving block of the present invention preferably has vertically oriented sides so that when the blocks are assembled together to form a road or other surface, they can be moved in a vertical direction into location one next to another. Assembly of a road or other surface from blocks with vertically oriented sides provides a surface wherein individual blocks can be removed and replaced generally independently one from another.</p><p id="p0054" num="0054">The paving block of the present invention may also be of a shape other than the rectangular prism shape as disclosed in the preferred embodiment. In any event, the blocks are placed juxtaposed one to another in order to form a road or other surface. The blocks merely interfit one with another. They do not actually interlock as do the pieces of a typical jigsaw puzzle.</p><p id="p0055" num="0055">In an alternative embodiment the continuous feed oven has in it a conveyor belt with a plurality of generally contiguously placed trays thereon, in place of the PTFE coated steel belt as described in the preferred embodiment. Segments of the composite material would be placed in each tray on the conveyor, and would be conveyed in the same manner through the oven.<!-- EPO <DP n="17"> --></p><p id="p0056" num="0056">It is also contemplated that the material of the present invention could be used more generally as a construction material to form entities such as preformed slabs for buildings and the like as defined by the appended claims.</p>
EP	0674732	B1	2000-08-16	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>Composite blocks (75) comprising:<claim-text>asphalt in a proportion of about 25% to about 55% by volume, polyethylene in a proportion of about 10% to about 40% by volume, monofilament fibre material in a proportion of about 5% to about 35% by volume, and elastomeric material in a proportion of 5% to about 30% by volume.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The block of Claim 1 in which the elastomeric material is rubber or flexible polyvinylchloride.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The block of Claim 1 or Claim 2 in which the asphalt is in a proportion of about 40% by volume, the polyethylene is in a proportion of about 25% by volume, the monofilament fibre material is in a proportion of about 20% by volume, and the elastomeric material is in a proportion of 15% by volume.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The block of any preceding claim which comprises waste reclaimed asphalt, recycled polyethylene, reclaimed elastomeric material, and reclaimed monofilament fibre material.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>Composite paving blocks (75) for use in paving roads, parking lots, driveways and the like, comprising:<claim-text>asphalt in a proportion of about 25% to about 55% by volume, phenolic resin in a proportion of about 10% to about 40% by volume, monofilament fibre material in a proportion of about 5% to about 35% by volume, and elastomeric material in a proportion of about 5% to about 30% by volume.</claim-text></claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A process for manufacturing composite blocks, comprising:<!-- EPO <DP n="19"> --><claim-text>placing asphalt and polyethylene into a heated blending drum (22);</claim-text><claim-text>blending and heating said asphalt and the polyethylene at a temperature of about 130Â°F (approximately 55Â°C) until a relatively uniform mixture is obtained;</claim-text><claim-text>adding an amount of elastomeric material and an amount of a monofilament fibre material to the mixture to obtain a composite material that is subsequently formed into the composite blocks;</claim-text><claim-text>discharging portions of the composite material into a heating oven (40);</claim-text><claim-text>allowing the temperature of the composite material to stabilize in the heating oven at a temperature of about 325Â°F (approximately 163Â°C) to 375Â°F (approximately 191Â°C); and</claim-text><claim-text>discharging the portions of the composite material from the heating oven and depositing the portions of composite material into a moulding system (56,57,58) and moulding the portions of material into moulded blocks.</claim-text></claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A process for manufacturing composite paving blocks, comprising:<claim-text>placing asphalt and phenolic resin into a heated blending drum (22);</claim-text><claim-text>blending and heating said asphalt and the phenolic resin at a temperature of about 130Â°F (approximately 55Â°C) until a relatively uniform mixture is obtained;</claim-text><claim-text>adding an amount of elastomeric material and an amount of a monofilament fibre material to the mixture to obtain a composite material that is subsequently formed into the composite paving blocks,</claim-text><claim-text>discharging portions of the composite material into a heating oven (40);<!-- EPO <DP n="20"> --></claim-text><claim-text>allowing the temperature of the composite material to stabilize in the heating oven at a temperature of about 325Â°F (approximately 163Â°C) to 375Â°F (approximately 191Â°C); and</claim-text><claim-text>discharging the portions of the composite material from the heating oven and depositing the portions of composite material into a moulding system (56,57,58) and moulding the portions of material into moulded paving blocks.</claim-text></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The process of Claim 6 or 7, further including the applying of pressure of about 750 psi (approximately 51 x 10<sup>4</sup> kp/m<sup>2</sup>) to each mould until the portion of composite material has set.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A process for manufacturing composite blocks, comprising the steps of:<claim-text>placing asphalt and polyethylene into a heated blending drum (22);</claim-text><claim-text>blending and heating the asphalt and the polyethylene at a temperature of about 130Â°F (approximately 55Â°C) until a relatively uniform mixture is obtained;</claim-text><claim-text>adding an amount of elastomeric material and an amount of monofilament fibre material to the mixture to obtain a composite material that is subsequently formed into the composite blocks;</claim-text><claim-text>discharging a continuous ribbon of the composite material into a heating oven (40);</claim-text><claim-text>allowing the temperature of the composite material to stabilize in the heating oven at a temperature of about 325Â°F (approximately 163Â°C) to 375Â°F (approximately (191Â°C);</claim-text><claim-text>discharging the continuous ribbon of the composite material from the heating oven and depositing the composite material into an extruder;<!-- EPO <DP n="21"> --></claim-text><claim-text>extruding the composite material;</claim-text><claim-text>cutting the extruded composite material into a slug of desired size as it exits the extruder (104); and</claim-text><claim-text>depositing the slug (110) into a moulding system and moulding said material into moulded blocks.</claim-text></claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A process for manufacturing composite paving blocks, comprising the steps of:<claim-text>placing asphalt and phenolic resin into a heated blending drum (22);</claim-text><claim-text>blending and heating the asphalt and the phenolic resin at a temperature of about 130Â°F (approximately 55Â°C) until a relatively uniform mixture is obtained;</claim-text><claim-text>adding an amount of elastomeric material and an amount of monofilament fibre material to the mixture to obtain a composite material that is subsequently formed into the composite blocks;</claim-text><claim-text>discharging a continuous ribbon of the composite material into a heating oven (40);</claim-text><claim-text>allowing the temperature of the composite material to stabilize in the heating oven at a temperature of about 325Â°F (approximately 163Â°C) to 375Â°F (approximately (191Â°C);</claim-text><claim-text>discharging the continuous ribbon of the composite material from the heating oven and depositing the composite material into an extruder;</claim-text><claim-text>extruding the composite material;</claim-text><claim-text>cutting the extruded composite material into a slug of desired size as it exits the extruder (104); and</claim-text><claim-text>depositing the slug (110) into a moulding system and moulding said material into moulded blocks.</claim-text></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The process of Claim 9 or 10, in which the extruder that keeps the mixture at a temperature of about 325Â°F (approximately 163Â°C) to about 375Â°F (approximately 191Â°C) thereby allowing it to be more easily extruded.<!-- EPO <DP n="22"> --></claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The process of Claim 9 comprising waste reclaimed asphalt, recycled polyethylene, reclaimed elastomeric material, and reclaimed monofilament fibre material, and in which the composite material is pre-plasticized in the extruder.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>A construction material comprising:<claim-text>asphalt in a proportion of about 25% to about 55% by volume;</claim-text><claim-text>polyethylene in a proportion of about 10% to about 40% by volume;</claim-text><claim-text>monofilament fibre material in a proportion of about 5% to about 35% by volume; and</claim-text><claim-text>elastomeric material in a proportion of about 5% to about 30% by volume.</claim-text></claim-text></claim>
EP	0674732	B1	2000-08-16	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>VerbundblÃ¶cke (75), umfassend:<claim-text>Asphalt in einem Anteil von etwa 25 Vol.-% bis etwa 55 Vol.-%, Polyethylen in einem Anteil von etwa 10 Vol.-% bis etwa 40 Vol.-%, Monofilamentfasermaterial in einem Anteil von etwa 5 Vol.-% bis etwa 35 Vol.-% und elastisches Material in einem Anteil von 5 Vol.-% bis etwa 30 Vol.-%.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Block nach Anspruch 1, wobei das elastische Material Gummi oder biegsames Polyvinylchlorid ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Block nach Anspruch 1 oder Anspruch 2, wobei der Asphalt in einem Anteil von etwa 40 Vol.-%, das Polyethylen in einem Anteil von etwa 25 Vol.-%, das Monofilamentfasermaterial in einem Anteil von etwa 20 Vol.-% und das elastische Material in einem Anteil von 15 Vol.-% vorliegt.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Block nach einem der vorangegangenen AnsprÃ¼che, welcher aus Abfall rÃ¼ckgewonnenen Asphalt, wiederverwertetes Polyethylen, rÃ¼ckgewonnenes elastisches Material und rÃ¼ckgewonnenes Monofilamentfasermaterial umfaÃŸt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>VerbundpflasterblÃ¶cke (75) zur Verwendung in PflasterstraÃŸen, ParkplÃ¤tzen, Fahrwegen und dergleichen, umfassend:<claim-text>Asphalt in einem Anteil von etwa 25 Vol.-% bis etwa 55 Vol.-%, Phenolharz in einem Anteil von etwa 10 Vol.-% bis etwa 40 Vol.-%, Monofilamentfasermaterial in einem Anteil von etwa 5 Vol.-% bis etwa 35 Vol.-% und elastisches Material in einem Anteil von etwa 5 Vol.-% bis etwa 30 Vol.-%.</claim-text><!-- EPO <DP n="24"> --></claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verfahren zur Herstellung von VerbundblÃ¶cken, umfassend:<claim-text>Einbringen yon Asphalt und Polyethylen in eine erhitzte Mischtrommel (22);</claim-text><claim-text>Mischen und Erhitzen des Asphalts und des Polyethylens bei einer Temperatur von etwa 130Â°F (ungefÃ¤hr 55Â°C), bis ein relativ einheitliches Gemisch erhalten wird;</claim-text><claim-text>HinzufÃ¼gen einer Menge an elastischem Material und einer Menge eines Monofilamentfasermaterials zu dem Gemisch, um ein Verbundmaterial zu erhalten, das nachfolgend zu den VerbundblÃ¶cken geformt wird;</claim-text><claim-text>Entladen von Portionen des Verbundmaterials in einen Heizofen (40);</claim-text><claim-text>Stabilisierenlassen der Temperatur des Verbundmaterials in dem Heizofen bei einer Temperatur von etwa 325Â°F (ungefÃ¤hr 163Â°C) bis 375Â°F (ungefÃ¤hr 191Â°C); und</claim-text><claim-text>Entladen der Portionen des Verbundmaterials aus dem Heizofen und Ablegen der Portionen von Verbundmaterial in ein Formsystem (56,57,58) und Formen der Portionen von Material zu geformten BlÃ¶cken.</claim-text></claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verfahren zur Herstellung von VerbundpflasterblÃ¶cken, umfassend:<claim-text>Einbringen von Asphalt und Phenolharz in eine erhitzte Mischtrommel (22);</claim-text><claim-text>Mischen und Erhitzen des Asphalts und des Phenolharzes bei einer Temperatur von etwa 130Â°F (ungefÃ¤hr 55Â°C), bis ein relativ einheitliches Gemisch erhalten wird;</claim-text><claim-text>HinzufÃ¼gen einer Menge an elastischem Material und einer Menge eines Monofilamentfasermaterials zu dem Gemisch, um ein Verbundmaterial zu erhalten, das nachfolgend zu den VerbundpflasterblÃ¶cken geformt wird;</claim-text><claim-text>Entladen von Portionen des Verbundmaterials in einen Heizofen (40);</claim-text><claim-text>Stabilisierenlassen der Temperatur des Verbundmaterials in dem Heizofen bei einer Temperatur von etwa 325Â°F (ungefÃ¤hr 163Â°C) bis 375Â°F (ungefÃ¤hr 191Â°C); und<!-- EPO <DP n="25"> --></claim-text><claim-text>Entladen der Portionen des Verbundmaterials aus dem Heizofen und Ablegen der Portionen von Verbundmaterial in ein Formsystem (56,57,58) und Formen der Portionen von Material zu geformten Blocks.</claim-text></claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verfahren nach Anspruch 6 oder 7, ferner einschlieÃŸend das Anwenden von Druck von etwa 750 psi (ungefÃ¤hr 51 x 10<sup>4</sup> kp/m<sup>2</sup>) auf jede Form, bis die Portion von Verbundmaterial fest geworden ist.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verfahren zur Herstellung von VerbundblÃ¶cken, umfassend die Schritte des:<claim-text>Einbringens von Asphalt und Polyethylen in eine erhitzte Mischtrommel (22);</claim-text><claim-text>Mischens und Erhitzens des Asphalts und des Polyethylens bei einer Temperatur von etwa 130Â°F (ungefÃ¤hr 55Â°C), bis ein relativ einheitliches Gemisch erhalten wird;</claim-text><claim-text>HinzufÃ¼gens einer Menge an elastischem Material und einer Menge eines Monofilamentfasermaterials zu dem Gemisch, um ein Verbundmaterial zu erhalten, das nachfolgend zu den VerbundblÃ¶cken geformt wird;</claim-text><claim-text>Entladens eines Endlosbandes des Verbundmaterials in einen Heizofen (40);</claim-text><claim-text>Stabilisierenlassens der Temperatur des Verbundmaterials in dem Heizofen bei einer Temperatur von etwa 325Â°F (ungefÃ¤hr 163Â°C) bis 375Â°F (ungefÃ¤hr 191Â°C);</claim-text><claim-text>Entladens des Endlosbandes des Verbundmaterials aus dem Heizofen und Ablegens des Verbundmaterials in einen Extruder;</claim-text><claim-text>Extrudierens des Verbundmaterials;</claim-text><claim-text>Schneidens des extrudierten Verbundmaterials in ein StÃ¼ck gewÃ¼nschter GrÃ¶ÃŸe, wenn es aus dem Extruder (104) austritt; und</claim-text><claim-text>Ablegens des StÃ¼cks (110) in ein Formsystem und Formens des Materials zu geformten BlÃ¶cken.</claim-text></claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verfahren zur Herstellung von VerbundpflasterblÃ¶cken, umfassend die Schritte des:<claim-text>Einbringens von Asphalt und Phenolharz in eine erhitzte Mischtrommel (22);<!-- EPO <DP n="26"> --></claim-text><claim-text>Mischens und Erhitzens des Asphalts und des Phenolharzes bei einer Temperatur von etwa 130Â°F (ungefÃ¤hr 55Â°C), bis ein relativ einheitliches Gemisch erhalten wird;</claim-text><claim-text>HinzufÃ¼gens einer Menge an elastischem Material und einer Menge eines Monofilamentfasermaterials zu dem Gemisch, um ein Verbundmaterial zu erhalten, das nachfolgend zu den VerbundpflasterblÃ¶cken geformt wird;</claim-text><claim-text>Entladens eines Endlosbandes des Verbundmaterials in einen Heizofen (40);</claim-text><claim-text>Stabilisierenlassens der Temperatur des Verbundmaterials in dem Heizofen bei einer Temperatur von etwa 325Â°F (ungefÃ¤hr 163Â°C) bis 375Â°F (ungefÃ¤hr 191Â°C);</claim-text><claim-text>Entladens des Endlosbandes des Verbundmaterials aus dem Heizofen und Ablegens des Verbundmaterials in einen Extruder;</claim-text><claim-text>Extrudierens des Verbundmaterials;</claim-text><claim-text>Schneidens des extrudierten Verbundmaterials in ein StÃ¼ck gewÃ¼nschter GrÃ¶ÃŸe, wenn es aus dem Extruder (104) austritt; und</claim-text><claim-text>Ablegens des StÃ¼cks (110) in ein Formsystem und Formens des Materials zu geformten BlÃ¶cken.</claim-text></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verfahren nach Anspruch 9 oder 10, wobei der Extruder, der das Gemisch bei einer Temperatur von etwa 325Â°F (ungefÃ¤hr 163Â°C) bis etwa 375Â°F (ungefÃ¤hr 191Â°C) hÃ¤lt, dadurch ermÃ¶glicht, daÃŸ es leichter extrudiert wird.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verfahren nach Anspruch 9, umfassend aus Abfall rÃ¼ckgewonnenen Asphalt, wiederverwertetes Polyethylen, rÃ¼ckgewonnenes elastisches Material und rÃ¼ckgewonnenes Monofilamentfasermaterial, und wobei das Verbundmaterial in dem Extruder vorplastiziert wird.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Konstruktionsmaterial, umfassend:<claim-text>Asphalt in einem Anteil von etwa 25 Vol.-% bis etwa 55 Vol.-%;</claim-text><claim-text>Polyethylen in einem Anteil von etwa 10 Vol.-% bis etwa 40 Vol.-%;</claim-text><claim-text>Monofilamentfasermaterial in einem Anteil von etwa 5 Vol.-% bis etwa 35 Vol.-%; und<!-- EPO <DP n="27"> --></claim-text><claim-text>elastisches Material in einem Anteil von etwa 5 Vol.-% bis etwa 30 Vol.-%.</claim-text></claim-text></claim>
EP	0674732	B1	2000-08-16	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Blocs composites (75) comportant:<claim-text>de l'asphalte selon une proportion d'environ 25 % Ã  environ 55 % en volume, du polyÃ©thylÃ¨ne selon une proportion d'environ 10 % Ã  environ 40 % en volume, un matÃ©riau de fibres monofilamentaires dans une proportion d'environ 5% Ã  environ 35 % en volume, et un Ã©lastomÃ¨re dans une proportion de 5 % Ã  environ 30 % en volume.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Bloc selon la revendication 1, dans lequel l'Ã©lastomÃ¨re est du caoutchouc ou du polychlorure de vinyle souple.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Bloc selon la revendication 1 ou 2, dans lequel l'asphalte est dans une proportion d'environ 40 % en volume, le polyÃ©thylÃ¨ne est dans une proportion d'environ 25 % en volume, le matÃ©riau de fibres monofilamentaires est dans une proportion d'environ 20 % en volume, et l'Ã©lastomÃ¨re est dans une proportion de 15 % en volume.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Bloc selon l'une quelconque des revendications prÃ©cÃ©dentes, qui comporte de l'asphalte de dÃ©chet rÃ©cupÃ©rÃ©e, du polyÃ©thylÃ¨ne recyclÃ©, de l'Ã©lastomÃ¨re rÃ©cupÃ©rÃ©, et du matÃ©riau de fibres monofilamentaires rÃ©cupÃ©rÃ©.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Blocs de pavage composite (75) destinÃ©s Ã  Ãªtre utilisÃ©s pour paver des routes, des parcs de stationnement, des voies privÃ©es et analogue, comportant :<claim-text>de l'asphalte dans une proportion d'environ 25 % Ã  environ 55 % en volume, de la rÃ©sine phÃ©nolique dans une proportion d'environ 10 % Ã  environ 40 % en volume, un matÃ©riau de fibres monofilamentaires dans une proportion d'environ 5 % Ã  environ 35 % en volume, et un Ã©lastomÃ¨re dans une proportion d'environ 5 % Ã  environ 30 % en volume.</claim-text><!-- EPO <DP n="29"> --></claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>ProcÃ©dÃ© pour fabriquer des blocs composites, comportant les Ã©tapes consistant Ã  :<claim-text>mettre de l'asphalte et du polyÃ©thylÃ¨ne dans un tambour de mÃ©lange chauffÃ© (22),</claim-text><claim-text>mÃ©langer et chauffer ledit asphalte et le polyÃ©thylÃ¨ne Ã  une tempÃ©rature d'environ 55Â°C (130Â°F) jusqu'Ã  ce qu'un mÃ©lange relativement uniforme soit obtenu,</claim-text><claim-text>ajouter une quantitÃ© d'Ã©lastomÃ¨re et une quantitÃ© de matÃ©riau de fibres monofilamentaires au mÃ©lange pour obtenir un matÃ©riau composite qui est par la suite formÃ© en blocs composites,</claim-text><claim-text>dÃ©charger les parties du matÃ©riau composite Ã  l'intÃ©rieur d'un four chauffant (40),</claim-text><claim-text>permettre que la tempÃ©rature du matÃ©riau composite se stabilise dans le four chauffant Ã  une tempÃ©rature d'environ 163Â°C (325Â°F) Ã  191Â°C (375Â°F), et</claim-text><claim-text>Ã©vacuer les parties du matÃ©riau composite du four chauffant et dÃ©poser les parties du matÃ©riau composite Ã  l'intÃ©rieur d'un systÃ¨me de moulage (56, 57, 58) et mouler les parties du matÃ©riau sous forme de blocs moulÃ©s.</claim-text></claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>ProcÃ©dÃ© pour fabriquer des blocs de pavage composites comportant les Ã©tapes consistant Ã  :<claim-text>mettre de l'asphalte et une rÃ©sine phÃ©nolique Ã  l'intÃ©rieur d'un tambour de mÃ©lange chauffÃ© (22),</claim-text><claim-text>mÃ©langer et chauffer ledit asphalte et le polyÃ©thylÃ¨ne Ã  une tempÃ©rature d'environ 55Â°C (130Â°F) jusqu'Ã  ce qu'un mÃ©lange relativement uniforme soit obtenu,<!-- EPO <DP n="30"> --></claim-text><claim-text>ajouter au mÃ©lange une quantite d'Ã©lastomÃ¨re et une quantite de matÃ©riau de fibres monofilamentaires pour obtenir un matÃ©riau composite qui est par la suite formÃ© en blocs composites,</claim-text><claim-text>Ã©vacuer les parties du matÃ©riau composite jusqu'Ã  l'intÃ©rieur d'un four chauffant (40),</claim-text><claim-text>laisser la tempÃ©rature du matÃ©riau composite se stabiliser dans le four chauffant Ã  une tempÃ©rature d'environ 163Â°C (325Â°F) Ã  191Â°C (375Â°F), et</claim-text><claim-text>Ã©vacuer les parties du matÃ©riau composite Ã  partir du four chauffant et dÃ©poser les parties du matÃ©riau composite Ã  l'intÃ©rieur d'un systÃ¨me de moulage (56, 57, 58) et mouler les parties du matÃ©riau sous forme de blocs moulÃ©s.</claim-text></claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>ProcÃ©dÃ© selon la revendication 6 ou 7, comportant de plus l'application d'une pression d'environ 51 Ã— 10<sup>4</sup> kp/m<sup>2</sup> (750 psi) Ã  chaque moule jusqu'a ce que la partie de matÃ©riau composite soit durcie.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>ProcÃ©dÃ© pour fabriquer des blocs composites, comportant les Ã©tapes consistant Ã  :<claim-text>mettre de l'asphalte et du polyÃ©thylÃ¨ne dans un tambour de mÃ©lange chauffÃ© (22),</claim-text><claim-text>mÃ©langer et chauffer ledit asphalte et le polyÃ©thylÃ¨ne Ã  une tempÃ©rature d'environ 55Â°C (130Â°F) jusqu'Ã  ce qu'un mÃ©lange relativement uniforme soit obtenu,</claim-text><claim-text>ajouter au mÃ©lange une quantitÃ© d'Ã©lastomÃ¨re et une quantitÃ© de matÃ©riau de fibres monofilamentaires pour obtenir un matÃ©riau composite qui est par la suite formÃ© en blocs composites,</claim-text><claim-text>dÃ©charger un ruban continu constituÃ© du matÃ©riau composite Ã  l'intÃ©rieur d'un four chauffant (40),<!-- EPO <DP n="31"> --></claim-text><claim-text>laisser la tempÃ©rature du matÃ©riau composite se stabiliser dans le four chauffant Ã  une tempÃ©rature d'environ 163Â°C (325Â°F) Ã  191Â°C (375Â°F), et dÃ©charger le ruban continu constituÃ© du matÃ©riau composite du four chauffant et dÃ©poser le matÃ©riau composite dans une extrudeuse,</claim-text><claim-text>extruder le matÃ©riau composite,</claim-text><claim-text>couper le matÃ©riau composite extrudÃ© en billettes de dimension voulue lorsqu'il sort de l'extrudeuse (104), et</claim-text><claim-text>dÃ©poser la billette (110) Ã  l'intÃ©rieur d'un systÃ¨me de moulage et mouler ledit matÃ©riau en blocs moulÃ©s.</claim-text></claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>ProcÃ©dÃ© pour fabriquer des blocs de pavage composites, comportant les Ã©tapes consistant Ã  :<claim-text>mettre de l'asphalte et de la rÃ©sine phÃ©nolique dans un tambour de mÃ©lange chauffÃ© (22),</claim-text><claim-text>mÃ©langer et chauffer ledit asphalte et le polyÃ©thylÃ¨ne Ã  une tempÃ©rature d'environ 55Â°C (130Â°F) jusqu'Ã  ce qu'un mÃ©lange relativement uniforme soit obtenu,</claim-text><claim-text>ajouter au mÃ©lange une quantitÃ© d'Ã©lastomÃ¨re et une quantitÃ© de matÃ©riau de fibres monofilamentaires pour obtenir un matÃ©riau composite qui est par la suite formÃ© en blocs composites,</claim-text><claim-text>dÃ©charger un ruban continu constituÃ© du matÃ©riau composite Ã  l'intÃ©rieur d'un four chauffant (40),</claim-text><claim-text>laisser la tempÃ©rature du matÃ©riau composite se stabiliser dans le four chauffant Ã  une tempÃ©rature d'environ 163Â°C (325Â°F) Ã  191Â°C (375Â°F), et</claim-text><claim-text>dÃ©charger le ruban continu constituÃ© du matÃ©riau composite du four chauffant et dÃ©poser le matÃ©riau composite dans une extrudeuse,</claim-text><claim-text>extruder le matÃ©riau composite,<!-- EPO <DP n="32"> --></claim-text><claim-text>couper le matÃ©riau composite extrudÃ© en billettes de dimension voulue lorsqu'il sort de l'extrudeuse (104), et</claim-text><claim-text>dÃ©poser la billette (110) Ã  l'intÃ©rieur d'un systÃ¨me de moulage et mouler ledit matÃ©riau en blocs moulÃ©s.</claim-text></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>ProcÃ©dÃ© selon la revendication 9 ou 10, dans lequel l'extrudeuse qui maintient le mÃ©lange Ã  une tempÃ©rature d'environ 163Â°C (325Â°F) Ã  environ (191Â°C (375Â°F) lui permet ainsi d'Ãªtre plus facilement extrudÃ©.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>ProcÃ©dÃ© selon la revendication 9, comportant de l'asphalte de dÃ©chet rÃ©cupÃ©rÃ©, du polyÃ©thylÃ¨ne recyclÃ©, un Ã©lastomÃ¨re rÃ©cupÃ©rÃ©, et du matÃ©riau de fibres monofilamentaires rÃ©cupÃ©rÃ©, et dans lequel le matÃ©riau composite est prÃ©-plastifiÃ© dans l'extrudeuse.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>MatÃ©riau de construction comportant :<claim-text>de l'asphalte dans une proportion d'environ 25 % Ã  environ 55 % en volume,</claim-text><claim-text>du polyÃ©thylÃ¨ne dans une proportion d'environ 10 % Ã  environ 40 % en volume,</claim-text><claim-text>un matÃ©riau de fibres monofilamentaires dans une proportion d'environ 5 % Ã  environ 35 % en volume, et</claim-text><claim-text>un Ã©lastomÃ¨re dans une proportion d'environ 5 % Ã  environ 30 % en volume.</claim-text></claim-text></claim>
EP	0674732	B1	2000-08-16	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0674732&ki=B1&pd=2000-08-16
EP	0644972	B1	2000-08-16	de	TITLE	1	BEFESTIGUNGSSYSTEM FÃœR NEBENEINANDER UND PARALLEL GESETZTE LATTEN
EP	0644972	B1	2000-08-16	en	TITLE	1	SYSTEM FOR FIXING JUXTAPOSED AND PARALLEL SLATS
EP	0644972	B1	2000-08-16	fr	TITLE	1	SYSTEME DE FIXATION DE LATTES JUXTAPOSEES ET PARALLELES
EP	0644972	B1	2000-08-16	fr	DESCR	1	<p id="p0001" num="0001">La prÃ©sente invention concerne un systÃ¨me de fixation pour assembler des lattes juxtaposÃ©es et parallÃ¨les, notamment en bois dont la surface supÃ©rieure est prÃ©-vernie, en vue de revÃªtir une surface, comme par exemple un plancher ou un mur. Chaque latte possÃ¨de un tenon et une mortaise, lesquels sont chacun disposÃ©s sur l'un de ses cÃ´tÃ©s longitudinaux. Lors de la pose, les lattes sont disposÃ©es de faÃ§on Ã  ce que leur tenon emboÃ®te la mortaise d'une latte adjacente.</p><p id="p0002" num="0002">La mÃ©thode conventionnelle la plus utilisÃ©e pour installer un revÃªtement en bois consiste Ã  fixer les planches directement au sous-plancher Ã  l'aide de clous ou d'agrafes que l'on enfonce dans le sous-plancher avec des marteaux pneumatiques. Ces clous ou ces agrafes maintiennent solidement les lattes au sous-plancher mais produisent par leur passage Ã  travers le bois, qui est relativement sec, de lÃ©gÃ¨res imperfections qui sont perceptibles Ã  la surface des lattes. De plus, les clous et les agrafes font occasionnellement fendre le bois jusqu'Ã  sa surface, les lattes ainsi endommagÃ©es devenant inutilisables.</p><p id="p0003" num="0003">La mÃ©thode d'installation conventionnelle n'assure pas un alignement parfait des lattes sur le sous-plancher. Plusieurs facteurs peuvent en effet faire varier l'alignement des lattes les unes par rapport aux autres si, par exemple, une planche plus Ã©troite que les autres est installÃ©e au milieu d'une rangÃ©e ou que l'une des lattes est arquÃ©e. Les lattes peuvent Ã©galement prÃ©senter entre elles une lÃ©gÃ¨re dÃ©viation angulaire, ce qui produit des rangÃ©es arrondies, notamment perceptible si la surface est grande.</p><p id="p0004" num="0004">La mÃ©thode de fixation conventionnelle gÃ©nÃ¨re des dÃ©fauts qui rendent souvent le plancher inesthÃ©tique. De plus, il est trÃ¨s difficile d'enlever les lattes sans les<!-- EPO <DP n="2"> --> endommager et bien souvent, les lattes doivent Ãªtre brisÃ©es pour Ãªtre enlevÃ©es. Il n'est donc pas possible pour quelqu'un de faire poser un plancher de lattes et de le dÃ©faire lorsque cette personne dÃ©mÃ©nage ou si le plancher n'est installÃ© que sur une base temporaire, comme par exemple lors d'une exposition.</p><p id="p0005" num="0005">Les lattes des planchers posÃ©es de faÃ§on traditionnelle peuvent se pousser les unes sur les autres sous l'effet de l'humiditÃ© et ainsi crÃ©er des vides importants Ã  certains endroits dus au retrait de l'humiditÃ©.</p><p id="p0006" num="0006">Lorsque le plancher est usÃ© et qu'il doit Ãªtre sablÃ© et verni, il n'est pas possible de l'enlever pour faire ces opÃ©rations ailleurs; le sablage et le vernissage doivent Ãªtre faits sur place avec tous les inconvÃ©nients que cela entraÃ®ne, tant pour les occupants que pour les ouvriers. Le sablage et le vernissage d'un plancher de bois dans une maison ou un Ã©difice commercial contraignent souvent les occupants Ã  quitter les lieux durant les travaux de rÃ©fection qui peuvent durer plusieurs jours. Durant ce temps, le sablage gÃ©nÃ¨re une poussiÃ¨re fine qui se rÃ©pand partout et qui nÃ©cessitera un nettoyage de toute la maison ou de l'Ã©difice. De plus, les machines utilisÃ©es pour effectuer le sablage peuvent endommager le plancher de faÃ§on permanente si elles ne sont pas bien utilisÃ©es, et donc nÃ©cessitent une main-d'oeuvre qualifiÃ©e. Quant aux vernis et autres produits de finition, la plupart dÃ©gagent des vapeurs de solvants nocives, parfois explosives, et des odeurs trÃ¨s fortes qui nuisent Ã  la santÃ© des ouvriers et qui contaminent l'air de la maison ou de l'Ã©difice. Les dÃ©lais de sÃ©chage et de durcissement du vernis allongent d'autant la pÃ©riode de non utilisation des piÃ¨ces affectÃ©es.</p><p id="p0007" num="0007">Afin de rÃ©soudre les inconvÃ©nients du sablage et du vernissage des lattes sur le site mÃªme de leur utilisation, il existe sur le marchÃ© des lattes prÃ©-vernies<!-- EPO <DP n="3"> --> et celles-ci peuvent Ãªtre renvoyÃ©es Ã  nouveau Ã  l'usine lorsqu'elles sont usÃ©es afin d'Ãªtre sablÃ©es et revernies. L'usine, avec des Ã©quipements appropriÃ©s, permet de faire toutes ces opÃ©rations sans affecter la santÃ© des travailleurs. De plus, les vapeurs de solvants peuvent Ãªtre filtrÃ©es.</p><p id="p0008" num="0008">Parmi les solutions proposÃ©es permettant d'enlever les lattes sans les endommager, on retrouve, par exemple, les systÃ¨mes dÃ©crits dans les brevets US-A-1 968 798, US-A-2 004 917, CA-A-898 480, CA-A-903 436, CA-A-965 569 et CA-A-1 165 088. Ces systÃ¨mes proposent des attaches, de diverses formes, coulissant dans des rails parallÃ¨les afin de maintenir en place les lattes transversales sans les endommager. Il faut que l'utilisateur enlÃ¨ve les attaches mobiles pour enlever les lattes de bois. Ces systÃ¨mes ne proposent rien quant Ã  la synchronisation du positionnement des lattes ou de la pose d'un plancher par-dessus un revÃªtement existant sans endommager ce dernier.</p><p id="p0009" num="0009">Certains brevets, comme par exemple les brevets US-A-3 187 389, US-A-4 272 938, CA-A-405 366 et CA-A-571 352, proposent des agrafes individuelles maintenant en place les lattes sans les endommager. Ces agrafes ne permettent pas de rÃ©soudre le problÃ¨me de synchronisation ou la pose d'un plancher par-dessus un revÃªtement existant sans endommager ce dernier. De plus, les agrafes peuvent se briser quand elles sont enlevÃ©es.</p><p id="p0010" num="0010">Le brevet US-A-1 988 201 prÃ©sente un systÃ¨me dans lequel des plaques, pliÃ©es de faÃ§on Ã  s'emboÃ®ter les unes aux autres, sont placÃ©es sous les lattes en les retenant. Toutefois, ce systÃ¨me requiert beaucoup de mÃ©tal et ne rÃ©sout pas le problÃ¨me de la pose d'un plancher par-dessus un revÃªtement existant sans endommager ce dernier. De plus, les lattes doivent Ãªtre usinÃ©es spÃ©cifiquement pour leur utilisation avec ce systÃ¨me.<!-- EPO <DP n="4"> --></p><p id="p0011" num="0011">Le brevet CA-A-579 973 prÃ©sente un systÃ¨me dans lequel des languettes de mÃ©tal ont des attaches rÃ©alisÃ©es par emboutissage, lesquelles emboÃ®tent les jonctions entre les tenons et les mortaises des lattes. Les attaches doivent toutefois Ãªtre pliÃ©es pour Ã©pouser la forme du tenon et de la mortaise, et donc, subir une dÃ©formation permanente. Ces attaches peuvent se casser lorsque les lattes sont enlevÃ©es et les languettes doivent donc Ãªtre remplacÃ©es. De plus, ce systÃ¨me ne rÃ©sout pas le problÃ¨me de la pose d'un plancher par-dessus un revÃªtement existant sans endommager ce dernier.<!-- EPO <DP n="5"> --></p><p id="p0012" num="0012">Le document DE-A-41 10 749 dÃ©crit un systÃ¨me qui ressemble Ã  celui du CA-A-579973 mentionnÃ© ci-dessus, mais qui propose une fixation aux mÃ»rs et aux plafonds. Il n'est pas utilisable comme surface de parquet, puisqu'il n'est pas assez stable.<!-- EPO <DP n="6"> --></p><p id="p0013" num="0013">La prÃ©sente invention exposÃ©e dans les revendications 1 et 2 propose un systÃ¨me de fixation de lattes juxtaposÃ©es et parallÃ¨les permettant la pose synchronisÃ©e et la dÃ©pose de lattes, notamment des lattes de bois prÃ©-vernies, sans les endommager et en leur assurant un alignement parfait. Elle propose Ã©galement un systÃ¨me permettant la pose d'un plancher par-dessus un revÃªtement existant sans endommager ce dernier.</p><p id="p0014" num="0014">Le systÃ¨me de la prÃ©sente invention a notamment l'avantage de pouvoir Ãªtre utilisÃ© avec des planches standards pouvant mÃªme Ãªtre fixÃ©es de la faÃ§on traditionnelle en plus d'Ãªtre rÃ©utilisable et de ne pas avoir besoin d'Ãªtre enlevÃ© en mÃªme temps que l'on enlÃ¨ve les lattes.</p><p id="p0015" num="0015">Un autre avantage de l'invention est de faciliter la pose du plancher afin qu'une personne ayant peu d'expÃ©rience dans le domaine et un minimum d'outillage puisse l'installer elle-mÃªme.<!-- EPO <DP n="7"> --></p><p id="p0016" num="0016">L'invention sera mieux comprise Ã  la lecture non limitative qui suit d'un mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention faite en se rÃ©fÃ©rant aux dessins annexÃ©s dans lesquels:<ul id="ul0001" list-style="none" compact="compact"><li>la figure 1 reprÃ©sente une vue du dessus d'une languette selon le premier mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention,</li><li>la figure 2 reprÃ©sente une vue de cÃ´tÃ© d'une languette retenant des lattes selon le premier mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention,</li><li>la figure 3 reprÃ©sente une vue d'Ã©lÃ©vation de la figure 2,</li><li>la figure 4 reprÃ©sente une vue du dessus des languettes retenant des lattes selon le premier mode de rÃ©alisation,<!-- EPO <DP n="8"> --></li><li>la figure 5 reprÃ©sente une vue du dessus d'une languette selon le deuxiÃ¨me mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention,</li><li>la figure 6 reprÃ©sente une vue du dessus d'une latte d'alignement,</li><li>la figure 7 reprÃ©sente une vue du dessus d'un support flexible,</li><li>la figure 8 reprÃ©sente une vue de cÃ´tÃ© d'une languette retenant des lattes selon un deuxiÃ¨me mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention,</li><li>la figure 9 reprÃ©sente une vue d'Ã©lÃ©vation de la figure 8,</li><li>la figure 10 reprÃ©sente une vue du dessus des languettes retenant des lattes selon le deuxiÃ¨me mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention.</li></ul></p><p id="p0017" num="0017">Le systÃ¨me de fixation selon l'invention, illustrÃ© aux figures 1 Ã  10, comprend des languettes 10 faites en acier trempÃ© et dans lesquelles sont embouties des appuis 12 projetant vers le haut. Les appuis 12 sont pourvus, Ã  leur extrÃ©mitÃ©, de deux dents 14 en forme de pointe, repliÃ©es Ã  90Â° parallÃ¨lement Ã  la surface des languettes 10 et projetant lÃ©gÃ¨rement vers le haut. Les appuis 12 et les dents 14 sont formÃ©s par emboutissage. Leur but est d'empÃªcher les lattes 20 de se soulever en les retenant au sol.</p><p id="p0018" num="0018">Les lattes 20 comprennent une surface supÃ©rieure 22, une surface infÃ©rieure 24, deux extrÃ©mitÃ©s 26 et 28 ainsi que deux cÃ´tÃ©s latÃ©raux 30 et 32. Le cÃ´tÃ© latÃ©ral 30 comporte un tenon 36 s'Ã©tendant sensiblement sur toute la longueur longitudinale de la latte 20, et le cÃ´tÃ© latÃ©ral 32 comporte une mortaise 38 s'Ã©tendant sensiblement sur toute la longueur longitudinale de la latte 20. Les extrÃ©mitÃ©s 26 et 28 comportent respectivement une mortaise 38 et 40. Des rainures longitudinales 46, pratiquÃ©es sur la surface<!-- EPO <DP n="9"> --> infÃ©rieure 24, permettent d'Ã©viter que les lattes 20 s'arrondissent s'il survient un excÃ©dent d'humiditÃ©.</p><p id="p0019" num="0019">Les lattes 20 ont une surface supÃ©rieure 22 prÃ©fÃ©rablement prÃ©-vernie en usine de faÃ§on Ã  ce qu'il n'y ait pas de vernissage Ã  faire aprÃ¨s la pose. Lorsque le plancher sera usÃ©, ou si un changement de couleur est nÃ©cessaire, les lattes 20 peuvent Ãªtre enlevÃ©es et retournÃ©es Ã  l'usine pour effectuer les opÃ©rations nÃ©cessaires. Toutefois, le sablage et le vernissage peuvent s'effectuer sur place si nÃ©cessaire.</p><p id="p0020" num="0020">Les appuis 12 ont une hauteur Ã©gale Ã  la distance entre la surface infÃ©rieure 24 des lattes 20 et le bas des mortaises 38. La distance entre les appuis 12 est Ã©gale Ã  la largeur des lattes 20. Tel qu'illustrÃ© sur les figures 2 et 8, les dents 14, qui pointent lÃ©gÃ¨rement vers le haut, viennent se placer juste sur la surface du bas des mortaises 38 et laissent quand mÃªme assez de place pour les tenons 36.</p><p id="p0021" num="0021">Lors du montage, les languettes 10 sont disposÃ©es parallÃ¨lement les unes par rapport aux autres sur la surface Ã  revÃªtir 11. Les appuis 12 des languettes 10 doivent Ãªtre alignÃ©es les unes avec les autres de faÃ§on Ã  ce que les lattes 20, placÃ©es transversalement sur les languettes 10, puissent Ãªtre posÃ©es. Chaque rangÃ©e de lattes 20 est montÃ©e l'une aprÃ¨s l'autre et dans la direction oÃ¹ pointent les dents 14.</p><p id="p0022" num="0022">D'abord, chaque latte 20 de la premiÃ¨re rangÃ©e est installÃ©e de faÃ§on Ã  ce que le bas de leur mortaise 38 s'insÃ¨re contre l'appui 12 et sous les dents 14, tel qu'illustrÃ© sur les figures 2 et 8. Les lattes 20 d'une mÃªme rangÃ©e sont placÃ©es bout Ã  bout et il n'est pas nÃ©cessaire qu'elles aient toutes la mÃªme longueur. Les lattes 20 sont ensuite rabaissÃ©es contre le sol de faÃ§on Ã  ce que leur tenon 36 viennent reposer librement sur la prochaine sÃ©rie d'appuis 12. Puisque chaque dent 14 pointe lÃ©gÃ¨rement vers<!-- EPO <DP n="10"> --> le haut, leur pointe s'enfonce lÃ©gÃ¨rement dans le tenon 36, permettant ainsi d'Ã©viter qu'elles nuisent Ã  l'insertion des lattes suivantes.</p><p id="p0023" num="0023">La deuxiÃ¨me rangÃ©e de lattes 20 est installÃ©e contre la sÃ©rie d'appuis 12 sur lesquels reposent les tenons 36 de la premiÃ¨re rangÃ©e. La partie du bas de leur mortaise 38 est insÃ©rÃ©e contre ces appuis 12 et sous leurs dents 14, emprisonnant ainsi les tenons 36 de la premiÃ¨re rangÃ©e de lattes 20. La rangÃ©e de lattes 20 prÃ©cÃ©dente se retrouve alors contrainte Ã  l'immobilitÃ©. Les autres rangÃ©es se posent de la mÃªme faÃ§on jusqu'Ã  ce que le plancher ait la largeur dÃ©sirÃ©e. Il est Ã  noter que les extrÃ©mitÃ©s 26 et 28 des lattes 20 ne sont pas alignÃ©es avec celles des rangÃ©es adjacentes. Ceci rend le plancher plus esthÃ©tique et plus solide.</p><p id="p0024" num="0024">La diffÃ©rence majeure entre les deux modes de rÃ©alisation prÃ©fÃ©rÃ©s de l'invention est les moyens utilisÃ©s pour maintenir en place les languettes 10 les unes par rapport aux autres.</p><p id="p0025" num="0025">Selon le premier mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention, illustrÃ© aux figures 1 Ã  4, la surface Ã  revÃªtir 11 est un sous-plancher dans lequel des vis peuvent Ãªtre enfoncÃ©es. Les languettes 10 comportent des trous 42 dans lesquelles sont placÃ©es des vis 44 servant Ã  fixer solidement les languettes 10 au sous-plancher 11. Ces vis 44 comportent chacune une tÃªte 45 trÃ¨s plate qui vient se placer dans de lÃ©gÃ¨res dÃ©pressions autour des trous 42.</p><p id="p0026" num="0026">Puisque les languettes 10 n'ont pas toujours exactement la bonne longueur, il est parfois nÃ©cessaire de les couper afin de les raccourcir ou d'en faire de courts bouts pour rallonger une languette 10 trop courte. La coupe des languettes 10, selon le premier mode de rÃ©alisation, comporte des marques 48 servant de marque de coupe et permettant ainsi de conserver la synchronisation de la pose.<!-- EPO <DP n="11"> --></p><p id="p0027" num="0027">Le systÃ¨me de fixation tel que dÃ©crit dans ce premier mode de rÃ©alisation peut s'appliquer autant au recouvrement d'un plancher, qu'Ã  celui d'un mur et mÃªme d'un plafond.</p><p id="p0028" num="0028">Selon le deuxiÃ¨me mode de rÃ©alisation prÃ©fÃ©rÃ© de l'invention, illustrÃ© aux figures 5 Ã  10, les languettes 10 ne sont pas vissÃ©es au sous-plancher 11, mais plutÃ´t maintenues en place les unes par rapport aux autres par le biais de lattes d'alignement 70 placÃ©es perpendiculairement aux languettes 10. Quant aux languettes 10, elles reposent sur les supports flexibles 80, faits en caoutchouc, ou autre matÃ©riau semblable, s'Ã©tendant sur toute leur longueur. Le systÃ¨me de fixation n'est maintenu en place sur la surface Ã  revÃªtir que par gravitÃ©, ce qui permet de l'installer directement sur un revÃªtement existant sans l'endommager. Il est mÃªme possible de l'installer sur du tapis s'il n'est pas possible, ou permis, d'enlever ce dernier.</p><p id="p0029" num="0029">La pose d'un plancher maintenu en place par gravitÃ© est notamment trÃ¨s utile pour les appartements ou les expositions temporaires, soit lÃ  oÃ¹ le locataire n'a pas le droit d'endommager le plancher existant et oÃ¹ il dÃ©sire l'emporter lorsqu'il dÃ©mÃ©nage afin de le rÃ©utiliser ailleurs.</p><p id="p0030" num="0030">Dans le deuxiÃ¨me mode de rÃ©alisation prÃ©fÃ©rÃ©, les languettes 10 comportent des parois latÃ©rales 90 projetant vers le bas et s'Ã©tendant sur toute leur longueur. Les parois 90 servent Ã  prendre les supports flexibles 80 en Ã©tau. Le bas des parois 90 repose sur les cÃ´tÃ©s 82 de la base des supports flexibles 80, tel qu'illustrÃ© sur la figure 9. Des renflements 92, placÃ©s Ã  l'intÃ©rieur des parois 90, permettent de serrer davantage les supports flexibles 80 afin de les maintenir plus efficacement. Ã€ cet effet, les parois latÃ©rales des supports flexibles 80 ont des rainures longitudinales 84 servant Ã  recevoir et Ã <!-- EPO <DP n="12"> --> bloquer les renflements 92.</p><p id="p0031" num="0031">Les parois latÃ©rales 90 ont des ouvertures 94, rÃ©guliÃ¨rement espacÃ©es, qui permettent de faire passer les lattes d'alignement 70 transversalement. La largeur des ouvertures 94 est plus petite que la largeur des lattes d'alignement 70, mais ces derniÃ¨res sont pourvues d'encoches 72, rÃ©guliÃ¨rement espacÃ©es, placÃ©es deux par deux sur leurs cÃ´tÃ©s tel qu'illustrÃ© Ã  la figure 6. La distance entre les encoches 72 d'une mÃªme arÃªte latÃ©rale est Ã©gale Ã  la largeur des languettes 10. Les lattes d'alignement 70 peuvent Ãªtre facilement raccourcies grÃ¢ce aux marques 74 servant de marque de coupe, permettant ainsi de conserver la synchronisation de la pose, les lattes d'alignement 70 Ã©tant aboutÃ©es au niveau des languettes 10.</p><p id="p0032" num="0032">Pour poser ce systÃ¨me de fixation, on place tout d'abord les supports flexibles 80, puis, perpendiculairement, les lattes d'alignement 70 vis-Ã -vis oÃ¹ vont Ãªtre les ouvertures 94. Ensuite, lorsque le tout est bien alignÃ©, on place les languettes 10 par-dessus les supports flexibles 80 et en emboÃ®tant au passage les lattes d'alignement 70. Les languettes 10 doivent Ãªtre placÃ©es de faÃ§on Ã  ce que leurs dents 14 soient toutes dans la mÃªme direction.</p><p id="p0033" num="0033">Tel qu'illustrÃ© Ã  la figure 10, la pose des lattes 20 se fait de la mÃªme faÃ§on que dans le premier mode de rÃ©alisation.</p><p id="p0034" num="0034">Les lattes 20 de la derniÃ¨re rangÃ©e posÃ©e doivent Ãªtre fixÃ©es par un moyen auxiliaire afin de les empÃªcher de se soulever. Si les derniÃ¨res lattes 20 s'Ã©tendent lÃ©gÃ¨rement dans le mur, ceci peut Ãªtre fait, par exemple, Ã  l'aide de quart de rond de finition placÃ©s par-dessus celles-ci. D'autres mÃ©thodes sont aussi possibles.</p><p id="p0035" num="0035">Le systÃ¨me de fixation des lattes dÃ©crit prÃ©cÃ©demment est trÃ¨s efficace pour corriger les lattes 20<!-- EPO <DP n="13"> --> qui sont arquÃ©es car elles sont maintenues droites dans les appuis 12 qui forment un Ã©tau individuel. Ceci permet de retenir les lattes 20 en contact plus Ã©troit entre elles en limitant le travail dÃ» Ã  l'humiditÃ©. De plus, les lattes 20 ne viennent plus en contact direct avec le sous-plancher, souvent beaucoup plus humide que les lattes 20, puisqu'elles reposent sur les languettes 10. Il empÃªche ainsi les lattes qui gonfleraient, Ã  cause d'un surplus d'humiditÃ©, d'empiÃ©ter sur l'espace occupÃ© par les lattes adjacentes, limitant ainsi la possibilitÃ© de vide entre les lattes Ã  cause d'une diminution de l'humiditÃ© par la suite.</p><p id="p0036" num="0036">Puisqu'aucun clou ne traverse les lattes 20, les probabilitÃ©s de craquement seront trÃ¨s rÃ©duites lorsque des gens marcheront sur celles-ci. En effet, l'absence de fissures importantes causÃ©es par les clous lors de la pose traditionnelle Ã©vite que deux parties d'une mÃªme latte 20 viennent se frotter ensemble et causent du bruit. La prÃ©sente invention, gardant les lattes 20 intactes, permet de solutionner ce problÃ¨me.</p><p id="p0037" num="0037">Enfin, il est possible de crÃ©er un plancher avec divers motifs en alternant des sections perpendiculaires l'une Ã  l'autre. Il est Ã©galement possible de crÃ©er des languettes 10 dont les appuis 12 sont Ã  angle ou bien parallÃ¨les Ã  leur axe longitudinal afin de rÃ©pondre Ã  certains critÃ¨res de design.</p>
EP	0644972	B1	2000-08-16	fr	CLAIM	1	<claim id="c-fr-01-0001" num="0001"><claim-text>SystÃ¨me de fixation pour assembler des lattes de bois (20) juxtaposÃ©es, parallÃ¨les et de largeur identique en vue de revÃªtir une surface (11), chacune desdites lattes (20) Ã©tant pourvue d'une surface supÃ©rieure (22) prÃ©-vernie, d'une surface intÃ©rieure (24) ainsi que de deux cÃ´tÃ©s latÃ©raux (26,28) dont l'un comporte un tenon (36) et l'autre une mortaise (38), ledit tenon (36) pouvant s'insÃ©rer dans la mortaise (38) d'une latte (20) adjacente, ledit systÃ¨me de fixation comprenant:<claim-text>- un ensemble de languettes (10) minces et rigides, lesquelles sont destinÃ©es Ã  Ãªtre disposÃ©es parallÃ¨lement les unes par rapport aux autres sur la surface Ã  revÃªtir (11) en vue de recevoir les surfaces infÃ©rieures (24) des lattes (20), lesdites languettes (10) s'Ã©tendant dans une direction transversale aux lattes (20);</claim-text><claim-text>- des moyens pour maintenir en place lesdites languettes (10) les unes par rapport aux autres;</claim-text><claim-text>- un ensemble d'appuis (12) projetant vers le haut, disposÃ©s sur lesdites languettes (10), les appuis (12) ayant entre eux une distance Ã©gale Ã  la largeur des lattes (20) Ã  fixer;<!-- EPO <DP n="15"> --></claim-text><claim-text>- lesdits appuis (12) Ã©tant pourvus d'une extrÃ©mitÃ© supÃ©rieure au bout de laquelle est situÃ©e une dent pointue (14), lesdits appuis (12) et dent (14) Ã©tant obtenus par l'emboutissage des languettes (10);</claim-text><claim-text>- ladite dent (14) de chaque appui (12) Ã©tant projettÃ©e dans une mÃªme direction longitudinale des languettes (10), lesdits appuis (12) et dents (14) Ã©tant dimensionnÃ©s de faÃ§on Ã  ce que ladite dent (14) puisse s'engager dans une mortaise (38) et qu'un tenon (36) puisse Ã  son tour y Ãªtre insÃ©rÃ© de faÃ§on Ã  empÃªcher les lattes (20) de se soulever et de permettre de les placer les unes par rapport aux autres Ã  une distance prÃ©dÃ©terminÃ©e;<br/>ledit systÃ¨me de fixation Ã©tant caractÃ©risÃ© en ce que:</claim-text><claim-text>- les moyens pour maintenir en place lesdites languettes (10) l'une par rapport Ã  l'autre comprennent des trous (42) faits au travers des languettes (10) et dans lesquels sont placÃ©es des vis (44) pourvues d'une tÃªte (45) et pÃ©nÃ©trant la surface Ã  revÃªtir (11) de faÃ§on Ã  attacher rigidement lesdites languettes (10) Ã  celle-ci;</claim-text><claim-text>- lesdits appuis (12) de chacune des languettes (10) sont alignÃ©s avec les appuis (12) des languettes (10) adjacentes; et</claim-text><claim-text>- lesdites languettes (10) comportent des marques de coupe (48) servant de rÃ©fÃ©rence et permettant de maintenir la synchronisation des languettes (10).</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>SystÃ¨me de fixation pour assembler des lattes de bois (20) juxtaposÃ©es, parallÃ¨les et de largeur identique en vue de revÃªtir une surface (11), chacune desdites lattes (20) Ã©tant pourvue d'une surface supÃ©rieure (22) prÃ©-vernie, d'une surface infÃ©rieure (24) ainsi que de deux cÃ´tÃ©s latÃ©raux (26,28) dont l'un comporte<!-- EPO <DP n="16"> --> un tenon (36) et l'autre une mortaise (38), ledit tenon (36) pouvant s'insÃ©rer dans la mortaise (38) d'une latte (20) adjacente, ledit systÃ¨me de fixation comprenant:<claim-text>- un ensemble de languettes (10) minces et rigides, lesquelles sont destinÃ©es Ã  Ãªtre disposÃ©es parallÃ¨lement les unes par rapport aux autres sur la surface Ã  revÃªtir (11) en vue de recevoir les surfaces intÃ©rieures (24) des lattes, lesdites languettes (10) s'Ã©tendant dans une direction transversale aux lattes (20);</claim-text><claim-text>- des moyens pour maintenir en place lesdites languettes (10) les unes par rapport aux autres;</claim-text><claim-text>- un ensemble d'appuis (12) projetant vers le haut, disposÃ©s sur lesdites languettes (10), les appuis (12) ayant entre eux une distance Ã©gale Ã  la largeur des lattes (20) Ã  fixer;</claim-text><claim-text>- lesdits appuis (12) Ã©tant pourvus d'une extrÃ©mitÃ© supÃ©rieure au bout de laquelle est situÃ©e une dent (14) en forme de pointe, lesdits appuis (12) et dents (14) Ã©tant obtenus par l'emboutissage des languettes (10);</claim-text><claim-text>- lesdites dents (14) Ã©tant projettÃ©es dans une mÃªme direction longitudinale des languettes (10), lesdits appuis (12) et dents (14) Ã©tant dimensionnÃ©s de faÃ§on Ã  ce que la dent (14) puisse s'engager dans une mortaise (38) et qu'un tenon (36) puisse Ã  son tour y Ãªtre insÃ©rÃ© de faÃ§on Ã  empÃªcher les lattes (20) de se soulever et de permettre de les placer les unes par rapport aux autres Ã  une distance prÃ©dÃ©terminÃ©e;<br/><!-- EPO <DP n="17"> -->ledit systÃ¨me de fixation Ã©tant caractÃ©risÃ© en ce que:</claim-text><claim-text>- les languettes (10) reposent sur des supports flexibles (80) en caoutchouc, placÃ©s entre la surface Ã  revÃªtir (11) et les languettes (10), s'Ã©tendant dans la direction longitudinale des languettes (10);</claim-text><claim-text>- les languettes (10) ont des parois latÃ©rales (90) projetant vers le bas et s'Ã©tendant dans la direction longitudinale des languettes (10) de faÃ§on Ã  ce que chaque languette (10) prenne en Ã©tau son support flexible (80) correspondant;</claim-text><claim-text>- les moyens pour maintenir en place lesdites languettes (10) les unes par rapport aux autres comprennent un ensemble de lattes d'alignement (70) placÃ©es perpendiculairement aux languettes (10) vis-Ã -vis des ouvertures latÃ©rales (94) rÃ©alisÃ©es dans les parois latÃ©rales (90) des languettes (10);</claim-text><claim-text>- lesdites lattes d'alignement (70) ont des arÃªtes latÃ©rales pourvues de paires d'encoches (72) symÃ©triques s'emboÃ®tant avec les parois latÃ©rales (90) autour des ouvertures (94) et croisent les languettes (10) en passant entre elles et leur support flexible (80), lesdites languettes (10) et lesdites lattes d'alignement (70) Ã©tant disposÃ©es de faÃ§on Ã  ce que chacune des languettes (10) soit emboÃ®tÃ©e avec des encoches (72) quand des lattes d'alignement (70) la croisent;</claim-text><claim-text>- les parois latÃ©rales (90) des languettes (10) comportent des paires de renflements (92) permettant de maintenir plus efficacement les languettes (10) en Ã©tau autour des supports flexibles (80);</claim-text><claim-text>- les languettes (10) sont disposÃ©es entre elles Ã  intervalles rÃ©guliers et que les encoches (72) des lattes d'alignement (70) sont rÃ©guliÃ¨rement espacÃ©es; et</claim-text><claim-text>- le systÃ¨me de fixation n'est maintenu en place sur la surface Ã  revÃªtir (11) que par gravitÃ©; ledit systÃ¨me permettant la pose et la dÃ©pose du bois sans<!-- EPO <DP n="18"> --> enlever le systÃ¨me de fixation et sans perdre la prÃ©synchronisation.</claim-text></claim-text></claim>
EP	0644972	B1	2000-08-16	en	CLAIM	2	<claim id="c-en-01-0001" num="0001"><claim-text>Fixing system for assembling wooden boards (20) juxtaposed, parallel and of identical width, so as to cover a surface (11), each of which boards (20) has a pre-varnished upper surface (22), a lower surface (24) and two lateral sides (26, 28), one of which carries a tenon (36) and the other a mortise (38), which tenon (36) may be inserted into the mortise (38) of an adjacent board (20), the fixing system comprising:<claim-text>a set of thin, rigid tongues (10) which are intended to be arranged parallel to each other on the surface (11) to be covered so as to receive the lower surfaces (24) of the boards (20), the tongues (10) extending in a direction transverse to the boards (20),</claim-text><claim-text>means for keeping the tongues (10) in place relative to each other,</claim-text><claim-text>a set of supports (12) projecting upwards, arranged on the tongues (10) and having a distance between them that is equal to the width of the boards (20) to be fixed,</claim-text><claim-text>the supports (12) being provided at the end of their upper extremity with a pointed tooth (14), the supports (12) and the tooth (14) being obtained through stamping of the tongues (10),</claim-text><claim-text>the tooth (14) of each support (12) projecting in the same longitudinal direction as the tongues (10), and the supports (12) and teeth (14) being dimensioned so that the tooth (14) can engage into a mortise (38) and a tenon (36) can on its part be inserted therein so as to prevent the boards (20) from rising and to allow them to be placed relative to each other at a predetermined distance,<br/><b>characterised</b> in that</claim-text><claim-text>the means for keeping the tongues (10) in place relative to each other consists of holes (42) made through the tongues (10), with screws (44) having a head (45) placed therein and<!-- EPO <DP n="20"> --> penetrating the surface (11) to be covered so that the tongues (10) are rigidly attached to it,</claim-text><claim-text>the supports (12) of each tongue (10) are aligned with the supports (12) of the adjacent tongues 810), and</claim-text><claim-text>the tongues (10) have cut marks (48) that serve as references and allow the tongues (10) to be kept synchronised.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>Fixing system for assembling wooden boards (20) juxtaposed, parallel and of identical width, so as to cover a surface (11), each of which boards (20) having a pre-varnished upper surface (22), a lower surface (24) and two lateral sides (26, 28), one of which carries a tenon (36) and the other a mortise (38), which tenon (36) may be inserted into the mortise (38) of an adjacent board (20), wherein the fixing system comprises:<claim-text>a set of thin, rigid tongues (10) which are intended to be arranged parallel to each other on the surface (11) to be covered so as to receive the lower surfaces (24) of the boards, the tongues (10) extending in a direction transverse to the boards (20),</claim-text><claim-text>means for keeping the tongues (10) in place relative to each other,</claim-text><claim-text>a set of supports (12) projecting upwards, arranged on the tongues (10) and having a distance between them that is equal to the width of the boards (20) to be fixed,</claim-text><claim-text>the supports (12) being provided at the end of their upper extremity with a pointed tooth (14), the supports (12) and teeth (14) being obtained through stamping of the tongues (10),</claim-text><claim-text>the teeth (14) projecting in the same longitudinal direction as the tongues (10), the supports (12) and teeth (14) being dimensioned so that the tooth 14 can engage in the mortise (38) and a tenon (36) can on its part be inserted therein so as to prevent the boards (20) from rising and to allow them to be placed relative to each other at a predetermined distance,<br/><!-- EPO <DP n="21"> --><b>characterised</b> in that</claim-text><claim-text>the tongues (10) rest on flexible rubber supports (80) placed between the surface (11) to be covered and the tongues (10) and extending in longitudinal direction of the tongues (10),</claim-text><claim-text>the tongues (10) have side walls (90) projecting downwardly and extending in the longitudinal direction of the tongues (10) so that each tongue (10) grips its corresponding flexible support (80),</claim-text><claim-text>the means for keeping the tongues (10) in place relative to each other comprises a set of alignment strips (70) placed perpendicularly to the tongues (10) across lateral openings (94) in the side walls (90) of the tongues (10),</claim-text><claim-text>the alignment strips (70) have in their lateral edges pairs of symmetrical notches (72) that fit with the side walls (90) around the openings (94), and cross the tongues (10) passing between them and their flexible supports (80), the tongues (10) and the alignment strips (70) being arranged so that each tongue fits with the notches (72) when the alignment strips (70) cross it,</claim-text><claim-text>the side walls (90) of the tongues (10) exhibit pairs of bulges (92) allowing the tongues (10) to grip the flexible supports (80) more effectively,</claim-text><claim-text>the tongues (10) are disposed with regular intervals between them and the notches (72) of the alignment strips (70) are regularly spaced, and</claim-text><claim-text>the fixing system is held in place on the surface (11) to be covered by gravity alone, the system allowing to place and remove the wood without lifting the fixing system and without disrupting the pre-synchronisation.</claim-text></claim-text></claim>
EP	0644972	B1	2000-08-16	de	CLAIM	3	<claim id="c-de-01-0001" num="0001"><claim-text>Befestigungssystem zur Montage parallel nebeneinanderliegender Holzlatten (20) gleicher GrÃ¶ÃŸe, um eine FlÃ¤che (11) abzudecken, wobei jede Latte (20) eine vorlackierte obere FlÃ¤che (22), eine untere FlÃ¤che (24) sowie zwei Querseiten (26, 28) aufweist, von denen die eine Seite eine Feder (26) und die andere eine Nut (38) aufweist, wobei die Feder (36) in die Nut (38) einer benachbarten Latte (20) eingefÃ¼hrt werden kann, wobei das System aufweist:<claim-text>einen Satz dÃ¼nner, starrer Zungen (10) zur Anordnung parallel zueinander auf der zu bedeckenden FlÃ¤che (11), um die untere FlÃ¤che (24) der Latten (20) aufzunehmen, wobei die Zungen (10) quer zu den Latten (20) verlaufen,</claim-text><claim-text>eine Einrichtung, um die Zungen (10) relativ zueinander festzuhalten,</claim-text><claim-text>einen Satz nach oben ragender Halteelemente (12) auf den Zungen (10), wobei der Abstand zwischen den Halteelementen (12) der Breite der zu befestigenden Latten (20) entspricht,<br/>wobei die Halteelemente an ihrem oberen Ende einen spitzen Zahn (14) aufweisen und die Halteelemente (12) und der Zahn (14) durch Pressen der Zungen (10) hergestellt sind,<br/>wobei der Zahn (14) jedes Halteelements (12) in die LÃ¤ngsrichtung der Zungen (10) ragt, die Halteelemente (12) und ZÃ¤hne (14) so dimensioniert sind, daÃŸ der Zahn (14) in eine Nut (38) eingreifen kann und darin ihrerseits eine Feder (36) eingefÃ¼hrt werden kann, so daÃŸ ein Hochkommen der Latten (20) verhindert wird und die Latten zueinander mit vorbestimmtem Abstand verlegt werden kÃ¶nnen,<br/>dadurch <b>gekennzeichnet</b>, daÃŸ</claim-text><claim-text>die Einrichtung zum Festhalten der Zungen (10) relativ zueinander LÃ¶cher (42) durch die Zungen (10) aufweist, in denen mit einem Kopf (45) versehene Schrauben (44) angeordnet werden, die in die zu bedeckende FlÃ¤che (11) so eindringen, daÃŸ die Zungen (10) an ihr starr befestigt werden,<!-- EPO <DP n="23"> --></claim-text><claim-text>die Halteelemente (12) jeder Zunge (10) auf die Halteelemente (12) der benachbarten Zungen (10) ausgerichtet sind, und</claim-text><claim-text>die Zungen (10) Trennmarkierungen (48) aufweisen, die als Bezugspunkt dienen und erlauben, die Synchronisation der Zungen (10) beizubehalten.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Befestigungssystem zur Montage parallel nebeneinanderliegender Holzlatten (20) identischer GrÃ¶ÃŸe zum Bedecken einer FlÃ¤che (11), wobei jede Latte (20) eine vorlackierte obere FlÃ¤che (22), eine untere FlÃ¤che (24) sowie zwei Querseiten (26, 28) aufweist, von denen die eine Seite eine Feder (36) und die andere eine Nut (38) aufweist, wobei die Feder (36) in die Nut (38) einer benachbarten Latte (20) eingefÃ¼hrt werden kann, wobei das Befestigungssystem aufweist:<claim-text>einen Satz dÃ¼nner starrer Zungen (10) zum parallelen Verlegen zueinander auf der zu bedeckenden FlÃ¤che (11), um die unteren FlÃ¤chen (24) der Latten aufzunehmen, wobei die Zungen (10) quer zu den Latten (20) verlaufen,</claim-text><claim-text>eine Einrichtung, um die Zungen (10) relativ zueinander festzuhalten,</claim-text><claim-text>einen Satz nach oben ragender Halteelemente (12) auf den Zungen (10), wobei der Abstand zwischen den Halteelementen (12) der Breite der zu befestigenden Latten (20) entspricht,<br/>wobei die Halteelemente (12) an ihren oberen Enden jeweils einen spitzen Zahn (14) aufweisen und die Halteelemente (12) und ZÃ¤hne (14) durch Pressen der Zungen (10) gewonnen sind,<br/>wobei die ZÃ¤hne in die LÃ¤ngsrichtung der Zungen (10) verlaufen und die Halteelemente (12) und ZÃ¤hne (14) so dimensioniert sind, daÃŸ der Zahn (14) in eine Nut (38) eingreifen und eine Feder (36) ihrerseits so darin eingefÃ¼hrt werden kann, daÃŸ ein Hochkommen der Latten (20) verhindert wird und die Latten zueinander mit vorbestimmtem Abstand verlegt werden kÃ¶nnen,<br/>dadurch <b>gekennzeichnet</b>, daÃŸ<!-- EPO <DP n="24"> --></claim-text><claim-text>die Zungen (10) auf flexiblen Gummihaltern (80) abgelegt sind, die zwischen der zu bedeckenden FlÃ¤che (11) und den Zungen (10) angeordnet sind und in LÃ¤ngsrichtung der Zungen (10) verlaufen,</claim-text><claim-text>die Zungen (10) SeitenwÃ¤nde (90) aufweisen, die nach unten ragen und in LÃ¤ngsrichtung der Zungen (10) verlaufen, so daÃŸ jede Zunge (10) ihren entsprechenden flexiblen Halter (80) greift,</claim-text><claim-text>die Einrichtung zum Festhalten der Zungen (10) relativ zueinander einen Satz Ausrichtungslatten (70) aufweist, die quer zu den Zungen (10) bezÃ¼glich QuerÃ¶ffnungen (94) in den SeitenwÃ¤nden (90) der Zungen (10) angeordnet sind,</claim-text><claim-text>die Ausrichtungslatten (70) in ihren Seitenkanten Paare symmetrischer Aussparungen (72) aufweisen, die mit den SeitenwÃ¤nden (90) um die Ã–ffnungen (94) zusammenpassen, und die Zungen (10) kreuzen, wÃ¤hrend sie zwischen diesen und deren flexiblem Halter (80) hindurchfÃ¼hren, wobei die Zungen (10) und die Ausrichtungslatten (70) so angeordnet sind, daÃŸ jede Zunge (10) in die Aussparungen (72) eingepaÃŸt ist, wÃ¤hrend sie von den Ausrichtungslatten (70) gekreuzt wird,</claim-text><claim-text>die SeitenwÃ¤nde (90) der Zungen (10) Wulstpaare (92) aufweisen, durch die die Zungen (10) die flexiblen Halter (80) besser im Griff halten kÃ¶nnen,</claim-text><claim-text>die Zungen (10) mit gleichmÃ¤ÃŸigen ZwischenrÃ¤umen angeordnet sind und die Aussparungen (72) der Ausrichtungslatten (70) gleichmÃ¤ÃŸige AbstÃ¤nde aufweisen, und</claim-text><claim-text>das Befestigungssystem auf der zu bedeckenden FlÃ¤che (11) lediglich durch die Schwerkraft gehalten wird und das System das Ablegen und Abnehmen von Holz ohne Aufnehmen des Befestigungssystems und ohne ein Verlieren der vorbestimmten Synchronisation erlaubt.</claim-text></claim-text></claim>
EP	0644972	B1	2000-08-16	fr	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0644972&ki=B1&pd=2000-08-16
EP	0619773	B1	2000-03-15	de	TITLE	1	VERFAHREN UND VORRICHTUNG ZUM HERSTELLEN VON BAUBLÃ–CKEN AUS EINEM HYDRAULISCHEN BINDEMITTEL WIE GIPS, EINEM INERTEN MATERIAL WIE SAND UND WASSER
EP	0619773	B1	2000-03-15	en	TITLE	1	METHOD AND DEVICE FOR MANUFACTURING CONSTRUCTION BLOCKS FROM A HYDRAULIC BINDER SUCH AS PLASTER, AN INERT FILLER SUCH AS SAND, AND WATER
EP	0619773	B1	2000-03-15	fr	TITLE	1	PROCEDE ET DISPOSITIF DE FABRICATION DE BLOCS DE CONSTRUCTION A PARTIR D'UN LIANT HYDRAULIQUE TEL QUE DU PLATRE, D'UNE CHARGE INERTE TELLE QUE DU SABLE ET D'EAU
EP	0619773	B1	2000-03-15	fr	DESCR	1	<p id="p0001" num="0001">L'invention concerne un procÃ©dÃ© et un dispositif de fabrication de blocs de construction par moulage sous pression Ã©levÃ©e d'un mÃ©lange d'un liant hydraulique tel que du plÃ¢tre, d'une charge inerte telle que du sable et d'eau.</p><p id="p0002" num="0002">Ces blocs de construction et leur procÃ©dÃ© de fabrication ont Ã©tÃ© dÃ©crits dans la Demande Internationale WO 88/03916 du mÃªme inventeur.</p><p id="p0003" num="0003">Ce procÃ©dÃ© consiste Ã  mouler sous pression Ã©levÃ©e le mÃ©lange de plÃ¢tre, de sable et d'eau pendant une durÃ©e suffisante, de l'ordre de 2 Ã  3 mn, correspondant Ã  l'hydratation sous pression du plÃ¢tre qui se traduit par une expansion contrariÃ©e du plÃ¢tre Ã  l'intÃ©rieur du moule, ainsi que par une densification et une rÃ©orientation de son rÃ©seau cristallin.</p><p id="p0004" num="0004">Les blocs de construction ainsi obtenus ont des caractÃ©ristiques remarquables : une rÃ©sistance Ã  la compression largement supÃ©rieure Ã  100 kg/cm<sup>2</sup>, une duretÃ© Ã©quivalente Ã  celle de la pierre tendre, une bonne rÃ©sistance Ã  l'humiditÃ© et au gel, et une prÃ©cision dimensionnelle de l'ordre du 1/10<sup>e</sup> de millimÃ¨tre, ce qui permet de les monter directement les uns sur les autres sans interposition de joints traditionnels entre les blocs.</p><p id="p0005" num="0005">Ces blocs sont de plus utilisables en construction Ã  leur sortie des moules, sans sÃ©chage.</p><p id="p0006" num="0006">Il en rÃ©sulte une Ã©conomie de construction considÃ©rable, aussi bien en temps qu'en qualification de main d'oeuvre, les frais de construction proprement dits Ã©tant divisÃ©s par un facteur au moins Ã©gal Ã  2 ou 3.</p><p id="p0007" num="0007">La demande internationale WO 88/03916 prÃ©citÃ©e dÃ©crit Ã©galement un dispositif de fabrication de ces blocs, comprenant les moyens dÃ©crits dans le prÃ©ambule de la revendication 4 et dans lequel la presse hydraulique est utilisÃ©e pour maintenir les plateaux du moule en<!-- EPO <DP n="2"> --> place pendant l'hydratation du plÃ¢tre et pour rÃ©sister Ã  l'expansion volumique du plÃ¢tre, ce qui amÃ¨ne Ã  laisser le moule dans la presse pendant 2 Ã  3 minutes environ et ne permet pas une cadence Ã©levÃ©e de fabrication des blocs.</p><p id="p0008" num="0008">La prÃ©sente invention a pour objet des perfectionnements importants au procÃ©dÃ© et au dispositif prÃ©citÃ©s, qui permettent d'amÃ©liorer encore les caractÃ©ristiques des blocs de construction prÃ©citÃ©s, d'uniformiser leur qualitÃ© et de rÃ©duire leur prix de revient.</p><p id="p0009" num="0009">Elle a Ã©galement pour objet des moyens permettant de fabriquer ces blocs en grande quantitÃ© et Ã  cadence Ã©levÃ©e.</p><p id="p0010" num="0010">L'invention propose Ã  cet effet un procÃ©dÃ© de fabrication de blocs de construction Ã  partir d'un mÃ©lange d'un liant hydraulique tel que du plÃ¢tre, d'une charge inerte telle que du sable et d'eau, le liant hydraulique augmentant de volume au cours de son hydratation et le mÃ©lange prÃ©citÃ© Ã©tant moulÃ© sous pression pendant une durÃ©e suffisante pour obtenir une hydratation sous pression du liant hydraulique et une densification de son rÃ©seau cristallin, le procÃ©dÃ© consistant Ã  placer une quantitÃ© dosÃ©e du mÃ©lange dans un moule Ã  parois latÃ©rales indÃ©formables et Ã  plateaux horizontaux supÃ©rieur et infÃ©rieur dÃ©plaÃ§ables en translation verticale dans le moule avec un jeu faible par rapport au parois latÃ©rales, caractÃ©risÃ© en ce qu'il consiste ensuite Ã  dÃ©placer lentement au moins l'un des plateaux vers l'intÃ©rieur du moule sur des courses successives prÃ©determinÃ©es pour tasser le mÃ©lange Ã  l'intÃ©rieur du moule, puis pour donner une hauteur prÃ©dÃ©finie au bloc Ã  obtenir en comprimant progressivement le mÃ©lange dans le moule, Ã  maintenir en place lesdits plateaux pendant la durÃ©e prÃ©citÃ©e d'hydratation du liant hydraulique en rÃ©sistant Ã  son<!-- EPO <DP n="3"> --> expansion volumique et ensuite Ã  Ã©carter l'un des plateaux pour dÃ©mouler le bloc par dÃ©placement de l'autre plateau vers l'intÃ©rieur du moule.</p><p id="p0011" num="0011">La compression lente du mÃ©lange placÃ© dans le moule a pour effet, successivement, de tasser le mÃ©lange dans le moule en rÃ©duisant son foisonnement, de chasser l'air contenu dans le mÃ©lange et d'accÃ©lÃ©rer le mouillage du mÃ©lange grÃ¢ce Ã  la mise en pression de l'eau, de chasser hors du moule un Ã©ventuel excÃ¨s d'eau par rapport Ã  la quantitÃ© d'eau juste nÃ©cessaire Ã  l'hydratation du plÃ¢tre, et de dÃ©finir avec prÃ©cision la hauteur (ou dimension encre les plateaux horizontaux du moule) du bloc de construction Ã  obtenir. Le maintien en place des plateaux du moule, dans la position qu'ils occupent Ã  la fin de la phase de compression, permet de conserver cette hauteur pendant la phase suivante, qui est une phase d'hydratation sous pression et d'expansion contrariÃ©e du plÃ¢tre dans le moule.</p><p id="p0012" num="0012">Les blocs de construction ainsi produits ont des dimensions bien dÃ©finies et une rÃ©sistance Ã  la compression qui est au moins Ã©gale Ã  une valeur prÃ©dÃ©terminÃ©e.</p><p id="p0013" num="0013">Selon une autre caractÃ©ristique de l'invention, ce procÃ©dÃ© consiste Ã©galement Ã  dÃ©tecter l'augmentation de pression dans le moule rÃ©sultant de l'expansion contrariÃ©e du liant hydraulique, pour dÃ©finir la fin de la durÃ©e d'expansion contrariÃ©e dans le moule et dÃ©mouler le bloc de construction, lorsque cette pression a atteint une valeur prÃ©dÃ©terminÃ©e.</p><p id="p0014" num="0014">De prÃ©fÃ©rence, cette valeur prÃ©dÃ©terminÃ©e de la pression dans le moule ne correspondra qu'Ã  70-90% environ de l'hydratation complÃ¨te du liant hydraulique dans le moule, de faÃ§on Ã  rÃ©duire l'effort Ã  fournir pour le dÃ©moulage des blocs de construction et l'usure des moules.<!-- EPO <DP n="4"> --></p><p id="p0015" num="0015">L'invention propose Ã©galement un dispositif pour l'exÃ©cution de ce procÃ©dÃ©, comprenant un moule Ã  parois verticales indÃ©formables et Ã  plateaux horizontaux supÃ©rieur et infÃ©rieur, qui sont dÃ©plaÃ§ables en translation dans le moule avec un jeu faible par rapport aux parois verticales, des moyens de positionnement du plateau infÃ©rieur dans le moule, des moyens de remplissage du moule par une quantitÃ© dosÃ©e du mÃ©lange prÃ©citÃ©, des moyens de mise en place du plateau supÃ©rieur dans le moule, au moins une presse hydraulique pour dÃ©placer au moins l'un des plateaux Ã  l'intÃ©rieur du moule pour tasser le mÃ©lange dans le moule et le comprimer sous pression Ã©levÃ©e jusqu'Ã  la hauteur dÃ©sirÃ©e du bloc Ã  obtenir, des moyens de retrait d'au moins un des plateaux du moule, et des moyens de dÃ©moulage Ã  vÃ©rin hydraulique pour sortir le bloc du moule, caractÃ©risÃ© en ce que la presse est commandÃ©e pour dÃ©placer lentement le ou les plateaux prÃ©citÃ©s Ã  l'intÃ©rieur du moule sur des courses successives prÃ©dÃ©terminÃ©es de tassement et de compression et en ce que le dispositif comprend des moyens indÃ©pendants de la presse pour maintenir en place les plateaux dans le moule pendant l'expansion du liant hydraulique rÃ©sultant de son hydratation.</p><p id="p0016" num="0016">Par ailleurs, le dispositif peut Ã©galement comprendre des moyens de dÃ©tection de l'augmentation de pression du mÃ©lange dans le moule, rÃ©sultant de l'expansion contrariÃ©e du liant hydraulique.</p><p id="p0017" num="0017">De prÃ©fÃ©rence, au moins le plateau supÃ©rieur du moule comprend un rebord oblique sur au moins une partie de la pÃ©riphÃ©rie de sa face de contact avec le mÃ©lange dans le moule, pour former un chanfrein (continu ou discontinu) sur au moins une partie du bord pÃ©riphÃ©rique supÃ©rieur du bloc de construction.</p><p id="p0018" num="0018">La prÃ©sence de ce chanfrein Ã©vite les risques de fissuration ou d'Ã©clatement du bord pÃ©riphÃ©rique supÃ©rieur du bloc de construction, lorsque les plateaux du<!-- EPO <DP n="5"> --> moule sont libÃ©rÃ©s Ã  la fin de la phase d'expansion contrariÃ©e, avant le dÃ©moulage.</p><p id="p0019" num="0019">Par ailleurs, en prÃ©voyant un chanfrein identique sur le bord pÃ©riphÃ©rique infÃ©rieur du bloc de<!-- EPO <DP n="6"> --> construction, on amÃ©liore l'aspect d'une construction formÃ©e par la pose de ces blocs les uns sur les autres.</p><p id="p0020" num="0020">Selon une autre caractÃ©ristique de l'invention, la presse hydraulique comprend des plateaux supÃ©rieur et infÃ©rieur entre lesquels est placÃ© le moule et qui sont reliÃ©s par une transmission mÃ©canique propre Ã  dÃ©finir de faÃ§on positive une distance dÃ©terminÃ©e entre les plateaux de la presse, correspondant Ã  la hauteur dÃ©sirÃ©e du bloc de construction, et Ã  assurer le parallÃ©lisme de ces plateaux.</p><p id="p0021" num="0021">On Ã©vite ainsi d'utiliser des butÃ©es mÃ©caniques sur lesquels les plateaux de la presse viendraient en appui, et l'on peut mesurer les efforts de tension ou de compression auxquels sont soumis des Ã©lÃ©ments de cette transmission mÃ©canique lors de la phase d'expansion contrariÃ©e du liant hydraulique dans le moule, pour dÃ©finir la fin de cette phase d'expansion contrariÃ©e.</p><p id="p0022" num="0022">De faÃ§on gÃ©nÃ©rale, l'invention permet d'automatiser de faÃ§on fiable et sÃ»re le procÃ©dÃ© de fabrication des blocs de construction, d'amÃ©liorer et d'uniformiser leur qualitÃ©, et d'augmenter trÃ¨s sensiblement leur cadence de fabrication.</p><p id="p0023" num="0023">L'invention sera mieux comprise et d'autres caractÃ©ristiques, dÃ©tails et avantages de celle-ci apparaitront plus clairement Ã  la lecture de la description qui suit, faite Ã  titre d'exemple en rÃ©fÃ©rence aux dessins annexÃ©s, dans lesquels :<ul id="ul0001" list-style="dash" compact="compact"><li>les figures 1, 2 et 3 sont des vues schÃ©matiques de dessus, en coupe verticale et de dessous respectivement, d'un bloc de construction selon l'invention;</li><li>la figure 4 est une vue schÃ©matique en coupe verticale d'un moule de fabrication de ce bloc;</li><li>la figure 5 est une vue schÃ©matique de dessus de ce moule, dont le plateau supÃ©rieur a Ã©tÃ© retirÃ©;<!-- EPO <DP n="7"> --></li><li>la figure 6 illustre schÃ©matiquement les diffÃ©rents postes de fabrication de ce bloc, dans une rÃ©alisation de l'invention;</li><li>les figures 7 et 8 sont des vues en coupe verticale et de dessus, respectivement, d'une variante de rÃ©alisation d'un moule;</li><li>la figure 9 reprÃ©sente schÃ©matiquement les postes d'une installation utilisant le moule des figures 7 et 8.</li></ul></p><p id="p0024" num="0024">Le bloc de construction qui a Ã©tÃ© reprÃ©sentÃ© dans les figures 1 Ã  3 est sensiblement identique Ã  celui qui a Ã©tÃ© dÃ©crit dans la Demande Internationale WO 88/03916 et est de tonne parallÃ©pipÃ©dique rectangle, avec des dimensions qui sont par exemple de 15cm x 15cm x 30 cm. Un bloc selon l'invention, ayant ces dimensions, pÃ¨se un peu plus d'une dizaine de kilos et est facilement manipulable Ã  la main. Bien entendu, l'invention permet Ã©galement la fabrication de blocs ayant des formes et dimensions diffÃ©rentes.</p><p id="p0025" num="0025">La face supÃ©rieure 12 de ce bloc comporte des saillies 14 de faible hauteur, de forme carrÃ©e ou circulaire par exemple.</p><p id="p0026" num="0026">La face infÃ©rieure 16 du bloc comprend une cavitÃ© 18 d'un volume relativement important (de l'ordre de 30% du volume total par exemple), qui s'Ã©tend sur une certaine hauteur Ã  l'intÃ©rieur du bloc 10 et dont le dÃ©bouchÃ© sur la face infÃ©rieure 16 du bloc est dÃ©limitÃ© par des bords longitudinaux 20 et transversaux 22 qui dÃ©finissent des logements des saillies 14 de la face supÃ©rieure d'un autre bloc.</p><p id="p0027" num="0027">En outre, la face infÃ©rieure 16 du bloc comporte une rainure ou un canal longitudinal 24 s'Ã©tendant sur toute sa longueur, qui communique avec la cavitÃ© 18 et qui dÃ©bouche Ã  l'une des ses extrÃ©mitÃ©s longitudinales dans une rainure verticale 26 formÃ©e sur toute la hauteur du bloc, dans une de ses faces verticales d'extrÃ©mitÃ©.<!-- EPO <DP n="8"> --></p><p id="p0028" num="0028">Comme cela est expliquÃ© dans la Demande Internationale prÃ©citÃ©e, les blocs 10 sont destinÃ©s Ã  Ãªtre posÃ©s les uns sur les autres et les uns Ã  cÃ´tÃ© des autres, en Ã©tant tous orientÃ©s dans le mÃªme sens, pour former un mur comprenant des rangÃ©es horizontales de blocs dans lesquels les blocs sont dÃ©calÃ©s entre eux d'une demi-longueur d'une rangÃ©e Ã  l'autre. Du plÃ¢tre relativement liquide est versÃ© en deux fois dans les rainures verticales 26 pour venir remplir partiellement les cavitÃ©s 18 des blocs en recouvrant les saillies 14 des faces supÃ©rieures des blocs infÃ©rieurs, puis pour remplir les rainures verticales 26.</p><p id="p0029" num="0029">Comme on le voit sur les figures 1 Ã  3, un chanfrein 28 est formÃ© sur au moins une partie des bords pÃ©riphÃ©riques des faces supÃ©rieure et infÃ©rieure du bloc de construction. Des chanfreins identiques peuvent aussi Ãªtre formÃ©s sur les bords verticaux du bloc.</p><p id="p0030" num="0030">Les figures 4 et 5 reprÃ©sentent schÃ©matiquement un moule utilisÃ© pour la fabrication du bloc reprÃ©sentÃ© dans les figures 1 Ã  3.</p><p id="p0031" num="0031">Ce moule comprend quatre parois verticales 30 en acier, qui sont assemblÃ©es rigidement entre elles, de prÃ©fÃ©rence par des boulons 32 et qui sont positionnÃ©es les unes par rapport aux autres au moyen de pions de centrage 34 pour dÃ©finir de faÃ§on prÃ©cise la longueur et la largeur de la cavitÃ© de moulage, avec une tolÃ©rance dimensionnelle de l'ordre de quelques centiÃ¨mes de millimÃ¨tre. Les faces intÃ©rieures des parois verticales 30 sont rectifiÃ©es pour Ãªtre parfaitement lisses et planes. L'une des parois verticales 30, formant une des petites faces verticales d'extrÃ©mitÃ© du moule, comporte sur toute sa hauteur une saillie verticale 36 de forme semi-cylindrique destinÃ©e Ã  former la rainure verticale 26 du bloc de construction Ã  obtenir.</p><p id="p0032" num="0032">Les parois verticales 30 du moule ont une hauteur supÃ©rieure Ã  celle du bloc Ã  obtenir, de faÃ§on Ã  recevoir<!-- EPO <DP n="9"> --> entre elles le plateau supÃ©rieur 38 et le plateau infÃ©rieur 40 du moule. Lorsque la hauteur du bloc Ã  obtenir est de 15 cm, les parois verticales 30 du moule auront une hauteur comprise entre 25 et 30 cm environ.</p><p id="p0033" num="0033">Les plateaux du moule sont des plaques rectangulaires en acier, dimensionnÃ©es pour pouvoir Ãªtre dÃ©plaÃ§ables par translation verticale Ã  l'intÃ©rieur du moule, avec un jeu faible de quelques dixiÃ¨mes de millimÃ¨tres par rapport aux parois verticales. Par ailleurs, les faces internes des parois verticales 30 forment avec la verticale un angle de dÃ©pouille faible de l'ordre de 0,5Â° pour faciliter le dÃ©moulage du bloc de construction.</p><p id="p0034" num="0034">La face infÃ©rieure du plateau supÃ©rieur 38 du moule comporte deux petites cavitÃ©s 42, dont les formes correspondent Ã  celles des saillies 14 de la face supÃ©rieure du bloc de construction Ã  obtenir, et un rebord pÃ©riphÃ©rique oblique 44 de formation du chanfrein 28 du bloc Ã  obtenir. Ce rebord oblique peut Ãªtre prÃ©vu uniquement sur une partie de la pÃ©riphÃ©rie de la face infÃ©rieure du plateau 38. Une petite face verticale du plateau 38 comporte une rainure semi-cylindrique correspondant Ã  la saillie verticale 36.</p><p id="p0035" num="0035">La face supÃ©rieure du plateau infÃ©rieur 40 porte un noyau 46 destinÃ© Ã  former la cavitÃ© 18 et le canal longitudinal 24 dans la face infÃ©rieure du bloc Ã  obtenir. De plus, une petite face verticale de ce plateau 40 et du noyau 46 comporte une rainure verticale semi-cylindrique, destinÃ©e Ã  recevoir la saillie verticale 36 de la paroi latÃ©rale 30 correspondante du moule. Le bord supÃ©rieur du plateau 40 comporte Ã©galement un rebord pÃ©riphÃ©rique oblique de formation du chanfrein 28 prÃ©citÃ© du bloc de construction. Comme prÃ©cÃ©demment, ce rebord oblique peut Ãªtre prÃ©vu uniquement sur une partie de la pÃ©riphÃ©rie du plateau 40.</p><p id="p0036" num="0036">Dans une variante de rÃ©alisation de ce moule, au moins l'une des grandes parois verticales 30 du moule<!-- EPO <DP n="10"> --> est fixÃ©e de faÃ§on facilement amovible aux autres parois par tout moyen appropriÃ©, comprenant par exemple des charniÃ¨res et/ou des leviers de verrouillage. Le retrait de cette grande paroi 30 du moule peut faciliter le dÃ©moulage du bloc de construction. De plus, cette paroi 30 peut Ãªtre destinÃ©e Ã  recevoir sur sa face interne une plaque d'une matiÃ¨re quelconque appropriÃ©e destinÃ©e Ã  former un parement de faÃ§ade sur le bloc de construction.</p><p id="p0037" num="0037">Les diffÃ©rents postes d'un dispositif de fabrication d'un bloc de construction selon l'invention ont Ã©tÃ© reprÃ©sentÃ©s schÃ©matiquement en figure 6.</p><p id="p0038" num="0038">Dans cette figure, le dessin du moule 50 a Ã©tÃ© simplifiÃ©, mais il est bien entendu que ce moule peut Ãªtre identique Ã  celui reprÃ©sentÃ© schÃ©matiquement dans les figures 4 et 5.</p><p id="p0039" num="0039">Le premier poste du dispositif selon l'invention, dÃ©signÃ© gÃ©nÃ©ralement par la rÃ©fÃ©rence A, est un poste de remplissage du moule 50. A ce poste, le moule 50 repose sur une surface de support 52, qui peut faire partie de moyens de transfert des moules entre les diffÃ©rents postes du dispositif de fabrication. Le plateau infÃ©rieur 40 du moule est Ã©galement portÃ© par cette surface de support 52, de faÃ§on Ã  occuper une position dÃ©finie Ã  l'intÃ©rieur du moule. Des moyens 54 permettent de dÃ©verser Ã  l'intÃ©rieur du moule une quantitÃ© dosÃ©e d'un mÃ©lange 56 d'un liant hydraulique tel que du plÃ¢tre, d'une charge inerte telle que du sable, et d'eau. Les moyens 54 d'amenÃ©e de ce mÃ©lange sont avantageusement conÃ§us pour rÃ©aliser Ã©galement l'humidification d'un mÃ©lange sec de plÃ¢tre et de sable avec une quantitÃ© d'eau qui sera sensiblement Ã©gale ou lÃ©gÃ¨rement supÃ©rieure Ã  la quantitÃ© d'eau nÃ©cessaire Ã  la compacitÃ© optimale du mÃ©lange (cette quantitÃ© d'eau Ã©tant supÃ©rieure Ã  celle nÃ©cessaire Ã  l'hydratation du plÃ¢tre).</p><p id="p0040" num="0040">Pour la fabrication d'un bloc de construction tel que reprÃ©sentÃ© aux figures 1 Ã  3, et ayant des dimensions<!-- EPO <DP n="11"> --> de 15cm x 15 cm x 30 cm, on utilise un mÃ©lange comprenant environ 6 kg de sable, 4 kg de plÃ¢tre et 1,3-1,5 litres d'eau selon les granulomÃ©tries du sable et du plÃ¢tre. Ce mÃ©lange est dÃ©versÃ© dans le moule en quelques secondes.</p><p id="p0041" num="0041">Le moule est ensuite transfÃ©rÃ© au poste suivant, dÃ©signÃ© par la rÃ©fÃ©rence B, oÃ¹ le plateau supÃ©rieur 38 du moule est placÃ© dans le moule et repose sur le mÃ©lange 56 de plÃ¢tre, de sable et d'eau.</p><p id="p0042" num="0042">Eventuellement, l'un ou l'autre des postes A et B ou les deux postes, peuvent comprendre une table vibrante permettant de rÃ©aliser un dÃ©but de tassement du mÃ©lange 56 dans le moule, une Ã©vacuation de l'air occlus et un meilleur mouillage.</p><p id="p0043" num="0043">Le poste suivant, dÃ©signÃ© par la rÃ©fÃ©rence C, comporte essentiellement une presse hydraulique Ã  deux plateaux horizontaux mobiles 58 et 60 entre lesquels est placÃ© le moule 50. Un ou plusieurs vÃ©rins hydrauliques 62 permettent de dÃ©placer les plateaux de la presse, par exemple en synchronisme, dans des directions opposÃ©es pour les rapprocher et pour les Ã©carter l'un de l'autre. Par exemple, les tiges de piston des vÃ©rins 62 s'appuient sur le plateau supÃ©rieur 58 de la presse tandis que leurs cylindres sont portÃ©s par une plaque horizontale 64 dÃ©plaÃ§able en translation verticale et reliÃ©e par des tirants 66 au plateau infÃ©rieur 60 de la presse.</p><p id="p0044" num="0044">Les tirants 66 permettent d'assurer l'obtention et le maintien de la distance voulue entre les plateaux du moule, et sont le siÃ¨ge d'efforts de tension que l'on peut mesurer pour contrÃ´ler la bonne exÃ©cution du procÃ©dÃ©.</p><p id="p0045" num="0045">Le plateau supÃ©rieur 58 de la presse s'applique sur le plateau supÃ©rieur 38 du moule tandis que les parois verticales 30 et le plateau infÃ©rieur 40 du moule s'appuient sur le plateau infÃ©rieur 60 de la presse.<!-- EPO <DP n="12"> --></p><p id="p0046" num="0046">La compression du mÃ©lange 56 dans le moule est rÃ©alisÃ©e de faÃ§on lente, de prÃ©fÃ©rence en deux temps :<ul id="ul0002" list-style="dash" compact="compact"><li>une premier temps au cours duquel le mÃ©lange 56 est simplement tassÃ© dans le moule par descente du plateau supÃ©rieur 38 Ã  l'intÃ©rieur du moule, sur une course de plusieurs centimÃ¨tres (de 4 Ã  10 cm par exemple), la durÃ©e de cette course Ã©tant de plusieurs secondes (par exemple de 5 Ã  10 s environ);</li><li>un deuxiÃ¨me temps au cours duquel le plateau supÃ©rieur 38 est enfoncÃ© dans le moule sur une course de plusieurs centimÃ¨tres jusqu'Ã  ce que la distance sÃ©parant les plateaux 38 et 40 du moule soit Ã©gale Ã  la hauteur dÃ©sirÃ©e du bloc de construction. La durÃ©e de ce deuxiÃ¨me temps est de plusieurs secondes et la pression appliquÃ©e au mÃ©lange 56 Ã  l'intÃ©rieur du moule atteint des valeurs comprises entre 50 et 100 kg/cm<sup>2</sup> environ, selon les cas.</li></ul></p><p id="p0047" num="0047">Ces deux temps de compression peuvent Ãªtre rÃ©alisÃ©s soit par dÃ©placement d'un des deux plateaux 38, 40 Ã  l'intÃ©rieur du moule, soit par dÃ©placement des deux plateaux 38,40 l'un vers l'autre.</p><p id="p0048" num="0048">Au cours de la compression du mÃ©lange 56 dans le moule, l'air contenu dans ce mÃ©lange est chassÃ© par le jeu entre les parois verticales et les plateaux du moule, l'eau se rÃ©partit uniformÃ©ment dans le mÃ©lange de plÃ¢tre et de sable grÃ¢ce Ã  la pression exercÃ©e, et un Ã©ventuel excÃ¨s d'eau est chassÃ© par le jeu entre les parois verticales et les plateaux du moule. La distance entre les plateaux 38 et 40 du moule, correspondant Ã  la hauteur dÃ©sirÃ©e du bloc Ã  obtenir, est de prÃ©fÃ©rence dÃ©finie de faÃ§on positive par une transmission mÃ©canique reliant entre eux les plateaux 58 et 60 de la presse et assurant leur parallÃ©lisme.</p><p id="p0049" num="0049">Lorsque les plateaux 38 et 40 du moule ont Ã©tÃ© amenÃ©s Ã  la distance voulue correspondant Ã  la hauteur du bloc Ã  obtenir, ils sont immobilisÃ©s. La pression dans le moule va alors chuter sensiblement pendant un laps de<!-- EPO <DP n="13"> --> temps bref, puis va augmenter progressivement au fur et Ã  mesure de l'expansion du plÃ¢tre, rÃ©sultant de son hydratation.</p><p id="p0050" num="0050">En consÃ©quence, lorsque les plateaux 38 et 40 du moule ont Ã©tÃ© amenÃ©s Ã  la distance voulue l'un de l'autre par les vÃ©rins hydrauliques 62 de la presse, ces vÃ©rins sont Ã  nouveau commandÃ©s pour Ã©carter les plateaux 58 et 60 et permettre le transfert du moule 50 au poste suivant, dÃ©signÃ© par la rÃ©fÃ©rence D, oÃ¹ les plateaux 38 et 40 du moule sont maintenus dans une position correspondant Ã  la hauteur dÃ©sirÃ©e du bloc Ã  obtenir. Pour cela, le poste D peut comprendre par exemple des moyens 68 de support du moule et du plateau infÃ©rieur 40, et des moyens d'appui sur le plateau supÃ©rieur 38, ces moyens pouvant Ãªtre du type mÃ©canique, par exemple des leviers 70 montÃ©s Ã  rotation sur un support 72, et/ou du type hydraulique, par exemple des vÃ©rins 74 portÃ©s par le support 72.</p><p id="p0051" num="0051">Le moule 50 est maintenu au poste D pendant une durÃ©e suffisante pour que l'hydratation du plÃ¢tre se produise Ã  70-90% environ Ã  l'intÃ©rieur du moule 50. Cette durÃ©e peut varier de 1,5 Ã  5 mn environ, en fonction de la tempÃ©rature, du type et de la quantitÃ© de plÃ¢tre utilisÃ©, et du degrÃ© d'hydratation du plÃ¢tre que l'on veut obtenir sous pression. L'augmentation de pression dans le moule 50, qui rÃ©sulte de l'expansion contrariÃ©e du plÃ¢tre, peut Ãªtre trÃ¨s importante et atteindre des valeurs de l'ordre de 100 kg/cm<sup>2</sup>.</p><p id="p0052" num="0052">Les moyens d'appui 70, 74 vont donc avoir une rÃ©sistance suffisante pour s'opposer Ã  la pression exercÃ©e sur le plateau supÃ©rieur 38 du moule.</p><p id="p0053" num="0053">De prÃ©fÃ©rence, la pression Ã  l'intÃ©rieur du moule est dÃ©tectÃ©e par des moyens appropriÃ©s, de faÃ§on Ã  ce que les moyens d'appui 70, 74 libÃ¨rent le plateau supÃ©rieur 38 du moule dÃ¨s que cette pression a atteint une valeur prÃ©dÃ©terminÃ©e. On peut, pour cela, mesurer par<!-- EPO <DP n="14"> --> exemple la pression Ã  l'intÃ©rieur des vÃ©rins hydrauliques 74 et mettre ces vÃ©rins Ã  l'Ã©chappement dÃ¨s que la pression atteint une valeur prÃ©dÃ©terminÃ©e, ou bien mesurer l'effort exercÃ© sur les leviers 70 et les faire pivoter pour libÃ©rer le plateau 38 quand cet effort atteint une valeur dÃ©terminÃ©e. On peut Ã©galement mesurer la tension de biellettes reliant les supports 68 et 72 et commander la libÃ©ration du plateau supÃ©rieur 38 dÃ¨s que cette tension atteint une valeur prÃ©dÃ©terminÃ©e.</p><p id="p0054" num="0054">On peut Ã©galement Ã©quiper les vÃ©rins hydrauliques 74 d'un limiteur de pression, de faÃ§on Ã  ce que la pression Ã  l'intÃ©rieur du moule 50 ne puisse dÃ©passer une valeur prÃ©dÃ©terminÃ©e.</p><p id="p0055" num="0055">A titre d'exemple, on a reprÃ©sentÃ© schÃ©matiquement au poste D un moyen 76 de mesure de la pression dans un vÃ©rin 74, ce moyen 76 Ã©tant associÃ© Ã  un moyen 78 de commande du vÃ©rin.</p><p id="p0056" num="0056">A l'issue de cette phase d'expansion contrariÃ©e du plÃ¢tre dans le moule 50, les moyens 70, 74 d'appui sur le plateau supÃ©rieur 38 du moule sont Ã©cartÃ©s et le moule est transfÃ©rÃ© au poste suivant dÃ©signÃ© par la rÃ©fÃ©rence E, oÃ¹ le plateau supÃ©rieur 38 du moule est retirÃ©.</p><p id="p0057" num="0057">Le moule est ensuite transfÃ©rÃ© au poste suivant, dÃ©signÃ© par la rÃ©fÃ©rence F et qui est un poste de dÃ©moulage.</p><p id="p0058" num="0058">A ce poste, les parois verticales 30 du moule sont immobilisÃ©es entre des butÃ©es, et un ou plusieurs vÃ©rins hydrauliques 80 exercent un effort important sur le plateau infÃ©rieur 40, pour le pousser vers le haut et permettre l'extraction du bloc 82 par des moyens 84 de prise et de transfert, le bloc 82 Ã©tant manipulable et utilisable dÃ¨s sa sortie du moule. Au dÃ©but du dÃ©moulage, l'effort fourni par le ou les vÃ©rins 80 peut Ãªtre trÃ¨s important (par exemple de l'ordre de 100 kg/cm<sup>2</sup>) sur une faible course, aprÃ¨s quoi la dÃ©pouille verticale des<!-- EPO <DP n="15"> --> faces 30 facilite le dÃ©placement vers le haut du plateau infÃ©rieur 40.</p><p id="p0059" num="0059">Il faut ensuite redescendre (par exemple au moyen des vÃ©rins 80) le plateau infÃ©rieur 40 en position dans le moule, qui est alors transfÃ©rÃ© au poste A, pour Ãªtre Ã  nouveau rempli d'un mÃ©lange de plÃ¢tre, de sable et d'eau.</p><p id="p0060" num="0060">Le poste occupÃ© le plus longtemps par les moules est le poste D oÃ¹ se produit l'expansion contrariÃ©e du plÃ¢tre pendant une durÃ©e comprise entre 1,5 et 5 mn environ. Le dispositif selon l'invention peut donc comprendre plusieurs de ces postes, agencÃ©s pour Ãªtre dÃ©plaÃ§ables sur un trajet de longueur dÃ©terminÃ©e entre le poste C et le poste E, par exemple au moyen d'un carrousel comprenant une dizaine des postes D, tournant pas Ã  pas entre le poste C et le poste E.</p><p id="p0061" num="0061">L'ensemble du dispositif peut Ã©galement se prÃ©senter sous forme d'un carrousel tournant entre les postes A, C et F, et comportant un certain nombre de postes D, ainsi que des moyens de pose et de retrait des couvercles supÃ©rieurs 38 des moules.</p><p id="p0062" num="0062">La cadence de fabrication n'est alors limitÃ©e que par la durÃ©e des opÃ©rations au poste C, qui est de l'ordre d'une quinzaine de secondes, et peut donc atteindre 200 blocs/heure environ.</p><p id="p0063" num="0063">On peut augmenter largement cette cadence en rÃ©alisant le premier temps de compression du mÃ©lange dans le moule au poste B, et le deuxiÃ¨me temps au poste C.</p><p id="p0064" num="0064">Si nÃ©cessaire, on peut, pour augmenter encore cette cadence, utiliser des moules Ã  empreintes multiples, ce qui permet de multiplier la cadence de fabrication par le nombre d'empreintes que comprend chaque moule.</p><p id="p0065" num="0065">Dans une forme simplifiÃ©e de rÃ©alisation, le dispositif selon l'invention ne comprend que les postes A, C et F, le plateau supÃ©rieur 38 du moule Ã©tant alors<!-- EPO <DP n="16"> --> fixÃ© Ã  demeure sous le plateau supÃ©rieur 58 de la presse. Dans ce cas, les opÃ©rations de tassement du mÃ©lange dans le moule, de compactage et de maintien en place des plateaux du moule pendant l'expansion contrariÃ©e du plÃ¢tre, sont rÃ©alisÃ©es au niveau de la presse. La cadence de fabrication est alors d'une vingtaine de blocs par heure (si l'on n'utilise que des moules Ã  empreinte unique), mais est obtenue au moyen d'une machine relativement simple ne comprenant que des postes de remplissage des moules et de dÃ©moulage des blocs et une presse hydraulique. Deux ouvriers suffisent pour assurer le fonctionnement de cette machine.</p><p id="p0066" num="0066">Inversement, lorsque le dispositif selon l'invention est conÃ§u pour offrir une cadence de production Ã©levÃ©e, il peut Ãªtre prÃ©vu en sortie d'une installation de production de plÃ¢tre et utiliser alors le plÃ¢tre chaud sortant directement de cette installation, ce qui rÃ©duit d'ailleurs la durÃ©e de l'expansion contrariÃ©e et est favorable Ã  l'augmentation de la cadence de production.</p><p id="p0067" num="0067">On a reprÃ©sentÃ© schÃ©matiquement dans les figures 7 et 8 une variante de rÃ©alisation du moule selon l'invention.</p><p id="p0068" num="0068">Dans cette variante, le moule constituÃ© essentiellement des quatre parois verticales 30, du plateau supÃ©rieur 38 et du plateau infÃ©rieur 40, est ceinturÃ© et supportÃ© par au moins un cadre rigide 86 de forme rectangulaire sur les cÃ´tÃ©s duquel les parois verticales 30 du moule sont fixÃ©es de faÃ§on dÃ©montable. Deux cÃ´tÃ©s adjacents du cadre 86 comportent des moyens 88 associÃ©s aux parois verticales 30 correspondantes du moule pour les dÃ©placer transversalement vers l'intÃ©rieur et vers l'extÃ©rieur du moule, comme indiquÃ© par les doubles flÃ¨ches en figure 8, sur une faible distance, par exemple de l'ordre de 1 Ã  10 mm environ. Ces moyens 88 peuvent Ãªtre mÃ©caniques, par exemple Ã  vis, Ã  came ou Ã  levier, ou hydrauliques.<!-- EPO <DP n="17"> --></p><p id="p0069" num="0069">La base du cadre 86 peut Ã©galement comprendre des moyens 90 sur lesquels repose le plateau infÃ©rieur 40 du moule.</p><p id="p0070" num="0070">De plus, le plateau supÃ©rieur 38 du moule comporte des moyens 92, par exemple mÃ©caniques, de verrouillage en position entre les parois verticales 30 lorsque le plateau supÃ©rieur 38 se trouve Ã  une distance prÃ©dÃ©terminÃ©e du plateau infÃ©rieur 40, cette distance Ã©tant Ã©gale Ã  la hauteur du bloc Ã  fabriquer.</p><p id="p0071" num="0071">On va maintenant dÃ©crire, en rÃ©fÃ©rence Ã  la figure 9, la faÃ§on dont le moule des figures 7 et 8 est utilisÃ© pour la fabrication de blocs de construction selon l'invention.</p><p id="p0072" num="0072">L'installation reprÃ©sentÃ©e en figure 9 comprend un certain nombre de postes A, B, C, D, E, F et G auxquels le moule des figures 7 et 8 est successivement amenÃ© par des moyens de transfert reprÃ©sentÃ©s schÃ©matiquement par les flÃ¨ches joignant les divers postes de la figure 9. Avantageusement, ces moyens de transfert vont agir sur le cadre 86 qui ceinture et supporte le moule proprement dit.</p><p id="p0073" num="0073">Le premier poste A de l'installation de la figure 9 est un poste de remplissage du moule par un mÃ©lange de plÃ¢tre, de sable et d'eau. A ce poste, le plateau infÃ©rieur 40 du moule est en appui sur les moyens de support 90, et les deux parois verticales mobiles 30 du moule ont Ã©tÃ© rapprochÃ©es, pour dÃ©limiter entre elles et avec des deux autres parois verticales 30 un volume de moulage Ã  la dimension du bloc Ã  fabriquer. Le plateau supÃ©rieur 38 du moule a Ã©tÃ© Ã©cartÃ©, pour permettre le remplissage du moule par le mÃ©lange de plÃ¢tre, de sable et d'eau.</p><p id="p0074" num="0074">Au poste suivant B, le plateau supÃ©rieur 38 est placÃ© sur le moule et le mÃ©lange humide placÃ© dans le moule peut Ãªtre lÃ©gÃ¨rement tassÃ© et comprimÃ© comme dÃ©jÃ  dÃ©crit en rÃ©fÃ©rence Ã  la figure 6.<!-- EPO <DP n="18"> --></p><p id="p0075" num="0075">Le poste suivant C est le poste de compression lente du mÃ©lange dans le moule, et comprend une presse qui va agir sur le plateau supÃ©rieur 38 pour comprimer le mÃ©lange dans le moule jusqu'Ã  la cÃ´te de hauteur dÃ©sirÃ©e du bloc Ã  fabriquer. A la fin de cette compression, les moyens 92 sont actionnÃ©s pour bloquer le plateau supÃ©rieur 38 en position sur les parois verticales 30 du moule, puis le moule et son cadre 86 sont transfÃ©rÃ©s du poste C au poste E d'ouverture du moule, la durÃ©e du trajet entre ces deux postes correspondant Ã  la durÃ©e de la phase d'expansion contrariÃ©e D du plÃ¢tre dans le moule. Cette durÃ©e peut Ãªtre suffisante pour que l'hydratation du plÃ¢tre soit complÃ¨te entre les postes C et E, ce qui garantit la stabilitÃ© dimensionnelle des blocs aprÃ¨s leur dÃ©moulage.</p><p id="p0076" num="0076">Au poste E, les moyens 92 sont actionnÃ©s pour libÃ©rer le plateau supÃ©rieur 38 et les moyens 88 sont Ã©galement actionnÃ©s pour Ã©carter vers l'extÃ©rieur les deux parois mobiles 30 du moule.</p><p id="p0077" num="0077">Le moule et son cadre 86 sont ensuite transfÃ©rÃ©s au poste F oÃ¹ il suffit de soulever le plateau infÃ©rieur 40 pour dÃ©mouler le bloc de construction. Du fait de l'Ã©cartement prÃ©alable des parois mobiles 30 du moule, ce dÃ©moulage s'effectue sans problÃ¨me et sans frottement du bloc sur les faces internes des parois 30 du moule, et donc sans usure sensible de ces faces.</p><p id="p0078" num="0078">Le moule et son cadre 86 sont ensuite transfÃ©rÃ©s au poste G, qui est un poste de nettoyage du moule, par exemple au moyen de jets d'air sous pression ou de jets d'eau sous pression, et qui peut Ãªtre aussi Ã©ventuellement un poste de pose d'une plaque de parement sur la face interne d'une des parois 30 du moule.</p><p id="p0079" num="0079">Le moule et le cadre 86 sont enfin ramenÃ©s au poste de remplissage A, oÃ¹ les moyens 88 peuvent Ãªtre Ã  nouveau actionnÃ©s pour replacer les parois mobiles 30 en<!-- EPO <DP n="19"> --> position de moulage, avant le remplissage du moule par le mÃ©lange de plÃ¢tre, de sable et d'eau.</p><p id="p0080" num="0080">Le moule des figures 7 et 8 prÃ©sente des avantages trÃ¨s importants, dans la mesure oÃ¹ il permet d'Ã©viter tout problÃ¨me au dÃ©moulage, et d'effectuer une hydratation totale du plÃ¢tre sous pression dans le moule, tout en garantissant une prÃ©cision dimensionnelle Ã©levÃ©e de l'ordre du 10Ã¨me de millimÃ¨tre sur le bloc de construction ainsi fabriquÃ©.</p><p id="p0081" num="0081">Le cadre 86 qui ceinture le moule est de construction robuste pour Ãªtre rigide et indÃ©formable. Les cadres 86 Ã©quipÃ©s chacun d'un moule peuvent Ãªtre juxtaposÃ©s, par exemple par deux ou par quatre, pour Ãªtre transfÃ©rÃ©s ensemble d'un poste Ã  l'autre dans l'installation de la figure 9, qui est alors Ã©quipÃ©e d'une presse multiple, pour doubler ou quadrupler la cadence de fabrication.</p><p id="p0082" num="0082">Le procÃ©dÃ© et le dispositif selon l'invention sont applicables Ã  la fabrication d'Ã©lÃ©ments et de blocs de construction ayant des formes et des dimensions diffÃ©rentes de celles du bloc reprÃ©sentÃ© dans les figures 1 Ã  3, et notamment des blocs pleins, des blocs Ã  cavitÃ©s multiples, des Ã©lÃ©ments plans, des chaÃ®neaux, etc...</p>
EP	0619773	B1	2000-03-15	fr	CLAIM	1	<claim id="c-fr-01-0001" num="0001"><claim-text>ProcÃ©dÃ© de fabrication de blocs de construction Ã  partir d'un mÃ©lange d'un liant hydraulique tel que du plÃ¢tre, d'une charge inerte telle que du sable et d'eau, le liant hydraulique augmentant de volume au cours de son hydratation et le mÃ©lange prÃ©citÃ© Ã©tant moulÃ© sous pression pendant une durÃ©e suffisante pour rÃ©aliser une hydratation sous pression du liant hydraulique et obtenir une densification de son rÃ©seau cristallin, le procÃ©dÃ© consistant Ã  placer une quantitÃ© dosÃ©e du mÃ©lange dans un moule Ã  parois latÃ©rales indÃ©formables (30) et Ã  plateaux horizontaux supÃ©rieur et infÃ©rieur (38, 40) dÃ©plaÃ§ables en translation verticale dans le moule avec un jeu faible par rapport aux parois latÃ©rales, Ã  dÃ©placer lentement au moins l'un des plateaux vers l'intÃ©rieur du moule sur des courses successives prÃ©dÃ©terminÃ©es pour tasser le mÃ©lange Ã  l'intÃ©rieur du moule, puis donner une hauteur prÃ©dÃ©finie au bloc Ã  obtenir en comprimant progressivement le mÃ©lange dans le moule, Ã  maintenir en place lesdits plateaux pendant la durÃ©e prÃ©citÃ©e d'hydratation du liant hydraulique en rÃ©sistant Ã  son expansion volumique, et ensuite Ã  Ã©carter l'un des plateaux pour dÃ©mouler le bloc par dÃ©placement de l'autre plateau vers l'intÃ©rieur du moule.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>ProcÃ©dÃ© selon la revendication 1, caractÃ©risÃ© en ce qu'il consiste Ã  dÃ©tecter l'augmentation de pression dans le moule rÃ©sultant de l'expansion contrariÃ©e du liant hydraulique, pour dÃ©finir la fin de la durÃ©e prÃ©citÃ©e et dÃ©mouler ensuite le bloc de construction lorsque cette pression atteint une valeur prÃ©dÃ©terminÃ©e.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>ProcÃ©dÃ© selon la revendication 1 ou 2, caractÃ©risÃ© en ce qu'il consiste Ã  dÃ©placer certaines parois latÃ©rales du moule sur une faible distance vers l'extÃ©rieur pour faciliter le dÃ©moulage.<!-- EPO <DP n="21"> --></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Dispositif pour l'exÃ©cution du procÃ©dÃ© selon la revendication 1, 2 ou 3, comprenant un moule Ã  parois verticales (30) indÃ©formables et Ã  plateaux horizontaux supÃ©rieur et infÃ©rieur (38, 40), qui sont dÃ©plaÃ§ables en translation dans le moule avec un jeu faible par rapport aux parois verticales, des moyens (52, 90) de positionnement du plateau infÃ©rieur dans le moule, des moyens (54) de remplissage du moule par une quantitÃ© dosÃ©e du mÃ©lange prÃ©citÃ©, des moyens de mise en place du plateau supÃ©rieur (38) dans le moule, au moins une presse hydraulique (62) pour dÃ©placer au moins l'un des plateaux (38, 40) Ã  l'intÃ©rieur du moule pour tasser le mÃ©lange dans le moule et le comprimer sous pression Ã©levÃ©e jusqu'Ã  la hauteur dÃ©sirÃ©e du bloc Ã  obtenir, des moyens de retrait d'au moins un des plateaux du moule, et des moyens de dÃ©moulage Ã  vÃ©rin hydraulique (80) pour sortir le bloc du moule, caractÃ©risÃ© en ce que la presse (62) est commandÃ©e pour dÃ©placer lentement le ou les plateaux prÃ©citÃ©s Ã  l'intÃ©rieur du moule sur des courses successives prÃ©dÃ©terminÃ©es de tassement et de compression et en ce que le dispositif comprend des moyens (70,74,90,92) indÃ©pendants de la presse pour maintenir en place les plateaux dans le moule pendant l'expansion du liant hydraulique rÃ©sultant de son hydratation.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Dispositif selon la revendication 4, caractÃ©risÃ© en ce qu'il comprend des moyens (76) de dÃ©tection de l'augmentation de pression du mÃ©lange dans le moule, rÃ©sultant de l'expansion contrariÃ©e du liant hydraulique.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Dispositif selon la revendication 4, caractÃ©risÃ© en ce que les parois verticales du moule sont ceinturÃ©es par au moins un cadre rigide (86) de support qui comprend des moyens (88) de dÃ©placement transversal sur une faible distance d'au moins deux parois verticales adjacentes du moule.<!-- EPO <DP n="22"> --></claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Dispositif selon l'une des revendications 4 Ã  6, caractÃ©risÃ© en ce qu'il comprend au moins un poste (A) de remplissage du moule, un poste (C) de compression du mÃ©lange dans le moule et un poste (F) de dÃ©moulage, ainsi que des moyens de transfert du moule entre ces trois postes.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Dispositif selon une des revendications 4 Ã  7, caractÃ©risÃ© en ce qu'il comprend Ã©galement des moyens (84) de prise et de transfert du bloc sorti du moule.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Dispositif selon l'une des revendications 4 Ã  8, caractÃ©risÃ© en ce qu'au moins le plateau supÃ©rieur (38) du moule comprend un rebord oblique (44) sur au moins une partie de la pÃ©riphÃ©rie de sa face de contact avec le mÃ©lange dans le moule, pour former un chanfrein (28) sur au moins une partie du bord pÃ©riphÃ©rique supÃ©rieur du bloc de construction.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Dispositif selon l'une des revendications 4 Ã  9, caractÃ©risÃ© en ce que le plateau infÃ©rieur du moule comprend, sur sa face de contact avec le mÃ©lange dans le moule, au moins un noyau (46) en saillie permettant de former au moins une cavitÃ© (18) dans le bloc de construction.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Dispositif selon l'une des revendications 4 Ã  10, caractÃ©risÃ© en ce que ladite presse comprend des plateaux supÃ©rieur et infÃ©rieur (58, 60) entre lesquels est placÃ© le moule et qui sont reliÃ©s par une transmission mÃ©canique propre Ã  dÃ©finir de faÃ§on positive une distance minimale entre les plateaux de la presse correspondant Ã  la hauteur dÃ©sirÃ©e du bloc de construction, et Ã  assurer le parallÃ©lisme des plateaux.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Dispositif selon l'une des revendications 4 Ã  11, caractÃ©risÃ© en ce que les moyens (70,74,90,92) de maintien en place des plateaux du moule sont du type mÃ©canique et/ou hydraulique.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Dispositif selon l'une des revendications 4 Ã  12, caractÃ©risÃ© en ce que les moyens de maintien en<!-- EPO <DP n="23"> --> place des plateaux du moule comprennent des moyens d'appui (70, 72) ou de verrouillage (92)</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Dispositif selon l'une des revendications 4 Ã  13, caractÃ©risÃ© en ce qu'au moins une des grandes parois verticales (30) du moule est destinÃ©e Ã  recevoir une plaque de parement du bloc de construction.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Dispositif selon l'une des revendications 4 Ã  14, caractÃ©risÃ© en ce qu'il est agencÃ© en sortie d'une installation de production de plÃ¢tre.</claim-text></claim>
EP	0619773	B1	2000-03-15	en	CLAIM	2	<claim id="c-en-01-0001" num="0001"><claim-text>A method for manufacturing blocks from a mixture of a hydraulic binder, such as plaster, an inert filler, such as sand, and water, the hydraulic binder increasing in volume during its hydration and the said mixture being molded under pressure during a period of time that is sufficient for obtaining hydration under pressure of the hydraulic binder and obtaining a densification of its crystal lattice, the method consisting in placing a measured quantity of the mixture in a mold having undeformable side walls (30) and top and bottom horizontal plates (38, 40) that are movable in vertical translation inside the mold with small clearance relative to the side walls, in slowly displacing at least one of the plates in the mold on successive predetermined strokes so as to settle the mixture inside the mold and to impart a predefined height to the block to be obtained by progressively compressing the mixture in the mold, in keeping said plates in place during the above hydration period of the hydraulic binder by resisting its volumic expansion, and then in moving one of the plates away for the purpose of unmolding the block by displacing the other plate towards the inside of the mold.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A method according to claim 1, characterized in that it consists in detecting the pressure increase in the mold that results from the hydration of the hydraulic binder for defining the end of the above period and then in unmolding the building block once this pressure has reached a predetermined value.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A method according to claim 1 or 2, characterized in that it consists in displacing some<!-- EPO <DP n="25"> --> of the side walls of the mold over a short distance in an outward direction in order to facilitate unmolding.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>An apparatus for carrying out of the method according to claims 1, 2 or 3, comprising a mold having undeformable side walls (30) and top and bottom horizontal plates (38, 40) which are movable in translation inside the mold with a small clearance relative to the side walls, means (52, 90) for positioning the bottom plate in the mold, means (54) for filling the mold with a measured quantity of said mixture, means for installing the top plate (38) in the mold, at least one hydraulic press (62) for displacing at least one of the plates (38, 40) inside the mold to settle the mixture inside the mold and to compress it under high pressure until the desired height of the block to be obtained, means for withdrawing at least one of the plates from the mold, and hydraulically actuated unmolding means (80) for extracting the block from the mold, characterized in that the press (62) is controlled for slowly displacing one or both of said plates inside the mold over successive predetermined settling and compressing strokes and in that the device comprises means (70,74,90,92) independent from the press for keeping the plates in place in the mold during the expansion of the hydraulic binder resulting from its hydration.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>An apparatus according to claim 4, characterized in that it comprises means (76) for detecting a pressure increase of the mixture in the mold that results from the hydration of the hydraulic binder.<!-- EPO <DP n="26"> --></claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>An apparatus according to claim 4, characterized in that the vertical walls of the mold are surrounded by at least one rigid support frame (86) which includes means (88) for transverse displacement of at least two adjacent vertical walls of the mold over a short distance.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>An apparatus according to any one of claims 4 to 6, characterized in that it comprises at least one station (A) for filling the mold, a station (C) for compressing the mixture inside the mold and an unmolding station (F) and means for transferring the mold between these three stations.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>An apparatus according to any one of claims 4 to 7, characterized in that it also comprises means (84) for grasping and transferring the block extracted from the mold.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>An apparatus according to any one of claims 4 to 8, characterized in that at least the top plate (138) of the mold includes an oblique rim (44) over at least a fraction of a periphery of its face that comes into contact with the mixture in the mold for forming a chamfer (28) over at least a fraction of a top peripheral edge of the building block.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>An apparatus according to any one of claims 4 to 9, characterized in that the bottom plate of the mold includes at least one projecting core (46) on its face that comes into contact with the mixture in the mold, the core enabling at least one cavity (18) to be formed in the building block.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>An apparatus according to any one of claims 4 to 10, characterized in that said press comprises<!-- EPO <DP n="27"> --> top and bottom plates (58, 60) between which the mold is placed, and which are connected by a mechanical transmission suitable for positively defining a minimum distance between the plates of the press that corresponds to the height desired for the building block, and for ensuring that the plates of the press are parallel.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>An apparatus according to any one of claims 4 to 11, characterized in that the means (70, 74, 90, 92) for keeping the mold plates in place in the mold are mechanical and/or hydraulic means.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>An apparatus according to any one of claims 4 to 12, characterized in that the means for keeping the mold plates in place comprise bearing means (70, 72) or locking means (92).</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>An apparatus according to any one of claims 4 to 13, characterized in that at least one of the large vertical walls (30) of the mold is designed to receive a plate for decorating the building block.</claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>An apparatus according to any one of claims 4 to 14, characterized in that it is disposed at an outlet from an installation for producing plaster.</claim-text></claim>
EP	0619773	B1	2000-03-15	de	CLAIM	3	<claim id="c-de-01-0001" num="0001"><claim-text>Verfahren zur Herstellung eines Baublockes, ausgehend von einer Mischung aus einem hydraulischen Bindemittel, wie Gips, einem inerten Material, wie Sand, und Wasser, wobei das hydraulische Bindemittel das Volumen wÃ¤hrend seiner Hydrierung vergrÃ¶ÃŸert und die vorgenannte Mischung unter Druck wÃ¤hrend einer Zeit geformt wird, welche ausreicht, um eine Hydrierung unter Druck des hydraulischen Bindemittels zu verwirklichen und eine Verdichtung seines Kristallnetzes zu erhalten, wobei das Verfahren darin besteht, eine abgemessene Menge der Mischung in eine Form mit unverformbaren lateralen WÃ¤nden (30) und oberen und unteren horizontalen Platten (38, 40) einzubringen, welche in vertikaler Richtung in der Form mit einem geringen Spiel bezÃ¼glich der lateralen WÃ¤nde versetzbar sind, um langsam wenigstens eine der Platten gegen das Innere der Form in vorbestimmten aufeinanderfolgenden GÃ¤ngen zu versetzen, um die Mischung in das Innere der Form zu pressen, dann dem Block eine vorbestimmte HÃ¶he zu verleihen, indem die Mischung nach und nach in der Form komprimiert wird, indem die Platten wÃ¤hrend der vorgenannten Dauer der Hydrierung des hydraulischen Bindemittels in Stellung gehalten werden, um seiner Volumenausdehnung zu widerstehen und dann eine der Platten entfernt wird, um den Block durch Verschieben der anderen Platte gegen das Innere der Form aus der Form zu brechen.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verfahren nach Anspruch 1, dadurch gekennzeichnet, daÃŸ es darin besteht, die ErhÃ¶hung des Druckes in der Form festzustellen, welcher durch die unerwÃ¼nschte Expansion des hydraulischen Bindemittels entsteht, um das Ende der genannten<!-- EPO <DP n="29"> --> Zeit zu definieren und dann den Baublock aus der Form zu brechen, wenn der Druck einen vorbestimmten Wert erreicht hat.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verfahren nach Anspruch 1 oder 2, dadurch gekennzeichnet, daÃŸ es darin besteht, bestimmte laterale WÃ¤nde der Form Ã¼ber eine geringe Distanz gegen das Ã„uÃŸere zu versetzen, um das aus der Form brechen zu erleichtern.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Vorrichtung zur DurchfÃ¼hrung des Verfahrens gemÃ¤ÃŸ den AnsprÃ¼chen 1, 2 oder 3, umfassend eine Form mit nicht verformbaren vertikalen WÃ¤nden (30) und mit oberen und unteren horizontalen Platten (38, 40), welche in der Form mit einem geringen Spiel bezÃ¼glich der vertikalen WÃ¤nde versetzbar sind, Einrichtungen (52, 90) zur Positionierung der unteren Platte in der Form, Einrichtungen (54) zum BefÃ¼llen der Form mit einer abgemessenen Menge der vorgenannten Mischung, Einrichtungen zum Einstellen der oberen Platte (38) in der Form, wenigstens eine hydraulische Presse (62), um wenigstens eine der Platten (38, 40) im Inneren der Form zu versetzen, um die Mischung in der Form zu pressen und sie unter erhÃ¶htem Druck zu komprimieren, bis die gewÃ¼nschte HÃ¶he des zu erhaltenden Blockes erreicht ist, Einrichtungen zum ZurÃ¼cknehmen wenigstens einer der Platten der Form und Einrichtungen zur Entformung mit hydraulischem Stellglied (80), um den Block aus der Form zu entfernen, dadurch gekennzeichnet, daÃŸ die Presse (62) zur langsamen Versetzung der vorgenannten Platte(n) im Inneren der Form bei vorbestimmten aufeinanderfolgenden Reihen der Verpressung und Komprimierung gesteuert wird, und dadurch, daÃŸ die Vorrichtung Einrichtungen (70, 74, 90, 92) umfaÃŸt, welche unabhÃ¤ngig von der Presse sind, um die Platten in der Form wÃ¤hrend der Expansion des hydraulischen Bindemittels, welche aus seiner Hydrierung resultiert, zu halten.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Vorrichtung nach Anspruch 4, dadurch gekennzeichnet, daÃŸ sie Einrichtungen (76) zur Feststellung der ErhÃ¶hung des<!-- EPO <DP n="30"> --> Druckes der Mischung in der Form umfaÃŸt, welcher aus der unerwÃ¼nschten Expansion des hydraulischen Bindemittels resultiert.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Vorrichtung nach Anspruch 4, dadurch gekennzeichnet, daÃŸ die vertikalen WÃ¤nde der Form durch wenigstens einen steifen Rahmen (86) zur StÃ¼tzung umfaÃŸt sind, welcher Einrichtungen (88) zur transversalen Versetzung Ã¼ber eine geringe Distanz wenigstens zweier vertikaler benachbarter WÃ¤nde der Form umfaÃŸt.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 6, dadurch gekennzeichnet, daÃŸ sie wenigstens einen Posten (A) zum BefÃ¼llen der Form, einen Posten (B) zum Verdichten der Mischung in der Form und einen Posten (F) zur Entformung sowie Einrichtungen zum Transport der Form zwischen diesen drei Posten umfaÃŸt.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 7, dadurch gekennzeichnet, daÃŸ sie des weiteren Einrichtungen (84) zur Aufnahme und zum Transport des aus der Form freigegebenen Blockes umfaÃŸt.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 8, dadurch gekennzeichnet, daÃŸ wenigstens die obere Platte (38) der Form eine abgeschrÃ¤gte Leiste (44) entlang wenigstens einem Teil des Umfanges ihrer KontaktflÃ¤che mit der Mischung in der Form umfaÃŸt, um eine KeilschrÃ¤gung (28) Ã¼ber wenigstens einen Teil der oberen Umfangskante des Baublockes auszubilden.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 9, dadurch gekennzeichnet, daÃŸ die untere Platte der Form an ihrer KontaktflÃ¤che mit der Mischung in der Form wenigstens einen Auskragungskern (46) umfaÃŸt, welcher es ermÃ¶glicht, wenigstens eine Ausnehmung (18) in dem Baublock auszubilden.<!-- EPO <DP n="31"> --></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 10, dadurch gekennzeichnet, daÃŸ die Presse obere und untere Platten (58, 60) umfaÃŸt, zwischen welchen die Form angeordnet ist, und welche durch eine mechanische Ãœbertragung verbunden sind, die dazu geeignet ist, in positiver Form einen minimalen Abstand zwischen den Platten der entsprechenden Presse und der gewÃ¼nschten HÃ¶he des Baublockes zu definieren und die ParallelitÃ¤t der Platten sicherzustellen.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 11, dadurch gekennzeichnet, daÃŸ die Einrichtung (70, 74, 90, 92) zum Instellunghalten der Platten der Form vom mechanischen und/oder hydraulischen Typ sind.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 12, dadurch gekennzeichnet, daÃŸ die Einrichtungen zum Instellunghalten der Platten der Form StÃ¼tz- (70, 72) oder Einrast(92) einrichtungen umfassen.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 13, dadurch gekennzeichnet, daÃŸ wenigstens eine der groÃŸen vertikalen WÃ¤nde (30) der Form zur Aufnahme einer Verbundplatte des Baublockes bestimmt ist.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Vorrichtung nach einem der AnsprÃ¼che 4 bis 14, dadurch gekennzeichnet, daÃŸ sie am Ausgang einer Vorrichtung zur Gipserzeugung installiert ist.</claim-text></claim>
EP	0619773	B1	2000-03-15	fr	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0619773&ki=B1&pd=2000-03-15
EP	0639149	B1	2000-03-29	de	TITLE	1	ABGABEVORRICHTUNG MIT EINEM DRUCKERZEUGER
EP	0639149	B1	2000-03-29	en	TITLE	1	DISPENSING APPARATUS UTILIZING A PRESSURE GENERATOR
EP	0639149	B1	2000-03-29	fr	TITLE	1	APPAREIL DISTRIBUTEUR METTANT EN OEUVRE UN GENERATEUR DE PRESSION
EP	0639149	B1	2000-03-29	en	DESCR	1	<p id="p0001" num="0001">The present invention relates to a pressure generator and, more particularly to a dispensing apparatus utilizing such a pressure generator for dispensing product from sealed containers.</p><p id="p0002" num="0002">Aerosol pressurized dispensers have become familiar, if not essential, products in both consumer and industrial use due to the efficient way in which they discharge a myriad of products.</p><p id="p0003" num="0003">A common example is the hair spray dispenser in which, inside the dispenser, the product spray is dispersed in and surrounded by a liquefied propellant gas under pressure forming a uniform, single phase measure of the product spray and the liquefied propellant. As the product release valve is pressed, the liquefied propellant immediately vaporizes forcing the product spray out of the dispenser in the form of a fine mist.</p><p id="p0004" num="0004">A second type of aerosol dispenser, the cheese spread dispenser being a common example, discharges the product, not as a fine mist, but as a solid. In this second category of aerosol dispensers, the propellant exists within the dispenser as a gas and does not mix with the product. Rather, it forms a separate layer over the product to be discharged. As the product release valve is pressed, the propellant, being under pressure, pushes the product out of the dispenser.<!-- EPO <DP n="2"> --></p><p id="p0005" num="0005">The most commonly used propellants are butane, nitrogen and chlorinated fluorohydrocarbons (CFC's), such as those sold under trade name of Freon. CFC's and butane are often preferred over nitrogen since their vapor pressures are independent of the volume of free headspace in the dispenser. Thus, as long as some of the CFC or butane is present in the dispenser, the pressure exerted on the product is virtually constant throughout the discharge life of the system.</p><p id="p0006" num="0006">However, both CFC's and butane have adverse effects on the environment. CFC's add to the destruction of the earth's protective ozone layer which has lead the world community to seek a complete ban of CFC usage. Many countries have already banned its use or have implemented programs and schedules designed to eliminate CFC usage in the near future. Butane, on the other hand, is extremely flammable, making storage, handling and use of butane charged containers very hazardous. In addition, butane contaminates the flavor and smell of the dispensed product, thereby further restricting its use.</p><p id="p0007" num="0007">Although nitrogen is available as a substitute propellant, its vapor pressure is such that as product is dispensed, the propellant pressure decreases. Therefore, the product cannot be dispensed at a constant pressure through the life of the product, and at some point, the propellant pressure will fall below that needed to propel any product from the dispenser. To enable all of the product to be dispensable, the nitrogen must be pressurized to dangerously high levels increasing the risk of rupture or requiring more costly dispenser construction.<!-- EPO <DP n="3"> --></p><p id="p0008" num="0008">It is an object of the present invention to overcome or mitigate the above disadvantage.</p><p id="p0009" num="0009">This object is achieved by the invention claimed in Claim 1.</p><p id="p0010" num="0010">Canadian Patent Application CA-A-2013636 discloses an apparatus according to the pre-characterising part of claim 1. However, in such apparatus the piston member is not physically retained axially in the cylinder member.</p><p id="p0011" num="0011">An embodiment of the invention will now be described, by way of example, with reference to the accompanying drawings, in which:<ul id="ul0001" list-style="none"><li>Fig. 1 is a front elevational view, partially in section, showing a dispensing apparatus which is not an embodiment of the present invention but which is included to assist in understanding the embodiment;</li><li>Figs. 2A and 2B are enlarged sectional views of the pressure generator of the apparatus of Fig. 1 shown in different operating modes;</li><li>Fig. 3 is an enlarged sectional view of an alternative piston for use in the pressure generator of Figs. 2A and 2B; and<!-- EPO <DP n="4"> --></li><li>Fig. 4 is a view similar to Fig. 1 of the embodiment of the dispensing apparatus of the present invention.</li></ul></p><p id="p0012" num="0012">Referring to Fig. 1 of the drawings, the reference numeral 10 refers in general to a container, or can, containing a product 12 and a pressurized headspace 14. The container 10 is formed by a cylindrical wall closed at its lower end by a bottom plate 18 and at its upper end by a cap 20. It is understood that the container 10 can be an aerosol can, a vat, a beer or beverage keg, a storage vessel, a bottle or any other type of container used for the storage and dispersement of a product and can have any desired shape or configuration.</p><p id="p0013" num="0013">The cap 20 has a raised central portion 20a which receives a valve 22. A hollow actuating stem 24 extends from the valve 22 and through an opening formed through the raised cap portion 20a and receives a hollow push button 26. A tube 28 is disposed in the container 10 in a coaxial relationship therewith. The lower end of the tube 28 is slightly spaced from the bottom plate 18 and the upper end extends into the valve 22. The valve 22 is normally closed but when the push button 26 is manually pushed downwardly, the valve opens to connect the tube 28 with the stem 24. This permits the product 12 in the container 10 to flow through the tube 28, the valve 22, the stem 24 and to the push button 26 from which it discharges outwardly through discharge openings in the push/button, as will be explained. Since these components are conventional they will not be described in any further detail.<!-- EPO <DP n="5"> --></p><p id="p0014" num="0014">A pressure generator for pressurizing the headspace 14 is disposed in the container 10, and is referred to in general by the reference numeral 30. Referring to FIG. 2A, the pressure generator 30 is formed by a vessel 32 having a closed lower end portion and an upper end which narrows to form a shoulder 32a and a neck 32b which defines an opening 32c. The neck 32b is adapted to receive a plug 34 having a continuous bore 34a extending therethrough. The neck 32b is pliable and the diameter of the plug 34 slightly larger than the opening 32c, such that the plug 34 press fits into the bore 34a, slightly deforming the neck 32b.</p><p id="p0015" num="0015">A cylinder 36 is disposed in the vessel 32 and has a closed lower end and an open upper end. The upper end is integrally connected to the shoulder 32a of the vessel 32 by welding or the like. The diameter and the length of the cylinder 36 are less than the diameter and length, respectively, of the vessel 32 to define a high pressure chamber 38.</p><p id="p0016" num="0016">An opening 36a is provided through the wall of the cylinder 36 and a notch, or groove, 36b is formed in the inner surface of the cylinder 36 and extends above the opening 36a, for reasons to be described. A piston 40 operates within the cylinder 36, the outer diameter of the piston 40 being slightly less than the inner diameter of the cylinder 36 to permit reciprocal movement of the piston 40 in the cylinder 36 and to define a flow passage therebetween. Two axially spaced annular grooves are provided near the respective ends of the piston 40 and receive two sealing members, preferably in the form of O-rings, 42 and 44. The<!-- EPO <DP n="6"> --> cross-sectional area of the O-ring 42 is less than that of the corresponding cross-sectional area of the notch 36b, for reasons to be described.</p><p id="p0017" num="0017">A pre-pressure chamber 46 is defined between the respective lower ends of the piston 40 and the cylinder 36 which is pressurized to urge the piston 40 upwardly, as will be described. A spring 48 extends in the chamber 46 which also urges the piston 40 upwardly. In the position shown in FIG. 2A, the piston 40 is in its upper position in which its upper end engages the plug 34, thereby preventing any further upward movement of the piston 40.</p><p id="p0018" num="0018">Before operation, the chambers 38 and 46 of the vessel 32 are charged to respective predetermined pressures with a quantity of inert gas such as air, nitrogen, nitrous oxide, carbon dioxide or the like. The chamber 46 is charged to a pressure that is approximately equal to the pressure found in the headspace 14 needed to propel the product 12 from the container 10. The chamber 38 is pressurized to a greater pressure than the chamber 46 to recharge the headspace 14 as is described below.</p><p id="p0019" num="0019">To charge the chamber 46, the piston 40 is moved downwardly such that the upper O-ring 42 is below the opening 36a of the cylinder 36. Then, pressurized gas is introduced from the opening 32c of the vessel 32 through the bore 34a of the plug 34, which gas passes through the opening 36a of the cylinder 36 and into the chamber 38. Once the pressure in the chamber 38 reaches a predetermined level, the plug 34 is removed and the piston 40 is raised such that the lower O-ring 44 is above the opening 36a of the cylinder 36 to allow the<!-- EPO <DP n="7"> --> gas to pass through the opening 36a and fill the chamber 46. The piston 40 is then lowered to the position shown in FIG. 2A such that the lower O-ring 44 is below the opening 36a to seal the gas in the chamber 46. The piston 40 is prevented from ejecting from the cylinder 36 by the reinsertion of the plug 34, or as shown in FIG. 2B by the neck 32b of the vessel 32 which is folded down to partially block the opening 32c.</p><p id="p0020" num="0020">To charge the chamber 38, the piston 40 is further lowered such that the upper O-ring 42 is below the opening 36a of the cylinder 36. Additional pressurized gas is then introduced from the opening 32c through the bore 34a, which additional gas passes through the opening 36a of the cylinder 36 and into the chamber 38.</p><p id="p0021" num="0021">The introduction of this additional gas is continued until the chamber 38 is pressurized to the predetermined level. Thereafter, the piston 40 is allowed to be urged to the position shown in FIG. 2A where the upper end of the piston 40 engages the plug 34. In this position, the upper O-ring 42 engages corresponding portions of the inner wall of the cylinder 36 to seal against the flow of the pressurized gas contained in the chamber 38 out of the vessel 32 and into the container 10 via the space between the piston 40 and the cylinder 36; while the lower O-ring 44 seals against the flow of gas to and from the chamber 46. While in this position, the pressure generator 30 can be moved and transported without accidentally depressurizing either of the chambers 38 or 46.<!-- EPO <DP n="8"> --></p><p id="p0022" num="0022">After the chambers 38 and 46 are charged, the pressure generator 30 is placed in the container 10 which contains the product 12 to be dispensed, and the headspace 14 in the container 10 is charged to a predetermined pressure with a gas similar to the gas used to charge the chambers 38 and 46 of the vessel 32, which pressure is selected to be initially greater than the combined force exerted on the piston 40 by the gas and the spring 48 in the chamber 46. After the container 10 is sealed off, or closed, the pressure in the container 10 acts through the opening 32c of the vessel 32 via the bore 34a of the plug 34 on the upper end of the piston 40 to force it downwardly to the operating position shown in FIG. 2B. In this operating position, both O-rings 42 and 44 engage the inner wall of the cylinder 36 to prevent any flow of the pressurized gas through the cylinder 36, and the upper O-ring 42 extends between the opening 36a and the notch 36b.</p><p id="p0023" num="0023">The piston 40 remains in the position shown in FIG. 2B until the container 10 is used by manually pressing the push button 26, in which case the pressure in the headspace 14 of the container 10 propels the product 12 through the tube 28, the valve 22, the stem 24 and outwardly through the openings in the push button 26. This causes the pressure in the container 10 to decrease until the pressures exerted on the lower end of the piston 40 by the pressurized gas in the chamber 46 and the spring 48 (if present) are greater than the corresponding pressure acting on the upper end of the piston 40 by the pressurized product 12 in the container 10. Upon this occurring, the piston 40 moves upwardly until the upper O-ring 42 extends in the notch 36b of the cylinder 36. This permits the high pressure<!-- EPO <DP n="9"> --> gas in the chamber 38 to pass through the opening 36a, through the space between the outer surface of the piston 40 and the inner surface of the cylinder 36, through the notch 36b and outwardly through the upper opening 32c of the vessel 32.</p><p id="p0024" num="0024">The pressure in the container 10 is thus increased accordingly until the pressure exerted thereby on the upper end of the piston 40 is sufficient to overcome the pressure exerted on the lower end of the piston 40 by the spring 48 and the pressure in the chamber 46. At this point, the piston 40 will move back to the position shown in FIG. 2B thus blocking any further flow of high pressure gas from the chamber 38 into the container 10 as described above. Note however, that should the pressure in the container 10 quickly drop a significant amount, such as due to a leak, the pressure in the chamber 46 will force the piston 40 against the plug 34 (or the folded down neck 32c), thereby sealing the high pressure gas in the chamber 38 by the upper O-ring 42.</p><p id="p0025" num="0025">This back-and-forth movement of the piston 40 relative to the cylinder 36 continues in the manner described above as the product 12 is periodically dispensed from the container 10. As a result, a constant pressure will be available in the container 10 at all times to propel the product 12 from the container 10, while the propellant utilized can be an inert gas which is not harmful to the environment.</p><p id="p0026" num="0026">To facilitate the previously described charging of the chambers 38 and 46 of the pressure generator 30, an alternative piston 40' may be disposed in the cylinder 36. The piston 40' is shown in FIG. 3 and has<!-- EPO <DP n="10"> --> two axially spaced annular grooves provided near its ends for receiving the O-rings 42 and 44. Upper and lower wells 50 and 52 having annular flanges 50a and 52a are provided in the upper and lower ends of the piston 40', respectively, for receiving a tool (not shown), such as a spheric pen, to axially position the piston 40' during charging of the chambers 38 and 46. Otherwise, the operation of the piston 40' is identical to that of FIGS. 2A and 2B.</p><p id="p0027" num="0027">Referring to FIG. 4. an embodiment of the present invention is shown in which the reference numeral 92 refers in general to a container for containing and dispensing a product. The container 92 is formed by a cylindrical wall 94 closed at its lower end by a bottom plate 96 and at its upper end by a cap 98. It is understood that the container 92 can be an aerosol can, a vat, a beer or beverage keg, a storage vessel, a bottle or any other type of container used for the storage and dispersement of a product and can have any desired shape or configuration.</p><p id="p0028" num="0028">A pipe 100 registers with and extends from an opening 98a in the cap 98. The pipe 100 branches into two branches 100a and 100b for passing product from the container 92 to two dispensing containers 102 and 104, respectively.</p><p id="p0029" num="0029">A pressure generator for pressurizing the container 92 is referred to in general by the reference numeral 106. The pressure generator 106 is formed by a cylindrical vessel 108 having a closed upper end and a lower end having a neck 108a which defines an opening 108b. The neck 108a is adapted to receive a cannulated plug (not shown) similar to the plug 34 previously<!-- EPO <DP n="11"> --> described. In a preferred embodiment, the neck 108a is pliable and can be folded down to partially block the opening 108b, as is shown in FIG. 4.</p><p id="p0030" num="0030">The outer diameter of the vessel 108 is slightly less than the inner diameter of the container 92 to permit reciprocal movement of the vessel 108 in the container 92. Two axially spaced annular grooves are provided near the respective ends of the vessel 108 and receive two sealing members, preferably in the form of O-rings, 110 and 112.</p><p id="p0031" num="0031">A gas chamber 114 is defined between the lower end of the vessel 108 and the bottom plate 96 of the container 92 and a further chamber 113 for containing product is defined above the vessel 108. To urge the vessel 108 upwardly for reasons described below, the chamber 114 is pressurized through an opening 96a in the bottom plate 96 which is sealed with a rubber valve 116.</p><p id="p0032" num="0032">A cylinder 118 is disposed in the vessel 108 and has a closed upper end and an open lower end. The lower end is integrally connected to the lower end of the vessel 108 in alignment with the opening 108b by welding or the like. The diameter and the length of the cylinder 118 are less than the diameter and length, respectively, of the vessel 108 to define a high pressure chamber 120.</p><p id="p0033" num="0033">A piston 122 operates within the cylinder 118 and defines a pre-pressure chamber 124. The cylinder 118 and the piston 122 are identical to the cylinder 36 and<!-- EPO <DP n="12"> --> the piston 40 of FIGS. 2A and 2B, and thus will not be described in further detail. Again, the spring 48 has not been shown for the convenience of presentation.</p><p id="p0034" num="0034">Before operation, the chambers 120 and 124 of the vessel 108 are charged to respective predetermined pressures with a quantity of inert gas such as air, nitrogen, nitrous oxide, carbon dioxide or the like. In a preferred embodiment, the chamber 124 is charged to a pressure that is equal to the pressure needed in the containers 102 and 104 to propel product from the containers 102 and 104 at a predetermined flow rate. The chamber 120 is pressurized to a greater pressure than the chamber 124 to recharge the pressure in the chamber 114 as will be described. Since the methods of charging the chambers 120 and 124 are identical to the methods of charging the chambers 38 and 46 of FIGS 2A and 2B, they will not be discussed here in detail.</p><p id="p0035" num="0035">After the chambers 120 and 124 are charged, the pressure generator 106 is placed in the container 92 in the orientation shown in FIG. 4. The chamber 113 is then filled with product, and the chamber 114 charged via the valve 116 to a predetermined pressure with a gas similar to the gas used to charge the chambers 120 and 124. The pressure in the chamber 114 is selected to be initially greater than force exerted on the piston 122 by the gas in the chamber 124 and any spring present therein. The pressure in the chamber 114 thus acts through the opening 108b of the vessel 108 on the lower end of the piston 122 to force it upwardly to its operating position as previously described in connection with FIGS. 2A and 2B.<!-- EPO <DP n="13"> --></p><p id="p0036" num="0036">When product is dispensed from either of the containers 102 or 104, the pressure in the containers 102 and 104, and therefore in the container 92, is decreased. This causes the vessel 108 to rise upwardly in the container 92 to equalize the pressures in the chamber 114 and in the containers 92, 102 and 104. The upward movement of the vessel 108 decreases the pressure in the chamber 114 and thus the force exerted on the lower end of the piston 122. Upon this occurring, the piston 122 is forced downwardly by the pressure in the chamber 124, thereby releasing pressurized gas from the chamber 120 as described in connection with the embodiment of FIGS. 2A and 2B.</p><p id="p0037" num="0037">The pressure in the chamber 114 is thus increased, which accordingly urges the vessel 108 to rise further within the container 92 which accordingly increases the pressure in the containers 92, 102 and 104. The release of the pressurized gas from the chamber 120 continues until the pressure in the containers 92, 102 and 104 and in the chamber 114 is equal to the pressure in the chamber 124. At this time, the piston 122 will move back to its blocking position.</p><p id="p0038" num="0038">This back-and-forth movement of the piston 122 relative to the cylinder 118 and the upward movement of the vessel 108 within the container 92 continues in the manner described above as product is periodically dispensed from the containers 102 and 104. As a result, a constant pressure will be available in the containers 102 and 104 at all times to propel product from the containers at a constant flow rate, while the propellant utilized can be an inert gas which is not<!-- EPO <DP n="14"> --> harmful to the environment. Further, the propellant gas is separated from the product to prevent any contamination.</p><p id="p0039" num="0039">It is thus seen that the dispensing apparatus of the present invention provides several advantages, not the least significant of which is that it provides a dispenser capable of dispensing a product at a substantially constant pressure throughout the life of the product without having to use an environmentally hazardous propellant, the intended propellants being air, nitrogen, nitrous oxide, carbon dioxide and the like. In fact, in the embodiment shown in FIG. 4, a dispensing apparatus is disclosed which does not discharge any propellant into the atmosphere. The present invention also enables a precise, constant pressure to be simultaneously maintained in numerous discharge vessels by the utilization of a single pressure generator in a common storage container, as is described in connection with FIG. 4.</p><p id="p0040" num="0040">The pressure generator of the present embodiment is also easily assembled due to the few components required and the simplicity of those components. Further, the pressure generator requires no manual actuation before or during use.</p><p id="p0041" num="0041">It is understood that variations may be made in the foregoing without departing from the scope of the present invention. For example, the pressure in the pre-pressure chamber 124 can be provided by high pressure gas alone, by a spring 48 alone, or by the combination of both.<!-- EPO <DP n="15"> --></p><p id="p0042" num="0042">In fact, external charging of the pre-pressure chamber 124 or the use of a spring 48 can be avoided altogether by the appropriate dimensioning of the cylinder 118. For example, as the pressure generator 106 is assembled, the air already present in the cylinder 118 is compressed by the insertion of the piston 122. Therefore, the cylinder 118 and the piston 122 can be appropriately dimensioned such that as the piston 122, moves to its operating position an shown in FIG. 2B, the air present in the chamber 124 is compressed to the desired pre-pressurized level.</p><p id="p0043" num="0043">The components of the pressure generator of the present embodiment have been primarily described and shown in the drawings as being metal. These components, however, such as the vessel, the cylinder and the piston, can be metal (preferably aluminium), plastic (preferably polyoxymethalene or polyethelene terephthalate), or any other like material. In addition, the O-rings 42, 44, 110 and 112 can be replaced with other types of movable seals such as quadring, rings, scrapers and the like, which can either be separate from the other components or jointly molded thereon. For example, a piston formed of plastic may have annular ridges formed thereon to provide the needed sealing and reciprocal movement within the cylinder.</p>
EP	0639149	B1	2000-03-29	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>Apparatus for maintaining a substantially constant predetermined pressure in a pressurized container (92) for dispensing product contained in the container at the substantially constant pressure, the apparatus comprising:<claim-text>a container (92),</claim-text><claim-text>a vessel (108) containing pressurized gas and disposed in the container (92), and</claim-text><claim-text>means responsive to a reduction of gas pressure in the container (92) for permitting the pressurized gas in the vessel (108) to pass from the vessel to the container to maintain the substantially constant predetermined pressure in the container, such means comprising:</claim-text><claim-text>a cylinder member (118) disposed in the vessel (108) and defining with the vessel a first chamber (120) for containing the pressurized gas,</claim-text><claim-text>a piston member (122) disposed in the cylinder member (118) and defining with the cylinder member a second chamber (124), one of the piston and cylinder members being exposed to the pressure in the container (92) for moving to a first position relative to the other member<!-- EPO <DP n="17"> --> in which position the pressure in the container equals the predetermined pressure,</claim-text><claim-text>means (48) including a pressurized gas in the second chamber (124) for moving the one member to a second position relative to the other member in response to the pressure in the container (92) decreasing below the predetermined pressure, and</claim-text><claim-text>connecting means (36a, 36b, 42) responsive to the one member moving to the second position for connecting the first chamber (120) with the container (92) to permit the pressurized gas to pass from the first chamber (120) to the container, the connecting means being responsive to the one member moving to the first position for disconnecting the first chamber (120) from the container to prevent the passage of the pressurized gas, thereby to maintain the substantially constant predetermined pressure in the container,<br/>wherein the vessel (108) is disposed in the container (92) so as to divide the container into a third chamber (113) for containing the product and a fourth chamber (114) for containing gas at a predetermined pressure, the vessel (108) being movable in the container in response to a reduction of pressure in the third chamber (113) as the product is dispensed such that the volume of the third chamber reduces and the volume of the fourth chamber (114) increases, such movement<!-- EPO <DP n="18"> --> reducing the pressure of the gas in the fourth chamber (114), and<br/>wherein the connecting means (36a, 36b, 42) permits the pressurized gas in the vessel (108) to pass from the vessel only to the fourth chamber (114) to maintain the predetermined pressure in the fourth chamber,<br/>characterised in that:</claim-text><claim-text>neck means (108a) are provided extending from an end of the cylinder member (118) such neck means permitting the piston member to initially project from the cylinder member so that the second chamber (124) can be charged with the pressurized gas, the neck means (108a) being adapted to thereafter partially block such end of the cylinder member (118) to retain the piston member (122) axially within the cylinder member.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The apparatus of claim 1 wherein the cylinder member (118) is secured relative to the vessel (108) and the piston member (122) is exposed to the pressure in the fourth chamber (114) and moves relative to the cylinder member to the first and second positions.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The apparatus of claim 2 wherein one end of the piston member (122) is exposed to the pressure in the fourth chamber (114) and wherein the second chamber<!-- EPO <DP n="19"> --> (124) is defined between the cylinder member (118) and the other end of the piston member.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The apparatus of claim 3 wherein the moving means comprises a spring (48) and/or pressurized gas disposed in the second chamber (124) and acting on said other end of the piston member (122).</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The apparatus of any preceding claim, wherein the outer diameter of the piston member (122) is slightly less than the inner diameter of the cylinder member (118) to permit the flow of the pressurized gas therebetween, and wherein the connecting means comprises an aperture (36a) in the wall of the cylinder member (118), a sealing member (42) extending between an outer surface of the piston member (122) and a corresponding inner surface of the cylinder member (118) for preventing the flow of pressurized gas when the piston member is in the first position, and a notch (36b) formed in one of the surfaces for receiving the sealing member for permitting the flow of pressurized gas when the piston member is in the second position.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The apparatus of claim 5 wherein the sealing member extends in a groove formed in the piston member (122) and engages the inner surface of the cylinder member (118) and wherein the notch (36b) is formed in the inner surface of the cylinder member.</claim-text></claim>
EP	0639149	B1	2000-03-29	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>GerÃ¤t um einen wesentlich unverÃ¤nderlichen voreingestellten Druck in einem Druckcontainer (92) einzuhalten, um Produkte, gelagert im Container am wesentlich unverÃ¤nderlichen Druck zu verteilen, und wobei das GerÃ¤t zusammengesetzt ist aus :<claim-text>ein Container (92),</claim-text><claim-text>ein BehÃ¤lter (108) der Druckgas enthÃ¤lt und im Container (92) gestellt wurde, und</claim-text><claim-text>Vorrichtung verantwortlich fÃ¼r eine Erniedrigung des Gasdrucks im Container (92) um den FluÃŸ des Druckgases im BehÃ¤lter (108) zu erlauben zwischen den BehÃ¤lter zum Container um den wesentlich unverÃ¤nderlichen Druck im Container zu behalten, und diese Vorrichtung umfaÃŸt :</claim-text><claim-text>ein Zylinder (118), abgestellt im BehÃ¤lter (108) und der mit dem BehÃ¤lter eine erste Kammer (120) fÃ¼r die Lagerung des Druckgases bestimmt,</claim-text><claim-text>ein Kolbenglied (122), abgestellt im Zylinderglied (118) und der mit dem Zylinderglied eine zweite Kammer (124) bestimmt, wobei ein der Kolben- und Zylinderglieder am Druck im Container (92) ausgesetzt wird um zum ersten Stand bezÃ¼glich<!-- EPO <DP n="21"> --> des andern Glieds zu bewegen, zum Stand in dem der Druck im Container dem voreingestellten Druck Ã¤hnlich ist.</claim-text><claim-text>Vorrichtung (48), einschlieÃŸlich eines Druckgases in der zweiten Kammer (124) um das eine Glied im Vergleich zum zweiten Glied zum zweiten Stand zu bringen, um den Druck im Container (92) unter dem voreingestellten Druck zu erniedrigen, und</claim-text><claim-text>Verbindungsvorrichtungen (36a, 36b, 42) die reagerieren mit dem ersten Glied, das zum zweiten Stand bewegt um die erste Kammer (120) mit dem Container (92) zu verbinden, damit das Druckgas von der ersten Kammer (120) zum Container laufen kÃ¶nnte, und wobei die Verbindungsvorrichtungen reagieren auf das zum ersten Stand fÃ¼r die AbschlieÃŸung der ersten Kammer (120) bewegende Glied, damit der FluÃŸ des Druckgases vorgebeugt wird, und wobei im Container ein wesentlicher unverÃ¤nderlicher voreingestellter Druck einbehalten wird.</claim-text><claim-text>In diesem Container (92) wird BehÃ¤lter (108) abgestellt, damit der Container in einer dritten Kammer (113) verteilt wird fÃ¼r die Lagerung des Produkts und in einer vierten Kammer (114) um Gas in einem voreingestellten Druck zu lageren, wobei der BehÃ¤lter (108) im Container bewegt zufolge einer Erniedrigung des Drucks in der dritten Kammer (113) durch den Austrieb des Produkts, derweise, daÃŸ das Volumen der dritten Kammer abnimmt und das Volumen der vierten Kammer erhÃ¶ht, wobei diese Bewegung den Druck des Gases in der vierten Kam<!-- EPO <DP n="22"> --> mer (114) verringert, und<br/>wobei die Verbindungsvorrichtung (36a, 36b, 42) dem Druckgas im BehÃ¤lter (108) erlaubt vom BehÃ¤lter nur zur vierten Kammer (114) zu flieÃŸen um in der vierten Kammer den voreingestellten Druck zu behalten,<br/>gekennzeichnet durch :</claim-text><claim-text>Halsvorrichtungen (108a) ragen von einem Endteil des Zylinderglieds (108) hinaus, wobei derartige Halsvorrichtung das Kolbenglied erlaubt beim Anfang aus dem Zylinderglied vorzuspringen damit die zweite Kammer (124) mit dem Druckgas geladen werden kann, und wobei die Halsvorrichtung (108a) abgeÃ¤ndert wird um nachher dieses Endteils des Zylinders (118) teilweise zu blockieren um die Kolbe (122) axial mit dem Zylinderglied zu halten.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Das GerÃ¤t des 1. Antrags in dem das Zylinderglied (118) in Bezug auf dem BehÃ¤lter (108) gesichert wurde und in dem das Kolbenglied (122) dem Druck im vierten Kammer (114) ausgestellt wird und bezÃ¼glich des Zylinderglieds zu den ersten und zweiten StÃ¤nden bewegt.<!-- EPO <DP n="23"> --></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Das GerÃ¤t in Antrag 2, in dem ein SchluÃŸend des Kolbenglieds (122) dem Druck in der 4. Kammer (114) ausgesetzt wirdt, und in dem die zweite Kammer (124) festgelegt wird zwischen dem Kolbenglied (118) und dem andern SchluÃŸend des Kolbenglieds.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Das GerÃ¤t in Antrag 3, in dem der Antrieb eine Welle (48) umfaÃŸt und/oder Druckgas in die zweiten Kammer (124) freigelassen wird und auf genanntes andern SchluÃŸend des Kolbenglieds (122) wirkt.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Das GerÃ¤t irgendwelches vorherigen Antrags, in dem der AuÃŸendurchmesser des Kolbenglieds etwas weniger ist als der Innendurchmesser des Zylinderglieds (118) um den FluÃŸ des Druckgases zwischendurch zu ermÃ¶glichen, und in dem die Verbindung eine Ã–ffnung (36a) in der Zylinderwand (118), eine Versiegelung (36a) zwischen der AuÃŸenseite des Kolbenglieds (122) und einer Ã¼bereinkommenden Innenseite des Zylinderglieds (118) damit der DruckgasfluÃŸ verhindert wird wenn der Kolbenglied sich im ersten Stand befindet, und eine Rille (36b) in einer der Seiten zum Empfang der Versiegelung damit den FluÃŸ des Druckgases ermÃ¶glicht wird wenn der Kolbenglied sich im zweiten Stand befindet, umfaÃŸt.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Das GerÃ¤t in Antrag 4, in dem die Versiegelung in einer Rille des Kolbenglieds (122) auslÃ¤uft und die Innenseite des Zylindergliedes (118) eingreift, und in dem die Rille (36b) in der Innenseite des Zylinderglieds gebildet wird</claim-text></claim>
EP	0639149	B1	2000-03-29	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text>Des appareils pour maintenir une pression prÃ©dÃ©terminÃ©e et substantiellement constante dans un conteneur (92) pour dispenser un produit contenu dans un conteneur Ã  une pression substantiellement constante, l'appareil comportant :<claim-text>un conteneur (92),</claim-text><claim-text>une nacelle (108) contenant du gaz sous pression et dÃ©posÃ©e dans le conteneur (92), et</claim-text><claim-text>des moyens rÃ©pondant Ã  une rÃ©duction de la pression du gaz dans le conteneur (92) pour permettre le gaz sous pression dans la nacelle (108) de passer de la nacelle au conteneur pour maintenir la pression substantiellement constante dans le conteneur, les dites moyens comprenant :</claim-text><claim-text>un moyen cylindre (118) dÃ©posÃ© dans une nacelle (108) et dÃ©finissant avec la nacelle une premiÃ¨re chambre (120) pour contenir du gaz sous pression,</claim-text><claim-text>un membre piston (122) dÃ©posÃ© dans le moyen cylindre (118) et dÃ©finissant avec le moyen cylindre une seconde chambre (124), une des membres du piston et du cylindre Ã©tant exposÃ©e Ã  la pression dans le conteneur (92) pour bouger Ã  une premiÃ¨re position relative Ã  l'autre moyen ;<!-- EPO <DP n="25"> --> position dans laquelle la pression dans le conteneur Ã©gale la pression prÃ©dÃ©terminÃ©e.</claim-text><claim-text>des moyens (48) incluant un gaz sous pression dans la seconde chambre (124) pour bouger l'un moyen Ã  une seconde position relative Ã  l'autre moyen en rÃ©ponse Ã  la pression dans le conteneur (92) diminuent en dessous de la pression prÃ©dÃ©terminÃ©e, et</claim-text><claim-text>des moyens de connexion (36a, 36b, 42) rÃ©pondant au moyen qui bouge vers la seconde position pour connecter la premiÃ¨re chambre (120) au conteneur (92) pour permettre le gaz sous pression de passer de la premiÃ¨re chambre (120) dans le conteneur, les moyens de connexion rÃ©pondant au moyen qui bouge vers la premiÃ¨re position pour dÃ©connecter la premiÃ¨re chambre (120) du conteneur pour ainsi Ã©viter le passage du gaz sous pression et maintenant ainsi la pression substantiellement constante dans le conteneur,<br/>caractÃ©risÃ© en ce que la nacelle (108) est dÃ©posÃ©e dans le conteneur (92) pour diviser le conteneur dans une troisiÃ¨me chambre (113) pour recevoir le produit et une quatriÃ¨me chambre (114) pour contenir du gaz Ã  une pression prÃ©dÃ©terminÃ©e, la nacelle (108) Ã©tant meuble dans le conteneur en rÃ©ponse Ã  une rÃ©duction de la pression dans la troisiÃ¨me chambre (113) au moment oÃ¹ le produit est dispensÃ© ainsi que le volume de la troisiÃ¨me chambre se rÃ©duit et que le volume de la quatriÃ¨me chambre (114) augmente, le dit mouvement<!-- EPO <DP n="26"> --> rÃ©duisant la pression du gaz dans la quatriÃ¨me chambre (114), et<br/>caractÃ©risÃ© en ce que les moyens de connexion (36a, 36b, 42) permettent le gaz sous pression dans la nacelle (108) de passer de la nacelle rien qu'Ã  la quatriÃ¨me chambre (114) pour maintenir la pression prÃ©dÃ©terminÃ©e dans la quatriÃ¨me chambre,<br/>caractÃ©risÃ© en ce que :</claim-text><claim-text>un moyen coude (108a) est prÃ©vu s'Ã©tendant d'une partie du moyen cylindre (118), le dit moyen coude permettant le moyen piston de projeter initialement du moyen cylindre ainsi que la seconde chambre (124) peut Ãªtre chargÃ©e de gaz sous pression, le moyen coude (108a) Ã©tant adaptÃ© pour aprÃ¨s partiellement bloquer la dite partie du moyen cylindre (118) pour retenir le moyen piston (122) de maniÃ¨re axiale dans le moyen cylindre.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>L'appareil de la revendication 1 caractÃ©risÃ© en ce que le moyen cylindre (118) est fixÃ© relatif Ã  la nacelle (108) et le moyen piston (122) est exposÃ© Ã  la pression dans la quatriÃ¨me chambre (114) et bouge relatif au moyen cylindre Ã  la premiÃ¨re et la seconde position.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>L'appareil de la revendication 2 caractÃ©risÃ© en ce qu'une partie du moyen piston (122) est exposÃ©e Ã  la pression dans la quatriÃ¨me chambre (114) et caractÃ©risÃ©e en ce que la seconde chambre<!-- EPO <DP n="27"> --> (124) est dÃ©finie entre le moyen cylindre (118) et l'autre bout du moyen piston.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>L'appareil de la revendication 3 caractÃ©risÃ© en ce que le moyen de mouvement comprend un ressort (48) et/ou du gaz sous pression, dÃ©posÃ© dans la seconde chambre (124) et agissant sur le dit autre bout du moyen piston (122).</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>L'appareil de toute autre revendication prÃ©cÃ©dente caractÃ©risÃ© en ce que le diamÃ¨tre extÃ©rieur du moyen piston (122) est un peu infÃ©rieur au diamÃ¨tre intÃ©rieur du moyen cylindre (118) pour permettre le passage de gaz sous pression entre les piÃ¨ces, et dans lequel le moyen de connexion comprend une ouverture (36a) dans la paroi du moyen cylindre (118), un membre de clÃ´ture (42) existant entre la surface externe du moyen piston (122) et la surface interne correspondante du moyen cylindre (118) pour Ã©viter le passage du gaz sous pression quand le moyen piston se trouve dans la premiÃ¨re position, et une encoche (36b) formÃ©e dans une des surfaces pour recevoir le moyen clÃ´ture pour permettre le passage du gaz sous pression quand le moyen piston se trouve dans la seconde position.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>L'appareil de la revendication 5 caractÃ©risÃ© en ce que le moyen clÃ´ture s'Ã©tende dans une rainure formÃ©e dans le moyen piston (122) et engage la surface interne du moyen cylindre (128) et dans lequel l'encoche (36b) est formÃ©e dans la surface interne du moyen cylindre.</claim-text></claim>
EP	0639149	B1	2000-03-29	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0639149&ki=B1&pd=2000-03-29
EP	0600893	B1	2000-03-22	de	TITLE	1	GENEXPRESSION IN BAZILLEN
EP	0600893	B1	2000-03-22	en	TITLE	1	GENE EXPRESSION IN BACILLI
EP	0600893	B1	2000-03-22	fr	TITLE	1	EXPRESSION GENIQUE DANS DES BACILLES
EP	0600893	B1	2000-03-22	en	DESCR	1	<heading id="h0001"><u>FIELD OF THE INVENTION</u></heading><p id="p0001" num="0001">The invention relates to novel genes, vectors aid Bacilli transformed with them useful in the hyperproduction of enzymes. Specifically, the invention relates to specific combinations of unlinked genes which, either mutated or wild type, synergistically induce hyperproduction of enzymes.</p><heading id="h0002"><u>BACKGROUND OF THE INVENTION</u></heading><p id="p0002" num="0002">Marry industrially important products are produced from members of the genus Bacilli. Some of these include proteases, amylases, and beta-glucanases (Priest, 1977, Bacteriological Review, 41:711-753). Most of these enzymes are either produced by Bacilli after the initiation of sporulation or are timed with the onset of the stationary phase.</p><p id="p0003" num="0003"><u>Bacillus</u> <u>subtilis</u> I-168 is the most extensively studied member of the Bacilli and has a well developed genetic system as the result of many years of academic research. As a result, there is a considerable amount of knowledge pertaining to the expression of extracellular enzymes and many mutants of <u>B.</u> <u>subtilis</u> I-168 exist that are altered in the expression of these enzymes. There are several different known genes which code for proteins that regulate the expression of extracellular enzymes. Although the exact molecular mechanism of this regulation is not completely understood, it is now clear that the product of these genes interact either directly or indirectly at the transcriptional level of the target enzymes (Ferrari et al, 1988, J. Bacteriol. 170:289-295; Henner et al, 1988, J. Bacteriol. 170:296-300).</p><p id="p0004" num="0004">Regions of the DNA around promoters can actively interact with certain transcriptional control factors and effectively regulate the strength and<!-- EPO <DP n="2"> --> efficiency of a particular promoter. This interaction will result either in a stimulation or in a repression of the transcription of that particular target gene. As a consequence, mutations in either the genes coding for these transcriptional control factors or in regions of the chromosome with which they interact are expected to yield more or less mRNA of the target gene. This in turn will results in higher or lower amount of enzyme synthesized by the cell.</p><p id="p0005" num="0005">With the advent of genetic engineering techniques, it has been possible to clone and express a gene from another species in <u>B.</u> <u>subtilis</u> I-168 or other Bacillus species. Most of these studies have involved the use of multicopy plasmids as cloning vectors. Although the yield of the cloned protein was increased significantly over the production in the wild type host, it was far below the yield of enzyme reported for production strains obtained through mutagenesis. This was also the case when the enzyme was under the control of strong transcriptional and translational elements derived from <u>B.</u> <u>subtilis</u>. Apparently the production of enzyme obtained from the multicopy, replicating plasmids was not affected by the presence of certain mutations, i.e. <u>sacU(Hy)</u>, <u>sacQ(Hy)</u> and <u>hpr</u> (Dedonder et al, Microbiology 1976, D. Schlessinger (Ed), pp 58-69, American Society for Microbiology, Washington, DC; Palva et al. 1983, FEMS Microbiology Letters, 17:81-85; Ferrari, unpublished observation), described as being able to induce hyperproduction of several secreted enzymes. These regulatory genes are unlinked to the structural gene for the affected enzymes and therefore one should expect that they exert their stimulating activity to a greater degree also when the gene is present in a multicopy plasmid.<!-- EPO <DP n="3"> --></p><p id="p0006" num="0006">There are at least 6 different regulatory genes known to interact either directly or indirectly with the transcription of the subtilisin gene: <u>sacU</u>, <u>sacQ</u>, <u>prtR</u>, <u>hpr</u>, <u>sin</u> and <u>abrB</u>.</p><p id="p0007" num="0007">Certain mutations in the <u>sacU</u> gene encode for a modified polypeptide which has the most pleiotropic effect among all these known regulatory genes. A strain carrying for example <u>sacU</u>(Hy) mutations can sporulate in presence of high levels of glucose, has a very low efficiency of transformation, lacks flagella and it is also responsible for the hyperproduction of several secreted enzymes. (Dedonder et al, Microbiology 1976, see above).</p><p id="p0008" num="0008">The <u>sacQ</u> gene from three different bacilli has been cloned and characterized (Amory et al, 1987, J. Bacteriol, 169, 234; Yang et al, 1986, J. Bacteriol, 166, 133; and Tomioka et al, 1985, J. Biotechnol 3,85). The gene isolated from <u>B.</u> <u>subtilis</u> encodes a 46 amino acid polypeptide. The <u>sacQ</u> gene when hyperexpressed either because of a mutation in its promoter or when present in a multicopy plasmid causes hyper production of certain extracellular enzymes, including the alkaline protease (Yang et al, 1986, J. Bacteriol <u>166</u>, 113-119).</p><p id="p0009" num="0009">The <u>prtR</u> gene encodes a 60 amino acid polypeptide. When this gene is present in <u>B.</u> <u>subtilis</u> in a multicopy plasmid it causes increased production of proteins. However, unlike for sacQ, there have been no chromosomal mutations to date for this gene which increase proteases production (Yang et al., 1987, J. Bacteriol. <u>169</u>, 434-437).</p><p id="p0010" num="0010">The <u>hpr</u> gene encodes a 203 amino acid protein and certain mutations in this gene stimulate alkaline protease production. It has been established that<!-- EPO <DP n="4"> --> mutations which cause the loss of this gene product stimulates transcription of the subtilisin gene (Perego and Hoch, 1988, J. Bacteriol. <u>170</u>, 2560-2567). The product of the <u>hpr</u> gene therefore is most likely a repressor of the subtilisin gene. It has also been determined that the <u>scoC</u> gene and possibly the <u>catA</u> gene are identical to the <u>hpr</u>. The notation <u>hpr</u> will be used thereafter to refer to any of the three alleles called <u>hpr</u>, <u>scoC</u> or <u>catA</u>.</p><p id="p0011" num="0011">The <u>sin</u> gene encodes a polypeptide of 111 amino acids (Gaur et al, 1986, J. Bacteriol, 168:860-869). An insertional inactivation of the gene causes the production of a higher level of alkaline protease, suggesting that this gene also acts as a repressor of the expression of alkaline protease.</p><p id="p0012" num="0012">Finally the <u>abrB</u> gene codes for a polypeptide of 97 amino acids. Also for this gene there is evidence that it is a repressor of the transcription of the alkaline protease and might have an important role in the temporal regulation of this gene.</p><heading id="h0003"><u>SUMMARY OF THE INVENTION</u></heading><p id="p0013" num="0013">It has been surprisingly discovered that a synergistic effect can be achieved in a strain carrying combinations of mutations in these genes. Such organism when transformed with an integrative vector or plasmid in which the enzyme to be expressed is under the control of the promoter with all its regulatory regions, will express more enzyme than predictable from using either a replicative multicopy plasmid or only one of the above described regulatory mutated genes.<!-- EPO <DP n="5"> --></p><p id="p0014" num="0014">Accordingly, the invention relates to a Bacillus able to hyperproduce an enzyme comprising:<ul id="ul0001" list-style="none" compact="compact"><li>a) the enzyme gene sequence;</li><li>b) a functional promoter gene sequence controlling the expression of the enzyme gene operably linked to the enzyme gene sequence; and</li><li>c) two or more mutated genes involved in the transcriptional regulation of the promoter wherein each individual mutated gene induces the increased production of the enzyme. The mutated genes are preferably selected from the group comprising: <u>hpr</u>, <u>sacQ</u>, <u>sacU</u> <u>sin</u>, <u>abrB</u>, or <u>prt R</u></li></ul></p><p id="p0015" num="0015">The invention also relates to vectors comprising the novel gene, to cells-transformed with the vectors aid to a processing for making enzymes.</p><heading id="h0004"><u>BRIEF DESCRIPTION OF THE FIGURES</u></heading><p id="p0016" num="0016"><ul id="ul0002" list-style="none" compact="compact"><li>Figure 1 shows the construction of the pSAR gene.</li><li>Figure 2 shows the construction of the pSAICM gene.</li><li>Figure 3 shows the integration of the pSAICM gene into the <u>B.</u> <u>subtilis</u> chromosome.</li></ul></p><heading id="h0005"><u>DETAILED DESCRIPTION</u></heading><p id="p0017" num="0017">Applicants have demonstrated novel combination of mutated or wild type genes, vectors and Bacilli transformed with then which are unique in their ability to induce hyperproduction of enzymes. Two mutated genes as described above are introduced in a strain carrying an appropriate promoter and gene sequence. The promoter sequence and the gene sequence of the enzyme are introduced into such host strain by mean of an integrative<!-- EPO <DP n="6"> --> vector. Such vector, which may or may not be amplified upon integration, is stably maintained as part of the host genome and replicates within the cell as integral part of its chromosome. Integration can occur at different region of the chromosome including but not limited to the region of homology with the promoter used in a particular construction. Such host may have its original enzyme sequences, or other gene sequences, deleterious to the desired enzyme production, deleted or otherwise made inoperative by standard techniques.</p><p id="p0018" num="0018">As used herein, the "enzyme gene sequence" refers to a DNA sequence encoding for the expression of an enzyme, in general either heterologous or homologous to Bacilli. Several enzymes are known and within the scope of this teaching including but not limited to those preferred enzymes from <u>Bacillus</u> <u>lentus</u>, <u>Bacillus</u> <u>amyloliquefaciens</u> (e.g., ATCC 23844), <u>Bacillus</u> <u>licheniformis</u> (e.g., ATCC 21415), <u>Bacillus</u> <u>alcalophilus</u> (e.g., ATCC 21522), <u>B.</u> <u>subtilis</u> (e.g., ATCC 6051) and <u>Bacillus</u> <u>cereus</u> (e.g., ATCC 21768). Also included are all the genes capable of being expressed in Bacillus such as the ones coding for proteases, lipases, cutinases, esterases, endoglycosidases, etc. A preferred enzyme as subtilisin. Other preferred enzymes include endoglycosidase H from Streptomyces species and lipase from <u>Pseudomonas</u> <u>mendocino</u> ATCC 53552 (available from American Type Culture Collection, Rockville, MD). Enymes such as subtilisin which act at an optimum at higher pH are among the preferred enzymes. It is also recognized that only those promoters which are affected (i.e. hyperproduce) by each of the transcriptional regulatory genes alone are intended to be covered by the invention (e.g. <u>aprE</u> and <u>nprE</u>). The enzyme gene sequence also includes the DNA sequence encoding for a naturally occurring enzyme gene sequence which is modified to produce a mutant DNA<!-- EPO <DP n="7"> --> sequence which encodes a substitution, insertion or deletion of one or more amino acids in the gene sequence. Suitable modification methods are disclosed in, for example, EPO Publication No. 0130756, published January 9, 1985.</p><p id="p0019" num="0019">Subtilisins are bacterial alkaline proteases which generally act to cleave peptide bonds of proteins or peptides. As used herein, "subtilisin" means a naturally occurring subtilisin or a recombinant subtilisin. A series of naturally occurring subtilisins is known to be produced and often secreted by various bacterial species. Amino acid sequences of the members of this series are not entirely homologous. However, the subtilisins in this series exhibit the same or similar type of proteolytic activity. This class of serine proteases shares a common amino acid sequence defining a catalytic triad which distinguishes them from the chymotrypsin related class of seine proteases. The subtilisins and chymotrypsin related serine proteases both have a catalytic triad comprising aspartate, histidine and serine. In the subtilisin related proteases the relative order of these animo acids, reading from the amino to carboxyl terminus is aspartate-histidine-serine. In the chymotrypsin related proteases the relative order, however, is histidine-aspartate-serine. Thus, subtilisin herein refers to a serine protease.</p><p id="p0020" num="0020">"Recombinant subtilisin" refers to a subtilisin in which the DNA sequence encoding the subtilisin is modified to produce a mutant DNA sequence which encodes the substitution, deletion or insertion of one or more amino acids in the naturally occurring subtilisin amino acid sequence. Suitable methods to produce such modification include those disclosed herein and in EPO Publication No. 0130756. For example, a subtilisin multiple mutant<!-- EPO <DP n="8"> --> containing the substitution of methionine at amino acid residues 50, 124 and 222 with phenylalanine, isoleucine and glutamine, respectively, can be considered to be derived from the recombinant subtilisin containing the substitution of glutamine at residue 222 (Gln-222) disclosed in EPO Publication No. 0130756. The multiple mutant thus is produced by the substitution of phenylalanine for methionine at residue 50 and isoleucine for methionine at residue 124 in the Gln-222 recombinant subtilisin.</p><p id="p0021" num="0021">As used herein, "a functional promoter sequence controlling the expression of the enzyme gene operably linked to the enzyme gene sequence" refers to a promoter sequence which controls the transcription and translation of the coding sequence in Bacillus. The promoter sequence is chosen so that it is functional in the microorganism chosen for expression. For example, promoter sequence (including ribosomal binding sites) formed from Lambda P (Renaut, <u>et al., Gene 15</u>, 81 [1981]) as well as the <u>trp</u> (Russell, <u>et al.,</u> Gene 20, 23 (1982)or tac (de Boer <u>et al</u>., PNAS. USA <u>80</u>, 21 [1983]) may be operably linked to coding sequences to express alkaline protease in E. Coli. When <u>B.</u> <u>subtilis</u> I-168 is the expression host, the B. <u>subtilis</u> alkaline protease promoter (Stahl et al, J. Bacteriol 158, 411-418 [1984]) alpha amylase promoter of <u>B.</u> <u>subtilis</u> (Yang et al., 1983, Nucleic Acids Res. 11, 237-249) or <u>B.</u> <u>amyloliquefaciens</u> (Tarkinen, <u>et al,</u> J. Biol. Chem. 258, 1007-1013 [1983]), the neutral protease promoter from <u>B.</u> <u>subtilis</u> (Yang et al, J. Bacteriol, 160, 15-21 [1984]) or any other promoter from <u>B.</u> <u>subtilis</u> or other related Bacilli, whose expression is affected by the described upstream regulatory genes my be used. The preferred promoter of the invention is the <u>aprE</u> promoter. Also preferred is the <u>nprE</u> promoter.<!-- EPO <DP n="9"> --></p><p id="p0022" num="0022">As used herein, "transcriptional regulatory genes" refers to any of the genes whose product affects the level of transcription from the enzyme promoter. These genes product can interact at the promoter level (e.g. AbrB) or with a region upstream or downstream of it (e.g. Hpr, SacU, SacQ, PrtR, Sin) either directly or indirectly. The definition above is comprehensive of the gene product or the lack of it and any possible mutation which my increase the level of transcription of a particular promoter (e.g. multiple copies). This definition is meant to include but not limited to certain mutations in the promoter region, downstream or upstream of the promoter region of the target gene which my result in an increase in transcription due to a better interaction or lack of it with the regulatory genes or with the transcriptional machinery (e.g. RNA polymerase, mutations which decrease production of a gene product which interferes with transcription). These genes and the effect of their mutations are described above. These specific combinations, applicant has discovered, exhibit a synergistic effect when compared with the results predicted from either single mutations alone.</p><p id="p0023" num="0023">It appears that in order to express the enzyme at high levels aid have its expression more effectively under the control of these regulatory mutations the promoter needs to be integrated into the genome of the host <u>Bacillus</u> cell or perhaps be carried by a low copy number plasmid. High copy number replicating plasmids carrying the enzyme gene seem to be poorly tolerated in strains bearing some of the regulatory mutations, and they are lost or rearranged at very high frequency.</p><p id="p0024" num="0024">It is preferred that the gene coding for the enzyme to be expressed at high levels is integrated into the genome of the host <u>Bacillus</u> cell.<!-- EPO <DP n="10"> --></p><p id="p0025" num="0025">"Expression vector" refers to a DNA construct containing a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host. Such control sequences can include a promoter to effect transcription or optional operation sequence to control such transcription, a sequence encoding a suitable ribosome binding sites (RBS) and sequences which control termination of transcription and translation. The vector may be a plasmid, a phage particle, or a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host gene or may integrate into the gene itself. A preferred vector is pSAI.</p><p id="p0026" num="0026"><u>Bacillus</u> host cells for the purpose of this invention are those <u>Bacillus</u> hosts capable of functionally accepting the expression vector. Preferably, they have been manipulated by the methods disclosed in EPO Publication No. 0130756 to render them incapable of secreting other enzymes deleterious to the desired enzyme. A preferred host cell for expressing subtilisin is the <u>B.</u> <u>subtilis</u> strain BG 2036 which is deficient in enzymatically active neutral protease aid alkaline protease (native subtilisin). The construction of strain BG 2036 is described in detail in EPO Publication No. 0130756 aid further described by Yang, et al (1984) J. Bacteriol. 160 15-21. Other host cells for expressing subtilisin include any derivative of <u>B.</u> <u>subtilis</u> I-168 aid any other member of the bacillus family in which such system might work (i.e. <u>B.</u> <u>amyloliquefaciens</u> and <u>B.</u> <u>licheniformis</u> (EPO Publication No. 0130756).</p><p id="p0027" num="0027">"Operably linked" as used herein describes the relationship between two DNA regions and means they are functionally related to one another. For<!-- EPO <DP n="11"> --> example, a promoter is operably linked to the gene sequence coding for an alkaline protease if it properly controls the transcription of the sequence.</p><p id="p0028" num="0028">The following examples are not intended to be limiting. One skilled in the art could choose other promoters, find or use other mutations and express other enzymes in <u>Bacillus</u>. Also, one can easily see that one skilled in the art could replicate the teachings of examples with materials generally available to the public. Accordingly, none of the strains herein need be deposited.</p><heading id="h0006"><u>DESCRIPTION OF THE PREFERRED EMBODIMENTS</u></heading><heading id="h0007"><u>Cloning of the Subtilisin Gene</u></heading><p id="p0029" num="0029">The subtilisin gene from <u>B.</u> <u>amyloliquefaciens</u> was isolated as described by Wells et al, 1983, <u>Nucleic Acid Res. 11</u>: 7911-7925. Briefly, partially <u>Sau3A</u> digested chromosomal DNA from <u>B.</u> <u>amyloliquefaciens</u> was ligated to <u>BamH1</u> digested pBS42 and used to transform <u>E.</u> <u>coli</u>. pBS42 is a plasmid vector composed of an origin of replication from pUB110 recognized as such by <u>B.</u> <u>subtilis</u>, an origin of replication from pBR322 which allows replication of the plasmid in <u>E.</u> <u>coli</u> and a chloramphenicol acetyltransferase (CAT or CmR) from pC194, a fully characterized plasmid from <u>Staphilococcus</u> <u>aureus</u> (Horinouchi and Weisblum, 1982), which can express CmR in both <u>E.</u> <u>coli</u> and <u>B.</u> <u>subtilis</u>. Synthetic DNA probes designed from the known amino acid sequence of the subtilisin were used to isolate a plasmid (p54) carrying the DNA coding for the gene. The isolated DNA fragment was able to code for subtilisin production when transferred to <u>B.</u> <u>subtilis</u> and the DNA sequence translated to match the published amino acid sequence of the alkaline protease (Wells et al, 1983, <u>Nucleic Acid Res. 11</u>:<!-- EPO <DP n="12"> --> 7911-7925).</p><p id="p0030" num="0030">A <u>Sau3A</u> <u>BamH1</u> fragment from pS4-5 (a derivative of pS4) comprising the subtilisin structural gene from the 8th codon of the signal sequence to 250 bp after the 3' end of the gene (all of which is <u>B.</u> <u>amyloliquefaciens</u> DNA), was fused to a 750 bp <u>EcoR1-Sau3A</u> fragment which carries the promoter and the first 8 codons of the translated sequence of the <u>B.</u> <u>subtilis</u> subtilisin gene (Fig. 1). The gene so reconstructed, carried in an <u>EcoR1-BamH1</u> fragment containing only <u>Bacillus</u> DNA, was inserted in <u>BamH1-EcoR1</u> digested pBS42 resulting in plasmid pSAR. This plasmid was shown to be able to produce subtilisin in <u>B.</u> <u>subtilis</u>.</p><p id="p0031" num="0031">The <u>EcoR1-BamH1</u> fragment from pSAR, carrying the <u>B.</u> <u>subtilis</u> aprE promoter fused to the <u>B.</u> <u>amyloliquefaciens</u> subtilisin gene was ligated to an <u>EcoR1-BamH1</u> digested pJH101 (Ferrari, et al, <u>Journal of Bacterial.</u> Vol. 154, pp 1513-1515). The resulting plasmid, which can replicate in <u>Escherichia. coli</u> but not in <u>B.</u> <u>subtilis</u> was called pSA1. Upon transformation in <u>B.</u> <u>subtilis</u>, followed by Chloramphenicol selection, this plasmid will integrate into the chromosome at the site of homology with the <u>aprE</u> promoter.</p><p id="p0032" num="0032">The CmR gene from pC194, contained in a 1.6 Kilobases (Kb) <u>ClaI</u> fragment, was cloned in <u>ClaI</u> digested pBR322. Upon digestion with <u>EcoR1</u> and <u>HindIII</u>, this plasmid will release the CmR resistance gene flanked by a few basepairs of pBR322 origin (see below).</p><p id="p0033" num="0033">The <u>EcoR1-BamH1</u> fragment from either pSAR or pSAI carrying the subtilisin gene was subcloned in the <u>EcoR1-BamH1</u> sites of the synthetic polylinker<!-- EPO <DP n="13"> --> region of pUC9. Upon digestion with <u>EcoR1</u> and <u>HindIII</u>, this plasmid will release a 2.2 Kb fragment carrying the subtilisin gene flanked on one side by 17 bp of the synthetic linker (Fig. 2).</p><p id="p0034" num="0034">These two <u>EcoR1-HindIII</u> fragments were ligated together and used to transform <u>B.</u> <u>subtilis</u>, selecting for CmR. Upon transformation this plasmid integrates into the chromosome, as has been shown by PBS1 transduction (Fig. 3). The final construction in <u>B.</u> <u>subtilis</u> consists of 1.6 Kb from pC194 and the subtilisin gene joined together by short linker regions. One linker is composed of 20 bp from pUC9, and the other one consists of the 17 bp from pBR322 included between the <u>EcoR1</u> and the <u>Cla1</u> sites.</p><p id="p0035" num="0035">In order to obtain a strain which produces mainly the protease we are interested in, we deleted the two major proteases, present in almost all Bacilli (the alkaline protease aid the neutral protease), as described by Stahl and Ferrari (1984), <u>J. Bacteriol., 158</u>: 411-418 and Yang et al (1984), <u>J. Bacteriol., 160</u>: 15-21. The plasmid described above was then introduced into BG 2036 by transformation selecting for CmR. This plasmid similarly to pSAI will integrate into the chromosome (we have never been able to detect any replicating plasmids) in the region of homology conferred by the <u>B.</u> <u>subtilis</u> subtilisin promoter (Fig. 3). Southern blot analysis of the chromosomal DNA digested with proper restriction enzymes and PBS1 mapping experiments confirmed the integration and the presence of the proper size fragments.</p><p id="p0036" num="0036">To obtain hyperproduction we then introduced chromosomal mutations known to increase the level of secreted enzymes, either through competent cell transformation or PBS1 transduction. Both these techniques are commonly<!-- EPO <DP n="14"> --> used for genetic studies in <u>B.</u> <u>subtilis</u>. The resulting strain is a prototrophic sporeforming derivative of <u>B.</u> <u>subtilis</u> I-168 (catalog No. 1-A1, Bacillus Genetic Stock Center) which carries the <u>B.</u> <u>amyloliquefaciens</u> subtilisin gene and the CmR gene from pC194 integrated into the chromosome.</p><p id="p0037" num="0037"><u>Construction of Hpr97, ScoC, Cat A strains</u>: All the strains construction described here have been carried at by using standard <u>B.</u> <u>subtilis</u> genetic techniques. Transformations have been done following the method described by Anagnostopoulos and Spizizen (J. Bacteriol., 81:741-746, 1961). Transduction have been done using the bacteriophage PBS1, following the method described by Hoch et al., (J. Bacteriol., 93:1925-1937, 1967). The integrative plasmid pSAI was introduced into strain BG2097 (a strain publicly available which carries deletions in the <u>aprE</u> and <u>nprE</u> genes) by transformation to generate strain BG3002. DNA prepared from BG3002 was used to transform strains IPCC 7698 (available from the Pasteur Institute Culture Collection, Paris, France), 1A151 (available from the Bacillus Genetic Stock Center, Columbus, Ohio) and Hpr97 (available from Dr J. A. Hoch, Research Institute of Scripps Clinic, La Jolla, California) containing respectively the <u>scoC1</u>, <u>catA</u> or <u>hpr-97</u> mutation to chloramphenicol resistance. The resulting chloramphenicol resistant strains were scored on solid medium (tryptose blood agar base agar, TBAB) containing skim milk for the detection of the hyperprotease producing characteristic (due to the presence of the <u>scoC</u>, <u>catA</u> and <u>hpr</u> mutations) of the parent strain. PBS-1 lysates (see above) were prepared on the ScoC, CatA and Hpr strains carrying the pSAI integrative plasmid by a standard published technique (Hoch et al 1967, see above). These lysates were used to transduce strain BG2097. These transductions introduced the subtilisin gene integrated in the chromosome with plasmid pSAI into BG2097 and also<!-- EPO <DP n="15"> --> transferred the <u>scoC</u> or <u>catA</u> or <u>hpr</u> mutations by virtue of their linkage to the <u>aprE</u> gene (that is pSAI). Approximately 10-20% of the chloramphenicol resistant transductants demonstrated a higher amount of protease production, suggesting that these strains had indeed acquired the <u>scoC</u> or <u>catA</u> or <u>hpr</u> hyperproducing phenotype.</p><p id="p0038" num="0038">Some of the transductant were screened on plates containing 1.6% skim milk and compared to BG3002. Transductants able to yield a larger halo on these type of plates were selected and strains BG 3008, BG3005 aid BG3007 were obtained. The genotype of these strains is isogeneic (<u>hisA</u>, <u>aprE</u>, <u>nprE</u>, pSAI: :CmR) except for the <u>hpr</u> gene were the mutations <u>scoC1</u>, <u>catA</u> or <u>hpr</u>97 are present respectively. When representatives of this transduction were examined in shake flasks using a nutrient broth medium, they produced âˆ¼19-17mg/L subtilisin or 5-10 fold more than the strain that did not contain the hyperproducing mutation.</p><p id="p0039" num="0039"><u>Construction of SacU(Hy) strains</u>: One of the properties of SacU(Hy) strains is that they lack the ability to produce flagella and to become motile. Since PBS-1 attaches to motile flagella, it is impossible to prepare a PBS-1 working lysate on SacU(Hy) strains. This problem was circumvented by the isolation of a spontaneous mutant that was motile and retained its protease hyperproducing phenotype. The nature of the mutation that results in motility is unknown. A lysate was prepared on the motile SacU(Hy) strain. This lysate was used to transduce either BG3002 (Î” <u>apr</u>, Î” <u>npr</u>, <u>hisA</u>) containing the pSAI plasmid to histidine prototropy. Since the <u>sacU</u> gene and the <u>hisA</u> gene are linked by transduction, a certain percentage of the transductants were expected to contain the <u>sacU(Hy)</u>32 gene. The presence of this mutation was verified on skim milk plates; âˆ¼90%<!-- EPO <DP n="16"> --> of the transductants exhibited the hyperproducing phenotype. A representative strain containing the <u>sacU(Hy</u>) mutation produced 35-45mg/L when grown in nutrient broth medium. The same general scheme applied when a strain containing the <u>scoC</u> or <u>catA</u> mutation was transduced with a PBS1 lysate prepared on a SacU(Hy) strain. Strains containing the <u>scoC</u> (BG3008) and <u>catA</u> (BG3005) mutations could be successfully transduced to <u>sacU(Hy)</u>. The strains containing both the <u>sacU(Hy)32</u> and either the <u>scoC</u> or <u>catA</u> mutations exhibited a larger zone of clearing on skim milk plates than did either of the strains containing the individual mutations. These strains produced âˆ¼55mg/L in nutrient broth medium.</p><p id="p0040" num="0040"><u>Construction of SacQ(Hy) strains</u>: A lysate was prepared on a SacQ(Hy) strain. This lysate was used to transduce a strain to threonine prototropy. Again, since the <u>thr</u> gene and <u>sacQ(Hy)</u> gene are linked by transduction, a certain percentage of the population would be expected to contain the hyperproducing <u>sacQ(Hy)</u> gene. The same procedure is used to construct strains containing either the <u>sacQ(Hy)</u> mutation alone or in combination with either the <u>scoC</u> or <u>catA</u> mutation.</p><p id="p0041" num="0041"><u>Construction of triple mutants</u>: Strains containing the <u>sacU(Hy)32</u>, <u>sacQ(Hy)</u> and either the <u>scoC</u> or <u>catA</u> mutation could be constructed by using a combination of the above procedures. Generally speaking, the <u>catA/scoC</u> mutation was introduced in one step along with the plasmid pSAI followed by the introduction of the <u>sacQ(Hy)</u> mutation and finally the <u>sacU(Hy)</u> mutation was introduced into the strain.<!-- EPO <DP n="17"> --> <tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="3" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" align="left">Results</entry></row><row rowsep="1"><entry namest="col1" nameend="col2" align="center">Strain</entry><entry namest="col3" nameend="col3" align="center">Enzyme Level Shake Flasks<sup>1</sup> (mg/l)</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="left">BG 3002</entry><entry namest="col2" nameend="col2" align="left">(wild type) pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">0.5</entry></row><row><entry namest="col1" nameend="col1" morerows="1" align="left">BG 3004</entry><entry namest="col2" nameend="col2" align="left"><u>sacU(Hy)</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">40</entry></row><row><entry namest="col2" nameend="col2" align="left"><u>sacU(Hy)</u>, pSAI, pBS7AS</entry><entry namest="col3" nameend="col3" align="char" char=".">36</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3005</entry><entry namest="col2" nameend="col2" align="left"><u>catA</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">2</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3006</entry><entry namest="col2" nameend="col2" align="left"><u>catA</u>, <u>sacU(Hy),</u> pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">56</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3007</entry><entry namest="col2" nameend="col2" align="left"><u>hpr97</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">10</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3008</entry><entry namest="col2" nameend="col2" align="left"><u>scoC</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">4</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3009</entry><entry namest="col2" nameend="col2" align="left"><u>sacQ(Hy)</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">5</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3010</entry><entry namest="col2" nameend="col2" align="left"><u>scoC</u>, <u>sacU(Hy)</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">60</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3013</entry><entry namest="col2" nameend="col2" align="left"><u>sacQ(Hy)</u>, <u>sacU(Hy)</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">30</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3015</entry><entry namest="col2" nameend="col2" align="left"><u>catA</u>, <u>sacQ(Hy)</u></entry><entry namest="col3" nameend="col3" align="char" char=".">26</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3016</entry><entry namest="col2" nameend="col2" align="left"><u>scoC</u>, <u>sacQ(Hy)</u></entry><entry namest="col3" nameend="col3" align="char" char=".">27</entry></row><row><entry namest="col1" nameend="col1" align="left">BG 3017</entry><entry namest="col2" nameend="col2" align="left"><u>catA</u>, <u>sacQ(Hy)</u>, <u>sacU(Hy)</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">55</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="left">BG 3020</entry><entry namest="col2" nameend="col2" align="left"><u>scoC</u>, <u>sacQ(Hy)</u>, <u>sacU(Hy)</u>, pSAI</entry><entry namest="col3" nameend="col3" align="char" char=".">89,61</entry></row></tbody></tgroup><tgroup cols="3" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="52.50mm"/><colspec colnum="2" colname="col2" colwidth="52.50mm"/><colspec colnum="3" colname="col3" colwidth="52.50mm"/><tbody valign="top"><row><entry namest="col1" nameend="col3" align="justify"><sup>1</sup> Medium: Schaeffers nutrient broth +0.1% glucose.</entry></row></tbody></tgroup></table></tables></p>
EP	0600893	B1	2000-03-22	en	CLAIM	1	<claim id="c-en-01-0001" num="0001"><claim-text>A <u>Bacillus</u> for use in the hyperproduction of an enzyme comprising:<claim-text>(a) an enzyme structural gene;</claim-text><claim-text>(b) a functional promoter sequence selected from the group consisting of <u>Bacillus</u> <u>aprE</u> and <u>nprE</u> wherein the promoter is operably linked to the enzyme structural gene; and</claim-text><claim-text>(c) a combination of two or more mutated transcriptional regulatory genes involved in the transcriptional regulation of the promoter, wherein the combination is selected from the group consisting of a catA mutation and a sacQ(HY) mutation, a catA mutation and a sacU(HY) mutation, a scoC1 mutation and a sacQ(HY) mutation, a scoC1 mutation and a sacU(HY) mutation; a catA mutation, sacQ mutation and a sacU mutation; and a scoC1 mutation, sacQ mutation and a sacU mutation.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A <u>Bacillus</u> according to claim 1 wherein the enzyme produced is subtilisin.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A <u>Bacillus</u> according to claim 1 wherein the enzyme produced is endoglycosidase H or lipase.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A <u>Bacillus</u> according to claim 1 wherein increased production of the enzyme is accomplished by hyperexpressing the transcriptional regulatory genes.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>A <u>Bacillus</u> according to claim 1 wherein the <u>sacU(Hy)</u> mutation is the <u>sacU(Hy)32</u> mutation.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>A <u>Bacillus</u> according to claim 1 wherein the <u>sacQ(Hy)</u> mutation is the <u>sacQ(Hy)36</u> mutation.<!-- EPO <DP n="19"> --></claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>A <u>Bacillus</u> according to claim 1 wherein the enzyme gene is integrated into the genome of the host Bacillus cell.</claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>A <u>Bacillus</u> according to claim 1 wherein increased production of the enzyme is accomplished by constructing the <u>Bacillus</u> with multiple copies of said combination of transcriptional regulatory genes.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>A <u>Bacillus</u> according to claim 1 which is derived from <u>B.</u> <u>subtilis</u> I-168.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>A process for hyperproducing an enzyme in <u>Bacillus</u> comprising:<claim-text>(a) constructing a <u>Bacillus</u> comprising an enzyme structural gene; a functional promoter sequence selected from the group consisting of <u>aprE</u> and <u>nprE</u> wherein the promoter is operably linked to the enzyme structural gene; and a combination of two or more mutated transcriptional regulatory genes involved in the transcriptional regulation of the promoter wherein the combination is selected from the group consisting of a catA mutation and a sacQ(HY) mutation, a catA mutation and a sacU(HY) mutation, a socC1 mutation and a sacQ(HY) mutation, a scoC1 mutation and a sacU(HY) mutation; a catA mutation, sacQ mutation and a sacU mutation; and a scoC1 mutation, sacQ mutation and a sacU mutation; and</claim-text><claim-text>(b) growing the <u>Bacillus</u> in a suitable medium for expression of the enzyme.</claim-text></claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>A method according to claim 10 wherein the enzyme is selected from the group consisting of subtilisin, endoglycosidase H and lipase.</claim-text></claim>
EP	0600893	B1	2000-03-22	de	CLAIM	2	<claim id="c-de-01-0001" num="0001"><claim-text>Bazillus zur Verwendung bei der Ãœberproduktion eines Enzyms umfassend:<claim-text>(a) ein Enzymstrukturgen,</claim-text><claim-text>(b) eine funktionelle Promotorsequenz, ausgewÃ¤hlt aus der Gruppe, bestehend aus Bacillus aprE und nprE, worin der Promotor operativ mit dem Enzymstrukturgen verbunden ist, und</claim-text><claim-text>(c) eine Kombination aus zwei oder mehr mutierten Transkriptionsregulationsgenen, die bei der Transkriptionsregulation des Promotors beteiligt sind, wobei die Kombination ausgewÃ¤hlt ist aus der Gruppe, bestehend aus einer catA Mutation und einer sacQ(HY) Mutation, einer catA Mutation und einer sacU(HY) Mutation, einer scoC1 Mutation und einer sacQ(HY) Mutation, einer scoC1 Mutation und einer sacU(HY) Mutation; einer catA Mutation, einer sacQ Mutation und einer sacU Mutation; und einer scoC1 Mutation, einer sacQ Mutation und einer sacU Mutation.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Bazillus nach Anspruch 1, wobei das hergestellte Enzym Subtilisin ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Bazillus nach Anspruch 1, wobei das hergestellte Enzym Endoglycosidase H oder Lipase ist.<!-- EPO <DP n="21"> --></claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Bazillus nach Anspruch 1, wobei eine erhÃ¶hte Herstellung des Enzyms durch Ãœberexpression der Transkriptionsregulationsgene erreicht wird.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Bazillus nach Anspruch 1, wobei die sacU(Hy) Mutation die sacU(Hy)32 Mutation ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Bazillus nach Anspruch 1, wobei die sacQ(Hy) Mutation die sacQ(Hy)36 Mutation ist.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Bazillus nach Anspruch 1, wobei das Enzymgen in das Genom der Wirtsbazilluszelle integriert ist.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Bazillus nach Anspruch 1, wobei die erhÃ¶hte Produktion des Enzyms durch Konstruieren des Bazillus mit einer Vielzahl von Kopien der Kombination der Transkriptionsregulationsgene erreicht wird.</claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Bazillus nach Anspruch 1, der von B. subtilis I-168 abgeleitet ist.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verfahren zur Ãœberproduktion eines Enzyms in Bazillus umfassend:<claim-text>(a) Konstruieren eines Bazillus, umfassend ein Enzymstrukturgen, eine funktionelle Promotorsequenz, ausgewÃ¤hlt aus der Gruppe, bestehend aus aprE und nprE, wobei der Promotor operativ mit dem Enzymstrukturgen verbunden ist und eine Kombination aus zwei oder mehr mutierten Transkriptionsregulationsgenen, die bei der Transkriptionsregulation des Promotors beteiligt sind, wobei die Kombination ausgewÃ¤hlt wird aus der Gruppe, bestehend aus einer catA Mutation und einer sacQ(HY) Mutation, einer catA Mutation und einer sacU(HY) Mutation, einer scoC1 Mutation und einer sacQ(HY) Mutation, einer scoC1 Mutation und einer sacU(HY) Mutation; einer catA Mutation, einer sacQ<!-- EPO <DP n="22"> --> Mutation und einer sacU Mutation; und einer scoC1 Mutation, einer sacQ Mutation und einer sacU Mutation; und</claim-text><claim-text>(b) Kultivieren des Bazillus in einem geeigneten Medium zur Expression des Enzyms.</claim-text></claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verfahren nach Anspruch 10, wobei das Enzym aus der Gruppe, bestehend aus Subtilisin, Endoglycosidase H und Lipase ausgewÃ¤hlt wird.</claim-text></claim>
EP	0600893	B1	2000-03-22	fr	CLAIM	3	<claim id="c-fr-01-0001" num="0001"><claim-text><u>Bacillus</u> destinÃ© Ã  Ãªtre utilisÃ© dans l'hyperproduction d'une enzyme, comprenant :<claim-text>(a) un gÃ¨ne structural d'enzyme ;</claim-text><claim-text>(b) une sÃ©quence de promoteur fonctionnelle choisie dans le groupe consistant en les sÃ©quences <u>aprE</u> et <u>nprE</u> de <u>Bacillus</u>, ledit promoteur Ã©tant liÃ© de maniÃ¨re fonctionnelle au gÃ¨ne structural d'enzyme ; et</claim-text><claim-text>(c) une association de deux ou plus de deux gÃ¨nes rÃ©gulateurs de transcription mutÃ©s impliquÃ©s dans la rÃ©gulation de transcription du promoteur, l'association Ã©tant choisie dans le groupe consistant en une mutation catA et une mutation sacQ(HY), une mutation catA et une mutation SacU(HY), une mutation scoC1 et une mutation sacQ(HY), une mutation scoC1 et une mutation sacU(HY) ; une mutation catA, une mutation sacQ et une mutation sacU ; une mutation scoC1, une mutation sacQ et une mutation sacU.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text><u>Bacillus</u> suivant la revendication 1, dans lequel l'enzyme produite est la subtilisine.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text><u>Bacillus</u> suivant la revendication 1, dans lequel l'enzyme produite est l'endoglycosidase H ou la lipase.</claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text><u>Bacillus</u> suivant la revendication 1, dans lequel la production accrue de l'enzyme est effectuÃ©e par une hyper-expression des gÃ¨nes rÃ©gulateurs de transcription.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text><u>Bacillus</u> suivant la revendication 1, dans lequel la mutation <u>sacU(Hy)</u> est la mutation <u>sacU(Hy)32</u>.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text><u>Bacillus</u> suivant la revendication 1, dans lequel la mutation <u>sacQ(Hy)</u> est la mutation <u>sacQ(Hy)36</u>.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text><u>Bacillus</u> suivant la revendication 1, dans lequel le gÃ¨ne d'enzyme est intÃ©grÃ© au gÃ©nome de la cellule de Bacillus hÃ´te.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text><u>Bacillus</u> suivant la revendication 1, dans lequel la production accrue de l'enzyme est effectuÃ©e par construction du <u>Bacillus</u> avec des copies multiples de ladite association de gÃ¨nes rÃ©gulateurs de transcription.<!-- EPO <DP n="24"> --></claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text><u>Bacillus</u> suivant la revendication 1, qui est dÃ©rivÃ© de <u>B.</u> <u>subtilis</u> I-168.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>ProcÃ©dÃ© pour l'hyperproduction d'une enzyme dans un <u>Bacillus</u>, comprenant :<claim-text>(a) la construction d'un <u>Bacillus</u> comprenant un gÃ¨ne structural d'enzyme ; une sÃ©quence de promoteur fonctionnelle choisie dans le groupe consistant en les sÃ©quences <u>aprE</u> et <u>nprE</u>, ledit promoteur Ã©tant liÃ© de maniÃ¨re fonctionnelle au gÃ¨ne structural d'enzyme ; et une association de deux ou plus de deux gÃ¨nes rÃ©gulateurs de transcription mutÃ©s impliquÃ©s dans la rÃ©gulation de transcription du promoteur, l'association Ã©tant choisie dans le groupe consistant en une mutation catA et une mutation sacQ(HY), une mutation catA et une mutation sacU(HY), une mutation SocC<sub>1</sub> et une mutation sacQ(HY), une mutation scoC1 et une mutation sacU(HY) ; une mutation catA, une mutation sacQ et une mutation sacU ; et une mutation scoC1, une mutation sacQ et une mutation sacU ; et</claim-text><claim-text>(b) la culture du <u>Bacillus</u> dans un milieu convenant pour l'expression de l'enzyme.</claim-text></claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>ProcÃ©dÃ© suivant la revendication 10, dans lequel l'enzyme est choisie dans le groupe consistant en la subtilisine, l'endoglycosidase H et la lipase.</claim-text></claim>
EP	0600893	B1	2000-03-22	en	PDFEP	1	https://data.epo.org/publication-server/pdf-document?cc=EP&pn=0600893&ki=B1&pd=2000-03-22
EP	0693879	B1	2000-07-19	de	TITLE	1	UMWÃ„LZHEIZSYSTEM FÃœR MIKROWELLENDREHSCHEIBE
EP	0693879	B1	2000-07-19	en	TITLE	1	MICROWAVE TURNTABLE CONVECTION HEATER
